,id,ticker,title,category,content,date,provider,url,article_id
170785,392301,LLY,Will Eli Lilly Outperform in 2020 ,news,"Eli Lilly and Company  NYSE LLY  offers an attractive opportunity for shareholders in 2020  The more than 140 year old drug company has a few compelling metrics that demonstrate significant value for investors  including a strong return on equity  ROE   a modest dividend payout ratio  and continued profitability when compared with peers including GlaxoSmithKline  NYSE GSK  and Pfizer  NYSE PFE  
Management at Eli Lilly is looking to expand its dealmaking activity through 2020 to create new growth opportunities and long term value for shareholders  The company is facing some favorable catalysts in the near term from its Phase 3 clinical trials  as well as potential regulatory actions that should offset some near term patent expirations and boost potential revenue streams 

Armed with cash and ready to deal
CFO John Smiley remarked at the recent J P  Morgan Healthcare Conference that the company intends to focus on dealmaking in 2020  aiming to announce roughly one agreement every quarter  This includes licensing agreements  acquisitions  and other structures 
Eli Lilly already made headlines earlier this year with its acquisition of Dermira  a biopharma working on therapies for chronic skin conditions  The acquisition expands the company s portfolio of Phase 3 clinical trial drugs  as well as one already approved medicated cloth to treat excessive armpit sweat  All of this should mean long term value  new revenue streams  and backup for its drugs that are nearing patent expiration 
Progress in the portfolio
One of Eli Lilly s drugs  Trijardy XR  was approved by the FDA this week  and top line results were announced from a Phase 3 clinical trial for another  Trijardy XR combines three type 2 diabetes medications into one pill that  combined with diet and exercise  lowers blood sugar levels in adults  This combination of different diabetes medications marks an important advancement in the treatment of the disease 
On the clinical trial front  Eli Lilly and Incyte  NASDAQ INCY  announced promising top line results from a Phase 3 clinical trial in patients with the common  chronic inflammatory skin disease called moderate to severe atopic dermatitis  AD   better known as eczema  Next  the company plans to apply for expanded approval for a drug that currently treats rheumatoid arthritis to be used for eczema as well  This treatment is currently approved in the European Union  and Eli Lilly expects to submit applications in the United States and Japan this year 
Strong shareholder value
Eli Lilly s forward price to earnings  P E  ratio  a measure of share price relative to per share earnings  is 20 5  Compared with peers including Pfizer  13 15  and GlaxoSmithKline  15   Eli Lilly looks poised for higher earnings in the future  A higher forward P E implies that the market thinks the company is likely to see growth 
For example  Eli Lilly anticipates revenue this year to be between  23 6 billion and  24 1 billion  driven by volume growth in key products including Tulicity  Jardiance  and many others  In the prior year  Eli Lilly s financial guidance called for revenue of  22 billion to  22 5 billion  This shows that management is clearly optimistic that they will meet or exceed their 7  revenue compound annual growth rate  CAGR  target   CAGR is a useful metric for investors who want to see the average annual growth rate of their returns over a period of time  
Investors will want to note that 7  revenue CAGR target and keep an eye on management s strategies for getting there  including high volume growth in their key products  promising results in their development pipeline  and a focus on acquiring new assets every quarter  Success on all these fronts will allow Eli Lilly to achieve the forward P E ratio expected by the market    and provide shareholder value 
The dividend yield is also worth watching  Currently  Eli Lilly s forward annual dividend yield is 2 13   with the trailing dividend yield at 1 80   That increase of 0 33  shows some optimism is already priced in  The dividend payout ratio  which measures the sustainability of a company s dividend stream  is 55 1     against peers such as Pfizer  49 7   and GSK  87 1    this implies that the dividend may have room to grow  With dividend payments dating back to 1973  this company may be appealing to investors who want to receive dividends in good times and bad 
Eli Lilly also offers strong shareholder value in the form of its return on equity  ROE   which reached 49 3  over the trailing 12 months    higher than GlaxoSmithKline s 46 4  and Pfizer s 23 7   ROE is a compelling metric because it reveals whether management is capable of making more profit with less capital  By this metric  Eli Lilly is clearly doing a better job than its peers at creating profits while effectively managing investments  
A profitable diagnosis for 2020
Eli Lilly offers an attractive investment for healthcare investors seeking long term value  Management s focus on acquiring companies and broadening the portfolio has paid off  and the market expects a great year ahead for Eli Lilly ",2020-01-30,The Motley Fool,https://invst.ly/pox06,2071622
170786,392302,LLY,Is Eli Lilly Stock Overvalued ,news,"Pharma behemoth Eli Lilly  NYSE LLY  posted better than expected fourth quarter results ahead of the opening bell this morning  Specifically  the drugmaker topped Factset s consensus revenue estimate for the three month period by a healthy 3 38  and Wall Street s non GAAP earnings per share forecast by a striking 13 8   Those are exceptional quarterly results by any measure  
Nonetheless  Lilly s shares don t come across as a screaming buy  despite the company s industry leading levels of top  and bottom line growth in the most recent quarter  Here s why investors may want to stick to the sidelines with this blue chip pharmaceutical stock right now 

Lilly s Q4 results are good    but not that good
Admittedly  Lilly s 8  year over year revenue growth in Q4 will likely take first place within the realm of big pharma once the smoke clears  Even AstraZeneca  NYSE AZN  and its supercharged portfolio of red hot diabetes  oncology  and respiratory medicines isn t expected to hit such lofty heights when the drugmaker reports its latest financial results next month 
But the fact of the matter is that Lilly s valuation may have already reached untenable levels following the company s meteoric rise during the tail end of 2019 and early days of 2020  At 20 7 next year s projected earnings  Lilly s stock is now the second most expensive among all large cap pharmas right now  The only drugmaker with a richer valuation  in fact  is Astra at 24 times forward looking earnings 
What s more  Lilly and Astra are both trading at nearly twice the prevailing average for their big pharma peer group  The market is clearly expecting big things from these two names in the near future  Unfortunately  Lilly may not be able to deliver the hyper revenue growth needed to justify such a pricey valuation 
Lilly s value proposition centers mainly around the forthcoming approval of new cancer meds like selpercatinib  the recent acquisition of the dermatology company Dermira  and a spate of future midsize acquisitions  While this strategy certainly has its merits  Lilly s aggressive business development activity could easily turn into a huge mistake 
Most acquisitions in this space  after all  fail to justify their enormous price tags at the end of the day  That s a key reason more frugal companies like Biogen have largely shied away from bolt on acquisitions  The most potent value creators in biopharma tend to come from internally discovered candidates or products in licensed during early stages of development  preclinical or immediately after a successful proof of concept trial   The point is that Lilly s ongoing M A bonanza is arguably a far riskier endeavor than the market seems to realize   
Should investors take profits 
Over the past five years  Lilly has returned a whopping 124  to investors  including dividends and assuming a dividend reinvestment plan   That is an extraordinary level of performance for any large cap stock  much less a top biopharma that has had to contend with a wave of patent expirations  But all good things come to an end 
Lilly s shares now appear to be trading mainly on speculation about the company s future acquisitions and management s ability to maximize their value  That s not a solid set of reasons to own any stock  It may indeed be time to consider taking profits on this high flying pharma stock ",2020-01-30,The Motley Fool,https://invst.ly/po-ut,2071902
170787,392303,LLY,How Eli Lilly Wowed With Its Q4 Earnings Results,news,"Eli Lilly  NYSE LLY  took investors on a roller coaster ride in 2019  with shares swinging by double digit percentages in both directions  The big drugmaker ended the year on a positive note  though  and entered 2020 with solid momentum 
Now the company has added another reason for investors to be optimistic  Lilly announced its fiscal 2019 fourth quarter and full year results before the market opened on Thursday  Here are the highlights of the big pharma company s Q4 update 

By the numbers
Lilly reported fourth quarter revenue of  6 1 billion  a year over year increase of 8   This result topped the average analysts  revenue estimate of  5 9 billion 
The company announced net income in Q4 of  1 5 billion  or  1 64 per share  based on generally accepted accounting principles  GAAP   This reflected significant improvement from the prior year period net income of  1 1 billion  or  1 10 per share 
On a non GAAP  adjusted  basis  Lilly s net income in the fourth quarter was  1 6 billion  or  1 73 per share  This was much higher than the company s adjusted net income of  1 3 billion  or  1 32 per share  posted in the same period of 2018  It also blew past the consensus Wall Street Q4 earnings estimate of  1 52 per share  
Behind the numbers
Lilly s top selling drug  Trulicity  delivered an impressive performance in Q4 with sales jumping 31  year over year to  1 2 billion  Two other diabetes drugs also generated strong growth  Sales for Basaglar increased by 32  to  307 million  while sales for Jardiance rose 39  to  268 million 
The company s immunology franchise was also a big winner in the fourth quarter  Sales of Taltz vaulted 37  higher year over year to  420 million  Olumiant s sales soared 82  higher to nearly  83 million 
In addition  migraine drug Emgality  which won FDA approval in September 2018  racked up sales of  66 3 million in Q4  compared to only  4 9 million in the prior year period  Sales for breast cancer drug Verzenio more than doubled year over year to  179 million 
There were a few not so bright spots  though  Cialis continued its decline  with sales plunging 44  year over year in Q4 to  197 8 million  Sales for osteoporosis drug Forteo fell 18  to  360 million 
Lilly s revenue growth trickled down to the bottom line  The company also benefited from the sale of its antibiotics business in China 
Looking ahead
Lilly upped its full year 2020 revenue guidance modestly from its previous outlook  The company now anticipates revenue of between  23 7 billion and  24 2 billion in full year 2020  compared to its previous guidance of between  23 6 billion and  24 1 billion 
The company also revised its full year GAAP earnings per share downward  to a range of  6 18 to  6 28 from the range of  6 38 to  6 48 provided in its previous guidance  However  Lilly maintained its earlier adjusted earnings guidance of  6 70 to  6 80 per share 
As with any pharmaceutical stock  the real key to Lilly s long term success is its pipeline  CEO David Ricks pointed to the company s pipeline in his comments about the Q4 results  stating that Lilly  is in the early phase of an exciting period of growth  and is working to expand its portfolio of drugs 
One key thing to watch on this front is Lilly s pending acquisition of Dermira for around  1 1 billion  Assuming there are no obstacles to the deal s going through  the acquisition will bring several promising experimental drugs targeting chronic skin conditions ",2020-01-30,The Motley Fool,https://invst.ly/pp1-m,2072087
170790,392306,LLY,Drugmaker Eli Lilly Reports Fourth Quarter Earnings,news,"Increasing demand for Eli Lilly s  NYSE LLY  diabetes and oncology treatments helped push its fourth quarter 2019 revenue up 8 5  year over year to  6 1 billion  The company also reported GAAP earnings per share  EPS  of  1 64  up 49 1  year over year  due to expanding margins  Those results exceeded industry watchers  consensus revenue and EPS estimates for  5 92 billion and  1 54  respectively 

As one of the largest manufacturers of medications used to control blood sugar levels  Eli Lilly benefited last quarter from increased sales of diabetes drugs Trulicity  Basaglar  and Jardiance 
Sales of Trulicity  a once weekly glucagon like peptide 1  GLP 1  drug that increases insulin production  grew 31  year over year to  1 2 billion  Basaglar  a biosimilar to the long lasting insulin Lantus  saw its revenue increase 32  year over year to  307 million  and sales of Jardiance  a sodium glucose co transporter 2  SGLT2  inhibitor that increases glucose excretion in urine  improved 39  to  268 million  Those gains more than offset a 1  slide in the sales of the fast acting insulin Humalog  
Eli Lilly also benefited from growing demand for the autoimmune disease drug Taltz and the launch of migraine treatment Emgality  Taltz revenue rose 37  year over year to  420 1 million  and Emgality sales totaled  66 3 million  Sales of erectile dysfunction drug Cialis dropped 44   due to the expiration in fall 2018 of its patent protection and the arrival of generic competition   
Overall  revenue was driven by a 10  increase in volume  slightly offset by a 1  decline in drug prices 
Impacting the bottom line  research and development spending increased 6  to  1 58 billion  while marketing  selling  and administrative expenses were essentially flat at  1 7 billion  Sales growth  cost controls  and share repurchases resulted in Lilly s better than expected earnings  
As for 2020  management now says it expects sales of at least  23 7 billion  up from its prior guidance for  23 6 billion  However  it lowered its EPS outlook from a range of  6 38 to  6 48 to a range of to  6 18 to  6 28 due to costs associated with its  1 1 billion acquisition of Dermira  a biotech company focused on treatments for chronic skin conditions ",2020-01-30,The Motley Fool,https://invst.ly/pp3mf,2072203
170795,392311,LLY,Eli Lilly   Co  LLY  Q4 2019 Earnings Call Transcript,news,"Eli Lilly   Co  NYSE LLY Q4 2019 Earnings CallJan 30  2020  9 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to the Eli Lilly Q4 2019 Earnings Call   Operator Instructions  As a reminder  today s call is being recorded  Now I d like to turn the conference over to your host  Kevin Hern  Please go ahead Kevin Hern    Vice President of Investor RelationsGood morning  Thank you for joining us for Eli Lilly and Company s Q4 2019 earnings call  I m Kevin Hern  Vice President of Investor Relations  Joining me on today s call are Dave Ricks  Lilly s Chairman and CEO  Josh Smiley  Chief Financial Officer  Dr  Dan Skovronsky  Chief Scientific Officer  Anne White  President of Lilly Oncology  Patrik Jonsson  President of Lilly Bio Medicines  and Mike Mason  President of Lilly Diabetes  We re also joined by Kim Macko and Mike Czapar of the Investor Relations team During this conference call  we anticipate making projections and forward looking statements based on our current expectations  Our actual results could differ materially due to a number of factors  including those listed on Slide 3 and those outlined in our latest Forms 10 K  10 Q and any 8 Ks filed with the Securities and Exchange Commission  The information we provide about our products and pipeline is for the benefit of the investment community  It is not intended to be promotional and is not sufficient for prescribing decisions As we transition to our prepared remarks  a reminder that our commentary will focus on non GAAP financial measures  which exclude the financial contribution from Elanco during 2018 and 2019  and present earnings per share as though the full disposition via the exchange offer was complete on January 1  2018 Now I ll turn the call over to Dave for a summary of our Q4 results David A  Ricks    Chairman and Chief Executive OfficerThanks  Kevin  2019 was a solid year for Lilly and our strong Q4 financial results highlight the strength of the underlying business  We exited 2019 with momentum and we ll continue to focus on executing our strategy in 2020  which is to deliver excellent business results  develop and launch new medicines for patients  and drive increased productivity Revenue growth accelerated in Q4  increasing 8  versus Q4 2018 or 9  in constant currency  This strong performance was driven entirely by volume  which contributed 10 percentage points of growth despite continued headwinds from the loss of exclusivity in the US of Cialis and the global withdrawal of Lartruvo  Excluding Cialis and Lartruvo  worldwide volume growth was an impressive 15  Newer medicines continue to be our growth engine  representing 46  of our revenue this quarter  We made good progress in Q4 on our productivity agenda as operating income grew 10  versus last year  We posted strong revenue growth and held marketing  selling and administrative expenses flat versus last year while increasing our investment in R D Our non GAAP operating margin was 26 3   an improvement of 40 basis points versus Q4 2018  We finished 2019 with a full year operating margin slightly below our guidance of approximately 28  as we made targeted strategic investments in Q4 across both our commercial portfolio and pipeline  which will enhance our opportunities for future growth  These investments provide good momentum heading into 2020 and keep us on track to achieve our 31  operating margin target this year We ve announced multiple pipeline milestones since our Q3 earnings call  These include positive results in the remaining two Phase 3 trials of the baricitinib BREEZE AD program in atopic dermatitis  the submission of selpercatinib in the US and Europe  and the FDA granting selpercatinib a Priority Review  the submission of tanezumab for OA pain in the US in collaboration with Pfizer  the submission of higher doses of Trulicity in the US and Europe  and the submission of baricitinib for atopic dermatitis in Europe and Japan During Q4 we put our strong operating cash flow to work  returning approximately  900 million to shareholders via share repurchase and dividend  In addition  as previously announced  we increased our dividend 15  for 2020  This marks the second consecutive year of a 15  dividend increase  reflecting our confidence in the outlook for the business Finally  we recently announced the pending acquisition of Dermira  a company focused on developing new therapies for chronic skin conditions  Dermira has an exciting asset in Phase 3 for atopic dermatitis  lebrikizumab  in addition to a currently marketed product for excessive underarm sweating  QBREXZA  This transaction enhances our Phase 3 pipeline and complements our existing efforts in atopic dermatitis with baricitinib  We look forward to closing that transaction here in Q1 Moving to Slide 5  you ll see the list of key events since our last earnings call  In our continued efforts to help make medicines more affordable and reduce out of pocket cost for patients  we recently announced plans to introduce two additional lower priced insulins  Humalog 75 25 KwikPen and Humalog Junior KwikPen  Both products will be available by mid April and will be offered at a 50  lower list price compared to the branded versions Once these additional options are available  more than 90  of Lilly s Humalog options will be accessible to help patients reduce their out of pocket costs and we hope to see payers provide increased access to patients for these solutions  During the month of December alone Insulin Lispro helped nearly 79 000 patients in the US  These recent additions complement existing offerings in the Lilly Diabetes Solution Center  which currently helps as many of 20 000 patients per month better afford their insulin  As a Company that has been in business for over 140 years and invests over  5 billion per year in long term research and development  we take our responsibility to pursue sustainable business  social and environmental practices very seriously Now I ll turn the call over to Josh to review our Q4 results and to provide an update on our 2020 financial guidance Joshua L  Smiley    Senior Vice President and Chief Financial OfficerThanks  Dave  Slide 6 summarizes our presentation of GAAP results to non GAAP measures and Slide 7 provides a summary of our GAAP results  So looking at the non GAAP measures on Slide 8  you ll see revenue increased 8  or 9  in constant currency  Gross margin as a percent of revenue declined 70 basis points to 79 9   Excluding the impact of FX on international inventories sold  gross margin as a percent of revenue was 79 6  and on the same basis  our gross margin percent decreased by approximately 50 basis points compared to Q4 2018 driven by unfavorable product mix and a negative impact of price on revenue Moving down the P L  operating expenses grew 6  versus last year s quarter  Marketing  selling and administrative expenses were flat as cost containment and productivity measures offset investments in key growth products  R D expenses increased 14   reflecting higher development expenses for late stage assets  including tirzepatide  selpercatinib and mirikizumab  Operating income increased 10  compared to Q4 2018 as sales growth outpaced expense growth  resulting in an operating income as a percent of revenue of 26 3  for the quarter and 27 2  for the full year This quarter s results are indicative of the potential for growth and margin expansion our portfolio of new medicines offers  We are well positioned to drive top tier revenue growth and invest in the next wave of new medicines while driving margin expansion at the same time  We exited 2019 with significant momentum executing our strategy and are on track to achieve our 2020 full year operating margin target of 31  Other income and expense was income of  206 million this quarter compared to income of  31 million in Q4 2018  driven by investment gains on public equities  As we highlighted previously  this line item can be volatile as public market valuations fluctuate  Gains in Q4 were primarily generated by our investments in China biotech companies through our late Lilly Asia Ventures arm and strategic investments in companies focused in newer technologies like RNAi While we appreciate the gains we are even more pleased with the relationships and the potential to develop new medicines for patients that accompany some of these investments Our tax rate was 12 6   a decrease of 300 basis points compared with the same quarter last year  driven primarily by an increase in net discrete tax benefits  including tax benefits from the resolution of US and foreign audits  At the bottom line  net income increased 26  while earnings per share increased 31  due to a reduction in shares outstanding from share repurchases Slide 9 outlines the same non GAAP measures for the full year  While we are excited with our performance in Q4 and the momentum headed into 2020  we re also pleased with our overall performance for the full year in 2019  Last year we experienced the full effect of the Cialis patent expiration and the impact of the withdrawal of Lartruvo  In spite of these headwinds  we grew the top line at 5  in constant currency and generated EPS growth of 11  while investing behind our newer products and pipeline We also generated good shareholder value and established a strong strategic foundation through our split off of Elanco and the acquisition of Loxo Oncology  As we highlighted in December last year  we are well positioned in 2020 to deliver our 5 year financial goals and continue this period of sustained growth Moving to Slide 10  you ll find a reconciliation between reported and non GAAP EPS  Additional details are provided on Slides 26 and 27  On Slide 11 we quantify the effect of price  rate and volume on revenue growth  As mentioned earlier  worldwide revenue grew 9  in constant currency during Q4  driven by strong volume growth of 10   partially offset by price  Foreign exchange had a modest negative impact on revenue growth For the fourth straight year we delivered worldwide revenue growth each quarter despite headwinds from patent expirations  US revenue grew 7  compared with the fourth quarter of 2018  Volume growth of 8  was led by Trulicity  Taltz  Verzenio  Jardiance and Emgality  Excluding Cialis and Lartruvo  volume grew over 15  Pricing was a 1  drag on US revenue growth this quarter impacted by increased funding during the coverage gap in Medicare  unfavorable changes in estimates for rebates and discounts  and disproportionate volume growth in lower net price segments  which was partially offset by the net of modest list price increases and higher rebates as well as reduced reliance on patient assistance programs  primarily due to improved commercial access for Emgality  The full year impact of price was a headwind of 3   consistent with our 2019 and 2020 expectations for US price having a moderate drag on revenue growth Moving to Europe  revenue grew 12  in constant currency driven by impressive 15  volume growth  partially offset by the negative effect of foreign exchange and price  Volume growth was led by Trulicity  Olumiant  Taltz and Verzenio  We re pleased with the uptake of our newer products across Europe and are looking forward to continued strong growth in 2020 In Japan  revenue grew 7  in constant currency driven entirely by volume growth  somewhat offset by a modest pricing headwind due to the government mandated price decreases that went into effect in 2019  Verzenio  Cymbalta  Trulicity and Olumiant were the key contributors to growth  Revenue in the rest of the world increased 14  in constant currency  led by 44  growth in China on the same basis  China growth was driven by strong performance across a number of key products  including Tyvyt  We re excited about the recent launches of Trulicity  Taltz and Olumiant  The same information for our full year revenue is at the bottom of this Slide As shown on Slide 12  our key growth products continue to drive impressive worldwide volume growth  These new medicines delivered nearly 15 percentage points of growth this quarter  continuing the strong trajectory we ve seen throughout 2019  Brands that have experienced loss of exclusivity provided a drag of over 400 basis points driven primarily by Cialis  As a reminder  generic tadalafil entered the US market in September 2018  significantly impacting Cialis revenues  with erosion further accelerating in Q2 2019 as multisource generics entered the market  While the impact of this event is beginning to sunset  it still had a meaningful negative impact on growth in Q4 2019 Slide 13 highlights the contributions of our key growth products  In total  these brands generated over  2 8 billion of revenue this quarter  making up 46  of revenue  Our newest medicines again had impressive results in large and growing therapeutic areas and our ability to reach more patients continues to demonstrate the strength of our commercial execution Within diabetes  the injectable GLP 1 class continues to add new patients despite the entry of a new oral therapy  In the US  total injectable GLP prescriptions grew 29  versus Q4 2018 and Trulicity grew faster than the market  posting an increase of 32  in total prescriptions during the same period  Net pricing in the US for Trulicity declined in the mid single digits  in line with our expectations for Q4 and for 2020  As we discussed on the Q3 call  Trulicity price in Q1 through Q3 of 2019 was impacted by a number of factors that we don t expect to persist in 2020 SGLT2 inhibitors accelerated their trajectory as full US prescriptions for the class grew nearly 20  versus last year s quarter and new therapy starts grew over 46   As the market leader  Jardiance continues to drive strong class growth and accounts for over 55  of total prescriptions  Our sustained market leadership in these two important growing classes within diabetes is a competitive advantage for our diabetes business and positions us well for future growth In immunology  Taltz continues to have strong growth as US total prescriptions grew nearly 40  versus Q4 2018  Despite an increasingly competitive market  Taltz gained over 3 share points in dermatology during 2019 and rheumatology weekly prescriptions have more than doubled during that same time frame  In 2020 we look to build on the strong momentum demonstrated in 2019 and reach even more patients In pain  Emgality continued its US leadership in share of market for new to brand prescriptions at over 47   While pleased with the uptake  we believe there is room for significant additional growth as we expand our commercial presence in primary care  We continue to see progress with roughly 80  of prescriptions reimbursed at the end of Q4  reflecting the strong access of Emgality Within oncology  Verzenio US total prescriptions grew over 46  versus Q4 2018 and the CDK 4 and 6 market is showing encouraging growth as total prescriptions increased by over 16  during the same time frame  Additionally  Cyramza continues to post solid growth as we realized thoracic synergies across our portfolio In addition to the strong performance of our key growth drivers  we look forward to potentially launching three new medicines in 2020 with Reyvow  selpercatinib and ultra rapid lispro  We believe all three new medicines have potential to be first in class or best in class and to improve the lives of patients  In addition  launching new medicines in the therapeutic areas where we have existing commercial infrastructure will support further margin expansion Slide 14 shows the year over year change in select lines of our income statement  Focusing on our non GAAP results  foreign exchange rates had a modest negative impact on revenue  gross margin  operating income and EPS  and a modest net positive impact on operating expenses  On Slide 15 we provide an update on capital allocation  In 2019 we invested over  13 billion to drive our future growth through a combination of business development  capital expenditures and after tax investment in R D  In addition  we returned approximately  7 billion to shareholders via dividends and share repurchases As Dave mentioned earlier  we also announced a 15  dividend increase for the second consecutive year  showing our confidence in the outlook for the Company  We are focused on utilizing the strong cash flow our business generates to develop the next wave of new medicines through both internal and external sources as highlighted by the recently announced acquisition of Dermira  We will remain active in assessing bolt on acquisitions or in licensing where we can create shareholder value and enhance our future growth prospects Turning to our 2020 financial guidance on Slide 16  you will see that we ve updated our non GAAP guidance to reflect the impact of the planned acquisition of Dermira and our recent strong business performance  Specifically  we are increasing our revenue range by  100 million to include QBREXZA and to reflect strong prescription trends we see in the underlying business  updating our SG A guidance to account for the addition of the Dermira sales force and the commercial expenses to support QBREXZA and maintaining all other line items and confirming our non GAAP earnings per share range of  6 70 to  6 80 and operating margin target of 31   On a reported basis  the impact of the Dermira acquisition will have an impact of  0 21 and earnings per share for 2020 is now expected to be in the range of  6 18 to  6 28 We continue to execute our innovation based strategy while leveraging our young commercial portfolio of new medicines to drive margin expansion over the mid term  So now I will turn the call over to Dan to highlight our progress on R D Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerThanks  Josh  Slide 17 shows select pipeline opportunities as of January 27  Positive movement since our last earnings call includes the submission of selpercatinib in the US and Europe  as well as the initiation of Phase 3 trials for selpercatinib in patients with RET fusion positive non small cell lung cancer or RET mutant medullary thyroid cancer  the submission of tanezumab in the US for osteoarthritis pain  the submission of higher doses of Trulicity for type 2 diabetes in the US and Europe  the submission of baricitinib for atopic dermatitis in Europe and Japan  the addition of lebrikizumab for atopic dermatitis to the Phase 3 portfolio  pending the closure of the Dermira acquisition  the initiation of a Phase 3 study of Tirzepatide in obesity  and a Phase 2 study of tirzepatide in NASH  the initiation of Phase 2 for our checkpoint agonist CD200R in immunology  and the initiation of Phase 1 for four assets  as well as the termination of three early stage oncology assets In addition  we had some important early stage readouts including LOXO 305  our novel BTK inhibitor which we highlighted on the 2020 Financial Guidance Call and continues to progress quickly in development  We also had internal data readouts from two Phase 2 trials of Pegilodecakin in combination with immunotherapy agents in patients with non small cell lung cancer  Cyprus 1 in Cyprus 2 Although the full data will be presented at a medical meeting later this year  I can say that both studies were negative  Though we are disappointed in the lack of efficacy for Pegilodecakin in combination with checkpoint inhibition in lung cancer  we remain committed to finding new therapies for people with cancer  Although we are still analyzing the totality of the data that we have obtained with Pegilodecakin  at present we do not anticipate additional trials with this agent Moving to Slide 18  we show a final tally of how we finished 2019 versus the key events we expected to occur  2019 was a very productive year and we made significant progress in bringing new medicines to patients  In total we added four new Phase 3 clinical programs to our pipeline  all with the potential to be first in class or best in class  We reported 12 positive Phase 3 or registrational trial readouts  including a mix of NMEs and new indications or new data for launched products We submitted 12 NMEs or new indications for regulatory review in geographies around the world and we received positive regulatory action on two new medicines  Reyvow and Baqsimi  as well as four important new indications across Trulicity  Taltz  Emgality and Cyramza  We re proud of the significant achievements we made in 2019 and we re focused on discovering and developing more new medicines to help patients as we enter another promising decade Moving to Slide 19  while it s early in the year we ve already made good progress on our 2020 goals  having announced the initiation of additional Phase 3 trials for selpercatinib  positive results in the remaining two trials of the baricitinib BREEZE program for atopic dermatitis  the submission of baricitinib for atopic dermatitis in the EU and Japan  the submission of Tanezumab for osteoarthritis pain in the US in collaboration with Pfizer  FDA approval of Trijardy  a fixed dose combination of empagliflozin  linagliptin and metformin XR  and regulatory approval of Cyramza for first line EGFR positive non small cell lung cancer in Europe Before turning the call back over to Dave  I d like to spend a few minutes providing additional details on important milestones for two clinical programs that I mentioned earlier  the initiation of additional clinical trials for tirzepatide and the completion of the baricitinib BREEZE AD atopic dermatitis program  Beginning with tirzepatide on Slide 20  we previously shared our plans to initiate a cardiovascular outcome study for tirzepatide this year  assessing tirzepatide head to head against the most widely used GLP 1 therapy  i e   Trulicity This is a bold move  It signals both our confidence in the strength of tirzepatide as well as our desire to deliver meaningful data for patients and physicians on how new medicines measure against leading therapies  Through very collaborative discussions with the FDA  we ve gained alignment on the key design features of this unique study called SURPASS CVOT  This trial will include approximately 12 500 patients with type 2 diabetes and confirmed atherosclerotic cardiovascular disease and will measure time to first occurrence of the composite endpoint of CV death  myocardial infarction or stroke This study will assess both non inferiority and superiority of tirzepatide versus Trulicity and we anticipate it will take just over four years to complete  In addition to SURPASS CVOT  we re pleased to share that the Phase 3 type 2 diabetes program SURPASS is progressing extremely well  Investigator interest has been very strong and four of the eight SURPASS clinical trials are already fully enrolled  We look forward to sharing top line results for the first study to readout from the SURPASS program later this year Finally  we re excited that the SURMOUNT Phase 3 obesity program is actively dosing patients and that the SYNERGY Phase 2 program in NASH is currently under way as well  Given the profound weight loss seen in Phase 2 trials of tirzepatide  we re excited about the potential opportunity these additional clinical programs presents to help patients  Together with the ongoing SURPASS studies  these additional studies will expand the current Phase 3 tirzepatide program to over 20 000 patients  We re excited about the breakthrough that tirzepatide represents for patients and we ll continue to invest fully to maximize this opportunity Moving to Slide 21  we recently announced the completion of the final two studies of the BREEZE AD clinical program  BREEZE AD4 and BREEZE AD5  The full BREEZE program was comprised of five studies  assessing baricitinib in both monotherapy and in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis  While not all the data have been up and presented  we re particularly encouraged by the strong results for the 2 milligram dose in the US trial  We believe that the full data package generated from BREEZE AD shows the potential that baricitinib could offer as an additional treatment option for patients with atopic dermatitis where there are limited choices In addition  these data add to the large safety database of baricitinib having over 10 000 patient years of safety data  We recently submitted baricitinib for atopic dermatitis in the EU and Japan and we expect regulatory action late in 2020  We plan to submit in the US later this year  We anticipate that baricitinib will be the first oral JAK inhibitor for the treatment of atopic dermatitis and we look forward to bringing a new treatment option to patients Finally  we recently announced the planned acquisition of Dermira  Pending deal closing  this transaction would add an additional medicine to the Lilly pipeline for moderate to severe atopic dermatitis  that is lebrikizumab which is an injectable antibody targeting IL 13 currently in Phase 3 trials  We view lebrikizumab as highly complementary to our efforts with baricitinib in atopic dermatitis  The unmet medical need here is large and we anticipate physicians and patients will use a range of oral injectable therapies similar to current common practice for the treatment of psoriasis Now I ll turn the call back over to Dave for some closing remarks David A  Ricks    Chairman and Chief Executive OfficerThank you  Dan  Before we go to Q A  let me briefly sum up the progress we ve made in the fourth quarter of 2019 and the full year  We delivered impressive performance in Q4  Our revenue grew 8  as our newest medicines were again the catalyst for volume based growth  Our worldwide prescription trends are strong and we are well positioned entering 2020 to continue our positive trajectory and deliver our 2020 financial guidance We advanced our productivity agenda  controlling operating expenses while investing behind key commercial growth drivers and our late stage pipeline  We grew sales in Q4 while keeping marketing  selling and administrative expenses flat versus Q4  18  demonstrating our ability to drive margin expansion We made important pipeline progress in Q4  capping a year that featured significant new additions to the Phase 3 portfolio  several positive readouts in Phase 2 trials and a multitude of regulatory submissions and approvals  Finally  we returned nearly  600 million to shareholders via the dividend and completed  300 million of share repurchases as well As we shared during our 2020 Financial Guidance Call last December  we are in the early stages of a period of sustained growth at Lilly  The balance of new medicines we plan to launch over the next five years and the continued scaling of our newer medicines compared to our limited patent exposure sets up an exciting period ahead  We are pursuing new medicines in some of the most important diseases with both significant unmet medical need and sizable business opportunities  We are pleased with our finish to 2019 and our position of strength as we enter 2020 and the next decade of this Company s history  This concludes our prepared remarks and now I ll turn the call over to Kevin to moderate the Q A Questions and Answers Kevin Hern    Vice President of Investor RelationsThanks  Dave  We d like to take questions from as many callers as possible  so we ask that you limit your questions to two per caller  Sean  please provide the instructions for the Q A session and then we re ready for the first caller OperatorThank you   Operator Instructions  Geoff Meacham  Phonetic  from Bank of America Merrill Lynch Geoff Meacham    Bank of America Merrill Lynch    AnalystGood morning  guys  thanks for the question  Just one on Taltz and one on the Olumiant filing in AD  so for Taltz the growth has been solid  but what would you say  it could be a demand tipping point looking into 2020 and beyond  Is it new contracts and agreements  is it a broader indication base  do you have to invest more commercially  And then on the Olumiant filing in AD  I wasn t sure if the effect of the 4 meg dose changes the regulatory conversation in the US    the like that you ve had in the RA indication since approval obviously was mostly focused on the 2 meg indication or the 2 meg approval  but I wasn t sure if that changes at all on the back of this new data  Thank you David A  Ricks    Chairman and Chief Executive OfficerThanks  Geoff  We will go to Patrik for both of those questions Patrik Jonsson    Senior Vice President and President  Lilly Bio MedicinesThank you very much  We are very pleased with the performance of Taltz in the fourth quarter last year with the growth of total Rx with    we have approximately 40   If we look at the different spaces  first of all  dermatology despite increased competition  we think we are holding ground very nicely and we are maintaining our total Rx share of market in Q4 despite the increased competition  Also added to the body of evidence  we had head to head data  Indecipherable  IL 23 where we again demonstrated superiority on the skin clearance and that s the third study combined with STELARA where we have again demonstrated superiority  So we have confidence in continued growth space of dermatology The biggest opportunity for us remains being in rheumatology where we in Q4 announced the only IL 17 to demonstrate superiority versus  Indecipherable  head to head study and we saw some significant acceleration in Q4 in terms of new to brand and we are confident that we will continue to grow in the rheumatology space where there are lot of opportunities for us We also filed during the second half of the last year the non radiographic AxSpA and that s an indication where we also see a lot of patients that are not being appropriately diagnosed and even if diagnosed not appropriately treated  Lastly  both in dermatology and rheumatology  a huge amount of patients are still treated with anti TNF alphas  in dermatology 40  and in rheumatology 70   and we believe that remains the biggest opportunity for all new assets to ensure that patients are being upgraded to new  modern  more efficacious and safer treatments In terms of Olumiant  well  we don t comment on regulatory actions for specific brands  We continue to explore options to get the 4 milligram dosage approved in the US  However  in light of most recent regulatory actions with other JAK inhibitors  we are also realistic in terms of our expectations to get 4 milligram approved in the US in the near term  But  as Dave mentioned  we are very much encountered by the 2 milligram data of Olumiant in atopic dermatitis and where we are demonstrating    hitting our primary objective in both in terms of at least 75  improvement on skin inflammation  but also in terms of patient reported outcomes improvements on itching  So that is encouraging for us in terms of the Olumiant submission in the US Kevin Hern    Vice President of Investor RelationsThanks  Patrik  Geoff  thanks for your questions  Next caller  please OperatorThank you  Chris Schott from JPMorgan Chris Schott    JPMorgan    AnalystGreat  thanks very much  First question was just on the quarterly progression of sales and earnings as we go through 2020  I think last year we saw a depressed first quarter sales relative to the rest of the year that surprised the Street a bit  Should we expect a similar gating of sales in 2020 and are there any particular products we should be watching where I guess 2020 kind of resets its plans could impact those first quarter results My second question was just on the Alzheimer s strategy more broadly  How would the approval or I guess the nod of etokimab impact how you re thinking about your pending Alzheimer s readouts and development strategies from here  Thanks very much David A  Ricks    Chairman and Chief Executive OfficerThanks  Chris  We ll go to Josh for the first question and Dan for the second one Joshua L  Smiley    Senior Vice President and Chief Financial OfficerThanks  Chris  If we look at 2020  we don t provide quarterly guidance  but if we look at sort of the trajectory of sales that we d expect  if you look at our guidance for the full year  we re in somewhere in the high single digits for sales growth  We d expect that kind of growth to be pretty consistent through the year  Although  keep in mind  in Q1 we still will have a little bit more of the overhang from things like Cialis  so you might expect to see a little bit more Cialis growth through the year  but pretty consistent On an absolute basis though  Chris  we do always see sales in Q1 lower than Q4  A lot of that just has to do with shipping patterns and otherwise  So  again  growth should look good in Q1 relative to the year  absolute sales will be less  I think that s a trend that you see  I m sure  across almost all companies  There s nothing unique going on there other than normal shipping patterns between Q4 and Q1 Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerChris  thanks for your question on Alzheimer s strategy  Of course  we  like many others  will be watching etokimab closely and of course we ll adapt our plans and thinking to meet wherever we see the regulatory bar placed  But I don t think you should expect us to pivot in our Alzheimer s strategy one way or another  We have placed some pretty important bets  We re excited to see those readouts over time both with solanezumab  but also our own plaque clearing antibody donanemab as well as our tau anti tau antibody that s in Phase 2  We also have a tau small molecule in Phase 1 and other agents earlier in development  So we ll continue to progress those  We think we have smartly designed trials that will give us important readouts over time Kevin Hern    Vice President of Investor RelationsThanks  Dan  Chris  thanks for your questions  Next caller  please OperatorThank you  Louise Chen from Cantor  Please go ahead Louise Chen    Cantor Fitzgerald    AnalystHi  thanks for taking my questions here  So first question I have for you is  can you provide more color on what might be driving your stronger volume growth when compared to other companies out there in this space and if this is durable over the longer term  And then my second question for you is  with this growing competition in atopic dermatitis  where do you see Lilly fitting into the evolving treatment paradigm  Thank you David A  Ricks    Chairman and Chief Executive OfficerThank you  So we ll go to Josh for the first question and Patrik for the second Joshua L  Smiley    Senior Vice President and Chief Financial OfficerThanks  Louise  Good morning  I think in terms of volume growth  what we see at a corporate level is a function of our portfolio  As we mentioned  about a little bit less than half of our sales are coming from new products that we ve launched since 2014  10 of those  They re all still in    very much in their growth phases  Trulicity growing at 31  for example  Taltz at 37  So we ve got a relatively young portfolio  We expect the volume gains that we saw in Q4 to be sustainable between 2020 and 2025 as we mentioned on our guidance call  We expect to see top tier revenue growth over that period  It ll be driven by volume gains  it ll be driven by that cohort of products  as well as the new launches that will expect over this period  including the three that we re planning for this year  You couple that going forward with last generic exposure  then probably most of the companies that we compete against or that you cover and I think that would certainly say to us that the volume gains we re seeing or something that we re planning for and think are sustainable Kevin Hern    Vice President of Investor RelationsThanks  Josh  Patrik Patrik Jonsson    Senior Vice President and President  Lilly Bio MedicinesWell  currently it s estimated that approximately 18 million Americans are suffering from atopic dermatitis and 10 million of those are suffering from severe to moderate atopic dermatitis and the treatment opportunities are very limited  One is saying that they feel atopic dermatitis is pretty much where psoriasis was 15 years ago And in the light of that we believe that we are extremely well positioned  As we shared  we are encouraged with the most recent data on Olumiant  both in the US and outside the US  and we have submitted Olumiant for approval in Japan and EU and we ll take regulatory actions in 2020 here in the US and we believe that Olumiant could definitely be an option for patients that are having fear of injection And we re also excited about the announcement we made a few weeks ago about our intent to acquire Dermira  and lebrikizumab is the big driver of that deal and we see lebrikizumab based upon its Phase 2b data as the medicine that will at least be competitive with Dupixent and we have an opportunity given the best in class differentiating on each So overall we believe that we can play a very important role in the field of atopic dermatitis  We built the first oral JAK inhibitor for patients of fear of injections and the potential best in class medicine in lebrikizumab Kevin Hern    Vice President of Investor RelationsThanks  Patrik  Louise  thanks for your questions  Next caller  please OperatorThank you  Tim Anderson from Wolfe Research  I apologize  Umer Raffat from Evercore ISI Umer Raffat    Evercore ISI    AnalystHi  thanks so much for taking my two questions  and both of them are Kevin s favorite topic  So the first one is on CNS penetrance of your GLP 1 and I have two parts on the first one  So there s feedback out there that Trulicity doesn t cross blood brain barrier very much  perhaps in part because of its size  A  can you comment on that  and in that same question I also want to ask  tirzepatide does not have an IGG  So presumably  it should have good CNS penetration  I just want to make sure I hear your take on the CNS penetrant of both Trulicity and tirzepatide Secondly  Dave perhaps for you  so the A4 trial in asymptomatic Alzheimer s  my understanding is it was fully enrolled in December 2017 and at this point it s already past two years in every single patient and by end of 2020 you would have hit a three year landmark in every single patient  So my question is  strategically thinking if regulators are being more accommodating of late  wouldn t it make strategic sense to possibly consider taking an efficacy read at three years  because even at three years it s 2 times the duration of all prior sola and aducanumab trials  Thank you very much Kevin Hern    Vice President of Investor RelationsThanks  Umer  for those questions  This is    Butler Bulldogs basketball is probably my favorite topic  but we don t cover that on the call  this is a close second though  We ll go to Dan for both of these Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerOkay  great  Thanks very much  So with respect to CNS penetration of GLP 1s  you re right that these are large molecular weight molecules  Actually both FC fusion molecules like Trulicity and also isolated peptides like tirzepatide  Those modifications to the peptides are what gives them the long half life that enables once weekly injection and molecules of that size typically don t penetrate the blood brain barrier Having said that  we don t see those attributes  blood brain barrier penetration as being important for the efficacy of this class of drugs as evidenced I think by the tremendous efficacy that we ve seen with Trulicity and unprecedented efficacy that we ve seen with tirzepatide  so I think that addresses that With respect to A4  you re right that this is a longer duration trial and really I think any other large Alzheimer s trial has ever been  The reason for that though is because these patients are asymptomatic at the beginning of the trial  so they are very early in the disease course and it takes a great deal of time to let these patients progress in their disease course and it s only through progression of patients on the placebo group and hopefully differential  less progression of patients on therapy that we could hope to see an effective drug  So that s why the design includes such a long follow up period Kevin Hern    Vice President of Investor RelationsThanks Dan  Umer  thanks for your questions and we ll go to the next caller please OperatorThank you  Tim Anderson from Wolfe Research Tim Anderson    Wolfe Research    AnalystHi  a question on your PD 1 with an event and really plans for that product outside the US  It seems like last summer when I talked to management it was really described as the China only opportunity with limited potential  but it seems that you may have pivoted in recent months and may have bigger plans to bring them in to other geographies  so I m hoping you can give us your latest thinking And then second question is just on the Dian Tu Alzheimer s trial  confirming that we should see those results really any time  can you confirm that  And then just how do you view odds of success  It kind of seems to me that it s highly improbable that this will yield positive results for solo  but what are your views  Thank you Kevin Hern    Vice President of Investor RelationsThanks  Tim  We ll go to Anne for the first question and Dan for the second Anne E  White    Senior Vice President and President  Lilly OncologyWell Tim  thanks for the question on Tyvyt and our Innovent collaboration  So as you said  our current focus is on development and commercialization of Tyvyt in China  However  Innovent has been really important and terrific strategic partner to us  And so we re always open to discussing opportunities to expand that for mutual benefit  There s really not more we can say at this time  We re really pleased I think as Josh and Dave mentioned  the performance of Tyvyt in China  it s been a remarkable story and really now as you know the only PD 1 that s included on the NRDL list and I think that demonstrates how the NHSA has recognized its clinical value and then we were able to share the great news that we had the first line non squamous read out at interim that s positive  so we ll be planning to submit that this year and we expect additional readout in first and second line squamous this year with Innovent  So it s been a great product and we look forward to what more we can do here  But thanks for the question Kevin Hern    Vice President of Investor RelationsThanks  Anne  Dan Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerYeah  Tim  on DIAN  just reminded for everyone that this is dominantly inherited type of Alzheimer s  It s rare and sort of severe and fast progressing form of Alzheimer s disease where we testing solanezumab  Your question on timing of results  we don t have the data yet  but we do expect that this quarter In terms of the odds of success  I think it s hard to speculate  but as you know this is a very small trial  small population is being studied and it is as I said a severe form of Alzheimer s  So those factors weigh against it  there is other factors that weight for it  We know that it s driven by mutations here and amyloid over production and has a relatively longer follow up  but we ll just have to wait and see that data Kevin Hern    Vice President of Investor RelationsThanks  Dan  Tim  thanks for your questions  Next caller  please OperatorThank you  Andrew Baum from Citi Andrew Baum    Citi    AnalystThank you  A couple of questions   Technical Issues Kevin Hern    Vice President of Investor RelationsAndrew  this is Kevin  Andrew  we are really having trouble hearing you and can t really pick up the question  other than we heard tirzepatide Andrew Baum    Citi    AnalystIs that any better Kevin Hern    Vice President of Investor RelationsNo  not much  we ll try it Andrew Baum    Citi    AnalystMy question is on tirzepatide  talking about your outcome trail  You are running a head to head trail versus Ozempic  which you described as a high bar  There is some literature on potentially GIP agonism could potentially be increased in cardiovascular rather than decreasing it  given its evidence is a marker for heightened cardiovascular disease as well as some preclinical data Perhaps you can talk to your thoughts on the relevant development literature and then second more broadly we d like to think that Lilly is perhaps second in place than many of your pears in understanding the direction of this particular administration in terms of healthcare reforms There has been some discussions about whether the IPI proposal could be expanded to include Medicare part D drugs rather than just part B  Perhaps you could share your thoughts on what you expect in that direction  Apologies for the long question Kevin Hern    Vice President of Investor RelationsThanks  Andrew  We ll got to Dan for the question on tirzepatide and then Dave on the policy question Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerYeah  thanks  First of all  just a clarification that tirzepatide trial just head to head against Trulicity  Look I think that there is a little bit of literature out there as you referenced about    it s actually GIP 1 but our thinking is really based on the clinical data that we ve already obtained with tirzepatide in the Phase 2 trials I think everything we see in those trials point to a large cardiovascular benefit for a drug like this  and so that s the driver  that s what gives us confidence is the real clinical data with this molecule  The combination of GLP 1 and GLP 1 gives certain effects which we are able to see  So for example the improved day 1 C control and notably the very dramatic improvement on weight loss  which I think will drive cardiovascular benefits even higher than we saw in Trulicity Kevin Hern    Vice President of Investor RelationsThanks  Dan  Dave David A  Ricks    Chairman and Chief Executive OfficerSo on the policy front  we continue to advocate for change in the US system because although we re in a    as an industry and certainly as Lilly a deflationary price environment those savings are not reaching consumers at the pharmacy counter  And so either through a combination of passing through a transparency of those discounts or insurance reform  we re for change  And our focus is primarily right now with the legislative pathway on both those fronts  There is one more vehicle probably left in this Congress to work on those  but progress is difficult in Congress  So we continue to advocate for change on the  Indecipherable  though As it relates to IPI  this proposal was part of the blueprint in spring of  18  It s been sitting out there for a while  We ve yet to see any draft guidance for proposed rulemaking or any version of this in detail  There is always a lot of swirling rumors about it  including expanding it to other parts of government programs or changes to it in terms of the objectives We see it largely as misguided  primarily because in Part B patients hardly have any cost sharing to begin with  So if we re worried about out of pocket costs for patients  IPI will do very little  it s mostly just a punitive measure against the industry going back to decisions made on European pricing sometimes decades ago  It won t probably change those prices in Europe if that s the present goal  and it certainly won t change the affordability equation for patients in the US  So we oppose it for those reasons That said  it s administrative potential action and want to read it if it comes out and decide what to do from there  but it pretty much is a difficult thing to support for our industry and you ll probably see pharma universally oppose it  So we ll wait and see Kevin Hern    Vice President of Investor RelationsThanks  Dave  Andrew  thanks for your questions  Next caller  please OperatorSeamus Fernandez from Guggenheim Seamus Fernandez    Guggenheim    AnalystThanks for the question  So maybe that the first question is really for Josh  Josh  can you just help us understand the progression of margins as we move through the balance of next year  or sorry this year in 2020 When I look at the original guidance from this year  I think you guys had said 28  was the target  I think ultimately we ended up at 27 2  at the final point in the year  But on the guidance call in December  you stated and reiterated the 31  target  Can you just help us understand the past to that 31  just because the second half of this year I think kind of came in below investors  expectations to some degree  and we re just trying to understand a little bit better the very strong move in margins going higher  Obviously  the pieces of guidance makes sense  I think we re just trying to understand the path as we move through the balance of the year And then the second question  the pegilodecakin update  thanks for that  Appreciate the understanding and the challenges  Can maybe    Jay can just sort of update us on his thoughts and also Dan  could update us on your thoughts for the growth of the oncology development portfolio and directionally where you re headed  Thanks OperatorJosh  and then Dan Joshua L  Smiley    Senior Vice President and Chief Financial OfficerGreat  Thanks  Seamus  In terms of margin this year  again we reiterated that we are on track for 31   And the one thing that we have said is Q1 will likely be below 31  that s mostly a function of the less absolute sales that I talked about on a prior question  on top of a relatively fixed opex absolute amount So I think as you look or model opex for the year  we see that it s pretty constant on an absolute base quarter over quarter  Of course some small variation  and then you ll see absolute sales dollars on a quarter over quarter basis grow  So we don t expect to be at 31  in Q1  but that s    again that the function of the dynamics of the growth through the quarters Remember though in terms of how to get there in totals for the year  we said for 2019 that we would grow our R D at a unusual growth rate in 2019 as we scale up programs like tirzepatide and Mirikizumab  In 2020 those programs are running at more like full speed  We are able to bring and a an asset like Dermira and keep that with relatively smaller growth rate and R D So I think we are confident that the sales growth that we are seeing that we talked about in Q4 should persist for the year on top of a slower growing opex that we can predict and manage  will get us to 31  and again I wouldn t be too concerned in Q1 if we are not at that level  but you should expect it as we move through the year Kevin Hern    Vice President of Investor RelationsThanks  Josh  Dan Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerThanks for the question on oncology strategy  Of course on the last call we talked about our Loxo Oncology at Lilly and how that s changed oncology strategy and we re quite pleased with the progress that we made on executing against that strategy  You can see some portfolio changes in our pipeline update and we also talked about the three key early stage programs  305  KRAS and SERD  all of which are progressing in the clinic While we said we re going to focus on a lot of our resources on high probability  biology that s well understood  bets like those  we will also from time to time continue to pursue more novel biology  higher risk  high reward bets like Pegilodecakin was and that will be a smaller part of our portfolio in the future Kevin Hern    Vice President of Investor RelationsThanks  Dan  Seamus  thanks for your question  Next caller  please OperatorDavid Risinger from Morgan Stanley David Risinger    Morgan Stanley    AnalystThanks very much  I have two questions  first just going back to the high level on GLP 1s and Alzheimer s  Novo has recently conveyed enthusiasm about the potential for GLP 1 treatment in Alzheimer s  Could you just comment on your view of whether GLP 1 treatment over a few years can actually change the progression of Alzheimer s  And then second with respect to high dose Trulicity  could you please frame what we should focus on when we see the Phase 3 data and your planned positioning of that product  Thank you OperatorThanks  Dave  We ll go to Dan for the first question and then Mike for the second one Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerThanks  Of course we are aware of the comments that Novo has make on GLP 1 and Alzheimer s disease and the potential there  Look forward to seeing data from that first trial  Look I think we know that GLP 1 treatment has beneficial cardiovascular outcomes  including we ve seen reductions on stroke  probably that s a tip of the iceberg and there s other micro infarcts that are decreased by GLP 1 therapy  That could over time contribute to a slower rate of cognitive decline  Is there a direct effective of GLP 1s on Alzheimer s pathology  I think that s not yet known So we ll watch how the field evolves  If it turns out that there are great opportunities  I think we have the best in class incretin in the form of tirzepatide and we d be opened to future opportunities for it OperatorThanks  Dan  Mike Mike Mason    Senior Vice President and President  Lilly DiabetesDavid  thanks for your question on our favorite subject  It proves we had another great quarter  growing by 32  on volume and 29  on revenue  We are still quite excited about the overall GLP market growth  The 52 week rate was at 29 7  while the monthly rate in December was at 31 5   So the market continues to grow and Trulicity continues to hold up in a very strong market share leadership position outpacing TRS class growth in the face of some of GLP type product launches So we expect that both the new Trulicity rewind  as well as the high dose label enhancements will continue to drive class growth as well as solidify our market leadership position place  So we re excited about that  I think as you take a look at the results of that  take a look at increased our A1C results  as well as the weight loss results And what we think is the strength of Trulicity is the fact that you get real world benefits by having powerful efficacy simply delivered and this will just give people using Trulicity another reason to stay on it Kevin Hern    Vice President of Investor RelationsThanks  Mike  David  thanks for your question  Next caller  please OperatorTerence Flynn from Goldman Sachs Terence Flynn    Goldman Sachs    AnalystGreat  good morning and thanks for taking the questions  The first one is on tirzepatide and the CVOT trial  I was wondering if you can share any more details on the stats or powering assumptions there  as well as the discontinuation rate that you re assuming in the arms of the trial And then for Emgality you mentioned  looking into the next phase of growth here in the primary care market  what are some of the markers beyond obviously sales that we should look to in terms of gauging successful uptake there and then any thoughts on potential impact from oral CGRP  Thank you Kevin Hern    Vice President of Investor RelationsOkay  thanks  We ll go to Dan for tirzepatide and then Mike and then Patrik for the oral CGRP question Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerYeah  thanks for your question asking for more detail on the tirzepatide SURPASS CVOT trial design  I think at this moment we don t sort of comment on any of the finer details around clinical trial design and dropout rates  But I would say that having a trial like this where it s a head to head with two great active drugs  one on each arm should be a very compelling opportunity for enrolling physicians and a great opportunity for treatment for patients as well  So I think those kinds of factors should help with both enrollment and retention in the trial Kevin Hern    Vice President of Investor RelationsGo ahead  Mike Mike Mason    Senior Vice President and President  Lilly DiabetesI think as we look at the opportunity and really learn from what providers and payers want  they want active competitors  I think this provides a lot of value and lot of insights into the incremental value of one product over another product  And so obviously doing a head to head trial versus Trulicity is a bold bat  but I think it really reinforces the confidence we have in tirzepatide in its population  So we re very excited about the study  It is a bold bat  but one that we are very excited about the potential of this product and CVOT Kevin Hern    Vice President of Investor RelationsThanks  Patrik Patrik Jonsson    Senior Vice President and President  Lilly Bio MedicinesThank you  If you look at on the prevention market with currency 6 million patients eligible for prevention treatment in the US  but only 3 million of those are being treated  So that s a big opportunity for us with increased competition in the market place as well to drive patient activation  And specifically for Emgality  if you look from the prescriber base today  it s relatively limited and only 15  of our targets are currently  regularly prescribing Emgality  so that s where we see a tremendous opportunity both in specialty care  as well as in primary care In terms of the oral CGRP  I think it s important to have in mind that they are only approved or will be approved for the treatment of acute migraine this year and the prevention indication is coming later on  We are very confident with the profile of Emgality  particularly taking into account that we are now the market leader and the preferred CGRP in the marketplace and particularly with a differentiation  we have been labeled with both efficacy of 50 75 and 100  level and also the convenience that the device offers from the same device platform as Trulicity The oral CGRPs will be competing in that huge space and we are also very excited about the announcement that was the pre publication notice from the DEA that was publicly displayed this morning and will result in an announcement in the Federal Register tomorrow  enabling us to bring Reyvow to the marketplace  probably late next week  And that s where we have a tremendous opportunity to bring more value in the space of acute migraine and for the first time we ll be able to talk about complete pain elimination already after two hours with one single dose of Reyvow and not just compete pain elimination  but also complete elimination of bothersome symptoms such as sun phobia  light sensitivity and nausea So we believe that we have very well positioned us in the preventive space as well as the acute phase but patient activation will be key and that s something that would be beneficial with also new entrants in the marketplace Kevin Hern    Vice President of Investor RelationsThank you  Patrik  Terence  thanks for your questions  Next caller  please OperatorSteve Scala from Cowen Steve Scala    Cowen    AnalystThank you  I have a couple of questions  I ll take the other side of an earlier question and suggest it would be surprising if DIAN TU didn t hit it endpoint given the signal you saw in the expedition trials and the fact that DIAN TU is testing a higher dose in a more homogeneous population for a longer time with the tailor made endpoint So Dan  I m trying to understand your pessimism and maybe you could please tell us on which of the points that I stated you disagree  And then there are four components to the primary endpoint  Do you need to hit all four to achieve success  Thank you Kevin Hern    Vice President of Investor RelationsThanks  Steve  Dan Daniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerOkay  Steve  So look most of the commons you said are right  The importance of those factors in the outcome of the study is what we don t know  and there are other factors as I said earlier going against us here  The one that should give anyone the most pause I think is the small sample size and Alzheimer s trials are    I think even in large trials notorious for surprising us because of the heterogeneity of the fact and variability in the outcome measures  So it s factors like that that could make it difficult to really know what is true Look I still think it s regardless an interesting scientific question  a partner experiment we ll look forward to seeing the data  With respect to the specifics around the composite  I think the nature of a composite is that you have to hit the overall composite score as the primary endpoint  which could be driven by the various sub measures or not  but as you point out this was custom made for this trial Kevin Hern    Vice President of Investor RelationsThanks  Dan  Steve  thank for your questions  Next caller  please OperatorNavin Jacob from UBS Navin Jacob    UBS    AnalystThanks for taking the questions  Just on Verzenio  Pfizer has slightly delayed its IBRANCE adjuvant trial PALLAS to early 2021  Wondering    and they highlight the event rate progressing much slower  Wondering how relative to your expectations the event rate has been progressing and MONARCH  And is the time line still for an early 2021 readout  and any color on the potential for an interim would be appreciated  That s on Verzenio And then just on Humalog  I think your press release suggested that pricing in the US benefit from a better segment mix  Is that because of the volume shift to the Humalog authorized generic and that s assuming that the authorized generic is being recorded within the Humalog revenue line  I just wanted any    if you can provide any clarity on that  Thank you so much Kevin Hern    Vice President of Investor RelationsGreat  thank you  We ll go to Anne for the question on Verzenio and Mike for the question on Humalog Anne E  White    Senior Vice President and President  Lilly OncologyNavin  thanks for the question on Verzenio  So as you know we have not disclosed any interim analysis  Now this is an event driven trial similar to PALLAS  but our estimates make us quite confident that we are looking at a readout in the first half of 2021  So we continue to expect that and as you know the trial unrolled remarkably well and so we re able to roll ahead of schedule  which helps obviously drive  Indecipherable  rates for that And again we specifically designed this trial with a high risk population and that was both a strategy of where we believe that Verzenio would really differentiate  but as well it drove the speed of the trial  So again we feel quite confident in that As you know the positive MONARCH 2 overall trial results  particularly as we saw those with primary resistance and visceral disease  really an eight month survival benefit in the patients with visceral disease really reinforce our confidence and the potential  the success of MONARCH  So we designed it with that high risk population and really used what we think are thoughtful selection factors the physicians use today to make prescribing decisions in that adjuvant setting  So things like the number of nodes involved  the tumor size and the measure of proliferation  And so we feel quite confident in the design of the study and again look forward to the readout in 2021 Kevin Hern    Vice President of Investor RelationsThanks  Anne  Mike Mike Mason    Senior Vice President and President  Lilly DiabetesThanks for your question on Humalog  The biggest drive in Humalog segment mix is the fact that with Humalog uptake they are taking volume away from Humalog in Medicaid since our Medicaid rebate rates are essentially 100   that TRx decline actually doesn t have    had a flat to positive impact on net revenues for Humalog Navin Jacob    UBS    AnalystAnd just to confirm the AG products are consolidated into the Humalog Kevin Hern    Vice President of Investor RelationsThanks  Mike  Navin  thanks for your questions  We ll go to Dave for the close David A  Ricks    Chairman and Chief Executive OfficerOkay  thank you all  I appreciate the participation in today s earnings call and your interest in Eli Lilly and Company  2019 was a strong year for the Company and we anticipate another great year in 2020  We remain focused on executing our innovation based strategy to bring new medicines to patients and create value for our shareholders  With our strong commercial portfolio complemented by our pipeline of exciting opportunities  Lilly continues to be a compelling investment Thanks again for dialing in  Please follow up with our Investor Relations team if you have any additional questions we weren t able to address on today s call  Hope you have a great day OperatorThank you  Ladies and gentlemen  this conference is available for replay after 11 15 today through January 30  2021  You may access the AT T teleconference replay system at any time by dialing 1 800 475 6701 and entering the access code of 2544079  Those numbers again are 1 800 475 6701 and internationally 320 365 3844 with an access code of 2544079  That does conclude our conference for today  Thank you for your participation  and for using AT T Executive Teleconference  You may now disconnect Duration  68 minutesCall participants Kevin Hern    Vice President of Investor RelationsDavid A  Ricks    Chairman and Chief Executive OfficerJoshua L  Smiley    Senior Vice President and Chief Financial OfficerDaniel M  Skovronsky    Senior Vice President and Chief Scientific OfficerPatrik Jonsson    Senior Vice President and President  Lilly Bio MedicinesAnne E  White    Senior Vice President and President  Lilly OncologyMike Mason    Senior Vice President and President  Lilly DiabetesGeoff Meacham    Bank of America Merrill Lynch    AnalystChris Schott    JPMorgan    AnalystLouise Chen    Cantor Fitzgerald    AnalystUmer Raffat    Evercore ISI    AnalystTim Anderson    Wolfe Research    AnalystAndrew Baum    Citi    AnalystSeamus Fernandez    Guggenheim    AnalystDavid Risinger    Morgan Stanley    AnalystTerence Flynn    Goldman Sachs    AnalystSteve Scala    Cowen    AnalystNavin Jacob    UBS    Analyst
More LLY analysis
All earnings call transcripts",2020-01-30,The Motley Fool,https://invst.ly/pp7ce,2072547
170796,392312,LLY,Lilly launches migraine med Reyvow,news,"Eli Lilly  LLY  1 7   announces that Reyvow  lasmiditan  C V 50 mg and 100 mg tablets  indicated for the acute treatment of migraine with or without aura  is now available for prescription and will be available in U S  pharmacies in the next several days 
Lasmiditan is an orally available 5 HT1F receptor agonist that blocks pain transmission without the side effects of the class of migraine therapies called triptans  The 5 HT1F receptor is a serotonin subtype that lacks the vasoconstrictive properties of other serotonin receptors which can cause adverse cardiac events in patients with cardiovascular or cerebrovascular disease 
The FDA approved the medicine in October 2019  The time lag before launch was due to a DEA review of the drug s classification ",2020-01-31,Seeking Alpha,https://invst.ly/ppi1r,2073116
170800,392316,LLY,Eli Lilly Launches a New Migraine Drug,news,"Eli Lilly  NYSE LLY  launched its new pill for the acute treatment of migraines Friday after the Drug Enforcement Administration  completed its review of the drug and classified it as having a low potential for abuse or dependence  Reyvow is the first drug of a new class  and treats not only pain  but sensitivity to light  sensitivity to sound  and nausea  It s the first new type of acute migraine drug to come to market in more than two decades 
Reyvow was approved by the Food and Drug Administration in October  but a DEA review was required because it acts on the central nervous system  Now that it has received a favorable decision on the scheduling of the drug  Lilly said it will be available for prescription immediately and will be in pharmacies in the next few days 

The new migraine drug joins Emgality in Lilly s portfolio  the company s relatively new monthly injection for the prevention of migraines  Sales of Emgality have been ramping up quickly    it  generated  66 million in revenue in the fourth quarter  Lilly thinks it ll be able to leverage the infrastructure and experience from the Emgality launch to strengthen its position with Reyvow 
However  Reyvow has some  will additional competition  Allergan  NYSE AGN   which is seeking to merge with AbbVie  NYSE ABBV   received approval in December for UBRELVY  an oral acute treatment of migraines that s in the same drug class as Emgality  and it is available to patients  
Editor s note  This article has been corrected  UBRELVY is available for prescription ",2020-01-31,The Motley Fool,https://invst.ly/ppmmn,2073562
170827,392343,LLY,FDA OKs Trijardy for patients with type 2 diabetes  Eli Lilly says,news,"Eli Lilly  NYSE LLY  says the Food and Drug  Administration approved its Trijardy XR tablet to help lower blood sugar in adults with  type 2 diabetes 
Lilly says Trijardy combines three medicines   Jardiance  empagliflozin   Tradjenta  linagliptin  and metformin hydrochloride  extended release   in one pill  which will be a once a day medication 
The FDA approval was based on two randomized open label  trials that assessed the bioequivalence of empagliflozin  linagliptin  and metformin hydrochloride extended release fixed dose combination  tablets and their individual components in healthy adults ",2020-01-27,Seeking Alpha,https://invst.ly/pnm0c,2068947
170828,392344,LLY,FDA Approves Eli Lilly s and Boehringer Ingelheim Pharmaceuticals  Triple Combination Diabetes Drug Trijardy XR,news,"On Monday  the Food and Drug Administration approved Trijardy XR  a combination treatment that contains three drugs already approved for type 2 diabetes  Jardiance  Tradjenta  and the generic drug metformin 
Eli Lilly  NYSE LLY  and its partner  Germany based Boehringer Ingelheim Pharmaceuticals  will market the drug  as they do Jardiance and Tradjenta  The companies formed a strategic alliance in 2011 that brought their diabetes pipelines together 
Boehringer Ingelheim arguably brought more to the deal    it owned both Jardiance and Tradjenta    while Eli Lilly initially made an upfront payment to its new ally to even out the alliance 

On the surface  Trijardy XR is simply designed for convenience since the healthcare companies aren t making any claims about how well the triple combination works  The FDA approval was based on two clinical trials that showed the single pill produced an equivalent effect to taking the three individual pills for healthy volunteers 
But both Jardiance  which is an SGLT2 inhibitor  and Tradjenta  which inhibits DPP 4  are in competitive drug classes    multiple other treatments use the same mechanisms of action  Merck  for instance  sells SGLT2 inhibitor Steglatro and DPP 4 inhibitor Januvia  AstraZeneca markets SGLT2 inhibitor Farxiga and DPP 4 inhibitor Onglyza 
This triple combination pill could help keep competition at bay and encourage diabetes patients to stay in the Eli Lilly Boehringer Ingelheim family when their doctors want to add drugs in additional classes to their regimens  In fact  the companies already sell pills that pair each of the available double combinations    Synjardy  Jardiance and metformin   Glyxambi  Jardiance and Tradjenta   and Jentadueto  Tradjenta and metformin     facilitating the progression from a single drug to two drugs  and eventually to Trijardy XR ",2020-01-28,The Motley Fool,https://invst.ly/pnxzq,2069479
170830,392346,LLY,FDA Reviewing Eli Lilly s Cancer Drug Candidate Selpercatinib,news,"The Food and Drug Administration has agreed to give Eli Lilly s  NYSE LLY  cancer drug selpercatinib a priority review  which will shave four months off the review time  The agency is expected to deliver a decision about the marketing application in the third quarter of 2020  although it could come sooner considering that the drug has been given a  breakthrough therapy  designation 
Eli Lilly inherited selpercatinib  which used to go by the code name LOXO 292  through its  8 billion acquisition of Loxo Oncology last year  Much of the value of that company was tied to its already approved cancer therapy Vitrakvi  but selpercatinib was touted as the pipeline drug to watch 
Selpercatinib inhibits a protein called RET  which is involved in cell signaling in the presence of growth factors  The gene becomes altered in some tumors  leading to uncontrolled cell growth 

Eli Lilly has applied for approval of the treatment in three different types of tumors with altered RET  non small cell lung cancer  medullary thyroid cancer  and thyroid cancer  Its application is based on data from the Libretto 001 phase 1 2 clinical trial  where initial results showed response rates between 45  and 77  in the different types of tumors  More recent results focused on lung cancer patients showed 68  of them responding to the treatment 
In December  the pharmaceutical company started two phase 3 clinical trials  Libretto 431 in lung cancer patients and Libretto 531 medullary thyroid cancer patients  Both studies will enroll patients who hadn t been previously treated  so in addition to confirming the results from the phase 1 2 study  data from the new studies could be used to pursue an expanded approval that would increase the population of patients approved to be treated with selpercatinib ",2020-01-29,The Motley Fool,https://invst.ly/pojn8,2070924
170859,392375,LLY,Drugmakers slash prices to be eligible for China s bulk buy program,news,"BEIJING  Reuters    Global pharmaceutical majors and generic drugmakers chopped by 53  on average prices of some of their off patent products in the latest bidding round under China s national bulk buy program  government officials said late on Friday 
Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large volume government procurement 
Some global firms such as AstraZeneca  L AZN  and Merck  N MRK  have already cautioned about intensifying price pressures on their mature brands in the world s second largest drug market  as China expands the usage of the program 
In the latest bidding on Friday that involved 33 drugs and 122 companies  Bayer  DE BAYGn  slashed the price of its popular diabetes treatment Acarbose to 0 18 yuan   0 0262  per pill  78 5  lower than the price ceiling set by the government in December last year  elbowing some Chinese generic providers out of the tender  according to a Reuters calculation based on the preliminary results released by the authority overseeing the program 
Bayer was not immediately available for a comment 
 Products that won bids in this round of centralized procurement saw a huge price drop  which squeezes out unreasonable overpricing that has existed in drug distribution for a long time   the authority said in a statement published alongside the preliminary result on Friday 
Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs  the statement said 
Chinese copycats won bids for most of the 33 drugs  including generic versions for drugs ranging from Johnson   Johnson s  N JNJ  prostate cancer treatment Zytiga to Eli Lilly s  N LLY  erectile dysfunction treatment Cialis  the results showed 
In Friday s bidding  for products with two bid winners  60  of the government procurement volume can be shared among the winners  according to official document detailing the tender rules released in December  For products with four winners and more  as much as 80  of the volume can be shared among the companies 
In the first round of the nationwide implementation of the bulk buy program in September  global drugmakers including Sanofi  PA SASY  and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers ",2020-01-18,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-slash-prices-to-be-eligible-for-chinas-bulkbuy-program-2062554,2062554
170860,392376,LLY,Lilly to invest  470M in North Carolina site,news,Eli Lilly  LLY  0 7   will invest over  470M to build a new pharmaceutical manufacturing facility in North Carolina s Research Triangle Park  The site will employ over 460 people once on line ,2020-01-21,Seeking Alpha,https://invst.ly/pkyd4,2064145
170861,392377,LLY,What Company Will Eli Lilly Buy Next ,news,"Targeting smaller  bolt on  acquisitions in the range of  1 billion to  5 billion  Eli Lilly  NYSE LLY  plans to expand its research and development pipeline by acquiring a company roughly every quarter  The company s CFO made these comments during the J P  Morgan Healthcare Conference as he discussed the company s  1 1 billion purchase of Dermira  NASDAQ DERM   

Knowing that the big pharmaceutical company is going shopping  some biotech deal makers and investors looking for exits hope their companies will be snapped up next  Here we will explore a few companies that could be on Lilly s shopping list 
Arvinas
Following its public debut in 2018  Arvinas  NASDAQ ARVN  is set to commence its first human clinical trial this year with its protein degraders  This approach aims to eliminate unwanted disease causing proteins  whereas many other cancer approaches  including Lilly s  try to stop those proteins from being made at all 
What s attractive for Lilly  Two cancer programs  for specific prostate and breast cancers  should enter clinical trials in 2020  The approach complements Lilly s targeted oncology R D and has further application into neuroscience  another therapeutic area of interest for Lilly  Priced at nearly  2 billion today  Arvinas would not be a cheap acquisition  but it would bring a whole new approach to targeted treatments in multiple disease areas 
Alector
To bolster its pipeline aimed at neurodegeneration  Lilly needs to look no further than Alector  NASDAQ ALEC   Alector s immunology driven approach tackles difficult diseases like dementia and Alzheimer s  both of which Lilly targets already  Alector s lead clinical stage programs aim to increase the expression of the protein progranulin  a regulator of immune activity in the brain  Pursuing the same diseases through different  unique mechanisms makes Alector a reasonable target should Lilly wish to expand its portfolio of drugs for neurodegeneration 
SpringWorks Therapeutics
Targeted therapies continue to be all the rage in oncology  and with good reason  Drugs are gaining approval from the Food and Drug Administration after relatively small clinical trials  This is the result of personalized medicine where patients receive specific drugs to match the genetic profile of their tumors  SpringWorks Therapeutics  NASDAQ SWTX  aims to acquire and develop treatments for genetically defined tumors which dovetails with the revamped oncology strategy Lilly announced in December 
SpringWorks  pipeline boasts three drugs  with two in potential registrational clinical trials for rare types of cancers  As a business model  it focuses on in licensing promising drugs rather than discovering them in house  That it has specific drug candidates and not a platform technology may make it more attractive for a potential pharmaceutical buyer  The buyer gets specific compounds and does not have to contend with integrating an early stage research operation  SpringWorks only went public last September  but shareholders and employees may prefer a buyout over the risk of potential clinical trial setbacks 
Rigel Pharmaceuticals
This one may be less obvious at first  but hear me out  First  Lilly would gain Tavalisse  a drug for adult immune thrombocytopenia purpura  ITP   a disease whereby the body attacks its own blood platelets  Tavalisse s sales continue to grow  but a broader push under the Eli Lilly brand could help it jump in market share  Rigel Pharmaceuticals  NASDAQ RIGL  hopes to expand Tavalisse s approval to include warm autoimmune hemolytic anemia  a disease affecting 45 000 Americans in which the body destroys its own blood cells  Rigel believes this could be a  1 billion market  
The remainder of Rigel s pipeline fits Lilly s therapeutic focus  Two early stage immunology drugs use mechanisms different from Lilly s own efforts  Rigel successfully licensed four other drugs  allowing it to sit back and collect milestones and royalties  The two oncology drugs fit the targeted therapy approach pursued by Eli Lilly  Rigel out licensed two dermatology drugs to Aclaris  One aims to tackle alopecia areata  an autoimmune disorder causing hair loss in around 6 8 million people in the U S   The other could treat atopic dermatitis  better known as eczema  Lilly has R D programs for these diseases  including one drug with a similar mechanism to Rigel s atopic dermatitis candidate   
Stay tuned
We will have to wait to see what Lilly ultimately buys    if anything  Don t forget Lilly can easily snap up private companies as it did in the 2018 acquisition of cancer company AurKa Pharma  The risks associated with investing in biotech are many  and trying to invest in companies likely to be acquired at a premium can be exceptionally challenging since big pharma companies often keep their cards close to the vest ",2020-01-23,The Motley Fool,https://invst.ly/plv9k,2065914
170865,392381,LLY,Eli Lilly and Incyte s Olumiant Helps Eczema Patients in a Late Stage Clinical Trial,news,"In a quest to expand the usage of Olumiant  Eli Lilly  NYSE LLY  and Incyte  NASDAQ INCY  have shown the drug can help patients with atopic dermatitis  commonly referred to as eczema  when used in combination with topical corticosteroids  All the patients had already failed treatment with cyclosporine  the first line generic drug used to treat the disease 
After 16 weeks of treatment  31 5  of patients taking the highest dose of the drug had at least a 75  or greater change from baseline in their Eczema Area and Severity Index score  EASI75   while only 17 2  of patients taking placebo met the EASI75 goal  The healthcare companies also tested two other doses of the drug  with the middle dose helping 27 6  of patients and the low dose helping 22 6  of patients  but neither dose was statistically better than placebo 

Olumiant is approved to treat rheumatoid arthritis in more than 60 countries  The drug generated almost  300 million in sales during the first nine months of 2019  Incyte  which licensed the drug to Eli Lilly  received  57 million in royalties from Eli Lilly over that time period 
The drug works by inhibiting a protein called Janus kinase  which is involved in cell signaling in immune cells  By inhibiting JAK  Olumiant dampens the immune response in autoimmune diseases such as rheumatoid arthritis and eczema 
Eli Lilly has already applied for expanded approval to treat eczema in the EU and plans to submit applications for the disease in the U S  and Japan this year ",2020-01-27,The Motley Fool,https://invst.ly/pnlox,2068925
170892,392408,LLY,Lilly s Tyvyt   Alimta successful in lung cancer study,news,"Eli Lilly  NYSE LLY  announces positive results from a China based Phase 3 clinical trial  ORIENT 11  evaluating the combination of Tyvyt  sintilimab injection   Alimta  pemetrexed  and platinum based chemo for the first line treatment of advanced recurrent nonsquamous non small cell lung cancer  nsqNSCLC   without sensitive EGFR mutation or ALK rearrangement 
The study met the primary endpoint of progression free survival based on an interim analysis by the Independent Data Monitoring Committee 
No new safety signals were observed 
The trial is being conducted by sentilimab development partner Innovent Biologics  A marketing application in China is next up 
Additional data will be presented at an upcoming medical conference ",2020-01-13,Seeking Alpha,https://invst.ly/phbkl,2057846
170893,392409,LLY,Eli Lilly Releasing Cheaper Insulin Generic to Compete With Lispro Products,news,"Eli Lilly  NYSE LLY  took another big swipe at America s rebate hungry reimbursement system by launching a generic competitor for two more of its popular insulin lispro containing products  
Diabetes patients that want to manage their blood sugar levels with Humalog Mix 75 25 or Humalog Junior will have a new less expensive option  Eli Lilly will offer generic versions of both insulin lispro containing brands 

Wider margins at half the price
A five pack of Insulin Lispro Protamine injector pens will have a list price set at  265 20  which is less than half as much as the identical product branded as Humalog Mix75 25  Despite the steep discount  Eli Lilly will probably record more net revenue from each pen sold as a generic 
Insurers and healthcare plan sponsors have a bottomless appetite for rebates and discounts that they don t always share with their customers  The gap between list prices Eli Lilly raises each year and the amount the company records as net revenue has finally reached a breaking point 
A not so big deal
During the first nine months of 2019  sales of Humalog and Humulin products fell to  3 0 billion but its continued decline isn t going to send Eli Lilly off a cliff  That s because the pharmaceutical company has done an impressive job expanding its line of successful product offerings in recent years  
If launching generic versions Humalog doesn t allow the company to increase total insulin sales  it s not the end of the world  Thanks to a handful of successful drugs that are much younger  Lilly relies on its Humalog franchise for less than one fifth of total revenue at the moment ",2020-01-14,The Motley Fool,https://invst.ly/phy1g,2059175
170894,392410,LLY,Eli Lilly to offer half priced versions of two more insulin products,news,"By Manas Mishra and Michael Erman
 Reuters    Eli Lilly  NYSE LLY  and Co said on Tuesday it plans to sell two versions of insulin products at half their current U S  list prices  eight months after it started selling a half priced version of its widely used Humalog injection 
Lilly will sell new versions of Humalog Junior KwikPen and Humalog Mix75 25  which contains a mix of fast  and intermediate acting insulin  at a list price of  265 20 for a pack of five KwikPens  They will be available at that price by mid April  the company said 
Major insulin makers Lilly  Sanofi  PA SASY  SA and  Novo Nordisk   CSE NOVOb  have been making some of their life sustaining diabetes medicine available at lower costs to counter heavy criticism from lawmakers and patients 
People with Type 1 diabetes need insulin to control blood sugar levels  and it is also used by some with advanced Type 2 diabetes as well  Its cost in the United States nearly doubled from 2012 to 2016  and stories have emerged of patients forced into risky rationing of the medicine 
Lilly has said insulin is highly rebated  meaning that list price does not reflect the actual cost  Drugmakers argue they have to keep list prices high because of rebates or discounts they must pay to pharmacy benefit managers and health insurers to get products on their lists of covered drugs 
 Insurance coverage should ensure no one with diabetes is forced to ration or skip doses for financial reasons   Lilly diabetes head Mike Mason said in a statement on Tuesday 
T1International  which represents people with Type 1 diabetes  said Lilly s half price insulin has been difficult to obtain and said the latest move  may be nothing more than a further PR response to continued pressure from advocates  
 The two pen types that were added to Lilly s half price offerings today will undoubtedly lead to positive headlines for Lilly  but these pens are not widely used in the type 1 diabetes community and will do little good for patients if they are unable to obtain them   the group s U S  advocacy manager  Allison Bailey  said in an email 
Lilly in May started selling a half priced version of Humalog called Insulin Lispro 
For the week of Dec  30  around 22  of U S  prescriptions for Humalog were filled with the company s half priced version  according to data compiled by retail drug price tracker GoodRx from sources including pharmacies and insurers 
Novo Nordisk said earlier this month it would offer free insulin to U S  patients in immediate need  following its September announcement that U S  patients can buy three vials or two packs of pens of its analog insulins for  99 
In April  a U S  congressional committee called on executives from Novo  Sanofi and Lilly to testify about rising insulin costs ",2020-01-14,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-to-offer-halfpriced-versions-of-two-more-insulin-products-2059407,2059407
170895,392411,LLY,Eli Lilly targets quarterly deals of  1 billion  5 billion in 2020  CFO,news,"By Carl O Donnell
SAN FRANCISCO  Reuters    Eli Lilly and Co  N LLY  aims to announce roughly one  1 billion to  5 billion deal every quarter in 2020  its chief financial officer told Reuters  as the U S  drugmaker looks to build up its pipeline of future products 
It will focus largely on earlier stage opportunities across key therapeutic areas including oncology  pain  immunology  and neurology  CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week 
Eli Lilly has been on a deal making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines  such as diabetes treatment Humalog  face generic competition and pressure to lower prices 
Last week  it announced a  1 1 billion deal to buy dermatology products maker  Dermira  Inc  O DERM   With the purchase  Lilly will acquire Dermira s experimental treatment for atopic dermatitis  a serious form of eczema  which is in late stage testing  as well as an approved medicated cloth to treat excessive armpit sweating 
 We are looking at Dermira like opportunities targeting assets in the  1 billion to  5 billion range   Smiley said   We d like to be doing something in the range of one per quarter or so  
In 2018 and 2019  it announced several deals for cancer companies  including an  8 billion acquisition of Loxo Oncology  U S  regulators in 2018 approved Vitrakvi  Loxo s first commercial medicine  which treats a wide variety of cancers triggered by a rare genetic mutation 
In a presentation to investors this week  Lilly Chief Executive David Ricks said most of its deals will be in the cancer space  but that other therapeutic areas remain of strong interest as well 
While the company is still looking at late stage assets  Smiley said the most opportunity for shareholders is in drugs in earlier stages of development 
Deals could include licensing agreements  outright acquisitions  or other structures  he added 
In its most recent earnings call  Lilly forecast a higher than expected profit for 2020  citing growing demand for its newer medicines including diabetes drug Trulicity and Taltz for psoriasis and other related autoimmune diseases 
However  sales of Trulicity and other newer medicines have been crimped by high rebates and discounts drugmakers pay to middlemen  such as pharmacy benefit managers  in order to make sure patients have access to their products ",2020-01-16,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-targets-quarterly-deals-of-1-billion5-billion-in-2020-cfo-2061565,2061565
170899,392415,LLY,Eli Lilly targets quarterly deals of  1 billion to  5 billion in 2020  CFO says,news,Eli Lilly aims to announce roughly one  1 billion to  5 billion deal every quarter in 2020  its chief financial officer told Reuters The U S  drugmaker looks to build up its pipeline of future products ,2020-01-17,CNBC,https://invst.ly/pjaoq,2061948
170900,392416,LLY,Eli Lilly s Shopping Spree Won t Stop With Dermira  CFO Shares Plans For More Deals In 2020,news,"Merger   acquisition activity at the 2020 J P  Morgan Healthcare Conference has been a little disappointing  but not for a lack of effort on the part of Eli Lilly  NYSE LLY   The big pharma went beyond the call of duty by announcing the  1 1 billion acquisition of Dermira  NASDAQ DERM  last week  and more recently its CFO John Smiley told investors to expect more deals this year 
The midwest s largest pharmaceutical company hasn t shared any specific details  but it s clear the company will get even larger in 2020  Smiley told Reuters to look for a new deal announcement in each quarter this year in the  1 billion and  5 billion range 

What s on Eli Lilly s wish list 
While there are plenty of young growth drivers in Lilly s product line  sales of aging insulin lispro products sold under the Humalog brand are under a lot of pressure  Instead of growing its presence in the increasingly crowded space for diabetes drugs  though  Eli Lilly will probably continue expanding into immunology and oncology 
The recent acquisition of Dermira gives Lilly access to an experimental treatment for eczema which could be an important revenue stream in the years ahead  Last year s purchase of Loxo Oncology showed us management is serious about developing new targeted cancer therapies and we can reasonably expect the company to buy more mid sized companies developing new tumor blasters treatments ",2020-01-17,The Motley Fool,https://invst.ly/pjdn1,2062142
170923,392439,LLY,Lilly launches new robotic drug discovery laboratory,news,"Eli Lilly  LLY  1 7    in collaboration with lab automation developer Strateos  announces a new San Diego based robotic laboratory  called the Lilly Life Sciences Studio Lab  designed to accelerate the drug discovery process 
The 11 500 sq  ft  studio lab  operated by Strateos  physically and virtually integrates several areas of the drug discovery process including design  synthesis  purification  analysis  sample management  and hypothesis testing into a fully automated platform 
Strateos will use the lab s robotic cloud platform to enable access of this remote controlled lab to other drug discovery companies and research scientists via its secure cloud based platform ",2020-01-09,Seeking Alpha,https://invst.ly/pfz3o,2056085
170928,392444,LLY,How This Dermira Acquisition Will Round Out Eli Lilly,news,"Dermira Inc   NASDAQ  DERM  shares made a handy gain to close out the week after it was announced that Eli Lilly and Co   NYSE  LLY  would be acquiring the firm  The transaction is expected to close by the end of the first quarter and is subject to customary closing conditions  regulatory approvals and the tender of a majority of the outstanding shares of Dermira s common stock Under the terms of the deal  Dermira shareholders will receive  18 75 per share in cash for a total consideration for  1 1 billion  This is an all cash transaction The purchase price represents a premium of roughly 86  to the 60 day volume weighted average trading price of Dermira s stock ending on January 9  2020 div connatix margin bottom  1 5em   div connatix img  margin  unset  The acquisition will expand Lilly s immunology pipeline with the addition of lebrikizumab  which is being evaluated in a Phase 3 clinical development program for the treatment of moderate to severe atopic dermatitis in adolescent and adult patients  Lebrikizumab was previously granted Fast Track designation from the U S  Food and Drug Administration  FDA  in December 2019 Also  this acquisition will expand Lilly s portfolio of marketed dermatology medicines with the addition of Qbrexza  glycopyrronium  cloth  a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis  uncontrolled excessive underarm sweating  Patrik Jonsson  Eli Lilly senior vice president and president of Lilly Bio Medicines  commented People suffering from moderate to severe atopic dermatitis have significant unmet treatment needs  and we are excited about the potential that lebrikizumab has to help these patients  The acquisition of Dermira is consistent with Lilly s strategy to augment our own internal research by acquiring clinical phase assets in our core therapeutic areas and leveraging our development expertise and commercial infrastructure to bring new medicines to patients  This acquisition provides an opportunity to add a promising Phase 3 immunology compound for atopic dermatitis  while also adding an approved dermatology treatment for primary axillary hyperhidrosis  We look forward to completing the acquisition and continuing Dermira s excellent work Shares of Eli Lilly were last seen trading at  136 73  in a 52 week range of  101 36 to  137 61  The consensus price target is  133 08  


				ALSO READ  20 Companies Profiting the Most From War				


By Chris Lange",2020-01-10,247wallst,https://invst.ly/pggl8,2056936
170930,392446,LLY,Eli Lilly to Boost Its Dermatology Pipeline with  1 1 Billion Dermira Acquisition,news,"The midwest s largest pharmaceutical company  Eli Lilly  NYSE LLY  recently made a big bet on a protein that nearly landed on a scrap heap just a couple of years ago  Today  Lilly announced its plans to acquire Dermira  NASDAQ DERM  a commercial stage biotechnology company developing a potential new eczema treatment called lebrikizumab  The deal is valued at  1 1 billion  
Dermira markets disposable cloths that prevent excessive underarm sweating under the Qbrexza brand  but sales reached just  20 7 million during the first nine months of 2019  The asset Eli Lilly s really interested in is lebrikizumab  an IL 13 IL 4 inhibitor that leans toward IL 13 

The one that got away
Dermira s developing lebrikizumab to treat patients with moderate to severe eczema  but this protein wasn t discovered by Dermira  Roche  OTC RHHBY  quickly out licensed lebrikizumab in 2017 after it failed to provide a clear benefit for asthma patients in a mid stage clinical trial 
Dermira stock began rocketing higher last spring after the company reported encouraging results from an eczema study with 280 patients  Although Roche probably wishes it held on to lebrikizumab  the Swiss pharmaceutical giant is still eligible to receive significant milestone payments if lebrikizumab continues to and a royalty percentage that tops out in the high teens 
Competition ahead
Regeneron  NASDAQ REGN  and Sanofi  NASDAQ SNY  market Dupixent  an IL 4 inhibitor that succeeded in studies with eczema patients and patients with severe asthma  Dupixent launched in 2017 and sales hit  1 6 billion during the first nine months of 2019  That suggests there s a good chance that annual lebrikizumab sales can reach  1 billion a few short years from now as a treatment for eczema alone ",2020-01-10,The Motley Fool,https://invst.ly/pghkv,2057020
170949,392465,LLY,Bayer Seeks FDA Approval For New Formulation Of Nifurtimox ,opinion,Bayer AG  DE BAYGN    OTC BAYRY   announced that it has submitted an application to the FDA for a new formulation of nifurtimox to improve the body weight adjusted dosing in pediatric Chagas patients  The application was supported by positive phase III data from the CHICO study  which is the largest clinical study to date in pediatric patients with Chagas disease Bayer filed the application on the World Neglected Tropical Diseases  NTDs  Day  which is part of Bayer s Sustainability Strategy launched in December 2019 The CHICO study evaluated the efficacy  safety and pharmacokinetics of nifurtimox in 330 pediatric patients with acute or chronic Chagas disease Chagas disease is caused by the protozoan parasite  Trypanosoma cruzi  The new formulation will improve dosing for newborns  infants and children suffering from Chagas disease and be a significant contribution in controlling the disease Shares of the company have gained 6 3  in the past year compared with the  s growth of 10 9  In a separate release  the company also announced results from the preplanned final overall survival analysis of the phase III ARAMIS study that evaluated darolutamide  a non steroidal androgen receptor inhibitor  ARi   in men with non metastatic castration resistant prostate cancer  nmCRPC   The results showed a statistically significant improvement in overall survival  OS  in patients receiving darolutamide plus androgen deprivation therapy  ADT  compared to placebo plus ADT  Darolutamide is developed jointly by Bayer and Orion Corporation  a globally operating Finnish pharmaceutical company We remind investors that darolutamide is approved in the United States  under the brand name Nubeqa  for the treatment of patients with nmCRPC  In January  the Ministry of Health  Labor and Welfare  MHLW  in Japan also approved darolutamide for the treatment of patients with nmCRPC  It is under review in the EU for the same  It is also being investigated in a phase III study  ARASENS  in metastatic hormone sensitive prostate cancer  Bayer Aktiengesellschaft Price    Zacks Rank and Stocks to ConsiderBayer currently has a Zacks Rank  4  Sell  A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE    Eli Lilly   Co    NYSE LLY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Pfizer sports a Zacks Rank  1  Strong Buy   Lilly and Roche carry a Zacks Rank  2  Buy   You can see  Pfizer s earnings per share estimates have moved up from  2 56 to  2 69 for 2019 and from  2 73 to  2 81 for 2020 in the past 90 days  The company delivered a positive earnings surprise of 7 46   on average  in the last four quarters Lilly s earnings per share estimates have increased from  5 79 to  5 80 for 2019 and from  6 56 to  6 77 for 2020 in the past 60 days  The company delivered a four quarter positive earnings surprise of 1 20   on average Roche s earnings per share estimates have increased from  2 61 to  2 66 for 2019 and from  2 82 to  2 90 for 2020 in the past 60 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7   This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/bayer-seeks-fda-approval-for-new-formulation-of-nifurtimox-200503551,200503551
170951,392467,LLY,Lilly s Olumiant Succeeds In Another Late Stage Eczema Study,opinion,"Eli Lilly and Company   NYSE LLY   and partner Incyte s   NASDAQ INCY   oral JAK inhibitor  Olumiant  baricitinib  met the primary endpoint in a phase III study evaluating it as a monotherapy  in moderate to severe atopic dermatitis   AD    a type of eczema 
Top line data from the BREEZE AD5 study showed that 16 week treatment with 2mg dose of Olumiant met the primary endpoint of at least 75  improvement in skin inflammation  measured by Eczema Area and Severity Index   EASI    from baseline  BREEZE AD5  conducted in North America  evaluated 1 mg and 2 mg doses of Olumiant as a monotherapy in AD patients 
The higher dose of the drug also met a key secondary endpoint of another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement in the validated Investigator s Global Assessment for AD  This marks the fifth successful completion of a late stage study evaluating Olumiant in AD patients 
Detailed data from the study will be presented at future scientific conferences and published in peer reviewed journals  Lilly has already submitted a regulatory application seeking approval for label expansion of Olumiant to treat AD patients in Europe  Data from the BREEZE AD5 study will support a supplemental new drug application or sNDA submission to the FDA for a similar label expansion of the drug 
The company previously completed successfully four phase III AD studies   BREEZE AD1  BREEZE AD2  BREEZE AD4 and BREEZE AD7  While 2mg and 4mg dosages of Olumiant met the primary endpoint of BREEZE AD1 and BREEZE AD2 studies  only 4mg dose of the drug met the primary endpoint in BREEZE AD7 study  Earlier this week  the company reported data from BREEZE AD4 study that demonstrated 4mg of Olumiant plus topical corticosteroids achieved at least 75  improvement in EASI from baseline after 16 weeks of treatment 
In the past year  shares of Lilly have gained 19  compared with the  s increase of 12 4  

 
Olumiant is one of the drugs in Lilly s new pharmaceutical product portfolio  which is anticipated to be a key top line driver going ahead  The drug generated  426 9 million in 2019  up more than 110  year over year mainly driven by upbeat sales in Europe 
Lilly is also developing Olumiant as a treatment for systemic lupus erythematosus and alopecia areata in mid to late stage studies 
Meanwhile  competition is on the rise in the JAK inhibitor segment as well as the eczema market  Regeneron Pharmaceuticals and Sanofi s Dupixent is approved for treating AD since 2017 while AbbVie   NYSE ABBV   and Pfizer   NYSE PFE   are developing their respective candidates for the indication in late stage studies Eli Lilly and Company Price
 

    
Zacks Rank
Lilly currently carries a Zacks Rank  2  Buy   You can see  
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  
This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-31,Zacks Investment Research,https://www.investing.com/analysis/lillys-olumiant-succeeds-in-another-latestage-eczema-study-200503704,200503704
170952,392468,LLY,Top Research Reports For Netflix  Eli Lilly   United Parcel Service,opinion,"Wednesday  February 5  2020The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Netflix  NASDAQ NFLX   NFLX   Eli Lilly  LLY  and United Parcel Service  NYSE UPS   UPS   These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Netflix s shares have underperformed the Zacks Broadcast Radio and Television industry over the past year   4 8  vs   7 8    The Zacks analyst believes that Netflix s fourth quarter 2019 subscriber addition rate declined in the United States  primarily due to price hike and stiff competition However  in international streaming markets  Netflix s subscriber growth continued unabated  driven by a solid content portfolio  Moreover  the launch of low priced mobile plans in India  Indonesia and Malaysia is expected to expand the subscriber base in the Asia Pacific  However  management expects net additions in the paid subscriber base to decline in first quarter 2020 Moreover  high streaming content obligation and increased spending are expected to hurt free cash flow generation  Nevertheless  a solid content portfolio and expanding bundle offerings through partnerships with telcos bode well for Netflix   You can  Shares of Eli Lilly have gained  28 8  in the past six months against the Zacks Large Cap Pharmaceuticals industry s rise of  15 1   The Zacks analyst believes that in 2020  Lilly s revenue growth is expected to be driven by higher demand for newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Emgality as well as newly launched Baqsimi and Reyvow Lilly is making significant pipeline progress with several positive late stage data readouts scheduled for 2020  Lilly is also regularly adding promising new pipeline assets through business development deals However  generic competition for several drugs including the expected generic entry of Forteo  rising pricing pressure in the United States and price cuts in some international markets are some top line headwinds expected in 2020  You can  United Parcel Service s shares have lost  15 2  over the past three months against the Zacks Transportation   Air Freight and Cargo industry s fall of  13 4   The Zacks analyst believes that UPS  fourth quarter 2019 performance was boosted by volume growth in the U S  Domestic segment  its main revenue generating unit Notably  segmental revenues increased 6 6  in 2019  E commerce growth is a huge positive for UPS  We are also impressed by the company s efforts to reward its shareholders through dividends   3 3 billion in 2019  and buybacks   1 billion   However  UPS  high capital expenditures might play spoilsport  Notably  2020 capex is expected to be higher than 2019 levels  The same is expected to dent 2020 earnings per share by roughly 33 cents  The company s high debts add to its woes  You can  Other noteworthy reports we are featuring today include Microsoft  MSFT   Disney  DIS  and NIKE  NKE  Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time Sheraz MianDirector of ResearchNote  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Robust Content Aids Netflix  NFLX  Amid Stiff Competition


New Drugs to Drive Lilly s  LLY  Revenues in 2020


Dividends   Buybacks Boost UPS  High Capex Remains a Woe


Featured Reports
Microsoft  MSFT  Strong on High Cloud   Office 365 Adoption
Per the Zacks analyst  Microsoft is benefiting from expanding Azure clientele  enterprise strength  and robust adoption of Office 365 suite 

Strong Slate of Movies  Disney  Adoption to Aid Disney  DIS 
Per the Zacks analyst  scintillating slate of movie titles  opening of Star Wars  Galaxy s Edge at Walt Disney World and solid adoption of Disney  are expected to boost Disney s growth prospects 

Digital Transformation Efforts to Boost NIKE  NKE  Top Line
Per the Zacks analyst  NIKE is leveraging its mobile apps like the NIKE app and sneakers app  which is now live in over 20 countries 

Higher Pricing   Volume to Fuel Colgate s  CL  Top Line
Per the Zacks analyst  higher global unit volume and pricing are aiding Colgate s sales 

Micron  NASDAQ MU  Banks on Rebound in Demand for DRAM Solutions
Per the Zacks analyst  Micron is benefiting from the revival in DRAM demand on the back of a progress in customer inventory adjustments in the cloud  graphics and the PC markets 

Climate Solutions Aids Ingersoll Rand  IR   High Costs Hurt
Per the Zacks analyst  strong traction of Ingersoll Rand s Climate Solutions segment  fueled by robust demand in commercial HVAC market should continue to drive sales 

Solid Investment Pipeline to Aid Realty Income s  O  Growth
Per the Zacks Analyst  Realty Income will gain from solid investments  and focus on service  non discretionary and low price retail business tenants 

New Upgrades
Qorvo  QRVO  Rides on Solid 5G Product Suite   GaN Solutions
Per the Zacks analyst  Qorvo s expanding portfolio of 5G and GaN solutions hold promise  Further  robust demand for the company s wireless connectivity as well as base station solutions is a positive 

Robust Demand for InfiniBand Solutions Aids Mellanox  MLNX 
Per the Zacks analyst  Mellanox is benefiting from robust demand for its InfiniBand solutions  Further  growing adoption of its Ethernet adapters  switches and LinkX cables is a key catalyst 

Big Lots   NYSE BIG  Transformational Efforts to Drive Growth
Per the Zacks analyst  Big Lots has been gaining from its transformation initiative  This focuses on four key strategies   Store of the Future  New Stores  Rewards loyalty program and e commerce 

New Downgrades
Higher Costs   Lower Prices to Hurt Packaging Corp  PKG 
Per the Zacks Analyst  Packaging Corp s results will be impacted by higher annual maintenance outage costs  softer prices as well as weaker sales volume 

Generic Competition Remains a Concern for Dr  Reddy s  RDY 
Per the Zacks analyst  generic competition remains a concern for Dr  Reddy s  The company also faces persistent pricing pressures in the North America base business 

Weakness in Weetabix Unit a Worry for Post Holdings  POST 
Per the Zacks analyst  weak Weetabix Unit is a concern for Post Holdings  Sales in the segment declined 2 6  in fourth quarter fiscal 2019 owing to reduced volumes and unfavorable currency rates 
undefined undefined",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-netflix-eli-lilly--united-parcel-service-200504964,200504964
170953,392469,LLY,The Zacks Analyst Blog Highlights  Netflix  Eli Lilly  United Parcel Service  Microsoft And Nike,opinion,For Immediate ReleaseChicago  IL   February 6  2020   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Netflix   NASDAQ NFLX    Eli Lilly   NYSE LLY    United Parcel Service   NYSE UPS    Microsoft   NASDAQ MSFT   and Nike   NYSE NKE   Here are highlights from Wednesday s Analyst Blog Top Research Reports for Netflix  Eli Lilly and UPSThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Netflix  Eli Lilly and United Parcel Service  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Netflix s shares have underperformed the Zacks Broadcast Radio and Television industry over the past year   4 8  vs   7 8    The Zacks analyst believes that Netflix s fourth quarter 2019 subscriber addition rate declined in the United States  primarily due to price hike and stiff competition However  in international streaming markets  Netflix s subscriber growth continued unabated  driven by a solid content portfolio  Moreover  the launch of low priced mobile plans in India  Indonesia and Malaysia is expected to expand the subscriber base in the Asia Pacific  However  management expects net additions in the paid subscriber base to decline in first quarter 2020 Moreover  high streaming content obligation and increased spending are expected to hurt free cash flow generation  Nevertheless  a solid content portfolio and expanding bundle offerings through partnerships with telcos bode well for Netflix   You can  Shares of Eli Lilly have gained  28 8  in the past six months against the Zacks Large Cap Pharmaceuticals industry s rise of  15 1   The Zacks analyst believes that in 2020  Lilly s revenue growth is expected to be driven by higher demand for newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Emgality as well as newly launched Baqsimi and Reyvow Lilly is making significant pipeline progress with several positive late stage data readouts scheduled for 2020  Lilly is also regularly adding promising new pipeline assets through business development deals However  generic competition for several drugs including the expected generic entry of Forteo  rising pricing pressure in the United States and price cuts in some international markets are some top line headwinds expected in 2020  You can  United Parcel Service s shares have lost  15 2  over the past three months against the Zacks Transportation   Air Freight and Cargo industry s fall of  13 4   The Zacks analyst believes that UPS  fourth quarter 2019 performance was boosted by volume growth in the U S  Domestic segment  its main revenue generating unit Notably  segmental revenues increased 6 6  in 2019  E commerce growth is a huge positive for UPS  We are also impressed by the company s efforts to reward its shareholders through dividends   3 3 billion in 2019  and buybacks   1 billion   However  UPS  high capital expenditures might play spoilsport Notably  2020 capex is expected to be higher than 2019 levels  The same is expected to dent 2020 earnings per share by roughly 33 cents  The company s high debts add to its woes  You can  Other noteworthy reports we are featuring today include Microsoft and Nike Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-netflix-eli-lilly-united-parcel-service-microsoft-and-nike-200505178,200505178
170954,392470,LLY,Incyte  INCY  To Report Q4 Earnings  What s In The Cards ,opinion,"Incyte Corporation   NASDAQ INCY   is scheduled to report fourth quarter 2019 results on Feb 13  before market open The company has a decent track record   In the last reported quarter  the company beat earnings estimates by 26 15   It beat earnings expectations thrice over the last four quarters and missed in one  The four quarter positive surprise is 32 80   on average Incyte Corporation Price  Consensus and EPS Surprise
    Factors Driving GrowthIncyte s lead drug  Jakafi  a first in class JAK1 JAK2 inhibitor  which is approved for the treatment of polycythemia vera and intermediate or high risk myelofibrosis  drove the third quarter results on strong demand  a trend that most likely continued in the fourth quarter  Jakafi sales grew 25  in the third quarter  The Zacks Consensus Estimate for Jakafi sales stands at  454 million Moreover  the FDA approved a label expansion of Jakafi for the treatment of steroid refractory acute graft versus host disease  GVHD  in adult and pediatric patients 12 years or older in May 2019  Hence  sales of the drug for this indication are likely to have boosted the top line in the fourth quarter The company also earns product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets  Novartis recorded 17  growth in sales in the fourth quarter and hence  Incyte must have received higher royalties for the same We remind investors that while Jakafi sales and royalties are key catalysts for the company s revenue growth  Iclusig sales and Olumiant royalties from Eli Lilly   NYSE LLY   also contribute to the top line  Hence  these are likely to have contributed significantly to the company s revenues in the fourth quarter Key Pipeline UpdatesApart from the regular top and bottom line numbers  we expect investors to focus on the company s updates on the label expansion of Jakafi into additional indications  The phase III TRuE AD2 study  which is part of the TRuE AD clinical program and evaluating the cream formulation of ruxolitinib for atopic dermatitis  AD   met its primary endpoint  The TRuE AD2 study evaluated the safety and efficacy of ruxolitinib cream in adult and adolescent patients aged at least 12 years and above with AD  The FDA accepted Incyte s new drug application  NDA  for its investigational FGFR inhibitor pemigatinib as a second line treatment for locally advanced or metastatic cholangiocarcinoma  also known as bile duct cancer  With the FDA granting priority review to the NDA  a decision from the regulatory body is expected on May 30  2020  The European Medicines Agency  EMA  also validated its Marketing Authorization Application  MAA  for the same However  a late stage study on pipeline candidate itacitinib   INCB039110  a novel and selective JAK1 inhibitor  in combination with corticosteroids in patients with treatment na ve  first line  acute GVHD did not meet the primary endpoint  Earnings WhispersOur proven model does not conclusively predict an earnings beat for Incyte this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  Unfortunately  that is not the case here  as you will see below  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Incyte is 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate stand at 0 00  Zacks Rank  The company currently carries a Zacks Rank  4  Sell  Share Price PerformanceIncyte s stock has lost 6 2  in the past year  while the witnessed no movement in the said timeframe  A Stock That Warrants a LookHere is a stock worth considering as our model shows that this has the right mix of elements to beat estimates this time around Immunomedics  Inc    NASDAQ IMMU   has an Earnings ESP of  3 37  and a Zacks Rank  2  You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-to-report-q4-earnings-whats-in-the-cards-200505697,200505697
170955,392471,LLY,Pharma ETFs Gain On Healthy Q4 Earnings,opinion,Total earnings of  of the healthcare market capitalization that has reported so far are up 3 5  on revenue growth of 5 8   Earnings and revenue beat ratios of 67 9  and 78 6   respectively  also appear good Most industry bigwigs delivered encouraging results  either beating on earnings or revenues or both and also raised revenue or earnings guidance or both  Let s delve deeper into a few of them Earnings in FocusJohnson and JohnsonThe world s biggest healthcare products maker continued its long streak of earnings beat  Earnings per share came in at  1 88  beating the Zacks Consensus Estimate by a couple of cents but declined 4 6  from the year ago quarter  Revenues grew 1 7  year over year to  20 75 billion but marginally fell short of the consensus estimate of  20 79 billion  For 2020  Johnson   Johnson  NYSE JNJ  projects revenues in the range of  85 4  86 2 billion  indicating 4 5  year over year growth  Earnings per share are expected in the range of  8 95  9 10  representing year over year growth of 3 1 4 8  Pfizer  NYSE PFE Pfizer lagged the consensus mark on both fronts  Earnings per share of 55 cents lagged the Zacks Consensus Estimate by a couple of cents  Revenues of  12 69 billion also fell shy of the consensus mark of  12 7 billion  On a year over year basis  earnings and revenues declined 13  and 9   respectively  For 2020  the U S  drug giant expects revenues in the range of  48 5  50 5 billion and earnings per share in the range of  2 82  2 92  read    MerckMerck reported better than expected earnings but lagged on revenues  Earnings per share of  1 16 surpassed the Zacks Consensus Estimate of  1 14 and also improved 12  from the year ago quarter  Revenues grew 8  year over year to  11 87 billion but fell short of the consensus mark of  12 14 billion  Merck expects revenues in the range of  48 8  50 3 billion and earnings per share of  5 62  5 77 for this year Bristol MyersBristol Myers s earnings per share of  1 22 beat the Zacks Consensus Estimate by 34 cents and also rose from the year ago figure of 94 cents  Revenues grew 33  year over year to  7 94 billion and also trumped the Zacks Consensus Estimate of  6 14 billion  The company provided revenues and earnings per share guidance of  40 5  42 5 billion and  6 00  6 20  respectively Eli Lilly  NYSE LLY Eli Lilly also posted better than expected earnings and revenues  Earnings of  1 73 per share topped the Zacks Consensus Estimate by 21 cents and came in 21  higher than the year ago quarter  Revenues grew 8  to  6 11 billion and edged past the estimated  6 07 billion  While Eli Lilly slightly raised its 2020 revenue projection to  23 7  24 2 billion from  23 6  24 1 billion  it maintained its earnings per share prediction of  6 70  6 80 ETF AngleStrong results led to solid trading in pharma ETFs over the past week  Below  we have highlighted those in detail  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 45 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top 10 holdings in the basket  accounting for 54 1  of the total assets  suggesting heavy concentration  The product has  361 5 million in AUM and charges 42 basis points  bps  in fees and expense  Volume is light as it exchanges about 19 000 shares a day  The fund has added 4 4  in a week and has a Zacks ETF Rank  3  Hold  with a High risk outlook  read    First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 37 3  of the assets  FTXH has a lower level of  7 2 million in AUM and 2 000 shares in average daily volume  It charges 60 bps in annual fees and is up 2 7  in the same time frame  The product has a Zacks ETF Rank  3 SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  222 4 million  it trades in good volume of around 92 000 shares a day and charges 35 bps in fees a year  In total  the product holds 40 securities with the in focus five firms making up for at least 4  share each  The product has gained 3 6  in the same period and has a Zacks ETF Rank  3 with a High risk outlook  read    VanEck Vectors Pharmaceutical ETF   ASX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus five firms account for a nearly 5  share each  The product has amassed  175 6 million in its asset base and trades in moderate volume of about 59 000 shares a day  Expense ratio is 0 36   The fund has gained 3 1  in a week and has a Zacks ETF Rank  3 with a Medium risk outlook Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  377 3 million and sees a lower volume of around 34 000 shares a day  The fund charges 56 bps in fees and expenses  Holding 30 stocks  the fund invests nearly 5  share each in the five firms  The ETF has gained 4 4  in a week and has Zacks ETF Rank  3 with a High risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-gain-on-healthy-q4-earnings-200505798,200505798
170956,392472,LLY,NewsBreak  Trump Looks to Let Florida  Others Import Prescription Drugs,news,"Investing com   President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower priced prescription drugs for residents 



 Hard working Americans don t deserve to pay such high prices for the drugs they need   Trump said in a  The plan will be released soon by the Department of Health and Human Services  Trump s tweet said  There were few details  although Trump attacked House Democrats for not passing drug pricing legislation  although it has passed 10 bills on the topic 
Trump has been talking for some time about a prescription drug plan to push prices lower  A key question is where the drugs would come from  Canada has said it doesn t have the supplies on hand to lower U S  prices appreciably Shares of pharmaceutical giants Merck  NYSE MRK     Pfizer    NYSE PFE   Eli Lilly  NYSE LLY  and Johnson   Johnson  NYSE JNJ  were all higher on Friday  The Dow was up 0 45 ",2019-11-22,Investing.com,https://www.investing.com/news/general/newsbreak-trump-looks-to-let-florida-others-import-prescription-drugs-2026486,2026486
170957,392473,LLY,Drugmakers slash prices in China to get on reimbursement list,news,"By Roxanne Liu and Brenda Goh
BEIJING SHANGHAI  Reuters    Drugmakers including Roche  S ROG  and Novartis   S NOVN  have agreed to cut the prices of some of their newest drugs by an average of 61  in China in order to get on a national reimbursement scheme list  regulators said 
Addition to the list is likely to boost sales volume by opening up markets in smaller and less affluent Chinese cities  but some industry insiders have cautioned that only offering deep price cuts in China could spark criticism of the drugmakers in other markets 
Seventy new drugs such as Roche s  S ROG  breast cancer treatment Pertuzumab  sold under the trade name Perjeta  Novartis s  S NOVN  dermatitis treatment Omalizumab  branded as Xolair  will be added to the list  the National Healthcare Security Administration said on its website on Thursday 
Chinese patients are allowed to use their state medical insurance to cover a significant portion of the cost of drugs named on the list 
Almost all the imported drugs added to the list in the latest update had the  lowest prices globally   the NHSA said in its statement 
 China is and will be the ultimate high volume  low price market  and so international companies feel that they ll have to take a big pay cut but make up for the volume   Brad Loncar  chief executive of biopharma sector dedicated Loncar Investments  told Reuters 
Tumor and diabetes medicines saw an average price cut of about 65   according to the NHSA 
Other drugs added included Adalimumab  an arthritis treatment which AbbVie  N ABBV  sells as Humira  one the top selling drugs in the world 
Also included was cancer treatment Tyvyt  or Sintilimab  co developed by Chinese drugmaker Innovent Biologics  HK 1801  and Eli Lilly  N LLY   It is considered to be a PD 1 PD L1 treatment  a category of novel drugs that work on the immune system to fight cancer cells 
China has already approved five PD 1 PD L1 treatments  including two top selling global blockbusters made by foreign firms Bristol Myers Squibb  N BMY  and Merck  N MRK   However neither have been added to the list 
Analysts say domestically developed Tyvyt s early inclusion could give it an advantage over its foreign rivals 
 Maybe  Chinese PD 1 PD L1 products  don t come in and compete on day one with international  pharmas  in all indications  but just getting a foot in the door might already be a big step for them   UBS analyst Michael Leuchten told Reuters before the NHSA announcement ",2019-11-28,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-slash-prices-in-china-to-get-on-reimbursement-list-2029938,2029938
170958,392474,LLY,New insulin affordability options from Novo now available in U S ,news,"Novo Nordisk  NVO  0 4   launches its My 99Insulin Program  generic insulin brands and an Immediate Supply option for U S  diabetes patients 
My 99Insulin provides up to three vials or two packs of FlexPen FlexTouch PenFill pens of any combination of Novo insulins 
Generic offerings and wholesale prices per package  Insulin Aspart vial   144 68   Insulin Aspart PenFill cartridge   5x3 mL   268 73   Insulin Aspart FlexPen   5x3 mL   279 41   Insulin Aspart Mix 70 30 10 mL vial   150 06  and Insulin Aspart 70 30 FlexPen   5 3 mL   279 41  
Potential for immediate shipment of up to three vials or two packs of pens at no charge under Immediate Supply option for patients with a prescription 
Related tickers  Sanofi  SNY  0 7    Eli Lilly  LLY  0 1  ",2020-01-02,Seeking Alpha,https://invst.ly/pcdd7,2051211
170959,392475,LLY,Better Buy  Eli Lilly vs  GlaxoSmithKline,news,"GlaxoSmithKline  NYSE GSK  and Eli Lilly  NYSE LLY  are two of the bigger names in healthcare  and they re great options for investors looking to add safe stocks to their portfolios  They have strong fundamentals  and as these two drug manufacturers continue to produce new and exciting medicines  they ll also provide investors with long term growth 
Let s look at how they ve been doing of late to see which stock has the edge today 
Does Eli Lilly offer investors enough growth 
One of the big challenges for Eli Lilly in recent years has been its struggle to generate much growth  Sales of  24 6 billion in 2018 were up a modest 7 4  from 2017 s tally of  22 9 billion  And they ve only grown 25  since 2014  when Eli Lilly reported revenue of  19 6 billion  The positive is that the company s bottom line has remained in the black in four of the past five years  with the only blemish relating to a large income tax bill in 2017  
But lack of sales growth is what s kept the stock down for much of the year  Although the company beat earnings forecasts in Q3 when it released its results in October  the stock still failed to impress investors  That s because one of its key drugs  Taltz  which treats autoimmune diseases  generated just  340 million  well shy of the  400 million expected by analysts 
Total revenue growth for the quarter was just 3 2  with sales reaching  5 5 billion  One area that continued to do well for the company was endocrinology  where sales from that segment were up 10 8  from the prior year quarter 

Eli Lilly got a boost in its share price in December when CFO Josh Smiley updated investors with guidance for 2020  The company anticipates sales for this coming year between  23 6 billion and  24 1 billion  which will be around a 7  increase from the  22 billion to  22 5 billion that the company anticipates it will finish 2019 with 
Is GlaxoSmithKline the safer bet 
One area that GlaxoSmithKline  GSK  hasn t struggled with is growing its sales  The company released its Q3 results in October  which saw revenue growth of 16  from the prior year quarter  totaling  9 4 billion British pounds   12 2 billion   The company upgraded its forecast  no longer expecting profits for the year to decline between 3  to 5  and instead expecting its bottom line to be in line with the prior year s results  
A driving force behind the strong performance has been the strong success of shingles vaccine Shingrix  which saw sales grow 76  during the quarter  coming in higher than analysts were expecting 
There s still a lot more in the works for GSK  Its ovarian cancer drug Zejula has been making progress  with the Food and Drug Administration approving it for use in the treatment of ovarian  fallopian tube  and peritoneal cancer  The company has a total of 41 medicines currently in development  In October  GSK filed a new drug application for Trelegy Ellipta  a single inhaler triple therapy to treat asthma and chronic obstructive pulmonary diseases  which the company says will make the treatment option the first of its kind in the U S  market 
GSK has the edge for multiple reasons
With many products in the works and the company showing better growth numbers than Eli Lilly  GSK makes a lot of sense for investors on many fronts  Its forward P E of 15 also makes it a better value buy than Lilly  which has a forward P E of over 19  GSK s dividend yield of 4 2  is an added bonus for investors  since it s well above the S P 500 average of 2  and higher than Eli Lilly s yield of 2 3  
Both of these healthcare stocks are good options for investors  but GSK is the better buy when factoring in its recent results  dividend yield  and overall valuation ",2020-01-03,The Motley Fool,https://invst.ly/pd1g5,2051801
170967,392483,LLY,Novo Nordisk to cut insulin prices in the U S ,news,"COPENHAGEN  Reuters     Novo Nordisk   CSE NOVOb  will offer cheaper insulin to U S  diabetics  the Danish drugmaker said on Friday  in response to criticism over the high price of the medication and after similar moves by rivals Sanofi  PA SASY  and Eli Lilly  NYSE LLY   President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were  getting away with murder   Novo will offer a generic version of its most heavily prescribed insulin drug Novolog  used by about a million U S  patients  at a 50  discount compared to the current list price  the company said in a statement   The list price for one vial will be  144 68  Novo will also introduce a so called  99 cash card program from Jan 2020  which patients can use to buy three vials or two packs of pens of Novo s analog insulins for a flat cost of  99  which for most diabetics is an adequate supply for one month  The cost of insulin for treating type 1 diabetes in the United States has nearly doubled over a five year period  leading some patients to put their own health at risk by rationing the medication   While we will continue to do what we can to help address affordability challenges in the short term  changes within the system are required to make sustainable and meaningful affordability a reality   said Novo in a statement   In April  France s Sanofi said it would cut the cost of its insulin products to  99 per month for uninsured patients and others who pay cash in the United States  Eli Lilly started selling a half price version of its Humalog insulin in May  The list price for Lilly s authorized generic insulin    sold under the name Insulin Lispro    is  137 35 per vial  
In April  a U S  congressional committee called on executives from Novo  Sanofi and Eli Lilly to testify about the rising costs of the lifesaving drug ",2019-09-06,Reuters,https://www.investing.com/news/stock-market-news/novo-nordisk-to-cut-insulin-prices-for-some-us-diabetics-1972155,1972155
170968,392484,LLY,With a backup to the backup  insulin makers say they re primed for Brexit,news,"By Kate Holton and Paul Sandle LONDON  Reuters    For two men trained as scientists  the bosses of Britain s major insulin providers have had to become experts in ferry schedules  trucking laws and warehouse capacity as they seek to guarantee the supply of life saving drugs through a chaotic Brexit  With Britain set to leave the European Union within weeks  Pinder Sahota at the world s biggest insulin maker  Novo Nordisk   CSE NOVOb   and Sanofi s Hugo Fry have rebuilt operations to withstand the most turbulent of events   The two companies told Reuters they had spent millions of pounds  which they cannot recoup  stockpiling millions of packets of insulin   used to treat diabetes   inside Britain and building new shipping and air freight routes  Their plans  formulated over three years  show the lengths companies across the continent are having to go to overhaul long standing supply chains that may not survive Britain s biggest trade upheaval in half a century   There is nothing comparable to this   Novo Nordisk s UK General Manager Sahota told Reuters of the Danish company s preparation   It s unprecedented from a logistics point of view  We re preparing for the worst case scenario  the most extreme   With two Brexit deadlines already been and gone  Prime Minister Boris Johnson has vowed to take Britain out of the EU with or without a deal by Oct  31   increasing the chance of a sudden departure that brings trade tariffs and customs checks with the continent for the first time in decades   The government s own planning shows that  in a worst case scenario  lorries seeking to enter Europe at the French port of Calais could face delays of two and a half days  creating supply disruptions that could last for months  That poses a real risk for the pharmaceutical industry which imports 37 million packs of drugs from Europe a month  According to the government  three quarters come via that route   While Britain s GSK and AstraZeneca are world leaders in respiratory and cardiovascular treatments  Britain s insulin is imported   In the case of pharmaceuticals  you can t just throw things onto a boat or a lorry  you have to test and validate these routes into the country   Fry told Reuters in his office to the west of London  adding they had backups to their backup plans   Both Sanofi  PA SASY  and Novo Nordisk have reserved space on ferries going the longer route to eastern English ports to avoid the main Calais Dover crossing if needed  and also air freight if required    We anticipate that route is going to become congested so what we ve done is open up other routes   said Sahota   So two other routes that we ve opened up are Denmark to Immingham  in north east England  and Netherlands to Immingham   SKY HIGH STOCKPILES Novo Nordisk  Britain s biggest insulin supplier  has tripled its warehouse capacity to hold 18 weeks  worth of stock   3 8 million packs that piled high would stand 12 times the height of the London Shard skyscraper   Eli Lilly  NYSE LLY  of the United States and France s Sanofi  the country s second and third biggest suppliers  have similar stockpiles  Frustration is growing that while they dedicate huge resources to such preparation  they are spending less time on their normal jobs   When we re doing this  we re not doing other stuff   Fry said   We re not working on projects that will bring our most innovative products to the market    Although we are happy to do it  it is starting to weigh on our balance sheet  on our logistics  keeping all this additional stock in the country  It s not an ideal situation    The companies are confident they will be able to guarantee the British supply of insulin to the around 1 million diabetes patients who need it   But some patients like Georgina from London  who was diagnosed with Type 1 diabetes more than 30 years ago  have become increasingly alarmed as the chances have grown of Britain leaving the EU without a deal to govern their trading relationship   For me  I can t tell you how worried I am about that  It s life threatening for me   she said  declining to give her last name  She added that she also worried about older patients she encountered at clinics  The British government is organising a regular freight service reserved just for drugs as part of its preparations alongside industry for Brexit on Oct  31    We are doing everything we can to help ensure the supply of medicines and medical products remains uninterrupted  including insulin   said the department of health and social care   The two drug companies did not say how much their Brexit preparations had cost  beyond many millions of pounds  With fixed contracts with Britain s health service  they cannot raise prices   Both Fry and Sahota have had to delve into arcane areas of transport   As part of their planning  for example  they have had to factor in how many drivers are needed to avoid breaking legally mandated rest laws  how long refrigerated lorries can operate in one stretch  and what happens in the event of fuel shortages   
 We re doing everything we can   said Fry   I know more about ferry crossings now than I ever thought I would  ",2019-09-17,Reuters,https://www.investing.com/news/stock-market-news/with-a-backup-to-the-backup-insulin-makers-say-theyre-primed-for-brexit-1979418,1979418
170969,392485,LLY,Lilly s Olumiant Meets Primary Goal In Dermatitis Study,opinion,Eli Lilly and Company   NYSE LLY   and partner Incyte   NASDAQ INCY   announced that the phase III  randomized  placebo controlled BREEZE AD4 study on oral JAK inhibitor  Olumiant  baricitinib   was successful BREEZE AD4 is a multicenter  double blind  randomized  placebo controlled study conducted outside of the United States  The study evaluated the efficacy and safety of 1 mg  2 mg and 4 mg doses of baricitinib in combination with topical corticosteroids  TCS  in patients with moderate to severe atopic dermatitis  AD   who have experienced failure to cyclosporine or are intolerant to or have a contraindication to cyclosporine The primary endpoint was defined by the proportion of patients achieving at least a 75  or greater change from baseline in their Eczema Area and Severity Index  EASI  at Week 16 Results show that the 4 mg dose of baricitinib plus TCS met the primary endpoint Notably  Olumiant 2 mg is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis  who have had an inadequate response to one or more tumor necrosis factor  TNF  antagonist therapies Lilly has already submitted baricitinib for regulatory review in Europe as a treatment for patients with moderate to severe AD  The company also plans to file for approval in the United States and Japan in 2020 A potential label expansion should boost the drug s sales  which came in at  299 1 million in the first nine months of 2019 Lilly s shares have rallied 20 2  in the past year compared with the  s growth of 15 7  However  competition is stiff in the AD space from the likes of Regeneron   NASDAQ REGN   and Sanofi s   NASDAQ SNY   Dupixent  which holds a dominant position in the same Lilly currently carries a Zacks Rank  2  Buy  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/lillys-olumiant-meets-primary-goal-in-dermatitis-study-200502196,200502196
170971,392487,LLY,Novo Nordisk targets bigger slice of diabetes market with new tablet,news,"By Stine Jacobsen
COPENHAGEN  Reuters    Danish drugmaker  Novo Nordisk   CO NOVOb  is aiming for a big slice of the multibillion dollar diabetes market with a new pill  approved by U S  authorities on Friday  that caters for patients with an aversion to needles 
The company built its position as the world s biggest insulin maker on the back of injectable drugs  but now aims to transform the market with a first of its kind tablet version of its semaglutide drug 
While more than 70  of diabetes prescriptions in the United States are already for oral treatments  none of these are from the GLP 1 class that Novo specializes in  and which are viewed as highly effective medicines that stimulate insulin production 
 We have only worked with around 25  of the patients so far and we see it as a breakthrough because we can now also address the tablet based market   chief scientific officer Mads Krogsgaard Thomsen told Reuters on Monday 
Investors have been concerned the once daily pill  known as Rybelsus  would be sold more cheaply than comparable injectable treatments as Novo tries to secure a foothold in the tablet market  where drugs tend to be cheaper 
However  chief financial officer Karsten Munk Knudsen told analysts the monthly price would be similar to the company s once weekly injectable version of semaglutide  Ozempic  which has a list price of nearly  800 per month 
 Overall this removes a concern that the company would have been forced much lower on price   said Bernstein analyst Wimal Kapadia  who has an  outperform  rating on Novo shares 
Competitors include Eli Lilly s  N LLY  injectable Trulicity and Merck s  N MRK  Januvia  an oral medication known chemically as sitagliptin  A study last year showed Novo s tablet was superior to Januvia in demonstrating reductions in both long term blood sugar level and weight 
 We have a very strong position if you look at the leading tablet treatments in the market   Thomsen said 
Novo hopes to convince doctors that Rybelsus  which brokerage Pareto estimates will have sales of at least 36 6 billion Danish crowns   5 4 billion  in 2026  provides a new weapon to tackle diabetes earlier  and highly effectively 
Thomsen said the U S  approval was a triumph of perseverance   We were laughed at when we told our peers about it  They thought we had eaten or smoked something weird   he said of the early plans for the drug 
The name Rybelsus was picked because of its similarity to the word rebellious   There is a revolt against why biological drugs should always be treated through injections   said Thomsen ",2019-09-23,Reuters,https://www.investing.com/news/stock-market-news/novo-nordisk-targets-bigger-slice-of-diabetes-market-with-new-tablet-1983763,1983763
170972,392488,LLY,AVEO Posts Data On Ficlatuzumab From Pancreatic Cancer Study,opinion,AVEO Pharmaceuticals  Inc    NASDAQ AVEO   and partner Biodesix  Inc  presented data from a phase Ib study evaluating ficlatuzumab in combination with nab paclitaxel and Eli Lilly s   NYSE LLY   Gemzar  gemcitabine  for addressing previously untreated patients with metastatic pancreatic ductal adenocarcinoma  PDAC   the most common type of pancreatic cancer The investigator sponsored early stage study was designed to find the maximum tolerated dose of ficlatuzumab when combined with gemcitabine and nab paclitaxel for treating the given patient population Per the press release  secondary outcome measures included response rate and progression free survival  Total 24 patients were enrolled  The ficlatuzumab combination was related to a promising durable response rate relative to expectations for gemcitabine and nab paclitaxel alone including a partial response rate of 29  and 92  rate of disease control  partial response   stable disease  The results were announced at the 2020 American Society of Clinical Oncology  ASCO  Gastrointestinal Cancers Symposium Shares of AVEO were up 2  following this presser on Monday  However  the stock has plunged 65 1  in the past year  underperforming the  decrease of 5  Ficlatuzumab is a potent hepatocyte growth factor  HGF  inhibitory antibody product candidate Apart from pancreatic cancer  AVEO is developing ficlatuzumab for treating squamous cell carcinoma of the head and neck  SCCHN   AVEO and Biodesix are also evaluating ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia  AML  In November 2019  AVEO and Biodesix initiated the phase II CyFi 2 study evaluating ficlatuzumab in combination with high dose cytarabine versus high dose cytarabine alone in patients with relapsed refractory AML Notably  AVEO and Biodesix have a worldwide agreement to develop and commercialize ficlatuzumab Zacks Rank   Other Stocks to ConsiderAVEO currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the biotech sector include PDL BioPharma  Inc    NASDAQ PDLI   and Denali Therapeutics Inc    NASDAQ DNLI    both sporting a Zacks Rank  1  Strong Buy   You can see  PDL BioPharma s earnings estimates have been revised 37 5  upward for 2020 over the past 60 days  The stock has inched up 3 2  in the past year Denali s loss per share estimates have narrowed 0 4  for 2020 over the past 60 days  The stock has surged 48 7  in the past year 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/aveo-posts-data-on-ficlatuzumab-from-pancreatic-cancer-study-200502187,200502187
170975,392491,LLY,FDA approves Pfenex s osteoporosis therapy,news," Reuters    The U S  Food and Drug Administration on Monday approved a bone building drug from Pfenex Inc to treat osteoporosis in certain patients at high risk for fractures  giving the company its first commercial product 
The company said it is seeking the FDA s authorization to designate the drug  PF708  as therapeutically equivalent to Eli Lilly  NYSE LLY  and Co s injectable drug Forteo 
This would permit PF708 to be automatically substituted for Forteo  which lost its market exclusivity in many U S  states in August 
Pfenex hopes to market PF708 as a cheaper option for Forteo  which brought in global revenue of  1 58 billion last year 
Pfenex said it was conducting a comparative study between PF708 and Forteo and expects to submit a final report to the FDA as early as the second half of October 
 We currently expect our commercial partner Alvogen to launch PF708 upon an FDA decision on the therapeutic equivalence rating   Pfenex Chief Executive Officer Eef Schimmelpennink said in a statement 
Analysts at William Blair expect PF708 to bring in sales of  96 1 million at its peak in 2021 
The company will receive a  2 5 million milestone payment from privately owned Alvogen for gaining U S  approval ",2019-10-07,Reuters,https://www.investing.com/news/general/fda-approves-pfenexs-osteoporosis-therapy-1992692,1992692
170977,392493,LLY,Eli Lilly lifts 2019 profit forecast after third quarter beat,news," Reuters    Eli Lilly and Co  N LLY  raised its 2019 profit forecast after reporting a better than expected quarterly profit on Wednesday  helped by performance of its diabetes drug  Humalog  and lower tax bill  The drugmaker is one of the three main providers of insulin products and had agreed earlier this year to offer a half priced version of its insulin injection Humalog in response to intensifying pressure from politicians to lower drug costs for consumers   Sales from both versions of the insulin injection fell 2 4  to  648 9 million  but narrowly beat analysts  average estimate of  645 33 million  according to three analysts polled by Refinitiv  The drugmaker now expects 2019 adjusted earnings per share to be in the range  5 75 to  5 85  up from the prior range of  5 67 to  5 77   Net income rose to  1 25 billion  or  1 37 per share  in the quarter ended Sept  30  from  1 15 billion  or  1 12 per share  a year earlier  Excluding items  Lilly earned  1 48 per share  Analysts on average had expected a profit of  1 41 per share  according to IBES data from Refinitiv  
Revenue rose 3 2  to  5 48 billion in the quarter but missed Wall Street expectation of  5 50 billion  largely due to flat overall sales in the United States ",2019-10-23,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-reports-9-rise-in-thirdquarter-profit-2002044,2002044
170978,392494,LLY,Eli Lilly  LLY  Tops Q4 Earnings   Sales  Keeps 2020 View,opinion,"Indianapolis  IN based Eli Lilly and Company   NYSE LLY    boasts of a wide range of products that serve a vast number of therapeutic areas  The company focuses primarily on central nervous system disorders  metabolic diseases  autoimmune diseases  cardiovascular diseases and cancer  which are all high growth areas and represent significant commercial potential Lilly s earnings performance has been mixed  Its earnings beat expectations in three of the last four quarters  with the average positive surprise being 1 20  Currently  Lilly has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Lilly beat fourth quarter earnings  The company reported EPS of  1 73 per share while our consensus called for EPS of  1 52 Revenues Beat  Revenues beat expectations  Lilly posted revenues of  6 11 billion  compared to our consensus estimate of  6 07 billion 2020 Outlook  Lilly re affirmed its 2020 adjusted earnings guidance while slightly raised its revenue guidance Adjusted earnings are expected in the range of  6 70  6 80 per share  Revenues are expected in a range of  23 7 billion  24 2 billion compared to  23 6 billion  24 1 billion previously The Zacks Consensus Estimate for earnings and revenues in 2020 is  6 77 per share and  23 93 billion  respectively Stock Price Impact  Shares were around 1 5  in pre market trading Check back later for our full write up on this Lilly earnings report later  Eli Lilly and Company Price and Consensus
     
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-tops-q4-earnings--sales-keeps-2020-view-200503037,200503037
170979,392495,LLY,Lilly s NDA For Selpercatinib Gets FDA s Priority Review,opinion,Eli Lilly and Company   NYSE LLY   announced that the FDA has granted priority review to its new drug application  NDA  for selpercatinib  LOXO 292   an oral RET inhibitor  The NDA is seeking approval of selpercatinib for treating advanced RET fusion positive non small cell lung cancer  NSCLC   RET mutant medullary thyroid cancer  MTC  and RET fusion positive thyroid cancer The FDA is expected to announce its decision in the third quarter of 2020 Notably  selpercatinib was added to Lilly s portfolio with the February 2019 acquisition of Loxo Oncology  which broadened its scope in precision medicines  If approved  selpercatinib will provide a new precision therapy for patients living with certain RET driven cancers The FDA generally grants a priority review to drugs with potential to treat a serious condition and if approved  would substantially improve safety or effectiveness The NDA was based on data from the phase I II LIBRETTO 001 study  which evaluated selpercatinib for RET altered lung and thyroid cancers  In September 2019  Lilly announced positive results from the above mentioned study Later in December  Lilly began two other phase III studies on selpercatinib  While the LIBRETTO 431 study evaluated selpercatinib for treating patients with treatment na ve RET fusion positive NSCLC  the LIBRETTO 531 study investigated the same for addressing patients with treatment na ve RET mutant MTC  Both studies are looking to enroll 400 patients Shares of Lilly have rallied 16 7  in the past year compared with the  increase of 12 1  Precision medicines are an emerging approach to cancer treatment  which tailors a regime depending on the patient s genetic  environmental and lifestyle factors  Many industry players are adopting this method to bring new cancer treatments One such company is Blueprint Medicines Corp    NASDAQ BPMC    which is developing transformational precision medicines to address patients with genomically defined cancers and rare diseases  The company is developing pralsetinib  an investigational precision therapy  to address the RET fusion positive NSCLC and RET mutant MTC  The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is expected to be filed in the second quarter Zacks Rank   Other Stocks to ConsiderLilly currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Roche Holding  SIX ROG  AG   OTC RHHBY   and Sanofi   NASDAQ SNY    both carrying a Zacks Rank of 2  You can see  Roche s earnings estimates have moved 1 9  north for 2020 over the past 60 days  The stock has soared 24 6  in the past year Sanofi s earnings estimates have been revised 1 5  upward for 2020 over the past 60 days  The stock has jumped 12 3  in the past year Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/lillys-nda-for-selpercatinib-gets-fdas-priority-review-200503226,200503226
170993,392509,LLY,Exclusive  Germany s Bayer seeks animal health merger with Elanco   sources,news,"By Arno Schuetze and Pamela Barbaglia
FRANKFURT LONDON  Reuters    Bayer  DE BAYGn  has approached U S  drug firm  Elanco Animal Health   N ELAN  to discuss a possible combination of their pet health businesses to create an industry giant  three sources familiar with the matter told Reuters 
The two companies are working with banks to ensure any merger would secure regulatory approval  the sources said  speaking on condition of anonymity 
Bayer has delayed the launch of an auction to private equity funds to clinch a bilateral deal with Elanco  the fourth largest player in the animal health industry globally  the sources said 
The German drugmaker is under pressure to raise cash and boost its share price after its  63 billion purchase of  Monsanto   NYSE MON  
Bayer ranks fifth in veterinary medicine  Aside from Elanco  its bigger rivals are former  Pfizer   NYSE PFE  unit Zoetis  unlisted Boehringer Ingelheim  which bought animal health assets from Sanofi  PA SASY   and drugmaker Merck   Co 
Bayer Chief Executive Werner Baumann said in November his company would divest several assets including its animal health division  which analysts have said could fetch 6 billion to 7 billion euros   6 7 billion  7 8 billion  
The sources said discussions with Elanco were at an early stage and Bayer remained interested in receiving bids from private equity investors later this year 
An auction process was initially expected to start in June but Bayer would only dispatch information packages to prospective bidders towards the end of the summer  they said 
A Bayer spokesman said the firm was  progressing as planned  with efforts to separate the animal health business 
 After the strategic review of the possibilities  the main focus is on a sale   he said  adding Bayer continued to  consider all value maximising options   He declined to comment on Elanco 
Elanco  which also declined to comment on any deal  offers more than 125 products to veterinarians and food animal producers in more than 90 countries 
The company  based in Greenfield in the U S  state of Indiana  has a market value of  12 billion but it might struggle to finance an outright acquisition of Bayer s unit unless the German drugmaker decided to retain a stake in the combined entity  two sources said 
Elanco inherited a significant amount of debt from its previous owner Eli Lilly  N LLY   which spun it off last year 
As of December  it had about  2 5 billion of overall senior debt  In its annual report  it warned investors about the risk of failing to generate sufficient cash to service all its debts 
The sources said an all cash sale to Elanco was unlikely  adding Bayer would need to keep a stake in the merged company to secure a deal 
Private equity firms may offer an easier exit for the German group but they are expected to value the company at a much lower price due to its declining business  the sources said 
Buyout funds had tried to take control of Elanco when it was part of Eli Lilly but the company opted for a more lucrative spin off and listed the business in New York where it trades at about 20 times earnings 
  1   0 8923 euros ",2019-07-09,Reuters,https://www.investing.com/news/stock-market-news/exclusive-germanys-bayer-seeks-animal-health-merger-with-elanco--sources-1918696,1918696
170994,392510,LLY,Exclusive  White House preparing order that would cut drug prices for Medicare   sources,news,"By Michael Erman and Carl O Donnell NEW YORK  Reuters    U S  President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs  according to two industry sources who had discussions with the White House  The order under discussion would be much broader than the Administration s previously disclosed proposal to lower prices on physician administered  or Part B  drugs by tying prices to lower costs in other countries  The administration is now looking at ways to use this or a similar method to lower prices in Medicare s much larger Part D  which is for widely used prescription drugs patients take at home  such as for cholesterol and blood pressure  the sources said  The White House declined to comment  and it was unclear how far along the any such plan was from being undertaken  The U S  Department of Health and Human Services  also declined to comment  Americans pay the highest prices for prescription drugs in the world as most other developed nations have single payer systems in which the government negotiates drug prices for its people  The U S  government in 2016 spent around  29 billion on prescription drugs in Medicare s Part B  which includes most injectable drugs  and nearly  100 billion in Part D  which covers as pills and other drugs usually dispensed in pharmacies   Trump is also considering extending the pricing controls to the U S  Department of Defense  which runs the Tricare health plan for military personnel and their families  as well as the Department of Veterans Affairs  the sources said   Executive orders often go through various drafts and incarnations  and sometimes competing versions of the same order are floated within the Trump White House  In addition  some executive orders do not end up being signed   The drug pricing executive order could come as soon as the next few weeks  the sources said  U S  Senators Chuck Grassley and Ron Wyden   the top Republican and Democrat on the U S  Senate Finance Committee   earlier this week announced a proposal to lower prescription drug prices that could save  100 billion in costs to government healthcare programs  The White House could delay the executive order if the Senate bill looks likely to garner bipartisan support  the sources said  If implemented  the executive order could significantly increase the number of drugmakers whose sales could take a hit  AbbVie  NYSE ABBV   Eli Lilly  NYSE LLY  and Co and  Pfizer  Inc  NYSE PFE  all have substantial exposure to Medicare Part D  Companies with major exposure to Part B include Merck   Co  Bristol Myers Squibb  NYSE BMY  Co and Roche  In early July  Trump said his administration was working on a drug pricing executive order with a  favored nation clause  where we pay whatever the lowest nation s price is   Trump has called the lower prices paid by other nations  global freeloading   Trump  a Republican  has struggled to deliver on a pledge to lower drug prices before the November 2020 election  Healthcare costs are expected to be a major focus of the campaign by Trump and Democratic rivals vying to run against him   The Trump administration earlier this month scrapped an ambitious policy that would have required health insurers to pass billions of dollars in rebates they receive from drugmakers to Medicare patients  
Also in July  a federal judge struck down a Trump administration rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising ",2019-07-25,Reuters,https://www.investing.com/news/politics-news/exclusive-white-house-preparing-order-that-would-cut-drug-prices-for-medicare--sources-1933819,1933819
170995,392511,LLY,Eli Lilly Earnings and Revenue beat in Q2,news,"Investing com   Eli Lilly  NYSE LLY  reported second quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 5 on revenue of  5 64B  Analysts polled by Investing com forecast EPS of  1 45 on revenue of  5 59B  That compared to EPS of  1 5 on revenue of  6 36B in the same period a year earlier  The company had reported EPS of  1 33 on revenue of  5 09B in the previous quarter 
 
Eli Lilly follows other major Healthcare sector earnings this month
On July 16  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 46 on revenue of  20 29B 
Pfizer earnings beat analysts  expectations on Monday  with second quarter EPS of  0 8 on revenue of  13 26B  Investing com analysts expected EPS of  0 75 on revenue of  13 41B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-30,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-earnings-and-revenue-beat-in-q2-1938634,1938634
170996,392512,LLY,Bristol Myers  Opdivo Yervoy SBLA For NSCLC Accepted By FDA,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the FDA accepted the supplemental biologics license application  sBLA  for anti PD 1 antibody Opdivo  nivolumab  in combination with Yervoy  ipilimumab  for the first line treatment of patients with metastatic or recurrent non small cell lung cancer  NSCLC  with no EGFR or ALK genomic tumor aberrations  The FDA granted a priority review designation to the same and set an action date of May 15  2020 The sBLA was based on data from Part 1 of the phase III CheckMate 227 study  evaluating Opdivo plus Yervoy versus chemotherapy in patients with previously untreated NSCLC  In the study  the dual immunotherapy combination demonstrated significant improvement in overall survival rates compared to chemotherapy alone Shares of Bristol Myers have surged 34 2  in the past year  outperforming the  growth of 14 8  We note that Opdivo is currently approved in several countries  including the United States  the EU and Japan  for several cancer indications  The company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  The Opdivo and Yervoy combination is approved for the treatment of patients with unresectable or metastatic melanoma and intermediate or poor risk  previously untreated advanced renal cell carcinoma  RCC   The combination is also approved for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  metastatic colorectal cancer  CRC   which has progressed following treatment with a fluoropyrimidine  oxaliplatin and irinotecan Opdivo generated sales of  5 4 billion in the first nine months of 2019  reflecting an increase of 10  year over year Label expansion of Opdivo into additional indications would lend the product access to a higher patient population and increase its commercial potential significantly However  the drug is facing competitive challenges in the United States from Merck s   NYSE MRK   PD L1 inhibitor  Keytruda  Bristol Myers Squibb Company Price    Zacks Rank   Other Stocks to ConsiderBristol Myers currently carries a Zacks Rank  2  Buy   A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE   and Eli Lilly   Co    NYSE LLY    While Pfizer sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank  2  You can see  Pfizer s earnings per share estimates have moved up from  2 93 to  2 94 for 2019 and from  2 58 to  2 59 for 2020 in the past 60 days  The company delivered a positive earnings surprise of 8 73   on average  in the last four quarters Lilly s earnings per share estimates have increased from  5 79 to  5 80 for 2019 and from  6 56 to  6 77 for 2020 in the past 60 days  The company posted a positive earnings surprise in one of the last four quarters  with an average beat of 1 20  Free  Zacks  Single Best Stock Set to Double Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all  This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivoyervoy-sbla-for-nsclc-accepted-by-fda-200499288,200499288
170997,392513,LLY,Pharma Stock Roundup  LLY Dermira Buyout Offer  Pipeline   Regulatory Updates,opinion,"This week  Lilly   NYSE LLY   offered to buy Dermira for  1 1 billion to add the latter s late stage candidate for atopic dermatitis eczema  lebrikizumab  Meanwhile  AstraZeneca   NYSE AZN   announced discontinuation of a late stage study on its fish oil pill  Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee  While AbbVie   NYSE ABBV   announced data from a phase III head to head study on new drug Skyrizi  J J   NYSE JNJ   and Bristol Myers   NYSE BMY   provided some regulatory updates Recap of the Week s Most Important Stories Lilly Offers to Buy Dermira  Lilly offered to buy Dermira for  18 75 per share in cash or approximately  1 1 billion to add the latter s promising interleukin inhibitor for atopic dermatitis eczema    Lebrikizumab  a monoclonal antibody that targets IL 13  is being developed in phase III studies for moderate to severe atopic dermatitis  The deal will also add Dermira s marketed medicated cloth  Qbrexza for the topical treatment of primary axillary hyperhidrosis to Lilly s immunology portfolio Lilly also announced plans to launch lower priced versions of two of its insulin    Humalog Mix75 25 KwikPen and Humalog Junior KwikPen  The list price of these low priced insulin injections  which will be available from mid April  will be 50  lower than the current list price of the branded options AstraZeneca Abandons Heart Risk Study on Fish Oil Drug  AstraZeneca announced that it will discontinue the phase III STRENGTH outcomes study on its fish oil pill   The study was evaluating the cholesterol medicine Epanova to reduce the risk of cardiovascular disease in patients with mixed dyslipidaemia  MDL  or high triglyceride  TG  levels  The decision to stop the STRENGTH study was taken based on the recommendation of an independent Data Monitoring Committee as it was unlikely to demonstrate a benefit to patientsMeanwhile  AstraZeneca and partner Merck   NYSE MRK   announced that the FDA has granted priority review to a supplemental new drug application  sNDA  seeking approval of their PARP inhibitor Lynparza as a first line maintenance treatment for advanced ovarian cancer regardless of patients  biomarker status or surgical outcome  The sNDA is based on data from the PAOLA 1 study  With the FDA granting priority review  a decision from the FDA is expected in the second quarter of 2020 AbbVie s Skyrizi Superior to Novartis  Cosentyx in Psoriasis Study  AbbVie announced data from a phase III head to head study  comparing its newly approved drug Skyrizi  risankizumab  to Novartis    NYSE NVS   Cosentyx in adults with moderate to severe plaque psoriasis  The data showed that Skyrizi was superior to Cosentyx across primary and all ranked secondary endpoints at 52 weeks  Treatment with Skyrizi led to significantly higher rates of skin clearance compared to Cosentyx  thereby meeting the primary endpoint of superiority  Of the total  87  of patients treated with Skyrizi achieved the primary endpoint   at least a 90  improvement from baseline in the Psoriasis Area and Severity Index  PASI 90   at week 52 compared to 57  of Cosentyx treated patients FDA Grants Priority Review to Bristol Myers  Opdivo sBLA  The FDA accepted Bristol Myers  supplemental biologics license application  sBLA   seeking approval of Opdivo plus low dose Yervoy for first line NSCLC in patients with no EGFR or ALK genomic tumor aberrations  The sBLA was based on data from part 1 of the phase III CheckMate 227 study  With the FDA granting priority review to the application  a decision is expected on May 15  2020 J J Seeks Approval of Spravato in Expanded Patient Group in EU  J J submitted a type II variation application to the European Medicines Agency  EMA   seeking label expansion of its  esketamine  nasal spray in patients with major depressive disorder  MDD  who have current suicidal ideation with intent in Europe   A supplemental new drug application seeking a similar label expansion was filed in the United States in October this year  The application was based on data from two phase III studies  ASPIRE I   II The NYSE ARCA Pharmaceutical Index was up 2 2  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the green  Pfizer  NYSE PFE  recorded the maximum gain  4 4   In the past six months  Bristol Myers has risen the most  51 6   while Pfizer  PFE  lost the maximum  5 7    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for J J s fourth quarter 2019 results and regular pipeline and regulatory updates next week 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lly-dermira-buyout-offer-pipeline--regulatory-updates-200499583,200499583
170998,392514,LLY,Novo Nordisk s Ozempic Gets FDA Nod For CV Risk Reduction,opinion,Novo Nordisk  CSE NOVOb  A S   NYSE NVO   announced that the FDA has approved a label expansion of its once weekly injection Ozempic to lower the risk of cardiovascular events  The FDA approved the supplemental new drug application  sNDA  for Ozempic for reducing the risk of major adverse cardiovascular  CV  events  MACE  including cardiovascular death  non fatal heart attack  or non fatal stroke in adults with type II diabetes and established cardiovascular disease  CVD  The approval was based on data from the SUSTAIN 6 cardiovascular outcomes trial  CVOT    The study showed that Ozempic statistically significantly reduced the risk of CV death  non fatal heart attack or non fatal stroke by 26  versus placebo  when added to standard of care in the above mentioned patient population We remind investors that Ozempic is approved in the United States as a once daily pre filled pen to improve glycemic control in type II diabetes patients  It is also approved in Europe  Japan and Canada for the same indication Shares of the company have gained 27 6  in the past year compared with the  s growth of 14 2  The company also said that the label of Rybelsus  semaglutide in tablet form  is being updated to include data from the PIONEER 6 CVOT study demonstrating CV safety  The drug demonstrated CV safety by meeting the primary endpoint of non inferiority for the composite MACE endpoint The proportion of patients who experienced at least one MACE was 3 8  with Rybelsus and 4 8  with placebo We note that  Novo Nordisk has a strong presence in the Diabetes care market  with a global value share of 28 4   The company has one of the broadest diabetes portfolios in the industry   In July  Novo Nordisk and Gilead Sciences   NASDAQ GILD   initiated a phase II proof of concept study combining the former s semaglutide and the latter s cilofexor  FXR agonist  and firsocostat  ACC inhibitor  for the treatment of patients with nonalcoholic steatohepatitis  NASH   Novo Nordisk A S Price    Zacks Rank and Stocks to ConsiderNovo Nordisk currently has a Zacks Rank  4  Sell  A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE   and Eli Lilly   Co    NYSE LLY    While Pfizer sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank  2  You can see  Pfizer s earnings per share estimates have moved up from  2 93 to  2 96 for 2019 and from  2 58 to  2 62 for 2020 in the past 60 days  The company delivered a positive earnings surprise of 8 73   on average  in the last four quarters Lilly s earnings per share estimates have increased from  5 79 to  5 80 for 2019 and from  6 56 to  6 77 for 2020 in the past 60 days  The company posted a positive earnings surprise in one of the last four quarters  with an average beat of 1 20  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2020-01-17,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction-200499597,200499597
170999,392515,LLY,Eli Lilly tops revenue estimates on diabetes drug boost,news," Reuters    Eli Lilly and Co  N LLY  beat analysts  estimates for quarterly profit and raised its full year earnings forecast on Tuesday  as higher sales of diabetes drugs Trulicity and Basaglar offset competition for its erectile dysfunction treatment  Cialis   The drugmaker has been working to retain its dominant position in the diabetes market  as its top sellers  including insulin injection Humalog  lose market share to rivals  amid political scrutiny over soaring healthcare costs  Lilly is also banking on its newer treatments such as Emgality  which won U S  approval to treat migraine last year and has been touted as a growth driver for Lilly  Emgality brought in sales of  34 3 million in the three months ended June 30  missing analysts  estimate of  42 3 million for a second straight quarter   Sales of Trulicity rose about 32  to  1 03 billion in the second quarter  just above the average analyst estimate of  1 02 billion  according to IBES data from Refinitiv  The drug accounted for nearly a fifth of Lilly s total sales   In contrast  revenue from Humalog  which included the cut price version of the drug  fell 12  to  677 6 million  Lilly in March agreed to offer a half priced version of Humalog after coming under intense pressure from U S  politicians to lower drug costs   The company raised its 2019 adjusted earnings forecast to a range of  5 67 to  5 77 per share from its prior range of  5 60 to  5 70 per share  Analysts were expecting a profit of  5 66 per share  However  revenue from the United States was nearly flat at  3 25 billion  mainly due to lower prices even as volumes rose   Total revenue rose to  5 64 billion from  5 59 billion  above estimates of  5 59 billion  Lilly had warned in April that its revenue growth will be hit by its programs that allow new patients to try new drugs at little or no cost   The drugmaker posted net income of  1 33 billion  or  1 44 per share  in the latest quarter  Excluding items  Lilly earned  1 50 per share  Analysts were expecting a profit of  1 45 per share  Separately  the company released late stage study results  which showed that Lilly s combination therapy that includes its cancer treatment  Verzenio  helped women with certain types of advanced breast cancer live longer  Verzenio competes with  Novartis  AG s  S NOVN  Kisqali and  Pfizer  Inc s  N PFE  Ibrance  The therapy brought in slightly better than expected sales of  133 9 million during the quarter  
Shares of the company rose 1  to  109 75 in trading before the bell ",2019-07-30,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-tops-revenue-estimates-on-diabetes-drug-boost-1938659,1938659
171000,392516,LLY,Glaxo s Multiple Myeloma Candidate Gets FDA s Priority Review,opinion,GlaxoSmithKline plc   NYSE GSK   announced that the FDA has granted priority review to its biologics license application  BLA  for belantamab mafodotin  The company is seeking approval of the candidate for the treatment of relapsed refractory multiple myeloma in patients who are previously treated with an immunomodulatory agent  a proteasome inhibitor and an anti CD38 antibody The regulatory body generally grants a priority review to drugs that have the potential to treat a serious condition and if approved  would substantially improve safety or effectiveness The BLA was based on data from the pivotal DREAMM 2 study  Last month  Glaxo announced detailed results from the above mentioned study  which evaluated two doses of belantamab mafodotin in patients with heavily pre treated multiple myeloma  Per the company  treatment with belantamab mafodotin led to a clinically meaningful 31  overall response rate  ORR  under the 2 5 mg kg regimen in such patients In August 2019  the study had met its primary endpoint by showing a clinically meaningful overall response rate with belantamab mafodotin in the above patients Per the company  belantamab mafodotin has potential to be the first anti BCMA treatment available to the given patient population  The candidate is also being evaluated in several studies for other forms of multiple myeloma Shares of Glaxo have gained 21 6  in the past year compared with the  rally of 15 1  Notably  Glaxo made a significant progress in its oncology pipeline of late and now boasts 16 assets in developmental stage  This is achieved through advancement of internal programs and targeted business development including the January 2019 acquisition of Tesaro and the February 2019 global alliance with Merck KGaA  to co develop bintrafusp alpha M7824  a promising new oncology medicine  The company is developing dostarlimab for treating second line endometrial cancer  The NDA filing for the candidate is expected soon Meanwhile  Glaxo now has a number of molecules with diverse mechanisms of action  providing an opportunity for many innovative cancer combinations  Last August  Glaxo and Pfizer   NYSE PFE   closed their previously announced merger of their respective consumer healthcare units into a new joint venture  JV  to focus on pharmaceuticals business  particularly oncology  Moreover  Zejula  the ovarian cancer drug added to Glaxo s portfolio from the Tesaro buyout  was approved in October 2019 for addressing late stage ovarian cancer Zacks Rank   Stocks to ConsiderGlaxo currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Roche Holding  SIX ROG  AG   OTC RHHBY   and Eli Lilly and Company   NYSE LLY    both carrying a Zacks Rank  2  Buy   You can see  Roche s earnings estimates have moved 1 9  north for 2020 over the past 60 days  The stock has rallied 30 7  in the past year Eli Lilly s earnings estimates have been revised 3 2  upward for 2020 over the past 60 days  The stock has jumped 18 6  in the past year Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/glaxos-multiple-myeloma-candidate-gets-fdas-priority-review-200500556,200500556
171001,392517,LLY,5 Best Performing Biotech Mutual Funds Of 2019,opinion,The biotechnology industry witnessed remarkable growth last year  owing to a series of mergers and acquisitions  initial public offerings  collaborative operations and new job additions in the space that boosted it throughout 2019  What s more  the products and services offered by the industry are always in demand because of their nature  which makes biotech a lucrative investment space irrespective of market conditions Biotech Indexes Fare Well in 2019The industry made headlines since the beginning of 2019  thanks to numerous mergers and acquisitions  and initial public offerings that kept the space in investors  focus  Bristol Myers Squibb s acquisition of Celgene Corporation  NASDAQ CELG  and Eli Lilly  NYSE LLY  and Company s acquisition of Loxo Oncology were some of the major deals that took place last year Second  the number of initial public offerings was also considerable  Biotech IPOs have been increasing steadily over the past few years  This is because biotech companies require significant financing  particularly as they advance their research  By going public  a significant portion of this much required financing is taken care of  This also makes these biotech firms more visible for collaborations and acquisitions Strategic collaborations also surfaced as major game changers for the industry  Amgen s collaboration with BeiGene and Biogen s partnership with C4 Therapeutics were some crucial alliances last year Owing to these factors  major biotech ETFs and indexes performed impressively in 2019  Specifically  the SPDR S P Biotech ETF  NYSE XBI   iShares Nasdaq Biotechnology ETF  IBB   ProShares Ultra Nasdaq Biotechnology  BIB  and NASDAQ Biotechnology Index  NBI  gained 30 5   23   41 8  and 22 9   respectively 5 Top Biotech Mutual Funds We have  therefore  selected five biotech mutual funds that carry a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   In addition  the minimum initial investment for these funds is within  5 000 We expect these funds to outperform their peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance but also on the likely future success of the fund The question here is why should investors consider mutual funds  Reduced transaction costs and diversification of portfolio without several commission charges that are associated with stock purchases are primarily why one should be parking money in mutual funds  read more    Fidelity Select Biotechnology Portfolio    aims for capital growth  The fund invests the majority of its assets in securities of companies primarily engaged in the research  development  manufacture and distribution of several biotechnological products and services  The fund also invests in companies that gain considerably from scientific and technological advancements in biotechnology  The non diversified fund invests in U S  and non U S  issuers This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   FBIOX carries a Zacks Rank  1 and has an annual expense ratio of 0 72   which is below the category average of 1 24   It has returned 36  over the period of a year  FBIOX has no minimum initial investment Live Oak Health Sciences Fund    invests the majority of its assets in equity securities of health science companies  The fund invests principally in common stocks of U S  companies  but may also invest in equity REITs  common stocks of foreign companies and ADRs that meet the investment criteria of LOGSX This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   LOGSX carries a Zacks Rank  1 and has an annual expense ratio of 1 01   which is below the category average of 1 24   It has returned 19  over the period of a year  LOGSX has a minimum initial investment of  2000 T  Rowe Price Health Sciences Fund    invests the majority of its assets in the common stocks of companies that are engaged in the research  development  production or distribution of products or services related to health care  medicine or the life sciences  The non diversified fund invests mostly in large  and medium capitalization companies This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   PRHSX carries a Zacks Rank  1 and has an annual expense ratio of 0 77   which is below the category average of 1 24   It has returned 29 1  over the period of a year  PRHSX has a minimum initial investment of  2500 Janus Henderson Global Life Sciences Fund Class A    seeks capital growth  The fund invests the majority of its assets in securities of companies that the fund s portfolio managers believe have a life science orientation  The fund has a fundamental policy to invest at least a quarter of its assets in securities of companies that are categorized in the life sciences sector This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   JFNAX carries a Zacks Rank  2 and has an annual expense ratio of 0 99   which is below the category average of 1 24   It has returned 29  over the period of a year  JFNAX has a minimum initial investment of  2500 PGIM Jennison Health Sciences Fund  Class A    invests the majority of its assets in equity and equity related securities of companies that operate in the health sciences sector  These consist of pharmaceutical companies  biotechnology companies  medical device manufacturers  healthcare service providers and health maintenance organizations etc  The fund aims for long term capital appreciation This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   PHLAX carries a Zacks Rank  2 and has an annual expense ratio of 1 14   which is below the category average of 1 24   It has returned 18 2  over the period of a year  PHLAX has a minimum initial investment of  2500 Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/5-bestperforming-biotech-mutual-funds-of-2019-200500474,200500474
171003,392519,LLY,J J s Stelara Gets EU Nod For Plaque Psoriasis In Children,opinion,Johnson   Johnson   NYSE JNJ   announced that the European Commission  EC  has approved the label expansion of Stelara  ustekinumab  for the treatment of moderate to severe plaque psoriasis in pediatric patients aged between six and 11 years for whom there are limited biologic treatment options Notably  in December 2019  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion recommending the marketing approval of Stelara to treat the above mentioned patient population With the latest nod in the EU  Stelara becomes the first available biologic treatment to deal with the given patient population to selectively address the IL 23 IL 12 pathway  an important therapeutic target for the given condition The EC s approval for plaque psoriasis in pediatric patients was based on data from the phase III CADMUS Jr study  Results from the same showed that treatment with Stelara led to improved signs and symptoms of plaque psoriasis as well as better health related quality of life in children aged from six to 11 years  who are living with this chronic disease Stelara is also under the FDA review for plaque psoriasis in pediatric patients Shares of J J have increased 15 8  in the past year compared with the  rally of 17 4  Stelara is already approved to treat plaque psoriasis in adolescent and adult patients with plaque psoriasis  aged 12 years and above  This apart  the drug is marketed for active ulcerative colitis  psoriatic arthritis and moderate to severe Crohn s disease for adult patients in both the United States and the EU  The drug is also being studied for axial spondylitis in phase III studies Notably  in the fourth quarter of 2019  Stelara generated sales of  1 7 billion  reflecting a year over year rise of 17 7   driven primarily by the Crohn s disease indication Continuous label expansion of the drug is not only expanding its eligible patient base but also contributing significantly to the company s top line Zacks Rank   Other Stocks to ConsiderJ J currently carries a Zacks Rank  2  Buy   Other stocks worth considering in the large cap pharma sector include Roche Holding  SIX ROG  AG   OTC RHHBY    Eli Lilly and Company   NYSE LLY   and Bristol Myers Squibb Company   NYSE BMY    all carrying a Zacks Rank of 2  You can see  Roche s earnings estimates have moved 1 5  north for 2020 over the past 60 days  The stock has rallied 32 2  in the past year Eli Lilly s earnings estimates have been revised 3 2  upward for 2020 over the past 60 days  The stock has jumped 22 8  in the past year Bristol Myers earnings estimates have moved 2 8  north for 2020 over the past 60 days  The stock has surged 36 7  in the past year Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children-200501395,200501395
171005,392521,LLY,Blue blooded crabs at heart of pharma dispute on drug testing,news,"By John Miller ZURICH  Reuters    If you ve received a vaccination  hip replacement or chemotherapy without suffering toxic shock  chances are you ve benefited from a vast bloodletting of horseshoe crabs  Every year  fishermen net hundreds of thousands of the creatures off the U S  East Coast and in Asia before their prized milky blue blood is drained for use in medical safety tests  Swiss biotech Lonza  S LONN  and U S  based Charles River Laboratories  N CRL  are the biggest suppliers of crab blood based endotoxin tests  which detect bacterial contamination in intravenous drugs and medical implants  They are now at odds over the future of this testing  as Lonza urges adoption of a synthetic alternative called recombinant Factor C  rFC   amid pressure from wildlife campaigners and worries about supply reliability   Meanwhile Charles River  which is still studying rFC  argues moving too quickly could compromise patient safety  There s much at stake   for both companies  the industry and  of course  horseshoe crabs  a 450 million year old species that s more closely related to scorpions than crustaceans   Endotoxin tests number 70 million annually and are rising  If rFC gains traction  it could re shuffle winners and losers in the global market for such testing that is seen growing about 13  a year to close to  700 million in annual revenue by 2021 and  1 billion by 2024  according to market researchers   For Lonza  whose internal testing growth estimates are more modest  the risk is that the synthetic method won t catch on  hurting efforts to capitalize on a  460 million investment it made in 2006 when it bought the technology along with a peer s biological businesses  Conversely  Charles River risks becoming a laggard if the technique wins wide acceptance  PHARMACOPOEIA PUSH The leading U S  pharmaceuticals standards organization  U S  Pharmacopoeia  USP   which publishes a compendium of drug information  told Reuters it was pressing ahead to recognize synthetic tests as comparable to crab blood based ones   There is a consensus on moving forward and USP is fully committed   said Fouad Atouf  USP s Science Global Biologics head   Making sure all the stakeholders are on board and all the data has been collected is what s happening right now   he said  with proposed revisions recognizing rFC due around September for public consultation  That coincides with a push by USP s European counterpart in Strasbourg  to recognize rFC  Japan is also working on the issue  France s  Biomerieux   PA BIOX  and Germany s privately held Haemochrom Diagnostica  which have versions of rFC  are also eager to see pharmacopoeias act   Lonza said its rFC product  PyroGene  now accounts for less than 5 percent of its endotoxin test sales but sees fortunes changing as global pharmacopoeias act   We would hope to see around 10  by 2021   Lonza said  It has won a big customer for PyroGene  Eli Lilly s  N LLY  migraine medicine Emgality last year became the first rFC tested drug to win U S  regulatory approval  Roche  S ROG  and Bayer  DE BAYGn  told Reuters they were also considering rFC   UNACCEPTABLE RISK  Charles River insists additional scrutiny is necessary before rFC technology wins equal standing   Companies pushing rFC must prove it can detect endotoxins in the real world  not just the manufactured strains used so far in studying the synthetic agent  said John Dubczak  Charles River s microbial solutions manager   A move by the pharmaceutical industry towards current rFC methods is premature   said Dubczak  adding more data is needed  Lonza points to analyses by multiple drugmakers demonstrating rFC was comparable to the crab blood tests in ensuring drugs were contaminant free  To be sure  Lonza has no plans to stop bleeding crabs  since many existing medical products will continue to be tested with traditional methods  it said   The industry predicts the global crab blood based test market will also expand in the next few years  But Lonza is counting on rFC emerging as a new pillar of its testing business  contributing to its goal of more than 7 billion Swiss francs   7 1 billion  in group annual revenue by 2022  from 5 5 billion francs  NATURE S INGENUITY Horseshoe crabs  copper rich blood has helped them survive since before the dinosaurs in brackish coastal waters by clotting around endotoxins  the potentially dangerous molecules found in cell walls of bacteria like E  coli   Scientists harnessed nature s ingenuity  using crab blood to make so called amebocyte lysate endotoxin tests which  by the 1970s  began displacing tests on rabbits that were injected with medicine then monitored for fever   However  concerns have since escalated over wildlife conservation and the supply chain s reliability   In Asia  where horseshoe crabs are also eaten by humans  the tri spine species is listed by the International Union for Conservation of Nature as at risk of extinction  Two other species are also imperiled   Glenn Gauvry  director of the Delaware based Ecological Research and Development Group which focuses on horseshoe crab conservation  said Asian crabs destined for dinner tables were first  rented  to biomedical companies for bleeding  Gauvry contends the biomedical industry is perpetuating consumption of crabs in Asia and contributing to their decline  Lonza does not harvest Asian crab blood   Charles River  which does  said it followed local rules    Horseshoe crab blood is collected only to a point where the crab naturally stops bleeding   Dubczak said  adding its Asian suppliers and local governments were responsible for ensuring crabs were released into  waters of appropriate salinity   RUFA RED KNOT Studies paint a mixed picture of the blood harvest s effects on U S  East Coast horseshoe crabs  hundreds of thousands of which are also killed annually for bait or caught incidentally by commercial fishermen hunting other marine species  Those caught by Lonza  Charles River and Associates of Cape Cod  owned by Japan s  Seikagaku Corp   T 4548   are drained of about a third of their blood  then returned alive to the sea  An Atlantic States Marine Fisheries Commission report from May indicates current harvest levels  appear to be sustainable    Additionally  a recent U S  Geological Survey study found bled crabs  survival rates may exceed those of non bled crabs in New Jersey s Delaware Bay   However  previous studies found anywhere between 4  to 30  of bled crabs may die prematurely  prompting pressure on the biomedical industry  largely out of concern for shorebird populations that rely on crab eggs  Advocates including the Audubon Society became increasingly vocal when the rufa red knot  which eats crab eggs on stopovers at Delaware Bay  was listed as threatened under the U S  Endangered Species Act in 2014   That was the tipping point   said Jay Bolden  an Eli Lilly biologist whose hobby as a birdwatcher spurred him to champion his company s switch to rFC that he believes will ensure supply chain reliability    If it got really serious  and they said nobody could touch the horseshoe crabs because they have to rebuild the red knot population  that was going to be significant   Lilly has shifted three of eight global drug manufacturing sites to rFC testing and is more than halfway to its goal of 90 percent rFC testing by 2020  he added    Until the global pharmacopoeias revise the test method to recognize rFC as on par with crab blood based tests  we can t just make the change for medicines that are already on the market   Bolden said   
 When that happens  then we can change over that final 10 percent  ",2019-08-01,Reuters,https://www.investing.com/news/stock-market-news/blueblooded-crabs-at-heart-of-pharma-dispute-on-drug-testing-1941886,1941886
171006,392522,LLY,Elanco to become No 2 in animal health with  7 6 billion Bayer deal,news,"By Ludwig Burger  Reuters     Elanco Animal Health   N ELAN  agreed to buy Bayer s  DE BAYGn  veterinary drugs unit on Tuesday in a cash and stock deal valued at  7 6 billion  creating the second largest maker of medicines for pets and livestock and expanding Elanco s reach online  The deal is the latest in the fast growing animal health market  which has recently seen Elanco floated by Eli Lilly and Co  N LLY  and rival U S  drugmaker  Pfizer   N PFE  also spinning off its veterinary medicine business  It also adds to the list of assets sold by Bayer  as the German company looks to slash debt from its  63 billion takeover of seed maker  Monsanto   NYSE MON  last year and as it braces for a potential settlement of lawsuits over an alleged cancer causing effect of weedkiller Roundup  The two companies said Bayer would receive  5 3 billion in cash and  2 3 billion worth of Elanco stock based on a price of  33 60 per share  the 30 day average price as of Aug  6  Elanco said the stock amounted to 68 million shares  or a stake of about 18 2  based on Refinitiv data  but the number of shares could rise or fall by as much as 7 5   depending on Elanco s share price performance on the closing date  Refinitiv data on 373 million outstanding shares does not yet take into account the dilutive effect from an as yet unspecified capital increase that Elanco plans to carry out  The price tag for the deal implies a multiple of 18 8 times adjusted core earnings  Bayer said  adding it would sell the equity stake over time  Reuters reported last month that Bayer had approached Elanco to discuss a possible combination that would be number two after industry leader Zoetis  N ZTS  and ahead of unlisted Boehringer Ingelheim   which bought animal health assets from Sanofi  PA SASY    and drugmaker Merck   Co  N MRK    Market researchers expect the  44 billion animal health sector to grow 5  6  per year  driven by an increase in livestock farming and  more importantly  by more people wanting to own pets and spending more money on their wellbeing  FUNDING Bayer is the world s largest maker of flea and tick control products for cats and dogs  with Elanco praising its  top presence on Amazon  with  industry leading e commerce retail capabilities    The move combines our long standing focus on the veterinarian  while meeting pet owners  changing expectation of pet care and access to products   said Elanco CEO Jeffrey Simmons  Elanco said it planned to fund the cash payout to Bayer with a combination of new debt and equity  with the size of the equity capital increase depending on future market developments  Its shares were down 6 7  at  27 81 at 1430 GMT  while Bayer shares were unchanged   Bayer has recently sold its 60  stake in a chemical park operator as well as consumer health brands Dr  Scholl s and Coppertone  with combined proceeds of close to 2 4 billion euros   2 7 billion   Credit rating agency Moody s said the Elanco deal would improve Bayer s ability to reduce its debt load and shoulder an expected settlement of the Roundup cases  S P and Fitch  in turn  flagged the risk of a credit rating downgrade for Elanco   Equity analysts at Citi said Bayer sold near the top of the price range the brokerage had projected  It expects Bayer to buy back 3 billion euros worth of its own shares in 2020 to offset lower earnings per share from the divestments  with the remainder of the proceeds used to speed up debt payments  Analysts have put the likely Roundup settlements at  5  10 billion  with many saying the share price reflects exaggerated market expectations of a  20  25 billion hit  Bayer strongly denies a carcinogenic effect from using Roundup  
Elanco said it expected the transaction to close by the middle of 2020 ",2019-08-20,Reuters,https://www.investing.com/news/stock-market-news/elanco-to-buy-bayers-animal-health-unit-for-76-billion-1958938,1958938
171014,392530,LLY,Verastem In Licenses KRAS Focused Drug From Chugai  Stock Up,opinion,"Verastem  Inc    NASDAQ VSTM   announced that it has signed a global licensing agreement with Japan based Chugai Pharmaceutical  Per the terms of the agreement  Verastem will gain worldwide development and commercialization rights to Chugai s RAF MEK inhibitor  CH5126766  Chugai is currently developing the candidate as a treatment of KRAS mutant solid tumors Verastem will pay Chugai  3 million in upfront payment along with royalties  Verastem will be responsible for future development of CH5126766 and its commercialization globally  The company may look for various partnering strategies for development of the candidate Investors cheered the news and shares were up 36 5  on Jan 8  However  the company s shares have declined 58  in the past year compared with the  s decrease of 2 9  Synergry has been observed in pre clinical KRAS mutant models for combination of FAK and MEK inhibitors  Based on this observation the company has gained rights to CH5126766 for developing it in combination with its FAK inhibitor  defactinib  Currently  CH5126766 in combination with defactinib is being evaluated in a phase I II study in patients with KRAS mutant advanced solid tumors  including low grade serous ovarian cancer  LGSOC   non small cell lung cancer  NSCLC  and colorectal cancer The company plans to present clinical data from a study on defactinib plus CH5126766 and discuss development plans and registration path for this regimen with regulatory authorities in the first half of 2020 Verastem is also developing defactinib as monotherapy or in combination regimens for ovarian cancer  pancreatic cancer  mesothelioma  NSCLC and other solid tumors  The candidate is being evaluated in combination with Merck s   NYSE MRK   PD 1 inhibitor Keytruda and Eli Lilly s   NYSE LLY   chemotherapy  Gemzar  for treating patients with advanced pancreatic cancer Meanwhile  Versatem continues to develop its leukemia drug  Copiktra  into additional indications including non Hodgkin lymphoma  lung cancer    and others  In 2016  Verastem had in licensed Copiktra from Infinity Pharmaceuticals   NASDAQ INFI    The drug received FDA approval in 2018 for treating chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies and follicular lymphoma after at least two prior systemic therapies  The drug generated  8 7 million in sales in the first nine months of 2019 Verastem  Inc  Price
    Zacks RankVerastem currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/verastem-inlicenses-krasfocused-drug-from-chugai-stock-up-200497586,200497586
171016,392532,LLY,Lilly To Buy Dermira For  1 1B  Add Phase III Eczema Candidate,opinion,Eli Lilly   Company   NYSE LLY   announced a definitive deal to buy dermatology company  Dermira  Inc    NASDAQ DERM   for  18 75 per share in cash or approximately  1 1 billion  The deal will add Dermira s promising interleukin inhibitor for atopic dermatitis eczema  lebrikizumab  thereby expanding Lilly s immunology pipeline  The purchase price represents a premium of 2 2  to Dermira s closing price on ThursdayWhile Lilly s shares were up 1 5  on Friday on the deal  Dermira s shares were up almost 5   Lilly s shares have outperformed the large cap pharma industry in the past year  The stock has returned 20 3  in the said timeframe compared with the  s increase of 14 7  Lebrikizumab  a monoclonal antibody that targets IL 13  is being developed in phase III studies for moderate to severe atopic dermatitis in adolescent and adult patients  aged 12 years and older  It also enjoys Fast Track designation from the FDA that was granted last month  The deal will also add Dermira s marketed medicated cloth  Qbrexza for the topical treatment of primary axillary hyperhidrosis to Lilly s immunology portfolio  which includes drugs like Taltz for psoriasis and Olumiant for rheumatoid arthritis  The transaction is expected to close by the end of the first quarter of 2020Sanofi   NASDAQ SNY   and Regeneron   NASDAQ REGN   also market interleukin inhibitor  Dupixent for atopic dermatitis as well as for asthma  Dupixent is now annualizing at around  2 billion in sales after just around two years in the market  If approved  lebrikizumab would compete with Dupixent Lilly added promising pipeline assets through business development deals in 2019 as well  At the beginning of 2019  the company bought small cancer biotech  Loxo Oncology  Inc   for  8 billion in cash  which broadened the scope of its oncology portfolio into precision medicines  It also formed small immunology collaborations with small  private biotechs Avidity Biosciences and ImmuNext Lilly currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/lilly-to-buy-dermira-for-11b-add-phase-iii-eczema-candidate-200498299,200498299
171018,392534,LLY,Glaxo Files Marketing Application For Fostemsavir In Europe,opinion,GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary ViiV Healthcare announced that it has submitted a marketing authorization application  MAA  to the European Medicines Agency  EMA  for its first in class attachment inhibitor fostemsavir to treat heavily treatment experienced adult patients with HIV 1 infection The company is seeking approval of fostemsavir for use in combination with other antiretroviral agents to treat adult patients with multidrug resistant HIV 1 infection  for whom it is otherwise not possible to form a suppressive regimen due to resistance  intolerance or safety considerations Notably  the EMA s Committee for Medicinal Products for Human Use  CHMP  granted an accelerated assessment to the MAA filing for fostemsavir  which reduces the review time for the same The MAA filing was based on data from the pivotal phase III BRIGHTE study  In July 2019  Glaxo presented week 96 data from the same study at the International AIDS Society Conference on HIV Science held in Mexico City The new drug application for fostemsavir in the United States was filed with the FDA in December 2019 Notably  ViiV Healthcare is an HIV company  majorly owned by Glaxo and Pfizer   NYSE PFE   Shares of Glaxo have rallied 21 2  in the past year  outperforming the increase of 14 7  We remind investors that HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  namely Tivicay  Triumeq and Juluca in its portfolio  HIV sales totaled  3 6 billion in the first nine months of 2019 Moreover  Glaxo gained FDA approval in April 2019 for Dovato  a single tablet regimen of Tivicay  dolutegravir    lamivudine for treatment na ve HIV patients  Later  it was also approved in the EU during July  The new HIV medicine is off to a strong start in both the United States and the EU However  last month  Glaxo faced a major setback when it received a complete response letter  CRL  from the FDA for its investigational long acting injectable regimen of cabotegravir and Johnson   Johnson s   NYSE JNJ   Edurant  rilpivirine  for the treatment of HIV 1 infection in virologically suppressed adults Zacks Rank   Key PickGlaxo currently carries a Zacks Rank  3  Hold   A better ranked stock in the large cap pharma sector is Eli Lilly and Company   NYSE LLY    which carries a Zacks Rank  2  Buy   You can see  Eli Lilly s earnings estimates have moved 3 2  north for 2020 over the past 60 days  The stock has increased 20 3  in the past year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/glaxo-files-marketing-application-for-fostemsavir-in-europe-200498344,200498344
171021,392537,LLY,Lilly To Launch Cheaper Versions Of Humalog KwikPen Insulins,opinion,Eli Lilly   Company   NYSE LLY   announced plans to launch lower priced versions of two of its insulin product  Humalog   Humalog Mix75 25 KwikPen and Humalog Junior KwikPen The list price of these low priced insulin injections will be 50  lower than the current list price of the branded options  The lower priced version of Humalog Mix75 25 will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75 25 KwikPen  100 units mL  while that of Humalog Junior KwikPen will be known as Insulin Lispro Injection Junior KwikPen  The cheaper KwikPens pack of five will cost  265 20 and are expected to be available from mid April We remind investors that in May last year Lilly had launched a cheaper version of Humalog U 100 called Insulin Lispro Injection  which contains an identical molecule as Humalog  Insulin Lispro Injection was also priced 50  lower than the list price of Humalog U 100  Lilly said that since then 10  of people using Humalog have transitioned to the cheaper injection Lilly s stock has risen 20 4  in the past year compared with 13 4  increase for the    The move comes as the three largest insulin manufacturers  Lilly  Sanofi   NASDAQ SNY   and Novo Nordisk   NYSE NVO   face increasing scrutiny for steep prices of insulins  Prices have reportedly nearly doubled in the past five years  The insulin makers have defended the high list prices by saying that they have to pay significant rebates to pharmacy benefit managers to secure market share  However  uninsured patients suffer a lot due to the high list prices of insulins Last year  executives from several big pharma companies including Pfizer   NYSE PFE    Sanofi  J J  NYSE JNJ   AbbVie  NYSE ABBV  and others were grilled by senators regarding high drug prices  Senators stated that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations  They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection Lilly currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/lilly-to-launch-cheaper-versions-of-humalog-kwikpen-insulins-200498967,200498967
171023,392539,LLY,Nektar s Pain Drug Gets Adverse Advisory Committee Decision ,opinion,"Nektar Therapeutics   NASDAQ NKTR   announced that two FDA advisory committees did not give recommendation for approval to its chronic pain candidate  oxycodegol  formerly NKTR 181   The company met Anesthetic and Analgesic Drug Products Advisory Committee  and Drug Safety and Risk Management Advisory Committee to discuss the new drug application   NDA   for oxycodegol  The company has withdrawn the NDA for the candidate and decided to stop further development of the candidate following the unfavorable decision Shares of Nektar were down 14 9  in pre market trading on Jan 14  following the unfavorable news  The company s shares have declined 37 2  in the past year compared with the  s decrease of 0 8  Please note that the company s NDA seeking approval for oxycodegol was accepted by the FDA in July 2018  A decision was previously expected in August 2019  However  the FDA postponed product specific advisory committee meetings to discuss the NDA due to a number of scientific and policy issues relating to opioid analgesics The company stated in its recent press release that it had used well established efficacy  safety and human abuse potential study designs for development of oxycodegol  These study designs had previously led to FDA approval for other opioid based analgesics Meanwhile  the company had raised concerns in its third quarter earnings report for oxycodegol approval due to substantial uncertainty related to approval of new opioid based drugs Nektar stated that discontinuation of oxycodegol development will help the company to generate cost savings in the range of  75  125 million in 2020  The savings will be led by reduction in estimated costs related to planned oxycodegol commercialization and post approval studies Meanwhile  Nektar continues to develop its oncology and auto immune disorder pipeline  The company is developing several immuno oncology candidates with bempegaldesleukin being its primary candidate  Earlier this month  it  its collaboration agreement with Bristol Myers   NYSE BMY   to include two new registrational studies  The studies will evaluate bempegaldesleukin plus Bristol Myers  Opdivo in adjuvant melanoma and muscle invasive bladder cancer The company is also developing several other candidates across important therapeutic areas including NKTR 358 in autoimmune diseases and NKTR 255 in virology indications  It has collaborations with Eli Lilly   NYSE LLY   and Gilead Sciences   NASDAQ GILD   for development of NKTR 358 and NKTR 255  respectively Nektar Therapeutics Price
    Zacks RankNektar currently carries a Zacks Rank  1  Strong Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/nektars-pain-drug-gets-adverse-advisory-committee-decision-200498960,200498960
171024,392540,LLY,Eli Lilly Earnings Beat  Revenue Misses In Q1,news,"Investing com   Eli Lilly  NYSE LLY  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 33 on revenue of  5 09B  Analysts polled by Investing com anticipated EPS of  1 28 on revenue of  5 19B  That compared to EPS of  1 34 on revenue of  5 7B in the same period a year earlier  The company had reported EPS of  1 33 on revenue of  6 44B in the previous quarter 

Eli Lilly follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Novartis ADR earnings Beat analysts  expectations on April 24  with first quarter EPS of  1 21 on revenue of  11 11B  Investing com analysts expected EPS of  1 11 on revenue of  11 09B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-earnings-beat-revenue-misses-in-q1-1850364,1850364
171025,392541,LLY,Eli Lilly misses estimates for diabetes drug Trulicity  cuts revenue forecast,news," Reuters    Eli Lilly  NYSE LLY  and Co reported lower than expected sales for its top selling diabetes drug Trulicity and cut its full year revenue forecast as it sees further hits from price declines in the United States  sending its shares down 3 percent  The company also cited a number of challenges for the year including increased generic competition for drugs such as erectile dysfunction treatment Cialis and the global withdrawal of its cancer drug Lartruvo  Under intensifying pressure from lawmakers to lower drug prices  Lilly agreed to offer a half priced version of insulin injection Humalog earlier this year  The drugmaker is one of the three main global providers of insulin products   Lilly said it now expects 2019 revenue to come in between  22 0 billion and  22 5 billion  lower than its prior forecast of  25 1 billion to  25 6 billion  Analysts had expected  22 17 billion  Trulicity brought in  879 7 million in the first quarter  missing the average analyst estimate of  952 million  partly hurt by lower realized prices and changes in estimates to rebates and discounts in the United States  Sales of psoriasis treatment Taltz  considered one of Lilly s growth drivers  came in at  252 5 million  also falling short of analysts  estimates   The results will     lead to some pressure on Lilly shares today given the underperformance of Trulicity and Taltz   said  Credit Suisse   SIX CSGN  analyst Vamil Divan  Sales of Cialis dropped 38 percent to  308 2 million as the drug continues to suffer from increased generic competition  Net income more than tripled to  4 24 billion  or  4 31 per share  in the quarter ended March 31  as the company benefited from a  3 7 billion gain from its spin off of animal health unit Elanco  Excluding items  the company earned  1 33 per share  beating the average estimate of  1 31  according to IBES data from Refinitiv  Revenue rose to  5 09 billion  but missed estimates of  5 13 billion due to lower realized prices  
The company raised its adjusted earnings forecast to  5 60 to  5 70 per share from a prior range of  5 55 to  5 65  beating the average analyst estimate of  5 63 ",2019-04-30,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-quarterly-profit-more-than-triples-on-elanco-gain-1850404,1850404
171027,392543,LLY,Eli Lilly quarterly sales beat expectations,news, Reuters    Eli Lilly  NYSE LLY  and Co posted better than expected fourth quarter revenue on Wednesday  helped by higher sales of its newer drugs such as diabetes treatment Trulicity and psoriatic arthritis medication Taltz  Revenue rose 4 5 percent to  6 44 billion  beating the average analyst estimate of  6 29 billion  according to IBES data from Refinitiv  The company posted net income of  1 13 billion  or  1 10 per share  in the fourth quarter ended Dec  31  compared with a net loss of  1 66 billion  or  1 58 per share  a year earlier  when it recorded charges related to the U S  tax overhaul ,2019-02-06,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly-quarterly-sales-beat-expectations-1770721,1770721
171028,392544,LLY,Moving Average Crossover Alert  Eli Lilly And Company,opinion,Eli Lilly and Company   NYSE LLY   is looking like an interesting pick from a technical perspective  as the company is seeing favorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for LLY broke out above the 200 Day Simple Moving Average  suggesting a short term bullish trend This has already started to take place  as the stock has moved higher by 12  in the past four weeks  Plus  the company currently has a Zacks Rank  1  Strong Buy  suggesting that now could definitely be the time for this breakout candidate More bullishness may especially be the case when investors consider what has been happening for LLY on the earnings estimate revision front lately  No estimate has gone lower in the past two months  compared to 3 higher  while the consensus estimate has also moved higher too So given this move in estimates  and the positive technical factors  investors may want to watch this breakout candidate closely for more gains in the near future  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-25,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert-eli-lilly-and-company-200494950,200494950
171029,392545,LLY,J J nasal spray gets U S  approval as first new type of anti depressant in decades,news,"By Saumya Joseph  Reuters    The U S  Food and Drug Administration on Tuesday said it approved a Johnson   Johnson  NYSE JNJ  nasal spray antidepressant for people resistant to other treatments but placed restrictions on use of the drug  which it warned could be misused and abused  The approval of nasal spray esketamine marks the first new type of treatment for depression in more than 30 years and has raised hopes for its relatively fast action and ability to treat some otherwise unreachable patients  Esketamine would be sold under the brand name Spravato and is a chemical mirror image of anesthetic ketamine  which is also abused as a recreational party drug and goes by the street nickname  Special K   To prevent abuse  patients must take the drug in a doctor s office or medical facility and cannot take it home  Currently available anti depressants such as Eli Lilly  NYSE LLY  and Co s Prozac work on neurotransmitters like serotonin and norepinephrine  but most drugs take at least four weeks to show effect and fail to produce an adequate response in about 30 percent to 40 percent of patients with major depressive disorder  MDD    Spravato has the potential to change the treatment paradigm and offer new hope to the estimated one third of people with major depressive disorder who have not responded to existing therapies   said Mathai Mammen  global head of J J s Janssen Research   Development  Spravato has been touted as an asset with blockbuster potential and is expected to improve investor sentiment toward the growth prospects of J J s pharma unit Janssen  as its top selling rheumatoid arthritis drug Remicade faces increased competition from cheaper biosimilars  The treatment carries a boxed warning   FDA s harshest   flagging the risk for sedation and difficulty with attention  judgment and thinking  abuse and misuse  and suicidal thoughts after administration of the drug  Spravato is absorbed by the lining of the nasal passages and into the blood stream and will be used along with a newly prescribed oral antidepressant  Johnson   Johnson said in a statement   During clinical trials  Spravato was found to relieve depression symptoms within 24 hours in some patients  said Janssen spokesman Greg Panico  The approval comes after an FDA advisory panel in February voted heavily in favor of the drug esketamine  saying its benefits outweighed the risks  However  the panel members echoed concerns raised by FDA staffers regarding the increased risk of sedation  dissociation and higher blood pressure observed in the study  The drug is also being tested in patients with depression who are at a high risk of committing suicide  
Recent research shows that depression involves deterioration of the quality and number of nerve cell connections in areas of the brain related to mood  J J s drug helps restore these nerve cell connections in the brain  leading to an improvement in depression symptoms  according to the company  Over 300 million people globally live with major depressive disorders  and the incidence of attempted suicide in people with this condition is about 20 fold higher than that among those without the disorder ",2019-03-05,Reuters,https://www.investing.com/news/stock-market-news/jj-nasal-spray-gets-us-approval-as-first-new-type-of-antidepressant-in-decades-1798840,1798840
171032,392548,LLY,3 Reasons Why You Should Buy Eli Lilly  LLY  Stock In 2020,opinion,Eli Lilly   Company   NYSE LLY   is known for its drugs like Humalog  Alimta  Taltz  and many others  Here are three reasons to invest in the stock in 2020 Good Rank   Rising Share Price and Earnings Estimates  Lilly currently carries a Zacks Rank  1  Strong Buy   You can see  Lilly s shares have outperformed the large cap pharma industry in the past year  The stock has returned 18  in the said timeframe against the  s increase of 14 8   Lilly s outperformance has been backed by higher demand for its newer drugs  accretive business development deals and rapid pipeline progress   Lilly s earnings estimates have risen 4 8  for 2020 over the past 60 days Its earnings surpassed expectations in three of the last four quarters  the average positive surprise being 1 2  The company is expected to record earnings and sales growth of 16 3  and 7 4   respectively  in 2020 Upbeat 2020 Outlook  In December  Lilly issued a better than expected financial guidance for 2020  It anticipates adjusted earnings of  6 70  6 80 per share in 2020  Revenues in 2020 are expected in the range of  23 6  24 1 billion It expects new products to help it achieve the sales growth target as headwinds from Cialis  loss of exclusivity and Lartruvo will abate in 2020  Lilly lost exclusivity for key erectile dysfunction drug  Cialis  in 2019  which affected the top line in the year  Also  Lartruvo s product withdrawal was a major setback in 2019  Lilly suspended the promotion of its advanced soft tissue sarcoma drug  Lartruvo  due to the failure of the ANNOUNCE confirmatory study The company said that if it achieves the aforementioned sales range for 2020  it will be able to exceed the 7  revenue CAGR target for the 2015 2020 period  The growth rate also exceeds Lilly s initial guidance of a 6  increase for 2020  which it had communicated in October Pipeline Progress   Strategic Deals  Lilly has made significant pipeline progress in the past year with several positive late stage data readouts  multiple approvals and regulatory submissions Key new drug approvals in the United States in 2019 were Baqsimi  Lilly s glucagon nasal powder to treat severe hypoglycemia in diabetes patients in July and Reyvow  lasmiditan  oral tablets to treat acute migraine in October  Important line extension approvals were Taltz for axial spondyloarthritis in August  Cyramza for second line liver cancer in May and Emgality for episodic cluster headache in June Importantly  in 2020  Lilly expects to come up with important data readouts for several key pipeline medicines  The company also expects approvals for two new drugs in 2020 and up to three new launches  Please note that regulatory applications for Lilly s key pipeline candidate  an ultra rapid acting insulin for type I and II diabetes  is under review in the United States and Europe  A new drug application  NDA  has already been filed for Alzheimer s disease candidate  flortaucipir  NDAs for tanezumab for osteoarthritis pain  in partnership with Pfizer   NYSE PFE    and oral RET inhibitor  selpercatinib  for RET altered thyroid cancers are expected to be filed in the next two to three months Lilly also added promising pipeline assets through business development deals in 2020  At the beginning of 2019  the company bought small cancer biotech  Loxo Oncology  Inc   for  8 billion in cash  which broadened the scope of its oncology portfolio into precision medicines  It also formed small immunology collaborations with small  private biotechs Avidity Biosciences and ImmuNext ConclusionLilly has its share of challenges lined up for 2020 like generic competition for several drugs  including the expected generic entry of Forteo  rising pricing pressure on its diabetes franchise in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets like China  Japan and Europe  and currency headwinds  However  it seems the company s strong pipeline  consistent outperformance of new drugs  cost cuts and regular strategic deals will keep the stock afloat through 2020 Other Stocks to ConsiderOther stocks worth considering are Bristol Myers   NYSE BMY   and Glaxo   NYSE GSK    both with a Zacks Rank  2  Buy  Bristol Myers  earnings estimates have increased 9  for 2020 over the past 60 days  The stock is up 42 3  in the past year Glaxo s stock is up 24 2  in the past year  Its earnings estimates have increased 4  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2020-200495973,200495973
171055,392571,LLY,Lilly s Cyramza Gets CHMP Recommendation For First Line NSCLC,opinion,"Eli Lilly and Company   NYSE LLY   announced that the European Medicines Agency s Committee for Medicinal Products for Human Use   CHMP   recommended the approval of label expansion for Cyramza  ramucirumab  in first line metastatic non small cell lung cancer   NSCLC   with EGFR mutation  The company is seeking an approval for the multi cancer drug in combination with Roche s   OTC RHHBY   Tarceva  erlotinib  in this indication in Europe The positive CHMP opinion was based on data from the phase III RELAY study evaluating Cyramza plus Tarceva in previously untreated patients with metastatic NSCLC whose tumors have activating EGFR mutations  Data from the study has demonstrated that the combination regimen has significantly improved progression free survival We note that the European Commission generally considers the CHMP recommendation while approving a drug but isn t bound by it  If approved  sales of the drug will likely get a significant boost as there is a large number of patients with first line lung cancer  Per the press release  nearly 470 000 patients are diagnosed with the disease every year in Europe The company has also submitted regulatory applications seeking similar label expansion for the Cyramza combination regimen in the United States and Japan  A decision in these countries is expected next year Please note that Cyramza is already approved in combination with chemotherapy  docetaxel  for treating metastatic NSCLC patients whose cancer has progressed after prior platinum based chemotherapy  The drug is also approved as monotherapy on in combination with other drugs for second line gastric  liver and colorectal cancer  Lilly is also developing Cyramza in combination with other anti cancer therapies for the treatment of multiple tumor types While the NSCLC market presents immense potential  competition is stiff in this space  In April 2019  Pfizer s   NYSE PFE    was approved for treating previously untreated EGFR mutated NSCLC patients in Europe  Several other therapies are also approved for treating similar indication including AstraZeneca s   NYSE AZN    So far this year  Lilly s shares have gained 8 9  compared with the  s rise of 5  In a separate press release  Lilly and its partner  Boehringer Ingelheim  announced updated data from two phase III studies  evaluating their diabetes drug  Jardiance  in patients with chronic heart failure with reduced and preserved ejection fraction  Data showed that there was no significant change in exercise ability in patients treated with Jardiance from baseline to week 12 compared to placebo Eli Lilly and Company Price
    Zacks RankLilly currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-15,Zacks Investment Research,https://www.investing.com/analysis/lillys-cyramza-gets-chmp-recommendation-for-firstline-nsclc-200492803,200492803
171056,392572,LLY,Lilly s Stock Up On Upbeat Sales   Profit Outlook For 2020,opinion,Eli Lilly   Company   NYSE LLY   issued a better than expected financial guidance for 2020  which pushed its shares up 2  on Tuesday  The drug giant  meanwhile  re affirmed the previously issued 2019 sales and earnings projections Year to date  Lilly s shares have risen 8 3  compared with the  s increase of 9 9    2020 Guidance Lilly expects adjusted earnings in the range of  6 70  6 80 per share in 2020  The current Zacks Consensus Estimate for earnings is pegged lower at  6 58 per share  Revenues in 2020 are expected in the range of  23 6  24 1 billion  The Zacks Consensus Estimate for sales stands at  23 76 billion It expects new products to help it achieve the sales growth target as the headwind from Cialis LOE and Lartruvo will abate in 2020 Lilly lost exclusivity for key erectile dysfunction drug  Cialis in 2019  which has been hurting its top line  Also  Lartruvo s product withdrawal was a key top line headwind in 2019  Lilly suspended promotion of its advanced soft tissue sarcoma drug  Lartruvo due to the failure of the ANNOUNCE confirmatory study in 2019 The company said that if it achieves this sales range for 2020  it will be able to exceed its 7  revenue CAGR target for the 2015 2020 period  The growth rate also exceeds Lilly s initial guidance of 6  growth in 2020  which it communicated in October Lilly expects its revenue growth to be driven by higher demand for its growth products  including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Cyramza Emgality as well as newly launched glucagon nasal powder  Baqsimi and potential launch of newly approved oral tablets to treat acute migraine  Reyvow However  generic competition for several drugs including the expected generic entry for Forteo  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  and price cuts in some international markets like China  Japan and Europe are some top line headwinds expected in 2020  In the United States  prices are expected to decline in a low single digit range Gross margin is still expected to be approximately 81   Adjusted tax rate is expected to be approximately 15   Adjusted operating margin is expected to be 31  in 2020  same as that provided in October Marketing  selling and administrative expense are expected to be in the range of  6 1billion to  6 3billion  Research and development expense is still expected to be in the range of  5 6billion to  5 9billion Importantly  in the year  Lilly is likely to come up with important data readouts for several key pipeline medicines  Lilly also expects approvals for two new drugs in 2020 and up to three new launches  Please note that regulatory applications for Lilly s key pipeline candidate  an ultra rapid acting insulin for type I and II diabetes  is under review in the United States as well as Europe  A new drug application  NDA  has already been filed for Alzheimer s disease candidate  flortaucipir  NDAs for tanezumab for osteoarthritis pain  in partnership with Pfizer    NYSE PFE     and oral RET inhibitor  selpercatinib for RET altered thyroid cancers are expected to be filed in the next 3 4 months 2019 Guidance ReaffirmedLilly maintained the previously issued 2019 adjusted earnings and sales outlook  Lilly expects full year earnings in the range of  5 75 to  5 85  The range indicates growth of 4  to 6  from the year ago levels The revenue guidance was maintained in the range of  22 0  22 5 billion  which indicates 5  growth  at mid point  over 2018 level on a constant currency basis Gross margin is still expected to be approximately 80   Adjusted tax rate is expected to be in the range of 12  13   Marketing  selling and administrative expense is expected to be in the range of  5 9 billion to  6 1 billion  Research and development expense is still expected to be in the range of  5 5 billion to  5 7 billion Lilly currently carries a Zacks Rank  3  Hold   Some better ranked large cap pharma stocks are Bristol Myers   NYSE BMY   and Merck   NYSE MRK    both with a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings estimates have increased 4 4  and 11 6   respectively  for 2019 and 2020 over the past 60 days  The stock is up 23 4  this year so far Merck s stock is up 16 5  this year so far  Its earnings estimates have risen 5 1  for 2019 and 2 6  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/lillys-stock-up-on-upbeat-sales--profit-outlook-for-2020-200493434,200493434
171057,392573,LLY,Lilly cancer drug fails key trial  will no longer be prescribed,news,"By Ankur Banerjee and Julie Steenhuysen  Reuters    Eli Lilly  NYSE LLY  and Co said on Friday that its cancer treatment Lartruvo  which had won conditional approval  failed to improve patient survival in a long term confirmatory study and will no longer be prescribed  driving the drugmaker s shares down nearly 3 percent  No new U S  patients will be started on the drug and Lilly is suspending promotion of the medicine  the company said   Lartruvo won accelerated approval in 2016 in the United States and conditional approval in Europe based on results from a promising mid stage trial  But its continued approval was contingent on the results of a larger  late stage trial confirming the drug s benefits  On Friday  Lilly said Lartruvo combined with the standard of care chemotherapy doxorubicin did not prolong survival more than doxorubicin alone in patients with advanced soft tissue sarcoma  Lilly oncology chief Anne White said in a phone interview the results were  completely unexpected   The disappointing outcome reflects the risk involved when drugs are approved based on smaller trials with promising data   In a sense  this is the way it s supposed to work   White said   You do that confirmatory study  Obviously  there are times when it doesn t work out   Lartruvo will continue to be available to patients who appear to be benefiting from it as global regulators determine the next steps for the treatment  White said  The Lartruvo news is a major setback to Lilly s efforts to significantly boost its presence in oncology  as evidenced by its announcement last week that it would buy Loxo Oncology Inc for  8 billion to acquire its cancer drugs that target rare genetic mutations  Analysts had forecast 2019 Lartruvo sales of  374 50 million  according to IBES data from Refinitiv   Lilly in the past had avoided large deals  preferring to develop its own drugs  But the Loxo deal  the biggest acquisition in Lilly s 143 year history  followed last year s  1 6 billion purchase of Armo Biosciences  a developer of immunotherapy drugs    Given Lilly s strategic focus on oncology  this increases the probability that Lilly will make more oncology acquisitions to improve scale   BMO Capital Markets analyst Alex Arfaei said of the Lartruvo setback in a research note  Lilly expects to take a first quarter pretax charge of  70 million to  90 million  or about 10 cents per share  after tax  and said the setback will cut about 17 cents per share from its full year 2019 earnings forecast  The company does not see a change in its 2020 minimum financial goals  
Eli Lilly shares were down 2 8 percent at  115 81 afternoon trading ",2019-01-18,Reuters,https://www.investing.com/news/stock-market-news/lilly-cancer-drug-fails-key-trial-will-no-longer-be-prescribed-1751261,1751261
171058,392574,LLY,Pfizer forecasts 2019 revenue  profit below Wall Street targets,news," Reuters     Pfizer  Inc  NYSE PFE  forecast 2019 profit and sales below Wall Street estimates on Tuesday as the company expects to take a blow from a stronger dollar and as well as the loss of patent on its blockbuster pain treatment Lyrica this year  The drugmaker  along with partner Eli Lilly  NYSE LLY    Co  also reported data from a late stage trial of painkiller tanezumab  that some analysts said could raise safety concerns  Pfizer has outlined tanezumab  an experimental non opioid drug for osteoarthritis pain  as one of its blockbuster drugs it intends to win approval for within five years   Credit Suisse   SIX CSGN  analyst Vamil Divan said the 2019 forecast  along with the data on tanezumab that will likely not ease any outstanding safety concerns on the drug  will lead to some pressure on Pfizer shares  The stock was down 3 percent in trading before the opening bell  To counter revenue loss from generic competition to Lyrica  the largest U S  drugmaker has been investing heavily in its portfolio of cancer treatments and expects to gain approval for a new heart drug later this year  The drugmaker s robust pipeline is seen by analysts as key to helping it ride out upcoming patent expirations and fighting increased competition from cheaper generics  In the quarter  sales of breast cancer drug Ibrance rose 58 percent to  1 13 billion  helped by demand in Europe  but came in slightly below the consensus estimate of  1 16 billion  according to Credit Suisse  In the fourth quarter  Lyrica brought in quarterly sales of  1 32 billion  compared with a consensus estimate of  1 21 billion  The company earned 64 cents per share excluding items  just above the average analyst estimate of 63 cents per share  Revenue rose about 2 percent to  13 98 billion  also beating the estimate of  13 90 billion  Pfizer forecast 2019 adjusted earnings of  2 82 to  2 92 per share and revenue of  52 billion to  54 billion  The outlook includes a  2 6 billion hit from patent expirations and about  1 billion from forex losses  the company said  
Analysts on average were expecting earnings of  3 04 per share and revenue of  54 25 billion   eporting by Tamara Mathias in Bengaluru  Editing by Saumyadeb Chakrabarty and Sweta Singh ",2019-01-29,Reuters,https://www.investing.com/news/stock-market-news/pfizer-fullyear-revenue-forecast-misses-estimates-1761243,1761243
171059,392575,LLY,U S  lawmakers request info from insulin makers on rising prices,news,"By Yasmeen Abutaleb WASHINGTON  Reuters    Two powerful U S  lawmakers sent letters to the three leading insulin manufacturers on Wednesday requesting information on why its cost has skyrocketed in recent years and how much the companies profit from the life sustaining diabetes treatment   Democratic Representatives Frank Pallone and Diana DeGette  the chairman and a top ranking member of the House Energy and Commerce Committee  respectively  wrote to the heads of Eli Lilly  NYSE LLY  and Co   Novo Nordisk   CO NOVOb  and Sanofi  PA SASY   the long time leading manufacturers of insulin  The drugmakers have all raised the price of insulin at similar rates over the last several years    Despite the fact that it has been available for decades  prices for insulin have skyrocketed in recent years  putting it out of reach for many patients   the lawmakers wrote    As one of the few manufacturers of insulin in the United States  your company is well suited to shed light on these issues and offer potential solutions   the letter to the three companies said   The committee has not set a date for a hearing  a spokesman for DeGette said  It has the power to subpoena the drugmakers if they do not answer the committee s request   The annual cost of insulin for treating a type 1 diabetes patient in the United States nearly doubled from 2012 to 2016 to  5 705 from  2 864  according to a recent study  The lawmakers  letters come amid intensifying scrutiny from Congress over the high cost of prescription drugs for U S  consumers  Both the House Oversight Committee and Senate Finance Committee held hearings on prescription drug prices on Tuesday  with a focus on insulin  Sanofi confirmed receipt of the letter and said it would work with the committee on its request  Neither Novo nor Lilly immediately responded to requests for comment  High prescription drug costs have consistently polled as a top voter concern and have been a top priority of the administration of U S  President Donald Trump  a Republican   U S  prescription drug prices are far higher than in other developed nations that either directly or indirectly control medicine costs   Democratic Representative Elijah Cummings earlier this month wrote to 12 pharmaceutical companies asking for detailed information on their pricing practices  including the makers of insulin  
About 1 2 million Americans have type 1 diabetes  requiring daily insulin  Type 2 diabetes  which affects nearly 30 million Americans  according to the American Diabetes Association  is treated with a variety of other medicines  But those patients may also eventually become dependent on insulin ",2019-01-30,Reuters,https://www.investing.com/news/politics-news/us-lawmakers-request-info-from-insulin-makers-on-rising-prices-1763807,1763807
171060,392576,LLY,Senator Sanders asks why drug  once free  now costs  375k,news,"By Yasmeen Abutaleb WASHINGTON  Reuters    U S  Senator Bernie Sanders sent a letter to  Catalyst Pharmaceuticals   O CPRX  on Monday asking it to justify its decision to charge  375 000 annually for a medication that for years has been available to patients for free   The drug  Firdapse  is used to treat Lambert Eaton Myasthenic Syndrome  LEMS   a rare neuromuscular disorder  according to the letter  made available to Reuters by the senator s office  The disorder affects about one in 100 000 people in the United States  The government is intensifying its scrutiny of the pharmaceutical industry and rising prescription drug prices  a top voter concern and a priority of President Donald Trump s administration  Both the Democratic led U S  House of Representatives and the Senate  controlled by Republicans  have begun holding hearings this year on the rising costs of medicines  Sanders is an independent who usually votes with Democrats  In the letter dated Feb  4  Sanders asked Catalyst to lay out the financial and non financial factors that led the company to set the list price at  375 000  and say how many patients would suffer or die as a result of the price and how much it was paying to purchase or produce the drug  Catalyst declined to comment on Sanders  letter  Catalyst shares fell nearly 8 percent to  2 31  For years  patients have been able to get the same drug for free from Jacobus Pharmaceuticals  a small New Jersey based drug company  which offered it through a U S  Food and Drug Administration  FDA  program called  compassionate use    The program allows patients with rare diseases and conditions access to experimental drugs outside of a clinical trial when there is no viable alternative  Florida based Catalyst received FDA approval of Firdapse in November  along with exclusive rights to market the medication for several years  The company  which bought rights to the drug from a company called BioMarin in 2012  develops and commercializes drugs for rare diseases  BioMarin and FDA did not immediately respond to requests for comment  In December  Catalyst announced it would price Firdapse at  375 000 a year    Catalyst s decision to set the annual list price at  375 000 is not only a blatant fleecing of American taxpayers  but is also an immoral exploitation of patients who need this medication   Sanders wrote in his letter  Sanders joins other U S  lawmakers in investigating the pricing practices of pharmaceutical companies this year   Democratic Representative Elijah Cummings  chairman of the House Oversight Committee  in January wrote to 12 pharmaceutical firms asking for detailed information on how they set drug prices   
Democratic Representatives Frank Pallone and Diana DeGette wrote to the heads of Eli Lilly and Co  N LLY    Novo Nordisk   CO NOVOb  and Sanofi SA  PA SASY   the long time leading manufacturers of insulin  requesting information on why the drug s price has skyrocketed in recent years ",2019-02-04,Reuters,https://www.investing.com/news/politics-news/us-senator-sanders-to-ask-why-drug-once-free-now-costs-375k-1768060,1768060
171061,392577,LLY,Eli Lilly Earnings miss  Revenue beats In Q4,news,"Investing com   Eli Lilly  NYSE LLY  reported fourth quarter earnings  that missed analysts  expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  1 33 on revenue of  6 43B  Analysts polled by Investing com anticipated EPS of  1 34 on revenue of  6 28B  That compared to EPS of  1 14 on revenue of  6 16B in the same period a year earlier  The company had reported EPS of  1 39 on revenue of  6 06B in the previous quarter 

Eli Lilly follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings beat analyst s expectations on January 29  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 63 on revenue of  13 9B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-06,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-earnings-miss-revenue-beats-in-q4-1770691,1770691
171083,392599,LLY,Why Is Incyte  INCY  Up 12 5  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Incyte  NASDAQ INCY   Shares have added about 12 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Incyte due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Incyte Beats on Q3 Earnings   Sales  Ups Jakafi ViewIncyte reported earnings of 82 cents per share  which easily surpassed the Zacks Consensus Estimate of 65 cents and 41 cents in the year ago quarter Including milestones and contracts  revenues came in at  551 6 million  which grew 22 6  year over year and beat the Zacks Consensus Estimate of  538 95 million Quarter in DetailTotal product related revenues came in at  453 9 million  up 23 4  from the year ago quarter  Jakafi revenues came in at  433 4 million  increasing 25  from the year ago quarter and beating the Zacks Consensus Estimate of  417 million  Robust demand for Jakafi in all three approved indications drove revenues Net product revenues of Iclusig amounted to  20 6 million  up from  20 1 million in the year ago quarter Jakavi  name outside the United States  royalty revenues from Novartis AG for commercialization in ex U S  markets grew 15  to  58 4 million  Olumiant s product royalty revenues from Eli Lilly  NYSE LLY  came in at  21 6 million R D expenses were  281 3 million  down from  292 5 million in the year ago quarter  SG A expenses amounted to  102 6 million  up from  96 5 million in the prior year quarter 2019 Outlook UpdatedBased on a strong performance of Jakafi in the first nine months of 2019  the company raised its revenue guidance for the same The company expects Jakafi revenues of  1 650  1 680 million for 2019  previous guidance   1 610  1 650 million   Iclusig revenues are still expected to be  90  100 million  R D expenses are expected to be  1 020  1 070 million  SG A expenses are anticipated to be  420  470 million Pipeline UpdatePipeline progress in the third quarter was impressive  REACH2  the phase III study evaluating Jakafi in patients with steroid refractory acute graft versus host disease  GVHD   met its primary endpoint of superior overall response rate at day 28 with Jakafi treatment compared to best available therapy  The REACH2 and REACH3 trials  evaluating steroid refractory acute and steroid refractory chronic GVHD  respectively  are being conducted in collaboration with Novartis An Independent Data Monitoring Committee  IDMC  recommended that the phase III REACH3 trial should continue without modification following an interim efficacy and safety analysis Results from the global phase III GRAVITAS 301 trial on itacitinib for the treatment of patients with newly diagnosed acute GVHD are expected before the end of 2019 Incyte submitted the NDA for pemigatinib as a second line treatment for cholangiocarcinoma patients with FGFR2 fusions or rearrangements to the FDA under Breakthrough Therapy designation The phase III TRuE V development program of ruxolitinib cream in patients with vitiligo was initiated in September  with initial results expected in 2021  The phase III TRuE AD development program of ruxolitinib cream in patients with atopic dermatitis is ongoing  with initial results expected in the first half of 2020  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in estimates review  The consensus estimate has shifted 11 34  due to these changes 
VGM Scores
At this time  Incyte has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  Following the exact same course  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise Incyte has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-incyte-incy-up-125-since-last-earnings-report-200488721,200488721
171084,392600,LLY,Stocks Bounce Back On Dec  4 With More Gains On The Way,opinion,"Stocks had a good day yesterday  bouncing back some from Tuesday s down day  The ISM non manufacturing index came in lower than expected 53 9 versus estimates for 54 5  and down from last months 54 7  It corresponds to a GDP growth rate of about 1 9   which is mostly in line with what we have seen from other data points recently  So it seems at this late point of the year  the recession or even near zero growth is not on the horizon 
S P 500  SPY 
The S P 500 did manage to close above 3 110  and I view that as a definite positive  I think it sets us up for a potential move a bit higher to the trend line up at 3 140 today 






Nvidia  NVDA  
NVIDIA  NASDAQ NVDA  failed at resistance at  212  and the RSI continues its trend lower  I think that it means the stock is going to head back to  198 






Eli Lilly  LLY Eli Lilly  NYSE LLY  is very close to breaking out should it rise above resistance at  119  The RSI is trending higher  and it looks healthy  suggests the stock could go to  123 






Qualcomm  QCOM Qualcomm  NASDAQ QCOM  tried to get back over resistance today at  82 but was not able too  Not a great sign for the stock  I still think there is a good chance shares fall to roughly  76 50 






Altria  MO Here s a new one Altria  NYSE MO   the stock appears it has broken free of a falling wedge and is challenging resistance at  51 and potentially on its way to  58 






Mastercard  MA Mastercard s RSI is changing trend as well  and perhaps that means the stock is setting up to take out its all time highs before year end  That would be nice for me since it has become my largest holding  One can only hope ",2019-12-05,Michael Kramer,https://www.investing.com/analysis/stocks-bounce-back-on-dec-4-with-more-gains-on-the-way-200490161,200490161
171085,392601,LLY,Aduro Biotech  ADRO  Up 7 5  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Aduro Biotech  ADRO   Shares have added about 7 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Aduro Biotech due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Aduro Q3 Loss Wider Than Expected  Revenues Rise Y YAduro incurred third quarter 2019 loss of 26 cents per share  wider than the Zacks Consensus Estimate of a loss of 23 cents but narrower than the year ago loss of 29 cents Revenues came in at  4 8 million  up 54 8  year over year  primarily owing to the recognition of an upfront payment received from Eli Lilly  NYSE LLY  in the first quarter of 2019  Meanwhile  sales almost came in line with the Zacks Consensus Estimate of  5 million Research and development expenses declined 17 1  in the reported quarter to  15 5 million owing to lower stock based compensation and reduced headcount plus decreased costs of deprioritized programs General and administrative expenses were  8 7 million  down 4 4  year over year  primarily on the back of lower stock based compensation and reduced headcount following the strategic reset announced in January this year Aduro had  235 4 million worth of cash  cash equivalents and marketable securities as of Sep 30  2019 compared with  251 6 million on Jun 30  2019 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in estimates review 
VGM Scores
Currently  Aduro Biotech has a subpar Growth Score of D  though it is lagging a bit on the Momentum Score front with an F  Following the exact same course  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Aduro Biotech has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-06,Zacks Investment Research,https://www.investing.com/analysis/aduro-biotech-adro-up-75-since-last-earnings-report-can-it-continue-200490933,200490933
171086,392602,LLY,Deal Or No Deal  Healthcare ETFs To Make A Sweep In 2020,opinion,"We are now at a juncture when new U S  tariffs on Chinese imports like  will be enacted this Sunday Dec 15  2019 if the Phase One trade deal does not get through 
Stocks could crash  in a no deal situation  per Matt Maley  the chief market strategist at Miller Tabak  He cautioned that stocks might retreat 4 6  even if the Dec 15 round of tariffs was deferred if not canceled 
Whatever be the case  alike many analysts  we too believe that one sector would stand tall amid trade tensions and that is  Healthcare 
In a no deal scenario  a safe haven rally will take place  Some sectors are normally steady irrespective of any geopolitical development  Healthcare is one  Below we highlight what can drive the healthcare sector in 2020 irrespective of a trade deal  read    
Inside the Drivers 
The issued on Dec 4 showed that total earnings of 98 1  from the entire healthcare market capitalization on the S P 500 index have been up 6 1  so far on revenue growth of 7 2   The earnings and revenue growth rates are the fifth highest among the 16 Zacks classified sectors  Meanwhile  the blended beat ratio of 70 6  is the third highest  Medical sector has the top Zacks rank at the current level 
There are about 13 industries in the broader medical sector  of which 11 carry a solid Zacks Rank  Below we highlight three key industries 
Medical   Drugs belongs to a favorable Zacks industry  placed at the top 24  of 250  industries   Shares of the same industry can be availed at 17 37x forward P E ratio against the S P 500 ETF IVV s P E multiple of 19 16x  Though a low P E is not indicative of the stock s future performance  cheaper valuation is always good news  The projected EPS growth rate of the sector is 7 80  compared with 5 52  of IVV  The debt to equity ratio of the industry  0 03x  is much lower than 0 72x of IVV 
Large Cap Pharmaceuticals also hails from a favorable Zacks industry  positioned at the top 24    The industry has a forward P E ratio of 14 85x  which reflects its undervalued status  The debt to equity ratio of the industry  0 68x  is slightly lower than that of the S P 500 
Medical   Biomedical And Genetics also belongs to a favorable Zacks industry  top 23    The forward P E ratio of 25 12x is pretty higher than IVV s average  Also  the projected EPS growth rate is above  12 76   the S P 500  5 52   
Solid M A
The US healthcare market witnessed a   per PricewaterhouseCoopers data  In total  there were 1 182 M A deals in 2018  Deal volume exceeded 250 in the first three quarters of 2019 
Some notable mergers completed this year were the mega merger deal between Bristol Myers and Celgene  NASDAQ CELG   acquisition of Loxo Oncology by Eli Lilly and Company  NYSE LLY    Roche s buyout of Spark Therapeutics for  4 8 billion and Merck s acquisition of Immune Design 
Other announcements include NextGen Healthcare s  NXGN  purchase of Medfusion  a patient experience platform leader Notably  the latest acquisition announcement was Merck taking over ArQule  strengthening its leadership role in Oncology  read    
Healthy Pace of FDA Drug Approvals
Apart from favorable financials and valuations as well as mergers and acquisitions  the sector is brimming with upbeat drug data  There were 46 drug approvals in 2017 followed by 59 and 41 drug nods to date in 2019  Though the momentum of approval wins slackened a bit  it can still be considered healthy 
Investors should also note that the healthcare sector offers a slightly defensive approach and thus could be a good bet if there is any uncertainty regarding the trade deal  In light of this  we choose five healthcare ETFs that could lead the market in 2020 
SPDR S P Biotech  NYSE XBI  ETF    Zacks Rank  2  Buy 
VanEck Vectors Biotech ETF   LON BBH     Zacks Rank of 2
Vanguard Health Care ETF   ASX VHT    Zacks  2 Ranked
Health Care Select Sector SPDR Fund     2 Ranked
iShares U S  Healthcare ETF   Zacks Rank  2
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/deal-or-no-deal-healthcare-etfs-to-make-a-sweep-in-2020-200491474,200491474
171087,392603,LLY,Lilly Initiates Phase III Lung Cancer Study On RET Inhibitor ,opinion,Eli Lilly and Company   NYSE LLY   initiated a phase III LIBRETTO 431 study  NCT04194944  on its oral RET inhibitor  selpercatinib  LOXO 292   in treatment na ve  RET fusion positive non small cell lung cancer  NSCLC  patients  The study aims to enroll 400 patients with advanced or metastatic RET fusion positive NSCLC  who have received no prior systemic therapy for metastatic disease The stock has gained 4 4  so far this year compared with the  s growth of 8 4  The patients enrolled in the study will be randomized to receive either selpercatinib or platinum based  carboplatin or cisplatin  and pemetrexed therapy with or without Merck and Co  s  MRK  Keytruda as initial treatment of their advanced or metastatic RET fusion positive NSCLC  The study s primary endpoint is progression free survival  PFS  and secondary endpoints include overall survival  OS   overall response rate  ORR   duration of response  DoR  and intracranial ORR The company is initiating the study after it announced positive results from the phase I II registrational study   LIBRETTO 001 in September 2019  The study showed that selpercatinib demonstrated a 68  ORR or shrinkage in tumor size in heavily pretreated patients with RET fusion positive NSCLC  Meanwhile  the median DoR was 20 3 months and median PFS was 18 4 months in the selpercatinib arm Notably  selpercatinib was added to Lilly s portfolio with the February 2019 acquisition of Loxo Oncology  which broadened its scope in precision medicines  Precision medicines are an emerging approach to cancer treatment  which tailors a regime depending on the patient s genetic  environmental and lifestyle factors  Many industry players are adopting this approach to bring new cancer treatments One such company is Blueprint Medicines Corp    NASDAQ BPMC    which is developing transformational precision medicines to address patients with genomically defined cancers and rare diseases  The company is developing pralsetinib for treating patients with RET fusion NSCLC previously treated with platinum based chemotherapy  and plans to submit an NDA for the same in the first quarter of 2020  Eli Lilly and Company Price    Zacks Rank   Stocks to ConsiderLilly currently carries a Zacks Rank  3  Hold  A few similar ranked stocks in the large cap pharma sector are GlaxoSmithKline plc    NYSE GSK   and Merck   Co  Inc    NYSE MRK    both carrying Zacks Rank  1  Strong Buy   You can see  GlaxoSmithKline s earnings per share estimates have increased from  2 98 to  3 17 for 2019 and from  3 01 to  3 10 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 17 23   on average Merck s earnings per share estimates have increased from  4 91 to  5 15 for 2019 and from  5 37 to  5 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 51   on average Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor-200492126,200492126
171088,392604,LLY,Pharma Stock Roundup  MRK  SNY To Buy Cancer Firms  LLY Starts New Lung Cancer Study,opinion,"The pharma M A saga continued this week with two drug giants  Merck   NYSE MRK   and Sanofi   NASDAQ SNY   offering hefty premiums to buy small cancer drugmakers to strengthen their oncology pipelines  Meanwhile  Lilly   NYSE LLY   began the first ever randomized late stage study in treatment na ve RET fusion positive non small cell lung cancer  NSCLC  Recap of the Week s Most Important Stories Merck to Buy ArQule for  2 7B  Merck offered to pay  20 per share in cash for an approximate total equity value of  2 7 billion to buy Massachusetts based   The acquisition of ArQule  if successfully closed  is expected to strengthen Merck s oncology pipeline with the addition of some strategic assets  most notably  ARQ 531  ArQule s novel  oral Bruton s tyrosine kinase inhibitor  ARQ 531 is currently being evaluated in a phase II dose expansion study for the treatment of B cell malignancies Sanofi to Buy Synthorx for  2 5B  Sanofi announced a definitive deal to buy small cancer biotech for  68 per share in cash  representing an aggregate equity value of approximately  2 5 billion  The deal will add Synthorx s lead pipeline asset  THOR 707 to Sanofi s immuno oncology portfolio  THOR 707 is being evaluated across multiple solid tumor types alone and in combination with immune checkpoint inhibitors Sanofi and Regeneron announced their intent to restructure their antibody collaboration for Kevzara and Praluent into a royalty based agreement while collaboration relating to Dupixent remains unchanged  Under the restructured deal  Sanofi is expected to gain sole global rights to Kevzara and sole ex U S  rights to Praluent while Regeneron is expected to gain sole U S  rights to Praluent Meanwhile at its Capital Markets Day  Sanofi said that it is discontinuing all its research activities in  and cardiovascular area  It said it does not plan to launch late stage type II diabetes candidate  efpeglenatide to help it focus on high growth franchises  Meanwhile  the company said it will prioritize key growth drivers   Dupixent and vaccines   and accelerate R D focus on six potentially transformative medicines Lilly Initiates Lung Cancer Study on Selpercatinib  Lilly began a phase III study to evaluate its oral RET inhibitor   LOXO 292in previously untreated patients with RET fusion positive non small cell lung cancer  The LIBRETTO 431 study  which aims to enrol 400 patients  will evaluate selpercatinib against standard of care medicines in the above patient population  Selpercatinib was added to Lilly s portfolio with the February 2019 acquisition of Loxo Oncology Bristol Myers  Lymphoma Candidate Meets Goal in Pivotal Study  Bristol Myers    NYSE BMY   pivotal study evaluating its investigational CAR T therapy lisocabtagene maraleucel  liso cel  for the treatment of patients with relapsed refractory large B cell lymphoma  met the primary and secondary endpoints  Data from the pivotal TRANSCEND NHL 001 study demonstrated that patients treated with  experienced a high rate of durable responses with low incidence of severe cytokine release syndrome and neurologic events  Based on the positive results from the study  Bristol Myers plans to submit a biologics license application to the FDA by the end of the year Roche Meets Goal in Study on Tecentriq in BRAF mutant Melanoma  Roche s   OTC RHHBY   phase III study evaluating its PD L1 inhibitor  Tecentriq plus Exelixis  Cotellic and Roche s Zelboraf in patients with previously untreated BRAF V600 mutation positive advanced melanoma  met the primary endpoint  The study demonstrated a significant and clinically meaningful improvement in progression free survival  which was the primary endpoint  The data from the study showed that when Tecentriq was added to Cotellic and Zelboraf  it helped to reduce the risk of disease worsening or death  compared to placebo plus Cotellic and Zelboraf AstraZeneca s Imfinzi Gets China Approval for Lung Cancer  AstraZeneca s   NYSE AZN   Imfinzi was granted marketing approval in China by National Medical Products Administration  NMPA  for an early stage lung cancer indication based on positive survival data from the phase III study  The approval is for the treatment of unresectable  stage III NSCLC patients whose disease has not progressed following concurrent platinum based chemotherapy and radiation therapy  Imfinzi is already approved for this indication in many countries including the United States and EUPfizer s Xeljanz XR Gets FDA Nod for Ulcerative Colitis  The FDA granted approval to Pfizer s   NYSE PFE   Xeljanz extended release tablets  11 mg and 22 mg  as a convenient once daily dosing option for the treatment of ulcerative colitis  Xeljanz was approved by the FDA in May last year for UC as 10 mg twice daily  BID  dose for at least eight weeks  followed by Xeljanz 5 mg BID or 10 mg BIDThe NYSE ARCA Pharmaceutical Index was up 1 9  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the green with Bristol Myers rising the most  7 5   In the past six months  Bristol Myers has risen the most  22 7   while Pfizer  PFE  lost the maximum  12    See the last pharma stock roundup here  What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases              Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-12-12,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study-200492409,200492409
171089,392605,LLY,Takeda Pharmaceutical completes Shire acquisition,news,The rapidly changing pharmaceutical landscape reached another milestone today as Takeda  NYSE TAK  became a top 10 global drugmaker by completing its  62B acquisition of Shire  NASDAQ SHPG  A flurry of multibillion dollar pharma deals is happening as traditional companies turn to acquisitions to replenish their drug pipelines and combat expiring patents Already in 2019  Eli Lilly  NYSE LLY  agreed to buy Loxo Oncology for  8B  just days after Bristol Myers Squibb  NYSE BMY  scooped up Celgene  NASDAQ CELG  for  74B Now read ,2019-01-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/takeda-pharmaceutical-completes-shire-acquisition-1740456,1740456
171090,392606,LLY,French court cancels permit for Monsanto s Roundup weedkiller,news,A French court cancels the license for one of Monsanto s  OTCPK BAYRY  0 5   glyphosate based weedkillers over safety concerns  placing an immediate ban on Roundup Pro 360 in the country The court says the environmental agency ANSES had not respected a precautionary principle in French law  notably by not conducting a specific evaluation of health risks for Roundup Pro 360 Bayer  DE BAYGN   which says it disagrees with the decision and will consider its legal options  has cited regulatory rulings as well as scientific studies that found glyphosate to be safe Bernstein analysts say the financial impact on Bayer should be limited  given it concerns one product in a market for glyphosate based weedkillers worth   40M Now read ,2019-01-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/french-court-cancels-permit-for-monsantos-roundup-weedkiller-1747735,1747735
171100,392616,LLY,Aduro  ADRO  Q3 Loss Wider Than Expected  Revenues Rise Y Y,opinion,Aduro BioTech  Inc    NASDAQ ADRO   incurred third quarter 2019 loss of 26 cents per share  wider than the Zacks Consensus Estimate of a loss of 23 cents but narrower than the year ago loss of 29 cents The third quarter loss included an expense for impairment of intangible assets Revenues came in at  4 8 million  up 54 8  year over year  primarily owing to the recognition of an upfront payment received from Eli Lilly   NYSE LLY   in the first quarter of 2019  Notably  in December 2018  Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS STING inhibitor platform Meanwhile  sales almost came in line with the Zacks Consensus Estimate of  5 million Shares of Aduro have plunged 59 4  so far this year against the  rise of 0 2  Quarter in DetailResearch and development expenses declined 17 1  in the reported quarter to  15 5 million owing to lower stock based compensation and reduced headcount plus decreased costs of deprioritized programs General and administrative expenses were  8 7 million  down 4 4  year over year  primarily on the back of lower stock based compensation and reduced headcount following the strategic reset announced in January this year We remind investors that as a result of the strategic reset in the month  Aduro slashed its current workforce by almost 37  and redirected resources to focus on its core programs Aduro had  235 4 million worth of cash  cash equivalents and marketable securities as of Sep 30  2019 compared with  251 6 million on Jun 30  2019 Pipeline UpdateAduro s lead pipeline candidates are STING pathway activator ADU S100 and anti APRIL antibody BION 1301 The company has a collaboration and license deal with Novartis   NYSE NVS   for developing its STING Activator candidate ADU S100  The candidate is being evaluated in a phase I program as a monotherapy in patients with cutaneously accessible metastatic solid tumors or lymphomas  Aduro is also conducting a phase Ib study to assess ADU S100 in combination with Novartis  anti PD 1 monoclonal antibody spartalizumab for the same indication The company is also performing an early stage study on ADU S100 in combination with Bristol Myers  Yervoy  ipilimumab  for addressing relapsed refractory melanoma Meanwhile  in September 2019  Aduro initiated dosing in a phase II study on ADU S100 in combination with Merck s   NYSE MRK   anti PD 1 antibody Keytruda  pembrolizumab  for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma  HNSCC   The study is designed to evaluate the safety and efficacy of the ADU S100 combo administered intratumorally in the first line setting Notably  in first quarter 2019  Aduro initiated the phase I clinical study on BION 1301 evaluating healthy volunteers for treating IgA nephropathy  The company plans to start dosing the IgAN patients in 2020 Aduro Biotech  Inc  Price  Consensus and EPS Surprise   Zacks RankAduro currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-08,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q3-loss-wider-than-expected-revenues-rise-yy-200484025,200484025
171101,392617,LLY,FDA Panel Votes Against Lilly s Jardiance For Type I Diabetes,opinion,Eli Lilly   Company   NYSE LLY   announced an the FDA advisory committee has voted against the label expansion of its SGLT 2 inhibitor Jardiance  empagliflozin 2 5 mg  as an adjunct to insulin for adults with type I diabetesThe supplemental new drug application  sNDA  filed by Lilly and partner Boehringer Ingelheim is seeking approval for their type II diabetes medicine Jardiance  2 5 mg  for type I diabetes under a separate brand name  The FDA s Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  met to review data from the EASE phase III studies and voted 14 2  suggesting that the benefits of Jardiance 2 5 mg do not outweigh the risks to support approval for the indication Data from the EASE studies have shown that empagliflozin 2 5 mg plus insulin provided a statistically significant reduction in A1C versus plus placebo  Meanwhile  empagliflozin treatment led to reduction in weight and decrease in systolic blood pressure  which were the secondary endpoints  While the FDA usually follows the advice of its advisory panel  it is not always required to do so Year to date  Lilly s shares have declined 2 5  against the  s increase of 3 6    Jardiance is a key top line driver for Lilly  Its sales surged 45  to  676 2 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and higher volume outside the United States Meanwhile  earlier this week  Lilly and partner Boehringer Ingelheim announced initiation of the first ever study to evaluate Jardiance in patients with and without type II diabetes hospitalized for acute heart failure and who have been stabilized  The aim of this study  known as EMPULSE  is to understand whether Jardiance has the potential to improve outcomes in this patient population  It is the sixth phase III study in the Jardiance heart failure program While the diabetes market holds immense commercial potential  it is pretty crowded with the presence of companies like Novo Nordisk  CSE NOVOb  A S   NYSE NVO    Johnson   Johnson   NYSE JNJ   and Merck   NYSE MRK   among others Lilly currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes-200485303,200485303
171102,392618,LLY,Celldex  CLDX  Q3 Loss Narrower Than Expected  Revenues Miss,opinion,"Shares of Celldex Therapeutics  Inc    NASDAQ CLDX   declined 2 5   following its earnings release on Nov 12  The company incurred a loss of 75 cents per share in third quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 84 cents but wider than the year ago loss of 66 cents Total revenues in the quarter declined 42  year over year to  0 5 million and missed the Zacks Consensus Estimate of  0 94 million  The year over year decline was due to a decrease in revenues from the collaboration agreement with Bristol Myers   NYSE BMY   and contract with the International AIDS Vaccine Initiative Celldex s share price performance has been disappointing so far this year  The stock has declined 21 5  against the  s 1 4  growth   Costs DeclineResearch and development expenses were down 6 7  year over year to  11 1 million in the quarter mainly due to lower personnel costs  and a decline in clinical study and contract manufacturing related expenses  General and administrative expenses were  3 4 million  down 8 1  year over year  mainly attributable to lower personnel and marketing expenses As of Sep 30  2019  Celldex had cash  cash equivalents and marketable securities of  72 9 million compared with  81 3 million as of Jun 30  2019 2019 OutlookThe company believes that its cash position as of the end of September plus anticipated net proceeds from future sales of its common stock under the agreement with Cantor will be adequate to fund working capital requirements as well as planned operations through 2020 Pipeline FocusCelldex is focused on the development of CDX 1140 and CDX 3379  Although the candidates are in early to mid stage studies  the company is progressing well with the studies On its third quarter earnings call  the company announced that it completed the monotherapy arm of the phase I study  evaluating CDX 1140 in patients with recurrent  locally advanced or metastatic solid tumors and B cell lymphomas  A dose of 1 5 mg kg of the candidate has been identified as the recommended dose for phase II study  The company will enroll patients with head and neck squamous cell carcinoma  HNSCC  in this study Meanwhile  another arm of the phase I study  evaluating CDX 1140 in combination with CDX 301  is progressing as expected  The company amended the phase I study design during the quarter to include a cohort  which will evaluate CDX 1140 in combination with Merck s   NYSE MRK   Keytruda in patients refractory to PD 1 PDL 1 treatment  Enrollment in the cohort is expected to start in the first quarter of 2020 Currently  enrollment is underway in a phase II study  evaluating CDX 3379 in combination with Eli Lilly s   NYSE LLY   Erbitux  for the treatment of advanced head and neck squamous cell cancer  Interim data announced in June supported further evaluation of CDX 3379  Based on the data  Celldex expanded the patient population to focus on the development of CDX 3379 in biomarker selected patient population and has initiated enrollment of patients During the quarter  the FDA accepted an investigational new drug application filed by Celldex to initiate a phase Ia study to evaluate monoclonal antibody candidate  CDX 0159  in inflammatory diseases  The company expects to initiate the study by the end of the year Celldex Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks RankCelldex currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss-200485302,200485302
171103,392619,LLY,Pharma Stock Roundup  MRK  GSK  ABBV  LLY s Pipeline   Regulatory Updates,opinion,"This week  Merck s   NYSE MRK   investigational vaccine for Ebola Zaire disease  V920  received approval in Europe  While Roche and Glaxo   NYSE GSK   announced positive data from pivotal studies  Pfizer s   NYSE PFE   late stage gastric cancer study on its PD L1 inhibitor  Bavencio  failed  AbbVie   NYSE ABBV    Bristol Myers   NYSE BMY    Merck  AstraZeneca   NYSE AZN   and Lilly   NYSE LLY   provided FDA updates Recap of the Week s Most Important Stories EU Approval for Merck s Ebola Vaccine   AstraZeneca s New Diabetes Tablet  The European Commission  has granted conditional marketing approval to Merck s investigational vaccine for Ebola Zaire disease  V920  which will be marketed by the trade name of   Ervebo is under priority review in the United States with a FDA decision expected on Mar 14  2020 The European Commission also granted marketing approval to AstraZeneca s Qtrilmet modified release tablets for type II diabetes  Qtrilmet is a combination of AstraZeneca s other diabetes drugs Farxiga  dapagliflozin  and Onglyza  saxagliptin  plus metformin  It was approved by the FDA with the trade name of Qternmet XR in May Meanwhile  the FDA accepted and granted priority review to Merck   AstraZeneca s new drug application  NDA  for MEK 1 2 inhibitor selumetinib pertaining to the treatment of neurofibromatosis type 1  NF1  related plexiform neurofibromas  an incurable genetic condition that affects newborns  The FDA s decision is expected in the second quarter of 2020 Roche s SMA Candidate Sees Success  Roche s pivotal study  SUNFISH  on spinal muscular atrophy  SMA  candidate    met its primary endpoint  Data from the study showed that treatment with risdiplam  an oral SMN2 splicing modifier  led to statistically significant improvement in the overall study population with type 2 or 3 SMA  patients aged 2 25 years  compared to placebo  Roche plans to submit the data to the FDA to get risdiplam approved for which it has partnered with PTC Therapeutics Meanwhile  a phase II study evaluating Roche s Gazyva  obinutuzumab  for adults with proliferative lupus nephritis  met the primary endpoint  Data from the phase II NOBILITY study showed that Gazyva  in combination with standard of care  more than doubled the percentage of lupus nephritis patients achieving complete renal response  compared to standard of care alone  Notably  40  of patients treated with Gazyva plus standard of care achieved complete renal response at Week 76  compared to 18  of patients treated with placebo plus standard of care Pfizer s 2nd Gastric Cancer Study on Bavencio Fails  Pfizer and partner Merck KGaA announced that a phase III study evaluating their PD L1 inhibitor  Bavencio  avelumab   for the treatment of gastric cancer as a first line maintenance therapy following induction chemotherapy  failed to meet the primary endpoint  Top line data from the study showed that treatment with avelumab did not result in superior overall survival compared with the standard of care in the overall intent to treat population or the PD L1 positive population  thereby failing to meet the primary endpoint of the study  In November 2017  another study gastric cancer study evaluating avelumab monotherapy in the third line setting had failed to meet the primary endpoint Meanwhile  Pfizer and Mylan  NASDAQ MYL  announced that the name of the new generic pharmaceutical company to be formed by the merger of Pfizer s Upjohn unit and Mylan will be Viatris  The transaction  which was announced in July  is expected to close in mid 2020 Glaxo s Nucala Study Meets Primary Endpoint  Glaxo announced its asthma drug  led to significant reduction in flares for patients with Hypereosinophilic Syndrome  HES   per data from a pivotal study evaluating the drug for this rare disease  The study met its primary endpoint with 50  fewer patients treated with Nucala experiencing a HES flare  compared to placebo  when added to standard of care treatment over the 32 week study period  Based on this data  Glaxo plans to file regulatory applications seeking approval of Nucala for HES in 2020 AbbVie Files sNDA for Imbruvica Rituxan Combo for First Line CLL SLL  AbbVie announced that it has submitted a supplemental NDA to the FDA seeking label expansion approval of Imbruvica in combination with Roche s Rituxan for the treatment of previously untreated  younger adults with chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL   The application is being reviewed under the FDA s Real Time Oncology Review pilot program and is based on data from the phase III E1912 study  If approved for the combination use  this will be the11th FDA approval for Imbruvica across six distinct disease areas FDA Accepts Bristol Myers  sBLA for Opdivo Yervoy Combo  Bristol Myers   BMY  supplemental biologics license application  sBLA  application seeking approval of  plus Yervoy combo regimen for previously treated advanced hepatocellular carcinoma  a form of liver cancer  was accepted by the FDA  With the FDA granting a priority review designation to the sBLA  a decision is expected on Mar 10  2020  Meanwhile  the FDA granted Opdivo plus Yervoy Breakthrough Therapy status for this potential indication FDA Panel Votes Against Lilly s Jardiance Label Expansion  An FDA advisory committee voted against the label expansion of Lilly Boehringer Ingelheim s type II diabetes medicine  2 5 mg  for type I diabetes  The FDA s Endocrinologic and Metabolic Drugs Advisory Committee voted 14 2 that the benefits of Jardiance 2 5 mg do not outweigh the risks to support approval for the indication  The companies are seeking approval for Jardiance  2 5 mg for type I diabetes under a separate brand name Meanwhile  Lilly and partner Boehringer Ingelheim initiated the first ever study to evaluate its SGLT2 inhibitor  Jardiance in patients with and without type II diabetes hospitalized for acute heart failure who have been stabilized  The aim of the study  EMPULSE  is to understand whether Jardiance has the potential to improve outcomes in this patient population  It is the sixth phase III study in the Jardiance heart failure program Novartis  Sandoz Strengthens Presence in Japan s Generic Market  Novartis  generic subsidiary  Sandoz  announced an agreement to acquire Aspen Global Incorporated s   AGI   Japanese operations and associated assets  Sandoz will make an initial cash payment of 300 million euros to AGI on closing of the deal  The deal will expand Novartis  presence in Japan  which is the world s third largest generics market  Aspen s portfolio in Japan consists primarily of off patent branded medicines with focus on anesthetics and specialty brands  which will complement Sandoz broad hospital portfolio and pipeline in Japan  The NYSE ARCA Pharmaceutical Index rose around 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  while Merck rose the most  2 0    Lilly lost the maximum  1 2   In the past six months  AstraZeneca has risen the most  25 3    while Pfizer lost the maximum  12 3    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-11-15,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-gsk-abbv-llys-pipeline--regulatory-updates-200485570,200485570
171104,392620,LLY,Lilly  LLY  Up 6 4  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Eli Lilly  LLY   Shares have added about 6 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Lilly due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Lilly Q3 Earnings Top Estimates  Sales LagLilly reported third quarter 2019 adjusted earnings per share of  1 48  which beat the Zacks Consensus Estimate of  1 43  Earnings rose 10  year over year as higher operating costs were partially offset by slightly higher revenues  a lower tax rate and reduction in shares outstanding due to buybacks Revenues in DetailRevenues of  5 48 billion missed the Zacks Consensus Estimate of  5 56 billion  Sales however grew 3  year over year  backed by robust volume growth of new products and international operations  which compensated for lower realized prices  lower sales of older products like Cialis due to the loss of U S  exclusivity and the impact of Lartruvo s product withdrawal Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 4  on sales due to rebates and legislated increases in Medicare Part D cost sharing in the United States and price cuts in some international markets  Volumes rose 8   Excluding Cialis  loss of exclusivity and the impact of Lartruvo  volume grew nearly 16  New pharma products  products launched since 2014  generated  2 4 billion in revenues and drove 12  of sales growth in the third quarter and represented nearly 44  total revenues  up from 43  in the previous quarter  The loss of exclusivity hurt volumes by 700 basis points primarily attributed to Cialis U S  revenues were flat at  3 06 billion while ex U S  revenues rose 8  to  2 42 billion Among the established products  Forteo sales declined 5  to  370 7 million  Alimta declined 2  to  508 2 million  Humalog sales dropped 2  to  648 9 million  Humulin sales were flat at  321 8 million Cialis sales declined 61  to  184 3 million as U S  sales were hurt by entry of generic products  Outside U S  sales were also hurt by generic competition  lower realized prices and currency headwinds Among the new products  Trulicity generated revenues of  1 01 billion  up 24  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices in the United States  The prices were lower mainly in the United States due to higher contracted rebates  changes in segment mix and increased coverage gap funding requirements in Medicare Part D  On the call  the company said that the negative factors  which hurt sales of Trulicity in the third quarter  should moderate substantially going forward as impacts from the donut hole are expected to diminish in the fourth quarter Cyramza revenues were  240 0 million  up 21  year over year driven by higher sales in both the United States and international markets Jardiance sales surged 44  to  240 7 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currency Basaglar recorded revenues of  263 2 million  up 31  year over year  In the United States  sales rose 29   benefiting from higher demand and the impact of higher realized prices  Outside U S  sales growth of 39  was driven by increased volume Taltz brought in sales of  340 0 million  up 29  year over year as U S  sales gained from higher demand  which offset the impact of lower realized prices due to changes in estimates for rebates and discounts  Ex U S  sales were driven by increased volume from launches in new countries Olumiant generated sales of  114 6 million in the quarter compared with  102 4 million in the previous quarter backed by increased demand in international markets  In the United States  Olumiant recorded sales of  12 1 million  higher than  10 7 million in the previous quarter  Revenues outside the United States were  102 5 million compared with  91 7 million in the previous quarter Verzenio generated sales of  157 2 million in the quarter  up from  133 9 million in the previous quarter  This was because of increased demand and higher realized prices in the United States wherein Verzenio recorded sales of  124 8 million Emgality generated revenues of  47 7 million in the quarter compared with  34 3 million in the previous quarter  In the United States  Emgality sales were  45 8 million compared with  33 8 million in the previous quarter  Emgality was launched in some international markets in the first quarter  which brought sales of  1 9 million in the third quarter Emgality captured 46  share of the market for new prescriptions in the United States  an increase of 5 points from the end of second quarter Regarding newly launched Baqsimi  Lilly said commercial uptake in the United States was strong as Baqsimi has already captured 33  share of new to brand prescriptions Gross Margin   Operating IncomeAdjusted gross margin of 79 6  in the quarter was down 60 basis points as favorable effect of foreign exchange rates on international inventories sold and greater manufacturing efficiencies were offset by the impact of unfavorable product mix due to lower volumes of Cialis and negative impact of price on revenues Operating income rose 3  year over year to  1 57 billion  Operating margin was 28 6  in the quarter Total operating expenses  including research and development and marketing  selling and administrative expenses  rose 2  in the quarter as the company invested in recently launched products and late stage assets  Marketing  selling and administrative expenses declined 3  due to cost control and lower litigation charges  partially offset by increased investment behind recent launches  R D expense rose 8  in the quarter due to higher development expenses for late stage assets Adjusted effective tax rate was 11 7   lower than 14 9  in the year ago quarter  driven primarily by the impact of U S  tax reform 2019 Earnings Guidance RaisedLilly raised its expectations for full year earnings while keeping its revenue guidance intact   The earnings forecast was increased from a range of  5 67 to  5 77 per share to  5 75 to  5 85 taking into account a lower tax rate The range indicates growth of 4  to 6  from the year ago levels  The guidance excludes discontinued operations results for Elanco  following disposition of Lilly s remaining ownership in the company The revenue guidance was maintained in the range of  22 0 billion    22 5 billion  which indicates 5  growth  at mid point  over 2018 level on a constant currency basis Gross margin is still expected to be approximately 80   Adjusted tax rate is expected to be in the range of 12 versus 13 expected previously  Adjusted operating margin is expected to be 28  in 2019 Marketing  selling and administrative expense are expected to be in the range of  5 9 billion to  6 1 billion  Research and development expense is still expected to be in the range of  5 5 billion to  5 7 billion Going forward  Lilly s revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio  Basaglar  Emgality as well as newly launched glucagon nasal powder  Baqsimi  However  generic competition for several drugs including Cialis  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line  In the United States  prices are expected to decline in a mid single digit range Maintains 2020 GoalsIn 2020  Lilly expects sales to grow 6   It expects new products to help it achieve the sales growth target as the headwind from Cialis LOE and Lartruvo will abate in 2020  It expects to achieve adjusted operating margin of 31  in 2020  
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended upward during the past month 
VGM Scores
Currently  Lilly has a subpar Growth Score of D  however its Momentum Score is doing a lot better with an A  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Lilly has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-up-64-since-last-earnings-report-can-it-continue-200487766,200487766
171105,392621,LLY,MarketPulse  Mylan Surges to Keep Health Care Stocks Well Above Flatline,news,"Investing com   A pulsating rally in shares of Mylan and CVS Health Tuesday offset weakness in Eli Lilly  keeping the broader health care sector well above the flatline 
Mylan s third quarter revenue fell short of estimates  but profit more than doubled  resurrecting bullish calls from Wall Street analysts  many of whom had previously claimed the drug company was on the brink of disaster following poor second quarter results  Mylan  NASDAQ MYL  shares surged more than 17  
J P  Morgan analyst Chris Schott said that recent weakness in Mylan shares was  overdone   asserting that the drug company was  one of the better positioned players in the space with a number of longer term growth drivers in place  biosimilars  the pending genetic Advair approval  a significant ex US business   
Mylan s stock  however  remains down roughly 10  so far this year 
CVS Health  NYSE CVS  posted earnings and revenue that beat on both the top and bottom lines Tuesday and said the acquisition of health insurer Aetna  NYSE AET  would be completed before Thanksgiving  sending its shares more than 5  higher 
An improving pharmacy retail business bolstered the company s performance in the third quarter as earnings of  1 73 a share on revenue of  47 3 billion beat Wall Street estimates 
Diabetes specialist Eli Lilly  NYSE LLY   meanwhile  fell 4  shrugging off a third quarter earnings and revenue beat as mixed results from key products weighed on performance 
Lilly s diabetes drug Trulicity and psoriasis medicine Taltz topped Wall Street forecasts  but newer treatments fell short 
 Performance of key products that are part of the new product story were mixed    Credit Suisse   SIX CSGN  analyst Vamil Divan said 
The S P 500 Health Care index rose 0 60  ",2018-11-06,Investing.com,https://www.investing.com/news/stock-market-news/marketpulse-mylan-surges-to-keep-health-care-stocks-well-above-flatline-1676372,1676372
171106,392622,LLY,Merck bolsters animal health unit with  2 4 billion Antelliq purchase,news,By Tamara Mathias  Reuters    Merck and Co  N MRK  said on Friday it will buy privately held French company Antelliq Group  which makes digital identification products for livestock  for about 2 1 billion euros   2 37 billion  to bolster its fast growing animal health business  The move affirms the drugmaker s commitment to the business  which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co  N LLY  and  Pfizer  Inc  N PFE  did   Pfizer s Zoetis  N ZTS  raised  2 2 billion in a 2013 IPO  while Elanco  N ELAN   the former animal health business at Lilly  raised  1 51 billion from an IPO in September  Merck s Chief Executive Officer Kenneth Frazier had said in October that the company was a  good owner  of its animal health unit   We believe that we run this business very well inside the company compared to our competitors   he had said  Merck s unit has been a big player in the animal health segment  bringing in sales of  3 88 billion in 2017  Zoetis recorded  5 31 billion in revenue  while Elanco brought Lilly  3 09 billion in sales the same year   Merck said Antelliq will be a wholly owned and separately operated subsidiary within its animal health division  Antelliq s products  which brought in 360 million euros   406 51 million  in sales in the year ended Sept  30  provide veterinarians  farmers and pet owners with digital technology that monitors animals and predicts disease in them  These products allow access to real time  actionable information to help improve livestock management and health outcomes  Merck said in a statement  Merck will assume Antelliq s debt of 1 15 billion euros   1 30 billion   which it intends to repay shortly after the closing of the deal  expected in the second quarter of 2019   Private equity firm BC Partners currently owns a majority stake in Antelliq  Merck s shares fell nearly 1 percent to  77 70 before the bell ,2018-12-14,Reuters,https://www.investing.com/news/stock-market-news/merck-to-bolster-animal-health-unit-with-24-billion-purchase-of-antelliq-1721794,1721794
171131,392647,LLY,Sanofi  SNY  Q3 Earnings Beat  Vaccines CHC Units Hurt Sales,opinion,"Sanofi  PA SASY    NASDAQ SNY   reported third quarter 2019 earnings of  1 07 per American depositary share  which beat the Zacks Consensus Estimate of 96 cents  Earnings increased 4 3  on a reported basis  At constant currency rates  CER   earnings were flat as lower costs were offset by lower revenues Third quarter net sales of the French pharma giant rose 1 1  on a reported basis to  10 54 billion   9 5 billion   Exchange rate movements benefited sales by 2 2   At CER  sales decreased 1 1  year over year  Sales however missed the Zacks Consensus Estimate of  10 624 billion       In September 2018  Sanofi closed the agreement to sell its European generics business  Zentiva to Advent International  Adjusting for the Zentiva divestiture and sales of Bioverativ products to Swedish Orphan Biovitrum AB  SOBI   sales rose 0 5  at constant structure and CER basis Sales decreased 4 5  at CER in the United States  At CER  sales rose 9 7  in the Emerging Markets  However  sales declined 7 5  in Europe at CER and 1 7  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico  All growth rates mentioned below are on a year on year basis and at CER Segmental PerformanceEarlier  Sanofi reported through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  However  beginning 2019  Sanofi implemented a new structure wherein General Medicines   Emerging Markets and Diabetes and Cardiovascular GBU were reorganized into two new GBUs  namely the Primary Care unit and the China and Emerging Markets unit  Importantly  Emerging Markets sales for Specialty Care and Primary Care are now included in China   Emerging Markets GBU Pharmaceuticals sales  including the emerging markets  rose 1 5  to  6 43 billion driven by key eczema drug  Dupixent  which was partially offset by lower Diabetes and Established Rx products sales and the Zentiva  European generics business  divestiture Sanofi Genzyme Specialty Care GBU sales  excluding the emerging markets  increased 19 5  to  2 36 billion  driven by Dupixent In the immunology franchise  Dupixent generated sales of  561 million in the quarter  up 140 8  year over year and 14 5  on a sequential basis  Sales were driven by continued growth in atopic dermatitis and rapid uptake in new asthma indication  Dupixent was launched for adolescent atopic dermatitis and for chronic rhinosinusitis with nasal polyposis in the United States in mid March and June  respectively and for the asthma indication in Japan in April  It was approved to treat asthma indication and adolescent atopic dermatitis in Europe in May and August  respectively  All the label expansion approvals contributed to sales growth of the drug in the third quarterSales of the drug in the United States were  455 million while the same in Europe were  54 million Kevzara recorded sales of  49 million in the quarter compared with  51 million in the previous quarter Sanofi markets Dupixent and Kevzara in partnership with Regeneron Pharmaceuticals   NASDAQ REGN   Sales of rare disease drugs increased 2 8  to  637 million driven by Gaucher  Pompe and Fabry therapies  Myozyme Lumizyme rose 5 6  to  192 million  Fabrazyme sales were  180 million  up 0 6   Cerezyme sales declined 4 2  to  114 million Oncology sales increased 7 4  to  297 million  Key cancer drug Jevtana s sales were up 9 1  to  112 million supported by higher sales in United States and Japan Sales of multiple sclerosis drugs rose 2 2  to  534 million  Aubagio sales increased 12 8  to  482 million while sales of Lemtrada fell 45 2  to  52 million Rare blood disorders franchise  added to Sanofi s portfolio with the acquisition of Bioverativ in 2018  fetched sales of  281 million versus  287 million in the previous quarter  New drug Cablivi  caplacizumab  generated sales of  20 million in the quarter compared with  15 million in the previous quarter  Cablivi was launched in the United States in April and generated sales of  13 million in the region  The remaining  6 million in sales came from the five European countries where the product is now commercially available  However  sales of Eloctate declined 22 8  in the quarter due to the ongoing competitive pressurePrimary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments  Sales in the Primary Care GBU declined 17 5  to  2 19 billion hurt by lower diabetes sales and Zentiva divestiture The Diabetes franchise  excluding the emerging markets  declined 17 7  to  837 million due to lower sales of key drugs   Lantus and Toujeo Sales of diabetes drugs in the United States declined 24 7  to  451 million due to pricing pressure and loss of Part D business  In Europe  it dropped 3  and in rest of the world it declined 21 37  Lantus sales decreased 27 5  to  487 million in the quarter  Lantus sales plunged 32 7  in the United States due to lower average net price and change in coverage with respect to Sanofi s Part D business  In Europe  sales decreased 13  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  175 million in the reported quarter  down 5   Sales rose 18 3  in Europe while it declined 25  in the United States Admelog  a rapid acting insulin  similar to Lilly s   NYSE LLY   Humalog  which was launched in the United States in April last year  achieved sales worth  51 versus  77 million in the previous quarter In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent  garnered worldwide sales of  56 million in the reported quarter  down 15 4  as growth in Europe was offset by decline in the United States  Sales in the United States declined due to significantly higher rebates offered by Sanofi and partner Regeneron to payers to improve access to the drug  Sales of the other drug  Multaq  in this franchise declined 9 9  to  85 million Sales of Established Rx Products came in at  1 21 billion  down 17 9  due to generic competition for Renvela Renagel in the United States  lower sales of Lovenox in Europe and the divestment of the European generics business  Zentiva Sales of China and Emerging Markets GBU rose 10  to  1 89 billion Consumer Healthcare  CHC  GBU  including the emerging markets  sales were  1 14 billion  up 0 4  as higher sales in Emerging Markets were offset by lower sales in the United States and Europe  Sales declined 4 4  in the United States due to Sanofi s voluntary recall of its over the counter acid reflux medicine Zantac  which is sold by the generic name of ranitidine by many other companies  FDA tests  whose results were released in September  found low levels of  a chemical   NDMA  which has been  classified as a probable human carcinogen   in multiple ranitidine products   This prompted Sanofi as well as a couple of companies including Novartis   NYSE NVS   owned Sandoz  which markets generic ranitidine  to recall their products Meanwhile  non core divestments and increased regulatory requirements also hurt the performance of the CHC segment Sanofi Pasteur  Vaccines  sales  including the emerging markets  declined 9 8  to  1 93 billion due to a decline in U S  sales  U S  sales of vaccines declined 19 5  in the quarter due to delay in flu vaccines supply  Sales  however  rose in Emerging Markets and Europe Costs DeclineSelling  general and administrative expenses declined 1 5  at CER in the quarter  reflecting cost control measures  Research and development expenses declined 8 1  at CER due to favorable phasing of expenses and lower research costs resulting from restructuring of the immuno oncology collaboration with Regeneron 2019 GuidanceSanofi maintained its previously issued earnings growth expectations  It expects earnings to grow approximately 5  at CER in 2019  It now anticipates a positive currency impact of around 3  on earnings versus prior expectation of 1  to 2  Our TakeSanofi s third quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales  Double digit growth in the Specialty Care was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the CHC and Vaccines units in the quarter  Shares were slightly down in pre market trading on Thursday  However  Sanofi s shares have outperformed the industry this year so far  It has risen 6 1  in the said time frame while the  has gone up 3 1    Nonetheless  Sanofi s Specialty Care segment is on a strong footing particularly with regular label expansion of Dupixent  The drug could prove to be an important growth driver  Sanofi s R D pipeline is strong and it has delivered important results with several positive data read outs and the achievement of regulatory milestones this year  However  weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent are headwinds Zacks Rank Sanofi currently carries a Zacks Rank  3  Hold   You can  Sanofi Price  Consensus and EPS Surprise
    
Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-q3-earnings-beat-vaccineschc-units-hurt-sales-200480976,200480976
171132,392648,LLY,Agios   AGIO  Q3 Loss Narrower Than Expected  Revenues Miss,opinion,Agios Pharmaceuticals  Inc    NASDAQ AGIO   reported third quarter 2019 loss of  1 81 per share  narrower than the Zacks Consensus Estimate of a loss of  1 85 but wider than the year ago loss of  1 63 Meanwhile  total revenues in the reported quarter were  26 million  lower than the Zacks Consensus Estimate of  29 million but higher than the year ago revenue figure of  15 million  Revenues increased year over year  driven by a strong uptake of Tibsovo in the frontline and relapsed refractory acute myeloid leukemia  AML  settings Agios  first wholly owned drug Tibsovo  ivosidenib  was approved for treating adult patients suffering relapsed or refractory AML with IDH 1 mutation last July  In May 2019  the FDA approved Tibsovo in the frontline setting  The drug generated sales of  17 4 million in the third quarter of 2019  reflecting a sequential surge of 27  Tibsovo is under review in the EU for treating relapsed or refractory AML with a potential approval expected in the second half of 2020 Shares of Agios were down 4 8  following this news on Thursday  probably as sales lagged investor expectations  In fact  the stock has plunged 34 8  so far this year versus the rally of 12  Meanwhile  royalty revenues earned from Celgene   NASDAQ CELG   were  2 7 million on Idhifa  enasidenib  net sales in the reported quarter while collaboration revenues were  5 5 million  Idhifa is owned by Agios  partner Celgene Corporation while the former is entitled to receive royalties on the drug s net sales  Idhifa is also under review in the EU Quarter in DetailResearch   development expenses rose 23 1  year over year to  101 7 million  largely due to higher cost of late stage clinical studies for pipeline development General and administrative expenses increased 6 1  year over year to  33 million on account of higher investments Agios ended the third quarter with cash  cash equivalents and marketable securities of  540 5 million  lower than the sequential quarter s tally of  624 million  The company expects this cash balance and revenues recognized from Tibsovo and royalties to effectively fund its current operational plans for at least through 2020 Tibsovo and Other Pipeline UpdatesIn September 2019  Agios presented detailed data from the phase III ClarIDHy study on Tibsovo being evaluated in previously treated patients with IDH1 mutant cholangiocarcinoma at the European Society for Medical Oncology Congress held in Spain Data from the study showed that patients who were treated with Tibsovo had a 6 month and 12 month progression free survival  PFS  rate of 32  and 22   respectively  while none of the patients in the placebo arm was free from disease progression for more than six months  Tibsovo also reduced the risk of disease progression or death by 63  Notably  in May 2019  Tibsovo met the primary endpoint in the ClarIDHy study  The company plans to file a supplemental new drug application  sNDA  to the FDA for including data from ClarIDHy study on Tibsovo s label by this year end  Currently  there are no treatment options available for this disease Agios  key pipeline candidate mitapivat is being developed to treat patients with PK deficiency  The company is also looking to close enrollment in two pivotal studies on mitapivat by the end of 2019  The studies are single arm ACTIVATE T analyses for addressing PK deficiency in up to 40 patients  who are on regular blood transfusions  and the ACTIVATE study for treating PK deficiency in up to 80 patients with no regular blood transfusions Agios also plans to initiate a phase II proof of concept analysis on mitapivat for thalassemia in the second half of 2019 This apart  Agios  other early stage cancer product candidates are vorasidenib  AG 270 and AG 636 Agios plans to begin a registration enabling phase III INDIGO study on vorasidenib for treating Grade 2 non enhancing glioma with an IDH1 mutation by this year end  The primary endpoint of this study is PFS AG 636 is in phase I development for treating advanced lymphoma Notably  AG 270 is being developed for treating cancers carrying a methylthioadenosine phosphorylase  MTAP  deleted tumors  During the reported quarter  Agios initiated two combination arms for the phase I study of AG 270 in MTAP deleted tumors One study is evaluating AG 270 in combination with docetaxel  a chemotherapy drug for addressing MTAP deleted second line non small cell lung cancer  The other study is evaluating AG 270 in combination with nab paclitaxel and Eli Lilly s   NYSE LLY   Gemzar  gemcitabine  for MTAP deleted first or second line pancreatic ductal adenocarcinoma Agios Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Key PickAgios currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Acorda Therapeutics  Inc    NASDAQ ACOR    sporting a Zacks Rank  1  Strong Buy   You can see  Acorda s loss per share estimates have been narrowed 20 4  for 2019 and 43  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-11-01,Zacks Investment Research,https://www.investing.com/analysis/agios-agio-q3-loss-narrower-than-expected-revenues-miss-200481448,200481448
171133,392649,LLY,Pharma ETFs Set To Benefit Post Strong Q3 Earnings,opinion,Total earnings of the  of the entire healthcare market capitalization that has reported so far are up 7 1  on revenue growth of 8 2   The earnings and revenue growth rates seem to be the fourth highest among all the sectors  Earnings and revenue beat ratios of 80 6  and 86 1   respectively also appear strong Most industry bigwigs delivered encouraging results  either beating on earnings or revenues or both and also raised revenue or earnings guidance or both  Let s delve into a few of them Earnings in FocusJohnson and JohnsonThe world s biggest healthcare products maker continued its long streak of earnings beat  It also outpaced revenue estimates  Earnings per share came in at  2 12  12 cents ahead of the Zacks Consensus Estimate and 3 4  higher than the year ago quarter  Revenues grew 1 9  year over year to  20 7 billion and edged past the Zacks Consensus Estimate of  20 1 billion  For 2019  Johnson   Johnson  NYSE JNJ  raised its sales forecast to  81 8  82 3 billion from  80 8  81 6 billion  which represents 0 2  0 7  year over year growth  on robust demand for its cancer drugs  It also upped its earnings per share guidance to  8 62  8 67 from  8 53  8 63  representing year over year growth of 5 4 6   read    Pfizer  NYSE PFE  Earnings per share of 75 cents were 12 cents above the Zacks Consensus Estimate and revenues of  12 68 billion also edged past the consensus mark of  12 15 billion  On a year over year basis  earnings per share and revenues declined 2  and 5   respectively  For 2019  the U S  drug giant revised sales guidance to  51 2  52 2 billion from  50 5  52 5 billion and earnings per share to  2 94  3 00 from  2 76  2 86 Merck Earnings per share of  1 51 surpassed the Zacks Consensus Estimate of  1 25 and also improved 27  from the year ago quarter  Moreover  revenues grew 15  year over year to  12 4 billion  edging past the consensus mark of  11 7 billion  Merck increased its revenue projection from  45 2  46 2 billion to  46 5  47 billion for this year and earnings per share view from  4 84  4 94 to  5 12  5 17  read    Bristol Myers Bristol Myers s earnings per share of  1 17 beat the Zacks Consensus Estimate by 11 cents and also rose from the year ago figure of  1 09  Revenues grew 6  year over year to  6 billion and also trumped the Zacks Consensus Estimate of  5 8 billion  The company lifted its earnings per share guidance to  4 25  4 35 from  4 20  4 30 Eli Lilly  NYSE LLY  Eli Lilly delivered better than expected earnings but lagged on revenues  Earnings of  1 48 per share were 5 cents ahead of the Zacks Consensus Estimate and came in 10  higher than the year earlier quarter  Revenues grew 3  to  5 48 billion but fell short of the estimated  5 56 billion  While Eli Lilly maintained its 2019 revenue guidance of  22  22 5 billion  it raised its earnings prediction to  5 75  5 85 from  5 67  5 77 ETF AngleRobust results led to solid trading in pharma ETFs in a month  Below  we have highlighted those in detail  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 45 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top 10 holdings in the basket  accounting for 56 8  of the total assets  suggesting heavy concentration  The product has  334 9 million in AUM and charges 42 bps in fees and expense  Volume is light as it exchanges about 17 000 shares a day  The fund has added 4 3  in a month and has a Zacks ETF Rank  3  Hold  with a High risk outlook First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 32  of the assets  FTXH has a lower level of  8 5 million in AUM and 2 000 shares in average daily volume  It charges 60 bps in annual fees and is up 5 1  in the same time frame  The product has a Zacks ETF Rank  3 SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  187 2 million  it trades in good volume of around 71 000 shares a day and charges 35 bps in fees a year  In total  the product holds 39 securities with the in focus five firms making up for at least 4  share each  The product has gained 12 2  in the same period and has a Zacks ETF Rank  3 with a High risk outlook  read    VanEck Vectors Pharmaceutical ETF   ASX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus five firms account for a nearly 5  share each  The product has amassed  179 1 million in its asset base and trades in moderate volume of about 46 000 shares a day  Expense ratio is 0 36   The fund has gained 7 5  of value in a month and has a Zacks ETF Rank  3 with a Medium risk outlook Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  362 3 million and sees a lower volume of around 40 000 shares a day  The fund charges 56 bps in fees and expenses  Holding 30 stocks  the fund invests nearly 5  share each in the five firms  The ETF has gained 8  in a month and has Zacks ETF Rank  3 with a High risk outlook Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-set-to-benefit-post-strong-q3-earnings-200482983,200482983
171134,392650,LLY,Lilly s Jardiance on CVS Caremark 2019 formulary,news,CVS Health s  CVS  1 5   Caremark PBM will include Boehringer Ingelheim and Eli Lilly s  LLY  0 8   type 2 diabetes med Jardiance  empagliflozin  in its 2019 commercial formulary  providing access to its  94M members Now read ,2018-10-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/lillys-jardiance-on-cvs-caremark-2019-formulary-1644891,1644891
171135,392651,LLY,Eli Lilly Earnings  Revenue beat in Q3,news,"Investing com   Eli Lilly  NYSE LLY  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 39 on revenue of  6 06B  Analysts polled by Investing com anticipated EPS of  1 35 on revenue of  6 04B  That compared to EPS of  1 05 on revenue of  5 66B in the same period a year earlier  The company had reported EPS of  1 5 on revenue of  6 36B in the previous quarter 
For the year  Eli Lilly shares are up 30 4   outperforming the S P 500 which is up 2 03  year to date 
Eli Lilly follows other major Healthcare sector earnings this month
 On October 16  J J reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
Pfizer earnings beat analyst s expectations on October 30  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 5B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-11-06,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-earnings-revenue-beat-in-q3-1675549,1675549
171136,392652,LLY,Lilly lifts earnings target after Trulicity boost,news,"By Aakash B and Tamara Mathias  Reuters    Eli Lilly and Co  N LLY  recorded higher sales of its newer drugs Trulicity and Taltz in the third quarter  helping the diabetes specialist top Wall Street profit estimates and raise its yearly earnings target on Tuesday  Shares of Lilly jumped 4 percent in premarket trading following the news  Lilly is relying on new drugs to drive growth after it took its animal health unit public in September and as its older treatments face rising competition from generic as well as branded medicines  Third quarter sales from both diabetes drug Trulicity and psoriasis medicine Taltz exceeded Wall Street forecasts but revenue from Lilly s other newer treatments   Basaglar  Jardiance and Cyramza   each fell short of expectations   Performance of key products that are part of the new product story were mixed    Credit Suisse   SIX CSGN  analyst Vamil Divan said  Trulicity  which recently overtook Humalog as Lilly s top selling drug  had revenue of  816 2 million  above analysts  consensus estimate of  801 million  according to brokerage SunTrust  On Monday Lilly announced that Trulicity significantly reduced the risk of heart attack  stroke and heart related death in a broad range of patients with type 2 diabetes  Results from that trial should strengthen  if not cement  the Indianapolis based drugmaker s position as a leader in diabetes treatments  analysts said   Trulicity has become our largest medicine in terms of sales and certainly we were pleased with data released yesterday   Lilly s Chief Financial Officer Josh Smiley said in an interview   It reinforces how important the class is to the treatment of diabetes   he added  Lilly raised its 2018 adjusted earnings forecast to between  5 55 and  5 60 per share  from  5 40 to  5 50 per share  Net income in the quarter ended September more than doubled to  1 15 billion  Results a year earlier included a write down of more than  400 million  Excluding one time items  Lilly earned  1 39 per share  above analysts  average estimate of  1 35 per share  according to IBES data from Refinitiv  Revenue rose about 7 percent to  6 06 billion  edging past analysts  expectations of  6 05 billion  
Lilly s shares were up 4 2 percent at  114 78 in premarket trading ",2018-11-06,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-lillys-thirdquarter-profit-more-than-doubles-1675566,1675566
171137,392653,LLY,Lilly to consider more acquisitions like  1 6 billion Armo buy,news," Reuters    Eli Lilly and Co  N LLY  will consider more acquisitions similar to its  1 6 billion purchase of cancer drug developer Armo Biosciences earlier this year  the drugmaker s chief financial officer said on Tuesday  The remarks come as Lilly gains access to fresh capital after it took its Elanco animal health unit public in September   We got a little bit less than  4 billion in the third quarter as a function of the first step of our Elanco divestiture and we ll put that money  to use  against our capital priorities   Lilly s Chief Financial Officer Joshua Smiley said in an interview   The Armo deal that we did earlier this year  we ll look to do more of those   Smiley said  but added that mergers with big drug companies were unlikely to be an important tool to grow in the future  In May Lilly said it would buy Armo Biosciences Inc to expand its portfolio of drugs that helps the body s immune system fight cancer  a move that could pit the company against several rivals in a lucrative market  
Separately on Tuesday  Lilly reported a better than expected third quarter profit and raised its earnings forecast for 2018 ",2018-11-06,Reuters,https://www.investing.com/news/stock-market-news/lilly-to-consider-more-acquisitions-like-16-billion-armo-buy-1675910,1675910
171163,392679,LLY,Lilly s Pancreatic Cancer Candidate Fails In Phase III Study,opinion,"Eli Lilly and Company   NYSE LLY   announced that its immunotherapy candidate  pegilodecakin  in combination with chemotherapies  failed to show survival benefit in a phase III SEQUOIA study  evaluating the regimen in metastatic pancreatic cancer Shares of the company fell 1 6  on Oct 16 following announcement of the study failure  The company s shares decreased 6 7  against the  s increase of 0 2  The SEQUOIA study evaluated pegilodecakin in combination with FOLFOX  which is a combination of chemotherapies  folinic acid  5 FU  oxaliplatin   in patients with metastatic pancreatic cancer whose disease had progressed during or following a first line gemcitabine containing regimen versus FOLFOX alone for improvement in overall survival  The study failed to meet the primary endpoint of overall survival Please note that Lilly added pegilodecakin to its pipeline with the acquisition of ARMO Biosciences in 2018 Apart from pancreatic cancer  Lilly is also evaluating pegilodecakin in combination with checkpoint inhibitors in two phase II studies as a treatment for non small cell lung cancer  Top line data from these studies are expected in early 2020  The company also has plans to develop the candidate for treating other tumor types including renal cell carcinoma Currently  pancreatic cancer is the third most common type of cancer leading to death in U S  patients per the American Cancer Society  Per the press release  more than 56 700 patients will be diagnosed with pancreatic cancer in 2019 Although Lilly markets Gemzar for pancreatic cancer  the drug  once a blockbuster  does not generate significant sales due to generic competition  Other drugs available for pancreatic cancer include Celgene s   NASDAQ CELG   Abraxane and Roche s Tarceva Several other pharma biotech companies are developing their treatment regimens to cater to this significantly growing market  NuCana plc   NASDAQ NCNA   is evaluating Acelarin in phase III study  Clovis Oncology s Rubraca is in mid stage development and Tyme Technologies  Inc    NASDAQ TYME   initiated a pivotal study on its pipeline candidate racemetyrosine last month We note that Lilly s oncology segment remained the second largest revenue generator for the company in the first half of 2019 with  2 2 billion in sales  Key oncology drugs of the company are Alimta  Cyramza and Erbitux  which are approved for multiple cancer indications  Successful development of pegilodecakin for treating pancreatic cancer would have offset lower sales of Gemzar as well as boosted oncology sales Eli Lilly and Company Price
    Zacks RankLilly currently carries a Zacks Rank  3  Hold  You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study-200474754,200474754
171164,392680,LLY,Eli Lilly  LLY  Surpasses Q3 Earnings Estimates,opinion,"Eli Lilly  LLY  came out with quarterly earnings of  1 48 per share  beating the Zacks Consensus Estimate of  1 43 per share  This compares to earnings of  1 39 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 50   A quarter ago  it was expected that this drugmaker would post earnings of  1 46 per share when it actually produced earnings of  1 50  delivering a surprise of 2 74  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Lilly  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  5 48 billion for the quarter ended September 2019  missing the Zacks Consensus Estimate by 1 48   This compares to year ago revenues of  6 06 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Lilly shares have lost about 5 1  since the beginning of the year versus the S P 500 s gain of 19 5  
What s Next for Lilly 
While Lilly has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Lilly was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 48 on  6 03 billion in revenues for the coming quarter and  5 73 on  22 26 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-surpasses-q3-earnings-estimates-200476554,200476554
171165,392681,LLY,Pharma Stock Roundup  LLY  NVS  AZN s Q3 Earnings  Updates From FDA,opinion,This week Lilly   NYSE LLY    Novartis   NYSE NVS   and AstraZeneca   NYSE AZN   released their third quarter results  Bristol Myers   NYSE BMY   and Roche s   OTC RHHBY   PD L1 inhibitors  Opdivo and Tecentriq  respectively  met their goals in label expansion cancer studies  Meanwhile  the FDA granted approval to Glaxo s   NYSE GSK   PARP inhibitor Zejula  AstraZeneca s SGLT2 inhibitor Farxiga and J J s   NYSE JNJ   blockbuster immunology medicine  Stelara for expanded patient populations  The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave positive recommendations  granting marketing approval to several drugs or their line extensions this week Recap of the Week s Most Important StoriesEarnings Update   beat estimates for third quarter earnings but missed the same for sales  Earnings rose 10  year over year while sales grew 3  year over year  backed by strong volume trends for its newer drugs  which compensated for lower sales of older products like Cialis due to the loss of U S  exclusivity and the impact of Lartruvo s product withdrawal  Lilly raised its expectations for full year earnings while keeping its revenue guidance intact    earnings and sales beat estimates in the third quarter  It expects to achieve the higher end of its previously provided sales growth target for the year  The company expects net sales in 2019 to grow in high single digits now compared with the previous guidance of mid to high single digit growth  also beat estimates on both counts  Its product sales rose 18  as higher sales of newer medicines offset lower sales of many other legacy medicines  The company updated its product sales guidance and now expects it to grow by a low to mid teens percentage versus prior expectation of a low double digit percentage Bristol Myers Opdivo Combo Meets Goal in First Line Lung Cancer Study  Bristol Myers  phase III study evaluating a combination ofplus low dose Yervoy combined with two courses of chemotherapy for the first line treatment of advanced non small cell lung cancer met the primary endpoint  Interim data from the pivotal CheckMate  9LA study showed that the combination led to superior overall survival  OS  compared to chemotherapy alone in previously untreated lung cancer patients Meanwhile  the European Commission approved Opdivo two and four week flat dosing schedule for the adjuvant treatment of melanoma patients with involvement of lymph nodes or metastatic disease who have undergone complete resectionFDA Approves Glaxo s Zejula for Late Line Ovarian Cancer  Zejula  the ovarian cancer drug Glaxo acquired from the Tesaro acquisition  was approved by the FDA for ovarian cancer patients who are HRD positive and have been treated with three or more previous chemotherapy regimen  This is the first time a PARP inhibitor  as a monotherapy  has been approved in patients beyond those with a BRCA positive mutation  The approval in this late line setting is based on data from the phase II QUADRA study Glaxo also announced that it is divesting its vaccines to prevent rabies  Rabipur Rabavert  and tick borne encephalitis  Encepur  to Bavarian Nordic   a Danish biotech  for an upfront payment of approximately EUR301 million   259m   In addition  Glaxo will also be entitled to receive milestone payments for a total consideration of up to EUR955 million   822m   Glaxo acquired these vaccines from Novartis in 2015 as part of the acquisition of its vaccines business FDA Approves AstraZeneca s Farxiga to Reduce Heart Risk  AstraZeneca announced that the FDA has approved inclusion of positive cardiovascular outcomes from the DECLARE outcomes study on the label of its SGLT2 inhibitor  Farxiga  With the latest nod  Farxiga can now be prescribed in the United States to reduce the risk of hospitalization for heart failure in patients with type II diabetes and established cardiovascular disease or multiple cardiovascular risk factors  An approval for a similar label update was obtained in the EU in August Roche s Cancer Combo Improves Survival in Liver Cancer Study  Roche s phase III IMbrave150 study  which evaluated Tecentriq in combination with Avastin in patients with unresectable hepatocellular carcinoma  the most common form of liver cancer  met both its co primary endpoints  The study demonstrated statistically significant and clinically meaningful improvements in OS and progression free survival  PFS    the co primary endpoints   compared with standard of care  Bayer s Nexavar  sorafenib   Roche will submit the data to regulatory authorities in the United States  Europe and China to get approval for this new indication of Tecentriq FDA Finds Asbestos in One Lot of J J s Baby Powders  J J Recalls  J J announced a voluntary recall of one lot of its Johnson s The product is the subject of numerous lawsuits  which claim that its talc based products contain asbestos that causes cancer  The recall was initiated following a test done by the FDA  which revealed traces of asbestos  a known carcinogen  in samples from one bottle purchased online  J J affirmed that its cosmetic talc is safe and said that it has initiated an investigation into the matter  The FDA  on the other hand  said its stands by the quality of its testing and advised the consumers to stop using the recalled affected products Meanwhile  the FDA granted approval to J J s blockbuster immunology medicine  Stelara for a new indication   moderately to severely active ulcerative colitis  The approval was based on data from the phase III UNIFI study J J also announced new data from a study evaluating the initial combination therapy with Opsumit  macitentan  and tadalafil in patients with pulmonary arterial hypertension  The data showed that patients treated with the combination regimen experienced hemodynamic improvement  as well as improvements in functional parameters and risk profiles  In the study  Opsumit plus tadalafIl  reduced the primary endpoint of mean pulmonary vascular resistance by 47  at week 16 compared with baseline FDA Approves 11th Therapeutic Indication for Allergan s Botox  The FDA approved Allergan s blockbuster product Botox for pediatric patients  2 to 17 years of age  with lower limb spasticity  excluding spasticity caused by cerebral palsy  In June  Botox was approved to treat upper limb spasticity in pediatric patients  Botox is already approved for both lower and upper limb spasticity in adults CHMP Nod to Several Products  The CHMP gave a positive opinion recommending conditional marketing approval of Merck s investigational vaccine for Ebola Zaire disease  V920  If approved by the European Commission  V920will be marketed by the trade name of Ervebo  Ervebo is under priority review in the United States with a FDA decision expected on Mar 14 next year The CHMP also recommended approval of two new regimens of Keytruda for the first line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma  HNSCC   The application seeks approval of Keytruda as a monotherapy or in combination with platinum and 5 fluorouracil  5 FU  chemotherapy  Keytruda was approved for a similar indication in the United States in June this year The European panel also recommended approving AbbVie s oral JAK1 selective inhibitor  Rinvoq  upadacitinib  for moderate to severe active rheumatoid arthritis and J J s Spravato  esketamine  nasal spray as a combination therapy for adults with major depressive disorder  While Rinvoq was approved by the FDA in August  Spravato got the green signal from the regulatory body in March The NYSE ARCA Pharmaceutical Index declined 0 5  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   ReturnHere is how the seven major stocks performed in the last five trading sessions  Last week  while J J lost the most  6 6   due to the baby powder recall news  AstraZeneca was the biggest gainer  7   due to strong results In the past six months  AstraZeneca has risen the most  24 4   while Lilly lost the most  10    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for third quarter results of Bristol Myers  Merck  Pfizer  NYSE PFE   AbbVie  NYSE ABBV  and others and regular pipeline and regulatory updates next week 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lly-nvs-azns-q3-earnings-updates-from-fda-200478517,200478517
171166,392682,LLY,FDA OKs BI s NexGard for prevention of Lyme disease in dogs,news,The FDA approves privately held Boehringer Ingelheim s NexGard  afoxolaner   a chewable flea and tick product   for the prevention of infections that cause Lyme disease  specifically  by killing the type of tick that transmits the bacterium that causes the disease Animal health related tickers  LLY  ZTS  MRK  OTCPK BAYRY  NVSNow read ,2018-08-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-bis-nexgard-for-prevention-of-lyme-disease-in-dogs-1588333,1588333
171167,392683,LLY,AstraZeneca plots China robot offensive to counter price cuts,news,"By Adam Jourdan and Ben Hirschler WUXI  China LONDON  Reuters    With smart cancer diagnostics  one stop shop diabetes kits and AI systems to improve ambulance pick ups for patients with chest pain  AstraZeneca  L AZN  aims to move from simply supplying drugs to become a broad healthcare provider in China  Tech tie ups with the likes of  Alibaba   N BABA  and Tencent  HK 0700  will not directly lift the British group s drug sales  since they are not specific for any one company s products and in many cases will be low cost or free  But it will expand the overall market and represents a soft power play that dovetails neatly with Beijing s support for Internet based healthcare systems to alleviate a lack of doctors  overcrowding and poor grassroots healthcare    Down the line we benefit  our products benefit  because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated   Chief Executive Pascal Soriot told Reuters   Surrounded by the latest gizmos at the World Internet of Things Exposition in Wuxi  eastern China  Soriot says he wants to use the power of artificial intelligence  robots and apps to help transform diagnosis and disease management   AstraZeneca has been on a tear in China  more than doubling its sales since 2012  helped by regulatory reforms to fast track new drugs  and today generates 18 percent of revenue in the country    a far higher proportion than rivals  Yet Soriot is anxious to do more to keep doctors and government officials on side in the world s second biggest drugs market  as soaring demand strains the state insurance system and squeezes medicine prices  The company s underlying conviction is that it has the right medicines across chronic diseases like cancer  diabetes and respiratory disorders to win in China  Soriot believes that can keep AstraZeneca growing in a pivotal market in the coming years  even though annual growth is likely to slow to nearer 15 percent from the breakneck 33 percent seen in the first half of 2018  The company has moved quickly to exploit China s new found willingness to use innovative Western drugs  Last year it won a record fast approval for lung cancer pill Tagrisso  which is designed for patients with a genetic mutation that is particularly common in China  It hopes to get a green light before the end of 2018    well before U S  approval    for a new anemia drug called roxadustat being developed with FibroGen  O FGEN   China first approvals for drugs like roxadustat and Elunate  a colorectal cancer treatment from Eli Lilly  N LLY  and Hutchison China MediTech  L HCM   mark a reversal of the historical pattern of Chinese patients getting new drugs years after their launch in the West  There is  however  a trade off  Multinationals that relied in the past on selling older drugs at premium prices in China are seeing prices slashed  AstraZeneca took a 50 percent haircut last year on the price of Iressa  its predecessor to Tagrisso   The government wants to give access to better medicines to more people   said Soriot  who admitted that pressure on prices had come sooner than he expected   To some extent the economy is growing so there is more money to do that  but there is not enough money     They have to make room in the budget for innovation    UNMET NEEDS  With 1 4 billion people  around 18 percent of the world s population  China has more cases of cancer and diabetes than any other nation  fueled by fast food  smoking and pollution  global health data show    There are enormous unmet medical needs in China  particularly in oncology  and 30 percent of the world s cancer patients are in China   Christian Hogg  Chief Executive of Hutchison China MediTech  told Reuters   There is almost an inevitability that the Chinese pharmaceutical industry is going to grow to be the largest in the world in due course   The firm  also known as Chi Med  is working with AstraZeneca on a novel oncology drug targeting kidney  lung and stomach tumors  AstraZeneca is bolstering its sales force to meet this growing demand  It has around 7 500 sales staff in China and is looking to push into smaller cities    boosting volume and helping offset lower prices  It aims to get more drugs onto a list of medicines covered by basic insurance schemes    the national drug reimbursement list    and onto fast track approvals  Soriot said  The list was most recently updated last year after an eight year hiatus  A drug joint venture  Dizal Pharmaceutical  backed by the China State Development   Investment Corporation  will promote Chinese discovered drugs    another priority for Beijing   It s the first time a government fund works with a foreign company in researching new drugs for Chinese patients   Leon Wang  AstraZeneca s China head  said in an interview at the firm s Shanghai headquarters   So we like that   Wang added there were still many patients who went undiagnosed or untreated  and that the firm s aggressive expansion  even to  village clinics   was helping make the difference against rivals tapping growing demand   Chronic disease  oncology drugs  specialty care  rare disease  these will all explode I think   he said  
 For a graphic on  Booming China sales  click  ",2018-09-19,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-plots-china-robot-offensive-to-counter-price-cuts-1615424,1615424
171168,392684,LLY,Lilly s diabetes drug data impresses  hurts rival Novo s shares,news,"By Saumya Joseph  Reuters    Eli Lilly and Co  N LLY  said on Thursday its new two in one diabetes drug was successful in lowering blood sugar and reducing weight  sending its shares to a record high and weighing on those of arch rival  Novo Nordisk   CO NOVOb   The novel drug targets two key gut hormones at the same time  and could pose a threat to currently available single hormone drugs  which form a large and growing part of Novo s business  Lilly s treatment reduced blood sugar levels in type 2 diabetes patients by up to 2 4 percent and produced an average weight reduction of up to 12 7 percent in a mid stage study by targeting the GLP 1 and GIP hormones  The trial results set a new industry gold standard versus marketed GLP 1s  including Novo s Ozempic for both blood sugar lowering and weight loss  Citi analyst Andrew Baum said  Lilly s shares were rose 6 5 percent to a record high of  115 68 in early trading  while those of Novo fell nearly 8 percent  Novo s existing GLP 1 products include Victoza and Omzepic  and the company is also developing an oral version of semaglutide  the active ingredient in Ozempic  Lilly said it intends to complete its late stage study for the drug in late 2021  and is also evaluating the drug for treating obesity  among other conditions  BMO Capital Markets analyst Alex Arfaei said the treatment provides Lilly with a reasonable shot at the large obesity market and should meaningfully strengthen the company s position in the rapidly growing GLP 1 market  About 30 million adults in the United States have diabetes  with 90 percent to 95 percent of them suffering from type 2 diabetes  Obesity is a major risk factor for developing type 2 diabetes  and weight loss as little as 5 percent of the total body weight has been found to help improve type 2 diabetes in patients who are obese or overweight  according to American Society for Metabolic and Bariatric Surgery  Lilly s wide portfolio of diabetes drugs  including GLP 1 drug Trulicity  contributed at least 38 percent to its total sales of  6 36 billion in the latest reported quarter  
 With Trulicity representing a core growth driver for Lilly and competitive concerns regarding Ozempic and oral semaglutide causing an overhang on shares over the past year  we see today s results as a clear positive for the Lilly story   JP Morgan analyst Chris Schott said in a note ",2018-10-04,Reuters,https://www.investing.com/news/stock-market-news/lillys-diabetes-drug-data-impresses-hurts-rival-novos-shares-1633983,1633983
171196,392712,LLY,Gilead  GILD  Files NDA For RA Candidate Filgotinib In Japan,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced that it has submitted a new drug application  NDA  for its oral JAK1 inhibitor filgotinib to treat adult patients with rheumatoid arthritis  RA  in Japan The NDA submitted to the Japanese Ministry of Health  Labor and Welfare was based on data from the phase III clinical program FINCH  which comprises three studies  Data from the study showed that once daily treatment with filgotinib demonstrated the potential to improve clinical signs and symptoms  and achieved low disease activity and remission Importantly  safety results across the FINCH program were consistent with previously reported data The 52 week phase III study FINCH 1 evaluated filgotinib compared to AbbVie s   NYSE ABBV   Humira  adalimumab  or placebo on a stable background dose of methotrexate  MTX  in patients with prior inadequate response to MTX In March  the company announced 24 week data from the study  The same achieved its primary endpoint for both doses of filgotinib   100 mg and 200 mg   measured by response on the scale of American College of Rheumatology  ACR  The phase III FINCH 3 study evaluated 100 mg or 200 mg doses of filgotinib in combination with MTX and as monotherapy in MTX naive patients The FINCH 2 study evaluated filgotinib in patients receiving conventional  synthetic disease modifying anti rheumatic drug  DMARD  and having prior inadequate response to one or more biological therapies Shares of Gilead have lost 1 4  so far this year compared with the  decrease of 8 6  In August 2019  Gilead and partner Galapagos   NASDAQ GLPG   announced that the European Medicines Agency  EMA  has accepted their marketing authorization application  MAA  for filgotinib as a treatment for RA in Europe Notably  a potential approval of filgotinib for RA and successful development in other inflammation indications are expected to favorably impact Gilead s revenues as the targeted indication has a significant market opportunity  However  filgotinib is likely to face competition from Eli Lilly s   NYSE LLY   Olumiant  which is already approved as a treatment for RA  Several other pharma companies are also developing drugs for inflammation indications including RA Zacks RankGilead currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan-200471979,200471979
171197,392713,LLY,Dermira Starts Lebrikizumab Dosing In Late Stage Eczema Study,opinion,"Dermira  Inc    NASDAQ DERM   announced that it has started dosing in a phase III study  evaluating its monoclonal antibody candidate  lebrikizumab  in patients with moderate to severe atopic dermatitis  the most common form of eczema  aged 12 years or older The phase III study is part of the phase III program  which includes two identical phase III studies to evaluate safety and efficacy of lebrikizumab as monotherapy in patients  The studies will enroll a total of 800 patients suffering from chronic atopic dermatitis  The patients will be administered a loading dose of 500mg at day zero and at Week 2  followed by a 250mg dose every two weeks in the first 16 weeks of induction period  Patients responding to lebrikizumab monotherapy during the induction period will further given 250mg dose every two weeks  250mg every four weeks or will be administered a placebo every two weeks for a period of 36 weeks The primary endpoints of the studies will be based on percentage of patients achieving an Investigator s Global Assessment score of one or zero  Dermira expects top line data from the 16 week induction period to be available in the first half of 2021 The company also has plans to include an additional study in the phase III program later  which will evaluate lebrikizumab in combination with topical corticosteroids Shares of Dermira have declined 21 1  so far this year compared with the  s decrease of 2 3  Positive data from the phase IIb study  evaluating lebrikizumab in patients with moderate to severe atopic dermatitis were announced in March Data from the study showed that treatment with the candidate achieved improvements of statistical significance compared to place as measured by Eczema Area and Severity Index score Notably  many companies are developing medicines to address atopic dermatitis  eczema  Sanofi   NASDAQ SNY   and Regeneron Pharmaceuticals   NASDAQ REGN   market Dupixent for treating atopic dermatitis  Others key immunology candidates in late stage studies for atopic dermatitis include AbbVie s upadacitiniband Lilly s   NYSE LLY   Olumiant We note that Dermira has one marketed drug  QBREXZA  which was approved in 2018 for the treatment of primary axillary hyperhidrosis  excessive underarm sweating   In the second quarter 2019  the drug registered an increase of more than 200  in sales compared to first quarter 2019  A successful development of lebrikizumab may boost the top line further  However  commercialization is years away and competition is likely to be stiff for lebrikizumab Dermira  Inc  Price
     Zacks RankDermira currently sports a Zacks Rank  1  Strong Buy   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/dermira-starts-lebrikizumab-dosing-in-latestage-eczema-study-200472242,200472242
171198,392714,LLY,J J  JNJ  To Start Q3 Earnings Season For Pharma Sector,opinion,Johnson   Johnson   NYSE JNJ   will report third quarter 2019 results on Oct 15  before market open  In the last reported quarter  the company delivered positive earnings surprise of 6 61  The healthcare bellwether s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters was 3 02 Johnson   Johnson Price and EPS Surprise   J J s stock has risen 0 1  this year so far against a decrease of 1 6  recorded by the    Factors to ConsiderCurrency headwinds and difficult comparisons with the year ago quarter  the highest sales growth quarter of the year  might have hurt J J s third quarter sales  Also  potentially accelerated generic biosimilar erosion of Zytiga  Procrit and Tracleer in the United States and Velcade outside the United States  due to generic entry in new markets and additional competitors  might have put pressure on J J s Pharmaceutical segment sales  However  its cancer drugs like Imbruvica and Darzalex should continue to perform well backed by market growth and market share gains  J J markets Imbruvica in partnership with AbbVie   NYSE ABBV    J J s psoriasis treatment  Stelara should also continue to be a key contributor to sales in the Pharma unit The Zacks Consensus Estimate for Imbruvica  Stelara and Darzalex is  917 million   1 64 billion   665 million  respectively Other core products like Simponi Simponi Aria and Invega Sustenna and new drugs like immunology medicine Tremfya and prostate cancer drug Erleada should also contribute to growth Meanwhile  sales of J J s other drugs like Invokana Invokamet and Xarelto declined in the first half  Xarelto s sales declined as prescription growth was offset by increased discounts and rebates  We do not see much chances of an improvement in the third quarter in the sales numbers of these drugs Sales in J J s Medical Devices unit were hurt by some supply disruptions last quarter  It remains to be seen if these issues were resolved and sales improved in the third quarter  In the Consumer Unit  sales improved sequentially in the second quarter  a trend which might have continued in the third quarter Meanwhile  potentially higher R D investments  due to potentially increased investment in the pipeline  and tax rate in the second half of the year are expected to have weighed on the bottom line The Zacks Consensus Estimate for J J s Pharmaceuticals  Consumer and Medical Device segments is  10 08 billion   3 52 billion and  6 36 billion  respectively On the investor call  management will face questions related to talc and opioid litigation issuesIn August 2019  J J was ordered by a district court in Oklahoma to pay  572 million to the state of Oklahoma in connection with a lawsuit filed by the latter  Last week  J J settled with two counties of Ohio for  10 million plus other cost reimbursements  in connection with the trial this month under the federal multidistrict litigation related to abuse of its opioid based drugs  Duragesic  Nucynta and Nucynta ER  All these lawsuits claim that J J is one of the several companies whose opioid based drugs were responsible for fueling the state s opioid epidemic  J J has decided to appeal against the rulings Earnings WhispersOur proven model does not conclusively show that J J will beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00  as the Zacks Consensus Estimate as well as the Most Accurate Estimate is pegged at  2 00  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  J J has a Zacks Rank of 4  Sell   We caution Zacks Rank  4 or 5  Strong Sell  stocks going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some large drug biotech stocks that have the right combination of elements to beat on earnings this time around Lilly   NYSE LLY   with an Earnings ESP of  1 22  and a Zacks Rank  2  The company is scheduled to release results on Oct 23  You can see  Pfizer   NYSE PFE   has an Earnings ESP of  1 99  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-to-start-q3-earnings-season-for-pharma-sector-200472272,200472272
171199,392715,LLY,Gilead Galapagos Report Efficacy   Safety Results On RA Drug ,opinion,Gilead Sciences  Inc    NASDAQ GILD   and partner Galapagos NV   NASDAQ GLPG   announced 52 week efficacy and safety results of an investigational  oral  selective JAK1 inhibitor  filgotinib  from FINCH 1 and FINCH 3 studies The candidate is being evaluated for the treatment of moderately to severely active rheumatoid arthritis  RA  The FINCH phase III program evaluated the efficacy and safety of 100 mg and 200 mg filgotinib once daily in early stage to biologic experienced RA patients  FINCH 1 was a 52 week  randomized  placebo  and Humira controlled study on filgotinib in combination with methotrexate  MTX  in 1 759 adult patients with moderately to severely active RA  who had an inadequate response to only MTX  The trial included a radiographic assessment at weeks 24 and 52  FINCH 3 was a 52 week  randomized study in 1 252 MTX na ve patients evaluating filgotinib 200 mg alone and filgotinib 100 mg or 200 mg combined with MTX versus MTX alone The 52 week data on filgotinib exhibited the same favorable safety profile seen in the first 24 weeks  including similar rates of thrombotic events as previously observed  and persistent efficacy We note that a Marketing Authorization Application  MAA  for filgotinib for the treatment of adults with RA is currently under review with the European Medicines Agency  EMA  and a New Drug Application  NDA  for the same has been submitted to the Japanese Ministry of Health  Labor and Welfare  MHLW   Gilead plans to file an NDA for filgotinib for the treatment of RA in the United States later in the year A potential approval of the candidate will broaden Gilead s portfolio  Notably  Eli Lilly s   NYSE LLY   Olumiant is also approved for RA Gilead s stock has gained 1 1  so far this year against the  s decline of 7 8  The company is also looking to diversify its portfolio and focus on therapeutic areas other than HCV  While the HIV portfolio maintains momentum  the company intends to develop drugs for inflammation diseases as well  Meanwhile  Gilead has also collaborated with Novo Nordisk   NYSE NVO   for NASH treatments Gilead currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/gileadgalapagos-report-efficacy--safety-results-on-ra-drug-200472717,200472717
171200,392716,LLY,Pharma Stock Roundup  NVS  New Eye Drug Gets FDA Nod  NVO  GSK  PFE Sign Deals,opinion,"This week  the FDA approved Novartis    NYSE NVS   potential blockbuster eye drug  Beovu  J J   NYSE JNJ   submitted a regulatory application seeking label expansion approval of its plaque psoriasis drug  Stelara for pediatric patients  Pfizer   NYSE PFE    Novo Nordisk   NYSE NVO   and Glaxo   NYSE GSK   announced licensing deals Recap of the Week s Most Important StoriesFDA Approves Novartis  New Eye Drug  The FDA granted approval to Novartis  ophthalmology drug    brolucizumab  injection to treat wet age related macular degeneration  AMD   Novartis claims that this anti VEGF therapy offers greater fluid resolution as compared to Regeneron Bayer s market leading drug Eylea  The FDA approval was based on data from the phase III HAWK and HARRIER studies  in which Beovu demonstrated significant advantages over Eylea Meanwhile  Novartis announced data from the phase IIb dose finding study  which showed that more patients treated with its investigational monoclonal antibody  ligelizumab  were completely symptom free from chronic spontaneous urticaria compared to Xolair  300 mg   which Novartis markets together with Roche J J Files sBLA for Stelara in Adolescent Patients  J J submitted a supplemental Biologics License Application  sBLA  to the FDA  seeking approval of Stelara for the treatment of pediatric patients  6 to 11 years of age  with moderate to severe plaque psoriasis  Stelara is already marked for adolescents and adults with moderate to severe plaque psoriasis  Stelara is also marketed to treat adults with active psoriatic arthritis and moderate to severe Crohn s disease Meanwhile  a  ordered J J to pay punitive damages of  8 billion to a man who claimed that the use of its antipsychotic drug  Risperdal caused him to develop breasts  The lawsuit filed by Nicholas Murray claimed that J J did not warn of the risk that young men using Risperdal can develop enlarged breasts  J J responded by saying that the award was  grossly disproportionate  and was confident that the jury verdict will be overturned in the court Pfizer  Glaxo and Novo Nordisk Sign New Deals  Pfizer in licensed global rights to Akcea Therapeutics  investigational antisense therapy AKCEA ANGPTL3 LRx which is being evaluated in a phase II study as a treatment for patients with type II diabetes  hypertriglyceridemia and non alcoholic fatty liver disease  NAFLD    AKCEA ANGPTL3 LRx is designed to reduce the production of a protein in liver  Akcea is an affiliate of Ionis Pharmaceuticals and the companies will receive an upfront payment of  250 million from Pfizer  which will be split equally between the two companies  This apart  they will be entitled to milestone payments of up to  1 3 billion as well as royalties Novo Nordisk signed a three year research deal with bluebird bio to develop in vivo genome editing candidates for  and other severe genetic diseases  Per the deal  bluebird bio s new platform technology   mRNA based megaTAL technology   will be utilized to create a highly differentiated approach to treat severe genetic diseases  No financial terms of the deal were disclosed Glaxo also announced a five year collaboration with small biotech Lyell Immunopharma to develop next generation cancer cell therapies The NYSE ARCA Pharmaceutical Index rose 0 4  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions  Last week  all stocks were in the green  except J J and Lilly   NYSE LLY    Bristol Myers   NYSE BMY   was the biggest gainer  2 5   while J J declined the most  1 6   In the past six months  Bristol Myers has risen the most  11 4   while Pfizer lost the most  14 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for J J s third quarter results and regular pipeline and regulatory updates next week Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals-200472807,200472807
171201,392717,LLY,This Is Why Eli Lilly  LLY  Is A Great Dividend Stock,opinion,"Getting big returns from financial portfolios  whether through stocks  bonds  ETFs  other securities  or a combination of all  is an investor s dream  However  when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
While cash flow can come from bond interest or interest from other types of investments  income investors hone in on dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends account for significant portions of long term returns  with dividend contributions exceeding one third of total returns in many cases 
Eli Lilly in Focus
Eli Lilly  LLY  is headquartered in Indianapolis  and is in the Medical sector  The stock has seen a price change of  6 76  since the start of the year  Currently paying a dividend of  0 64 per share  the company has a dividend yield of 2 39   In comparison  the Large Cap Pharmaceuticals industry s yield is 2 75   while the S P 500 s yield is 1 91  
Taking a look at the company s dividend growth  its current annualized dividend of  2 58 is up 14 7  from last year  Eli Lilly has increased its dividend 5 times on a year over year basis over the last 5 years for an average annual increase of 5 54   Any future dividend growth will depend on both earnings growth and the company s payout ratio  a payout ratio is the proportion of a firm s annual earnings per share that it pays out as a dividend  Lilly s current payout ratio is 46   meaning it paid out 46  of its trailing 12 month EPS as dividend 
LLY is expecting earnings to expand this fiscal year as well  The Zacks Consensus Estimate for 2019 is  5 72 per share  which represents a year over year growth rate of 3 14  
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  It s important to keep in mind that not all companies provide a quarterly payout 
Big  established firms that have more secure profits are often seen as the best dividend options  but it s fairly uncommon to see high growth businesses or tech start ups offer their stockholders a dividend  During periods of rising interest rates  income investors must be mindful that high yielding stocks tend to struggle  With that in mind  LLY is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/this-is-why-eli-lilly-lly-is-a-great-dividend-stock-200473539,200473539
171202,392718,LLY,Eli Lilly  LLY  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on lower revenues when Eli Lilly  LLY  reports results for the quarter ended September 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on October 23  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  1 44 per share in its upcoming report  which represents a year over year change of  3 6  
Revenues are expected to be  5 58 billion  down 7 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 03  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Lilly 
For Lilly  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 61  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Lilly would post earnings of  1 46 per share when it actually produced earnings of  1 50  delivering a surprise of  2 74  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Lilly doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth-200474005,200474005
171203,392719,LLY,Xeris Pharmaceuticals on deck for IPO,news,Chicago  IL based Xeris Pharmaceuticals  XERS  has filed a prospectus for a  75M IPO The specialty pharmaceutical firm develops ready to use injectable and infusible drug products  including Glucagon Rescue Pen  a room temperature stable liquid formulation that does not require any preparation or reconstitution  for the treatment of severe low blood sugar  hypoglycemia  in diabetics  The company expects to file a U S  marketing application next quarter 2018 Financials  Q1   M   Grant Revenue  0 2  Operating Expenses  12 0   138 9    Net Loss   11 9    156 1    Cash Burn   7 8    121 8   Diabetes related tickers  LLY  NVO  SNY  ZEAL  OPK  LGND  MRKNow read ,2018-05-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/xeris-pharmaceuticals-on-deck-for-ipo-1463438,1463438
171204,392720,LLY,Pfizer pumps  600 million into venture capital arm,news," Reuters     Pfizer  Inc  N PFE  said on Wednesday it planned to invest  600 million in its venture capital fund  a quarter of which would be earmarked for promising research on neuroscience  The new funding will bring total assets managed by Pfizer Ventures to over  1 billion  the company said in a statement  The announcement comes six months after the U S  drugmaker said it was abandoning research to find new drugs aimed at treating Alzheimer s and Parkinson s diseases  Several drugmakers  including Pfizer  have cut back on neuroscience research after a string of costly trials yielded disappointing results  with some of them betting on startups that are focusing on such areas  Pfizer has already invested in six neuroscience companies and  alongside drugmakers such as GlaxoSmithKline  L GSK  and Eli Lilly  N LLY   is part of the Dementia Discovery Fund  which has raised more than  190 million since its 2015 launch  
Pfizer Ventures will seek to invest  150 million in early stage neuroscience companies  particularly those focusing on neuro degeneration  neuro inflammation and neuro metabolic disorders ",2018-06-06,Reuters,https://www.investing.com/news/stock-market-news/pfizer-pumps-600-million-into-venture-capital-arm-1482368,1482368
171230,392746,LLY,Pfizer s JAK1 Inhibitor Meets All Goals In 2nd Phase III Study,opinion,Pfizer Inc    NYSE PFE   announced that its investigational oral JAK1 inhibitor abrocitinib has met all co primary and key secondary endpoints in the second pivotal phase III study  B7451013   The candidate is being evaluated as a monotherapy for the treatment of moderate to severe atopic dermatitis  AD  also known as eczema in patients aged 12 years and above The double blind  placebo controlled  parallel group study  B7451013  evaluated the safety and efficacy of abrocitinib  100mg and 200mg once daily  as a monotherapy given to patients for a period of 12 weeks  The co primary endpoints of the study were to see the proportion of patients who achieved clear or almost clear skin improvement and those who secured at least 75  or a greater level of change in their eczema area score  The key secondary endpoint was to see the proportion of patients achieving a four point or larger reduction in itch severity or pruritus Top line data from this study showed that by week 12  both doses of abrocitinib led to a statistically significantly higher percentage of patients achieving the respective co primary efficacy endpoints and each key secondary endpoint compared to placebo  Importantly  a statistically significant number of patients attained a reduction in pruritus or itching severity by week two Meanwhile  both doses were well tolerated in the study Detailed data from this second study will be presented at a future medical meeting and also published in a medical journal Importantly  the safety result from this study  B7451013  was consistent and similar to the  on abrocitinib announced in May 2019  The first study too met all the co primary and secondary endpoints Shares of Pfizer have lost 17 1  so far this year  wider than the  decrease of 0 6  We would like to remind investors that Pfizer s PDE4 inhibitor Eucrisa topical ointment is already approved in the United States and Canada to treat eczema in patients aged two years and older  In July 2019  the company announced positive top line results from a late stage study on Eucrisa  crisaborole ointment  2   for the treatment of mild to moderate AD in children aged from three months to two years Notably  many companies are developing medicines to address AD eczema  A key new entrant in the AD market is Sanofi   NASDAQ SNY   Regeneron Pharmaceuticals    NASDAQ REGN   Dupixent  Lilly s   NYSE LLY   rheumatoid arthritis  RA  drug Olumiant and AbbVie  NYSE ABBV  s newly approved RA drug upadacitinib are also being evaluated in late stage studies for AD In a separate press release  Pfizer announced that Mr  Ian C  Read  executive chairman of the board  has decided to retire on Dec 31  2019  The company has appointed its current chief executive officer Dr  Albert Bourla as the new chairman effective Jan 1  2020 Zacks RankPfizer currently carries a Zacks Rank  4  Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-29,Zacks Investment Research,https://www.investing.com/analysis/pfizers-jak1-inhibitor-meets-all-goals-in-2nd-phase-iii-study-200469225,200469225
171231,392747,LLY,Novartis  NVS  Announces Data On Asthma Drugs   Kisqali ,opinion,Novartis AG   NYSE NVS   announced mixed results from the phase III IRIDIUM study on investigational  once daily  inhaled QVM149  indacaterol acetate  glycopyrronium bromide and mometasone furoate or IND GLY MF  QVM149 demonstrated statistically significant improvement in lung function as compared to QMF149  indacaterol acetate and mometasone furoate or IND MF   thereby meeting the primary endpoint in asthma patients  whose disease was uncontrolled on treatment with a long acting beta agonist inhaled corticosteroid  LABA ICS  However  the key secondary endpoint   improvement in the Asthma Control Questionnaire  ACQ 7  score for IND GLY MF versus IND MF   was not met We note that IRIDIUM is the largest study in the phase III PLATINUM clinical development program  which evaluates inhaled combinations   QVM149 and QMF149 We remind investors that the regulatory submission for QVM149 was accepted for review by the European Medicines Agency earlier this year Concurrently  Novartis announced positive results from the late stage study on investigational  once daily  fixed dose inhaled QMF149 Results showed that once daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate  MF   meeting the primary endpoint in the phase III PALLADIUM study  This was achieved in asthma patients  whose disease was uncontrolled on treatment with inhaled corticosteroid  ICS  at medium or high dose  or long acting beta agonist  LABA  ICS at low dose  QMF149 also met the key secondary endpoint of improvement in the Asthma Control Questionnaire  ACQ 7  as combined doses of IND MF showed a statistically significant improvement of asthma control achieved from baseline at Week 26 when compared to combined doses of MF The approval of these candidates will strengthen Novartis  asthma care franchise  The company s Xolair is already approved for the treatment of moderate to severe  or severe  persistent allergic asthma  The company has a collaboration agreement with Roche   OTC RHHBY   for the same in the United States Earlier  Novartis announced results from the MONALEESA 3 study  which showed that breast cancer drug Kisqali  ribociclib  achieved statistically significant improvement in overall survival  OS  MONALEESA 3 evaluated the efficacy and safety of CDK4 6 inhibitor Kisqali plus Faslodex in postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer This is the second phase III study  in which the Kisqali combination therapy met the secondary endpoint of OS at the pre planned interim analysis  Per Novartis  Kisqali is the only CDK4 6 inhibitor to show positive OS in two pivotal phase III trials  consistently demonstrating approximately 30  reduction in the risk of death Kisqali is already approved in the United States and Europe as initial endocrine based therapy for postmenopausal women with HR  HER2  locally advanced or metastatic breast cancer in combination with an aromatase inhibitor Novartis is evaluating the drug in early breast cancer  The NATALEE study is a phase III clinical study of Kisqali with endocrine therapy in the adjuvant treatment of HR  HER2  early breast cancer being conducted in collaboration with Translational Research In Oncology However  competition is stiff in the breast cancer market with the likes of Eli Lilly s   NYSE LLY   Verzenio and Pfizer s   NYSE PFE   Ibrance 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-announces-data-on-asthma-drugs--kisqali-200469901,200469901
171232,392748,LLY,Agios  Tibsovo Improves Survival In Cholangiocarcinoma Study,opinion,Agios Pharmaceuticals  Inc    NASDAQ AGIO   presented detailed data from the phase III ClarIDHy study on its leukemia drug Tibsovo  ivosidenib   which is being evaluated in previously treated patients with IDH1 mutant cholangiocarcinoma  also called bile duct cancer In the study  the median progression free survival  PFS  was 2 7 months for patients who received Tibsovo compared to 1 4 months in the placebo arm  Importantly  patients who were treated with Tibsovo had a 6 month and 12 month PFS rate of 32  and 22   respectively  while none of the patients in the placebo arm was free from disease progression for more than six months Tibsovo also reduced the risk of disease progression or death by 63   In the Tibsovo arm  partial response was achieved by 2  of patients and 51  of patients had stable disease while in the placebo arm  28  of patients had stable disease The results were presented at the European Society for Medical Oncology Congress held in Spain Notably  in May 2019  Tibsovo met the primary endpoint in the ClarIDHy study  Back then  the study demonstrated statistically significant improvement in PFS compared to patients who received placebo  The company plans to file a supplemental new drug application  sNDA  to the FDA for including the above indication on Tibsovo s label by this year end  Currently  there are no treatment options available for this disease Tibsovo is presently marketed for treating adult patients suffering relapsed or refractory acute myeloid leukemia  AML  with IDH 1 mutation  The drug is currently under review in the EU for the same indication Tibsovo generated sales of  13 7 million in the second quarter of 2019  reflecting a sequential surge of more than 50   Several label expansion studies on Tibsovo are currently underway  which upon potential approval  can fuel sales growth for the drug Meanwhile  in March 2019  the FDA granted a Breakthrough Therapy designation to Tibsovo in combination with Celgene s   NASDAQ CELG   Vidaza for treating the newly diagnosed AML in adult patients with an IDH 1 mutation  aged 75 and above and are ineligible for intensive chemotherapy Notably  Agios is riding high on the success of Tibsovo of late  However  the company is likely to face stiff competition from pharma giants and several other leading industry players like AstraZeneca   NYSE AZN    Eli Lilly   NYSE LLY    AbbVie  NYSE ABBV  and Roche  These companies  candidates are lined up for studies to treat cancer and rare genetic metabolic disorders by targeting cellular metabolism 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/agios-tibsovo-improves-survival-in-cholangiocarcinoma-study-200469995,200469995
171233,392749,LLY,Why Lilly  LLY  Could Beat Earnings Estimates Again,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Eli Lilly  LLY   This company  which is in the Zacks Large Cap Pharmaceuticals industry  shows potential for another earnings beat 
This drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 1 75  
For the most recent quarter  Lilly was expected to post earnings of  1 46 per share  but it reported  1 50 per share instead  representing a surprise of 2 74   For the previous quarter  the consensus estimate was  1 32 per share  while it actually produced  1 33 per share  a surprise of 0 76  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Lilly  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Lilly currently has an Earnings ESP of  1 22   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on October 23  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-02,Zacks Investment Research,https://www.investing.com/analysis/why-lilly-lly-could-beat-earnings-estimates-again-200470371,200470371
171234,392750,LLY,Novo Nordisk Focuses On Pipeline Development Amid Competition,opinion,Novo Nordisk  CSE NOVOb  A S   NYSE NVO   has a strong presence in the Diabetes care market  with a global value market share of 28 3   The company has one of the broadest diabetes portfolios in the industry  A solid performance from Tresiba  Victoza  Ozempic  Xultophy and Saxenda drove sales in the first half of 2019 Novo Nordisk s top line is driven by a strong performance of products such as Victoza  liraglutide   The company continues to be the global market leader in the GLP 1 segment  with a 46 4  value market share  Going forward  we expect Victoza to continue being a significant contributor to the company s top line  We are encouraged by the company s efforts to develop new treatments for diabetes  which is its core area of expertise In September  the FDA approved semaglutide in tablet form  which will be marketed under the brand name Rybelsus  It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus Rybelsus is the first approved glucagon like peptide 1  GLP 1  receptor agonist in a tablet  The FDA approval was supported by results from 10 PIONEER studies  which included 9 543 adults with type II diabetes  Rybelsus more effectively lowered blood sugar than Januvia and Jardiance  Furthermore  treatment with the drug resulted in up to 4 4 kg reduction in body weight Rybelsus is also under review by several regulatory agencies  including the European Medicines Agency  and the Japanese Pharmaceuticals and Medical Devices Agency The company s efforts to diversify its portfolio are encouraging as well In February  the FDA approved the company s biologics license application  BLA  for Esperoct  turoctocog alfa pegol  N8 GP  regarding the treatment of hemophilia A in adult patients and children  The drug is approved for the routine prophylactic to reduce the frequency of bleeding episodes  on demand treatment and control of bleeding episodes plus perioperative management of bleeding in the given patient population  Per the company  due to third party intellectual property  IP  agreements  it will not be able to launch the drug before 2020 in the United States In July  the European Commission granted marketing authorization to Esperoct for the treatment of adolescents   12 years of age  and adults with hemophilia A  The authorization covers all 28 European Union member states In March  Novo Nordisk and Gilead Sciences  Inc    NASDAQ GILD   announced a collaboration to develop treatments for non alcoholic steatohepatitis  NASH   The companies will initiate a proof of concept study combining Novo Nordisk s semaglutide  GLP 1 analogue  and Gilead s cilofexor  FXR agonist  and firsocostat  ACC inhibitor  for the treatment of NASH Novo Nordisk also has other candidates in development like concizumab  NN7415  to treat patients with hemophilia A and  somapacitan  NN8640  for treatment of growth hormone deficiency However  it is going through a rough patch with several drugs in its portfolio losing patent protection  The company is also facing pricing pressure for some of its drugs Moreover  the diabetes market is already crowded with several drugs  Merck s   NYSE MRK   Januvia and Janumet  type II diabetes   Eli Lilly s   NYSE LLY   Trulicity  type II diabetes   and Sanofi s Toujeo  type I and II diabetes  are already approved for the same Just Released  Zacks  7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year  These 7 were selected because of their superior potential for immediate breakout ,2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-focuses-on-pipeline-development-amid-competition-200471139,200471139
171235,392751,LLY,Lilly s Cyramza successful in late stage liver cancer study,news,A Phase 3 clinical trial  REACH 2  assessing Eli Lilly s  NYSE LLY  CYRAMZA  ramucirumab  as monotherapy for the second line treatment of certain patients with hepatocellular carcinoma  HCC  met the primary endpoint of overall survival  OS  and the secondary endpoint of progression free survival  PFS  The specific patients evaluated where those with HCC who progressed on or were intolerant of sorafenib  Bayer  DE BAYGN  s NEXAVAR  and had high levels of a biomarker called alpha fetoprotein  AFP High   a profile with a poor prognosis The safety profile was consistent with earlier studies  The only grade 3  serious  or greater adverse events occurring at a rate of at least 5  were hypertension and hyponatremia  low blood sodium  The company will initiate regulatory filings this summer CYRAMZA  a human vascular endothelial growth factor receptor 2  VEGFR2  antagonist  is currently approved in the U S  to treat gastric cancer or gastroesophageal junction adenocarcinoma  non small lung cancer and colorectal cancer Now read ,2018-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/lillys-cyramza-successful-in-latestage-liver-cancer-study-1377126,1377126
171236,392752,LLY,Pfenex s PF708 on par with Lilly s Forteo in late stage study,news,Topline results from a Phase 3 clinical trial  PF708 301  demonstrated that Pfenex s  NYSEMKT PFNX  PF708 had comparable overall profiles with Eli Lilly s  NYSE LLY  Forteo  teriparatide  after 24 weeks of treatment in osteoporosis patients Pfenex expects to file a U S  marketing application next quarter seeking approval for PF708 as a therapeutic equivalent to Forteo Management will host a conference call today at 4 45 pm ET Now read ,2018-05-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfenexs-pf708-on-par-with-lillys-forteo-in-latestage-study-1446515,1446515
171268,392784,LLY,AstraZeneca s Farxiga Gets Fast Track Tag For Heart Failure,opinion,AstraZeneca PLC   NYSE AZN   announced that the FDA has granted a Fast Track designation to its SGLT2 inhibitor Farxiga  dapagliflozin  for reducing the risk of cardiovascular  CV  death or worsening of heart failure in heart failure patients The blockbuster drug  approved to treat type II diabetes  T2D   is being evaluated in two phase III studies  namely DAPA HF and DELIVER to see its effect in adults suffering heart failure with reduced ejection fraction  HFrEF  and preserved ejection fraction  HFpEF   respectively The FDA provides a Fast Track designation to help development and faster review of drugs  which treat serious and unmet medical conditions Last month  the FDA granted a Fast Track designation to Farxiga for chronic kidney disease  CKD   The drug is being evaluated in the phase III DAPA CKD study to see its effect on renal outcomes and CV mortality in patients suffering CKD with or without type 2 diabetes  T2D  All these studies are part of AstraZeneca s DapaCare clinical program to explore the CV  metabolic and renal profile of Farxiga in T2D patients  Farxiga is also being developed to treat patients with heart failure  HFrEF and HFpEF  in DETERMINE study Shares of AstraZeneca have rallied 12 6  so far this year against the decline of 1 9  We remind investors that last month  AstraZeneca released positive results from the DAPA HF study on Farxiga  The study showed that Farxiga met the primary composite endpoint with a statistically significant and clinically meaningful reduction in CV death or the worsening of heart failure compared to placebo  The study was conducted in patients with HFrEF who are on standard of care treatment including those with and without T2D Also  in the same month  the European Commission approved a label expansion for Farxiga to include positive CV outcomes and renal data from the phase III DECLARE TIMI 58 study on adults with T2D  A similar filing is under review in the United States  The DECLARE study is also part of the extensive DapaCare clinical program Farxiga Forxiga  a key top line driver of AstraZeneca  generated sales of  726 million in the first half of 2019  representing 19  growth at constant exchange rates  Farxiga enjoys global leadership with voluminous market share Other SGLT2 inhibitors available in the market are Johnson   Johnson s   NYSE JNJ   Invokana and Lilly s   NYSE LLY   Jardiance  Synjardy  a fixed dose combination of Jardiance and metformin  and Glyxambi  a fixed dose combination of Jardiance and Tradjenta  Zacks Rank   Key PickAstraZeneca currently carries a Zacks Rank  3  Hold   A better ranked stock in the large cap pharma sector is Bristol Myers Squibb Company   NYSE BMY    which sports a Zacks Rank  1  Strong Buy   You can see  Bristol Myers  earnings estimates have moved 2 9  north for 2019 and 21 5  for 2020 over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-farxiga-gets-fast-track-tag-for-heart-failure-200465035,200465035
171269,392785,LLY,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert,opinion,"The FDA  on Friday  warned of rare but severe lung inflammation associated with the use of some advanced breast cancer medicines   Pfizer s   NYSE PFE   Ibrance  Eli Lilly s   NYSE LLY   Verzenio and Novartis    NYSE NVS   Kisqali  The FDA said that the related lung issues can prove to be fatal for the patients The FDA approved new warnings about the inflammation risk to be added to the labels of these cyclin dependent kinase 4 6  CDK 4 6  inhibitor medicines  The FDA also approved a patient package insert for the entire class of these medicines  which work by inhibiting cyclin dependent kinases 4 and 6  which interferes with the division of cancer cells and helps stop tumor growth While shares of Pfizer declined 1   that of Lilly and Novartis went down by 0 5  and 2 8   respectively  on Friday The FDA reviewed data from completed and ongoing clinical studies on CDK 4 6 inhibitors that mentioned some serious cases of patients experiencing lung inflammation issues like interstitial lung disease  ILD  and pneumonitis  including fatal cases The FDA has asked patients using these drugs to watch for symptoms like difficulty in breathing  shortness of breath even while at rest and other worsening symptoms involving their lungs  It also instructed doctors to regularly monitor patients for symptoms indicative of ILD pneumonitis  In patients  who have developed ILD pneumonitis  the FDA instructed permanent discontinuation of CDK 4 6 inhibitor medicines Nonetheless  the FDA s safety alert emphasized that the overall benefit of these CDK 4 6 inhibitor medicines are greater than the risks  However  we believe that these additional warnings may affect sales of the three drugs  to an extent  in future quarters While Ibrance was approved by the FDA in 2015  the other two medicines were given the green signal much later in 2017  Ibrance generated sales of  2 39 billion in the first half of 2019 while Verzenio and Kisqali  garnered sales of  243 3 million and  202 million  respectively in the same time frame  All three medicines are approved for use in combination with an aromatase inhibitor to treat adults with HR   HER2  breast cancer that is metastatic  or in other words  has spread to other parts of the body Though several drugs with different mechanism of action are approved to treat breast cancers  a relatively newer class of drugs approved to treat the disease is PARP inhibitors like Merck   NYSE MRK   and AstraZeneca s   NYSE AZN   Lynparza While Lilly and Novartis have a Zacks Rank  2  Buy   Pfizer has a Zacks Rank  4  Sell  You can see  Large Cap Pharmaceuticals Industry 5YR   Return 
7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert-200464879,200464879
171270,392786,LLY,AstraZeneca Gets CHMP Nod For Forxiga Onglyza Combo Tablet,opinion,AstraZeneca PLC   NYSE AZN   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion recommending the marketing approval for Qtrilmet modified release tablets to treat type II diabetes  T2D   Qtrilmet is a combination of AstraZeneca s diabetes drugs Forxiga  dapagliflozin  and Onglyza  saxagliptin  plus hydrochloride Qtrilmet is marketed as Qternmet XR in the United States after the FDA approved it in May 2019 The CHMP opinion was based on data from the five phase III studies that evaluated the combination of Farxiga   Onglyza on a background of metformin in patients with inadequately controlled T2D  The primary endpoint of these studies was to see the mean change from baseline in average blood glucose levels at week 24 or week 52 of the regimen Notably  the combo of Farxiga and Onglyza plus metformin was superior in reducing the blood glucose level in all these studies  The three drug combo was also better than other combination regimens  such as Farxiga   metformin  Onglyza   metformin or Sanofi  PA SASY  s   NASDAQ SNY   Amaryl  glimepiride  plus metformin Shares of AstraZeneca have rallied 17 3  so far this year  outperforming the  increase of 0 5  We remind investors that Forxiga was approved for type I diabetes indication in Europe this March and is under review in the United States for the same indication  Forxiga is known by the name Farxiga in the United States  Several studies on Farxiga to evaluate its effect on renal outcome and cardiovascular mortality in patients suffering chronic kidney disease with or without T2D are currently underway Farxiga Forxiga  a key top line driver of AstraZeneca  generated sales of  726 million in the first half of 2019  representing 19  growth at constant exchange rate  Onglyza generated sales of  269 million in the first half of 2019  reflecting an increase of 10  at constant exchange rate Notably  diabetes is one of AstraZeneca s key focus areas  heavily crowded with a number of products present in the market  The diabetes franchise is facing an increased pricing pressure too  The company s Farxiga Forxiga belongs to the same class  SGLT2  as Johnson   Johnson s   NYSE JNJ   Invokana and Lilly s   NYSE LLY   Jardiance Zacks Rank AstraZeneca currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-gets-chmp-nod-for-forxigaonglyza-combo-tablet-200467563,200467563
171271,392787,LLY,Incyte  INCY  Stock Up 16  YTD On Strong Jakafi Performance,opinion,Shares of Incyte Corporation   NASDAQ INCY   have gained 16  in the year so far against the  s decline of 3 8  The strong performance has been driven by the solid performance of the company s lead drug  Jakafi  and encouraging pipeline progress in the year so far The growth in Jakafi in the first half of 2019 was driven by consistent uptake in two approved indications   polycythemia vera   PV   in patients who have had an inadequate response to or are intolerant to hydroxyurea and intermediate or high risk myelofibrosis  MF   including primary MF  post PV MF and post essential thrombocythemia MF Moreover  the FDA approval of the drug for the treatment of steroid refractory acute graft versus host disease  GVHD  in adult and pediatric patients aged 12 years or older in May 2019 has boosted its growth prospects Hence  concurrent with the second quarter results  the company stated that it now expects Jakafi revenues of  1 610  1 650 million in 2019  previous guidance   1 580  1 650 million  Meanwhile  Incyte is working on expanding the drug s label further  The cream formulation of ruxolitinib is currently in phase III development for the treatment of patients with mild to moderate atopic dermatitis  TRuE AD   with initial results expected in the first half of 2020  It is also being evaluated for the treatment of adolescents and adults with vitiligo  TRuE V   A potential approval in these indications will propel sales further  given the market potential Additionally  two studies evaluating the drug in steroid refractory acute and steroid refractory chronic GVHD are ongoing in collaboration with Novartis   NYSE NVS   Incyte s pipeline is highly encouraging and key updates are expected later this year  Apart from ruxolitinib  Incyte is evaluating a promising candidate  itacitinib  as a treatment for patients with newly diagnosed acute GVHD in a late stage study  The candidate is also being evaluated as a treatment for patients with newly diagnosed chronic GVHD in a phase III study  which was initiated in January 2019  A potential approval will further strengthen its GVHD franchise Another promising candidate in the pipeline is pemigatinib  The phase III study of pemigatinib for the first line treatment of patients with FGFR2 translocated cholangiocarcinoma was initiated in June   Incyte is planning to submit a New Drug Application  NDA  seeking approval for the candidate as a second line treatment for patients with FGFR2 translocated cholangiocarcinoma later this year Capmatinib  an oral reversible inhibitor of the MET receptor tyrosine kinase  is being evaluated for the treatment of non small cell lung cancer  NSCLC   The FDA granted the Breakthrough Therapy designation to capmatinib as a treatment for patients with metastatic NSCLC harboring MET exon 14 skipping mutation  with disease progression on or after platinum based chemotherapy  Partner Novartis expects to submit an NDA seeking approval of the candidate later this year Incyte also earns royalties from partner Eli Lilly   NYSE LLY   on sales of Olumiant  baricitinib  Though pipeline setbacks and potential competition from Celgene s   NASDAQ CELG   Inrebic are concerns  we expect Jakafi and potential new drug approvals to maintain momentum for the company Incyte currently carries a Zacks Rank  3  Hold    You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-26,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-stock-up-16-ytd-on-strong-jakafi-performance-200468809,200468809
171272,392788,LLY,Lilly s Taltz successful in late stage study in ankylosing spondylitis,news,A Phase 3 clinical trial  COAST V  evaluating Eli Lilly s  NYSE LLY  Taltz  ixekizumab  for the treatment of ankylosing spondylitis  AS  met the primary and all key secondary endpoints Taltz demonstrated a statistically significant improvement in AS symptoms as measured by the proportion of patients who achieved ASAS40 at week 16  ASAS40 means that AS patients improved at least 40  in three of four domains  patient global  pain  function and inflammation   This is a higher bar since the historical metric has been ASAS20  20  improvement in three of four domains  The study included a placebo arm and an active control arm  AbbVie s Humira  adalimumab   for comparison to placebo  It also evaluated patients who had never received a biologic disease modifying anti rheumatic drug Detailed results will be submitted for presentation at future scientific conferences and for publication Regulatory submissions are on tap for later this year pending additional data from the ongoing development program The FDA approved Taltz in December 2017 for psoriatic arthritis Now read ,2018-02-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/lillys-taltz-successful-in-latestage-study-in-ankylosing-spondylitis-1236729,1236729
171273,392789,LLY,Lilly s Taltz shows treatment benefit in genital psoriasis study,news,A 149 subject Phase 3b clinical trial assessing Eli Lilly s  NYSE LLY  Taltz  ixekizumab  in patients with moderate to severe genital psoriasis showed a treatment benefit  Specifically  patients in the treatment group experienced a reduced impact on sexual activity compared to placebo after 12 weeks of treatment  The results were presented at AAD in San Diego 92 0  of patients in the treatment group reported no or little sexual difficulties caused by skin symptoms compared to 56 8  for placebo  p 0 001   78 4  of patients receiving Taltz reported that the frequency of sexual activity was either never or rarely limited by genital psoriasis versus 21 4  for placebo  p 0 001  Up to 63  of psoriasis sufferers experience symptoms in the genital area Taltz is currently approved in the U S  for the treatment of plaque psoriasis and psoriatic arthritis Now read ,2018-02-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/lillys-taltz-shows-treatment-benefit-in-genital-psoriasis-study-1277936,1277936
171274,392790,LLY,FDA OKs Sanofi s long acting insulin pen Toujeo Max SoloStar,news,The FDA approves  Sanofi  s  NYSE SNY  Toujeo  insulin glargine 300 Units mL  Max SoloStar  The product holds 900 Units of Toujeo and can deliver up to 160 Units in a single injection The company says it is the highest capacity long acting insulin pen on the market Related tickers   NYSE LLY  NYSE NVO Now read ,2018-03-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-sanofis-longacting-insulin-pen-toujeo-max-solostar-1364178,1364178
171294,392810,LLY,J J s Stelara Gets Approval In EU For Ulcerative Colitis,opinion,Johnson   Johnson   NYSE JNJ   announced that the European Commission  EC  has approved the label expansion of Stelara  ustekinumab  for the treatment of adults with moderately to severely active ulcerative colitis  UC   With the latest approval in EU  Stelara can now be prescribed to treat UC patients who have had an inadequate response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies Stelara is also under review in the United States for the same indication Notably  Stelara  presently  has the approval to treat plaque psoriasis  psoriatic arthritis  and  moderate to severe Crohn s disease in both the United States and EU  The EC s approval for UC is based on data from the pivotal phase III UNIFI study  The study was divided into an initial Induction study  UNIFI I  of at least eight weeks  followed by a Maintenance study  UNIFI M  of 44 weeks  Both studies demonstrated ustekinumab s efficacy as a treatment for UC Ulcerative colitis or UC is a complicated immune disease in which patients suffer from persistent diarrhea  abdominal pain  blood in stool  loss of appetite  weight loss and fatigue  More than half of UC patients fail to achieve remission with the currently available conventional or biologic therapies  The successful induction data from the UNIFI study highlights the potential of Stelara for them The stock has rallied 2   so far this year  compared with the 3 3  increase recorded by the  Sales of Stelara  one of the key drugs of J J  grew 23 3  in the first half of 2019  The drug has been gaining market share  particularly owing to the uptick in Crohn s disease  the approval for the treatment of which was received both in the United States and the EU in 2016 Other marketed UC treatments include Pfizer s   NYSE PFE   JAK inhibitor  Xeljanz  and AbbVie s   NYSE ABBV   Humira  Another company  Lilly   NYSE LLY    is developing mirikizumab which is in late stage studies for the treatment of UC J J currently carries a Zacks Rank  3  Hold   You can see   Johnson   Johnson Price     It s Illegal in 42 States  But Investors Will Make Billions Legally In addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year  That s twice as much as they spend on marijuana  legally or otherwise  Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis-200461948,200461948
171295,392811,LLY,AstraZeneca s Tagrisso Gets Nod In China For First Line NSCLC,opinion,AstraZeneca PLC   NYSE AZN   announced that it has secured an approval from China for the label expansion of its marketed drug Tagrisso  osimertinib  for the first line treatment of adult patients with locally advanced or metastatic non small cell lung cancer  NSCLC  whose tumors have EGFR mutations The nod by China s National Medical Products Administration was based on positive data from the phase III FLAURA study In the study  treatment with Tagrisso showed a statistically significant and clinically meaningful improvement in progression free survival  PFS   increasing the time patients lived without disease progression in the first line setting  The median PFS was 18 9 months for patients on Tagrisso compared with 10 2 months in the comparator arm So far  Tagrisso was approved in China as a second line treatment option for patients with EGFR mutation positive NSCLC In August 2019  AstraZeneca announced overall survival  OS  data from the FLAURA study  which showed that Tagrisso substantially improved OS in the above mentioned patient population  Tagrisso was approved for the above indication based on PFS data from the same study in the United States and the EU in 2018  OS was the secondary endpoint in the study and AstraZeneca expects to present this data at an upcoming medical meeting Shares of AstraZeneca have rallied 19 3  so far this year against the  decline of 0 7  Since its approval  Tagrisso has been a steady performer and a key contributor to AstraZeneca s top line During the first half of 2019  Tagrisso generated sales of  1 4 billion  driven by consistent underlying demand growth and a rapid uptake in the first line setting  The label expansion nod for this important cancer drug should drive sales higher in the future quarters Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Merck   Co   Inc    NYSE MRK    Novartis AG   NYSE NVS   and Eli Lilly and Company   NYSE LLY    all carrying a Zacks Rank  2  Buy   You can see  Merck s earnings estimates have moved 3 2  north for 2019 and 1 3  for 2020 over the past 60 days  The stock has gained 12 6  year to date Novartis  earnings estimates have been revised 2 8  upward for 2019 and 3 4  for 2020 over the past 60 days  The stock has inched up 4  year to date Eli Lilly s earnings estimates have been inched 1 1  up for 2019 and 0 6  for 2020 over the past 60 days It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalizedindustry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more stateslegalize this activity  the industry could expand by as much as 15X  Zacks  has just released a SpecialReport revealing 5 top stocks to watch in this space ,2019-09-05,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-tagrisso-gets-nod-in-china-for-firstline-nsclc-200462059,200462059
171296,392812,LLY,Lilly s RET Inhibitor Shrinks Tumors In Lung Cancer Study,opinion,"Eli Lilly and Company s   NYSE LLY   oral RET inhibitor selpercatinib  LOXO 292  demonstrated a 68  objective response rate  ORR  or shrinkage in tumor size in heavily pretreated patients with RET fusion positive non small cell lung cancer  NSCLC  
This data was presented from a phase I II registrational study   LIBRETTO 001   at the World Conference on Lung Cancer  WCLC  2019  held in Spain 
This registration dataset consisted of the first 105 patients who had previously received chemotherapy  The median duration of response  DOR  was 20 3 months and median progression free survival  PFS  was 18 4 months in the selpercatinib arm as of the cutoff date of Jun 17  2019  Moreover  in the subset of patients with brain metastases  treatment with selpercatinib demonstrated a central nervous system  CNS  ORR of 91  
Additionally  in the LIBRETTO 001 program  selpercatinib was well tolerated with only nine of the 531 patients enrolled in the safety analysis discontinuing the therapy due to treatment related adverse events 
The company also presented data from 34 treatment na ve RET fusion positive NSCLC patients treated with selpercatinib  In this analysis  selpercatinib achieved an ORR of 85   However  duration of response  DOR  and progression free survival  PFS  in the given patient population were not reached 
Lilly s shares were up more than 2  in pre market trading in response to the positive data  However  the stock has lost 1 4  so far this year  wider than the  decrease of 0 5  

 
Lilly plans to submit a new drug application  NDA  for selpercatinib by this year end  If approved  selpercatinib will become the first genomically guided precision medicine for RET fusion positive NSCLC patients 
Notably  selpercatinib was added to Lilly s portfolio with the February 2019 acquisition of Loxo Oncology  which broadened its scope into precision medicines  The positive data presented now validates the buyout of Loxo Oncology 
Noatbly  precision medicine is an emerging approach to cancer treatment  which tailors a regime depending on the patient s genetic  environmental and lifestyle factors  Many industry players are adopting this approach to bring new cancer treatments 
One such company is Blueprint Medicines Corp    NASDAQ BPMC    which is developing transformational precision medicines to address patients with genomically defined cancers and rare diseases  The company is developing pralsetinib for treating patients with receptor tyrosine RET fusion NSCLC and plans to submit an NDA for pralsetinib pertaining to the NSCLC indication in the first quarter of 2020 
Zacks Rank   Other Stocks to Consider
Lilly currently carries a Zacks Rank  2  Buy   Other stocks worth considering in the pharma sector include Roche Holding  SIX ROG  AG   OTC RHHBY   and Merck   Co   Inc    NYSE MRK    While Roche sports a Zacks Rank  1  Strong Buy   Merck has a Zacks Rank of 2  You can see  
Roche s earnings estimates have moved 1 2  north for 2019 and 2  for 2020 over the past 60 days  The stock has gained 11 2  year to date 
Merck s earnings estimates have been revised 3 2  upward for 2019 and 1 3  for 2020 over the past 60 days  The stock has rallied 13 3  year to date 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-09,Zacks Investment Research,https://www.investing.com/analysis/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study-200463051,200463051
171297,392813,LLY,Premarket analyst action   healthcare,news,Dicerna Pharmaceuticals  NASDAQ DRNA  initiated with Outperform rating and  14  66  upside  price target by Evercore ISI IDEXX Labs  NASDAQ IDXX  initiated with Overweight rating and  200  15  upside  price target by Piper Jaffray Molina Healthcare  NYSE MOH  upgraded to Overweight by JPMorgan  NYSE JPM  Gilead Sciences  NASDAQ GILD  upgraded to Outperform by  Wells Fargo   NYSE WFC  Spark Therapeutics  NASDAQ ONCE  downgraded to Underperform with a price target of  35  34  downside risk  by Wedbush  Shares are down 5  premarket on light volume TiGenix  NASDAQ TIG  downgraded to Neutral by BTIG Research Allscripts Healthcare  NASDAQ MDRX  downgraded to Hold by SunTrust Eli Lilly  NYSE LLY  downgraded to Neutral by Goldman Sachs  NYSE GS  Now read ,2018-01-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1109060,1109060
171298,392814,LLY,Senate votes to confirm Azar as health secretary,news,"WASHINGTON  Reuters    The U S  Senate on Wednesday voted to confirm former pharmaceutical industry executive and lobbyist Alex Azar as the next Health and Human Services secretary   Azar will oversee the Trump administration s response to the opioid epidemic  its efforts to weaken the Affordable Care Act  commonly called Obamacare  and address rising prescription drug prices  The Senate voted 55 43 in favor of his nomination  Most Democrats opposed Azar s nomination  and several delivered impassioned speeches on Tuesday and Wednesday that criticized Azar for raising drug prices while he was at U S  pharmaceutical firm Eli Lilly   Co  N LLY   where he spent five years as president of its U S  unit  Several patient and consumer advocacy groups opposed Azar s nomination because of drug price increases at Lilly under his watch   Mr  Azar s nomination is a perfect encapsulation of the president s broken promises on prescription drugs and healthcare overall   Democratic Senator Ron Wyden said on Tuesday in a Senate floor speech  Republicans and some medical groups said Azar  who also served as general counsel and deputy secretary for Health and Human Services under former Republican President George W  Bush  had extensive qualifications for the job   
Trump s first health secretary  former U S  Representative Tom Price  resigned in September amid a furor over his use of expensive taxpayer funded private charter jets for government travel ",2018-01-24,Reuters,https://www.investing.com/news/politics-news/majority-of-us-senate-votes-to-confirm-azar-as-health-secretary-1146966,1146966
171299,392815,LLY,AbbVie  Lilly particularly vulnerable to BRK AMZN JPM venture   BMO,news, Increased adoption of biosimilars will be one of the key drivers to lower drug costs   says analyst Alex Arfaei This poses risk for all drugmakers  but especially AbbVie  ABBV  5    given its perky valuation and possible drug price erosion of 30  50  Eli Lilly  LLY  1 8   faces biosimilar threats to Humalog and its insulin franchise Source  Bloomberg s Bailey LipschultzPreviously  Height weighs in on Amazon Berkshire JPMorgan healthcare venture  Jan  30 Now read ,2018-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbvie-lilly-particularly-vulnerable-to-brkamznjpm-venture--bmo-1172759,1172759
171317,392833,LLY,AstraZeneca s Kidney Drug Roxadustat Gets Second Nod In China,opinion,"AstraZeneca PLC   NYSE AZN   announced that its partner FibroGen China has received the second marketing approval for roxadustat in China  This time  the Chinese regulatory authority has granted a nod to roxadustat for the treatment of anaemia caused by chronic kidney disease  CKD  in non dialysis dependent  NDD  patients 
FibroGen China is a wholly owned subsidiary of FibroGen  Inc    NASDAQ FGEN   
China s National Medical Products Administration  NMPA  granted the approval based on data from the phase III study  which evaluated roxadustat in the above mentioned patient population  In the study  roxadustat demonstrated a statistically significant improvement in haemoglobin levels from baseline averaged over week seven to nine of treatment 
Notably  last December  the Chinese regulatory agency approved roxadustat for treating anaemia in CKD patients  who are dialysis dependent 
Following this label expansion nod  China became the first country to approve roxadustat for all CKD patients  who experience anaemia whether on dialysis or not  Both AstraZeneca and FibroGen China plan to launch roxadustat later this year  The former will take care of the commercialization activities in China while the latter will look after manufacturing  clinical development and other regulatory affairs 
Roxadustat  a first in class hypoxia inducible factor prolyl hydroxylase inhibitor  is being jointly developed by AstraZeneca and FibroGen for treating anaemia in CKD patients 
Meanwhile  both companies are planning to file a new drug application  NDA  to the FDA for getting roxadustat approved in the United States in the second half of 2019 
Shares of AstraZeneca have rallied 19 5  so far this year against the decrease of 2 2  

 
In a separate press release  the company announced that it has agreed to buy an FDA priority review voucher from a subsidiary of Swedish Orphan Biovitrum AB  Sobi  for  95 million in cash 
The transaction is subject to close under the Hart Scott Rodino  HSR  Antitrust Improvements Act 
With the help of this priority voucher  AstraZeneca can ask for a priority review from the FDA for any candidate of its choice to reduce the review time and get an expedited approval 
Zacks Rank   Stocks to Consider
AstraZeneca currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Merck   Co   Inc    NYSE MRK   and Eli Lilly and Company   NYSE LLY    both carrying a Zacks Rank  2  Buy   You can see  
Merck s earnings estimates have moved 3 2  north for 2019 and 1 1  for 2020 over the past 60 days  The stock has gained 13 7  year to date 
Eli Lilly s earnings estimates have been revised 1 1  upward for 2019 and 0 5  for 2020 over the past 60 days 
It s Illegal in 42 States  But Investors Will Make Billions Legally
In addition to the companies you read about above  today you get details on the newly legalizedindustry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ",2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-kidney-drug-roxadustat-gets-second-nod-in-china-200457767,200457767
171318,392834,LLY,Lilly s Olumiant Meets Primary Endpoint In 3rd Eczema Study,opinion,Eli Lilly   Company   NYSE LLY   and partner Incyte s   NASDAQ INCY   oral JAK inhibitor  Olumiant  baricitinib  met the primary endpoint in a pivotal late stage study evaluating it in a new indication   moderate to severe atopic dermatitis  AD   a type of eczema Notably  top line results from the phase III BREEZE AD7 study showed that after 16 weeks of treatment  patients treated with baricitinib plus standard of care topical corticosteroids experienced a significant improvement in disease severity   the primary endpoint   compared to those treated with placebo  The primary endpoint was defined by the validated Investigator s Global Assessment for AD  vIGA  score of  clear or almost clear  skin  Lilly said that the safety data was consistent with previous studies on baricitinib So far this year  shares of Lilly have declined 5 3  compared with the  s decrease of 2 8  Lilly is conducting five studies on baricitinib under the AD program and BREEZE AD7 is the third study to be completed this year  BREEZE AD1 and BREEZE AD2 were the other two studies wherein baricitinib 4 mg and 2 mg both met the primary endpoint  Top line data from the remaining two studies are expected to be presented later this year or early next yearOlumiant is presently marketed globally for the treatment of moderate to severe rheumatoid arthritis  However  while it was approved for both the 2 mg and 4 mg dose in the EU in 2017  it was approved only for the lower dose in the United States in 2018  after being rejected by the FDA in 2017  The FDA did not approve the higher dose  4 mg  and the drug s label was approved with a boxed warning  stating risk of serious infections  malignancies and thrombosis Other than atopic dermatitis  Olumiant is also being studied in phase III studies for systemic lupus erythematosus and in a phase II III study in alopecia areata Olumiant generated sales of  184 5 million in the first half of 2019 backed by launch uptake in new European markets  If the drug is approved for additional indications  it can bring in more sales for Lilly Baricitinib is being co developed by Lilly and Incyte under an exclusive global license and collaboration agreement inked in December 2009 Last week  AbbVie   NYSE ABBV   gained FDA approval for its JAK inhibitor  upadacitinib  for the treatment of moderate to severe RA in patients who experience inadequate response or are intolerant to methotrexate  The drug will be marketed with the trade name of Rinvoq  The company is expected to launch the drug later this month  Upadacitinib is also being studied in a late stage study for AD Lilly currently carries a Zacks Rank  2  Buy   You can see  Another large cap pharma stock with the same Zacks Rank as Lilly is Novartis   NYSE NVS    Novartis  earnings estimates for 2019 have gone up 1 8  while that for 2020 have increased 0 4  over the past 30 days  Novartis stock has returned 3 1  so far in 2019 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/lillys-olumiant-meets-primary-endpoint-in-3rd-eczema-study-200458570,200458570
171319,392835,LLY,J J  JNJ  Loses Landmark Opioid Case  What s Next For Pharmaceuticals ,opinion,"An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson   Johnson   NYSE JNJ   would have to pay  572 million to the state  J J is accused of helping fuel the opioid epidemic that killed more than 400 000 people from 1999 2017  The verdict was much better than what many investors and analysts had been anticipating  falling on the low end of the  500 million and  5 billion estimated range  Let s take a closer look at how the trial went for J J and how pharma investors can navigate the litigated market 
Oklahoma Trial 
District Judge Thad Balkman  ruled that J J s marketing of their opioid products was misleading and in turn compromised the health and safety of thousands of Oklahomans  He noted that the defendants  caused an opioid crisis that s evidenced by increased rates of addictions and overdose deaths   The ruling concludes that J J and their pharmaceutical subsidiary  Janssen  downplayed the risks of addiction to their opioid products  marketing the risks as low as 2 6  or less 
The  572 million awarded to the state covers one year of the states plan to combat the opioid crisis despite the state s plea that it would take up to 20 years to successfully carry out the campaign  J J is planning to appeal the verdict  they believe that the decision is flawed because the state failed to present evidence that J J s actions caused a public nuisance 
J J expressed their innocence in court stating that the marketing of their opioid products was appropriate and responsible  The company provided testimonies from doctors and current and former employees who agreed that their marketing practices were appropriate 
The verdict was significantly less than the penalties sought by the state  sending JNJ up about 2  after the verdict announcement  Teva Pharmaceutical   NYSE TEVA   and Purdue Pharma both reached a settlement with the state of Oklahoma before the trial began 
Looking Ahead
While the verdict makes owning J J stock a little easier  Oklahoma is only one plaintiff in a plethora of cases pending before a federal judge in Ohio  The consolidated lawsuit includes 22 defendants who were opioid manufacturers and distributers  including J J 
Recession fears have already plagued the stock market this month and pending lawsuits is not what pharmaceutical companies need  If investors do wish to stay in the sector  dividend paying pharmaceutical companies would be their best bet 
Novo Nordisk  CSE NOVOb  A S   NYSE NVO   sports a 1 22  dividend yield and has a beta of 0 6  providing stability for investors  Estimates anticipate Y Y growth of 6 9  in earnings and a 3 39  revenue jump to  4 46 billion this quarter  NVO has gained 13 2  YTD  outpacing the broader drug market  NVO is sitting at a Zacks Rank  2  Buy  
Novartis AG   NYSE NVS   is a large cap pharma that pays out a dividend yield of 2 06  and has a beta of 0 58  NVS has beaten our earnings estimates twice in the last four quarters for an average EPS surprise of 2 84   Earnings estimates anticipate a 4 58  jump to  1 37 per share this quarter  Earnings estimates have been revised upwards for NVS earning it a Zacks Rank  2  Buy  
Eli Lilly   NYSE LLY   is an additional large cap pharma that boasts a dividend yield of 2 33   Eli Lilly is also resilient to broader market trends with a beta ratio of 0 19  The company has surpassed our earnings estimates three out of the past four quarter for an average EPS surprise of 0 69   Consensus estimates project the company s bottom line to increase 3 06  to  5 72 in fiscal 2019  LLY is a Zacks Rank  2  Buy  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-loses-landmark-opioid-case-whats-next-for-pharmaceuticals-200459585,200459585
171320,392836,LLY,Why Is Aduro Biotech  ADRO  Down 12 1  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Aduro Biotech  ADRO   Shares have lost about 12 1  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Aduro Biotech due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Aduro Earnings Miss in Q2  Revenues Meet EstimatesAduro incurred second quarter 2019 loss of 23 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents but narrower than the year ago loss of 31 cents Revenues in the reported quarter came in at  4 9 million  up 88 5  year over year  primarily owing to the ratable recognition of the upfront payment received from Eli Lilly  NYSE LLY  during the first quarter of 2019  Sales almost came in line with the Zacks Consensus Estimate of  5 million Research and development expenses declined 12 9  in the reported quarter to  16 9 million owing to lower stock based compensation and reduced headcount plus decreased costs for de prioritized programs General and administrative expenses were  8 million  down 9 1  year over year  primarily owing to strategic reset announced in January  which resulted in lower stock based compensation and reduced headcount 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 8  due to these changes 
VGM Scores
Currently  Aduro Biotech has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision has been net zero  Notably  Aduro Biotech has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/why-is-aduro-biotech-adro-down-121-since-last-earnings-report-200460502,200460502
171321,392837,LLY,5 Cancer Fighting Stocks To Add To Your Portfolio,opinion,Cancer has become a major health scare in the 21st century  with nearly every individual knowing someone or the other who has been affected  This life threatening disease has attracted many big companies to invest in and develop solutions Majority of the drug makers in the world are spending millions on developing treatment for oncology patients  with focus on the prevention  diagnosis and treatment  With still a diverse area left to explore and companies trying desperately to  lead the market  with its unique cancer drug composition  investors can select stocks to gain attractive returns Cancer   100 and Still CountingCancer in layman s term is a disease that is caused by the uncontrolled division of cells in the body  Doctors and researchers across the world have so far found more than 100 diseases  which can be collectively called cancer  The vast cancer fighting industry has been broken down into several categories pre  in and post cancer treatment Companies that focus on prevention of cancer produce cessation products  for example smoking cessation products to reduce the risk of developing lung cancer  Others focus on diagnostics that involve analyzing and identification through tissue biopsies to determine the presence of cancerous cells  The treatment of cancer remains the primary focus  whether it is invasive and non invasive surgeries or chemotherapies  Some cancer patients need personalized medicines caused by mutation in DNA from the cancer cells  Developing a generic medicine for cancer has a lot of grey area to cover and decades of research work still waits Why Invest in Cancer Fighting Stocks In 2018  IQVIA Institute for Human Data Science reported around  150 billion was spent on medicines to treat cancer and this would rise to  250 billion in 2023  The investment in cancer fighting stocks attracts investors with the potential to generate higher returns over the long term and beat the market So far this year  the biotech sector has seen a boom boosted by new drug discovery  approval of patents and most importantly  mega mergers  The S P Biotechnology Select Industry Index is up by 12  on a year to date basis and is still growing The biotech space took a flight in January 2019 with the announcement of the merger of Bristol Myers Squibb Company   NYSE BMY   and Celgene Corporation   NASDAQ CELG    two leading oncological drug makers  Bristol Myers Squibb has offered to acquire Celgene for  74 billion 5 Stocks to Buy NowWith the growing rate of cancer patients every year  cancer fighting stocks seem to be gaining immensely  Hence we have shortlisted five stocks that flaunt a Zacks Rank  1 Strong Buy  or 2  Buy  and have a bright future with their strong patents and drug development Roche Holding  SIX ROG  AG   OTC RHHBY   is a publicly traded pharmaceutical and diagnostic company  The company provides and develops drugs especially in oncology  On Aug 16  US Food and Drug Administration  FDA  approved Rozlytre for the treatment of metastatic non small cell lung cancer  Rozlytrek holds a record of shrinking 78  tumors Roche s expected earnings growth rate for the current year is 7 8   The Zacks Consensus Estimate for current year earnings has improved 3 7  over the past 60 days  Roche s stock carries a Zacks Rank  1 Bristol Myers Squibb Company is a publicly traded biopharma company  FDA had authorized Empliciti  a vast portfolio of regime therapy in November 2018 made to fight plasma cell cancer  On Aug 28  the European Commission also approved the Empliciti drug for the treatment of adult patients with multiple myeloma  which boosted the portfolio further Bristol Myers Squibb s expected earnings growth rate for the current year is 7 5   The Zacks Consensus Estimate for current year earnings has improved 2 6  over the past 60 days  The stock carries a Zacks Rank  1  You can see Abbott Laboratories   NYSE ABT   is publicly traded offering cancer diagnostic equipment  The company has a portfolio of instrumental cancer detecting laboratory systems that include  Alinity  Architect and Cell Dyn Abbott Lab s expected earnings growth rate for the current year is 12 5   The Zacks Consensus Estimate for current year earnings has improved 0 6  over the past 60 days  The stock carries a Zacks Rank  2 Eli Lilly and Company   NYSE LLY   is a publicly traded company that targets the treatment of cancer  The company still benefits from the first won FDA approval on Alimta in 2004  a drug for treating non small cell lung cancer  After the  1 6 billion acquisition of ARMO Biosciences in 2018  Eli Lilly now has three cancer programs in the late stage pipeline Eli Lilly s expected earnings growth rate for the current year is 3 1   The Zacks Consensus Estimate for current year earnings has improved 1 1  over the past 60 days  Eli Lilly stock carries a Zacks Rank  2 Novartis AG   NYSE NVS   is a publicly traded pharmaceutical company with a massive portfolio of cancer fighting drugs  In 2018  Tasigna  Novartis  chronic myeloid leukemia drug alone generated  1 9 billion from a total of  13 4 billion revenues in the cancer drug franchise Novartis  expected earnings growth rate for the current year is 1 2   The Zacks Consensus Estimate for current year earnings has improved 2 8  over the past 60 days  Novartis stock carries a Zacks Rank  2 Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-03,Zacks Investment Research,https://www.investing.com/analysis/5-cancerfighting-stocks-to-add-to-your-portfolio-200460984,200460984
171322,392838,LLY,FDA OKs expanded use of AstraZeneca s breast cancer med Faslodex,news,The FDA approves AstraZeneca s  NYSE AZN  FASLODEX  fulvestrant  to include its use with Eli LIlly s  NYSE LLY  Verzenio  abemaciclib  in patients with HR  HER2  advanced metastatic breast cancer who have progressed after endocrine therapy Abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes CDK4 and CDK6 Fulvestrant is an estrogen receptor antagonist Now read ,2017-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-expanded-use-of-astrazenecas-breast-cancer-med-faslodex-863699,863699
171323,392839,LLY,Lilly to release 2018 guidance December 13,news,Eli Lilly  LLY  0 3   will host a conference call on December 13 at 10 00 am ET to present its 2018 guidance Current consensus is EPS of  4 63 on revenues of  23B Now read ,2017-11-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/lilly-to-release-2018-guidance-december-13-888991,888991
171324,392840,LLY,FDA OKs Merck s ertugliflozin for T2D,news,The FDA approves Merck s  MRK  0 2   Steglujan  ertugliflozin  for glycemic control in type 2 diabetics Ertugliflozin inhibits sodium glucose co transporter 2  SGLT2   a protein that facilitates glucose reabsorption in the kidney  Inhibiting SGLT2 increases the excretion of glucose which lowers blood glucose levels  Merck and  Pfizer   PFE  1 2   are co developing and co commercializing the product under their April 2013 collaboration agreement On a monotherapy basis  Steglujan will compete head to head with Eli Lilly s  LLY  1   Jardiance  empagliflozin  Previously  Merck and Pfizer type 2 diabetes candidate ertugliflozin successful in another late stage study  Sept  15  2016 Now read ,2017-12-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-mercks-ertugliflozin-for-t2d-1015897,1015897
171325,392841,LLY,Pfizer ends research for new Alzheimer s  Parkinson s drugs,news,"NEW YORK  Reuters     Pfizer  Inc  N PFE  is abandoning research to find new drugs aimed at treating Alzheimer s and Parkinson s disease  the U S  pharmaceutical company announced on Saturday  The company said it expects to eliminate 300 positions from the neuroscience discovery and early development programs in Andover and Cambridge  Massachusetts  and Groton  Connecticut  as it redistributes the money spent on research  according to the emailed statement   Pfizer is not making any changes to research and development funding for tanezumab  which is marketed as a treatment for joint pain from osteoarthritis  fibromyalgia treatment Lyrica  or its rare disease program    This was an exercise to re allocate spend across our portfolio  to focus on those areas where our pipeline  and our scientific expertise  is strongest   the company said  Pfizer has invested heavily in research for Parkinson s and Alzheimer s  and is one of several drugmakers  along with GlaxoSmithKline  L GSK  and Eli Lilly  N LLY   that is part of the Dementia Discovery Fund  a venture capital fund launched in 2015 by industry and government groups that seeks to develop treatments for Alzheimer s   However  some of Pfizer s investments have resulted in disappointment  In 2012  Pfizer and partner Johnson   Johnson  N JNJ  called off additional work on the drug bapineuzumab after it failed to help patients with mild to moderate Alzheimer s in its second round of clinical trials  The company said on Saturday that it will launch a new venture fund to invest in neuroscience research projects   
Pfizer is expected to make a presentation on Monday at the JP Morgan healthcare conference in San Francisco  a key annual event for healthcare investors ",2018-01-07,Reuters,https://www.investing.com/news/stock-market-news/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-1073072,1073072
171326,392842,LLY,Elanco and Aratana announce marketing authorization of GALLIPRANT in Europe,news,Elanco Animal Health  a division of Eli Lilly and Company  NYSE LLY  and Aratana Therapeutics  NASDAQ PETX  announce that the European Commission has granted marketing authorization of GALLIPRANT  grapiprant tablets  in the European Union  Galliprant is a new veterinary medicine for the treatment of pain associated with mild to moderate osteoarthritis in dogs Shares of LLY are up 2  premarket on light volume  Now read ,2018-01-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/elanco-and-aratana-announce-marketing-authorization-of-galliprant-in-europe-1091957,1091957
171327,392843,LLY,Drugmakers see a pricing blueprint in an  850 000 gene therapy,news,"By Caroline Humer SAN FRANCISCO  Reuters    Global drugmakers are looking to a tiny biotech s  850 000 therapy for a rare type of blindness as a model for getting paid for highly expensive   and effective   new medicines   Spark Therapeutics Inc   O ONCE  plans to launch its recently approved Luxturna treatment for an inherited genetic mutation that causes blindness in March  The drug is to be administered only once  by injection  and Spark plans to charge  425 000 per eye  an unprecedented price  But what is grabbing the attention of other drugmakers is not just what might be called an eye popping price to treat a condition that Spark estimates affects 1 000 to 2 000 people in the United States  but the ways Spark is looking to help payers ranging from the federal government to private insurers absorb the drug s high cost  including spreading out payments over several years   We re laying the groundwork for the future of our pipeline and the future of one time curative gene therapy treatments   Spark s chief executive officer  Jeffrey Marrazzo  said in an interview at the JPMorgan  NYSE JPM  Healthcare Conference in San Francisco this week   The high cost of prescription drugs has become an increasingly critical and contentious issue  The independent Institute for Clinical and Economic Review  ICER  issued a report on Friday saying the proposed Luxturna price was far too high in most cases  Healthcare spending accounts for 18 percent of the U S  economy and has been rising faster than the rate of inflation as drugs and medical services costs increase  An influx of very expensive drugs that offer a one time cure   such as a hepatitis C treatment from  Gilead Sciences Inc   O GILD    has already stretched state and federal budgets   The U S  Centers for Medicare and Medicaid Services  CMS   which provides coverage for 125 million elderly  poor and disabled Americans  spends hundreds of billions of dollars annually on medicines  CMS is trying to tackle the overall high drug costs  It has asked for input from private health insurers and drugmakers on payment models that are expected to influence how medical breakthroughs for millions more patients are covered   Spark itself is working with CMS on a legal structure to allow government and private sector health plans to pay for Luxturna  which restores some vision for most patients with the inherited mutation  over several years  rather than in a single payment  without hurting its profits   Spark has also offered refunds if the treatment stops working and ways for payers to buy the drug outside of hospitals  which can significantly mark up the price of a medicine administered in their facilities  In interviews with Reuters  executives from large drugmakers including Eli Lilly   Co  N LLY   GlaxoSmithKline Plc  L GSK   Roche Holding AG  S ROG   Merck   Co Inc  N MRK  and Bristol Myers Squibb Co  N BMY  said they would pay close attention to the outcome of Spark s payment discussions  They are also following two revolutionary gene based therapies for blood cancers from  Novartis  AG  S NOVN  and Gilead Sciences  Novartis  Kymriah  with a list price of  475 000  is covered by CMS based on outcomes achieved for pediatric and young adult leukemia patients by the end of the first month of treatment  Spark is also looking at guaranteeing its product  It is working on a plan with pharmacy benefits manager Express Scripts Holding Co  O ESRX  on a long term payment schedule for privately insured patients   Spark plans to sell Luxturna through specialty pharmacies  including one owned by Express Scripts  so that large employers and health plans can avoid hospital markups that could reach hundreds of thousands of dollars  Express Scripts is working with Spark on provisions to refund money to insurers if the drug does not work as promised   Spark is willing to guarantee its product over a period of time and potentially extend that payment over a period of time  it needs someone to be a chassis   Express Scripts CEO Tim Wentworth said  POTENTIAL ROADBLOCKS Large drugmakers already offer refunds on some drugs  including treatments for diabetes or high cholesterol  if they do not provide a benefit  But it is tougher to create a long term payment model for a very expensive drug administered only once  The U S  system is built to cover the whole cost immediately  and CMS needs to determine how smaller payments could be made without triggering bigger than intended discounts   CMS does not negotiate prices or purchase drugs  but it sets ground rules for the managed care companies and state Medicaid agencies that do  CMS chief Seema Verma told Reuters last year that she was looking at new payment models for high priced breakthrough treatments   Another road block under discussion  Patients often change insurance  or move between private and government sponsored health coverage depending on their age or employment status  Under a deferred payment plan  the government could be billed for patients who they no longer cover    The innovation is there  but the financing vehicles need to catch up   said Jack Bailey  GlaxoSmithKline s U S  pharmaceuticals head    Paul Biondi  head of business development at Bristol Myers  said the drugmaker is closely following the payment outcome for gene therapies   I m glad other people are plowing the ground   he said  The next U S  approved gene therapy may come from Bluebird Bio  O BLUE   The small biotech company expects to submit this year a potentially one time treatment for the inherited blood disorder beta thalassemia  which can cause severe anemia  Bluebird also aims to seek approval for a gene based cancer therapy in 2019   We ve been thinking about pricing for years   Jeffrey Walsh  Bluebird s chief financial and strategy officer  said   Now we can bring in the regulators   The company is talking to the U S  government  as well as governments in the UK  France  Germany and Italy  about pricing over a period of time and how to prove a drug is working   
 The system in the U S  isn t built for a single intervention   Walsh said ",2018-01-12,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-see-a-pricing-blueprint-in-an-850000-gene-therapy-1099478,1099478
171343,392859,LLY,Lilly s Taltz Outshines J J s Tremfya In Psoriasis Study,opinion,Eli Lilly   Company   NYSE LLY   announced superiority of its plaque psoriasis drug Taltz over J J s   NYSE JNJ   new drug  Tremfya  guselkumab   in delivering total skin clearance at week 12 in a head to head comparison study The phase IV IXORA R study  n  1 027  compared the efficacy between an IL 17A inhibitor  Taltz and an IL 23 p19 inhibitor  Temfya  The primary endpoint of the study was the proportion of patients who achieve complete skin clearance  in other words  100  improvement from the baseline as measured by Psoriasis Area Severity Index  PASI  100 scoreTop line data from the study showed that a higher proportion of patients treated with Taltz achieved complete skin clearance compared to Tremfya as measured by PASI 100  thereby meeting the study s primary endpoint  The study also met all major secondary endpoints  Detailed data from the study is expected to be presented at the upcoming scientific meetings Lilly s shares were up 1 9  on Tuesday in response to the news  So far this year  shares of Lilly have been roughly flat against the decrease of 1 8    Taltz is presently marketed for moderate to severe plaque in adults who are candidates for systemic therapy or phototherapy and also for active psoriatic arthritis  PsA   Taltz also demonstrated superiority in improving the signs and symptoms of PsA while also providing skin clearance in a head to head study comparing it with AbbVie  Inc  s   NYSE ABBV   blockbuster medicine  Humira  This data was presented in December last year  Taltz is also under review in the United States for the axial spondyloarthritis indicationTaltz is an important revenue driver for Lilly  recording sales of  606 3 million in the first half of 2019  up 65  year over year  Lilly currently carries a Zacks Rank  2  Buy   You can see  Another large cap pharma stock with the same Zacks Rank as Lilly is Novartis   NYSE NVS    Novartis  earnings estimates for 2019 have gone up 1 2  while that for 2020 have increased 2 3  over the past seven days  Novartis stock has returned 6 2  so far in 2019 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/lillys-taltz-outshines-jjs-tremfya-in-psoriasis-study-200455152,200455152
171344,392860,LLY,Immunotherapy Stocks With Multiple Catalysts Ahead,opinion,"As our understanding of the human body and the ailments that attack it continues to improve  so to do our medical approaches toward conditions of all levels of severity  While this medical renaissance  so to speak  has led to options that we never thought imaginable  there are still indications that are met with few or no options  
A relatively new approach to addressing some of these conditions is sweeping the medical community as early results show incredible promise  This approach is known as immunotherapy  
In immunotherapy   and pharmaceutical companies aren t working to develop treatment options that attack a specific type of cell  Instead  they are looking to enhance them  The idea is that by enhancing the body s innate immune system  the patient s own line of defense will have the ability to break down and destroy cells and pathogens known to cause adverse medical conditions  
Immunotherapies are being developed to target severe  rare  and debilitating diseases with few options available to patients  Targeting these types of indications not only gives patients that suffer from them hope  but presents tremendous market opportunities in spaces with little to no competition  
As a result  when we see catalystic events out of immunotherapy companies  we tend to see incredible movement in the values of their shares  With that said  here are five immunotherapy companies that have multiple catalysts to look forward to 
Eli Lilly  NYSE LLY   A Classic Not Afraid To Change With The Times 
Founded in the 1800s  Eli Lilly  NYSE LLY  is no stranger to the development of blockbuster medications  However  the traditional approach taken by the company may lead many of you to wonder why it is on a list of immunotherapy stocks with catalysts to watch for ahead  The answer is simple  the company fits the bill  
Sure  Eli Lilly  NYSE LLY  may be best known for its leading treatments like Trulicity and Basaglar in the diabetes space  but the company is also breaking into immunotherapy  and doing so with a splash  In fact  according to Eli Lilly s  Lilly Oncology  website  the company currently has 10 active clinical trials in various phases  assessing immunotherapies as potential options for patients facing multiple cancer types  
The most promising clinical candidate in Ely Lilly s immunotherapy pipeline to date is known as Pegilodecakin  The treatment has already shown incredible promise in the potential treatment of pancreatic cancer  As a result  the company is in the midst of assessing the treatment for the pancreatic cancer indication in a Phase 3 trial  
Should the Phase 3 clinical trial prove to yield positive results  Ely Lilly will likely quickly advance the asset into regulatory submission and could push the treatment to market relatively soon  Pegilodecakin is also in multiple Phase 2 clinical trials for the treatment of non small cell lung cancer  and in early development for an undisclosed indication  
With several immunotherapy treatment candidates in early stage development  and one option nearing regulatory submission  there are several catalysts ahead  This  combined with the strength that more than a decade in the industry provides  makes Ely Lilly a stock that s well worth paying attention to  
Gilead Sciences  NASDAQ GILD   A Comeback Waiting To Happen
Over the past year  Gilead Sciences  NASDAQ GILD  has seen some weakness in the market  As AbbVie  NYSE ABBV  competes with the company s hepatitis C virus franchise  ultimately taking market share  many have been counting on declining sales in some of the company s key drug products  
Nonetheless  I believe that the declines in sales have been priced in at the moment  Moreover  a bounceback is likely in the making  
Gilead Sciences  innovation in immunotherapy led to its position as a pioneer in the treatment of HIV  In fact  with six blockbuster HIV drugs on the market  Gilead Sciences  NASDAQ GILD  is a clear leader in the space  
Importantly  in February of 2018   the company received FDA approval for Biktarby  yet another immunotherapy designed to target HIV  Nonetheless  this treatment is expected to become the best selling HIV drug of all time due to strong efficacy and minimal adverse events  As such  sales reports surrounding Biktarby will likely prove to be catalystic events  causing strong movement in the value of the stock  
It s also worth mentioning that the Gilead Sciences  NASDAQ GILD  pipeline is a strong one  In fact  the company currently has 5 treatment candidates under Phase 3 development and more than 15 in Phase 2 clinical studies  Considering the multiple ongoing clinical trials and anticipated sales reports surrounding Biktarby  Gilead Sciences likely has multiple catalysts ahead  
INmune Bio  INMB   An Undervalued Play With Multiple Ongoing Clinical Trials
INmune Bio is a relatively small company by market cap  Nonetheless  the stock comes with explosive potential  That s because not only does INmune Bio have multiple ongoing clinical development programs  but it is targeting high value indications with little by way of competition  
In my view  the most interesting candidate at INmune Bio is known as XPro1595  The treatment is being studied as a potential option for the treatment of patients with Alzheimer s disease  
XPro1595 is believed to work by suppressing microglia  Microglia is present in high levels in Alzheimer s patients  In fact  it s thought that this is a key factor in the neuroinflammation believed to be a causative factor in Alzheimer s disease  The idea is that by targeting and reducing Microglia  we will see a reduction in Alzheimer s disease related symptoms among the treated patients  
I find this treatment to be compelling because  if it is approved  it will be the only treatment on the market that addresses Alzheimer s disease in this way  Moreover  it will become one of very few options available  giving INmune Bio a leg up in a market that is expected to grow to be worth more than  12 billion annually by the year 2026  
At the moment  XPro1595 is progressing through Phase 1 clinical studies  Moreover  it s one of three candidates under development at INmune Bio  In fact  the company is currently developing INKmune and INB103 as potential options in oncology indications  yet another market with incredible potential  
All in all  with multiple ongoing clinical trials and preclinical development programs  INmune Bio is likely to generate several catalysts ahead  Considering its relatively small market cap  combined with tremendous market potential  this is a stock worth paying close attention to  
Bluebird Bio  BLUE   Breaking Into Commercial Stages With A Potential Blockbuster
Bluebird Bio is a company that is just starting to enter the commercialization phase  In June 2018  the company won European approval for Zynteglo  a gene therapy that s indicated to treat a rare blood disease  The indication  known as transfusion dependent beta thalassemia  or TDT  offers up a blockbuster opportunity  but that s not why the company is on this list  
The truth of the matter is that gene therapy and immunotherapy are two completely different things  Nonetheless  the company is actively involved in the development of immunotherapy options  
In fact  Bluebird is working in collaboration with Celgene  NASDAQ CELG  on very promising CAR T treatment options  In fact  by the end of the year 2019  the two are expected to release clinical data from a Phase 2 study of ide cel  also known as bb2121  The treatment is currently being assessed as a potential option for multiple myeloma  yet another high value indication  
It s also worth mentioning that bb2121 is not the only CAR T treatment that the company has under development  It is also working on a similar treatment option known as bb21217 as a potential option for the treatment of multiple myeloma  The company expects to report data from this study by the end of 2019 as well  
All in all  Bluebird is working on four immunotherapy assets  one of which has achieved European regulatory approval  and all of which have the potential to become blockbuster treatment options  Considering the recent approval  sales reports surrounding Zynteglo  and clinical data likely coming from the company s other assets  we re likely to see several catalysts ahead  
ZioPharm Oncology  ZIOP   Yet Another Immunotherapy Play With Compelling Potential
Finally  we have ZioPharm Oncology  The company is focused on two primary assets within its pipeline  The first  immunotherapeutic asset  known as Ad RTS hIL 12  is believed to change the tumor microenvironment  turning immunologically cold tumors into hot ones  
Cold tumors are cancers that  for multiple reasons  contain few infiltrating T cells  As a result  these cancers are not recognized by the body s innate immune system  thereby they do not elicit a response from the body s innate immune system  
Nonetheless  it is believed that Ad RTS hIL 12 has the potential to change the tumor microenvironment  turning cold tumors into hot ones that are targeted by the immune system  Should this method of action prove effective  the treatment would not only be a strong monotherapy  but would come with tremendous combination potential  especially in combination with immune blockade inhibitor treatments  
Currently  ZioPharm is in the midst of 3 Phase 1 clinical trials and 1 Phase 2 clinical trial assessing the treatment as a potential option in various oncology indications  
Ziopharm is also working on an asset that it has dubbed  Sleeping Beauty   The treatment is currently at the center of one Phase 1 clinical trial and multiple preclinical development programs  Moreover  the company has partnered with big names like the MD Anderson Cancer Center and National Cancer Institute for the development of its Sleeping Beauty asset  
All in all  with several clinical development programs under way and promising early results out of Ad RTS hIL 12  Ziopharm Oncology likely has multiple positive catalysts ahead  So  keep your eyes peeled for opportunity here  
Final Thoughts
Immunotherapy is a promising new approach to the treatment of several serious and debilitating conditions  With so much clinical activity in the space  new opportunities are being spotted every day  In my view  the stocks mentioned above represent some of the strongest opportunities in the space ",2019-08-14,Modest Money,https://www.investing.com/analysis/immunotherapy-stocks-with-multiple-catalysts-ahead-200454902,200454902
171345,392861,LLY,OTC Markets Group  A Year Of Investment For The Future,opinion,"Hutchison China MediTech  Ltd  NASDAQ HCM  continues to make progress towards its global strategic aspirations  The interim results highlight the opportunities for Elunate  fruquintinib  capsules in China  with potential inclusion in China s exclusive NRDL list in Q419  and the breadth of clinical and regulatory catalysts that lie ahead for multiple R D assets  Surufatinib s China NDA submission is on track  Q419  and approval in NET would seal HCM s position as a premier  innovative  China based oncology company  The years 2021 22 are pivotal  partner AstraZeneca  AZN  could launch savolitinib in China for NSCLC  MET exon 14  and it could become HCM s first asset to launch globally  2022  in combination with Tagrisso for NSCLC  c Met  ve   Given the recent underperformance of the shares and the real potential for HCM to become a global oncology player  we believe it is appropriate to revisit the shares  We value HCM at  5 7bn 




Pipeline coming to fruition
Elunate is now being commercialised in China  third line CRC  by partner Eli Lilly  NYSE LLY   Lilly   a major inflection point for HCM and validation of its R D philosophy  While the early sales trajectory is notable  H119 in market of sales of  11 4m   the most interesting opportunity lies in inclusion on China s NRDL  as this would translate into automatic inclusion in all state funded hospitals  more eligible patients  and automatic reimbursement  albeit it at a lower price   Next for potential launch in China is surufatinib  launch for treatment of NET expected early 2021   In addition  a interim analysis of the pivotal China Phase III study  SANET p  in pancreatic NET is due in H120  which  if positive  could further widen its market potential in this area of unmet need 
Financials  Funded to key inflection points
HCM has reduced its FY19 R D expense guidance to  130 170m  from  160 200m   reflecting the depreciation of Chinese yuan versus the US dollar  China R D  and the phasing of global surufatinib and fruquintinib Phase IIb III trials  HCM reported available cash resources of  383 6m  which  combined with the net profit generation from the CP division  means it is well funded to key value inflection points  NDA submissions for savolitinib  surufatinib and fruquintinib in 2019 21  
Valuation   5 7bn   6 99 share 
We value HCM at  5 7bn   6 99 share  vs  5 6bn previously  We make no changes to our product forecasts  but have trimmed R D costs for 2019  phasing costs into 2020  to reflect FY19 guidance  rolled forward our model  and updated for FX and net cash of  237 3m at 30 June 2019 
Business description
Hutchison China MediTech is an innovative China based biopharmaceutical company targeting the global market for novel  highly selective oral oncology and immunology drugs  Its established commercial platform business continues to expand its outreach 
Global aspirations
HCM s recent share price underperformance provides an opportunity to revisit the investment case  We believe the long term investment case is solid  with multiple near term catalysts  regulatory filing and potential approval for surufatinib and savolitinib  as HCM successfully launches numerous assets to market   2020 21 and beyond  in China and internationally  Its broad mid  to late stage innovation platform  IP  will translate into diverse global revenue streams with a multitude of other compounds coming to the fore from HCM s established and proven innovative R D platform  Existing partnering deals for savolitinib and fruquintinib support the investment case as milestones and royalties on sales continue to bolster the P L  HCM has global strategic aspirations  and it is only a matter of when rather than if its aspirations are met  in our view  HCM continues to invest in expanding its global innovation organisation  it now has  440 scientific personnel based in China and the US  Shanghai  Suzhou and New Jersey  




CK Hutchison Holdings  CKH  completed a secondary offering of ADSs in July 2019  which has reduced its holding to 51 15   from 60 2  previously   We see this as a significant positive for HCM as it increases the free float  potentially leading to better liquidity  We note that this had no effect on shares in issue and does not dilute any current shareholders  An eventual listing on SEHK will be determined by a number of factors including  but not limited to  management decisions and market conditions  In our view  a capital raise on existing markets  AIM Nasdaq  is still likely in the next 24 months  However  cash resources as last reported  30 June 2019  of  383 6m are more than sufficient to fund HCM to key inflection points  NDA submissions for savolitinib  surufatinib and fruquintinib in 2019 21   HCM could explore non dilutive finance options such as divesting non core commercial platform  CP  assets  Exhibit 1 highlights the plethora of clinical and regulatory catalysts ahead  For more details  see our outlook note  An emerging global biopharma 
Elunate early sales encouraging  NRDL inclusion is key
The launch of Elunate  fruquintinib capsules  for metastatic colorectal cancer  third line and above  by partner Lilly was a defining moment for HCM  as it was the first of its IP assets to launch in China  and the first China discovered and developed new drug for oncology to have full approval and reach the market  HCM reported H119 royalties of  1 7m and  3 0m of sales of Elunate manufactured by HCM for Lilly  The reported  1 7m royalties translates into  11 4m Elunate end user sales in H119  as reported by Lilly 
At the interim results  HCM presented data on the sales evolution of oncology drugs by its international and domestic peers  A key inflection in sales growth is inclusion on China s National Reimbursement Drug List  NRDL   which will define the opportunity for full scale reimbursement nationally  albeit on lower pricing  discount to be agreed by Eli Lilly  NYSE LLY  and China s central government   A fourfold ramp in the second full year from launch would require us to revisit our overall peak sales expectations  Inclusion on the NRDL is expected in Q419  Elunate has been added to two regional reimbursement lists in China during the last six months  Zhuhai and Shanghai   which highlights that Elunate s utility in third line CRC has been recognised at a local level 
Elunate s next China development focus is on Phase III gastric cancer  FRUTIGA   for which approval could occur in 2021 22  Life cycle management and extending the labelled use to other solid tumour types will expand Elunate s commercial opportunity further  The global development programme is underway in colorectal cancer  with Phase Ib enrolling patients in the US  HCM has started planning the global Phase II III US EU registration trial  starting in 2020  in third fourth line mCRC in patients who are resistant or intolerant to Bayer s Stivarga  It has filed the FALUCA data for publication  potentially at ESMO 2019 or WCLC 2019  the data should shed light on the failure of fruquintinib monotherapy to meet the overall survival  OS  endpoint in third line non small cell lung carcinoma  NSCLC   having demonstrated statistically significant improvement in all secondary efficacy endpoints 
Surufatinib next in line for China launch
Surufatinib  previously known as sulfatinib  could be the first of HCM s non partnered assets to reach the China market in early 2021  NDA submission expected in late 2019   The strategy for surufatinib was recently validated as positive interim data were announced in the SANET ep Phase III trial testing surufatinib in non pancreatic NET China patients  This was based on the trial meeting its primary endpoint of progression free survival  PFS  at the interim analysis and the trial was unblinded a year ahead of schedule 
NETs are cancers that arise out of cells of the endocrine and nervous systems  predominately the digestive and respiratory tracts  While the current prevalence of NET in the US is  141 000 patients  incidence of  19 000 new cases per year  source    current treatment modalities are limited to subsets of NET with no broadly effective drugs across the NET spectrum  HCM believes that actual incidence of NET in China could be higher than the reported incidence of 67 600  and prevalence could be even greater once an effective broad spectrum treatment becomes available  Expanding the treatment paradigm could improve diagnosis rates and increase eligible patient numbers  Surufatinib could improve on the profiles of existing NET treatments  including somatostatin based treatments and kinase inhibitor therapies  such as Afinitor and Sutent   Broad spectrum use will yield commercial success if it can be used for treating the broad base of NET patients  An interim analysis for the pivotal China Phase III study in pancreatic NET SANET p  is due at H120  which  if positive  could further widen its market potential in this area of large unmet need 
A US Phase Ib II trial in pancreatic NET and biliary tract cancer has completed enrolment of NET patients  An end of Phase II meeting with the FDA is planned for Q419  to discuss the Phase III US EU registration study which HCM expects to start in Q120  HCM retains full worldwide rights to surufatinib 
Savolitinib could coat tail Tagrisso
An estimated 2 3  of newly diagnosed NSCLC patients have a specific mutation known as MET Exon 14 skipping  Exon 14 of the MET gene is not functioning or deleted   leading to c Met over expression  In China  HCM estimates this to be 10 000 patients  A registrational Phase II clinical trial is underway  enrolment complete  in patients who have progressed on prior chemotherapy  or are unable to tolerate additional rounds of chemotherapy  Although the patient size is relatively small  this indication could be savolitinib s first China NDA submission in 2020 and its first monotherapy indication in the region  In the longer term in China  we believe a savolitinib plus Tagrisso combination will expand use in other subsets of NSCLC 
In the field of lung cancer  AZN s Tagrisso is raising the bar as it moves into the first line setting in EGFR mutation positive NSCLC  reporting sales of  1 41bn in H119  Savolitinib s largest opportunity could be in combination with Tagrisso in EGFRm MET  NSCLC patients as MET mutations are one of the biggest drivers for Tagrisso resistance  Following the encouraging data seen from the TATTON study  in December 2018 AZN and HCM initiated the global registrational study SAVANNAH for Tagrisso refractory NSCLC patients  HCM s partnership with AZN remains crucial to the development of savolitinib and our forecast peak sales  Interim data are expected in mid 2020 and the strength of the data will determine whether a larger Phase III is required as part of the US regulatory submission package  although it could be sufficient for NDA filing 
Commercial platform profits reinvested in R D
HCM has multiple strings to its bow  Its China commercial platform division continues to deliver year on year revenue growth of 2   7  at CER  and net income growth of 3   9  at CER   Contributions from non consolidated JVs  primarily Shanghai Hutchison Pharma  SHPL  and Hutchison Baiyunshan  HBYS   are reported below the loss from operations line under US GAAP as equity in earnings of equity investee  net of tax  HCM receives the majority of profits generated from this division as dividends  which the company has reinvested in its innovation pipeline since inception  To date   423m has been reinvested in the business  HCM s non consolidated JV HBYS s vacant land  Plot 2  in Guangzhou remains for sale as part of the Guangzhou municipal government urban development scheme  HCM expects an auction value in excess of  100m  of which 40 50  would be paid to HBYS as compensation for return of the land use rights  We expect that half of this would make its way to HCM via special dividends and would likely be reinvested in the business  although this is not reflected in our forecasts given the uncertainty on timing  Exhibit 2 highlights HCM s objectives for existing assets spanning the breadth of its businesses in 2019 21 




Valuation




We value HCM at  5 7bn   6 99 share  vs  5 6bn previously  We make no changes to our product forecasts  we have trimmed R D costs for 2019  phasing into 2020  to reflect FY19 guidance  rolled forward our model and updated for FX and net cash of  237m at 30 June 2019 
We use a risk adjusted net present value  NPV  method to discount future cash flows for the innovation platform  IP   valuation of  4 050m   We use earnings based multiples for HCM s commercial platform  CP   subs and JVs   and applying a 20 4x multiple on our forecast 2019 net attributable profit  equity in earnings of equity investees  net of tax  for the JVs of  39 2m yields a valuation of  800 4m  Exhibit 3  
Financials
HCM reported consolidated group revenues of  102 2m in H119   0  as reported   5  CER  H118   102 2m  and group net loss of  45 4m  H118   32 7m   Depreciation of the Chinese yuan versus the US dollar has affected top line growth as reported in US dollars given the translation impact  as all revenues related to its China commercial platform  CP  business are generated in Chinese yuan 
CP reported consolidated sales of  90 2m   2  as reported   7  CER  H118   88 6m   Sales of non consolidated JVs SHPL and HBYS grew  2    8  CER  to  276 9m  H118   271 7m   Total consolidated net income from CP increased  3    9  at CER  to  27 7m  H118   26 9m   We forecast consolidated CP revenues of  154 2m in 2019 and  157 6m in 2020 
IP reported consolidated revenues of  12 0m in H119   5 5m of which was received from Lilly for Elunate manufacturing  service fee revenues and royalty income  compared to  13 6m in H118  In H119  IP reported a net loss of  63 8m  H118   52 9m   We forecast IP revenues of  28 7m in 2019 and  36 8m in 2020  largely driven by developmental royalties on sales on Elunate and service fees from partners 
Profit before tax and equity in earnings of equity investees at group level reported a loss of  68 3m in H119  vs a loss of  50 5m in H118   R D expenses increased significantly to  69 3m in H119   60 1m in H118   reflecting investment throughout the portfolio  expansion of the US and international clinical and regulatory operations  and establishment of the China oncology commercial infrastructure  S M expenses decreased to  7 5m in H119  vs  9 4m in H118  and administrative expenses increased to  18 8m  vs  14 5m in H118   For FY19  HCM has reduced its guidance for R D expenses to  130 170m from  160 200m and adjusted non GAAP group net cash flow excluding financing activities to  90 120m from  120 150m  The depreciation of the Chinese yuan has effectively reduced China R D expenses in US dollar terms  and start up costs for the global Phase II III registration studies for surufatinib and fruquintinib will move into 2020 
We now expect R D expenses to increase to  152 5m in 2019 and  190 0m in 2020  reported GAAP basis   reflecting the substantial need for investment in the burgeoning clinical trial programmes across the IP division  including the increased investment in China and global trials plus the initiation of combination strategies across the portfolio 
We forecast net losses at group level of  117 8m in 2019 and  147 6m in 2020  HCM reported a healthy cash position  with available cash resources of  383 6m  at 30 June 2019  at group level  cash and cash equivalents and short term investments of  237 3m  and unutilised bank borrowing facilities of  146 3m   Additionally  HCM s non consolidated joint ventures  SHPL  HBYS  and NSP  held  64 0m  at 30 June   HCM reported no debt at 30 June 2019 after paying down debt in H119  with the intention of drawing down debt from a facility with HSBC in H219  In terms of cash utilisation by operations  we forecast  99 2m in 2019 and  130 0m in 2020 ",2019-08-14,Edison,https://www.investing.com/analysis/otc-markets-group-a-year-of-investment-for-the-future-200454975,200454975
171346,392862,LLY,Agios Rides High On Tibsovo Sales Amid Acute Competition,opinion,On Aug 14  we issued an updated research report on Agios Pharmaceuticals  Inc    NASDAQ AGIO   The company s top line mainly consists of product revenues from the sale of its newly launched precision medicine Tibsovo  ivosidenib  and royalties plus milestone payments related to the sales of Idhifa  which is owned by its partner Celgene Corporation   NASDAQ CELG   Tibsovo was approved by the FDA last July for treating adult patients suffering relapsed or refractory acute myeloid leukemia  AML  with IDH 1 mutation  The drug is currently under review in the EU for the same indication Tibsovo generated sales of  13 7 million in the second quarter of 2019  reflecting a sequential surge of more than 50  Meanwhile  several label expansion studies on Tibsovo are currently underway  In May  the FDA approved the supplemental new drug application  sNDA  for Tibsovo in the first line setting  The nod came much earlier than the expected date of Jun 21 Also  in May  Tibsovo met the primary endpoint in a late stage study  which evaluated it for the previously treated IDH1 mutant cholangiocarcinoma also called bile duct cancer  Agios plans to file an sNDA to the FDA for including the above indication in Tibsovo s label by this year end  Notably  no treatment options are currently available for this disease  On approval  it can fuel sales growth for the drug In March  Agios achieved another goal when the FDA granted a Breakthrough Therapy designation to Tibsovo in combination with Celgene s Vidaza for treating the newly diagnosed AML in adult patients with an IDH 1 mutation  who are aged 75 and above and are ineligible for intensive chemotherapy Apart from Tibsovo  Agios has several interesting candidates in its portfolio that are in early to mid stage development targeting various cancers and other indications Agios  key pipeline candidate mitapivat is being developed to treat patients with  PK  deficiency  The company plans to close enrollment in two pivotal studies on mitapivat by 2019 end Agios plans to begin a registration enabling phase III study on another candidate vorasidenib for treating low grade glioma with an IDH1 mutation by this year end  Moreover  the company initiated dosing in the phase I dose escalation study on AG 636 for treating advanced lymphoma in the second quarter of 2019 Notably  AG 270 is being developed for the treatment of cancers carrying methylthioadenosine phosphorylase  MTAP  deleted tumors Although Agios is riding high with the success of Tibsovo of late and its pipeline candidates showing great progressing well  the company s heavy dependence on partner Celgene for royalty revenues remains a woe  Stiff competition from pharma giants is another headwind for the company as several other leading industry players like AstraZeneca   NYSE AZN    Eli Lilly   NYSE LLY    AbbVie  NYSE ABBV  and Roche have their candidates lined up for treating cancer and rare genetic metabolic disorders by targeting cellular metabolism Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/agios-rides-high-on-tibsovo-sales-amid-acute-competition-200455541,200455541
171347,392863,LLY,Hutchison China MediTech  Onwards And Upwards,opinion,"Hutchison China MediTech  Ltd  NASDAQ HCM  continues to make progress towards its global strategic aspirations  The interim results highlight the opportunities for Elunate  fruquintinib  capsules in China  with potential inclusion in China s exclusive NRDL list in Q419  and the breadth of clinical and regulatory catalysts that lie ahead for multiple R D assets  Surufatinib s China NDA submission is on track  Q419  and approval in NET would seal HCM s position as a premier  innovative  China based oncology company  The years 2021 22 are pivotal  partner AstraZeneca  AZN  could launch savolitinib in China for NSCLC  MET exon 14  and it could become HCM s first asset to launch globally  2022  in combination with Tagrisso for NSCLC  c Met  ve   Given the recent underperformance of the shares and the real potential for HCM to become a global oncology player  we believe it is appropriate to revisit the shares  We value HCM at  5 7bn 




Pipeline coming to fruition
Elunate is now being commercialized in China  third line CRC  by partner Eli Lilly  NYSE LLY   Lilly   a major inflection point for HCM and validation of its R D philosophy  While the early sales trajectory is notable  H119 in market of sales of  11 4m   the most interesting opportunity lies in inclusion on China s NRDL  as this would translate into automatic inclusion in all state funded hospitals  more eligible patients  and automatic reimbursement  albeit it at a lower price   Next for potential launch in China is surufatinib  launch for treatment of NET expected early 2021   In addition  an interim analysis of the pivotal China Phase III study  SANET p  in pancreatic NET is due in H120  which  if positive  could further widen its market potential in this area of unmet need 
Financials  Funded to key inflection points
HCM has reduced its FY19 R D expense guidance to  130 170m  from  160 200m   reflecting the depreciation of Chinese yuan versus the US dollar  China R D  and the phasing of global surufatinib and fruquintinib Phase IIb III trials  HCM reported available cash resources of  383 6m  which  combined with the net profit generation from the CP division  means it is well funded to key value inflection points  NDA submissions for savolitinib  surufatinib and fruquintinib in 2019 21  
Valuation   5 7bn   42 62 ADS 
We value HCM at  5 7bn   42 62 ADS  vs  5 6bn previously  We make no changes to our product forecasts  but have trimmed R D costs for 2019  phasing costs into 2020  to reflect FY19 guidance  rolled forward our model  and updated for FX and net cash of  237 3m at 30 June 2019 
Business description
Hutchison China MediTech is an innovative China based biopharmaceutical company targeting the global market for novel  highly selective oral oncology and immunology drugs  Its established commercial platform business continues to expand its outreach 
Global aspirations
HCM s recent share price underperformance provides an opportunity to revisit the investment case  We believe the long term investment case is solid  with multiple near term catalysts  regulatory filing and potential approval for surufatinib and savolitinib  as HCM successfully launches numerous assets to market   2020 21 and beyond  in China and internationally  Its broad mid  to late stage innovation platform  IP  will translate into diverse global revenue streams with a multitude of other compounds coming to the fore from HCM s established and proven innovative R D platform  Existing partnering deals for savolitinib and fruquintinib support the investment case as milestones and royalties on sales continue to bolster the P L  HCM has global strategic aspirations  and it is only a matter of when rather than if its aspirations are met  in our view  HCM continues to invest in expanding its global innovation organization  it now has  440 scientific personnel based in China and the US  Shanghai  Suzhou and New Jersey  




CK Hutchison Holdings  CKH  completed a secondary offering of ADSs in July 2019  which has reduced its holding to 51 15   from 60 2  previously   We see this as a significant positive for HCM as it increases the free float  potentially leading to better liquidity  We note that this had no effect on shares in issue and does not dilute any current shareholders  An eventual listing on SEHK will be determined by a number of factors including  but not limited to  management decisions and market conditions  In our view  a capital raise on existing markets  AIM Nasdaq  is still likely in the next 24 months  However  cash resources as last reported  30 June 2019  of  383 6m are more than sufficient to fund HCM to key inflection points  NDA submissions for savolitinib  surufatinib and fruquintinib in 2019 21   HCM could explore non dilutive finance options such as divesting non core commercial platform  CP  assets  Exhibit 1 highlights the plethora of clinical and regulatory catalysts ahead  For more details  see our outlook note  An emerging global biopharma 
Elunate early sales encouraging  NRDL inclusion is key
The launch of Elunate  fruquintinib capsules  for metastatic colorectal cancer  third line and above  by partner Lilly was a defining moment for HCM  as it was the first of its IP assets to launch in China  and the first China discovered and developed new drug for oncology to have full approval and reach the market  HCM reported H119 royalties of  1 7m and  3 0m of sales of Elunate manufactured by HCM for Lilly  The reported  1 7m royalties translates into  11 4m Elunate end user sales in H119  as reported by Lilly 
At the interim results  HCM presented data on the sales evolution of oncology drugs by its international and domestic peers  A key inflection in sales growth is inclusion on China s National Reimbursement Drug List  NRDL   which will define the opportunity for full scale reimbursement nationally  albeit on lower pricing  discount to be agreed by Eli Lilly  NYSE LLY  and China s central government   A fourfold ramp in the second full year from launch would require us to revisit our overall peak sales expectations  Inclusion on the NRDL is expected in Q419  Elunate has been added to two regional reimbursement lists in China during the last six months  Zhuhai and Shanghai   which highlights that Elunate s utility in third line CRC has been recognized at a local level 
Elunate s next China development focus is on Phase III gastric cancer  FRUTIGA   for which approval could occur in 2021 22  Life cycle management and extending the labeled use to other solid tumor types will expand Elunate s commercial opportunity further  The global development program is underway in colorectal cancer  with Phase Ib enrolling patients in the US  HCM has started planning the global Phase II III US EU registration trial  starting in 2020  in third fourth line mCRC in patients who are resistant or intolerant to Bayer s Stivarga  It has filed the FALUCA data for publication  potentially at ESMO 2019 or WCLC 2019  the data should shed light on the failure of fruquintinib monotherapy to meet the overall survival  OS  endpoint in third line non small cell lung carcinoma  NSCLC   having demonstrated statistically significant improvement in all secondary efficacy endpoints 
Surufatinib next in line for China launch
Surufatinib  previously known as sulfatinib  could be the first of HCM s non partnered assets to reach the China market in early 2021  NDA submission expected in late 2019   The strategy for surufatinib was recently validated as positive interim data were announced in the SANET ep Phase III trial testing surufatinib in non pancreatic NET China patients  This was based on the trial meeting its primary endpoint of progression free survival  PFS  at the interim analysis and the trial was unblinded a year ahead of schedule 
NETs are cancers that arise out of cells of the endocrine and nervous systems  predominately the digestive and respiratory tracts  While the current prevalence of NET in the US is  141 000 patients  incidence of  19 000 new cases per year  source    current treatment modalities are limited to subsets of NET with no broadly effective drugs across the NET spectrum  HCM believes that actual incidence of NET in China could be higher than the reported incidence of 67 600  and prevalence could be even greater once an effective broad spectrum treatment becomes available  Expanding the treatment paradigm could improve diagnosis rates and increase eligible patient numbers  Surufatinib could improve on the profiles of existing NET treatments  including somatostatin based treatments and kinase inhibitor therapies  such as Afinitor and Sutent   Broad spectrum use will yield commercial success if it can be used for treating the broad base of NET patients  An interim analysis for the pivotal China Phase III study in pancreatic NET SANET p  is due at H120  which  if positive  could further widen its market potential in this area of large unmet need 
A US Phase Ib II trial in pancreatic NET and biliary tract cancer has completed enrolment of NET patients  An end of Phase II meeting with the FDA is planned for Q419  to discuss the Phase III US EU registration study which HCM expects to start in Q120  HCM retains full worldwide rights to surufatinib 
Savolitinib could coat tail Tagrisso
An estimated 2 3  of newly diagnosed NSCLC patients have a specific mutation known as MET Exon 14 skipping  Exon 14 of the MET gene is not functioning or deleted   leading to c Met over expression  In China  HCM estimates this to be 10 000 patients  A registrational Phase II clinical trial is underway  enrolment complete  in patients who have progressed on prior chemotherapy  or are unable to tolerate additional rounds of chemotherapy  Although the patient size is relatively small  this indication could be savolitinib s first China NDA submission in 2020 and its first monotherapy indication in the region  In the longer term in China  we believe a savolitinib plus Tagrisso combination will expand use in other subsets of NSCLC 
In the field of lung cancer  AZN s Tagrisso is raising the bar as it moves into the first line setting in EGFR mutation positive NSCLC  reporting sales of  1 41bn in H119  Savolitinib s largest opportunity could be in combination with Tagrisso in EGFRm MET  NSCLC patients as MET mutations are one of the biggest drivers for Tagrisso resistance  Following the encouraging data seen from the TATTON study  in December 2018 AZN and HCM initiated the global registrational study SAVANNAH for Tagrisso refractory NSCLC patients  HCM s partnership with AZN remains crucial to the development of savolitinib and our forecast peak sales  Interim data are expected in mid 2020 and the strength of the data will determine whether a larger Phase III is required as part of the US regulatory submission package  although it could be sufficient for NDA filing 
Commercial platform profits reinvested in R D
HCM has multiple strings to its bow  Its China commercial platform division continues to deliver year on year revenue growth of 2   7  at CER  and net income growth of 3   9  at CER   Contributions from non consolidated JVs  primarily Shanghai Hutchison Pharma  SHPL  and Hutchison Baiyunshan  HBYS   are reported below the loss from operations line under US GAAP as equity in earnings of equity investee  net of tax  HCM receives the majority of profits generated from this division as dividends  which the company has reinvested in its innovation pipeline since inception  To date   423m has been reinvested in the business  HCM s non consolidated JV HBYS s vacant land  Plot 2  in Guangzhou remains for sale as part of the Guangzhou municipal government urban development scheme  HCM expects an auction value in excess of  100m  of which 40 50  would be paid to HBYS as compensation for return of the land use rights  We expect that half of this would make its way to HCM via special dividends and would likely be reinvested in the business  although this is not reflected in our forecasts given the uncertainty on timing  Exhibit 2 highlights HCM s objectives for existing assets spanning the breadth of its businesses in 2019 21 




Valuation




We value HCM at  5 7bn   42 62 ADS  vs  5 6bn previously  We make no changes to our product forecasts  we have trimmed R D costs for 2019  phasing into 2020  to reflect FY19 guidance  rolled forward our model and updated for FX and net cash of  237m at 30 June 2019 
We use a risk adjusted net present value  NPV  method to discount future cash flows for the innovation platform  IP   valuation of  4 050m   We use earnings based multiples for HCM s commercial platform  CP   subs and JVs   and applying a 20 4x multiple on our forecast 2019 net attributable profit  equity in earnings of equity investees  net of tax  for the JVs of  39 2m yields a valuation of  800 4m  Exhibit 3  
Financials
HCM reported consolidated group revenues of  102 2m in H119   0  as reported   5  CER  H118   102 2m  and group net loss of  45 4m  H118   32 7m   Depreciation of the Chinese yuan versus the US dollar has affected top line growth as reported in US dollars given the translation impact  as all revenues related to its China commercial platform  CP  business are generated in Chinese yuan 
CP reported consolidated sales of  90 2m   2  as reported   7  CER  H118   88 6m   Sales of non consolidated JVs SHPL and HBYS grew  2    8  CER  to  276 9m  H118   271 7m   Total consolidated net income from CP increased  3    9  at CER  to  27 7m  H118   26 9m   We forecast consolidated CP revenues of  154 2m in 2019 and  157 6m in 2020 
IP reported consolidated revenues of  12 0m in H119   5 5m of which was received from Lilly for Elunate manufacturing  service fee revenues and royalty income  compared to  13 6m in H118  In H119  IP reported a net loss of  63 8m  H118   52 9m   We forecast IP revenues of  28 7m in 2019 and  36 8m in 2020  largely driven by developmental royalties on sales on Elunate and service fees from partners 
Profit before tax and equity in earnings of equity investees at group level reported a loss of  68 3m in H119  vs a loss of  50 5m in H118   R D expenses increased significantly to  69 3m in H119   60 1m in H118   reflecting investment throughout the portfolio  expansion of the US and international clinical and regulatory operations  and establishment of the China oncology commercial infrastructure  S M expenses decreased to  7 5m in H119  vs  9 4m in H118  and administrative expenses increased to  18 8m  vs  14 5m in H118   For FY19  HCM has reduced its guidance for R D expenses to  130 170m from  160 200m and adjusted non GAAP group net cash flow excluding financing activities to  90 120m from  120 150m  The depreciation of the Chinese yuan has effectively reduced China R D expenses in US dollar terms  and start up costs for the global Phase II III registration studies for surufatinib and fruquintinib will move into 2020 
We now expect R D expenses to increase to  152 5m in 2019 and  190 0m in 2020  reported GAAP basis   reflecting the substantial need for investment in the burgeoning clinical trial programs across the IP division  including the increased investment in China and global trials plus the initiation of combination strategies across the portfolio 
We forecast net losses at group level of  117 8m in 2019 and  147 6m in 2020  HCM reported a healthy cash position  with available cash resources of  383 6m  at 30 June 2019  at group level  cash and cash equivalents and short term investments of  237 3m  and unutilized bank borrowing facilities of  146 3m   Additionally  HCM s non consolidated joint ventures  SHPL  HBYS  and NSP  held  64 0m  at 30 June   HCM reported no debt at 30 June 2019 after paying down debt in H119  with the intention of drawing down debt from a facility with HSBC in H219  In terms of cash utilization by operations  we forecast  99 2m in 2019 and  130 0m in 2020 ",2019-08-15,Edison,https://www.investing.com/analysis/hutchison-china-meditech-onwards-and-upwards-200455320,200455320
171348,392864,LLY,Gilead s  GILD  Filgotinib MAA For RA Accepted In Europe,opinion,"Gilead Sciences   NASDAQ GILD   and partner Galapagos   NASDAQ GLPG   announced that the European Medicines Agency   EMA   has accepted their marketing authorization application   MAA   related to JAK inhibitor candidate  filgotinib  The MAA is seeking approval of the drug as a treatment for rheumatoid arthritis   RA   in Europe The MAA includes data from the phase III clinical program  FINCH  which comprises three studies  Data from the studies have shown that once daily treatment with filgotinib improved clinical signs and symptoms  and achieved low disease activity and remission  The candidate also inhibited structural damage in different sub populations of RA patients In July  the company announced its plan to submit a new drug application to the FDA for filgotinib  seeking approval in similar indication  by the end of the year Shares of Gilead have increased 0 5  so far this year against the  s decline of 3 4  The 52 week phase III study  FINCH 1  evaluated filgotinib in comparison with AbbVie s   NYSE ABBV   Humira  adalimumab  or placebo on a stable background dose of methotrexate   MTX   in patients with prior inadequate response to MTX  In March  the company announced 24 week data from the study  The study achieved its primary endpoint for both doses of filgotinib   100 mg and 200 mg   measured by response on the scale of American College of Rheumatology   ACR    The drug demonstrated significantly higher ACR20 50 70 responses compared to placebo in patients with prior inadequate methotrexate response  The higher dose of filgotinib also demonstrated non inferiority to Humira In the same month  the company also announced 24 week data from the ongoing phase III FINCH 3 study  The study evaluated 100 mg or 200 mg doses of filgotinib in combination with MTX and as monotherapy in MTX naive patients  Both doses of filgotinib in combination with MTX demonstrated significantly higher ACR20 50 70 responses than MTX alone  The study achieved its primary endpoint  as higher percentage of patients achieved the ACR20 response at week 24 for filgotinib 200 mg plus MTX and filgotinib 100 mg plus MTX compared with MTX alone In September 2018  Gilead announced top line data from the phase FINCH 2 study  which evaluated filgotinib in patients receiving conventional  synthetic disease modifying anti rheumatic drug  DMARD  and showing prior inadequate response intolerance to biologic DMARD  The study achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20  response  ACR20  at week 12   Both doses   100 mg and 200 mg   achieved significantly higher ACR20 50 70 responses than placebo in patients with active RA and prior inadequate response to biologic agents In July  Gilead  its collaboration with Galapagos by signing a 10 year global research and development agreement for an upfront payment of  3 95 billion and  1 1 billion of equity investment in the latter  Galapagos is also eligible to receive a significant amount in milestone payments  The deal will provide Gilead exclusive product license and option rights to develop and commercialize an innovative portfolio of compounds  which includes six molecules in clinical stage development  more than 20 preclinical programs and a proven drug discovery platform in all countries outside Europe Notably  Eli Lilly   NYSE LLY   received approval for Olumiant as a treatment for RA last year  Several other pharma companies are developing drugs for inflammation indications  including RA Gilead Sciences  Inc  Price
    Zacks RankGilead currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/gileads-gild-filgotinib-maa-for-ra-accepted-in-europe-200455906,200455906
171349,392865,LLY,Pharma Stock Roundup  Pipeline Regulatory Updates From JNJ  LLY  AZN  RHHBY,opinion,"This week  the FDA granted approval to Roche s   OTC RHHBY   tumor agnostic medicine  Rozlytrek  entrectinib   and J J s   NYSE JNJ   tuberculosis tablet Sirturo for adolescent patients  Meanwhile  Lilly   NYSE LLY   and AstraZeneca   NYSE AZN   announced data from studies on psoriasis drug Taltz and cancer drugs Tagrisso and Lynparza  respectively Recap of the Week s Most Important StoriesRoche s Personalized Medicine Rozlytrek Gets FDA Nod  The FDA granted approval to Roche s personalized medicine Rozlytrek  entrectinib  for patients with ROS1 positive  metastatic non small cell lung cancer  NSCLC  and neurotrophic tyrosine receptor kinase  NTRK  fusion positive  advanced recurrent solid tumors  Per Roche  Rozlytrek is the first tumour agnostic medicine to be approved in the United States that selectively targets both ROS1 and NTRK fusions  Rozlytrek has also shown responses in these two rare types of cancer that have spread to the brain  Japan was the first country to grant approval to Rozlytrek in June J J s Sirturo Gets FDA Approved for Young TB Patients  J J s pulmonary multidrug resistant  Sirturo  bedaquiline  was approved by the FDA for the treatment of adolescent patients  12 to less than 18 years of age and weighing at least 30 kgs   The drug is already approved for use in adults and is being evaluated in a phase II pediatric research and development program in different age groups Lilly s Taltz Shows Superiority Over J J s Tremfya  Lilly announced top line data from a phase IV IXORA R study  a  comparison between its plaque psoriasis drug Taltz and J J s new drug  Tremfya  guselkumab   Data from the study demonstrated that Taltz helps more plaque psoriasis patients achieve 100  skin clearance compared to Tremfya at week 12  This was measured by the proportion of patients who achieve complete skin clearance  in other words  100  improvement from their baseline as measured by Psoriasis Area Severity Index  PASI  100 score   the study s primary endpoint AstraZeneca Tagrisso Improves Overall Survival in First Line Study  AstraZeneca s Tagrisso significantly improved overall survival  OS  in the phase III FLAURA study for first line treatment of adult patients with metastatic NSCLC whose tumors have EGFR mutations  Tagrisso was approved for this indication based on progression free survival  PFS  data from the same study in the United States and EU in 2018  OS was the secondary endpoint in the study and AstraZeneca expects to present this data at an upcoming medical meeting A phase III study  PAOLA 1  evaluating AstraZeneca and Merck s   NYSE MRK   PARP inhibitor  Lynparza  for a broader advanced ovarian cancer patient population met the primary endpoint  The study evaluated Lynpazra as a first line maintenance treatment in combination with Roche s Avastin  bevacizumab  versus Avastin alone in women with advanced ovarian cancer with or without BRCA gene mutations  Data from the study showed that treatment with Lynparza plus Avastin led to a statistically significant and clinically meaningful improvement in progression free survival  PFS  in the intent to treat  ITT  population versus Avastin alone  Lynparza is presently approved as first line maintenance treatment in BRCAm advanced ovarian cancer following response to platinum based chemotherapy Meanwhile  the FDA granted Breakthrough Therapy Designation  BTD  to Calquence for chronic lymphocytic leukemia  CLL  as a monotherapy treatment  Calquence is presently marketed for previously treated mantle cell lymphoma  MCL   However  AstraZeneca expects to file regulatory applications for Calquence to get approval for the CLL indication  in frontline and the relapsed recurrent disease setting   which includes a much larger patient population base  later this year The NYSE ARCA Pharmaceutical Index declined 2 2  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return 
Here is how the seven major stocks performed in the last five trading sessions 
All the stocks were in the red last week expect AstraZeneca  0 1    Pfizer   NYSE PFE   saw the steepest decline  6 4  In the past six months  AstraZeneca has been the biggest gainer  8 0   while Pfizer declined the most  18 6    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pipelineregulatory-updates-from-jnj-lly-azn-rhhby-200455933,200455933
171350,392866,LLY,Bayer Sells Animal Health Division To Elanco  Now What ,opinion,"On Tuesday  Bayer   OTC BAYRY   announced the sale of its animal health division to American competitor Elanco   NYSE ELAN    for a net price of  7 6 billion  The deal is expected to close in mid 2020 after regulatory approval 
Bayer will receive  5 4 billion in cash and  2 3 billion of stake in Elanco  which it plans to sell off gradually  The combined company will have an estimated market share of about 13   making it the second largest animal health firm by revenue  behind only U S  rival Zoetis   NYSE ZTS    which was owned by Pfizer   NYSE PFE   until 2013 
Bayer s Restructuring
Bayer is in the middle of a lengthy corporate restructuring that was initiated as a result of its June 2018 acquisition of Monsanto  NYSE MON   The firm now is involved in a class action lawsuit due to claims that the active ingredient  glyphosate  in its popular weed killer Roundup causes cancer  There are currently about 18 000 claims in the suit 
Bayer has responded to mounting pressure from investors to prepare for what looks likely to be large fallout from these Roundup lawsuits  Therefore  it has decided to restructure and spin off certain divisions to raise the capital necessary  as it already holds  40 billion in debt  So far  Bayer has spun off its Coppertone and Dr  Scholl s divisions  raising over  1 billion  with its animal health division the latest to be let go  Bayer s goal is to focus on its core agricultural and pharmaceutical businesses going forward 
Bayer s Financial Outlook
Bayer currently holds a Zacks Rank  3  Hold   but has a forward P E ratio much lower than the large cap pharma industry  Our Zacks Consensus Estimates show earnings for this quarter at  0 46 per share  no change over a year ago  Full year estimates call for  1 87 per share  for a 6 86  increase over last year  Next year  the company s earnings are projected to grow another 13 37  over 2019  showing predicted growth from consolidation plans 
Bayer stock is up 4 6  YTD  despite continued hits from the uncertainty surrounding the Roundup suit  BAYRY has also outperformed broader large cap pharma market s 1 5  loss  which consists of firms such as Abbvie   NYSE ABBV    Merck   NYSE MRK    and Lilly   NYSE LLY   

Elanco s Financial Outlook
Elanco stock is down 5 5  YTD  to lag the large cap pharma market  It is  however  above the broader medical care market industry s 7 2  drop  Elanco is also a Zacks Rank  3  Hold  at the moment  with earnings estimates having been revised marginally downward in the past 60 days 
Earnings estimates show a current quarter shrinkage of 10 34  to  0 26 per share  Next quarter is projected to come in at no change from last year  along with a full year estimate of  1 08 per share  an 8 47  decline  However  fiscal 2020 is predicted to see earnings recover 16 36  to  1 26 for the full year  Elanco has consistently reported earnings beats for the past 4 quarters  with an average surprise of 13 43   Therefore  earnings could come in higher 
Bottom Line
This deal is a necessity for Bayer  as the company needs cash and wants to focus on its two core areas  It will likely help Elanco significantly by giving new products and increasing market share and power  Interested investors need to look for how revenue and earnings for both companies change if and when the deal is cleared by authorities 
Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as theyspend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks hasidentified 5 stocks that could soar in response to the powerful demand  One industry insider describedthe future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/bayer-sells-animal-health-division-to-elanco-now-what-200456909,200456909
171351,392867,LLY,Merck to cut 1 800 U S  sales jobs  add 960 in chronic care,news,By Deena Beasley  Reuters    Drugmaker Merck   Co Inc  N MRK   moving to a new sales team structure in the United States  plans to cut 1 800 sales positions  while adding 960 jobs to a new chronic care sales force  the company said on Friday  Three of Merck s U S  sales teams will be cut  primary care  disease focused endocrinology and hospital chronic care  spokeswoman Claire Gillespie said in an emailed statement   The aim is  to better support changes in our business in the United States   she said  The spokeswoman said Merck s new chronic care team will focus on diabetes drug Januvia  as well as other primary care products such as sleep medication Belsomra  and products for respiratory conditions and women s health  She noted that Merck s pipeline also has potential new candidates in primary care   for Alzheimer s disease  asthma  chronic cough and heart failure   Merck s stock was little changed in midday trading on the New York Stock Exchange  at  63 78  Earlier this month  Merck said it would not seek regulatory approval for once promising cholesterol drug anacetrapib after disappointing trial results  Last month  the drugmaker discontinued developing an experimental drug combination for chronic hepatitis C  as competition rises and patient population shrinks  The company has previously written off an earlier hepatitis C program  Other pharmaceutical companies have also downsized  Eli Lilly   Co  N LLY  earlier this month said it would lay off about 8 percent of its employees as the drugmaker  which has suffered setbacks over the past year in the development of two potential blockbuster drugs  works to cut costs   Merck said none of the jobs being eliminated are being moved outside of the United States ,2017-10-20,Reuters,https://www.investing.com/news/stock-market-news/merck-to-cut-1800-us-sales-jobs-add-960-jobs-in-chronic-care-545048,545048
171352,392868,LLY,Eli Lilly Q3 revenues up 9   non GAAP EPS up 19   revises guidance,news,"Eli Lilly  LLY  Q3 results  Revenues   5 658M   9 0    Operating Income   605 5M   35 8    Net Income   555 6M   28 6    EPS   0 53   27 4    Non GAAP EPS   1 05   19 3   
Key Product Sales  Humalog   696 2M   9    Cialis   564 9M   4    Alimta   514 5M   10    Forteo   441 7M   13    Humulin   300 5M   7    Cymbalta   183 2M   42    Erbitux   159 1M   11 9    Erbitux   163 5M   11    Strattera   137 1M   31    Zyprexa   140 6M   6    Effient   55 9M   56   
New Pharmaceutical Products  Trulicity   527 7M   117    Cyramza   196M   23    Taltz   151 3M  Jardiance   127 2M   168    Basaglar   145 7M  Lartruvo   54 5M  Olumiant   16 2M  Portrazza   2 3M   57   
2017 Guidance  Total Revenues   22 4B   22 7B from  22B   22 5B  EPS   1 73   1 83 from  2 51   2 61  Non GAAP EPS   4 15   4 25 from  4 10   4 20 
Shares are up 2  premarket on light volume 
Now read ",2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/eli-lilly-q3-revenues-up-9-nongaap-eps-up-19-revises-guidance-546541,546541
171353,392869,LLY,Piper defends Lilly  says selloff overdone,news,Piper Jaffray says today s down move in Eli Lilly  LLY  2 4   is  clear buying opportunity  considering its attractive long term growth prospects  Analyst Richard Purkiss believes investor fears are  overblown  after management stated that it does intend to challenge  Sanofi   PA SASY  s  SNY  1 3   Humalog  insulin lispro injection  biosimilar  He adds that the company s potential spinout of its animal health business makes sense  Overweight  107  Source  BloombergNow read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/piper-defends-lilly-says-selloff-overdone-546860,546860
171354,392870,LLY,Trump nominates Azar to head HHS,news,In a tweet  President Trump announces that he has nominated Alex Azar as the next HHS Secretary  He is the former chief of Eli Lilly s  NYSE LLY  U S  operations and a former general counsel of HHS ETFs  GRX  THW  IXJ  BME IBB XBI PJP IHE XPH PPHNow read ,2017-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/trump-nominates-azar-to-head-hhs-849712,849712
171355,392871,LLY,Trump taps ex pharma executive Azar as U S  health secretary,news,"By Caroline Humer and Yasmeen Abutaleb WASHINGTON  Reuters    President Donald Trump on Monday said he is nominating former pharmaceutical executive and industry lobbyist Alex Azar to serve as U S  Health and Human Services secretary  saying Azar would push to lower the price of medicines  Republicans as well as the lead lobby groups for drugmakers and health insurers welcomed Azar as an experienced hand who could help overhaul the world s most costly healthcare system   But several Democratic lawmakers questioned whether he would tackle changes that cut into pharmaceutical profits  If confirmed  Azar also would take the lead in implementing Trump s campaign promise to dismantle the Affordable Care Act  former Democratic President Barack Obama s 2010 healthcare overhaul that extended health insurance to 20 million Americans  Democratic Representative Elijah Cummings said Trump s pick of a former pharmaceutical executive was  like a fox guarding the hen house   Trump  who is in the Philippines on a diplomatic trip  announced the nomination on Twitter by saying Azar would  be a star for better healthcare and lower drug prices   Trump s first health secretary  former U S  Representative Tom Price  resigned in September amid a public furor over his use of expensive taxpayer funded private charter jets for government travel   Azar worked at Eli Lilly  N LLY  and Co for a decade  including five years as president of its Lilly USA unit  and left the company in January  according to his LinkedIn  NYSE LNKD  page   Cummings and Senator Bernie Sanders  a 2016 Democratic presidential candidate  last year called for a federal probe into whether Eli Lilly  Sanofi SA  PA SASY   Merck   Co Inc  N MRK  and  Novo Nordisk  A S  CO NOVOb  colluded to set prices on insulin and other diabetes drugs   This is a slap in the face to millions of Americans who are waiting on  the President  to take action to lower drug prices   Cummings wrote on Twitter  He also pointed to Eli Lilly raising drug prices by double digits while Azar was an executive at the company  Azar  though a spokesman  declined to comment  Other Democrats were more cautious in their response to Trump s announcement  with Senator Chuck Schumer calling for the health agency to turn over a new leaf with Azar  Democratic Senator Patty Murray  who has been working on bipartisan healthcare legislation  tweeted   Given Alex Azar s professional background  there are concerns on whether he can fairly execute any significant effort to lower drug prices for patients   families   Republicans were supportive with Senate health committee head Lamar Alexander of Tennessee describing Azar as a qualified  experienced nominee  Azar also drew praise from PhRMA  the largest pharmaceutical industry trade group and America s Health Insurance Plans  the key lobbyist for the insurer industry  Azar served several years on the board of directors of the Biotechnology Innovation Organization  a drug industry lobbying group  and earlier was general counsel and deputy secretary for Health and Human Services under former Republican President George W  Bush  Patient advocacy organization Public Citizen said Azar has made it clear he is opposed to measures  to restrain prescription companies  profiteering and limit improper marketing  and that he favors weaker safety approval standards  As head of HHS  Azar would have oversight responsibility for the U S  Food and Drug Administration  which regulates the drug industry including approving new treatments   
Azar s nomination must be approved by the U S  Senate  which is controlled by Trump s fellow Republicans ",2017-11-13,Reuters,https://www.investing.com/news/politics-news/trump-says-will-nominate-expharma-executive-azar-as-health-secretary-849646,849646
171381,392897,LLY,FDA OK s Novo s fast acting insulin Fiasp,news,Reuters reports that the FDA has approved  Novo Nordisk   CO NOVOb  s  NVO  0 2   fast acting insulin aspart  branded as Fiasp  The company says it is designed to work faster than Eli Lilly s  LLY  0 2   Humalog  insulin lispro injection  and its own NovoLog  insulin aspart injection  Fiasp was approved in Europe in January Previously  Novo Nordisk refiles U S  marketing application for fast acting insulin aspart  March 29 Now read ,2017-09-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-novos-fastacting-insulin-fiasp-534746,534746
171382,392898,LLY,Lilly prevails in challenge to patent covering vitamin regimen for lung cancer med Alimta  shares up 1  after hours,news,Eli Lilly  NYSE LLY  is up 1  after hours in response to the news of a favorable ruling in a challenge to its patented vitamin regimen for lung cancer drug Alimta  pemetrexed for injection  In an inter partes review initiated by Neptune Generics and Novartis   NYSE NVS  Sandoz  the USPTO s Patent Trial and Appeal Board  PTAB  found that all claims of the patent covering the vitamin regimen are valid  If upheld through all remaining challenges  Alimta will maintain U S  exclusivity until May 2022 Now read ,2017-10-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/lilly-prevails-in-challenge-to-patent-covering-vitamin-regimen-for-lung-cancer-med-alimta-shares-up-1-after-hours-537626,537626
171383,392899,LLY,Lilly s breast cancer med abemaciclib flunks late stage lung cancer study  shares slip 2  premarket,news,Eli Lilly  NYSE LLY  is off 2  premarket on light volume in response to its announcement of a negative outcome from its Phase 3 JUNIPER study evaluating Verzenio  abemaciclib  for the treatment of KRAS positive advanced non small cell lung cancer  NSCLC   The study failed to achieve the primary endpoint of overall survival  OS  due  at least in part  to the control arm showing a higher than expected OS  Secondary endpoints of progression free survival  PFS  and overall response rate  ORR  demonstrated evidence of monotherapy activity The results will be submitted for presentation at a medical meeting next year Abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes CDK4 and CDK6  The FDA approved it in September for the treatment of HR  HER2  breast cancer when combined with AstraZeneca s Faslodex  fulvestrant  Previously  FDA OKs Lilly s breast cancer drug abemaciclib  shares up 1   Sept  28 Now read ,2017-10-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/lillys-breast-cancer-med-abemaciclib-flunks-latestage-lung-cancer-study-shares-slip-2-premarket-539254,539254
171398,392914,LLY,Eli Lilly  LLY  Tops Q2 Earnings Estimates,opinion,"Eli Lilly  LLY  came out with quarterly earnings of  1 50 per share  beating the Zacks Consensus Estimate of  1 46 per share  This compares to earnings of  1 50 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 74   A quarter ago  it was expected that this drugmaker would post earnings of  1 32 per share when it actually produced earnings of  1 33  delivering a surprise of 0 76  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Lilly  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  5 64 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 0 29   This compares to year ago revenues of  6 36 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Lilly shares have lost about 6 1  since the beginning of the year versus the S P 500 s gain of 20 5  
What s Next for Lilly 
While Lilly has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Lilly was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 45 on  5 50 billion in revenues for the coming quarter and  5 66 on  22 11 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 18  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-tops-q2-earnings-estimates-200446990,200446990
171399,392915,LLY,Pharma Stock Roundup  PFE  MRK  LLY Q2 Earnings  Upjohn MYL Merger,opinion,"The strong earnings performance of pharma companies continued this week with AbbVie   NYSE ABBV    Merck   NYSE MRK   and Lilly   NYSE LLY   delivering better than expected results and also boosting their guidance for the year  Pfizer   NYSE PFE   and Sanofi   NASDAQ SNY   reported mixed results  Pfizer also announced plans to spin off its Upjohn unit and merge it with generic drugmaker Mylan  NASDAQ MYL  to create a leading generic pharmaceutical company  Meanwhile  the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency   EMA   gave positive recommendations to grant marketing approval to several drugs this week Recap of the Week s Most Important StoriesEarnings Reports Continue to be Impressive  Lilly   and Merck beat estimates for both earnings and sales in the second quarter  While  and Sanofi beat earnings estimates  they fell short of the consensus mark for revenues AbbVie and  raised their full year outlook for both earnings and sales on a strong first half performance  Pfizer  however  lowered its guidance for full year sales and earnings to reflect the formation of the Consumer Healthcare  CHC  JV with Glaxo and the completion of Array BioPharma  ARRY  acquisition  Pfizer announced completion of the formation of the CHC JV with Glaxo and the closing of the Array acquisition this week  raised its earnings guidance  for the second time this year  while keeping the revenue guidance intact   also upped its earnings growth expectations for the yearPfizer to Merge Off Patent Unit  Upjohn with Mylan to Form New Company  Pfizer announced a definitive agreement to spin off its Upjohn unit and combine it with generic drugmaker Mylan in a Reverse Morris Trust transaction to create a new generic pharmaceutical company  Together Mylan and Upjohn  with brands like EpiPen  Lipitor and Viagra  expect to generate revenues between  19 billion and  20 billion Per the terms of the deal  each Mylan share would be converted into one share of the new company  Pfizer shareholders will own 57  of the combine new company while Mylan s stockholders will get a 43  stake in the new entity  Pfizer s current head of the Upjohn unit  Michael Goettler will become the CEO of the new company while Mylan s current CEO  Heather Bresch will retire when the deal closes  The deal is expected to close by mid 2020  The deal has been approved by the boards of both the companies  From Mylan s perspective  the deal is considered to be well valued  However  Pfizer s stock declined the day the deal was announced indicating that investors were probably not impressed by it CHMP Nod to Several Drugs  The CHMP gave a positive opinion recommending approval of Roche s Tecentriq in combination with carboplatin and Celgene s Abraxane for the first line treatment of metastatic non squamous non small cell lung cancer  The cancer immunotherapy regimen is under review for a similar indication in the United States with a decision expected in September this year  The CHMP also recommended approving Bayer s precision oncology treatment  Vitrakvi for the treatment of locally advanced or metastatic solid tumors that have a rare genetic mutation called an NTRK gene fusion  Vitrakvi was approved by the FDA in November last year Bristol Myers  label expansion application looking for approval of a Empliciti based combination for multiple myeloma patients who have relapsed or are refractory to prior therapies was also granted a positive opinion by the CHMP  Novartis also received positive CHMP opinion for label expansion of eye drug Lucentis for the treatment of preterm infants with retinopathy of prematurity  a disease causing visual impairment and blindness Merck also gained a CHMP nod for an application for label expansion of its antibacterial medicine  Zerbaxa for two types of pneumonia infections   hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  The CHMP also gave a positive opinion recommending approval of Merck s blockbuster PD L1 inhibitor Keytruda in combination with Pfizer s Inlyta  axitinib  for the first line treatment of advanced renal cell carcinoma  While the authority to grant final approvals is with the European Commission  it generally follows the CHMP s recommendation and is expected to give its decisions in a few months FDA Approves Merck s Keytruda for Advanced Esophageal Cancer   The FDA granted approval to Merck s Keytruda as a monotherapy  for previously treated patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD L1  The approval was based on data from the KEYNOTE 181 study Meanwhile  Keytruda in combination with chemotherapy met one of the dual primary endpoints in a pivotal phase III study  KEYNOTE 522  in patients with triple negative breast cancer  regardless of PD L1 status  Data from the study demonstrated that Keytruda plus chemotherapy led to a statistically significant improvement in pathological complete response rate   the primary endpoint   as a neoadjuvant therapy in such patients  The study has another primary endpoint of event free survival  EFS   Per the recommendation of the independent Data Monitoring Committee  the study will continue to evaluate the EFS endpoint Glaxo Files for Long Acting Two Drug HIV Regimen in EU  Glaxo s   NYSE GSK   HIV subsidiary  ViiV Healthcare filed a marketing application in the EU looking for approval of long acting  two drug regimen of ViiV Healthcare s cabotegravir and J J s Edurant  rilpivirine   The filing was based on data from the phase III ATLAS study  which showed that the two drug regimen  injected once a month  had similar efficacy to a standard of care  daily  oral three drug regimen at week 48  A NDA was filed in the United States in April this year The European Commission granted approval to two new self administered options for Glaxo s severe eosinophilic asthma drug Nucala  a pre filled pen anda pre filled safety syringe These new administration options of Nucala are expected to be launched this month and were approved in the United States in June Novartis  Heart Failure Drug Fails in Outcomes Study  Novartis    NYSE NVS   phase III PARAGON HF outcomes study evaluating its drug Entresto  sacubitril valsartan  for heart failure in patients with preserved ejection fraction  HFpEF   narrowly missed statistical significance on the primary endpoint  The primary endpoint was reducing cardiovascular death and total heart failure hospitalizations in the abovementioned patient population  Entresto is presently marketed for the treatment of heart failure in patients with reduced ejection fraction  There is currently no approved treatment for HFpEF Meanwhile  Novartis CDK4 6 inhibitor Kisqali  as a combination therapy  met the key secondary endpoint of overall survival in the phase III MONALEESA 3 study  In MONALEESA 3  Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post menopausal women with HR  HER2  advanced breast cancer in first  and second line setting  Earlier  at ASCO 2019  Kisqali combination therapy demonstrated improved overall survival in another phase III study  MONALEESA 7  evaluating Kisqali plus aromatase inhibitor in pre  peri menopausal women FDA Approves Bayer s New Prostate Cancer Medicine  The FDA granted approval to Bayer s darolutamide for the treatment of men with non metastatic castration resistant prostate cancer  Darolutamide will be marketed under the brand name Nubeqa  The approval came three months ahead of FDA s target action date  The candidate is under review in the EU and Japan for the same indication The NYSE ARCA Pharmaceutical Index declined 0 9  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions  AstraZeneca recorded the highest increase  3 1   while Pfizer declined the most  10 4  In the past six months  AstraZeneca has been the biggest gainer  19 7   while Bristol Myers declined the most  11 1    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for second quarter earnings of Novo Nordisk  CSE NOVOb  and regular pipeline and regulatory updates next week Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfe-mrk-lly-q2-earnings-upjohnmyl-merger-200450058,200450058
171400,392916,LLY,Aduro  ADRO  Earnings Miss In Q2  Revenues Meet Estimates,opinion,Shares of Aduro BioTech  Inc    NASDAQ ADRO   were down around 3 6  on Friday after it announced second quarter 2019 results on Aug 1  In fact  so far this year  the stock has plunged 48 9   underperforming the  decrease of 1 8  Aduro incurred second quarter 2019 loss of 23 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents but narrower than the year ago loss of 31 cents Revenues came in at  4 9 million  up 88 5  year over year  primarily owing to the recognition of the upfront payment received from the pharma giant Eli Lilly   NYSE LLY   during the first quarter of 2019  Meanwhile  sales almost came in line with the Zacks Consensus Estimate of  5 million Notably  last December  Aduro entered into an exclusive collaboration and license agreement with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS STING inhibitor platform  The upfront payment received from this contract with Eli Lilly enhanced Aduro s cash position at the end of the reported quarter Quarter in DetailResearch and development expenses declined 12 9  in the reported quarter to  16 9 million owing to lower stock based compensation and reduced headcount plus decreased costs for deprioritized programs General and administrative expenses were  8 million  down9 1  year over year  primarily owing to strategic reset announced in January  which resulted in lower stock based compensation and reduced headcount Pipeline UpdateAduro s three distinct technology platforms  designed to harness the body s natural immune system  are being utilized to develop treatments for several cancer indications and show potential for label expansion into auto immune and infectious diseases  The three well defined platforms are the LADD technology  STING pathway activator and the B select monoclonal antibody Aduro s lead assets are STING agonist ADU S100 and anti APRIL antibody  BION 1301 Aduro has a collaboration and license agreement with Novartis   NYSE NVS   for developing its lead STING Activator candidate ADU S100 In June this year  Aduro and Novartis presented data from the ongoing phase Ib study evaluating a combination of Aduro s lead candidate ADU S100 and Novartis  PD 1 inhibitor spartalizumab in patients with advanced solid tumors or lymphomas However  investors seemed underwhelmed with response rates  which caused a plunge in share prices back then  Data from the study was presented at the annual meeting of the American Society of Clinical Oncology  ASCO  We would like to remind investors that Aduro is currently enrolling patients in an early stage study evaluating ADU S100 in combination with Bristol Myers  Yervoy  ipilimumab  for relapsed refractory melanoma  Another study to evaluate ADU S100 in combination with Merck s   NYSE MRK   Keytruda  pembrolizumab  for first line head and neck cancer is expected to start in the second half of 2019 Aduro initiated the phase I clinical study on BION 1301  evaluating healthy volunteers for treating IgA nephropathy  in first quarter 2019  In May  the company announced that the first cohort in a phase I study on BION 1301 was cleared for recruiting patients to treat IgA nephropathy  IgAN  with initial data for healthy volunteers expected in the first half of 2020 and for IgAN patients  in the second half of 2020 Meanwhile  as a result of the strategic reset in January  Aduro slashed its current workforce by almost 37  and redirected resources to focus on its core programs  The reduction in operating expenses is expected to strengthen the company s cash  cash equivalents and marketable securities through 2022 Aduro Biotech  Inc  Price  Consensus and EPS Surprise   Zacks RankAduro currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-earnings-miss-in-q2-revenues-meet-estimates-200450899,200450899
171401,392917,LLY,Novo s semaglutide beats Lilly s dulaglutide in late stage study in type 2 diabetics  shares ahead 3 ,news,Novo Nordisk   CO NOVOb   NVO  2 9   is up at Eli Lilly s  LLY  0 9   expense after it announced results from the Phase 3b SUSTAIN 7 study comparing glucose control and weight loss in type 2 diabetics treated with either once weekly semaglutide or Lilly s once weekly Trulicity  dulaglutide  over 40 weeks From a mean baseline HbA1c of 8 2   patients receiving 0 5 mg of semaglutide achieved a statistically significant reduction of 1 5  compared to 1 1  for 0 75 mg of dulaglutide  Patients receiving 1 0 mg of semaglutide experienced a reduction of 1 8  versus 1 4  for 1 5 mg of dulaglutide The percentages of patients achieving their target HbA1c levels or below for the lower and higher doses of semaglutide and dulaglutide were 69  52  and 79  68   respectively On the weight loss front  patients treated with 0 5 mg  0 75 mg and 1 0 mg of semaglutide experienced mean weight loss of 4 6 kg  2 3 kg  and 6 5 kg  respectively  Patients receiving 1 5 mg of dulaglutide lost an average of 3 0 kg  The percentages of patients who lost at least 5  of their body weight across the three doses of semaglutide were 44   23  and 63   respectively  compared to 30  for 1 5 mg of dulaglutide Novo s marketing applications for semaglutide are currently under review in seven jurisdictions  including the U S   EU and Japan Previously  Novo submits U S  marketing application for long acting diabetes med semaglutide in T2D  Dec  5  2016 Now read ,2017-08-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/novos-semaglutide-beats-lillys-dulaglutide-in-latestage-study-in-type-2-diabetics-shares-ahead-3-519390,519390
171402,392918,LLY,Lilly to refile U S  marketing application for RA med baricitinib in January 2018,news,Eli Lilly  NYSE LLY  gives shareholders some good news this morning with its announcement that  after discussions with the FDA  it plans to resubmit its New Drug Application  NDA  for rheumatoid arthritis  RA  med baricitinib by the end of January 2018  The refiling will include new safety and efficacy data The company received a CRL in April citing the need for additional clinical data to support the optimum doses and additional data to further characterize the safety profile across treatment arms In July  the company said it did not anticipate refiling for at least 18 months  It also believes the FDA will regard it as a Class II resubmission which has a six month review cycle Lilly co developed baricitinib  an oral JAK inhibitor  with Incyte  NASDAQ INCY   under a December 2009 agreement  It was approved in Europe in February and Japan in July Previously  FDA rejects Lilly s marketing application for RA candidate baricitinib  April 14 Previously  Refiling of U S  marketing application for arthritis med baricitinib at least 18 months away  Lilly down 1   Incyte down 4  premarket  July 25 Now read ,2017-08-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/lilly-to-refile-us-marketing-application-for-ra-med-baricitinib-in-january-2018-523801,523801
171403,392919,LLY,Potential share moving presentations ahead at key European cancer meeting,news,The abstract drop for the European Society for Medical Oncology  ESMO  will launch in less than six hours  The conference will take place September 8 12 in Madrid  Presentations to watch AstraZeneca  NYSE AZN   Top line data from Phase 3 FLAURA study assessing Tagrisso  osimertinib  in EGFR  NSCLC patients  Primary endpoint  PFS Data from Phase 3 PACIFIC study of durvalumab in NSCLC  Clovis Oncology   NASDAQ CLVS   Data from Phase 3 ARIEL3 study of Rubraca  rucaparib  in advanced ovarian cancer  Curis   NASDAQ CRIS   Phase 1 data on CA 170 Exelixis  NASDAQ EXEL   Data on Phase 2 CABOSUN study comparing cabozantinib to SUTENT  sunitinib  in treatment naive RCC  Phase 1b data on cabozantinib   Yervoy   Opdivo in genitourinary cancers Eli Lilly  NYSE LLY   Data from Phase 3 MONARCH 3 study of abemaciclib in breast cancer and data from Phase 3 RANGE study of ramucirumab in urothelial cancer Merck  NYSE MRK  Incyte  NASDAQ INCY   Data from Phase 1 2 ECHO 202 study of pembrolizumab epacadostat combo in selected cancers  specifically the melanoma cohort  Kite Pharma   NASDAQ KITE   Updated data from ZUMA 3 and ZUMA 4 TESARO  NASDAQ TSRO   Data from Phase 1 2 TOPACIO study of niraparib   Keytruda  pembrolizumab  in TNBC Source  BloombergNow read ,2017-08-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/potential-sharemoving-presentations-ahead-at-key-european-cancer-meeting-524028,524028
171404,392920,LLY,FDA tentatively OKs Sanofi s fast acting insulin Admelog  shares up 1   Lilly down 2 ,news,The FDA tentatively approves  Sanofi   PA SASY  s  SNY  0 8   rapid acting human insulin analog Admelog  insulin lispro injection  100 Units mL for glycemic control in adults and children with diabetes mellitus The tentative approval was based on Admelog s chemical and clinical similarity to Eli Lilly s  LLY  1 7   Humalog Tentative approval means the data in the marketing application was complete enough to qualify for approval but patent issues need to be resolved The European Commission approved the product in July under the trade name Insulin lispro Sanofi Now read ,2017-09-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-tentatively-oks-sanofis-fastacting-insulin-admelog-shares-up-1-lilly-down-2-524924,524924
171405,392921,LLY,Lilly to lay off 8 percent of employees in bid to cut costs,news,By Michael Erman  Reuters    Eli Lilly and Co  N LLY  said on Thursday it would lay off about 8 percent of its employees as the drugmaker  which has suffered setbacks over the past year in the development of two potential blockbuster drugs  works to cut costs  Lilly will cut about 3 500 positions around the world  resulting in yearly savings of about  500 million  beginning in 2018  The company s shares rose 1 8 percent  The company expects most of the cuts to come from a voluntary early retirement program it is offering in the United States  It is also closing a plant in Iowa and research and development offices in New Jersey and China  Lilly s operating margins have lagged behind those of the company s rivals  according to Morningstar analyst Damien Conover   Lilly s R D as a percentage of sales has trended a bit high over the last couple of years   Conover said   Part of this is to try to get its operating margins more in alignment with the overall group    Lilly expects charges of about  1 2 billion before tax  or  0 80 per share after tax  Lilly outlined in July a likely multi year delay for its experimental rheumatoid arthritis drug baricitinib  after the U S  Food and Drug Administration declined to approve the drug  calling for an additional clinical study   That delay followed the failure of a trial in November of Lilly s experimental Alzheimer s treatment solanezumab  which the company had hoped would be the first medicine approved to slow progression of the disease  The company said it has the potential to launch two new medicines by the end of 2018   a breast cancer drug and a treatment for migraines  The FDA is currently reviewing abemaciclib to treat advanced breast cancer   Lilly shares rose  1 46 to  81 97 in afternoon trading ,2017-09-07,Reuters,https://www.investing.com/news/stock-market-news/lilly-to-cut-8-percent-jobs-focus-on-developing-new-medicines-526423,526423
171406,392922,LLY,Lilly and Incyte s baricitinib successful in mid stage dermatitis study,news,Eli Lilly  LLY  and development partner Incyte  INCY  announce positive results from a Phase 2 clinical trial assessing baricitinib  branded as OLUMIANT in Europe  in patients with moderate to severe atopic dermatitis  AD   The results were presented today at the European Academy of Dermatology and Venereology Annual Meeting in Geneva The data showed treatment with baricitinib  in combination with a mid potency topical corticosteroid  TCS  significantly improved AD symptoms compared to TCS alone  Specifically  after 16 weeks  treatment  61  of patients in the 4 mg baricitinib arm achieved at least a 50  reduction in symptoms  EASI 50  compared to 37  in the TCS arm  p 0 05   The proportion of patients achieving EASI 50 in the 2 mg baricitinib arm was 57   but the treatment effect was not statistically valid  p 0 065  At week 4  the proportions achieving EASI 50 favored baricitinib  68  for 4 mg and 62  for 2 mg  compared to TCS alone  16    p 0 001   which was a more pronounced treatment effect than what was observed at week 16  although the trial participants were all treatment resistant to begin with Baricitinib was approved in the EU in February and Japan in July for the treatment of adults with moderate to severe rheumatoid arthritis  The marketing application in the U S  for RA should be refiled by the end of January Previously  FDA rejects Lilly s marketing application for RA candidate baricitinib  April 14 Now read ,2017-09-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/lilly-and-incytes-baricitinib-successful-in-midstage-dermatitis-study-528891,528891
171420,392936,LLY,Eli Lilly  LLY  Is A Top Dividend Stock Right Now  Should You Buy ,opinion,"Whether it s through stocks  bonds  ETFs  or other types of securities  all investors love seeing their portfolios score big returns  But when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
While cash flow can come from bond interest or interest from other types of investments  income investors hone in on dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends make up large portions of long term returns  and in many cases  dividend contributions surpass one third of total returns 
Eli Lilly in Focus
Eli Lilly  LLY  is headquartered in Indianapolis  and is in the Medical sector  The stock has seen a price change of  6 38  since the start of the year  The drugmaker is currently shelling out a dividend of  0 64 per share  with a dividend yield of 2 38   This compares to the Large Cap Pharmaceuticals industry s yield of 3 06  and the S P 500 s yield of 1 87  
In terms of dividend growth  the company s current annualized dividend of  2 58 is up 14 7  from last year  Over the last 5 years  Eli Lilly has increased its dividend 5 times on a year over year basis for an average annual increase of 4 89   Looking ahead  future dividend growth will be dependent on earnings growth and payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Lilly s current payout ratio is 46   This means it paid out 46  of its trailing 12 month EPS as dividend 
Looking at this fiscal year  LLY expects solid earnings growth  The Zacks Consensus Estimate for 2019 is  5 66 per share  representing a year over year earnings growth rate of 1 98  
Bottom Line
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages  investors like dividends for a variety of different reasons  However  not all companies offer a quarterly payout 
High growth firms or tech start ups  for example  rarely provide their shareholders a dividend  while larger  more established companies that have more secure profits are often seen as the best dividend options  Income investors must be conscious of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  LLY is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-07-18,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-is-a-top-dividend-stock-right-now-should-you-buy-200442038,200442038
171421,392937,LLY,Earnings Preview  Eli Lilly  LLY  Q2 Earnings Expected To Decline,opinion,"Eli Lilly  LLY  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 30  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  1 47 per share in its upcoming report  which represents a year over year change of  2  
Revenues are expected to be  5 67 billion  down 10 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 34  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Lilly 
For Lilly  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 51  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Lilly would post earnings of  1 32 per share when it actually produced earnings of  1 33  delivering a surprise of  0 76  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Lilly doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-eli-lilly-lly-q2-earnings-expected-to-decline-200443134,200443134
171422,392938,LLY,Eli Lilly  LLY  To Report Q2 Earnings  What s In Store ,opinion,"Eli Lilly and Company   NYSE LLY   will report second quarter 2019 results on Jul 30  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 0 76  Lilly s shares have declined 6 5  this year so far compared with the  s decline of 1 3    Lilly s earnings performance has been mixed  Its earnings beat expectations in three of the last four quarters  with the average positive surprise being 3 63   Eli Lilly and Company Price and EPS Surprise
    
 Let s see how things are shaping up for this announcement Factors to ConsiderAs in the previous couple of quarters  strong demand for new products like Trulicity  Basaglar  Jardiance  Taltz  Cyramza  Verzenio as well as new migraine drug  Emgality should make up for the decline in sales of established products like Cialis due to loss of exclusivity  Among the new drugs  in May  Cyramza gained FDA approval for second line liver cancer  which expanded the drug s eligible patient population  This may drive sales of the drug higher in the soon to be reported quarter Meanwhile  rising pricing pressure in the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line in the second quarter Importantly  sales of advanced soft tissue sarcoma drug  Lartruvo is expected to decline sharply in the to be reported quarter as the company has suspended promotion of the medicine due to the failure of the ANNOUNCE confirmatory study The loss of exclusivity of Cialis  Effient  Strattera  Zyprexa  Cymbalta  Evista and Axiron in some countries will continue to hurt volumes  Lilly lost exclusivity for Cialis in September 2018 and generic versions entered the market in the same month resulting in rapid erosion of sales Also  competitive pressure and loss of exclusivity in certain countries are hurting Alimta sales  particularly international sales   a trend expected to continue in the second quarter Investors will be keen to know the sales numbers of Emgality  Lilly s newly launched CGRP antibody  for the preventive treatment of migraine  Emgality generated U S  revenues of  14 2 million in the first quarter  We expect sales to be much higher in the second quarter  Emgality was launched in some ex U S  markets in the first quarter of 2019  However  international sales contributed a meager  2 1 million in the first quarter  International sales of Emgality should be higher in the second quarter Moreover  Emgality was granted FDA approval for the preventive treatment of episodic cluster headache in adult patients  We expect management to update on the launch plans for the expanded indication on the second quarter conference call Earnings WhispersOur proven model does not conclusively show that Lilly will beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP   Its Earnings ESP is  0 51  as the Zacks Consensus Estimate of  1 47 is higher than the Most Accurate Estimate of  1 46  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Lilly s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some large drug biotech stocks that have the right combination of elements to beat on earnings this time around AbbVie   NYSE ABBV   has an Earnings ESP of  0 12  and a Zacks Rank  2  The company is slated to release results on Jul 26  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  6 25  and a Zacks Rank  3  The company is scheduled to release results on Aug 6 Gilead Sciences   NASDAQ GILD   has an Earnings ESP of  3 20  and a Zacks Rank  2  The company is scheduled to release results on Jul 30 The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-to-report-q2-earnings-whats-in-store-200443871,200443871
171423,392939,LLY,Eli Lilly  LLY  Stock Down 6 8  In 2019  Can Q2 Earnings Boost Performance ,opinion,"Eli Lilly and Company   NYSE LLY   stock is down 6 8  YTD  slightly worse than a large cap pharma average of  5 4   Let s dive into Eli Lilly and see what to expect from its results heading into its Q2 earnings report that will be released before the market opens on Tuesday  July 30 
Overview
Eli Lilly is the  in the world  with a market share in 2018 of 2 57   The company was founded in 1876 in Indianapolis by Eli Lilly and has been on the cutting edge of medicine ever since  with innovative products such as Jonas Salk s polio vaccine and the first publicly available human insulin 
Lilly currently focuses on three pharmaceutical areas  oncology  mental health  and diabetes  LLY s stock price has done very well in the past five years  with a huge jump in 2018  The price has backed off from those highs a bit  but we may see it push higher in the coming months 

 
Currently  Lilly sells many widely used drugs such as Cialis  Cymbalta  Methadone  and Prozac  The  for the company is now Trulicity  a once weekly injection treatment for Type II diabetics that helps the body increase insulin levels  Last year  it brought in over  3 billion in revenue 
In January  Lilly announced that it would acquire Loxo Oncology for about  8 billion in cash  The firm s Loxo investment added a lot of weight to Lilly s oncology efforts  Loxo  in partnership with Bayer   OTC BAYRY    currently has one cancer treatment approved by the FDA  but is awaiting approval in the EU  It also has three drugs in clinical development 
The FDA also just approved on Wednesday Lilly s hypoglycemia treatment drug  This drug  called Baqsimi  is a nasally administered glucagon powder approved for emergency treatment  Hypoglycemia is a condition in which blood sugar falls to very low levels  and happens most often in diabetics  Many diabetics keep injectable glucagon on hand in case of emergencies  so this product has a large addressable market as many people may see this as a better and safer alternative to an injection and switch 
Outlook
Lilly currently has   with another 54 in clinical trials  This is a strong pipeline that will hopefully drive Lilly s future growth  Some of these drugs are very promising revenue generators  such as a migraine drug currently under FDA review  Migraine drugs have a very large addressable market  since an estimated 12  of the U S  suffers from them 
Our Zacks Consensus Estimates predict a year over year Q2 revenue will decrease by 11 05  to  5 65 billion  Our estimates also call for fiscal year revenue to fall 9 96  to  22 11 billion  However  revenues have increased each year since 2014  so the company is not exactly in a tight spot  And estimates do show a projected 6 64  comeback in 2020 
Earnings estimates look much more promising for the firm in the coming quarters  This quarter  earnings are projected to shrink by just 2 67  over Q2 2018  While next quarter earnings are projected to grow by 4 32   representing a bounce back 
Full year fiscal 2019 earnings are estimated to expand by 1 98   Plus  next year s estimates project full year EPS to jump 16 14  higher than our current year estimate  Compared to the rest of the large cap pharmaceutical industry  these yearly growth numbers look quite impressive  The industry s earnings are estimated to shrink by 2 3  in 2019 and grow only half as much as Lilly in 2020 at 8 4 
Lilly stock is slightly overvalued compared to its peers at the moment  with a forward P E of 17 58x  against its peer group s 15 18x average  This means investors are willing to pay more for Lilly s future earnings than for other large cap pharma companies  
Bottom Line
Eli Lilly currently holds a Zacks Rank  3  Hold   as earnings estimates have remained roughly the same throughout the quarter  What little estimate change there was  happened downward  but Lilly does have a strong history of earnings beats so we could be surprised  Investors should watch this stock long term as LLY s strong pipeline comes into production in the next few years 
This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-stock-down-68-in-2019-can-q2-earnings-boost-performance-200445295,200445295
171424,392940,LLY,FDA Fast Tracks Pfizer and Lilly s biologic pain candidate tanezumab,news,Consistent with its aim to up its game to fight the opioid epidemic  the FDA designates  Pfizer   PFE  and Eli Lilly s  LLY  0 7   Phase 3 stage tanezumab for Fast Track review for the treatment of chronic pain in patients with osteoarthritis and chronic back pain Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the Biologics License Application  BLA  Tanezumab is a humanized monoclonal antibody that inhibits  binds to  nerve growth factor  the first NGF inhibitor so designated The companies are co developing and will co commercialize tanezumab under a global 2013 agreement Now read ,2017-06-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-fast-tracks-pfizer-and-lilly's-biologic-pain-candidate-tanezumab-494930,494930
171425,392941,LLY,Lilly s Taltz shows sustained treatment effect in psoriatic arthritis in late stage study,news,Results from the extension period of a Phase 3 clinical trial  SPIRIT P1  assessing Eli Lilly s  LLY  0 2   Taltz  ixekizumab  for the treatment of patients with active psoriatic arthritis  PsA  showed no or minimal progression of joint damage through 52 weeks of treatment  The data are being presented today at EULAR in Madrid During the double blind period of SPIRIT P1  participants who had never received a biologic disease modifying antirheumatic drug received 80 mg of Taltz every two or four weeks or AbbVie s HUMIRA  adalimumab  or placebo  After the treatment period  patients were re randomized to receive 80 mg of Taltz every two or four weeks for another 28 weeks Patients treated with both doses of Taltz showed no or minimal progression of structural joint damage through week 52 as measured by the change from baseline in a scale called van der Heijde modified Total Sharp Score for PsA  The same treatment benefit was also observed in patients who switched from HUMIRA or placebo after the 24 week treatment period Lilly has filed a marketing application in the U S  seeking approval for the use of Taltz in PsA  It was approved by the FDA in March 2016 for the treatment of plaque psoriasis  Regulatory submissions will be made later this year  Taltz is already approved in Japan for PsA Now read ,2017-06-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/lilly's-taltz-shows-sustained-treatment-effect-in-psoriatic-arthritis-in-late-stage-study-496340,496340
171426,392942,LLY,Eli Lilly declares  0 52 dividend,news,Eli Lilly  NYSE LLY  declares  0 52 share quarterly dividend  in line with previous Forward yield 2 52 Payable Sept  8  for shareholders of record Aug  15  ex div Aug  11 Now read ,2017-06-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/eli-lilly-declares-$0.52-dividend-496945,496945
171427,392943,LLY,Refiling of U S  marketing application for arthritis med baricitinib at least 18 months away  Lilly down 1   Incyte down 4  premarket,news,Eli Lilly  NYSE LLY  is down 1  premarket and development partner Incyte  NASDAQ INCY  is down 4   both on light volume  on the heels of the news that Lilly does not anticipate resubmitting its New Drug Application  NDA  for rheumatoid arthritis  RA  med baricitinib to the FDA for at least 18 months Lilly received a CRL in April citing the need for a new clinical trial to further characterize the benefit risk profile across doses due to the observed imbalance in thromboembolic events that occurred during the placebo controlled studies President of Lilly Bio Medicines Christi Shaw says   We disagree with the FDA s conclusions  and believe the existing comprehensive clinical data demonstrate there is a positive benefit risk profile that supports baricitinib s approval as a new treatment option for people suffering from RA in the United States  We are disappointed that resubmission will not occur this year  but are committed to bringing baricitinib to people with RA and we will work with the FDA on the path forward  Previously  FDA rejects Lilly s marketing application for RA candidate baricitinib  April 14 Now read ,2017-07-25,Seeking Alpha,"https://www.investing.com/news/stock-market-news/refiling-of-u.s.-marketing-application-for-arthritis-med-baricitinib-at-least-18-months-away,-lilly-down-1,-incyte-down-4-premarket-509504",509504
171449,392965,LLY,4 Best Performing Biotech Mutual Funds In 2019 So Far,opinion,After stumbling into the bear market territory in the second half of last year  the U S  biotechnology sector recovered in the first six months of this year  SPDR S P Biotech  NYSE XBI  ETF  iShares Nasdaq Biotechnology ETF  ProShares Ultra Nasdaq Biotechnology and NASDAQ Biotechnology Index have surged 18 2   8 7   14 5  and 8 7   respectively  in the year to date  YTD  period Historically  the space has been risky from investors  standpoint  This is because  they bet on the assumption that products in the pipeline would turn out be highly successful  But any failure in a key clinical trial can make things really unpleasant for investors  Nonetheless  a higher number of mergers and acquisitions  M A  and an increased number of FDA approvals have been pivotal in shaping up the fortunes for the biotech sector  Let s look at some of the best performing mutual funds from the space so far in 2019 A Banner Year for BiotechSo far this year  25 of the 32 healthcare IPOs have been from the biotech sector  Furthermore  the average first day return from such offerings has been 9  so far  The most successful biotech IPOs this year have been Turning Point Therapeutics  Inc  and Cortexyme  Inc  Shares of Turning Point and Cortexyme have risen 100  since they went public in April and May  respectively Moreover  June turned out to be the best month for biotech IPOs  with six biotech companies going public in a week s time in mid June  BridgeBio Pharma  Inc  and Adaptive Biotechnologies Corporation went public in the month and had successful IPOs  Both companies have a market cap of over  3 billion The trend began early in the year when pharmaceutical giant Bristol Myers Squibb  NYSE BMY  offered in January  74 billion to acquire cancer drugmaker Celgene  NASDAQ CELG   Following this  Eli Lilly and Company  NYSE LLY  acquired Loxo Oncology for  8 billion in February 4 Best Funds to Buy NowGiven such bullish circumstances  we have highlighted four biotech mutual funds carrying a Zacks Mutual Fund Rank  1  Strong Buy  and are poised to gain from such factors  Moreover  these funds have encouraging year to date  YTD  returns  Additionally  the minimum initial investment is within  5000  We expect these funds to outperform their peers in the future The question here is  why should investors consider mutual funds  Reduced transaction costs and diversification of portfolio without several commission charges that are associated with stock purchases are primarily why one should be parking money in mutual funds  read more    Fidelity Select Biotechnology  fund invests the majority of its net assets in common stocks of companies mostly engaged in the research  development and distribution of biotechnological products  The fund primarily seeks capital growth  The non diversified fund invests in U S  and non U S  companies alike This Zacks sector   Health product has a history of positive total returns for more than 10 years  Specifically  the fund s return over the YTD benchmark is 18 6  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   FBIOX carries a Zacks Mutual Fund Rank  1 and has an annual expense ratio of 0 72   which is below the category average of 1 23  Vanguard Specialized Portfolios Health Care Fund  seeks long term capital growth by investing in securities of companies that are engaged in production and distribution of products and services from the healthcare industry  The fund may invest about half of its assets in non U S  stocks This Zacks sector   Health product has a history of positive total returns for more than 10 years  Specifically  the fund s return over the YTD benchmark is 6 9  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   VGHCXcarries a Zacks Mutual Fund Rank  2and has an annual expense ratio of 0 34   which is below the category average of 1 23  Invesco Health Care Fund Class Y  aims for long term capital appreciation  The fund invests the majority of its assets in securities of companies that are engaged in operations in healthcare related industries  The fund mostly invests in equity securities  depositary receipts and securities convertible into equity securities This Zacks sector   Health product has a history of positive total returns for more than 10 years  Specifically  the fund s return over the YTD benchmark is 15 4  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   GGHYX holds a Zacks Mutual Fund Rank  1and has an annual expense ratio of 0 85   which is below the category average of 1 23  T  Rowe Price Health Sciences Fund  invests a minimum of 80  of its assets in common stocks of companies mostly engaged in research  production and distribution of products and services in the healthcare related industry  The non diversified fund mostly invests in mid  and large capitalization companies This Zacks sector   Health product has a history of positive total returns for more than 10 years  Specifically  the fund s return over the YTD benchmark is 17 5  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   PRHSX carries a Zacks Mutual Fund Rank  1 and an annual expense ratio of 0 77   which is below the category average of 1 23  Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/4-bestperforming-biotech-mutual-funds-in-2019-so-far-200441590,200441590
171450,392966,LLY,Eli Lilly Q1 EPS  0 98 vs  estimate  0 96 ,news,Investing com    NYSE Eli Lilly  first quarter earnings beat analyst estimates The pharmaceutical reported an 18  rise in Q1 non GAAP EPS to  0 98 vs  estimate of  0 96 Revenues climbed 7  to  5 23 bn boosted by an increase in volumes of 8  Eli Lilly reaffirmed full year non GAAP EPS guidance of   4 05  4 15 ,2017-04-25,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-q1-eps-$0.98-vs.-estimate-$0.96-477046,477046
171451,392967,LLY,U S  FDA approves Merck immunotherapy chemo combo for lung cancer,news,"By Bill Berkrot  Reuters    Merck   Co  N MRK  said on Wednesday U S  health regulators approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer  solidifying the drugmaker s lead position in the field of medicines that help the immune system fight cancer  Lung cancer is by far the largest oncology market and the approval significantly expands the number of patients available for Keytruda therapy  Merck shares were up 3 2 percent at  65 99 in extended trading   This is the key game changer for Keytruda   said Leerink Partners analyst Seamus Fernandez  adding that he expects physician acceptance to be  pretty robust   The accelerated approval was based on data from a study of 123 previously untreated patients with metastatic non squamous non small cell lung cancer  NSCLC    It was a small trial but the results were really quite striking   said Roy Baynes  head of global clinical development for Merck Research Labs  The Food and Drug Administration approved Keytruda in combination with Eli Lilly s  N LLY  Alimta  the chemotherapy drug used in the study that led to the agency s decision  Merck may be asked to conduct another trial to confirm the clinical benefit of the combination  Keytruda alone was already approved as an initial  or first line  therapy for advanced NSCLC in patients whose cancer cells have a high level of the PD L1 protein the drug targets  The combination allows for treatment regardless of level of PD L1  Merck scored a coup last year  when Keytruda extended patient survival in a first line lung cancer trial  supplanting Bristol Myers Squibb  N BMY  as the perceived leader in the field  Bristol s rival drug Opdivo surprisingly failed to show a survival benefit compared with chemotherapy in a similar study  Both drugs and one from Roche  S ROG  were already approved for lung cancer once a prior treatment fails or stops working  The medicines belong to a new class of cancer drugs  called PD 1 or PD L1 inhibitors  that block a mechanism tumors use to evade detection by the immune system  There are now five approved for a variety of cancers  but all companies involved are aiming for a slice of the lung cancer market  Bristol Myers is testing Opdivo with its other immunotherapy  Yervoy  as a first line NSCLC treatment  but did not seek accelerated approval  AstraZeneca  L AZN  is also testing an all immuno oncology combination with highly anticipated data expected mid year  
The original Keytruda first line approval allowed for treatment of about 30 percent of NSCLC cases  The combination could be used on all patients with non squamous NSCLC  which accounts for about 75 percent of lung cancer cases ",2017-05-10,Reuters,https://www.investing.com/news/stock-market-news/u.s.-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-482800,482800
171468,392984,LLY,Lilly s Study On Higher Doses Of Trulicity Meets Endpoint,opinion,Eli Lilly and Company s   NYSE LLY   phase III study evaluating higher doses of its GLP 1 receptor agonist  Trulicity  demonstrated superiority in A1C  a measure of blood glucose  reduction in type II diabetes patients compared to Trulicity doses already availableData from AWARD 11 phase III study showed that 3 0 mg and 4 5 mg doses of Trulicity significantly reduced A1C from baseline compared to once weekly Trulicity 1 5 mg after 36 weeks  thereby meeting the study s primary efficacy endpoint of superiority  The study also demonstrated superiority in weight loss  its secondary efficacy endpoint The study will continue for 52 weeks and Lilly plans to file for regulatory approval of the higher doses by late 2019 Lilly s shares have declined 3 8  this year so far compared with the  s increase of 3 3    Trulicity is a key drug in Lilly s diabetes portfolio  In the first quarter of 2019  Trulicity generated revenues of  879 7 million  up 30  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices However  Trulicity is facing stiff competition from Novo Nordisk s   NYSE NVO   Ozempic semaglutide  launched in 2018  In fact  Lilly is seeing pricing pressure across all its diabetes products  which creates uncertainty around the franchise s long term growth prospects  A number of competitors are entering the diabetes space  For example  with the approval of Merck   NYSE MRK   Pfizer s   NYSE PFE   Steglatro and its combinations  competition in the SGLT2 inhibitors class is expected to increase  The class includes Lilly s key diabetes medicine  Jardiance Lilly currently has a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/lillys-study-on-higher-doses-of-trulicity-meets-endpoint-200435308,200435308
171469,392985,LLY,Gilead To Submit NDA For Inflammation Drug Filgotinib In  19,opinion,"Gilead Sciences   NASDAQ GILD   announced that it is planning to submit a new drug application   NDA   seeking approval for its oral JAK1 inhibitor  filgotinib  as a treatment for rheumatoid arthritis   RA   in 2019  The decision was taken by the company following a pre NDA meeting with the FDA The NDA will likely include data from the ongoing phase III clinical program  FINCH  which comprises three studies  The company had discussion on the phase III FINCH studies with the regulatory authority during the pre NDA meeting  In 2016  the company had collaborated with Galapagos   NASDAQ GLPG   for the development and commercialization of filgotinib  for inflammatory disease indications including RA Shares of Gilead have increased 8 4  so far this year compared with the  s rise of 5 3  The 52 week phase III study  FINCH 1 evaluated filgotinib in comparison with AbbVie s   NYSE ABBV   Humira  adalimumab  or placebo on a stable background dose of methotrexate   MTX   in patients with prior inadequate response to methotrexate  In March  the company announced 24 week data from the study  The study achieved its primary endpoint for both doses of filgotinib   100 mg and 200 mg  Filgotinib demonstrated significantly higher ACR20 50 70 responses compared to placebo in patients with prior inadequate methotrexate response  The higher dose of filgotinib also demonstrated non inferiority to Humira The company also announced 24 week data from the ongoing phase III FINCH 3 study in the same month  The study evaluated 100mg or 200mg doses of filgotinib in combination with MTX and as monotherapy in MTX naive patients  Both the doses of filgotinib in combination with MTX demonstrated significantly higher ACR20 50 70 responses than methotrexate alone  The study achieved its primary endpoint  as higher percentage of patients achieved the primary endpoint of ACR20 response at week 24 for filgotinib 200 mg plus MTX and filgotinib 100 mg plus MTX compared with MTX alone In September 2018  Gilead announce top line data from the phase FINCH 2 study  which evaluated filgotinib in patients receiving conventional synthetic disease modifying anti rheumatic drug  DMARD  and prior inadequate response intolerance to biologic DMARD  The study achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20  response  ACR20  at week 12   Both the doses   100 mg and 200 mg   achieved significantly higher ACR20 50 70 responses than placebo in patients with active rheumatoid arthritis and prior inadequate response to biologic agents Meanwhile  interim safety data from the phase III FINCH program along with updated week 156 safety data from the phase IIb DARWIN 3 long term extension study showed that the safety profile of the candidate was consistent with previous studies The FINCH studies are among several clinical trials of filgotinib in inflammatory diseases including ulcerative colitis Gilead is looking to expand into HIV and newer avenues to boost its top line and offset the loss of sales in HCV products  A potential approval to filgotinib for RA and successful development in other inflammation indications are expected to favorably impact the company s revenues as the targeted indication has significant market opportunity  We note that Eli Lilly   NYSE LLY   received approval for Olumiant as a treatment for RA last year  Several other pharma companies are developing their drugs for inflammation indications including RA Gilead Sciences  Inc  Price
    Zacks RankGilead currently carries a Zacks Rank  2  Buy   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/gilead-to-submit-nda-for-inflammation-drug-filgotinib-in-19-200436419,200436419
171470,392986,LLY,Pfizer s Eucrisa Proves Safety In Kids With Atopic Dermatitis,opinion,"Pfizer Inc    NYSE PFE   announced top line results from a late stage study  which evaluated its PDE4 inhibitor  Eucrisa  crisaborole ointment  2    for the treatment of mild to moderate atopic dermatitis  AD  or eczmema in children aged three months to two years 
The steroid free topical treatment is already approved for eczema in patients aged two years and older in the United States and Canada  The drug is also marketed in Israel and Australia under the brand name Staquis for the given patient population 
The phase IV CrisADe CARE 1 study showed that Eucrisa was well tolerated over a four  week regimen and its safety profile was consistent with the previous clinical studies  Pfizer plans to present detail results from this label expansion study at an upcoming scientific conference 
Shares of Pfizer have inched up 0 3  so far this year  underperforming the  rise of 2 1  

 
We would like to remind investors that Pfizer added Eucrisa to its portfolio with the acquisition of Anacor Pharmaceuticals in June 2016  The company estimates Eucrisa s peak sales potential to be at least  2 billion 
Another interesting eczema candidate in Pfizer s portfolio is its investigational JAK1 inhibitor  abrocitinib  In May this year  the company announced that a pivotal late stage study evaluating abrocitinib for the treatment of moderate to severe AD  met all the co primary and secondary endpoints 
The phase III program  B7451012  examined two doses  100mg and 200mg once daily  of abrocitinib  PF 04965842  monotherapy in patients aged 12 and above for over 12 weeks 
Notably  many companies are developing medicines to address AD eczema  A key new entrant in the AD market is Sanofi   NASDAQ SNY   Regeneron Pharmaceuticals    NASDAQ REGN   Dupixent  Others also developing key immunology candidates in late stage studies for AD include AbbVie  NYSE ABBV   upadacitinib  and Lilly   NYSE LLY    Olumiant  
Zacks Rank
Pfizer currently carries a Zacks Rank  3  Hold   You can see  
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-02,Zacks Investment Research,https://www.investing.com/analysis/pfizers-eucrisa-proves-safety-in-kids-with-atopic-dermatitis-200436580,200436580
171471,392987,LLY,Incyte Out Licenses INCMGA0012 Rights In China To Zai Lab,opinion,Incyte Corporation   NASDAQ INCY   announced that it is out licensing the development and commercialization rights to its investigational PD 1 monoclonal antibody  INCMGA0012  in Greater China to Zai Lab  The transaction takes effect immediately INCMGA0012 is currently being developed as a monotherapy for treating MSI high endometrial cancer  merkel cell carcinoma and anal cancer  Incyte in licensed global rights to INCMGA0012 from MacroGenics   NASDAQ MGNX   in 2017 Per the collaboration and license agreement  Incyte will receive an upfront payment of  17 5 million from Zai Lab and be also eligible to earn an additional  60 million as potential milestone fees apart from tiered royalties in low to mid twenties  range  However  Incyte will be responsible for all the royalties and pass through payments to its licensing partner  MacroGenics With this deal  Zai Lab will gain exclusive rights to develop commercialize INCMGA0012 for addressing hematology and oncology indications in mainland China  Hong Kong  Macau and Taiwan  Zai Lab is looking to explore the potential of INCMGA0012 both as a monotherapy and in combination with its existing pipeline candidates Moreover  Incyte will retain an option to assist the promotion of INCMGA0012 at Zai Lab s licensed territories Shares of Incyte have rallied 33 7  so far this year  outperforming the  rise of 7  We would like to remind investors that Incyte has several encouraging collaboration deals with big pharma companies like Novartis   NYSE NVS   and Lilly   NYSE LLY   wherein the former gets a considerable amount of milestones for the same Notably  Incyte has a strategic collaboration pact with China based Innovent Biologics for the development of three clinical stage product candidates  namely pemigatinib  FGFR1 2 3 inhibitor   itacitinib  JAK1 inhibitor  and parsaclisib  PI3K  inhibitor   The contract triggered an upfront payment of  40 million in cash for Incyte  which is also entitled to clinch an additional  20 million in connection with the first investigational new drug  IND  application  expected to be filed by Innovent in China this year Zacks RankIncyte currently carries a Zacks Rank  3  Hold  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-02,Zacks Investment Research,https://www.investing.com/analysis/incyte-outlicenses-incmga0012-rights-in-china-to-zai-lab-200436825,200436825
171472,392988,LLY,Hutchison China MediTech  An Emerging Global Biopharma,opinion,"Hutchison China MediTech  NASDAQ HCM   has announced positive data that key late stage asset surufatinib met the primary endpoint of PFS in non pancreatic at the Phase III interim analysis  This translates to an earlier than expected China NDA submission  H219  and the potential launch of HCM s first un partnered asset  early 2021   In China  partner Lilly has launched Elunate  fruquintinib  capsules  Early sales look promising and its potential inclusion on the China NRDL later this year will be definitive to the China opportunity  However  failure of fruquintinib monotherapy in third line NSCLC and the changes in strategy to savolitinib in RCC has negatively affected our valuation  We forecast two further product launches on the horizon in 2021 2022  China launch of fruquintinib in gastric cancer and global launch of savolitinib in NSCLC   HHHL has completed a secondary offering of ADSs  which has reduced its holding to 51 15   from 60 2  previously   We see this as a significant positive for HCM as it increases the free float  potentially leading to better liquidity  We value HCM at  5 6bn   6 72 share  vs  6 5bn previously 


Business description
Hutchison China MediTech is an innovative China based biopharmaceutical company targeting the global market for novel  highly selective oral oncology and immunology drugs  Its established commercial platform business continues to expand its outreach 
Elunate launched  surufatinib to follow shortly
Elunate is now being commercialised in China  third line CRC  by partner Eli Lilly  NYSE LLY   Lilly   a major inflection point for HCM and validation of its R D philosophy  The positive interim readout of surufatinib  met primary endpoint of PFS  in the SANET ep Phase III trial in non pancreatic NET  trial was able to be stopped early  is of huge importance and these data will support a China NDA submission in late 2019  The years 2021 2022 are pivotal  partner AstraZeneca  AZN  could launch savolitinib in China for NSCLC  MET exon 14  and could become HCM s first asset to launch internationally  2022  in combination with Tagrisso for NSCLC 
Combination strategies to drive future growth
HCM has accelerated global  ex China  development of its wholly owned assets  fruquintinib  surufatinib  HMPL 523 and HMPL 689   Ongoing advances and thus changes in treatment paradigms in many oncology indications mean that combination therapy is the best approach to treat resistant cancers  With this in mind  HCM has announced four new PD 1 collaborations for fruquintinib and surufatinib  HCM AZN are focusing savolitinib s ex China strategy on its use in combination with Tagrisso in MET driven NSCLC  a blockbuster opportunity 
Valuation   5 6bn   6 72 share 
We value HCM at  5 6bn   6 72 share  vs  6 5bn previously  Our revised valuation takes into account the success of the SANET ep Phase III trial  failure of fruquintinib monotherapy in third line NSCLC and the changes in strategy to savolitinib in RCC  We have additionally adjusted our product timelines to include combination strategies across the portfolio and revisited our R D and S M costs 
Investment summary
Our long term investment cases rests on HCM s ability to develop and commercialise its assets in both China and the rest of the world  RoW   HCM is rapidly investing in international expansion with five drug candidates in or about to enter global clinical trial development  Fruquintinib  savolitinib and surufatinib lead the pack with the earlier stage spleen tyrosine kinase  Syk  and PI3K inhibitors coming to the fore  The launch of Elunate  fruquintinib  in China  November 2018  is a significant milestone for HCM  while the successful and early readout  June 2019  of surufatinib in the SANET EP Phase III trial in non pancreatic neuroendocrine tumours  NET  supports a China New Drug Application  NDA  submission in late 2019 and a potential launch early 2021  Key to HCM s global ambitions is SAVANNAH  the registrational study of savolitinib in combination with Tagrisso in non small cell lung cancer  NSCLC  patients  Clinical trials design and execution will become ever more critical in the fast changing treatment landscape for oncology and we believe HCM remains committed to driving forward only assets and strategies that will have a material impact on returns  Combining its pipeline with approved and novel targets will be of great importance in the future of cancer treatment paradigms 
Recent market update  Increased free float
Hutchison Healthcare Holdings Limited  HHHL  has completed a secondary offering of ADSs  which has reduced its holding to 51 15   from 60 2  previously   We see this as a significant positive for HCM as it increases the free float  potentially leading to better liquidity  We note this has had no effect on shares in issue and does not dilute any current shareholders  In connection with this offering  HCM  its officers and directors  in addition to HHHL have agreed to a 90 day lock up on sale or transfer of ordinary shares  As a result of this the proposed Hong Kong  SEHK  listing is now on hold  However  HCM has reiterated its commitment to the listing and a concurrent global offering of ordinary shares and may still pursue both following the cessation of the lock up  An eventual listing on SEHK will be determined on a number of factors including  but not limited to  management decisions and market conditions  In our view  a capital raise on existing markets  AIM NASDAQ  still remains likely in the next 12 24 months  however  cash resources as last reported  at 31 March 2019  of  391 2m are more than sufficient to enable current operational and strategic goals 
Valuation   5 6bn   6 72 share 
We value HCM at  5 6bn   6 72 share  vs  6 5bn previously  We use a risk adjusted net present value  NPV  method to discount future cash flows for the innovation platform  IP   valuation of  4 004m   We have adjusted our valuation to reflect the success of the SANET ep Phase III trial  the failure of fruquintinib monotherapy in third line NSCLC  FALUCA   the cessation of enrolment in the SAVOIR  savolitinib monotherapy in the papillary renal cell carcinoma  PRCC   study and the discontinuation of the clear cell RCC monotherapy trial  component of CALYPSO trial  in favour of combination strategies  Additionally  launch dates for key assets have been pushed back  while time to peak sales in China has been brought in line with our assumptions for the RoW and peak sales assumptions have been updated  We use earnings based multiples for HCM s commercial platform  CP   subs and JVs   applying a 20 4x multiple on our forecast 2019 net attributable profit  equity in earnings of equity investees  net of tax  for the JVs of  39 2m yields a valuation of  800 4m  We note that the significant increase in our terminal value from  0 56 share to  1 22 share is driven by the adjustment of time horizons  notably the terminal value now captures a greater proportion of key product sales  Adding April 2019 net cash and netting out unallocated costs results in a value of  5 6bn 
Sensitivities  Changing treatment landscapes
HCM is subject to the usual biotech and drug development risks  including clinical development delays or failures  regulatory risks  competitor successes  partnering setbacks  and financing and commercial risks  We note that the rapidly advancing oncology treatment landscape remains a key sensitivity with potential for clinical trial programmes to become irrelevant while in progress  as evidenced by the cessation of the SAVIOR Phase III study  or for early efficacy readouts  eg surufatinib SANET ep  to bring forward regulatory submissions and potential launch dates  In China  regulatory and reimbursement changes mean drugs have a potential faster route to approval and reimbursement than historically  China is becoming an increasingly important market for innovation drugs given supportive government policies and population size 
Financials  Funded to inflection points
Full year 2018 results published in March 2019 highlighted robust growth in net profit attributable to the commercial platform division in China  coupled with clinical progress within the IP portfolio  HCM reported available cash resources of  391 2m  at 31 March 2019  at the group level  cash and cash equivalents including short term investments of  271 9m  and unutilised bank borrowing facilities of  119 3m   In May 2019 HCM entered into a credit agreement with HSBC for an additional  51 3m unsecured credit facility  This  combined with the net profit generation from the CP division  means that HCM is well funded to key value inflection points  NDA submissions for savolitinib  surufatinib and fruquintinib in 2019 2021   even taking into account the considerable rise in R D expenses seen in 2018  which we expect to continue to rise in the near term 
China  A stepping stone to global ambitions
With HCM s financial strength and its drive to retain the economic value of its assets  the next steps for the company are to commercialise its own assets in China then internationally  outside of current partnerships   The launch of Elunate  HCM s first internally developed asset  in China is a significant milestone for HCM and gives us confidence in the company s ability to execute on its R D philosophy of building first  or best in class molecules with lower toxicity profiles to enable combination based strategies for the treatment of cancers  We expect next approvals in China for surufatinib in NET  savolitinib in NSCLC  MET Exon 14 skipping  and fruquintinib in gastric cancer 
Outside China  HCM is now accelerating its operations as it transitions into a global biopharma  importantly  clinical and regulatory teams are now fully operational in the US and EU  HCM s first global approval  we forecast launch in 2022  in the US EU could be for a savolitinib combination with AZN s Tagrisso in epidermal growth factor receptor mutant  EGFRm   MET  NSCLC  Exhibit 1 highlights the numerous clinical milestones  both in China and globally  likely in 2019 

China  Launch of Elunate marks the start of things to come
Eli Lilly launched Elunate  third line colorectal cancer  CRC  patients  in November 2018  at 31 March 2019 HCM reported  0 978m in royalties  implying  6 5m Elunate end user sales in Q119  and the next development focus is on Phase III gastric cancer  FRUTIGA   for which approval could occur in 2021 22 
The recent successful efficacy read out of surufatinib in the SANET EP Phase III trial in non pancreatic NET was earlier than we had anticipated and positions surufatinib as the next internally developed R D asset to launch in China  HCM will hold a pre NDA meeting with the China National Medical Products Administration to discuss the preparation of the NDA  Additionally  in China  registration studies continue for savolitinib in MET Exon 14 deleted NSCLC patients  primary data early 2020  and in surufatinib in pancreatic NET  interim data end 2019   Elunate and surufatinib mark the start of multiple potential drug launches in the near term 
Global  Infrastructure in place as clinical programme expands
Our analysis concludes that much higher economic value resides in the strategy to develop and commercialise HCM s own assets  in particular with respect to fruquintinib  ex China   surufatinib  epitinib  HMPL 523 and HMPL 689  HCM is now accelerating its global operations as it transitions into a global biopharma with clinical and regulatory  C R  teams now fully operational in the US and EU  HCM plans to expand its US and EU C R operations  headquartered in New Jersey  US  to 30 employees by end 2019 and further expansions should be expected in subsequent years as HCM builds ex China commercial infrastructure ahead of the potential launch of non partnered assets surufatinib and fruquintinib  subject to positive clinical trial data and regulatory approval  
Global development is currently focused on savolitinib  with partner AZN  with multiple late stage trials in progress  including SAVANNAH  second line third line EGFRm  Tagrisso refractory  MET positive NSCLC with Tagrisso   CALYPSO  papillary and clear cell RCC with without PD L1 Imfinzi   and VIKTORY  MET positive gastric cancer   Additionally  a proof of concept trial has initiated in Canada testing savolitinib in MET positive prostate cancer 
HCM s first approval  we forecast launch in 2022  in the US and EU could be for a savolitinib plus Tagrisso combination in MET  NSCLC patients  AZN s Tagrisso has quickly become the standard of care in first line NSCLC patients who have an EGFR mutation  EGFRm   Following Tagrisso treatment  the most common mutation is c MET and AstraZeneca sees savolitinib as key to its strategy for MET driven NSCLC  In addition to savolitinib  HCM has already commenced the global development programme for fruquintinib  CRC US registration study in planning based on China FRESCO data and completed US Phase I II data  and surufatinib  US Phase I II pancreatic NET ongoing   Additionally  development programmes for HMPL 523  Syk inhibitor  and HMPL 689  PI3K  inhibitor  in indolent NHL are expected to start Phase I Ib trials shortly  We forecast global launches from 2022 
Worldwide  Combinations the focus across regions
HCM s R D efforts has successfully generated a portfolio of candidates that address existing  well validated targets with lower toxicity profiles as a result of target selectivity  Cleaner toxicity profiles should enable drug combination as often lack of tolerability leads to failure  Combinations of targeted therapies  TKI  tyrosine kinase inhibitor   monoclonal antibodies and immunotherapies  and chemotherapy is increasingly becoming the best approach to treating the complex and constantly mutating disease that is cancer 
In the last 12 months HCM has signed four co development collaborations for fruquintinib and surufatinib in combination with a variety of China developed PD 1  programmed cell death protein 1  monoclonal antibodies  Advances in the field of immune oncology in the last few years and the increasing understanding that different classes of cancer drugs  targeted therapies and checkpoint inhibitors  may act synergistically together means that the industry needs to keep up the pace and ensure that trial design and combinations address the most pertinent question of all  which drug regimen is best for a given cancer  HCM s partnership with AstraZeneca means that savolitinib s international focus is on combinations with a number of AZN s oncology drugs including Tagrisso and Imfinzi  The renegotiated deal with Lilly for fruquintinib has given HCM freedom to explore different line extensions and combinations through non restrictive collaborations 
Pipeline overview
HCM has multiple tyrosine kinase inhibitors in clinical development  with eight assets in the clinical phase of development across over 30 trials globally  including five registration studies that are expected to read out over the next 24 months  Exhibit 2 provides an overview of the pipeline and segments the asset opportunity by China NDA opportunities  blue  and the international drug development programmes  red   Assets marketed through China CP are in green 

In the next sections we discuss in turn 
Elunate fruquintinib capsules  launched with partner Lilly in China for mCRC in November 2018  FRUTIGA is another trial investigating combination with Taxol in gastric cancer  top line data are expected in 2020  With FALUCA missing its primary endpoint in NSCLC  HCM will now explore PD 1 combinations that could drive earlier use 
Savolitinib  two pivotal studies in NSCLC are ongoing   in China for MET Exon 14 skipping and globally for a Tagrisso savolitinib combination  SAVANNAH   The PRCC strategy will focus on a combination with a PD L1 inhibitor following changes in renal cancer treatment paradigms 
Surufatinib  China NDA filing in 2019 for non pancreatic NET  This would be the first un partnered launch of a HCM asset 
HMPL 523 and HMPL 689  a Phase I Ib study in Australia and China has expanded its enrolment  blood cancers   IND applications for both HMPL 523 and HMPL 689 have been accepted for US and EU clinical development to start 
Elunate  Innovation into commercialisation
The launch of Elunate  fruquintinib capsules  for metastatic colorectal cancer  third line and above  by partner Lilly in November 2018 was a defining moment for HCM  as the first of its IP assets to launch in China and the first China discovered and developed new drug for oncology to have full approval and reach the market  At 31 March 2019 HCM reported  0 978m in royalties  implying  6 5m Elunate sales in Q119  Elunate has been priced at  3 300 per monthly cycle  RMB21 960  and a patient access programme has been implemented to widen availability in China  patients pay for the first  second and fifth cycle   HCM s target patient population for third line CRC is  55 000 60 000 patients  third line is 15  of incidence in China of 380 000 patients per year   Importantly  inclusion on China s National Reimbursement Drug List  NRDL  will define the opportunity given full scale reimbursement nationally  Inclusion on the list is conceivable in H219 as the Chinese government agencies are reviewing inclusions and exclusions on the list much more frequently than in the past 
Exhibit 3 highlights the status of Fruquintinib clinical trials in China and internationally in a broad range of oncology indications 

Positive renegotiated Eli Lilly deal terms
In December 2018  HCM and Eli Lilly renegotiated their 2013 agreement on Elunate  Under the terms of the new deal  Exhibit 4   HCM has acquired the rights to determine for which indications  LCI  life cycle indications  it will further develop Elunate  HCM will now pay the full development costs of any future clinical development in China and in return will benefit from higher economic value retention including both higher approval milestones and royalties  HCM additionally now has the option to co promote Elunate in China  On the occurrence of non fruquintinib related Eli Lilly commercial action  which we assume is related to a China launch of Cyramza   HCM will be able to promote Elunate in provinces that represent 30 40  of sales of Elunate  Lilly will pay HCM a service fee for all promotional activities in the HCM regions  While HCM already has a significant salesforce in China  the co promotion deal enables HCM to gain experience in commercialising its own in house developed products and expand its oncology salesforce prior to launching other pipeline assets  Importantly  HCM retains the full development and commercial rights to fruquintinib outside of China  assuming regulatory approvals are achieved  

The renegotiated deal terms on Elunate  fruquintinib  are a major positive in our view as these give HCM freedom of control on development of the asset into multiple oncology indications  not just as a monotherapy but also in combination therapies  the newly announced collaborations with Innovent Biologics and Genor Biopharma signal this  With the simplification of the LCI decision making process from two parties to one  we expect HCM will accelerate Elunate s commercial development in China beyond the indications currently in development  particularly in immunotherapy combinations 
FRUTIGA top line data in gastric cancer expected in 2020
The National Central Cancer Registry of China reports an incidence of 679 000 gastric cancer cases and 498 000 gastric cancer deaths in China in 2015  Most Chinese gastric cancer patients receive chemotherapy and few targeted therapies are approved  with limited salvage treatments in third line and above  HCM has initiated a pivotal Phase III  FRUTIGA  combination trial  second line  evaluating fruquintinib and established chemotherapy agent Taxol  paclitaxel  for the treatment of advanced gastric cancer patients  n 500  who have progressed after first line standard chemotherapy  5 fluorouracil and platinum doublets   If the FRUTIGA Taxol combination data are positive  this would enable fruquintinib use in earlier lines of gastric cancer  The full top line data are expected in 2020  The primary efficacy endpoint for FRUTIGA was overall survival  OS   secondary endpoints included PFS  progression free survival   ORR and DCR 
FALUCA primary OS endpoint not met in NSCLC
In November  HCM announced data from FALUCA  HCM s China based Phase III trial for fruquintinib monotherapy in third line NSCLC  after failure on two lines of systemic chemotherapy   The trial missed its primary endpoint of improving overall survival compared to placebo  The full dataset is yet to be presented  has been submitted for publication at a scientific conference   but statistically significant improvements were observed across all secondary endpoints  data not disclosed   PFS  duration of response  DoR  and objective response rate  Without a fully analysed dataset  and ascertaining the underlying cause for missing this endpoint  the future direction for fruquintinib monotherapy in third line NSCLC is unclear  What is becoming clear is that advances in cancer therapy  including targeted therapies and in the more nascent field of immunoncology  are changing treatment paradigms and this has implications for ongoing clinical trials that were designed and initiated a few years back  including FALUCA   Higher than expected survival rates seen in placebo arms could be a function of patients receiving other therapies at higher lines not accounted for when FALUCA was initially designed skewing the results  Thus we now assume that any future development in NSCLC is focused on combination therapies  particularly immunotherapy combinations  see below   While there are no planned combinations of fruquintinib with Tagrisso and or savolitinib in NSCLC  we believe any combinations could be synergistic and provide a point of differentiation for fruquintinib 
PD 1 combination the focus for future development
Targeted therapies and immunotherapies  monotherapy  have improved patient outcomes across many tumour types  combinations that work synergistically could enhance results further  HCM has developed Elunate to compete in the   16bn vascular endothelial growth factor receptor  VEGFR  market  which is dominated by Roche s Avastin  bevacizumab   a VEGF A inhibitor that is an intravenously administered monoclonal antibody  Roche reported 2018 sales of  6 9bn   Avastin inhibits VEGF A protein  whereas fruquintinib targets VEGF receptors 
In December 2018 the US FDA approved the triple combination of Tecentriq  Avastin and chemotherapy  carboplatin and paclitaxel  for first line NSCLC  non squamous   which is not driven by EGFR or ALK mutations  Exhibit 5   This serves as a strong validation that a combination of an anti angiogenic agent  Avastin  with an immune checkpoint inhibitor  Tecentriq  can have added benefit to patients with NSCLC  this highlights the potential for fruquintinib and surufatinib  which both inhibit VEGFR1 2 3  in combination with PD 1 antibodies  Similarly  data from three pivotal studies investigating analogous combination therapies for RCC  IMmotion151  JAVELIN renal 101 and KEYNOTE426  look promising  Exhibit 5  and support combination use 
In November  HCM entered into a range of collaborations to test surufatinib and fruquintinib with PD 1 inhibitors  For fruquintinib  HCM has a global partnership with Innovent Biologics and its PD 1 inhibitor sintilimab  IBI308  and a China focused collaboration with Genor BioPharma and its PD 1 inhibitor genolimzumab  GB226  

Fruquintinib  Elunate  peak sales assumptions
We have revisited our fruquintinib  Elunate  expectations  in the light of the differing pricing strategy to our expectations  and the disappointing FALUCA data in NSCLC monotherapy and move to combination strategy in this indication  We forecast global peak sales for fruquintinib of  2 6bn across all indications under investigation  CRC  NSCLC and gastric cancer   The magnitude of fruquintinib s success in part will depend on the global opportunity  we forecast RoW launches from 2023  In China Elunate gross pricing is  3 300 month  but as a result of HCM s Patient Access Programme  the median cost for Elunate over an average five months of use is  1 980 month  We now forecast peak sales of  199m in China vs  149m previously  We believe this pricing strategy and patient access programme could increase hospital formulary access and we assume that Elunate will be added to China s NRDL in the near term  inclusion will be a major growth driver 

Savolitinib  Striving for combination success
Since our last report was published  much clinical progress in the field of MET driven cancers has occurred  Foremost is changes in the renal cancer treatment paradigm  We had previously anticipated that savolitinib monotherapy for PRCC would be the first launched indication  potentially in late 2019 through a breakthrough approval in the US  However  recent paradigm shifts in the treatment of renal cell carcinomas are moving towards combinations with a PD 1 inhibitor  As such  AZN has suspended the Phase III monotherapy study in PRCC  SAVOIR  and future development will likely focus on a combination with AZN s PD L1 inhibitor Imfinzi  see below   this decision also took into account data from the MES  molecular epidemiology study  which showed smaller than expected applicable MET  status 
In the field of lung cancer  AZN s Tagrisso is raising the bar as it moves into the first line setting in EGFR mutation positive NSCLC  reporting sales of  1 9bn in 2018  its second full year on the market  The implication here is savolitinib s largest opportunity could be in combination with Tagrisso in EGFRm MET  NSCLC patients as MET mutations are the biggest driver in Tagrisso resistance  The savolitinib Tagrisso combination could rewrite the second line third line treatment paradigm and our forecast peak sales could be conservative  Following the encouraging data seen from the TATTON study  AZN and HCM in December 2018 initiated the global registrational study SAVANNAH for Tagrisso refractory NSCLC patients  HCM s partnership with AZN remains crucial to the development of savolitinib and our forecast peak sales 
Savolitinib is a highly selective inhibitor of the c Met signalling pathway and targets patients with resistant cancers whose tumour type tests positive for MET mutation  amplification or over expression  Savolitinib is hypothesised to have a greater beneficial impact on c Met driven tumours than approved multi kinase inhibitors  particularly in EGFR resistant patient subgroups  C Met  or hepatocyte growth factor receptor HGFR  is a signalling pathway  dysregulation of which mediates proliferation  apoptosis and migration in many tumour types including NSCLC  RCC and gastric cancer  This aberrant functioning can arise through c Met gene amplification  c Met over expression and gene mutations and the extent of each will differ by tumour type and patient  A key challenge in the area is identifying which biomarker and thus which diagnostic is most relevant to select the appropriate patients for MET targeted treatment as monotherapy and as combinations  Exhibit 7 highlights the incidence of MET dysregulation in NSCLC  the type  eg gene over expression  HGF expression  gene amplification  gene mutation  and the relevant biomarker for testing 

We highlight that the field is still in many ways in its infancy as companies such as HCM and Novartis  capmatinib  are at the forefront of developing c MET inhibitors  In late 2016 Phase III trial results of onartuzumab plus erlotinib in NSCLC did not prove clinical benefit over the comparator arm and it is thought that the clinical eligibility of patients based on MET over expression as measured by IHC may not be sufficiently sensitive and specific as a diagnostic tool to identify MET positivity 

Tagrisso combination could rewrite NSCLC paradigm
In the NSCLC setting savolitinib is being evaluated as a monotherapy in the MET Exon 14 skipping China Phase III registration study  in combination with Tagrisso  global TATTON and SAVANNAH studies   We highlight the largest opportunity is increasingly becoming the Tagrisso plus savolitinib combination in resistant driven EGFRm  MET   patient populations  In our view savolitinib s first approval for NSCLC ex China will likely be in combination with Tagrisso  AZN  for MET   T790M  patients who have progressed following Tagrisso  This specific subset of patients has an unmet medical need and  although we forecast a 2022 launch  BTD award could lead to earlier approval and launch 
AZN has presented analyses of FLAURA  first line Tagrisso  and AURA3  second line Tagrisso  data examining mutation status  via plasma sampling  of patients who become resistant to Tagrisso  While no known mechanism of resistance was identified in 60  of patients in AURA3  MET amplification was identified as an acquired resistance mechanism in 19  of patients and 15  of patients in FLAURA  Understanding the mechanism of acquired resistance following Tagrisso therapy is a key clinical question to inform the next treatment choice  AURA3 suggests that patients could benefit from addition of savolitinib to Tagrisso in MET  ve patients as second line therapy 
Critical for the future clinical trials planned for savolitinib is understanding the width and breath of MET alteration and how it can be best detected  tissue biopsy vs plasma testing   More recently it has been recognised that MET amplification in NSCLC is implicated in acquired resistance to EGFR inhibitors in  20  of cases with EGFR inhibitor resistance  A 2018 analysis of plasma samples from Tagrisso s AURA3 trial identified MET implication to be the cause of Tagrisso resistance in 19  of these patients in second line and above  Data from the Tagrisso FLAURA trial suggest that MET amplification is implied in 15  of cases in first line  In both cases  plasma samples were measured and it is thought that the frequency of MET amplification could be higher in tissue samples  This provides further therapeutic rationale for combinations of MET inhibitors with EGFR inhibitors to resistant NSCLC and the question is how high up in the paradigm savolitinib can be used  in combination with Tagrisso   The SAVANNAH and ORCHARD  see below  studies that are underway should shed light on these questions 
TATTON data  Consistent with interim analysis
In 2014 AZN initiated the TATTON study  a multi arm Phase Ib II study to test the suitability of an array of therapies with Tagrisso  osimertinib  in EGFRm  NSCLC patients who have progressed following treatment with EGFR TKIs  Patients who had cancer progression driven by MET amplification  identified by either NGS  next generation sequencing   FISH  fluorescence in situ hybridization  or IHC  were placed on a combination regime of savolitinib and osimertinib  stratified into two cohorts based on whether they had progressive disease  PD  while on a first  or second generation EGFR TKI  ie Iressa Tarceva  or a third generation EGFR TKI  ie osimertinib   Data from these two dose expansion cohorts were presented at AACR2019  Cohort 1 and Cohort 2   and reaffirmed the tolerable safety profile and promising efficacy data from the preliminary analysis that was presented at WCLC2017 
Following the encouraging data seen from these arms of the TATTON study  AZN and HCM in December 2018 initiated the global registrational study SAVANNAH  a Phase II  single arm trial assessing the efficacy of Tagrisso in combination with savolitinib for patients with EGFRm  MET amplified  locally advanced or metastatic NSCLC who have progressed  following treatment with Tagrisso  Primary data is expected in 2021  Likewise  AZN is planning to conduct ORCHARD  a Phase II  multiple arm trial looking to identify the drivers of resistance in NSCLC patients who have progressed following first line treatment with Tagrisso  this should act as a feeder to SAVANNAH and aid in patient recruitment 
NSCLC first China NDA submission in 2021
An estimated 2 3  of newly diagnosed NSCLC patients have a specific mutation known as MET Exon 14 skipping  Exon 14 of the MET gene is not functioning or deleted  leading to c MET over expression  In China  HCM estimates this to be 10 000 patients  A registrational Phase II clinical trial is underway in such patients who have progressed on prior chemotherapy  or who are unable to tolerate additional rounds of chemotherapy  Although the patient size is relatively small  this indication could be savolitinib s first NDA in China  Interim data were presented at AACR2019 and of the 31 evaluable patients  17 had a confirmed partial response  ORR of 54 8    12 patients had stable disease and two patients showed disease progression  DCR of 93 5    Savolitinib was generally well tolerated  with only 14 5   six of 41 patients  discontinuing treatment due to treatment emergent adverse events  mainly drug induced liver toxicity  three patients   six patients died on treatment  one of which was suspected to be treatment related  tumour lysis syndrome   Trial recruitment  in China  is expected to complete in 2019 and completion primary data can be expected in 2020  potentially with a Chinese NDA submission in 2021  We forecast launch in this indication in 2022  In the longer term in China  we believe a savolitinib plus Tagrisso combination will expand use in other subsets of NSCLC 
Data presented at ASCO2019 have highlighted the competitive landscape emerging  globally  for targeted treatments of MET Exon 14 skipping NSCLC patient populations  both Merck s c Met inhibitor tepotinib and Novartis s capmatinib demonstrated impressive ORR when used in treatment na ve patients  59  and 68  respectively  and as 2 third line treatments  45  and 41  respectively  
Kidney cancer  ICI combinations are game changing
The savolitinib registration strategy for kidney cancers  in particular PRCC  is being reassessed  taking into account findings from the molecular epidemiology study  MES  in PRCC patients and the realisation that treatment paradigms for RCC have shifted with the approval of PD  L 1 inhibitors and increasing use of VEGFR inhibitors  As a result AZN and HCM have stopped enrolment of patients into SAVOIR  a Phase III global registration study evaluating savolitinib monotherapy  vs sunitinib monotherapy  in MET driven PRCC patients  Successful commercialisation of savolitinib in kidney cancer  both ccRCC and PRCC  now hinges on CALYPSO  an investigator sponsored Phase II study combining savolitinib with AstraZeneca s PD L1 inhibitor Imfinzi  durvalumab  
In clear cell renal cell carcinoma  ccRCC  PD  L 1 immune checkpoint inhibitor are revolutionising the treatment landscape   the combination of MET inhibition with PD  L 1 inhibition could have utility in this space  as underlined by promising preliminary data from CALYPSO presently at ASCO GU 2019 
Savolitinib  Combined peak sales potential of  4 3bn
We forecast global peak sales for savolitinib of  4 3bn  PRCC  ccRCC  NSCLC and gastric cancer indications   lowered from our previous  5 9bn expectation  We have re evaluated our assumptions following changes in market dynamics  and changes in cancer treatment paradigms  In our view savolitinib s first RoW approval for NSCLC will likely be in combination with Tagrisso  AZN  for MET   T790M  patients  Additionally  we have reassessed our expected launch dates  and thus peak year of sales  and have pushed back launch years across indications  Exhibit 9   notably with the first indication launch  in second line third line NSCLC  now forecast for 2022 

Surufatinib  Positive Phase III data  China NDA H219
Surufatinib  previously known as sulfatinib  could be the first of HCM s non partnered assets to reach the China market in early 2021  The strategy for surufatinib was recently validated as positive interim data were announced in the SANET ep Phase III trial testing surufatinib in non pancreatic NET China patients  This was based on the trial meeting its primary endpoint of progression free survival  The data support a China NDA submission in late 2019 and we forecast a launch in 2021  However  a launch could occur in late 2020  It previously took 15 months from submission of the NDA to approval for fruquintinib  Elunate   However  three months was to gain GMP certification for HCM s Suzhou manufacturing plant  which should not be necessary for surufatinib  If the NDA is submitted within four months  October 2019  of the recent announcement of the top line data  as was the case for fruquintinib   then we believe a launch in late 2020 is possible  However  predicting review timelines for the China FDA is notoriously difficult and this timeline could slip  As such  we currently retain our 2021 launch date  Additionally  a pivotal China Phase III study  SANET p  in pancreatic NET is ongoing with data expected by the year end  If positive  this could further widen the market potential of surufatinib 
NETs are cancers that arise out of cells of the endocrine and nervous systems  predominately the digestive and respiratory tracts  While the current prevalence of NET in the US is  150 000 patients  incidence of  19 000 new cases per year   current treatment modalities are limited to subsets of NET with no broadly effective drugs across the NET spectrum  Data from Frost   Sullivan indicate the global NET market in 2018 was worth approximately  5 8bn and is expected to grow to  21 2bn by 2030  In particular  in China there is significant market opportunity with reported incidence of NET in 2018 of approximately 67 600 
Surufatinib is an oral angio immunokinase inhibitor that targets VEGF1  2 and 3  FGFR1 and colony stimulating factor 1 receptor  CSF 1R  kinases  CSF 1R is a cell surface protein that acts as the receptor for the cytokine CSF1  which controls macrophage  a type of white blood cell  function  Inhibition of CSF 1R limits the production of pro tumour macrophages  which  among other functions  is believed to aid in angiogenesis  tumour cell invasion and evasion of the immune system 
Following encouraging POC data from the Phase II study in biliary tract cancer  BTC   a pivotal open label Phase IIb III BTC trial  NCT03873532  in China has recently initiated  with the first patient dosed on 22 March  BTC represents a high unmet need due to limited treatment options and an increasing patient population  HCM is additionally developing the drug internationally  the global Phase Ib II study  NCT02549937  in pancreatic NET  second line in Sutent Afinitor refractory cancer  and BTC started enrolling US patients in July 2018  These trials will be managed by HCM s clinical and regulatory team that is now in place in New Jersey  US 
With the growth and widespread use of PD  L 1 inhibitor in the treatment of solid tumours  clinical trials combining these immune checkpoint inhibitors  ICIs  with CSF1 R  inhibitors have been initiated by several multinational pharmaceutical companies  HCM has recently initiated a Phase I dose escalation study  NCT03879057  in combination with Shanghai Junshi Biosciences  PD 1 inhibitor Tuoyi  toripalimab   which was recently approved in China for melanoma 

Peak sales potential of  1 0bn across all indications
We forecast global peak sales for surufatinib of  953m across the NET and BTC indications  We have removed thyroid cancer and adjusted sales forecasts  Our peak sales forecasts for surufatinib in NET   169m China   454m RoW  are conservative as at this point  We have updated our assumptions for NET in China and now assume an incidence of 68 000  vs 50 000 prevalence rate previously  and 19 months of treatment  vs 12 months previously  in China  This is based on new data from Frost   Sullivan and Phase II median PFS data  19 4 months   However  we note a patient access programme similar to Elunate could reduce the number of months HCM receive reimbursement for surufatinib  Additionally  following the positive SANET ep Phase III data we have upgraded our probability of success in NET to 90  from 75  previously  We forecast peak sales of  187m in BTC in China and  143m in RoW 
Global development of HMPL 523 and HMPL 689
Longevity for R D driven biopharmaceutical companies is dependent on having a pipeline of innovative assets that span both indications and development phases  HCM s strategy to date has focused on developing best in class kinase inhibitors that target solid cancers  the next wave of internally developed assets  HMPL 523  Syk inhibitor  and HMPL 689  PI3K  inhibitor   are kinase inhibitors  which have a clinical focus for various haematological  blood  cancers and autoimmune conditions  Concurrent Global and Chinese clinical programmes are ongoing  and recent IND approvals mean both assets have started US EU Phase I clinical development for indolent NHL 
B cell malignancies are a huge commercial opportunity
Haematological cancers arise in blood forming tissue  leukaemias and myelomas  or in the cells of the immune system  lymphomas   such as B cells or T cells  Treatment options vary according to cancer type and genetic burden  HMPL 523 and HMPL 689 are being developed for a range of B cell malignancies  Exhibits 12 and 13   The commercial opportunity in treating haematological malignancies is substantial  Many novel treatments have reached blockbuster status in haematological cancer sales alone  for example  Revlimid   8 9bn   Rituxan   5 4bn  and Imbruvica   4 5bn  in 2018  The US National Cancer institute SEER data estimate that in 2018 there were c 170 000 new cases of blood cancers  33  of which were leukaemias   18  multiple myeloma  MM   5  of Hodgkin s lymphoma  HL  and 44  with non Hodgkin  NHL   which comprises over 30 types of aggressive  fast  and indolent  slow  B cell and T cell malignancies  Five year survival rates  2008 2014  range from 27 4  in AML to 71 4  in NHL as patients relapse or become refractory  r r  to current treatment options  Efficacy and safety data from the ongoing Phase I studies of both HMPL 523 and HMPL 689 will further define in which patient populations these assets could have utility  as well as give an early indication as to whether they could be used in combination with other treatments  safety data  
The B cell signalling pathway is critical in haematological cancers  Approved novel drugs that target this pathway include Imbruvica  Zydelig  Jafaki and Rituxan  Exhibit 11   Targeting aberrant B cells is not only a proven strategy for the treatment of B cell related malignancies  but also in autoimmune disorders such as multiple sclerosis  MS  and rheumatoid arthritis  RA   highlighted by the commercial success of antibodies such as Rituxan  rituximab  and Ocrevus  ocrelizumab   HCM is evaluating HMPL 523 in idiopathic thrombocytopenic purpura  ITP   an immune mediated disease that results in low platelet levels 

Both HMPL 523 and HMPL 689 are small molecules designed to target kinases in the same B cell receptor signalling axis as the Bruton s tyrosine kinase  BTK  inhibitor Imbruvica and Zydelig  which  like HMPL 689  acts through inhibition of PI3K   Importantly  HCM retains the global development and commercialisation rights to both of these assets and both could present significant growth drivers in the medium and long term  We believe a key factor in success will be whether both assets can demonstrate good safety profiles as monotherapy as this will indicate potential combination regimes  which is where we believe treatment paradigms are shifting in treating B cell malignancies  Likewise  a well tolerated treatment will be essential for these to show any utility in autoimmune disorders  To date  HMPL 523 has been dosed in c 110 patients and c 118 healthy volunteers  HMPL 689 in c 30 patients and c 48 healthy volunteers and both have shown no off target toxicity 
HMPL 523  First in class opportunity for blood cancers
HMPL 523 targets Syk  an enzyme believed to be involved in diverse range of biological functions including in autoimmune disorders and haematological malignancies  In particular  Syk is involved in BCR signalling and is thought to promote the survival and maintenance of malignant cells  Syk sits just upstream of BTK and PI3K  and mediates their activation  therefore targeting it presents an alternative way of treating patients who are resistant or intolerant to Imbruvica or Zydelig  Exhibit 11   The clinical landscape for Syk inhibitors remains relatively competitive and in 2018 the US FDA approved the first Syk inhibitor  Rigel Pharmaceutical s fostamatinib  Tavalisse  for treating ITP  Entospletinib  developed by Gilead  NASDAQ GILD   is one of the most advanced clinical candidates for treating haematological malignancies 
HCM believes HMPL 523 is a potential best in class molecule and potentially first in class for haematological malignancies and we anticipate that launch in China in 2023 is feasible  Preliminary data presented at ASH2018 from the ongoing the Phase I Ib study in China showed some promising signs of efficacy 
21 evaluable patients  with relapsed or refractory disease  median of three prior treatment lines  predominately chemotherapy and CD20 targeting antibodies  
19  showing partial response  3 10 follicular lymphoma  FL   1 3 CLL SLL   and
40  achieving stable disease  3 4 mantle cell lymphoma  MCL   3 10 follicular lymphoma  FL   1 3 CLL SLL  1 2 marginal zone lymphoma  MZL   1 1 Waldenstrom macroglobulinemia  WM   
Click on the link to read the full report   ",2019-07-05,Edison,https://www.investing.com/analysis/hutchison-china-meditech-an-emerging-global-biopharma-200437211,200437211
171473,392989,LLY,Eli Lilly Q4 earnings miss but revenues beat estimates ,news,Investing com    NYSE Eli Lilly s  fourth quarter earnings missed estimates but revenues beat The U S  pharmaceutical firm reported Q4 EPS of  0 95 against a consensus estimate of  0 98 and  0 78 a year earlier Revenues came in at  5 76 bn  compared with a forecast of  5 61 bn Eli Lilly said revenues were up 7  year year driven by volume growth  Full year EPS was  3 52 vs   3 43 a year earlier as revenues rose 6  to  21 22 bn ,2017-01-31,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-q4-earnings-miss-but-revenues-beat-estimates-456850,456850
171474,392990,LLY,U S  health stocks fall on latest Trump tweets ,news,Investing com   U S  health stocks were lower Tuesday after Trump s latest remarks on lowering prices  I am working on a new system where there will be competition in the drug industry    Trump said in a Twitter post  Pricing for the American people will come way down   Trump added The Trump administration is planning to introduce a new healthcare plan to replace Obamacare Among stocks that fell was  NYSE Eli Lilly   which shed 1 98  to  82 17  NASDAQ Mylan  fell 2 24  to  43 08   Pfizer   NYSE PFE  lost 1 09  to  33 98 ,2017-03-07,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-health-stocks-fall-on-latest-trump-tweets-464343,464343
171475,392991,LLY,Wall St mixed as Snap  health stocks suffer ,news,Investing com   U S  stocks were narrowly mixed Tuesday with health stocks and Snap suffering The DJI was up 0 02  at 10 45 ET at below the 21 000 mark The S P 500 fell 0 04  The tech heavy Nasdaq composite added 0 16  The dollar index was higher as the market odds of a March rate hike rise to 86  Oil steadied ahead of API stockpile data  NYSE Snap  shed 7 87  to  21 90 after losing over 12  on Monday A number of analysts have sell recommendations on the stock after questioning its valuations Health stocks fell as Trump reiterated his pledge to bring drug prices down  NYSE Eli Lilly  was off 1 15  at  82 87 ,2017-03-07,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st-mixed-as-snap,-health-stocks-suffer-464346",464346
171488,393004,LLY,Pfizer s  PFE  Xeljanz Effective As Monotherapy In RA Study,opinion,Pfizer  Inc    NYSE PFE   announced positive data from a study  which was conducted to demonstrate the efficacy of its Janus kinase inhibitor  JAK  Xeljanz extended release as a monotherapy after withdrawing use of methotrexate  MTX  in adults with moderately to severely active rheumatoid arthritis  RA  The phase III IV ORAL Shift study was conducted to evaluate the efficacy and safety of Xeljanz XR 11 mg once daily  QD  as monotherapy after MTX withdrawal compared with Xeljanz XR with continued MTX in RA patients who achieved low disease activity after combination therapy  Data from the study showed that at week 48  Xeljanz XR after MTX withdrawal was non inferior compared with Xeljanz XR with continued MTX as measured by the primary endpoint  The primary endpoint of the study was to measure the change in the Disease Activity Score from randomization at week 24 to the end of the double blind MTX withdrawal phase at week 48 The results are expected to be presented during a late breaking oral session at the Annual European Congress of Rheumatology  The results of the study  if approved to be included in the label  will give doctors the option to prescribe Xeljanz to RA patients who are unable or unwilling to use MTX Xeljanz  a key drug in Pfizer s portfolio  recorded sales of  423 million in the first quarter of 2019  up 34  year over year  Sales growth was driven by continued growth in RA revenues and contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis in certain developed markets  Xeljanz was approved in the United States for new indications  psoriatic arthritis in December 2017 and ulcerative colitis in May 2018  Xeljanz is also being evaluated in late stage studies for ankylosing spondylitis Pfizer s shares have declined 1 3  this year so far against an increase of 1 9  for the    JAK inhibitors are emerging as a potential treatment option for RA  eczema and other inflammatory diseases  These medicines work by blocking a particular signal of a body s immune response  cytokines  instead of suppressing the immune system as done by disease modifying antirheumatic drugs  Other JAK inhibitors approved for different autoimmune or inflammatory diseases are Incyte s   NASDAQ INCY   Jakafi and Eli Lilly s   NYSE LLY   Olumiant Several pharma companies are also developing JAK inhibitors including AbbVie s   NYSE ABBV   upadacitinib and Galapagos NV Gilead s filgotinib  which are in late stage developmentPfizer currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-xeljanz-effective-as-monotherapy-in-ra-study-200431334,200431334
171489,393005,LLY,This Big Pharma Stock Is Dropping And Should Fall Further  Here s The Trade,opinion,"Eli Lilly  NYSE LLY  has been under pressure over the past couple of months  In fact the stock topped on March 26  2019 at  132 13 a share  Since that high pivot  LLY has declined by 14  and is currently trading at  112 84  Traders and investors should note that the stock is now trading below its 50  and 200 day moving averages 
Watch This Level
This weak chart formation usually signals further downside in the near term  Eli Lilly s next key support level is around  105  which is an important level that was defended in October and December 2018  Often  when a stock trades down to a major support area it will be defended again when initially retested ",2019-06-13,Nicholas Santiago,https://www.investing.com/analysis/this-big-pharma-stock-is-dropping-and-should-fall-further-heres-the-trade-200431427,200431427
171490,393006,LLY,Pharma Stock Roundup  MRK Buys Small Cancer Biotech  RHHBY  MRK Drugs Get FDA Nod,opinion,"This week Merck   NYSE MRK   announced a definitive deal to buy private preclinical cancer biotech Tilos Therapeutics  In other news  Roche   OTC RHHBY   won FDA approval for polatuzumab vedotin  to be marketed as Polivy  for diffuse large B cell lymphoma  DLBCL  while Merck s blockbuster PD L1 inhibitor Keytruda won approval for first line treatment of head and neck cancer Recap of the Week s Most Important StoriesMerck to Buy Tilos Therapeutics  Gets FDA Nod for Keytruda for First Line Head Neck Cancer  Merck announced a definitive deal to for a total potential purchase price of up to  773 million  The deal includes an undisclosed upfront payment and contingent milestone payments  The acquisition will add Tilos  portfolio of pre clinical antibodies  targeting a protein called TGF   being developed for various forms of cancer  fibrosis and autoimmune disease The FDA granted approval to Keytruda for first line treatment of metastatic or unresectable  recurrent   HNSCC  as monotherapy in patients whose tumors express PD L1 or in combination with chemotherapy regardless of PD L1 expression  The sBLA was based on data from the phase III KEYNOTE 048 study  wherein Keytruda  as a monotherapy and in combination with chemotherapy  demonstrated significant improvement in overall survival  OS  compared to the standard of care in the given patient population  Keytruda was approved in 2016  on an accelerated basis  for recurrent or metastatic HNSCC with disease progression on or after platinum containing chemotherapy  With the approval to include data from the KEYNOTE 048 study on Keytruda s label  the accelerated approval gets converted to a regular approval FDA Grants Approval to Roche s Polivy for DLBCL  The FDA granted accelerated approval to Roche s biologics license application  BLA  looking for approval of its anti CD79b antibody drug conjugate  ADC    for the treatment of relapsed or refractory  R R  DLBCL  Polatuzumab vedotin will be marketed by the trade name of Polivy and has been approved for use in combination with bendamustine plus Rituxan  BR   The decision came earlier than expected in August  Polatuzumab vedotin is being evaluated for the treatment of several types of non Hodgkin lymphoma  NHL  The FDA also accepted and granted priority review to Roche s supplemental biologics license application  sBLA  looking for   in combination with glucocorticoids  to treat children with two rare blood vessel disorders  granulomatosis with polyangiitis  GPA  or microscopic polyangiitis  MPA  Meanwhile  Rituxan met the primary and secondary endpoints in the phase III PEMPHIX study comparing it to mycophenolate mofetil  MMF   an immunosuppressive drug  in adults with pemphigus vulgaris  PV   In the study  Rituxan was demonstrated to be superior to MMF in achieving sustained complete remission  Rituxan is already approved to treat PV and the latest data provides additional clinical evidence on the effectiveness of Rituxan for the rare and serious disease Update from ADA  Key players in the diabetes market  Lilly   NYSE LLY    Sanofi   NASDAQ SNY   and Novo Nordisk   NYSE NVO   made data presentations from key diabetes studies at the scientific session of the American Diabetes Association  ADA  Lilly presented  from two phase III studies   PRONTO T1D and PRONTO T2D   evaluatingits investigational ultra rapid acting lispro  URLi  for the treatment of type I and type II diabetes  Data from the study showed URLi provided similar A1C  an overall measure of glucose control  reductions compared to Humalog and also led to superior reduction in blood glucose spike post meals At ADA  Lilly also presented data from an outcomes study  REWIND  on Trulicity  which showed that the GLP 1 receptor agonist led to a 12  reductionin cardiovascular  CV  events like CV death  non fatal myocardial infarction  heart attack  or non fatal stroke in a broad range of type II diabetes patients  However  the 12  reduction fell short of investor expectations  In addition  Lilly also presented data from a study on tirzepatide  its dual GIP and GLP 1 receptor agonist and detailed results from CAROLINA outcomes study on DPP 4 inhibitorTradjenta Novo Nordisk presented data from the PIONEER 6 cardiovascular outcomes study evaluating oral semaglutide versus placebo in patients with type II diabetes and established cardiovascular disease  The data demonstrated that oral semaglutide does not increase the risk of major adverse cardiovascular events  Novo Nordisk also presented 26 and 52 week data from two phase IIIa studies evaluating oral semaglutide versus Lilly s Jardiance  PIONEER 2 study  and its own GLP 1 receptor agonist Victoza  PIONEER 4 study  in type II diabetes  The data demonstrated that at 26 weeks  treatment with oral semaglutide led to superior reductions in blood sugar versus Jardiance and non inferior blood sugar reductions versus Victoza Sanofi presented data from a phase III study evaluating Soliqua in type II diabetes patients whose disease was inadequately controlled by GLP 1 receptor agonist  The data showed that Soliqua significantly lowered blood sugar levels compared to GLP 1 receptor agonist treatments in such patients AstraZeneca s   NYSE AZN   Farxiga showed reduced progression of kidney disease or renal death in patients with type II diabetes per data from a pre specified analysis of the phase III DECLARE TIMI 58 outcomes study on the SGLT2 inhibitor  Farxiga showed a 47  reduction in the composite of kidney function decline  end stage renal disease or renal death compared to placebo in the study  The DECLARE TIMI 58 is evaluating Farxiga to reduce the risk of renal or cardiovascular death or to slow the progression of kidney disease in type II diabetes patients J J   NYSE JNJ   presented new data from the CREDENCE outcomes study on a SGLT2 inhibitor  Invokana The NYSE ARCA Pharmaceutical Index rose 1 6  in the last five trading sessions Here is how the seven major stocks performed in the last five trading sessions 
 

 Last week  while J J and Glaxo recorded the highest gain  3    Lilly declined the most  4 2   In the past six months  Merck has been the biggest gainer  10 2   while Bristol Myers declined the most  7 1    See the last pharma stock roundup here   
What s Next in the Pharma World 
Watch out for regular pipeline and regulatory updates next week 
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-14,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod-200431776,200431776
171491,393007,LLY,Novo Nordisk s Victoza Gets FDA Nod For Pediatric Patients,opinion,Novo Nordisk  CSE NOVOb  A S   NYSE NVO   announced that the FDA has approved a label expansion of Victoza  liraglutide   The drug is now approved for the treatment of pediatric patients aged 10 years or older with type II diabetes  It is the only non insulin drug approved for children other than metformin  which was approved for pediatric use in 2000 In fact  the drug was approved by the FDA to treat adults with type II diabetes in 2010 Victoza has now been proved to improve blood sugar control in pediatric patients with type II diabetes  The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease Type II diabetes is the most common form of diabetes  occurring when the pancreas cannot make enough insulin to keep blood sugar at normal levels Shares of the company have increased 12  compared with the  s growth of 5 8    Victoza improves blood sugar levels by creating the same effects in the body as the glucagon like peptide  GLP 1  receptor protein in the pancreas  GLP 1 is often found in insufficient levels in type II diabetespatients  Like GLP 1  Victoza slows digestion  prevents the liver from producing too much glucose  and helps the pancreas produce more insulin when needed The efficacy and safety of Victoza for reducing blood sugar in patients with type II diabetes were studied in several placebo controlled trials in adults and one placebo controlled trial with 134 pediatric patients aged 10 years or older for more than 26 weeks  The studies have shown that about 64  of patients in the pediatric study had a reduction in their hemoglobin A1c  HbA1c  below 7  while on Victoza compared to only 37  who achieved these results with placebo  Novo Nordisk s top line is driven by strong performance of products like Victoza  The company continues to be the global market leader in the GLP 1 segment  with a 46 1  value market share  With this approval  sales of the company should rise further Novo Nordisk has a strong presence in the Diabetes care market  with a global value market share of 28 1   Also  the company has strong presence in the total insulin market  with a global value market share of 46 7  However  Novo Nordisk is going through a rough patch  with several drugs in its portfolio losing patent protection  The company is also facing pricing pressure for some of its drugs Moreover  the diabetes market is already crowded with a number of drugs  Merck s   NYSE MRK   Januvia and Janumet  type II diabetes   Eli Lilly s   NYSE LLY   Trulicity  type II diabetes   and Sanofi s   NASDAQ SNY   Toujeo  type I and II diabetes  are already approved Novo Nordisk A S Price   Zacks RankNovo Nordisk currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients-200432584,200432584
171493,393009,LLY,Kazia Therapeutics  Higher MTD  New Collaboration For GDC 0084,opinion,"Kazia Therapeutics  NASDAQ KZIA  has identified a higher maximum tolerated dose  MTD  from a Phase IIa study of its brain penetrant phosphoinositide 3 kinase  PI3K  inhibitor GDC 0084 in glioblastoma  GBM   which may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study  A new collaboration with the Alliance for Clinical Trials in Oncology  Alliance  means Kazia will soon have four clinical trials of GDC 0084 underway in primary or secondary brain cancers  It also expects further preliminary efficacy data from its Cantrixil Phase I study in ovarian cancer in H219  We adjust our valuation to between  64m and  103m 

Higher MTD for GDC 0084 in target population
Kazia s Phase I study showed that recently diagnosed GBM patients were able to tolerate a higher  and therefore potentially more efficacious  dose of its oral PI3K inhibitor GDC 0084 than Genentech had reported from its prior study in patients with late stage disease  A 20 patient expansion cohort is expected to report top line efficacy data in Q419 
GDC 0084 is targeting an unmet need in GBM
The GBM trials will test GDC 0084 in patients who have an unmethylated MGMT promotor  This subgroup   61  of GBM patients  obtains little benefit from standard temozolomide chemotherapy  Kazia may seek to position the planned Phase IIb study in GBM as a pivotal study designed to support filing for approval for this patient population who have no effective treatments  If this strategy is accepted  Kazia could be in a position to file for approval in this indication in 2023 
New collaboration targeting brain metastases
Kazia s collaboration with the Alliance will target brain metastases that have genetic alterations of the PI3K pathway  The Phase II study will target brain metastases from a wide range of solid tumor types  allowing Kazia to fully capitalize on the capacity of GDC 0084 to penetrate the brain  The trial is expected to be completed in 2021 
Cantrixil expansion cohort data in H219
Potential efficacy signals from the 12 patient expansion cohort of the Phase I study of Cantrixil in ovarian cancer are expected to read out in H219  We expect Kazia to seek a partner to support the further development of Cantrixil in this indication 
Valuation  Adjusted to  64 103m in two scenarios
We adjust our indicative valuation range to  64 103m or  10 27 16 50 ADR  vs  64 111m   10 31 17 82 ADR   due to revised timelines for post Phase III approval or single pivotal study approval scenarios for GDC 0084  Kazia had  4 1m cash at 31 December 2018 and will likely need to raise funds in H219  We estimate   11 15m will be needed to fully fund the GDC 0084 Phase IIb study 

Business description
Kazia Therapeutics is an ASX  and NASDAQ listed biotechnology company  It is developing the PI3K mTOR inhibitor GDC 0084 for brain cancer and Cantrixil for ovarian cancer  GDC 0084 was in licensed from Genentech in 2016 
Investment summary
Company description  Two novel classes of anti cancer drugs
Kazia Therapeutics is an Australian biotechnology company focused on oncology drug development  listed on both the ASX  KZA  and Nasdaq  KZIA   It is developing GDC 0084  a brain penetrant PI3K inhibitor licensed from Genentech  and a third generation benzopyran drug  Cantrixil  A Phase IIa trial of GDC 0084 in GBM identified a higher MTD than previously reported by Genentech  and is treating an expansion cohort at the higher dose  Kazia is supporting investigator initiated studies of GDC 0084 in breast cancer brain metastases and in the childhood brain cancer known as diffuse intrinsic pontine glioma  DIPG   It is also supporting a study of GDC 0084 in brain metastases from a range of solid tumor types that have genetic alterations of the PI3K pathway  A Phase I trial of Cantrixil in ovarian cancer is expected to report preliminary efficacy data from an expansion cohort in H219  The company s product pipeline is summarized in Exhibit 1 

Valuation   64 103m   10 27 16 50 per ADR
We value Kazia between  64m and  103m  We now consider a scenario where approval is obtained in 2024 after a single study as our base case  with a valuation under this scenario of  103m  Our alternative valuation of  64m models a potential approval in 2026 after a confirmatory pivotal study  Our base case valuation is equal to  16 50 ADR  or  15 85 ADR after diluting for options and convertible notes  Our valuation is based on a risk adjusted NPV analysis  which includes net cash and our forecasts for GDC 0084 and Cantrixil  with probability of success of 10 25  to reflect the stage of development of each product 
Financials  Additional funds likely required in H2 CY19
Kazia had  4 1m cash at 31 December 2018 and also had a  2 2m R D tax rebate receivable  It subsequently raised  1 8m through the sale of its Noxopharm shares  We expect the available funds to be sufficient to support operations into H2 CY19  We estimate that Kazia will need additional funds of  11 15m to finance the GDC 0084 Phase IIb GBM study  While the preliminary efficacy data from the GDC 0084 Phase IIa study is expected to read out in Q419  depending on the timing  funds may need to be raised in H2 CY19 before the GDC 0084 trial data are available 
Sensitivities
The key sensitivities for Kazia will be funding risk and the success of its lead drugs in clinical trials  A key question will be whether GDC 0084 works sufficiently well as a single agent in GBM to justify filing for approval after a single pivotal study  or whether a confirmatory Phase III trial  possibly in combination with radiotherapy or temozolomide  will be required for approval  Our base case scenario models a potential approval in 2024 after a single pivotal study  If a confirmatory trial is required  approval could be delayed to 2026 or later  While Kazia has fully funded the ongoing Phase IIa study of GDC 0084 in GBM  it would require additional funds of   11 15m for a Phase IIb trial  which could result in significant dilution of existing shareholders 
Improved tolerability of GDC 0084 in first line GBM
Kazia reported in early May that its Phase IIa study of GDC 0084 in patients with recently diagnosed GBM had determined that the MTD in this patient population is substantially higher than the MTD previously reported by Genentech  60mg day vs 45mg day   Genentech s Phase I study was conducted in a sicker patient population with late stage disease 
The safety and tolerability profile reported for GDC 0084 was encouraging  The dose limiting toxicities in the Phase IIa study included mouth ulcers and elevated blood sugar  hyperglycemia   both of which are anticipated effects of the PI3K inhibitor class of drugs  Notably  Kazia did not observe any of the more serious side effects that are sometimes associated with this class of drugs  such as infections  liver toxicity or gastrointestinal problems 
A dose expansion cohort of 20 patients is being recruited to gather additional safety and efficacy data at the 60mg dose 
If good tolerability is confirmed in the expansion cohort  Kazia will use the 60mg dose in its planned randomized Phase IIb study  This is a positive outcome  in our view  as the higher dose is likely to be more efficacious  thus improving the prospects for a positive result from the study 
GDC 0084 was developed by Genentech to target brain cancer
Kazia in licensed GDC 0084 from Genentech in October 2016  The drug is an orally administered small molecule PI3K inhibitor that targets an important growth signaling pathway in cancer cells  The drug is also deliberately designed to be a moderately potent inhibitor of mammalian target of rapamycin  mTOR  kinase  to avoid the toxicity seen with drugs that are potent inhibitors of both targets  GDC 0084 was specifically developed to cross the blood brain barrier and target GBM  which is an aggressive brain cancer for which there are few effective therapies  Abnormal PI3K signaling is associated with over 80  of cases of GBM 1
Higher doses inhibited tumor growth in Genentech Phase I
Genentech conducted a Phase I trial of GDC 0084 in patients with advanced disease  which confirmed it readily crosses the blood brain barrier and led to dose dependent inhibition of tumor growth  Seven of the eight patients treated at 45mg day  the MTD identified by Genentech in patients with advanced disease  demonstrated levels of drug in the bloodstream that were associated with significant inhibition of tumor growth in preclinical models 
Exhibit 2 illustrates the tumor responses for the patients treated with GDC 0084 in Genentech s Phase I study  The bars pointing upward from the zero baseline  x axis  in the exhibit represent how much the tumor grew  while the downward pointing bars represent tumors that shrank in volume over the period of treatment with GDC 0084  The upper red dotted line marks the 25  increase in tumor size  sum of product diameters  that is the maximum cut off for stable disease according to the RANO2 response assessment criteria  while the lower red dotted line marks the 50  reduction in tumor volume that is the threshold for a partial response 
Although none of the patients reached the 50  reduction in tumor size that would qualify as a partial response  there was a clear dose response in terms of the impact on tumor growth  with much less tumor growth in patients treated at higher doses  For example  five of the six patients treated at the highest dose  65mg day  achieved a best response of  25  tumor growth  the upper limit for stable disease in the RANO criteria   compared to only three of the six subjects meeting this criterion in the 45mg day cohort  In this patient population  which has no effective treatments available  delaying disease progression by even a month or two would be a meaningful benefit 
The dose response shown in Exhibit 2 highlights the potential importance of the higher MTD identified for GDC 0084 in recently diagnosed patients in Kazia s Phase IIa study  It suggests that using the higher 60mg day dose of GDC 0084 in the upcoming Phase IIb may inhibit tumor growth to a greater degree  and therefore may increase the chances of improving progression free survival  PFS   thus meeting the primary endpoint of the study 

Top line data from expansion cohort expected Q419
Kazia is recruiting an expansion cohort of 20 patients who will be treated at 60mg day  This second part of the study is designed to provide additional safety data and confirmatory efficacy signals and is expected to report top line data in Q419  The subjects will undergo intensive monitoring to better understand the pharmacokinetic and toxicity profile of the drug  including the effect on major organs including the heart 
Kazia s Phase II studies are being conducted in newly diagnosed  first line  patients who have undergone surgery to remove the bulk of the tumor and a course of chemoradiotherapy to further reduce the tumor burden  Many patients will not have measurable tumors at the start of the study and so they will not be able to be assessed for tumor response  shrinkage  according to the RANO criteria  Therefore  we expect the key efficacy criteria to be PFS and overall survival  OS   FDG PET brain scans will also be assessed to see whether they can predict PFS or OS 
GBM  An aggressive brain cancer with few effective treatments
GBM is the most common and most aggressive primary brain cancer  Approximately 11 500 patients are diagnosed with GBM each year in the US  GBM tumors are characterized by invasive and diffuse growth  which makes complete surgical removal difficult  Standard treatment for GBM entails surgical resection of the tumor followed by radiotherapy with concurrent chemotherapy with temozolomide  TMZ   followed by adjuvant chemotherapy with the same drug to treat the residual infiltrative component of the tumor  Despite this aggressive treatment  the disease invariably returns  resulting in a five year survival rate of only 5  3
Randomised Phase IIb in GBM the next step for GDC 0084
The company s plan is for the Phase IIa study to be followed by a randomized Phase IIb study in 228 patients with recently diagnosed GBM  Exhibit 3   although this trial design could be modified after further discussions with regulators  The planned Phase IIb study will compare maintenance therapy with GDC 0084 vs standard of care TMZ in recently diagnosed GBM patients who have undergone standard therapy comprising surgery to remove the bulk of the tumor followed by a course of radiation therapy  XRT  combined with TMZ  After completing XRT  patients will be randomized to receive maintenance therapy with either GDC 0084 or TMZ to treat residual tumor cells and delay recurrence of the disease 
The study will target the 61  of GBM patients where tumor cells have an unmethylated MGMT promoter  which counteracts the cytotoxic effect of TMZ   as these patients receive only minimal benefit from treatment with TMZ and are in urgent need of more effective therapies  GDC 0084  which blocks the PI3K signaling pathway  is not affected by the methylation status of the MGMT promoter 


Revised accelerated approval scenario could see GDC 0084 launched in 2024
There are no effective therapies for GBM in patients whose tumor cells have an unmethylated MGMT promoter  Therefore  if the Phase IIb trial shows a meaningful improvement in PFS or OS in these patients  there is a good prospect that it could be eligible to seek approval based on the single pivotal Phase II study  rather than waiting for completion of a confirmatory Phase III trial before filing for approval  Therefore  we model timelines for the approval of GDC 0084 following a single pivotal Phase IIb study and for a scenario of approval following a confirmatory Phase III trial 
With top line data from the GDC 0084 expansion cohort expected in Q419  we have revised our trial timelines  We now model a pivotal Phase IIb study commencing in Q220 and reporting top line data in Q4 CY22  vs Q3 CY21  with a market launch in Q2 CY24  vs Q2 CY23   as shown in Exhibit 5 


In its presentation to the Biotech Showcase in January  the company referred to the upcoming randomized trial of GDC 0084 in GBM as a registration study  which indicates it may be designed to support an application for full regulatory approval in this indication  This has prompted us to adopt the single pivotal study scenario in our base case valuation model  our base case previously assumed that two efficacy studies would be conducted before filing for approval  
We now evaluate the two trial model as an alternative valuation scenario rather than the base case 
GDC 0084 joins NCI sponsored brain metastases study
Kazia announced in May that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology  a US based cancer research network that is sponsored by the National Cancer Institute  NCI   to study GDC 0084 in the treatment of brain metastases  cancer that has spread to the brain from a primary tumor elsewhere in the body  
The Alliance study is expected to recruit around 150 patients with brain metastases in an open label Phase II study  Patients with genetic alterations in the PI3K pathway will be treated with GDC 0084  and it is expected that around 50 patients will fall into this group  Patients with other genetic mutations will be allocated to receive either abemaciclib  Verzenio  Eli Lilly  NYSE LLY    a CDK inhibitor approved for certain forms of breast cancer  or entrectinib  Genentech  a Trk ALK inhibitor undergoing FDA priority review for solid tumors that are positive for NTRK or ROS1 gene fusions 
The study is expected to start recruiting patients in H219 and to take around two years to complete 
Brain metastases are quite common  according to estimates from the American Brain Tumor Association  there are around 200 000 new cases of brain metastases in the US each year 4 Treatment options for brain metastases are limited  as  unlike GDC 0084  many anti cancer drugs do not cross the blood brain barrier 
Kazia s announcement did not spell out whether there is any limitation on the type of primary tumor that will be included in the study  but we note that lung  breast  colorectal  melanoma and renal cancers account for the majority of people diagnosed with brain metastases 5
The Alliance study is in addition to the company s ongoing study in patients with breast cancer brain metastases  in collaboration with the Dana Farber Cancer Institute  One of the advantages of the new study is that it will generate data in patients with a range of different tumor types who have been treated with GDC 0084 
Kazia will support the study including by providing GDC 0084 drug as well as a financial grant  we model Kazia providing  0 4m of financial support  
We leave our modelling of the market potential of GDC 0084 in brain metastases unchanged  Our model is based on the treatment of brain metastases in patients with HER2 positve breast cancer as an illustrative indication  We may look to revise this assumption  depending on the outcome of the Alliance study 
There will soon be four GDC 0084 clinical trials underway
Once the Alliance study in brain metastases is underway  there will be four ongoing clinical trials of GDC 0084 in cancer patients  as shown in Exhibit 7  In addition to the GBM and Alliance studies described above  Kazia is collaborating in two other investigator led trials of GDC 0084 
The first of these is a Phase II trial in collaboration with the Dana Farber Cancer Institute to investigate GDC 0084 in combination with Herceptin in women with HER2 positive breast cancer who have developed brain metastases  Genentech showed that GDC 0084 improves survival in this indication in animal studies and the recent approval of Novartis s alpelisib  Piqray  previously known as BYL719  validates targeting PI3K in breast cancer 
The second collaboration is with St Jude Children s Research Hospital in a Phase I study of GDC 0084 in the aggressive childhood brain cancer DIPG  Although the number of patients with this disease is small  the lack of approved treatments for this aggressive cancer could open pathways to an accelerated approval or Breakthrough Designation  Approval could also earn a valuable FDA pediatric priority review voucher 

First PI3K inhibitor approval in solid tumors
The PI3K signaling pathway plays a crucial role in cellular proliferation  metabolism  survival and apoptosis  programmed cell death   PI3K signaling is initiated by receptor tyrosine kinases or G protein coupled receptors located at the cell surface  and by some oncogenic proteins such as Ras 
The PI3K pathway is frequently overactivated in cancer  This can occur through a variety of mechanisms including mutation and amplification of genes in the pathway  or by loss of function of the tumor suppressor PTEN  which is a negative regulator of PI3K signaling 
Of particular relevance to Kazia  the PI3Kalpha inhibitor alpelisib  Piqray  Novartis  was approved by the FDA on 24 May 2019 for treating patients with hormone receptor positive  HER2 negative breast cancer  whose tumors carried mutations in the PIK3CA gene  In the Phase III Solar 1 study  adding alpelisib to standard fulvestrant hormone therapy almost doubled PFS  11 0 months vs 5 7 months  hazard ratio 0 65  p 0 0013  in patients with PIK3CA mutations  This is the first example of a PI3K inhibitor being approved for treating solid tumors  vs blood cancers  
The first three PI3K inhibitors that were approved all target hematological cancers  cancers of the blood cells   Idelalisib  Zydelig  Gilead Sciences  NASDAQ GILD   was first approved by the FDA in 2014 and is approved to treat several types of leukemia and lymphoma  Idelalisib is a selective inhibitor of the delta isoform of PI3K  PI3K    A second PI3K inhibitor copanlisib  Aliqopa  Bayer  DE BAYGN    was approved for treating lymphoma in September 2017  whereas a third  duvelisib  Copiktra  Verastem  was approved for treating two types of leukemia and lymphoma in October 2018 
The approvals of these four drugs provide validation for PI3K as a target for anticancer drug development  However  none of those drugs was designed to cross the blood brain barrier  whereas GDC 0084 was specifically designed to do just that  To the best of our knowledge  Kazia is the only company that is developing a PI3K inhibitor in GBM 
Encouraging efficacy in Cantrixil dose escalation study
Kazia s second drug in clinical development  Cantrixil  is being developed to target ovarian cancer  and potentially other cancers that have spread to the abdominal cavity  Cantrixil is a third generation benzopyran drug that was the product of an in house discovery program  Cantrixil is delivered by infusion into the abdominal cavity  intraperitoneal administration   which increases the exposure of abdominal organs  including the ovaries  to the drug  The company initiated a dose escalation Phase I study of Cantrixil in December 2016  The study recruited women with ovarian  fallopian tube or primary peritoneal cancer who had failed at least two prior lines of therapy  including standard platinum based therapy  eg cisplatin  carboplatin or oxaliplatin  
Kazia presented a poster summarising the safety and efficacy of data from the dose escalation cohorts of the Phase I study of intraperitoneal Cantrixil  TRX E 002 1  at the American Association for Cancer Research  AACR  conference held from 29 March to 3 April 2019 in Atlanta  Georgia  In total  11 subjects were treated with Cantrixil at doses ranging from 0 24mg kg to 20mg kg  Nine subjects received at least three doses  ie one full cycle  and were evaluated for efficacy 
The study identified the MTD as 5mg kg  The main side effects were gastrointestinal  with abdominal pain and fatigue the most common drug related observations  although generally not dose limiting  Treatment centres have strategies in place to manage side effects such as pain  nausea and vomiting  but they were not used in this study because the investigators did not want to mask any adverse events 
Cantrixil also showed encouraging signs of anti cancer efficacy  Five of the nine subjects  56   who had received at least three weekly doses  one cycle  of Cantrixil achieved stable disease when evaluated six weeks after treatment commenced  Exhibit 8  
The five subjects with stable disease at the end of the six week Cantrixil monotherapy treatment period went on to receive Cantrixil in combination with a range of chemotherapy agents  At the end of the 24 week study period  three of the five had developed progressive disease  one remained stable and one had gone on to experience a partial response  as detailed below 

Exhibit 9 shows the progressive tumor reduction in the patient  subject 03 002  who went on to experience a partial response when treated with Cantrixil in combination with paclitaxel after completing Cantrixil monotherapy treatment 
This subject experienced substantial tumor shrinkage during the six week period when she was treated with Cantrixil at 2 5mg kg as a monotherapy  At the completion of Cantrixil monotherapy the patient subsequently received six cycles  18 weeks  of treatment with 2 5mg kg Cantrixil combined with paclitaxel  The tumors continued to shrink and 12 weeks after entering the study the patient had achieved a partial response  The response was ongoing at the end of the 24 week follow up period when the patient exited the study  Exhibit 9 also shows that the tumor shrinkage was maintained at a further assessment two months after the end of the study 

Recruitment of Cantrixil expansion cohort well advanced
Kazia is recruiting a 12 patient expansion cohort that is being treated with Cantrixil monotherapy at the MTD of 5mg kg  As of March 2019  nine of the 12 patients had been recruited  Kazia expects to fully recruit the expansion cohort in Q219 and report initial efficacy data in H219 
The 56  of subjects with stable disease at the end of the 6 week monotherapy treatment period and the substantial reduction in tumor size seen in one patient receiving combination therapy are encouraging signs that Cantrixil may inhibit tumor growth  However  it is not yet clear whether the efficacy is sufficient for it to be a commercially successful product  The expansion cohort will provide additional data to help assess the safety and potential efficacy of Cantrixil 
Future options for Cantrixil  First  or second line combinations
Kazia s overall business strategy is to in license drug candidates then add value by conducting early  to mid stage clinical development  before out licensing or selling the program to a partner that would conduct late stage development 
Therefore  we expect the company to seek a partner for late stage development of Cantrixil  Depending on the level of interest from potential pharma partners and on Kazia s available financial resources  it could also seek a partner for the next stage of Cantrixil development  Another option would be for Kazia to conduct a small study if there is a particular question that potential pharma partners want to have addressed before they commit to a transaction 
Cantrixil has shown encouraging signs of efficacy as a single agent and good tolerability when used in combination with standard second line therapies  These two factors mean Cantrixil is likely to be well suited to use in combination therapy 
If the data from the expansion cohort are sufficiently encouraging and there is enough interest from potential partners  we suspect the likely next step would to be to test Cantrixil in combination with the investigator s choice of standard chemotherapy drugs in either a first  or second line setting 
High unmet need in ovarian cancer
Ovarian cancer accounts for 22 400 new cases and 14 100 deaths in the US each year  with a five year survival rate of 47   Worldwide  there are an estimated 239 000 new cases and 152 000 deaths annually according to the International Agency for Research on Cancer with the highest rates coming from developed countries  The majority of those diagnosed already have distant metastases  which is associated with a 28 9  five year survival rate  see Exhibit 10  

Patients who present with ovarian cancer are typically treated with surgery followed by a platinum based chemotherapy  such as paclitaxel and carboplatin   Unfortunately  around 70  of patients relapse in the first three years following therapy 6 although this is expected to improve  especially among the 10  of ovarian cancer patients with BRCA mutations  with the approval of the PARP inhibitor niraparib by the FDA as a maintenance therapy  PARP inhibitors are also used in those with BRCA mutations in later lines of therapy 
The situation is dire for patients who are platinum refractory or who become platinum resistant  a condition that eventually occurs to all surviving platinum sensitive patients following repeated platinum courses   The current standard of care for platinum resistant or refractory patients is either PEGylated lysosomal doxorubicin  PLD  FDA approved in 1999  or topotecan  FDA approved in 1996   both of which typically have shown a response rate of 10 15   PFS of approximately 3 5 months and OS of 12 months in large trials 7 This segment of the ovarian cancer population continues to be an unmet medical need and would likely be a key target for Cantrixil 
Sensitivities
The key sensitivity for Kazia will be the success of its two lead drugs in clinical trials  A crucial question regarding GDC 0084 will be whether it works sufficiently well as a single agent in adjuvant therapy to receive approval based on a single pivotal study  In this regard  it is encouraging to note that Avastin was granted accelerated approval in 2009 for treating recurrent GBM based on the response rates observed in 141 patients  If GDC 0084 needs to be used concurrently with radiotherapy or with TMZ in order to deliver sufficient efficacy in GBM then one or more additional efficacy trials may be required  delaying potential launch until 2026 vs 2024 under a single pivotal study approval scenario  There is also a significant risk that GDC 0084 may not provide sufficient benefit to justify approval either as a single agent or combination therapy 
Although Kazia is approaching the final stages of the Phase IIa study of GDC 0084 in GBM  we estimate it would require additional funds of   11 15m for the randomized Phase IIb trial  This could result in significant dilution of existing shareholders given the current market capitalization of   15m 
Our valuation includes revenues from the development of two drugs in four disease indications  as well as  risk adjusted  upfront and milestone payments for two licensing deals  While each of these targeted indications is supported by the current preclinical efficacy studies and evidence of a dose response in the GDC 0084 Phase I trial  the company may not ultimately pursue development of the drugs for all of these indications  In contrast  ongoing preclinical efficacy studies could identify additional disease indications that should be investigated in clinical trials  While we believe the drug development timelines used in our forecasts are achievable  at this early stage it is hard to accurately predict how long it will take to get the drugs to market 
Valuation
As explained on page 6  we have swapped the GDC 0084 development programs that we model for our base case and alternative valuation scenarios for Kazia  We have also adjusted our valuation range to reflect our revised timelines for clinical development of GDC 0084 in GBM  Our revised valuation range is  64 103m  vs  64 111m   with the upper end of the range now representing our base case scenario 
Our base case valuation of  103m models a GDC 0084 market launch in 2024 following a single pivotal study  The valuation is slightly lower than in our previous report  which modelled a launch one year earlier  in 2023  Our valuation is equivalent to  16 50 ADR and  15 85 ADR after diluting for options and convertible notes  Kazia s primary listing is on the ASX under the code KZA  each NASDAQ listed ADR represents 10 ordinary shares  Our undiluted base case valuation equals A 2 17 per ASX listed ordinary share at current exchange rates 
Our base case valuation assumes a 40  likelihood that GDC 0084 is out licensed to a marketing partner in 2023 after reporting positive PFS data from the Phase IIb trial in a deal that includes  40m upfront and  120m in clinical and regulatory milestone payments  We also assume Kazia pays a royalty of 10  of net sales to Genentech and that global sales for GBM reach  1 050m in 2030 
Exhibit 11 shows our base case market assumptions for GDC 0084 and Cantrixil and the contribution of product royalties and milestone payments to the rNPV  We have offset the risk adjusted trial cost against milestone revenue for each drug  rather than against royalty revenue  This understates the contribution of the milestone payments to the rNPV and overstates the contribution of royalties 

We have also valued Kazia under an alternative accelerated approval scenario for GDC 0084  which assumes a market launch in 2026 and that Kazia receives a lower 15  royalty rate and a smaller  20m upfront payment due to the need for the partner to complete an confirmatory efficacy study before filing for approval  with other deal terms the same as for the accelerated approval base case scenario  Exhibit 12 shows that requirement for a confirmatory pivotal study for GDC 0084 would reduce our valuation for Kazia to  64m or  10 27 ADR  undiluted  

Financials
Kazia had  4 1m cash plus an  2 2m R D tax rebate receivable at 31 December 2018  It has subsequently raised  1 8m  before costs  through the sale of its shareholding in Noxopharm  We expect the available funds to be sufficient to support operations into H2 CY19  While the preliminary efficacy data from the GDC 0084 Phase IIa study are expected to read out in Q419  depending on the timing  funds may need to be raised in H2 CY19 before the trial data are available  We estimate Kazia will need additional funds of  11 15m to finance the GDC 0084 Phase IIb GBM study 
We have revised our FY20 financial forecasts to include an  0 2m contribution to the Alliance collaborative study  plus a further  0 2m contribution in FY21 ",2019-06-21,Edison,https://www.investing.com/analysis/kazia-therapeutics-higher-mtd-new-collaboration-for-gdc0084-200433571,200433571
171494,393010,LLY,Athenex and Lilly team up in cancer collaboration,news,Privately held Athenex and Eli Lilly  NYSE LLY  will work together in a Phase 1b study assessing the combination Athenex s oral paclitaxel  Oraxol  and Lilly s CYRAMZA  ramucirumab  in patients with advanced gastric cancer and esophageal cancer  Patient enrollment will commence in 2017 Athenex will sponsor the study while Lilly will supply product ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/athenex-and-lilly-team-up-in-cancer-collaboration-442249,442249
171495,393011,LLY,Eli Lilly falls 15  as trial shows Alzheimer treatment ineffective ,news,Investing com   Eli Lilly  NYSE LLY  shares plunged Wednesday as trial shows solanezumab Alzheimer drug ineffective  Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline  Eli Lilly said The results of the trial  were not what we had hoped for   CEO John C  Lechleiter said in a statement Eli Lilly shares were down 14 89  at  64 68 in pre market trade ,2016-11-23,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-falls-15-as-trial-shows-alzheimer-treatment-ineffective-443224,443224
171496,393012,LLY,Wall St down before holiday as dollar jumps on data ,news,Investing com   U S  stocks were lower early Wednesday after record highs as dollar jumps on strong data The  DJI was down 0 01  at 09 45 ET  while the S P 500 shed 0 25  The tech heavy Nasdaq composite lost 0 57  Durable goods and jobless claims figures underscored strength of U S  economy Treasury yields spiked while the odds of a December Fed hike back at 100  Investors were also unwinding positions ahead of the Thanksgiving holiday Eli Lilly  NYSE LLY  was down 13 13 at  66 02 as a trial of its Alzheimer drug proved ineffective ,2016-11-23,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-down-before-holiday-as-dollar-jumps-on-data-443269,443269
171497,393013,LLY,Dow hits record  U S  yields  dollar at multi year highs,news,"By Sam Forgione NEW YORK  Reuters    The Dow Jones industrial average hit a record high for a third straight day on Wednesday  while U S  two year Treasury yields and the dollar hit multi year peaks after upbeat U S  economic data reinforced expectations of interest rate increases   The Dow s peak of 19 074 51 marked its third straight record intraday high  while the benchmark S P 500 and Nasdaq slipped after touching record intraday and closing highs over the past two days  Expectations that markets would benefit from U S  President elect Donald Trump s policies have helped boost shares   The Dow was helped by gains in industrial stocks  with the S P 500 industrial sector  SPLRCI  last up 0 7 percent  Ahead of the Thanksgiving Day holiday on Thursday and an early market close on Black Friday  a drop in tech heavyweights kept the S P 500 and Nasdaq subdued  while a nearly 11 percent drop in Eli Lilly  N LLY  also weighed on the S P  European shares steadied  with basic resources companies underpinning the broader market following a rise in metals prices  The European basic resources index  SXPP  ended 1 2 percent higher after hitting its highest level since mid 2015  U S  two year Treasury note yields  US2YT RR  rose to 6 1 2 year highs of 1 151 percent after data showed that U S  manufactured capital goods rebounded in October  boosting expectations of faster economic growth  Short and intermediate dated debt has come under pressure  partly as investors worry that the Federal Reserve may raise rates faster than previously expected  Fed policymakers  at a policy meeting a week before the presidential election  appeared confident the economy was strengthening enough to warrant interest rate increases soon  minutes from the Fed s Nov  1 2 meeting showed on Wednesday   People are in a holiday mindset today  but nothing appears to be in the horizon to derail the recent market strength   said Andre Bakhos  managing director at Janlyn Capital in Bernardsville  New Jersey   MSCI s all country world equity index  MIWD00000PUS  fell 0 63 points  or 0 15 percent  to 412 74  The Dow Jones industrial average  DJI  was last up 41 67 points  or 0 22 percent  at 19 065 54  The S P 500  SPX  was down 0 94 points  or 0 04 percent  at 2 202  The Nasdaq Composite  IXIC  was off 17 18 points  or 0 32 percent  at 5 369 17  Europe s broad FTSEurofirst 300 index  FTEU3  closed roughly flat at 1 344 19  The dollar index  DXY   which measures the greenback against a basket of six major currencies  surged to a more than 13 year peak of 101 910  bolstered by expectations of interest rate increases by the Fed next month and in 2017   Speculation of a December rate hike reached mind boggling levels   said Lukman Otunuga  research analyst at Forex Time Ltd  FXTM  in Croydon  England   This could ensure dollar strength remains a key theme moving forward   Oil prices were little changed in volatile trade amid investor doubts that OPEC would agree to a production cut large enough to make a significant dent in the global glut of crude  Brent crude  LCOc1  was last down 1 cent at  49 11 a barrel  U S  crude  CLc1  was up 6 cents at  48 09 per barrel  
Gold slid to a 9 1 2 month low of  1 181 45 an ounce  Spot gold prices  were last down  20 76  or 1 71 percent  at  1 191 10 an ounce ",2016-11-23,Reuters,"https://www.investing.com/news/stock-market-news/asia-stocks-try-to-share-wall-street-joy,-u.s.-yields-a-burden-443120",443120
171508,393024,LLY,Lilly  LLY  Presents Data From Diabetes Studies At ADA Meet,opinion,Eli Lilly and Company   NYSE LLY   presented additional data from two phase III studies    PRONTO T1D and PRONTO T2D   evaluating its investigational ultra rapid acting lispro  URLi  for the treatment of type I and type II diabetesat the scientific session of the American Diabetes Association  ADA  In October last year  Lilly had announced that the studies met the primary efficacy endpoint  Data presented from the studies showed that URLi was non inferior to Humalog in controlling A1C  an overall measure of glucose control  while significantly lowering post meal blood glucose levels in type I and type II diabetes patients Lilly confirmed these observations along with the latest release and also said that treatment with URLi led to superior reduction in blood glucose spikes at both one hour and two hours after a test meal compared to Humalog  The data also showed that URLi significantly improved glucose time in range during the day  The data thus indicates that URLi may help control blood glucose post meals  thereby addressing a concern for patients taking mealtime insulin who experience high blood glucose levels after eatingLilly has submitted regulatory applications for URLi based on data from these studies in Europe and Japan  It plans to submit the same in the United States later this year Lilly s shares have risen 2 2  this year so far compared with the  s increase of 1 7  At ADA  Lilly also presented data from an outcomes study  REWIND  on Trulicity  which showed that the GLP 1 receptor agonist led to a 12  reductionin cardiovascular events like CV death  non fatal myocardial infarction  heart attack  or non fatal stroke in a broad range of type II diabetes patients Importantly  only 31  of the participants in the REWIND study had established CV disease compared to other CV outcomes studies  which have a much greater percentage of type II diabetes patients already with a heart disease  The statistically significant heart risk reduction shown by Trulicity in the study demonstrates that the drug may be able to cater to a much broader patient population if the data is approved to be included on the label  Regulatory applications are already under review in the United States and Europe seeking approval to include REWIND data on Trulicity s label At ADA  Lilly also presented new data from a study on tirzepatide  Lilly s dual GIP and GLP 1 receptor agonist  GIP GLP 1 RA   which reinforced tirzepatide s potential to meaningfully reduce A1C and body weight in type II diabetes patients Other big pharma companies like Sanofi  PA SASY   SNY  and Novo Nordisk  CSE NOVOb   NVO   which also hold a strong position in the diabetes market  made data presentations from key diabetes studies at ADA  Other important players in the diabetes market are AstraZeneca  Bristol Myers and Merck  MRK  Lilly currently has a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet-200430091,200430091
171509,393025,LLY,Lilly Announces Tradjenta Cardiovascular Outcome Study Data ,opinion,"Eli Lilly   NYSE LLY   and Boehringer Ingelheim announced detailed data from the cardiovascular outcome study   CAROLINA   evaluating their type II diabetes drug  Tradjenta  linagliptin  in patients with type II diabetes In February  the companies announced that the study met the primary endpoint of non inferiority to Sanofi s   NASDAQ SNY   Amaryl  glimepiride   Detailed data from the study were presented at the American Diabetes Association s Scientific Sessions Shares of Lilly have decreased 1 6  so far this year against the  s increase of 1 7  Patients treated with the DPP 4 inhibitor  Tradjenta  did not show increased cardiovascular risk compared to Amaryl The time to first occurrence of cardiovascular death  non fatal myocardial infarction or non fatal stroke  3P MACE  in patients was non inferior to Amaryl  which was the primary endpoint of the study  It was seen that 11 8  of the patients treated with Tradjenta suffered 3P MACE compared to 12  for Amaryl Moreover  data from the study showed that patients treated with Tradjenta experienced fewer events of hypoglycemia  low blood sugar  and resulted in modest weight reduction versus Amaryl  Tradjenta reduced the relative risk of hypoglycemia by 77  compared to Amaryl  Tradjenta was also associated with modest weight reduction of 1 5 kg versus Amaryl  Treatment with Tradjenta and Amaryl resulted in a similar effect on A1C  a measure of average blood glucose levels over the past 3 months The CAROLINA study assessed the safety profile for Tradjenta for a median follow up of more than six years  The overall safety profile for the drug was consistent with previous data  Study results from CAROLINA  along with previously completed CARMELINA outcomes study  which showed similar long term cardiovascular safety for Tradjenta compared with placebo  may boost the drug s prospects as a better therapeutic option for patients with type II diabetes Tradjenta is a key drug in Lilly s Endocrinology segment  which generated sales of  131 9 million  Lilly also markets a combination of Tradjenta and SGLT 2 inhibitor  Jardiance  under the trade name Glyxambi for type II diabetes patients  Earlier this month  a triple combination of Jardiance  Tradjenta and metformin extended release was approved by the FDA as a fixed dose tablet for type II diabetes Lilly and Boehringer Ingelheim jointly develop and commercialize Trajenta  Jentadueto  Jardiance  Glyxambi  Synjardy and Basaglar as a part of their diabetes alliance Ina separate press release  Lilly announced data from a new post hoc analysis of the EMPA REG OUTCOME cardiovascular study evaluating Jardiance in type II diabetes patients  Data from the study showed that treatment with Jardiance reduced cardiovascular and renal risk in patients with chronic kidney disease without overt proteinuria Eli Lilly and Company Price
    Zacks Rank   Stocks to ConsiderLilly currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks from the same space are Merck   Co   Inc    NYSE MRK   and AbbVie Inc    NYSE ABBV    Both the stocks sport a Zacks Rank  2  Buy   You can see  Merck s earnings per share estimates have increased from  4 65 to  4 73 for 2019 and from  5 18 to  5 21 for 2020 over the past 60 days  The stock has rallied 7 9  so far this year AbbVie s earnings per share estimates have increased from  8 69 to  8 81 for 2019 and from  9 26 to  9 38 for 2020 over the past 60 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/lilly-announces-tradjenta-cardiovascular-outcome-study-data-200430536,200430536
171510,393026,LLY,Merck  MRK  To Buy Private Biotech Tilos For Up To  773M,opinion,"Merck   Co   Inc    NYSE MRK   announced a definitive deal to buy private biotech Tilos Therapeutics for a total potential purchase price of up to  773 million  The deal includes an undisclosed upfront payment and contingent milestone payments The acquisition will add Tilos  portfolio of investigational antibodies targeting a protein called TGF   which is believed to play an important role in the development of cancer and fibrotic diseases  Tilos is developing TGF  inhibiting antibodies in preclinical studies for various forms of cancer  fibrosis and autoimmune diseaseMerck has been aggressively buying private and relatively early stage biotech firms this year Last month  Merck announced a definitive agreement to buy small private cancer biotech  Peloton Therapeutics for an upfront payment of  1 05 billion in cash  The acquisition will add Peloton s novel late stage renal cell carcinoma  RCC  candidate  PT2977 to Merck s oncology pipeline  In addition to the upfront payment  Merck will also be entitled to pay a further  1 15 billion of potential milestones payments  The transaction is expected to close in the third quarter of 2019 
In April  Merck closed its previously announced acquisition of small cancer focused biotech  Immune Design for an approximate value of  300 million Merck s shares have performed well this year so far  Merck s shares have risen 7 9  this year so far compared with the  s increase of 1 7    This year has been good as far as M A activity in the pharmaceuticals biotech industry is concerned  Oncology and immuno oncology are key areas of focus  Bristol Myers Squibb   NYSE BMY    one of the largest pharma giants  is on track to close its previously announced acquisition of leading biotech company  Celgene   NASDAQ CELG   for a whopping  74 billion  This will be one of the largest acquisitions in recent times Another large cap pharma company Eli Lilly   NYSE LLY   bought Loxo Oncology in February for  8 0 billion to broaden its oncology portfolio  Roche also announced an agreement to acquire Spark Therapeutics in February 2019 for  4 8 billion   Post completion of the buyout  Roche will get access to Spark Therapeutics  novel gene therapy  SPK 8011 for the treatment of hemophilia A  which is expected to enter phase III in 2019A surge in M A activity during 2019 is expected in the overall drug biotech sector on the lines of Bristol Myers and Eli Lilly as companies look to use huge cash reserve and combat rivalry woes Merck currently carries a Zacks Rank  2  Buy   You can see Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-to-buy-private-biotech-tilos-for-up-to-773m-200430538,200430538
171511,393027,LLY,Galapagos Ends Enrollment In Osteoarthritis Study Before Time,opinion,"Galapagos NV   NASDAQ GLPG   announced that it has completed patient recruitment in the phase II study on its pipeline candidate  GLPG1972 S201086  for the treatment of osteoarthritis  OA   The company closed the patient enrollment ahead of the scheduled time 
GLPG1972 S201086 is being evaluated in a phase II study  ROCCELLA  conducted by Galapagos along with France s Servier to treat patients with knee OA  Last November  the FDA granted a Fast Track designation to this candidate for the given indication 
Galapagos is developing an investigational molecule of GLPG1972 S201086 with potential to become a first in class disease modifying osteoarthritis drug  DMOAD  
Shares of Galapagos have surged 30  so far this year  outperforming the  increase of 1 7  

 
Last June  Galapagos and Servier initiated the global 52 week ROCCELLA study  The primary goal of this program is to investigate the efficacy of at least one dose of GLPG1972 S201086 as compared to placebo in reducing the cartilage loss after 52 weeks of treatment  which will be assessed through an MRI  The secondary objectives of the study are to check the safety and tolerability of the candidate with several additional measures of structural progression  pain  function  stiffness and patient global assessment 
Galapagos is looking forward to learn more about the results from this probe sometime next year 
The above mentioned study enrolled more than 850 patients across 12 countries  Galapagos will be responsible for conducting the ROCCELLA study in the United States where 300 patients are enrolled  Servier will run the analysis in all other countries 
Notably  Galpagos signed a collaboration agreement with Servier for GLPG1972 S201086 in 2010  Galapagos has full U S  commercial rights to the candidate with Servier retaining the ex U S  rights  Per the deal  the company will receive development  regulatory and other milestone payments along with royalties upon commercialization outside the United States 
We remind investors that Pfizer   NYSE PFE   and partner Lilly   NYSE LLY   are also evaluating tanezumab  subcutaneous   an investigational monoclonal antibody  in a late stage study for the treatment of OA pain of the knee or hip 
Apart from OA  Galpagos is intending to foray into the rheumatoid arthritis  RA  market  The company has a partnership with GileadSciences   NASDAQ GILD   for developing an experimental candidate  filgotinib  for addressing RA  In March this year  both companies announced encouraging interim safety information from four evaluations on filgotinib for the given indication 
Zacks Rank
Galapagos carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/galapagos-ends-enrollment-in-osteoarthritis-study-before-time-200431074,200431074
171512,393028,LLY,NuCana s Biliary Tract Cancer Candidate Gets Orphan Drug Tag,opinion,NuCana plc   NASDAQ NCNA   announced that the FDA has granted an orphan drug designation to its pipeline candidate  Acelarin  for the treatment of patients with biliary tract cancer  better known as cholangiocarcinoma A phase Ib study is evaluating Acelarin in combination with chemotherapy drug  cisplatin  compared with the combination of Eli Lilly s   NYSE LLY   Gemzar  gemcitabine  plus cisplatin  which is the current standard of care treatment  Data from this study showed that the combo of Acelarin   cisplatin nearly doubled the expected response rate as compared to the standard of care  Moreover  several patients in the Acelarin   cisplatin arm achieved significant reductions in the volume of their tumor as well as experienced tumor shrinkage over time Per the company  the Acelarin combo is a notable advancement for treating patients with biliary tract cancer  a disease with an unmet medical need  NuCana plans to begin a global phase III study later in 2019 on the Acelarin combo as a front line treatment for patients with advanced biliary tract cancer Notably  the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200 000 people in the United States  This designation also makes the company entitled to certain other benefits including the tax credits related to clinical trial expenses and an exemption from the FDA user fee Shares NuCana have declined 18 1  so far this year against the increase of 1 2  Acelarin is the most advanced product candidate in NuCana s portfolio  It is a ProTide transformation of Gemzar  The ProTide technology is a prodrug approach used in molecular biology and drug design Apart from this combination study  Acelarin is being evaluated in a phase II program for treating patients with platinum resistant ovarian cancer  The company plans to report interim results from the study  later in 2019  The candidate is also being investigated in a phase III analysis for pancreatic cancer Zacks Rank   Stocks to ConsiderNuCana currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Acorda Therapeutics  Inc    NASDAQ ACOR   and Repligen Corporation   NASDAQ RGEN    both sporting a Zacks Rank  1  Strong Buy   You can see  Acorda s loss per share estimates have been narrowed 6 5  for 2019 and 6 9  for 2020 over the past 60 days Repligen s earnings estimates have been revised 12  upward for 2019 and 12  for 2020 over the past 60 days  The stock has surged 44 3  year to date Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/nucanas-biliary-tract-cancer-candidate-gets-orphan-drug-tag-200431367,200431367
171516,393032,LLY,Aratana surges 17  after animal drug company strikes deal with Eli Lilly,news,"Investing com    Shares in Aratana Therapeutics surged more than 17  in after hours trading after the Indiana based animal drug manufacturer came to terms on a deal with Eli Lilly and Company s Elanco pet health unit on an animal health rights licensing agreement 
Under the agreement  Aratana Therapeutics  NASDAQ PETX  grants Elanco with exclusive rights to develop  manufacture and market Galliprant tablets  which have received FDA approval for pain and inflammation control of dogs with osteoarthritis  The condition reportedly affects as much as 20  of the adult canine population  Aratana said  citing a 2010 study from the Journal of American Veterinary Medical Association  Osteoarthritis can appear in dogs when joint cartilage or the protective material that allows flexible movement in a joint  breaks down over time  The resulting inflammation in a pet s joints can create stiffness  preventing the animal from running  jumping or climbing 
 Aratana understands the value of relationships with the right collaborators   Aratana Therapeutics CEO Steven St  Peter said in a statement   We believe that this collaboration with Elanco  a leading animal health company  is a watershed event for the emerging pet biotech sector and further validates our focus on the pet therapeutics opportunity  
As part of the deal  Aratana said it will receive an upfront payment of  45 million from Elanco  NYSE LLY    The agreement also calls for Aratana to receive up to  83 million in total if certain development  regulatory and sales milestones are met 
 This deal expands Elanco s robust companion animal portfolio  which will now give our customers and their patients a spectrum of treatments for managing osteoarthritic pain   said Jeff Simmons  president of Elanco Animal Health   At Elanco  we understand the powerful role healthy animals play in making life better  As pets become important parts of our families  the need to help them live longer  healthier  higher quality lives increases as well  
Shares in Aratana soared 1 19 or 17 22  to 8 10 in after hours trading ",2016-04-25,Investing.com,https://www.investing.com/news/stock-market-news/aratana-surges-17-after-animal-drug-company-strikes-deal-with-eli-lilly-397812,397812
171517,393033,LLY,Merck sales disappoint as Januvia  Remicade fall short,news,"By Ransdell Pierson  Reuters    Merck   Co Inc  N MRK  on Thursday reported lower than expected quarterly revenue  hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug   But the second largest U S  drugmaker beat first quarter earnings forecasts because of cost controls and a weakening dollar  and it slightly raised its full year profit outlook   Combined sales of Januvia and a related combination medicine called Janumet edged up 1 percent to  1 41 billion   30 million shy of Wall Street expectations  Demand for the drugs  Merck s biggest franchise and former sparkplugs for company growth  has waned due to new competition  including from Eli Lilly   Co s  N LLY  Jardiance and other members of a family of medicines called SGLT 2 inhibitors   Remicade sales fell 30 percent to  349 million   25 million below forecasts  The injectable treatment for rheumatoid arthritis faces escalating competition in Europe from cheaper biosimilars   A bright spot in the earnings report was Keytruda  a new cancer treatment that works by taking the brakes off the immune system  Its sales rose to  249 million from  83 million a year earlier  slightly above expectations   But Keytruda sales are ramping up more slowly than those of Bristol Myers Squibb Co s  N BMY  similar new immuno oncology product called Opdivo  which also treats melanoma and lung cancer and is being tested for an array of other types of cancer  Its sales jumped to  704 million in the quarter   For Merck   pressure on important marketed products such as Januvia and Remicade will likely limit near term growth opportunities  and offset faster growing products like Keytruda   Credit Suisse   SIX CSGN  analyst Vamil Divan said in a research note  Sales of animal health products were flat at  829 million  about  20 million below Wall Street forecasts  but would have risen 9 percent if not for the weakening dollar  which reduces sales outside the United States  Merck said  Total revenue slipped 1 percent to  9 31 billion  below the average estimate of  9 46 billion among analysts surveyed by Thomson Reuters I B E S  Net income rose to  1 12 billion  or 40 cents per share  from  953 million  or 33 cents per share  a year earlier  Excluding special items  Merck earned 89 cents per share  beating Wall Street expectations by 4 cents  
Merck raised its full year earnings forecast to a range of  3 65 to  3 77 per share from its prior outlook of  3 60 to 3 75  It increased the low end of its sales forecast to  39 0 billion from  38 7 billion while keeping the top end at  40 2 billion ",2016-05-05,Reuters,"https://www.investing.com/news/stock-market-news/merck-posts-better-than-expected-profit,-raises-forecast-400086",400086
171518,393034,LLY,Novo diabetes drug cuts heart risks by 13 percent in key trial,news,"By Ben Hirschler  Reuters    Novo Nordisk s  CO NOVOb  top selling diabetes drug Victoza cut the risk of heart attack  stroke and cardiovascular death by 13 percent in a closely watched study that may help boost sales of the injectable medicine  Victoza is only the second diabetes drug to show such heart benefits  after Eli Lilly  N LLY  and Boehringer Ingelheim s pill Jardiance  Victoza s effect was evident in all areas   To me  the impressive thing about this trial is the consistency across clinical endpoints and its robustness   said John Buse  professor of medicine at the UNC School of Medicine  who worked on the study  He believes doctors  approach to type 2 diabetes treatment will now start to shift to a greater focus on minimizing overall risks  rather than simply cutting blood sugar levels  Because about half of deaths in people with diabetes are caused by heart disease  reducing heart risk is considered essential to their care  Novo  the world s biggest diabetes company  had already said in March that Victoza cut heart risks  significantly  in the study but the scale of the benefit was only disclosed on Monday  Researchers told the American Diabetes Association s  ADA  annual meeting that 13 0 percent of patients on Victoza died from cardiovascular cases or suffered non fatal heart attacks or strokes  against 14 9 percent of those on placebo  The clinical trial  known as Leader  had been designed to show Victoza did not increase heart risk  so its superiority is welcome news for Novo  especially as Sanofi s  PA SASY  rival Lyxumia failed to show heart benefits in an earlier test  Victoza  which had sales of  2 7 billion last year  is the biggest seller in a class of drugs known as GLP 1 analogues that stimulate insulin production   I think physicians will look to GLP 1s with greater enthusiasm   Buse said in an interview  Once daily Victoza is typically prescribed as a third or fourth option after patients have first tried various oral medicines   The significance of this is that now we can start to change the conversation around diabetes management from one of  let s manage your blood sugar  to one of  let s manage your risk of complications    Buse said  The Leader trial was the most keenly anticipated at this year s ADA meeting and industry analysts had been hoping for a heart benefit of at least 10 percent  with some thinking it could exceed 15 percent  The Jardiance trial last year showed a similar 14 percent relative risk reduction  The findings  which involved following 9 340 patients for a median 3 8 years  were also published online in the New England Journal of Medicine  Gastrointestinal upset was the biggest side effect with Victoza  There were fewer cases of pancreatitis  which has been viewed as a potential problem  but more cases of pancreatic cancer  although the difference was not statistically significant  Since 2008  U S  regulators have demanded studies for new diabetes medicines to show there is no increase in heart risk  opening a new battleground between different treatments  Lilly is conducting a similar large study to try and prove the heart benefits of its once weekly GLP 1 drug Trulicity  
The Leader study was funded by Novo and the U S  National Institutes of Health ",2016-06-13,Reuters,https://www.investing.com/news/stock-market-news/novo-diabetes-drug-cuts-heart-risks-by-13-percent-in-key-trial-408134,408134
171528,393044,LLY,Why Is Incyte  INCY  Down 1 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Incyte  NASDAQ INCY   Shares have lost about 1 7  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Incyte due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Incyte Q1 Earnings   Revenues Beat Estimates  Up Y YIncyte reportedearnings of 62 cents per share  which beat the Zacks Consensus Estimate of 40 cents  Incyte reported a loss of 7 cents in the year ago quarter Including milestones and contracts  revenues came in at  497 8 million  which increased 30  year over year and beat the Zacks Consensus Estimate of  475 6 million Quarter in DetailTotal product related revenues came in at  457 8 million  up 20  from the year ago quarter  Of these  Jakafi revenues came in at  375 6 million  up 20  from the year ago quarter  However  Jakafi revenues missed the Zacks Consensus Estimate of  379 million  Net product revenues of Iclusig amounted to  20 6 million  down from  20 8 million in the year ago quarter   Product royalty revenues from Novartis or the commercialization of Jakafi in ex U S  markets grew 10  to  45 6 million  Olumiant s product royalty revenues came in at  16 million R D expenses were  243 million  down from  279 million in the year ago quarter  SG A expenses amounted to  124 million  up from  121 million in the prior year quarter 2019 Outlook UpdatedThe company expects Jakafi revenues of  1 580  1 650 million  same as before   Iclusig revenues are expected to be  90  100 million  R D expenses are expected to be  1 020  1 070 million compared with the earlier estimate of  1060  1 130 million  SG A expenses are anticipated to be  420  470 million Pipeline UpdatePipeline progress in the first quarter was impressive  The global phase III GRAVITAS 301 trial on itacitinib for the treatment of patients with steroid na ve acute GVHD has completed enrollment  Results from the study are expected later in the year Incyte expects to submit the NDA for pemigatinib as a second line treatment for patients with FGFR2 translocated cholangiocarcinoma in the second half of 2019  The company plans to initiate a phase III trial for the first line treatment of patients with cholangiocarcinoma in the coming months The primary endpoint was met in the phase II trial of ruxolitinib cream in patients with vitiligo Incyte has elected to no longer co fund the development of baricitiniband in order to reallocate the capital to develop its pipeline  However  Incyte will continue to receive royalties on global net sales of Olumiant  baricitinib   per the terms of its agreement with partner Eli Lilly  NYSE LLY   
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 44 68  due to these changes 
VGM Scores
At this time  Incyte has a strong Growth Score of A  a grade with the same score on the momentum front  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Incyte has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/why-is-incyte-incy-down-17-since-last-earnings-report-200426580,200426580
171529,393045,LLY,Lilly  LLY  Down 2 3  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Eli Lilly  LLY   Shares have lost about 2 3  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Lilly due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Lilly Beats on Q1 Earnings  Lowers Sales ViewLilly reported first quarter 2019 adjusted earnings per share of  1 33  which beat the Zacks Consensus Estimate of  1 32 by a penny  Earnings rose 2  year over year as higher operating costs were offset by a lower tax rate and reduction in shares outstanding from shares repurchase With the completion of spin off of Elanco Animal Health business  the unit was reflected as discontinued operation for both the first quarter of 2018 and 2019 Including asset impairment  amortization  acquired in process R D  charges for Lartruvo failure and a gain on sale associated with the disposal of Elanco  first quarter earnings per share were  4 31 compared with  1 16 reported in the first quarter of 2018 Revenues in DetailQuarterly revenues of  5 09 billion rose 3  year over year backed by strong demand for its new drugs Trulicity  Taltz  Jardiance and Basaglar  which made up for lower sales of older products like Cialis Foreign exchange hurt sales growth by 2  in the quarter  Also  lower realized prices had a negative impact of 3  on sales driven by increased utilization of patient affordability programs Volumes rose 7  as increased demand for new products like Trulicity  Basaglar  Taltz  Jardiance and Verzenio offset lower volumes of some established products like Cialis due to loss of exclusivity  Volumes rose 13  excluding Cialis New pharma products  products launched since 2014  drove 14 8  of volume growth and generated nearly  2 billion in revenues  representing nearly 39  total revenues  up from 38  in the previous quarter  The loss of exclusivity hurt volumes by 530 basis points driven primarily by Cialis U S  revenues grew 3  to  2 89 billion and ex U S  revenues rose 2  to  2 20 billion Among the established products  Forteo sales were flat at  312 9 million  Alimta sales were flat at  499 2 million  Humalog sales dropped 8  to  730 8 million  Humulin sales declined 9  to  297 7 million Cialis sales declined 38  to  308 2 million as U S  sales were hurt by entry of generic products  Outside U S  sales were hurt by currency headwindsAmong the new products  Trulicity generated revenues of  879 7 million  up 30  year over year driven by higher demand in the United States and higher volumes n ex U S  markets  which offset the impact of lower realized prices Cyramza revenues were  198 3 million  up 8  year over year driven by higher sales in both U S  and international markets Jardiance sales surged 35  to  203 6 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currency Basaglar recorded revenues of  251 4 million  up 51  year over year  In the United States  sales rose 56   benefiting from higher demand and the impact of higher realized prices and changes in rebates and discounts estimates  Outside U S  sales growth was driven by increased volume  which offset the impact of lower realized prices Taltz brought in sales of  252 5 million  up 72  year over year as U S  sales gained from higher demand  which made up for lower realized prices  Ex U S  sales were driven by increased volume from launches in new countries  which offset the impact of currency headwinds Lartruvo generated sales of  43 9 in this quarter compared with 83 5 million in the previous quarter   Due to the failure of the ANNOUNCE confirmatory study  Lilly suspended promotion of Lartruvo and sales of the drug declined sharply Olumiant generated sales of  82 1 million in the quarter backed by launch uptake in new European markets  compared with  70 1 million in the previous quarter  In the United States  Olumiant recorded sales of  6 4 million  higher than  4 2 million in the previous quarter Verzenio generated sales of  109 4 million in the quarter  which was more than  83 1 million in the previous quarter  This is because of increased demand and to some extent higher realized prices in the United States Verzenio was launched in several international markets in the fourth quarter of 2018 and generated ex U S  revenues of  15 9 million versus  6 6 million in the previous quarter Emgality generated revenues of  14 2 million in the quarter  which is more than  4 9 million generated in the previous quarter  In the United States  the drug generated sales of  12 2 million compared with  7 2 million realized in the fourth quarter of 2018  Emgality captured 33  share of market for new prescriptions in the United States  an increase of almost 13 points from end of 2018  Emgality was launched in some ex U S  markets in the first quarter of 2019 and generated revenues of  2 1 million from these markets Gross Margin   Operating IncomeAdjusted gross margin of 80 2  in the quarter rose 160 basis points driven by favorable effect of foreign exchange rates on international inventories sold  Excluding the effect of foreign exchange rates on international inventories sold  gross margin declined about 130 basis points due to the negative impact of manufacturing shutdowns  unfavorable product mix due to lower volumes from post patent products and lower price Operating income decreased 8  year over year to  1 33 billion due to higher operating expenses  Total operating expenses  including research and development and marketing  selling and administrative expenses  rose 12  in the quarter as the company invested in recently launched products and late stage assets  Marketing  selling and administrative expenses rose 13   R D expense rose 11  in the quarter Adjusted effective tax rate was 12 9   lower than 15 5  in the year ago quarter  driven primarily by the impact of U S  tax reform 2019 Sales Guidance LoweredLilly updated its previously issued earnings and sales guidance range for 2019 to reflect the separation of its Elanco animal health business The earnings forecast was increased from a range of  5 55 to  5 65 per share to  5 60 to  5 70  The previous earnings guidance  however  included a reduction of approximately 8 cents per share to reflect the non controlling interest portion of Elanco profits in 2019 Lilly now expects revenues to be between  22 0 billion and  22 5 billion in 2019  down from the prior expectations of  25 1 billion and  25 6 billion Gross margin is expected to be approximately 80  versus 76 5  previously  Adjusted tax rate is expected to be in the range of 14 versus approximately 15  expected previously Marketing  selling and administrative expense are expected to be in a range of  5 7 billion to  6 0 billion versus  6 4 billion to  6 7 billion previously  Research and development expense is expected to be in the range of  5 5 billion to  5 7 billion versus  5 8 billion to  6 0 billion previously In 2019  revenue growth is expected to be driven by higher demand for its newer medicines including Trulicity  Jardiance  Taltz  Verzenio and Emgality as some older drugs like Cialis lose patent exclusivity Lilly expects U S  regulatory action for nasal glucagon for hypoglycemia and lasmiditan for acute migraine in 2019 as well as line extension approvals for several medicines  which could drive revenue growth in 2019 However  generic competition for several drugs including Cialis  rising pricing pressure in the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line 
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions 
VGM Scores
Currently  Lilly has a subpar Growth Score of D  however its Momentum Score is doing a bit better with a C  Following the exact same course  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Lilly has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-down-23-since-last-earnings-report-can-it-rebound-200426572,200426572
171530,393046,LLY,Merck s Keytruda Improves 5 Year Survival In Lung Cancer ,opinion,Merck   Co   Inc    NYSE MRK   presented encouraging five year survival data on its PD L1 inhibitor  Keytruda in patients with advanced non small cell lung cancer  NSCLC  at the annual meeting of American Society of Clinical Oncology  ASCO  Data from the phase Ib KEYNOTE 001 study  n 550  showed that five year overall survival  OS  rates for Keytruda were 23 2  in treatment na ve patients and 15 5  in previously treated lung cancer patients  In lung cancer patients whose tumors express PD L1 protein levels of 50 percent or greater  TPS of  50 percent   the five year OS rate was 29 6  in treatment na ve patients and 25  in previously treated patients Historically  the five year survival rate in advanced lung cancer patients in the United States has been around 5   Keytruda s five year survival rates thus represent a huge improvement over these historical rates At ASCO  Merck also presented follow up lung cancer data from the KEYNOTE 189 study at ASCO  After a median follow up of 18 7 months  an updated analysis of the OS endpoint showed that Keytruda in combination with Lilly s   NYSE LLY   Alimta  pemetrexed  and platinum chemotherapy reduced the risk of death by 44  compared with chemotherapy alone as a first line treatment option for metastatic non squamous NSCLC in patients with no EGFR or ALK genomic tumor aberrations The data also showed that the Keytruda chemo arm led to 52  reduction in the risk of progression or death  progression free survival  compared with chemotherapy alone Notably  data from the KEYNOTE 189 study is already included in Keytruda s U S  and EU label Merck also presented full data from the phase III KEYNOTE 062 study evaluating Keytruda as monotherapy and in combination with chemotherapy for the first line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma  The data showed that a statistically significant improvement in overall survival was not reached for the Keytruda chemo arm  Top line data from the study were earlier announced in April Merck s shares have performed well this year so far   Merck s shares have risen 6 2  this year so far against the  s decrease of 2 5   Keytruda  Merck s biggest product  is already approved for use in 15 cancer indications across 10 different tumor types in the United States Keytruda generated sales of  2 27 billion in the first quarter of 2019  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous NSCLC The encouraging five year survival rates  which represent the longest follow up for Keytruda in lung cancer  further strengthens its position in the lung cancer market where it competes with Bristol Myers    NYSE BMY   Opdivo  AstraZeneca s Imfinzi  Roche s Tecentriq and Pfizer s Bavencio This year so far  Keytruda has gained several label expansion approvals  Keytruda was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan in the first quarter  In April  the FDA gave approval to Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced renal cell carcinoma  RCC  as well as for an expanded first line lung cancer patient population  All these label expansion approvals should drive sales of Keytruda higher in the future quarters of 2019 Several regulatory decisions for new indications in the United States as well as in Europe are pending in 2019  which  if approved  can further boost sales of Keytruda  In June  FDA decisions are expected on regulatory applications looking for label expansion of Keytruda for previously treated advanced small cell lung cancer  SCLC  and first line treatment of recurrent or metastatic HNSCC Merck currently carries a Zacks Rank  2  Buy   You can see Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-improves-5year-survival-in-lung-cancer-200427789,200427789
171531,393047,LLY,Why Cancer Fighting Stocks   ETFs Are Soaring,opinion,"In this episode of ETF Spotlight  I speak with Brad Loncar  CEO of Loncar Investments  Brad is in Chicago to attend the annual meeting of ASCO  American Society of Clinical Oncology   It is the world s largest and most prestigious cancer conference where participants learn about the latest developments in treating the disease 
Brad explains why ASCO is so important and how he uses it as an investor 
The global market for cancer drugs is estimated to be about  123 billion and big players are investing heavily to gain an edge in this increasingly competitive market   Pharmaceutical giant Bristol Myers   NYSE BMY    a pioneer in immunotherapy  is acquiring rival Celgene   NASDAQ CELG   for  74 billion 
Merck   NYSE MRK   is acquiring cancer drug developer Peloton Therapeutics for  1 05 billion  The announcement came as Peloton was preparing for its IPO  Earlier this year  Eli Lilly   NYSE LLY   bought Loxo Oncology for  8 billion 
Should we expect more M A in the space 
Brad created the index for the Loncar Cancer Immunotherapy ETF   which invests in companies at the forefront of immunotherapy research   He explains why immunotherapy  which harnesses the body s immune system to fight cancer  is often called a game changer for cancer treatment 
He also talks about important developments in the space and promising work being done by some smaller  innovative biotech companies 
Mirati Therapeutics   NASDAQ MRTX    Iovance Biotherapeutics  formerly Lion Biotechnologies    NASDAQ IOVA   and Nektar Therapeutics   NASDAQ NKTR   are soaring today  These are among the top holdings in CNCR  Find out more about them on the podcast 
WSJ recently reported that AstraZeneca   NYSE AZN   is planning to target early stages of the disease  whereas traditionally  pharma companies focus on drugs that treat advanced forms of cancer  Will the new approach help AstraZeneca gain an edge over competitors 
Health Care is the worst performing sector this year  thanks mainly to policy concerns  Will there be a big focus on policy related issues at the conference 
Tune into the podcast to learn more 
Brad also created the index for the Loncar China BioPharma ETF   SI CHNA   which focuses on the booming biopharma industry in China  To learn more about these ETFs  please visit  
Please also visit the  to learn about this cancer treatment and clinical trials 
Make sure to be on the lookout for the next edition of ETF Spotlight  If you have any comments or questions  please email podcast zacks com 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/why-cancerfighting-stocks--etfs-are-soaring-200427937,200427937
171533,393049,LLY,Lilly beats forecasts on cost cuts  raises 2015 view,news,By Ransdell Pierson  Reuters    Eli Lilly   Co  N LLY  reported better than expected quarterly earnings due to cost controls and sales of new treatments for diabetes and cancer  keeping the U S  drugmaker on track for its planned return to growth this year  Lilly raised its full year profit forecast to reflect expected investment gains and lower spending on research and marketing    We are encouraged by the combination of Lilly s new product cycle coupled with expense management  which we see driving healthy earnings growth over the next five years  or longer  J P  Morgan analyst Chris Schott said in a research note  Lilly has been strapped with declining sales and earnings since 2011 after sales of its biggest products plunged due to competition from cheaper generics  But the Indianapolis drugmaker has refused to consider merging with another large drugmaker  saying its own pipeline of experimental drugs would restore earnings growth by 2015  Cyramza  the company s new treatment for lung cancer  posted sales of  111 million in the quarter  while the company s recently approved diabetes drug Trulicity pulled in  74 million   One the company s most promising drugs is Jardiance  following data last month from a large trial that showed the pill slashed deaths 32 percent among patients with type 2 diabetes at risk of heart attack  Jardiance had sales of just  15 million in the quarter  but analysts expect it to eventually post big sales if medical societies recommend early use of the drug   Lilly expects a profit of  3 40 to  3 45 per share this year  excluding special items  from its earlier view of  3 20 to  3 30 per share  That would reflect growth of up to 24 percent over last year  Edward Jones analyst Ashtyn Evans on Thursday maintained her  hold  rating on Lilly  saying its shares trade at a premium to most rivals and already reflect the company s improving earnings prospects and strong lineup of experimental drugs  Company sales rose 2 percent in the quarter to  4 96 billion  slightly below Wall Street expectations  They would have risen 10 percent if not for the stronger U S  dollar  Net quarterly profit rose to  799 7 million  or 75 cents per share  from  500 6 million  or 47 cents per share  a year earlier  Excluding special items  Lilly earned 89 cents per share  handily beating the average analyst estimate of 76 cents per share  according to Thomson Reuters I B E S  Lilly shares fell 0 6 percent  amid a 0 5 percent decline for the drug sector ,2015-10-22,Reuters,https://www.investing.com/news/stock-market-news/eli-lilly's-third-quarter-profit-beats-street-estimates-as-costs-fall-367420,367420
171534,393050,LLY,Eli Lilly plunges 6  amid concerns of unfair price hikes for top drugs,news,"Investing com    Shares in Eli Lilly and Company  N LLY  plummeted more than 6  even as the prominent pharmaceutical company saw its quarterly earnings surge considerably last quarter  as investors voiced concerns relating to escalating drug prices in the industry 
For Eli Lilly s fourth quarter of 2015  which ended in late December  the drug maker reported net income of  478 4 million  a 12  increase from the same period a year earlier when the Indianapolis based company recorded earnings of  428 5 million  Eli Lilly also reported a sharp gain of 13  in per share earnings of 0 45  up from earnings per share of 0 40 over the final quarter of 2014 
The strong earnings  however  came at a substantial cost for customers as some of the company s top performing drugs skyrocketed over the three month period  Sales for Humalog  the company s short acting insulin to treat Type I and Type II Diabetes  soared approximately 10  for the quarter  The productive quarter helped drive revenues among the company s U S  pharmaceutical division by 20   At a maximum price of  472  Humalog is the most expensive brand of short acting insulin on the market  Additionally  Eli Lilly hiked the prices for Strattera  its drug aimed a treating Attention Deficit Hyperactivity Disorder  Forteo  its Osteporosis drug  Effinet  a drug taken to help treat blood clots and Cialis  its drug for erectile dysfunction 
When asked on a conference call to explain the substantial increase in Humalog prices  Eli Lilly CEO John Lechleiter responded that while the treatment is costly  the disease itself is a  lot more expensive  
 Lilly s 2015 results reinforce our confidence in the future with six FDA approvals and multiple positive Phase III data readouts  as well as encouraging results from newly launched products including Cyramza  Trulicity  Jardiance and Basaglar   Lechleiter added   In 2016  we aim to continue revenue growth  margin expansion and value creation for our shareholders  all while sustaining a flow of innovative medicines from our pipeline to improve people s lives   
Eli Lilly has been a global leader in diabetes care for more than 90 years when it introduced the world s first commercial insulin  according to the company s website  In June  the company donated 780 000 vials of insulin to the Life of a Child program  building on its annual donation of approximately 260 000 vials to the initiative  The program provides life saving medicine to children living in impoverished communities without access to insulin  The company also helped launch the International Diabetes Federation s Bridges Program in 2006 by providing a seven year educational grant of  10 million to the foundation 
Shares in Eli Lilly fell 4 93 or 6 03  to 76 83 in after hours ",2016-01-28,Investing.com,https://www.investing.com/news/stock-market-news/eli-lilly-plunges-6-amid-concerns-of-unfair-price-hikes-for-top-drugs-382293,382293
171546,393062,LLY,J J s Invokana SNDA Gets Priority Review Status From FDA,opinion,Johnson   Johnson   NYSE JNJ   announced that the FDA has granted priority review to a supplemental new drug application  sNDA  looking for label expansion of its type II diabetes medicine  Invokana  The sNDA is looking for approval of Invokana  a SGLT2 inhibitor  for slowing the progression of chronic kidney disease  CKD  in patients with type II diabetes when used in addition to standard of care The sNDA filing is based on data from the phase III CREDENCE renal outcomes study  data from which has shown that Invokana significantly reduces the risk of renal failure  dialysis or kidney transplantation  and renal or cardiovascular death in patients with type II diabetes and CKD J J had filed a sNDA in March to include data from the CREDENCE study on the label of Invokana We remind investors that in July last year  the study was stopped early based on positive pre specified efficacy data  The decision was based on a recommendation from the study s Independent Data Monitoring Committee  IDMC  that met to review the data during a planned interim analysis  Almost half of all patients with type II diabetes develop CKD  causing a high risk of kidney failure and cardiovascular disease  If the sNDA is approved  Invokana will be the first new therapy in nearly 20 years to reduce the risk of kidney failure and prevent life threatening cardiovascular events in patients with CKD and type II diabetes when added to current standard of careIn October last year  the U S  label of Invokana was updated to include the cardiovascular outcomes data from the CANVAS program  With the label expansion  Invokana can now be prescribed to reduce the risk of cardiovascular events like heart attack  stroke or cardiovascular death in adults with type II diabetes and established cardiovascular disease  However  the label includes a warning about an increased risk of amputations Notably  many pharma companies are working hard to get the labels of their diabetes medicines updated to include renal outcomes data  A phase III study is evaluating Lilly s   NYSE LLY   successful SGLT2 inhibitor  Jardiance in CKD J J s shares have risen 7 5  this year so far against the  s decline of 0 9  J J currently carries a Zacks Rank  3  Hold  Some better ranked large cap pharma stocks are Merck   Co   Inc    NYSE MRK   and AbbVie  Inc    NYSE ABBV    both carrying a Zacks Rank  2  Buy   You can see  Shares of Merck have gained 6  so far this year while estimates for 2019 and 2020 have risen 1 5  and 0 2   respectively  over the past 30 days  AbbVie s earnings estimates for 2019 and 2020 have risen 1 5  and 1 4   respectively  over the past 30 days  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-05-23,Zacks Investment Research,https://www.investing.com/analysis/jjs-invokana-snda-gets-priority-review-status-from-fda-200424266,200424266
171547,393063,LLY,Pharma Stock Roundup  MRK s Cancer Biotech Buyout  ABBV  LLY s Pipeline Updates,opinion,"The biggest news this week was Merck s   NYSE MRK   offer to buy small cancer biotech Peloton Therapeutics  which will add a late stage kidney cancer candidate to its oncology pipeline  In other news  AbbVie s   NYSE ABBV   late stage study on a brain cancer candidate failed while Lilly s   NYSE LLY   Crohn s disease candidate succeeded in a mid stage study Recap of the Week s Most Important StoriesMerck to Buy Small Cancer Biotech  Keytruda Breast Cancer Study Fails  Merck announced a definitive agreement to buy small private biotech   to boost its oncology pipeline  The acquisition will add Peloton s novel oral HIF 2  inhibitor  PT2977 to Merck s oncology pipeline  PT2977 is currently being evaluated in multiple studies for renal cell carcinoma  the most common form of kidney cancer  In addition to the upfront payment  Merck will also be entitled to pay a further  1 15 billion of potential milestones payments  The transaction is expected to close in the third quarter of 2019 Merck s pivotal phase III KEYNOTE 119 study evaluating its blockbuster PD L1 inhibitor  Keytruda in previously treated metastatic triple negative breast cancer  of overall survival   OS    Data from the study showed that Keytruda did not achieve superiority in OS compared to chemotherapy  Keytruda is presently not approved for any breast cancer indication AbbVie s First Line Brain Cancer Phase III Study Fails  AbbVie s phase III study on Depatux M  an investigational candidate   in patients with newly diagnosed glioblastoma  an aggressive form of brain cancer  At an interim analysis  the Independent Data Monitoring Committee recommended the study be stopped due to lack of survival benefit in patients receiving Depatux M  Enrollment has been stopped in all ongoing Depatux M studies Lilly s Mirikizumab Meets Endpoints in Crohn s Disease Study  Lilly s pipeline candidate  mirikizumab in a phase II Crohn s disease study  Data from the phase II SERENITY study showed that treatment with mirikizumab led to significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo   Lilly plans to begin phase III studies on mirikizumab in Crohn s disease later this year  Mirikizumab is already being evaluated in phase III studies in other immune diseases  psoriasis and ulcerative colitis Lilly also announced that its lower priced version of Humalog  for order in pharmacies across the United States  The list price of Insulin Lispro  which contains an identical molecule as Humalog  is 50  lower than the current list price of Humalog U 100  insulin lispro injection   Insulin Lispro will be available in vial  priced at  137 35  and pen  KwikPen   pack of five will cost  265 20  options FDA s Priority Review Status to Invokana sNDA  The FDA granted priority review designation to J J s   NYSE JNJ    sNDA  for the treatment of chronic kidney disease   CKD   in patients with type II diabetes when used in addition to standard of care  The sNDA filing was based on data from the phase III CREDENCE renal outcomes study  J J had filed a sNDA in March  If the sNDA is approved  Invokana will be the first new therapy to be approved for reducing the risk of kidney failure and preventing renal or cardiovascular death in patients with CKD and type II diabetes in nearly 20 years Update from Novartis s Analyst Day  Novartis   NYSE NVS   discussed its transformation strategy at its annual meet  Novartis in core therapeutic areas over the next two years   Mayzent  Zolgensma  Brolucizumab  RTH258   Ofatumumab  OMB157   and Fevipiprant  QAW039    Novartis also has multiple 2019 pipeline milestones  including six major readouts  The company also said that it has more than 10 biosimilar products in the pipelineNovartis also presented data from two phase II studies on IND GLY MF  indacaterol acetate  glycopyrronium bromide and mometasone furoate   its investigational  once daily  fixed dose inhaled combination asthma treatment  In one study  IND GLY MF was superior to the standard of care  long acting beta agonist inhaled corticosteroid   LABA ICS  in terms of lung function  In the other study  IND GLY MF was superior to placebo in lung function improvement irrespective of administration time of morning or evening Glaxo s Shingrix Gets Approval in China  Glaxo   NYSE GSK   gained approval for its successful vaccine  Shingrix in China for the prevention of shingles  herpes zoster  in adults aged 50 years or older  Shingrix is already marketed in the EU  United States  Canada  Japan and Australia and is the main driver of Glaxo Vaccine segment sales  Shingrix sales more than doubled to  357 million in the first quarter of 2019 driven by market expansion in new patient population The NYSE ARCA Pharmaceutical Index rose 1 04  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions  Last week  all the stocks were in the green with Merck gaining the most  2 4   In the past six months  Merck has been the biggest gainer  7 4   while Bristol Myers   NYSE BMY   declined the most  10 3    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-05-23,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrks-cancer-biotech-buyout-abbv-llys-pipeline-updates-200424842,200424842
171548,393064,LLY,Nektar  NKTR  Announces Formation Of CNS Focused Subsidiary,opinion,"Nektar Therapeutics   NASDAQ NKTR   announced that it has formed a new wholly owned subsidiary  Inheris Biopharma  Inc   which will its pipeline of pre clinical central nervous system   CNS   candidates  The new subsidiary will mainly be responsible for the potential launch and commercialization of Nektar s opioid based pain candidate  NKTR 181  which is under review in the United States  A decision from the FDA for NKTR 181 is expected by the end of August 2019 Inheris Biopharma will be led by Jay Galeota  who has been appointed as the president and chief executive officer of the entity  Galeota has more than three decades of experience in the pharma industry  He held several leadership positions at Merck   NYSE MRK   in the past  Joe Stauffer and George Shiebler have been appointed as chief medical officer  and senior vice president and general counsel  respectively  Both of them have rich experience in their field of work The separation will likely help Nektar to collaborate with one or more potential capital partners to commercialize NKTR 181 without impacting the company s other pipeline candidates Shares of the company have increased 0 6  so far this year compared with the  s rise of 5 6  A potential approval to NKTR 181  which is under review as analgesic for treating chronic low back pain in patients new to any opioid therapy  will be a positive for Nektar  The drug may generate significant sales as low back pain is a major factor leading to disability in adults in the United States  Moreover  NKTR 181  a mu opioid  has exhibited reduced incidence of euphoria associated with opioids  which can lead to abuse and addiction  This may boost demand for the drug in a country  which is fighting opioid abuse However  investors should be aware of the fact that NKTR 181 may face regulatory and commercialization hurdles due to its opioid based formulation We expect Nektar to focus on its oncology and auto immune disorder pipeline following the separation of launch activities for NKTR 181 and pre clinical CNS pipeline into a new subsidiary Nektar is developing several immuno oncology candidates with bempegaldesleukin being its primary candidate  The company is also developing several other candidates across important therapeutic areas including Onzeald in breast cancer and NKTR 255 in virology indications The company has collaborations with major pharma companies for developing some of its pipeline candidate  These include Bristol Myers for bempegaldesleukin  Eli Lilly   NYSE LLY   for auto immune disorder candidate  NKTR 358  and Gilead Sciences   NASDAQ GILD   for pre clinical immuno oncology candidate  NKTR 255 Nektar Therapeutics Price
    Zacks RankNektar currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-05-23,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-announces-formation-of-cnsfocused-subsidiary-200424928,200424928
171549,393065,LLY,Exclusive  Alzheimer s group may scrap early look at coveted Lilly data,news,By Ransdell Pierson  Reuters    The Alzheimer s Association may not offer an early look at highly sought clinical trial data on an experimental drug from Eli Lilly and Co  N LLY  after news of the impending release led to a jump in the company s shares  The influential patient group had been expected to post abstracts containing detailed trial findings on its website in the coming days  ahead of a conference planned for July in Washington  D C   Data in the abstracts would have been subject to an embargo  barring their public release until the conference  But participants who were registered to attend the meeting would have had access to their contents  raising questions about whether that would give them information that could influence stock market trading  Shares of Lilly have jumped 7 percent this week  largely on Wall Street expectations that favorable long term effectiveness data could emerge from the study of solanezumab  an injectable drug with potential to become the first approved treatment to delay progression of Alzheimer s   A spokesman for the Alzheimer s Association told Reuters on Thursday that the abstracts  summaries of clinical trial data to be presented at the meeting  could be posted within a few days on a special website for those registered for the event  He said the data would be strictly  embargoed  from publication or distribution until the meeting next month  Asked if industry analysts  investors or others who might be tempted to trade on the information would be held to the same secrecy ground rules  he said  everyone  would be  But on Friday  the Alzheimer s Association seemed to be reconsidering its plans  saying   AAIC abstracts have not been published and there is no plan to publish them at this time  If and when they are published  we will alert people who are registered for AAIC to their availability   Nicole Hebert  a spokeswoman for Lilly  said the company received numerous queries on Thursday from people about whether embargoed data from the trial were available  She said the company did not have discussions with the Alzheimer s Association about its embargo policy  and had no position on it   Some Wall Street analysts had alerted their clients in research notes that the Alzheimer s Association would publish the abstracts as soon as today  Eric Siemers  head of Lilly s Alzheimer s programs  on Thursday told Reuters the main abstract for solanezumab would contain virtually all important data from the study  He said that would be a departure from usual practice  in which abstracts provide only limited information  Registration for the July 18 23 meeting is open to anyone  regardless of profession  who has paid the registration fee of up to  1 040  The Alzheimer s Association s wide access policy to embargoed materials contrasts with embargo policies of other leading patient groups  which tightly restrict such information to journalists who sign confidentiality agreements  The vast majority of research abstracts at the annual meeting of the American College of Cardiology  ACC  are posted online two weeks before the studies are presented  without an embargo   But data for about 15 or 20 of the most important studies  called late breakers  are not posted  Instead  they are made exclusively available to the media a day or so before the presentations   Embargos give journalists time to digest the information  maybe run it past trusted experts and to prepare a good story   said ACC spokeswoman Beth Casteel  The American Society of Clinical Oncology  ASCO  has similar policies   Nobody except the media has access   a spokeswoman said  Donald Langevoort  a professor at the Georgetown University Law Center  said the Alzheimer s Association s wide access to embargoed materials  raises lots of red flags  At the very least it s a public relations risk  and maybe a legal risk  ,2015-06-12,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-alzheimer's-group-may-scrap-early-look-at-highly-sought-lilly-data-346408,346408
171550,393066,LLY,Lilly In Licenses Private Biotech s Non Opoid Pain Candidate,opinion,Eli Lilly and Company   NYSE LLY   announced that it is in licensing the worldwide rights to a non opioid pain candidate from Massachusetts based privately held Centrexion Therapeutics Corporation for an upfront payment of  47 5 million  The move will strengthen Lilly s pain pipeline portfolio Centrexion s small molecule somatostatin receptor type 4  SSTR4  agonist  CNTX 0290  is being evaluated in a phase I study for the potential non opioid treatment of chronic pain conditions Other than the upfront payment  Lilly is entitled to pay up to  575 million as development and regulatory milestones  Upon successful commercialization of the candidate  Centrexion will be eligible to receive  375 million as sales based milestones and high single digit to low double digit royalties  On approval  both companies may choose to co promote the drug in the United States  The transaction is subject to customary closing conditions Shares of Lilly have inched up 0 9  so far this year  outperforming the  increase of 0 7  We would like to remind investors that pain management has been a key area of focus for Lilly  The company along with Pfizer   NYSE PFE   is developing NGF inhibitor  tanezumab  subcutaneous   in late stage studies for osteoarthritis pain  chronic low back pain and cancer pain In February 2019  both Lilly and Pfizer announced that a higher dose of tanezumab met the primary endpoint in a phase III study  evaluating it for patients with chronic low back pain Both companies also successfully completed the two late stage studies  evaluating tanezumab in patients with osteoarthritis pain  Notably  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Teva Pharmaceutical Industries Limited   NYSE TEVA   are also developing a NGF antibody  fasinumab  for treating osteoarthritis pain Meanwhile  in its pain portfolio  Lilly launched Emgality  galcanezumab   its CGRP antibody  for the preventive treatment of migraine in the United States last September  The drug generated revenues of  14 2 million in the first quarter of 2019  which is more than  4 9 million recognized in the previous quarter Lilly is also looking to expand the label of Emgality injection as a preventive treatment of episodic cluster headache in adult patients  In March 2019  the FDA granted a priority review to this regulatory application Zacks RankLilly currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-28,Zacks Investment Research,https://www.investing.com/analysis/lilly-inlicenses-private-biotechs-nonopoid-pain-candidate-200426118,200426118
171556,393072,LLY,Wall Street falls as Greece crisis unresolved  energy shares dip,news,"By Caroline Valetkevitch  Reuters    U S  stocks fell on Friday as Greek debt talks hit a stalemate and as concern over how soon the Federal Reserve might raise interest rates kept investors cautious  Energy shares dropped as oil prices fell for a second straight day  The energy index   down 1 2 percent  led the day s decline  followed by a 1 1 percent drop in the healthcare index   Upbeat consumer sentiment and other data added to views the economy may be regaining momentum  which increased anxiety for investors ahead of next week s Federal Open Market Committee meeting  the U S  central bank s last meeting before September  Also of concern  a day after the International Monetary Fund quit bailout talks with Greece  EU officials said they had held their first formal discussions on the worst case scenario for the country   It s the Greek situation again  and that s been played out on a day to day basis  where you had a huge rally followed by a decline  predicated on whether they are coming closer or moving further from a resolution over this situation   said Mark Luschini  chief investment strategist at Janney Montgomery Scott in Philadelphia   The Dow Jones industrial average  DJI  fell 140 53 points  or 0 78 percent  to 17 898 84  the S P 500  SPX  lost 14 75 points  or 0 7 percent  to 2 094 11 and the Nasdaq Composite  IXIC  dropped 31 41 points  or 0 62 percent  to 5 051 10  For the week  the Dow was up 0 3 percent  the S P 500 was up 0 1 percent  while the Nasdaq Composite fell 0 3 percent  its third straight week of declines  U S  consumer confidence surged in early June  The University of Michigan s consumer sentiment index rose to 94 6 from 90 7 in May  The upbeat report capped a week of strong economic data and was the latest indication that growth was regaining momentum after a sluggish start to the second quarter  That added to investor caution   particularly in light of the fact that we re just days ahead of the Fed meeting   Luschini said  Higher rates will tighten the flow of easy money  Economists and top Wall Street banks expect the Fed to raise rates in September  in what could be its first hike in almost a decade   Twitter Inc   N TWTR  shares were up 0 2 percent at  35 90  a day after Chief Executive Officer Dick Costolo said he was stepping down  Among the biggest decliners in health care  shares of Eli Lilly  N LLY  ended down 2 7 percent at  84 21  It hit its low for the session and volume spiked after Reuters reported the Alzheimer s Association may not offer an early look at trial data on an experimental drug from Eli Lilly  News of the impending release had led to a jump in the company s shares  Eli Lilly s stock had gained 10 3 percent from Monday s close to Thursday s finish  Declining issues outnumbered advancing ones on the NYSE by 1 945 to 1 075  for a 1 81 to 1 ratio on the downside  on the Nasdaq  1 586 issues fell and 1 146 advanced for a 1 38 to 1 ratio favoring decliners  The benchmark S P 500 index posted five new 52 week highs and eight new lows  the Nasdaq Composite recorded 73 new highs and 28 new lows  
About five billion shares changed hands on U S  exchanges  compared with the 6 1 billion daily average for the month to date  according to data from BATS Global Markets    Editing Meredith Mazzilli and James Dalgleish ",2015-06-12,Reuters,https://www.investing.com/news/stock-market-news/u.s.-futures-slip-as-greece-continues-to-weigh-346344,346344
171557,393073,LLY,Pharma Stock Roundup  FDA Okays Line Extensions Of LLY  PFE  ABBV Cancer Drugs,opinion,This week the FDA granted quite a few approvals for line extensions of Lilly   NYSE LLY    Pfizer   NYSE PFE   and Roche   OTC RHHBY   AbbVie s   NYSE ABBV   cancer drugs  In other news  Bayer   OTC BAYRY   was fined  2 billion by California jury over allegations that its popular weed killer caused cancer  J J   NYSE JNJ   detailed a new five year growth plan for its Pharmaceutical segment  its largest unit  at its analyst day Recap of the Week s Most Important StoriesLilly s Cyramza Gets FDA Nod for New Indication  The FDA granted approval to Lilly s cancer drug treatment of patients with hepatocellular carcinoma  HCC   a common form of liver cancer  Importantly  along with this approval  the FDA also removed the boxed warning from Cyramza s label  which included warnings for hemorrhage  ruptured bowel and non healing wounds  The approval for HCC was based on data from the REACH  2 study  Cyramza is already marketed for other cancer indications like gastric cancer  non small cell lung cancer  NSCLC  and metastatic colorectal cancer Pfizer Gets FDA Nod for Bavencio Inlyta Combo in Kidney Cancer  Pfizer and partner Merck KGaA gained FDA approval for Bavencio  avelumab  in combination with Inlyta  axitinib  for first line treatment of patients with advanced renal cell carcinoma  RCC   the most common form of kidney cancer  The FDA s decision comes earlier than expected  The decision was originally scheduled in June  A similar application is under review in the EU  which was validated for review by the European Medicines Agency this March  The regulatory filings in the EU and the United States were based on interim data from the phase III   which showed that the Bavencio Inlyta combination significantly lowered risk of disease progression or death by 31  and extended progression free survival by 5 4 months versus Pfizer s older kidney cancer drug  Sutent Moreover  Pfizer s investigational JAK1 inhibitor abrocitinib  PF 04965842  in a pivotal late stage study  In the phase III study  which tested two doses of the drug  abrocitinib achieved statistically significantly higher improvement in clearing the skin of patients compared to placebo FDA Grants Approval to Venclexta Gazyva in First Line CLL  The FDA granted approval to a combination of AbbVie Roche s Venclexta and Roche s Gazyva as a fixed duration treatment for first line chronic lymphocytic leukemia  CLL    The approval was based on data from the phase III CLL14 study  which demonstrated that the combination significantly reduced risk of disease progression or death by 67  compared to the current standard of care  The supplementary new drug application was filed under the Real Time Oncology Review  RTOR  pilot program  which meant that the agency expedited the review Data from a phase I II study on Roche s personalized medicine entrectinib showed that the candidate had an objective response or shrank tumors harboring NTRK  ROS1 or ALK gene fusions including those in the central nervous system  CNS  in children and adolescents  Moreover  two patients achieved a complete response  The data will be presented at the ASCO meeting in June Bayer Fined  2B by a California Jury  A California state jury ordered Bayer to pay  2 billion in damages to a couple  Alva and Alberta Pilliod  who claimed the company s Roundup weed killer was the cause of their cancer  The active ingredient in Roundup  glyphosate  is being blamed for causing the cancer  This is the third jury verdict against Bayer in litigation over the herbicide  which Bayer acquired as part of its  63 billion buyout of Monsanto  NYSE MON  last year  However  Bayer is disappointed with the verdict and said will appeal against the verdict J J s Analyst Day  At its meeting with industry analysts  J J said it expects its Janssen pharmaceutical business to deliver above market growth through 2023  J J expects to launch or file for approval of more than 10 new products with blockbuster potential between 2019 and 2023  J J said it has gained regulatory approvals for 18 new products since 2011 in HIV  cancer and cardiovascular areas  The company is targeting more than 40 line extensions of existing and new drugs through 2023  10 of which have more than half a billion dollars of opportunity  However  the unit s growth is expected to be a little bit slow in 2019 due to more than  3 billion of patent expirations that it is currently facing AbbVie Resolves U S  Patent Litigation With Boehringer Ingelheim  AbbVie announced over U S  patents for its blockbuster rheumatoid arthritis drug Humira  Per the settlement  AbbVie grants Boehringer Ingelheim a non exclusive license to launch its biosimilar version of Humira in the United States on July 1  2023  Several companies have made biosimilar versions of Humira  AbbVie has similar settlement with seven manufacturers  per which Humira biosimilars are expected to be launched in the United States in 2023  In the EU  however  Humira biosimilars have already been launched  which are causing a rapid decline in Humira sales in international markets The NYSE ARCA Pharmaceutical Index rose 0 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   ReturnHere is how the seven major stocks performed in the last five trading sessions Last week  in a mixed performance  Pfizer gained the most  2 5   while AstraZeneca declined the most  1 7  In the past six months  Merck   NYSE MRK   has been the biggest gainer  3 7   while Bristol Myers declined the most  11 8    See the last pharma stock roundup here  Pharma Stock Roundup   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-17,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs-200422458,200422458
171558,393074,LLY,Why Eli Lilly  LLY  Is A Top Dividend Stock For Your Portfolio,opinion,"Whether it s through stocks  bonds  ETFs  or other types of securities  all investors love seeing their portfolios score big returns  But when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends account for significant portions of long term returns  with dividend contributions exceeding one third of total returns in many cases 
Eli Lilly in Focus
Headquartered in Indianapolis  Eli Lilly  LLY  is a Medical stock that has seen a price change of 0 25  so far this year  The drugmaker is paying out a dividend of  0 64 per share at the moment  with a dividend yield of 2 22  compared to the Large Cap Pharmaceuticals industry s yield of 2 98  and the S P 500 s yield of 1 97  
Taking a look at the company s dividend growth  its current annualized dividend of  2 58 is up 14 7  from last year  Eli Lilly has increased its dividend 5 times on a year over year basis over the last 5 years for an average annual increase of 4 06   Looking ahead  future dividend growth will be dependent on earnings growth and payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Lilly s current payout ratio is 46   meaning it paid out 46  of its trailing 12 month EPS as dividend 
Looking at this fiscal year  LLY expects solid earnings growth  The Zacks Consensus Estimate for 2019 is  5 66 per share  representing a year over year earnings growth rate of 1 98  
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  However  not all companies offer a quarterly payout 
High growth firms or tech start ups  for example  rarely provide their shareholders a dividend  while larger  more established companies that have more secure profits are often seen as the best dividend options  Income investors have to be mindful of the fact that high yielding stocks tend to struggle during periods of rising interest rates  That said  they can take comfort from the fact that LLY is not only an attractive dividend play  but also represents a compelling investment opportunity with a Zacks Rank of  2  Buy  ",2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio-200423040,200423040
171560,393076,LLY,Merck To Buy Private Cancer Drugmaker Peloton Therapeutics,opinion,Merck   Co   Inc    NYSE MRK   announced a definitive agreement to buy small private cancer biotech  Peloton Therapeutics for an upfront payment of  1 05 billion in cash  The acquisition will add Peloton s novel late stage renal cell carcinoma  RCC  candidate  PT2977 to Merck s oncology pipeline  which is currently riding on the success of its blockbuster PD L1 inhibitor Keytruda PT2977  an oral HIF 2  inhibitor  is currently being evaluated in multiple cancer studies including phase II studies in von Hippel Lindau  VHL  disease associated RCC and in combination with Exelixis  Inc  s   NASDAQ EXEL   Cabometyx  cabozantinib    a VEGFR targeting agent  in metastatic RCC and a phase I II study in metastatic RCC In addition to the upfront payment  Merck will also be entitled to pay a further  1 15 billion of potential milestones payments  The transaction is expected to close in the third quarter of 2019 This is Merck s second acquisition of cancer focused biotech this year  In April  Merck closed its previously announced acquisition of small cancer focused biotech  Immune Designfor an approximate value of  300 million Merck s stock has risen 4  this year so far against the  s decline of 1 3    This year has been good as far as M A activity in the pharmaceuticals biotech industry is concerned  Oncology and immuno oncology are key areas of focus  Bristol Myers Squibb Co    NYSE BMY    one of the largest pharma giants  announced that it will acquire leading biotech company Celgene  NASDAQ CELG   for a whopping  74 billion  This will be one of the largest acquisitions in recent times Another large cap pharma company Eli Lilly   NYSE LLY   bought Loxo Oncology in February for  8 0 billion to broaden its oncology portfolio  Roche also announced an agreement to acquire Spark Therapeutics in February 2019 for  4 8 billion   Post completion of the buyout  Roche will get access to Spark Therapeutics  novel gene therapy  SPK 8011 for the treatment of hemophilia A  which is expected to enter phase III in 2019A surge in M A activity during 2019 is expected in the overall drug biotech sector on the lines of Bristol Myers and Eli Lilly as companies look to use huge cash reserve and combat rivalry woes Merck currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/merck-to-buy-private-cancer-drugmaker-peloton-therapeutics-200423842,200423842
171562,393078,LLY,Lilly s Crohn s Disease Candidate Meets Phase II Study Goals ,opinion,Eli Lilly and Company   NYSE LLY   announced that a phase II study evaluating its pipeline candidate mirikizumab in patients with moderately to severely active Crohn s disease   CD   met the primary and secondary endpoints Data from the phase II SERENITY study showed that treatment with mirikizumab led to significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo  The data were presented at Digestive Disease Week medical conference in San Diego  CA  Lilly plans to begin phase III studies on mirikizumab in Crohn s disease later this year  Mirikizumab is already being evaluated in phase III studies in other immune diseases  psoriasis and ulcerative colitis Some popular drugs approved to treat Crohn s disease are AbbVie s   NYSE ABBV   Humira and UCB s Cimzia  among others while several others like AbbVie s newly approved psoriasis drug Skyrizi  risankizumab   Theravance Biopharma  Inc  s   NASDAQ TBPH   JAK inhibitor TD 1473 Galapagos and Gilead s   NASDAQ GILD   filgotinib and RedHill Biopharma Ltd  RHB 104 are in late stage studies for CD Immunology is a key therapeutic area for Lilly and its portfolio includes popular drug Taltz  which is marketed for the treatment of psoriasis and psoriatic arthritis  Meanwhile  regulatory applications seeking approval of Taltz for axial spondyloarthritis are also under review with the FDA  Lilly is also seeking to expand its immunology pipeline  In the first quarter  Lilly announced global licensing and research collaboration with two companies  ImmuNext  Inc  and Avidity Biosciences  Inc to make new medicines in immunology and autoimmune diseases Lilly s shares have risen 0 7  this year so far against the  s decline of 1 2   Lilly currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/lillys-crohns-disease-candidate-meets-phase-ii-study-goals-200423962,200423962
171570,393086,LLY,European stocks push higher in thin trade  Dax jumps 1 52 ,news,"Investing com   European stocks pushed higher in thin trade on Tuesday  as global financial centers returned from the long Easter weekend and as concerns over tensions in Ukraine continued to ease 
During European afternoon trade  the DJ Euro Stoxx 50 gained 1   France s CAC 40 advanced 0 89   while Germany s DAX jumped 1 52  
Concerns over the crisis in eastern Ukraine eased last Thursday after Russia  Ukraine  the U S  and the European Union said an agreement on steps to  de escalate  the crisis had been reached 
Elsewhere  upbeat U S  data on manufacturing and employment last week pointed to underlying strength in the economy 
The Labor Department reported the number of people filing for unemployment benefits edged up to 304 000  below analysts  forecasts and not far from the six and a half year low of 300 000 touched the previous week 
Financial stocks remained mixed  as French lenders BNP Paribas  BNPP PAR  and Societe Generale  SOGN PAR  rallied 1 21  and 0 95   while Germany s Deutsche Bank  DBKGn XETRA  slid 0 76  
Among peripheral lenders  Italy s Intesa Sanpaolo  ISP MILAN  and Unicredit  CRDI MILAN  gained 0 70  and 0 73  respectively  while BBVA  BBVA MADRID  rose 0 35  and Banco Santander  SAN MADRID  slipped 0 23  in Spain 
Elsewhere  Novartis  NOVN SIX  surged 2 48  after the Swiss drugmaker agreed to buy Glaxosmithkline  GSK LSE  s cancer drug business for  16 billion  to form a consumer health venture with Glaxo and to sell its animal health unit to Eli Lilly and Company  NYSE LLY  for  5 4 billion 
In earnings news  Philips Kon  PHG AMS  reported first quarter results that missed analysts  estimates  sending shares in the world s largest lighting company down 6 98  
In London  FTSE 100 advanced 1   still led by Astrazeneca  up 6 72   amid reports Pfizer  NYSE PFE  may come back to bid for the British drug company  after its  60 billion takeover approach was rejected 
Rival company GlaxoSmithKline continued to add to gains  with shares surging 5 36   on news of Novartis  plan to buy the company s cancer drug business 
Financial stocks also remained broadly higher  as Lloyds Banking  LLOY LSE  edged up 0 08  and the Royal Bank of Scotland  RBS LSE  added 0 10   while Barclays  BARC LSE  and HSBC Holdings  HSBA LSE  rose 0 21  and 0 44  respectively 
Meanwhile  minings stocks were still on the downside  Shares in Glencore Xstrata  GLEN LSE  declined 0 48  and Rio Tinto  RIO LSE  dropped 0 81   while Randgold Resources  RRS LSE  tumbled 0 96  
In the U S   equity markets pointed to a steady open  The Dow 30 futures pointed to a 0 02  dip  S P 500 futures signaled a 0 02  downtick  while the Nasdaq 100 futures indicated a 0 08  gain 
Later in the day  the U S  was to release private sector data on existing home sales ",2014-04-22,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-push-higher-in-thin-trade;-dax-jumps-1.52-278626,278626
171571,393087,LLY,Novartis Overhauls Business Portfolio Through Deals With GSK And Eli Lilly,news,"By    Novartis AG NYSE NVS on Tuesday announced that it will acquire GlaxoSmithKline s NYSE GSK cancer drug business for  14 5 billion and would sell most of its vaccine business to GSK for  7 1 billion plus royalties  At the same time  the Swiss company announced the sale of its animal health division to Eli Lilly and Co NYSE LLY for nearly  5 4 billion 
Under the agreement  Novartis and British drug maker GSK will create a joint venture that combines the companies  consumer oriented divisions to create a business that will sell medicines that do not require prescriptions  Novartis  decision of selling its animal health division to Indianapolis based Eli Lilly is expected to help the Basel  Switzerland based company to focus on innovative pharmaceuticals  eye care and generics  the company said in a statement 
  The transactions  improve our financial strength  and are expected to add to our growth rates and margins immediately   Joseph Jimenez  CEO of Novartis  said in a statement released Monday  adding   Patients will benefit from even higher levels of innovation that this focus may afford  
Upon completion of the transaction between Novartis and GSK  the former will own 36 5 percent of the joint venture and four out of eleven seats on the new entity s board  Novartis will also have customary minority rights and exit rights at a pre defined  market based pricing mechanism  the statement said  The deal will make GSK the world s largest provider of vaccines with 20 more vaccines currently under development 
In February  Novartis acquired CoStim Pharmaceuticals  a privately held Massachusetts based biotechnology company  to broaden its cancer immunotherapy research program  without disclosing the financial details of the transactions 
Eli Lilly said  in a separate statement  that Elanco  the company s animal health division would become the world s second largest company in the segment in terms of global revenue  after its acquisition of Novartis  business 
 Combining these two great companies will enable us to provide more diversified brands  reach more market segments  expand our global footprint  and strengthen our pipeline  capabilities and expertise   Jeff Simmons  senior vice president of Eli Lilly and head of Elanco Animal Health  said in a company statement 
The transactions are expected to affect about 15 000 employees worldwide in all three companies but no jobs will be lost  Associated Press reported  citing Jimenez 

GSK s stock gained 1 16 percent on Monday on the New York Stock Exchange  or NYSE  and was trading up 4 5 percent in pre market trading Tuesday  Novartis stock gained 0 93 percent on Monday and was up more than 1 percent before markets opened Tuesday  Eli Lilly s stock  which rose 0 71 percent on Monday on the NYSE  was trading down more than 3 percent in pre market trading on Tuesday ",2014-04-22,International Business Times,https://www.investing.com/news/stock-market-news/novartis-overhauls-business-portfolio-through-deals-with-gsk-and-eli-lilly-278632,278632
171573,393089,LLY,Ex GSK China staff seek compensation for illegal dismissal,news,"By Li Hui and Adam Jourdan  BEIJING SHANGHAI  Reuters    Three former Chinese employees of GlaxoSmithKline PLC  which is embroiled in a long running corruption probe in China  are seeking compensation for illegal dismissal from their jobs  a lawyer representing them told Reuters   The plaintiffs are seeking two months  pay for each year of their employment from Britain s biggest drugmaker for dismissing them between April and May for expenses that were  not compliant with company regulation   Shanghai based Liu Feng said   They are also seeking reimbursement for unpaid expenses which they said were part of the bribe money they paid to doctors and hospital staff with approval from their managers  the lawyer added   Some sales staff were laid off with unpaid expenses worth more than 200 000 yuan   32 200   according to Liu   The labor dispute arbitration committee in Shanghai s Huangpu district will hear the case on Thursday   A similar labor arbitration case filed by a former GSK salesperson was heard in the central province of Henan in May  That plaintiff  who did not want to be named  said by telephone that the decision would be issued soon   While any compensation GSK could end up paying will be relatively minor  it is another headache for the drugmaker and could further tarnish its reputation in the Chinese market   EXECUTIVES ARRESTED  Chinese police in May charged Briton Mark Reilly  the former head of GSK in China  and two Chinese executives for allegedly orchestrating a widespread network of bribery to promote sales in the biggest corruption scandal to hit a foreign firm in China since 2009  Prosecutors are reviewing the case     The workers think the company is very dishonest and its attitude abominable  They are very dissatisfied with the company s actions   Liu said in a telephone interview   In an email to Reuters  a GSK spokesman in China declined to comment on individual cases  But he said that a  single digit  number of Chinese ex employees  who had been dismissed because of issues related to expenses  had brought cases against the firm through labor arbitration channels    We have zero tolerance to expense fraud  and where we have found potential issues  we have thoroughly reviewed them and taken disciplinary action including dismissal where appropriate   he said   He declined to comment further on the allegations from the ex employees about GSK s conduct   Liu said about two dozen other former GSK staff had contacted him about filing similar cases  but they were waiting to see the outcome of the Shanghai case    My expenses were approved by my manager     but they are saying it was a personal action not a company one   said one of the plaintiffs  speaking on condition of anonymity   The same plaintiff added that  during recent dismissals  GSK urged some China employees to resign and told them that if they did not  their contract would be terminated and the company would give them a bad reference reflecting problematic expenses   SMALL PROPORTION  GSK has declined to specify the number of staff that were dismissed as result of a crackdown on illegal expenses  but a source familiar with the matter told Reuters that it was a very small proportion of the company s total workforce in China of around 7 000   GSK is facing the biggest corruption scandal to hit a foreign company in China since the Rio Tinto affair in 2009  which resulted in four executives  including an Australian  being jailed for between seven and 14 years   The allegations against GSK have damaged its reputation  thrown its China management team into turmoil and forced it to change its China business model  although the firm says head office had no knowledge of the alleged wrongdoing    China is a key growth market for large drugmakers  which are counting on its swelling middle class to offset declining sales in Western countries   China is set to be the second biggest pharmaceuticals market behind the United States within three years  according to consultants IMS Health   But bribery between sales staff and doctors is believed to be rife in the world s second biggest economy  and it remains to be seen whether the GSK case will be a one off or the first of a broader campaign to clean up the Chinese health sector   Other large international drugs manufacturers including Novo Nordisk A S  AstraZeneca Plc  Sanofi SA  Eli Lilly   Co and Bayer AG were also visited by Chinese officials in 2013 as part of a broad investigation into the business     1   6 2035 Chinese Yuan   
 This version of the story corrects wording in paragraph 3     Editing by Kazunori Takada and Mike Collett White ",2014-07-16,Reuters,https://www.investing.com/news/stock-market-news/ex-gsk-china-staff-seek-compensation-for-illegal-dismissal-295358,295358
171574,393090,LLY,Wall Street to open lower  eyes on Fed meeting,news,By Rodrigo Campos  NEW YORK  Reuters    U S  stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U S  interest rates   Futures held on to slight losses after data showed U S  producer prices were flat in August  pointing to muted inflation pressures that should see the Fed in no hurry to raise rates   Later on Tuesday  the Fed will begin a two day policy meeting  A statement and forecasts will be released Wednesday at 2 00 p m  EDT followed by a press conference half an hour later    The big news comes  Wednesday  from the Fed and we ll work our way a bit lower before the announcement  Key points will likely suggest the Fed stays on hold until the middle of next year and that is already baked in   said Peter Cardillo  chief market economist at Rockwell Global Capital in New York     Markets are in a bit of a technical pullback   he said  adding the benchmark S P 500  will test 1 975 and probably could work toward 1 940 1 950  which I think would represent a buying opportunity    S P 500 e mini futures  were down 4 points and fair value   a formula that evaluates pricing by taking into account interest rates  dividends and time to expiration on the contract   indicated a lower open  Dow Jones industrial average e mini futures  1YMc1  fell 31 points and Nasdaq 100 e mini futures  lost 11 points   U S  traded AstraZeneca  N AZN  shares fell 1 6 percent in premarket trading after it signed a partnership deal with U S  rival Eli Lilly  N LLY  that could earn the British company up to  500 million if an experimental Alzheimer s drug proves successful      Editing by Bernadette Baum ,2014-09-16,Reuters,"https://www.investing.com/news/stock-market-news/futures-dip-ahead-of-data,-fed-eyed-309609",309609
171577,393093,LLY,Novo Nordisk  NVO  Q1 Earnings And Revenues Miss Estimates,opinion,"Novo Nordisk  CO NOVOb  A S   NYSE NVO   reported first quarter 2019 earnings of 58 cents per American Depositary Receipt  ADR   missing both the Zacks Consensus Estimate of 62 cents and the year ago figure of 59 cents Although quarterly revenues were up 8 6  year over year  up 4  at constant exchange rate  CER   to  3 92 billion  the top line lagged the Zacks Consensus Estimate of  4 35 billion In the past year  Novo Nordisk s shares have increased 6 1   outperforming the  s flat growth All growth rates mentioned below are on a year over year basis Quarter in DetailNovo Nordisk operates through two segments  Diabetes and Obesity care plus Biopharmaceuticals The Diabetes and Obesity Care segment sales increased 8  in Danish kroner and 4  at CER  Sales of insulin rose 5   measured in Danish kroner to DKK 15 393 million  and 2  at CER  Sales of long acting insulin  Tresiba  Xultophy and Levemir  improved 8  in Danish Kroner to DKK 5 244 million Sales at the Biopharmaceuticals segment inched up 3   measured in Danish kroner  and have been unchanged at CER to DKK 4 473 million  Hemophilia sales were nudged up 1  in Danish kroner and dipped 3  at CER Research and development  R D  expenses were down 19  in Danish kroner and 21  at CER  reflecting reversal of write downs on clinical prelaunch inventory of approximately DKK 500 million following the filing of oral semaglutide to the FDA Also  administrative costs climbed 5  in Danish kroner and 3  at CER  mainly due to higher expenditure across regions in International Operations    Sales and distribution costs ascended 8  in Danish kroner and 3  at CER owing to resource allocation to the growth markets and promotional activities for Victoza  and Saxenda as well as launch activities for Ozempic Other Updates
In February 2019  Novo Nordisk announced the FDA s approval of its biologics license application  BLA  for Esperoct to treat adults and children with haemophilia A  Esperoct is the brand name for turoctocog alfa pegol  N8 GP  In the United Sttaes  Esperoct is indicated for use in adults and minors with haemophilia A  using routine prophylaxis to reduce frequent bleeding episodes as well as on demand treatment for controlling bleeding episodes and the perioperative management of bleeding Later this March  concizumab was granted a Breakthrough Therapy Designation  BTD  for prophylaxis to prevent or lower the frequency of bleeding episodes in people with haemophilia B and inhibitors by the FDA 2019 Outlook
Novo Nordisk expects 2 5  sales growth  in local currencies   This reflects a strong performance for the portfolio of new generation insulin and the GLP 1 pipeline  now comprising both Victoza and Ozempic as well as a solid contribution from Saxenda and the suite of new generation insulin  However  this sales rise is expected to be partly offset by an intensifying global competition within Diabetes Care and Biopharmaceuticals  especially in the haemophilia inhibitor segment 
Persistent pricing pressure within Diabetes Care  especially in the United States  might also  negatively impact the sales drive  A positive currency impact of 3 percentage points is expected as well Operating profit growth is anticipated to be 2 6   reflecting the outlook for sales growth and an impact from the firm focus on cost control  Growth reported in Danish kroner is estimated to be around 5 percentage points  higher than the tally in local currencies Our TakeContinued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy are likely to be partly offset by the impact of lower realized prices in the Unites States  loss of exclusivity for products in hormone replacement therapy and a stiff rivalry within the diabetes and biopharmaceuticals markets besides macroeconomic conditions in many markets under International Operations  The company is optimistic about Ozempic and results for oral semaglutide  It is looking forward to making the first oral GLP 1 treatment available for people with type II diabetes In April 2019  Gilead Sciences  Inc    NASDAQ GILD   and Novo Nordisk announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis  NASH   This intended clinical trial will be a proof of concept study combining Novo Nordisk s semaglutide and Gilead s cilofexor  FXR agonist  and firsocostat  ACC inhibitor  for the treatment of patients with NASH  Novo Nordisk A S Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderNovo Nordisk has a Zacks Rank  3  Hold  Some better ranked stocks from the same space are Eli Lilly and Co   LLY  and AbbVie Inc   ABBV   both carrying a Zacks Rank  2  Buy   You can see  Lilly s   NYSE LLY   earnings per share estimates have increased from  5 60 to  5 66 for 2019 and from  6 42 to  6 59 for 2020 in the past 90 days  The company delivered a positive surprise in three of the trailing four quarters  the average being 3 63  AbbVie s   NYSE ABBV   earnings per share estimates have increased from  8 68 to  8 81 for 2019 and from  9 26 to  9 36 for 2020 over the past 60 days  The company came up with a positive surprise in three of the trailing four quarters  the average being 2 58  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-nvo-q1-earnings-and-revenues-miss-estimates-200416666,200416666
171578,393094,LLY,Aduro  ADRO  Q1 Earnings And Revenues Fall Shy Of Estimates,opinion,Aduro BioTech  Inc    NASDAQ ADRO   incurred first quarter 2019 loss of 29 cents per share  wider than the Zacks Consensus Estimate of a loss of 17 cents as well as the year ago loss of 28 cents Revenues came in at  3 9 million  down 40 9  year over year due to an absence of a  3  million milestone payment received from Merck   NYSE MRK   in 2018  The top line also missed the Zacks Consensus Estimate of  8 08 million Shares of Aduro have soared 67 1  so far this year  outperforming the  increase of 6  Quarter in DetailResearch and development expenses dipped 3  in the reported quarter to  19 5 million owing to lower stock based compensation and personnel costs General and administrative expenses were  9 2 million  up 2 2  year over year  primarily due to higher professional services and consulting costs Pipeline UpdateAduro s three distinct technology platforms  designed to harness the body s natural immune system  are being utilized to develop treatments for several cancer indications and show potential for label expansion into auto immune and infectious diseases  The three well defined platforms are the LADD technology  STING pathway activator and the B select monoclonal antibody Aduro s lead assets are STING agonist ADU S100 and anti APRIL antibody  BION 1301 Aduro has a collaboration and license agreement with Novartis   NYSE NVS   for developing its lead STING Activator candidate  ADU S100 In February this year  Aduro dosed the first patient in a phase I study  evaluating ADU S100 in combination with Bristol Myers    NYSE BMY   Yervoy  ipilimumab  for the treatment of relapsed refractory melanoma Earlier  ADU S100 was being investigated as a single agent  However  the protocol was amended later to include the analysis of ADU S100 in combination with Yervoy on a homogeneous patient population Meanwhile  during the quarter  Aduro initiated the planned phase I clinical program on BION 1301 evaluating healthy volunteers for treating IgA nephropathy   the primary indication of the BION 1301 program  However  due to the current competitive landscape  Aduro has decided to discontinue with the planned phase I II probe on BION 1301 for MM We would like remind investors that last December  Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly  NYSE LLY  to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS STING inhibitor platform  In the first quarter of 2019  Aduro received an upfront payment  12 million from this contract with Eli Lilly  which enhanced its cash position at the end of the period Aduro Biotech  Inc  Price  Consensus and EPS Surprise   Zacks RankAduro currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q1-earnings-and-revenues-fall-shy-of-estimates-200418983,200418983
171579,393095,LLY,Pharma ETFs Down Despite Solid Q1 Results,opinion,"Total earnings of  of the entire healthcare market capitalization reported so far are up 8 1  on revenue growth of 6 8   The growth rates seem impressive when compared with some of the other sectors  Earnings and revenue beat ratios of 85 4  and 70 8   respectively  also appear strong  read    Most industry bigwigs delivered encouraging results  either beating on earnings or revenue or both and also raised revenue or earnings outlook or both  Let s delve into a few of them Earnings in FocusJohnson and JohnsonThe world s biggest maker of healthcare products continued with its long streak of earnings beat and also outpaced revenue estimates  Earnings per share came in at  2 10  ahead of the Zacks Consensus Estimate by 7 cents and also 1 9  higher than the year ago quarter  Revenues inched up 3 9  year over year to  20 02 billion and edged past the Zacks Consensus Estimate of  19 63 billion  Though Johnson   Johnson  NYSE JNJ  lifted the guidance for full year sales growth to 2 5 3 5  from 2 3   it narrowed its earnings per share outlook to  8 53  8 63 from the  8 50  8 65 range  read    Pfizer  NYSE PFE Earnings per share of 85 cents were 8 cents above the Zacks Consensus Estimate and revenues of  13 12 billion also exceeded the consensus estimate of  12 80 billion  On an annual basis  earnings per share and revenues rose 13  and 2   respectively  For 2019  the U S  drug giant continues to expect revenues in the band of  52  54 billion while it raised its earnings per share from  2 82  2 92 to  2 83  2 93 MerckEarnings per share of  1 22 surpassed the Zacks Consensus Estimate of  1 05 and also improved 16  from the year ago quarter  Moreover  revenues grew 8  year over year to  10 8 billion  edging past the consensus mark of  10 32 billion  Merck increased its revenue projection from  43 2  44 7 billion to  43 9  45 1 billion for this year and earnings per share view from  4 57  4 72 to  4 67  4 79 Bristol MyersBristol Myers reported earnings per share of  1 10  beating the Zacks Consensus Estimate by a penny and also rose from the year ago earnings of 94 cents  Revenues grew 14  year over year to  5 92 billion and also trumped the Zacks Consensus Estimate of  5 80 billion  The company reiterated its earnings per share guidance of  4 10  4 20 and the revenue growth expectation in mid single digits  read    Eli Lilly  NYSE LLY Eli Lilly also delivered better than expected earnings as well as revenues  Earnings of  1 33 per share were a penny ahead of the Zacks Consensus Estimate and came in 2  higher than the year earlier quarter  Revenues grew 3  to  5 1 billion  While Eli Lilly lowered its 2019 revenue guidance to  22  22 5 billion from  25 1  25 6 billion  it raised its earnings prediction to  5 60  5 70 from  5 55  5 65 ETF AngleDespite such robust results  pharma ETFs have been trending downward in a month  Below  we have highlighted those in detail iShares U S  Pharmaceuticals ETF This ETF provides exposure to 45 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top 10 holdings in the basket  accounting for a combined 55 4  of total assets  suggesting heavy concentration  The product has  393 5 354 4 million in AUM and charges 43 bps in fees and expense  Volume is light as it exchanges about 15 000 shares a day  The fund has lost 3 1  in a month and has a Zacks ETF Rank  3  Hold  with a High risk outlook SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  233 7 million  it trades in good volume of around 73 000 shares a day and charges 35 bps in fees a year  In total  the product holds 41 securities with the in focus five firms making up for at least 4  share each  The product is down 4 5  in the same period and has a Zacks ETF Rank of 3 with a High risk outlook  see    VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus five firms account for a combined 23 8  share  The product has amassed  178 7 million in its asset base and trades in moderate volume of about 53 000 shares a day  Expense ratio comes in at 0 36   The fund has shed 3 2  of value in a month and has a Zacks ETF Rank  2  Buy  with a High risk outlook Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  415 9 million and sees a lower volume of around 32 000 shares a day  The fund charges 57 bps in fees and expenses  Holding 30 stocks  the fund invests nearly 5  share each in the five firms  The ETF has declined 4  in a month and is a Zacks  3 Ranked ETF with a High risk outlook First Trust Nasdaq Pharmaceuticals ETF 
This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 31 7  of assets  FTXH has a lower level of  6 2 million in AUM and 3 000 shares in average daily volume  It charges 60 bps in annual fees and is down 3 2  in the same time frame  The product has a Zacks ETF Rank of 2 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-down-despite-solid-q1-results-200419647,200419647
171593,393109,LLY,Dainippon schizophrenia drug meets goals in trial,news,"  Lurasidone significantly better than placebo in study
   Discontinuation rate similar to placebo
   Company to seek U S  FDA approval in early 2010
 By Bill Berkrot
 NEW YORK  Aug 26  Reuters    Japan s Dainippon Sumitomo
Pharma Co Ltd  4506 T  said its experimental schizophrenia
drug  lurasidone  was significantly better than placebo in a
pivotal late stage clinical trial  according to data released
on Wednesday 
 The company said it plans to submit its application seeking
U S  approval to sell the medicine early next year 
 Patients with acute schizophrenia in the 478 subject 
six week  Phase III trial received either 40 milligrams or 120
milligrams of lurasidone daily or a placebo 
 Both doses of the drug proved to be statistically
significantly better than placebo in the primary goal of the
study  which was 30 percent or better improvement in the
Positive and Negative Syndrome Scale  the company said 
 Fifty three percent of patients who received 40 mg of
lurasidone and 47 percent of those on the 120 mg dose achieved
the primary goal compared with 38 percent on placebo 
 Both doses of lurasidone were also significantly more
effective than placebo on a secondary measure used to test
antipsychotic drugs called the Clinical Global Impressions
Severity scale  the company said 
 In previous trials  lurasidone was also tested at 80 mg and
Dainippon Sumitomo said it would submit all three doses for FDA
approval 
 Lurasidone belongs to a class of drugs known as atypical
antipsychotics and works by blocking serotonin receptors in the
brain  If approved  it would join an already crowded field of
such treatments 
  We re still searching for the right drug for many of these
patients  There s no one size fits all   Dr Herbert Meltzer 
one of the study s lead investigators and professor of
psychiatry at Vanderbilt University School of Medicine  said in
a telephone interview 
 Patients in the trial had been diagnosed with schizophrenia
on average for more than 13 years and most had been previously
hospitalized prior to entering the study 
  If you look at the weight gain  the lipid changes  it s
among the most benign of any antipsychotic drugs  clearly
better than olanzapine  clozapine and Seroquel   Meltzer said 
 Olanzapine is the chemical name for Eli Lilly and Co s
 widely used Zyprexa  clozapine in sold by Novartis AG
 under the brand name Clozaril  and Seroquel is sold
by AstraZeneca Plc  
 Zyprexa and similar drugs can cause significant weight gain
and have been linked to increased risk of diabetes 
 But  this class of drugs as a whole is so superior to the
first generation drugs   said Meltzer  who plans to present the
data from the lurasidone trial at a major medical meeting in
December 
 Lurasidone was well tolerated with a discontinuation rate
nearly identical to placebo    40 percent versus 39 percent   
and the adverse events were generally mild  such as
restlessness and sleepiness 
  From the point of view of efficacy and side effect
profile  once a day administration  the fact that the lower
dose works as well as the higher dose  I think this is going to
have a very good chance of major acceptance among my
colleagues   Meltzer added 
   Reporting by Bill Berkrot  editing by Andre Grenon ",2009-08-26,Reuters,https://www.investing.com/news/equities-news/dainippon-schizophrenia-drug-meets-goals-in-trial-81879,81879
171594,393110,LLY,European stocks gain ground after Easter weekend  Dax jumps 1 17 ,news,"Investing com   European stocks were higher in light trade on Tuesday  as global financial centers returned from the long Easter weekend and as concerns over tensions in Ukraine continued to ease 
During European morning trade  the DJ Euro Stoxx 50 gained 0 78   France s CAC 40 advanced 0 77   while Germany s DAX jumped 1 17  
Concerns over the crisis in eastern Ukraine eased last Thursday after Russia  Ukraine  the U S  and the European Union said an agreement on steps to  de escalate  the crisis had been reached 
Elsewhere  upbeat U S  data on manufacturing and employment last week pointed to underlying strength in the economy 
The Labor Department reported the number of people filing for unemployment benefits edged up to 304 000  below analysts  forecasts and not far from the six and a half year low of 300 000 touched the previous week 
Financial stocks were mixed  as French lenders BNP Paribas  BNPP PAR  and Societe Generale  SOGN PAR  gained 0 73  and 0 94   while Germany s Deutsche Bank  DBKGn XETRA  tumbled 1 39  
Among peripheral lenders  Italy s Intesa Sanpaolo  ISP MILAN  and Unicredit  CRDI MILAN  fell 0 25  and 0 27  respectively  while BBVA  BBVA MADRID  rose 0 31  and Banco Santander  SAN MADRID  edged down 0 12  in Spain 
Elsewhere  Novartis  NOVN SIX  surged 2 74  after the Swiss drugmaker agreed to buy Glaxosmithkline  GSK LSE  s cancer drug business for  16 billion  to form a consumer health venture with Glaxo and to sell its animal health unit to Eli Lilly and Company  NYSE LLY  for  5 4 billion 
In earnings news  Philips Kon  PHG AMS  reported first quarter results that missed analysts  estimates  sending shares in the world s largest lighting company down 5 86  
In London  FTSE 100 advanced 0 99   led by Astrazeneca  AZN LSE   up 7 85   amid reports Pfizer  NYSE PFE  may come back to bid for the British drug company  after its  60 billion takeover approach was rejected 
Rival company Glaxosmithkline  GSK LSE  added to gains  with shares surging 4 41   on news of Novartis  plan to buy the company s cancer drug business 
Financial stocks were also broadly higher  as Lloyds Banking  LLOY LSE  added 0 20  and the Royal Bank of Scotland  RBS LSE  climbed 0 53   while HSBC Holdings  HSBA LSE  and Barclays  BARC LSE  gained 0 40  and 0 53  respectively 
Minings stocks were on the downside  Shares in Glencore Xstrata  GLEN LSE  slipped 0 27  and Rio Tinto  RIO LSE  dropped 0 65   while Randgold Resources  RRS LSE  tumbled 1 26  
In the U S   equity markets pointed to a steady open  The Dow 30 futures pointed to a 0 05  gain  S P 500 futures signaled a 0 03  uptick  while the Nasdaq 100 futures indicated a 0 14  rise 
Later in the day  the U S  was to release private sector data on existing home sales ",2014-04-22,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-gain-ground-after-easter-weekend;-dax-jumps-1.17-278590,278590
171602,393118,LLY,4 Best Biotech Funds To Buy In Q2,opinion,"The biotechnology sector provided excellent returns in the first quarter  Mergers and acquisitions  initial public offerings  collaborative operations  remarkable new job additions and implementation of new technology in the biotechnology domain are some factors boosting the sector 
Investors who aren t afraid of taking risks could find this sector highly lucrative in the coming months 
Biotech Indexes Fare Well in 2019
Major biotechnology indexes had a spectacular Q1  SPDR S P Biotech ETF  NYSE XBI   iShares Nasdaq Biotechnology ETF  IBB   ProShares Ultra Nasdaq Biotechnology  BIB  and NASDAQ Biotechnology Index  NBI  surged 24 3   14 8   29 3  and 14 9   respectively  in the January March period 
Factors Boosting Biotechnology Sector
While the sector has benefited from many developments so far this year  mergers and acquisitions  M As  have been rather prominent in changing the overall landscape of the sector  M As are rather common in the biotechnology sector  and why not  Given the high prices involved in the research and development of drugs  M As help companies build new platforms  cluster sub critical businesses and fund R D programs better 
This year has already been earmarked as another one for M As  starting with pharmaceutical giant Bristol Myers Squibb s offer in January to acquire cancer drugmaker Celgene  NASDAQ CELG  for  74 billion  Following this  Eli Lilly and Company  NYSE LLY  acquired Loxo Oncology for  8 billion in February 
In addition  companies entering collaborative operations are also driving the sector  Collaborative arrangements basically refer to joint operating activities  which significantly help biotechnology companies to conduct research and drug development as well as share risks and costs 
Apart from M As and collaborative arrangements  a notable number of initial public offerings are also boosting the biotechnology sector  In 2018 alone  the sector witnessed about 60 companies filing IPOs and raising a whopping  6 3 billion in the process  In the United States last year  biotechnology and biopharmacy startups constituted 42  of U S  IPOs in terms of the number of deals  the highest in any sector   
Also  new job additions in the healthcare sector are a definitive indicator of the sector s unprecedented growth  According to the labor department s latest report  the healthcare sector added 49 000 new jobs in March and 398 000 over the past one year 
Last but not the least  the increasing implementation of new technologies such as artificial intelligence and cloud based applications are changing the operational structure  and research and development processes in the biotechnology sector  Drug discovery and development  monitoring patients and other functions have become faster and easier with these 
These encouraging factors make the biotechnology sector a great choice for investments and therefore  investors could consider a few biotech mutual funds  At this point  a rather vital question crosses one s mind  Why should investors consider mutual funds 
This is because reduced transaction costs and diversification of portfolio without several commission charges that are associated with stock purchases are primarily why one should be their parking money in mutual funds  read more    
Our Choices
We have selected four mutual funds from the biotechnology sector that carry a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   Moreover  these funds have encouraging three and five year returns  Additionally  the minimum initial investment is within  5000 
We expect these funds to outperform their peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance  but also on the likely future success of the fund 
Fidelity Select Biotechnology  fund invests the majority of its net assets in common stocks of companies mostly engaged in the research  development and distribution of biotechnological products  The fund primarily seeks capital growth  The non diversified fund invests in U S  and non U S  companies alike  The fund has a minimum initial investment of  2500 
This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   
FBIOX carries a Zacks Mutual Fund Rank  1  The fund has an annual expense ratio of 0 74   which is below the category average of 1 26   FBIOX has three and five year annualized returns of 13 5  and 8 4   respectively 
Schwab Health Care Fund  primarily invests in equity securities of companies that are engaged in operations of the healthcare sector  The fund aims for long term capital appreciation  The fund invests at least 80  of its assets in biotechnology and pharmaceutical companies  medical service firms  medical product manufacturers and suppliers etc  The fund has no minimum initial investment 
This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   
SWHFX carries a Zacks Mutual Fund Rank  1  The fund has an annual expense ratio of 0 80   which is below the category average of 1 26   SWHFX has three and five year annualized returns of 11 1  and 10   respectively 
Invesco Health Care Fund Class Y  aims for long term capital appreciation  The fund invests the majority of its assets in securities of companies that are engaged in operations in healthcare related industries  The fund mostly invests in equity securities  depositary receipts and securities convertible into equity securities  The fund may also invest a prominent part of its assets in securities of small  and mid capitalization companies  The fund has a minimum initial investment of  1000 
This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   
GGHYX holds a Zacks Mutual Fund Rank  2  The fund has an annual expense ratio of 0 85   which is below the category average of 1 26   GGHYX has three and five year annualized returns of 9 8  and 6 7   respectively 
T  Rowe Price Health Sciences Fund  invests a minimum of 80  of its assets in common stocks of companies mostly engaged in research  production and distribution of products and services in the healthcare related industry  The non diversified fund mostly invests in mid  and large capitalization companies  The fund has minimum initial investment of  2500 
This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   
PRHSX carries a Zacks Mutual Fund Rank  2 and an annual expense ratio of 0 77   which is below the category average of 1 26   PRHSX has three and five year annualized returns of respectively 15 2  and 13 5  
Want key mutual fund info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/4-best-biotech-funds-to-buy-in-q2-200407387,200407387
171603,393119,LLY,Sanofi  SNY  Q1 Earnings Top  Genzyme   Vaccines Drive Sales,opinion,Sanofi  PA SASY    NASDAQ SNY   reported first quarter 2019 earnings of 81 cents per American depositary share  which beat the Zacks Consensus Estimate of 74 cents  Earnings increased 10 9  on a reported basis  At constant currency rates  CER   earnings grew 9 4   driven by strong top line growth First quarter net sales of the French pharma giant rose 6 2  on a reported basis to almost  9 53 billion   8 39 billion   Exchange rate movements benefited sales by 2   At CER  sales increased 4 2  year over year  Sales however missed the Zacks Consensus Estimate of  9 73 billion       In March 2018  Sanofi completed its acquisition of Bioverativ and in September it closed the agreement to sell its European generics business  Zentiva  to Advent International  Adjusting for the Bioverativ acquisition and the Zentiva divestiture  sales rose 3 8  at constant structure  CS  and CER basis Sales increased 7 1  at CER in the United States  At CER  sales rose 13 6  in the Emerging Markets and 8 3  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico   However  sales declined 9 4  in Europe at CER All growth rates mentioned below are on a year on year basis and at CER Segmental PerformanceSanofi reported through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  However  beginning the first quarter of 2019  Sanofi implemented a new structure wherein the General Medicines   Emerging Markets and Diabetes and Cardiovascular GBU were reorganized into two new GBUs  namely the Primary Care unit and the China and Emerging Markets unit  Importantly  Emerging Markets sales for Specialty Care and Primary Care are now included in China   Emerging Markets GBU Pharmaceuticals sales  including the emerging markets  rose 3 1  to  6 26 billion driven by growth in Rare Blood Disorder and Immunology franchises  partially offset by lower Diabetes and Established Rx products sales and the Zentiva  European generics business  divestiture Sanofi Genzyme Specialty Care GBU sales  excluding the emerging markets  increased 30 8  to  2 02 billion  driven by its eczema drug Dupixent and consolidation of Bioverativ  Sales rose 16  on a CS basis Sales of rare disease drugs increased 3 9  to  613 million driven by Gaucher and Pompe therapies  Important drugs like Myozyme Lumizyme rose 6 5  to  188 million  Fabrazyme sales were  167 million  up 4 6   Cerezyme sales declined 5 2  to  113 million Oncology sales increased 2 1  to  273 million  Key cancer drug Jevtana s sales were up 6 4  to  105 million supported by growth in all regions In the immunology franchise  Dupixent generated sales of  326 million in the quarter  up 16 4  on a sequential basis  Sales were driven by continued growth in adult atopic dermatitis indication and the recent U S  launch in asthma  In October  Dupixent was approved by the FDA for the asthma indication  which played a key role in driving sales of the drug higher this quarter  Sales of the drug in the United States were  266 million while the same in Europe were  36 million  New rheumatoid arthritis drug  Kevzara recorded sales of  30 million in the quarter compared with  31 million in the previous quarter Sales of multiple sclerosis drugs rose 4 6  to  507 million  Aubagio sales increased 10 9  to  421 million while sales of Lemtrada fell 18  to  86 million Rare blood disorders franchise  added to Sanofi s portfolio with the acquisition of Bioverativ  fetched sales of  270 million  In February  Cablivi  caplacizumab  for the treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura was approved by the FDA and was launched in the U S  market in early April  Cablivi was approved by the European Commission in September last year  The drug generated sales of  5 million in Germany and France in the first quarter compared with  3 million in the previous quarter The Primary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments  Sales in the Primary Care GBU declined 17  to  2 29 billion hurt by lower diabetes sales and Zentiva divestiture The Diabetes franchise  excluding the emerging markets  declined 15 9  to  849 million due to lower sales of key drugs   Lantus and Toujeo   in the United StatesSales of diabetes drugs in the United States declined 22 8  to  445 million due to pricing pressure and loss of Part D business  In Europe  it decreased 5 6  and in rest of the world it declined12 1  Lantus sales decreased 29 3  to  493 million in the first quarter  Lantus sales plunged 36 6  in the United States due to lower average net price and change in coverage with respect to Sanofi s Part D business  In Europe  sales decreased 16  due to branded biosimilar competition and patient switching to Toujeo Toujeo generated sales of  167 million in the reported quarter  down 4 1   Sales rose 19 4  in the Europe while it declined 24 7  in the United States Admelog  a rapid acting insulin  similar to Lilly s   NYSE LLY   Humalog  which was launched in the United Sales in April last year  achieved sales worth  66 versus  57 million in the previous quarter In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent  garnered worldwide sales of  52 million in the reported quarter  up 6 4  as growth in Europe made up for the decline in the United States  U S  Sales declined due to significantly higher rebates offered by Sanofi and Regeneron   NASDAQ REGN   to payers to improve access to the drug  Sales of the other drug  Multaq  in this franchise declined 7 8  to  77 million Sales of Established Rx Products came in at  1 31 billion  down 18 8  due to generic competition for Renvela Renagel in the United States  lower sales of Lovenox in Europe and thedivestment of the European generics business  Zentiva Sales of China and Emerging Markets GBU rose 10 3   to  1 96 billionConsumer Healthcare GBU  including the emerging markets  sales were  1 26 billion  up 0 6  as higher sales in Emerging Markets were partially offset by lower sales in the more mature markets of United States and Europe  Non core divestments also hurt sales in this segment Sanofi Pasteur  Vaccines  sales  including the emerging markets  rose 20 1  to  873 million driven by a strong performance of the Polio Pertussis Hib vaccines in Emerging Markets and JapanCosts RiseSelling  general and administrative expenses  SG A  inched up 0 6  at CER in the quarter  reflecting investments in product launches  R D expenses were up 4 9  at CER due to increased spending on late stage pipeline  Costs incurred for the consolidation of Bioverativ and Ablynx acquisitions also induced higher operating costs in the reported quarter 2019 OutlookSanofi still expects business earnings to grow between 3  and 5  at CER in 2019  It now anticipates a positive currency impact of around 2  on business earnings  compared with the earlier range of 1  2  Our TakeSanofi s first quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales  Double digit growth in the Specialty Care and Vaccines unit and higher sales in Emerging Markets offset persistent sluggishness in Diabetes and Cardiovascular franchises due to lower demand Sanofi s shares were up 2 5  in pre market trading on Friday in response to the fairly decent results  However  so far this year  the stock has underperformed the industry  It has declined 5  in the said time frame compared with a 2 6  decrease for the  Sanofi s Specialty Care segment is on a strong footing with the recent FDA approvals of new drugs Libtayo and Cablivi  and Dupixent for its second indication in asthma  Particularly  we believe Dupixent could prove to be an important growth driver  The performance of the Vaccines and Consumer Healthcare franchises has also improved lately  However  weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent are headwinds Another European pharma giant  AstraZeneca plc   NYSE AZN   also reported first  quarter 2019 results  It beat estimates for both earnings and sales The company s top line was driven by new drugs and emerging markets Zacks Rank   Stock to ConsiderSanofi currently carries a Zacks Rank  3  Hold   You can   Sanofi Price  Consensus and EPS Surprise   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-25,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-q1-earnings-top-genzyme--vaccines-drive-sales-200411774,200411774
171604,393120,LLY,AstraZeneca s  AZN  Q1 Earnings Beat  New Drugs Drive Sales,opinion,"AstraZeneca plc   NYSE AZN   beat the Zacks Consensus Estimate for both earnings and sales in the first quarter of 2018  The company s top line was driven by new drugs and emerging markets  However  the stock fell 1 4  in pre market trading on Apr 26 This year so far  AstraZeneca s shares have increased 2 8  against its  s decrease of 2 6  First quarter 2018 core earnings of 45 cents per American Depositary Share   ADS   beat the Zacks Consensus Estimate of 43 cents  Core earnings per share of 89 cents increased 100  year over year at constant exchange rates   CER    benefiting from higher revenues and operating profit Total revenues were up 11  at CER to  5 5 billion in the reported quarter  Revenues also beat the Zacks Consensus Estimate of  5 27 billion All growth rates mentioned below are on a year over year basis and at CER Product Sales RiseProduct sales rose 14  at CER in the quarter to  5 47 billion  Higher sales of newer medicines  particularly cancer drugs  and strong performance in emerging markets  mainly China  offset lower sales of many other legacy medicines and drove product sales growth Collaboration revenues  formerly Externalization revenues  were down 86  from the year ago period to  26 million Among AstraZeneca s various therapeutic areas  Oncology was up 59   New Cardiovascular  Renal and Metabolism   CVRM   was up 19  and Respiratory rose 14   However  other medicines declined 21  Newer ProductsAmong the newer medicines  Lynparza sales rose 13 4  sequentially to  237 million in the quarter on the back growth in all regions  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK    U S  sales of the drug increased 80   following its approval in first line maintenance treatment for BRCA mutated ovarian cancer in late 2018 Tagrisso recorded sales of  630 million  up 92  year over year  driven by rapid uptake in the first line setting  Tagrisso was approved in the first line setting for advanced lung cancer in the United States in April  in EU in June and in Japan in August  The drug was also established as the standard of care for first line lung cancer last year  Sales in second line setting drove sales in emerging markets  which more than doubled Imfinzi generated sales of  295 million in the quarter  up 12 6  compared to the fourth quarter of 2018  Sales were mainly driven by strong demand in last stage lung cancer patients Calquence  which was launched in the United States in October 2017  generated sales of  29 million in the first quarter compared with  24 million in the previous quarter Brilinta Brilique sales were  348 million in the reported quarter  up 24  year over year Farxiga recorded sales of  349 million in the quarter  up 23  year over year mainly driven by growth in emerging markets and Japan New asthma medicine  Fasenra recorded sales of  129 million in the quarter compared with  125 million in the previous quarter  AstraZeneca said Fasenra enjoy leadership position among novel biologic asthma medicines Bevespi  a LAMA LABA in a pressurized metered dose inhaler  recorded sales of  10 million in the quarter  similar to the previous quarter  amid slower than anticipated growth in LAMA LABA class Among other medicines  Iressa sales gained 7  to  134 million  Bydureon sales increased 4  to  142 million and Onglyza sales gained 23  to  153 million  However  Byetta sales were flat at  30 million and Movantik Moventig recorded sales of  25 million in the quarter  down 11  Older ProductsCrestor sales declined 9  to  335 million  U S  and Europe sales were weak as multiple generic versions of the drug entered the market Symbicort sales declined 3  in the quarter to  585 million due to pricing pressure in the United States and stiff competition in Europe  Pulmicort sales rose 16  to  383 million as higher sales in the emerging markets made up for weaker performance in the United States and Europe Nexium recorded sales of  363 million  down 16  due to lower sales in the United States and Europe  Sales of other legacy drugs including Faslodex  Zoladex  Seloken and Daliresp Daxas grew in the quarter while sales of others like Synagis  Casodex and Atacand declined In late 2018  AstraZeneca announced its decision to divest prescription medicine rights to Nexium in Europe and U S  rights to Synagis Regional PerformanceIn the United States  product sales were up 20  to  1 8 billion on the back of higher sales of newer products  However  European markets witnessed a 6  decline in sales to  982 million  Revenues from Emerging Markets were up 22  to  2 billion  primarily on the back of strong growth in China  up 28  to  1 2billion   In Established ROW market  comprising Japan  Canada and other markets   sales were up 16  to  693 million Profit DiscussionAstraZeneca s core gross margin increased two percentage points to 80 5   Core selling  general and administrative  SG A  expenses rose 6  to  2 1 billion In the quarter  core research and development  R D  expenses rose 3  to  1 23 billion  Operating margin increased 13 percentage points to 30  in the quarter due to higher revenues and gross margin 2019 OutlookAstraZeneca maintained its earnings and sales outlook for 2019 AstraZeneca expects core earnings for 2019 in the range of  1 75 to  1 85 per ADS  The Zacks Consensus Estimate is pegged at  1 78  The company expects product sales to grow in high single digit percentage Currency movements are expected to unfavorably impact product sales and core earnings per share by a low single digit percentage Adjusted tax rate is expected to be in the range of 18  22  AstraZeneca PLC Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the healthcare sector are Celsion Corporation   NASDAQ CLSN   and Eli Lilly and Company   NYSE LLY    While Celsion sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank  2  Buy   You can see  Celsion s loss estimates have narrowed from 94 cents to 78 cents for 2019 and 2020 over the past 60 days Lilly s earnings per share estimates have moved upward from  5 60 to  5 66 for 2019 and  6 42 to  6 63 for 2020 over the past 60 days Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-25,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales-200411660,200411660
171605,393121,LLY,Is A Beat In The Cards For Incyte  INCY  In Q1 Earnings ,opinion,"Incyte Corporation   NASDAQ INCY   is scheduled to report first quarter 2019 results on Apr 30  before the market opens 
In the last reported quarter  the company missed earnings estimates by 7   Incyte s earnings track record has been disappointing so far  The company missed earnings expectations thrice  over the last four quarters  delivering average negative earnings surprise of 34 45  
Why a Likely Positive Surprise 
Our proven model indicates that Incyte is likely to beat on earnings this quarter  as it has the right combination of two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates 
Earnings ESP  Earnings ESP for Incyte is  28 6   The Zacks Consensus Estimate is pegged at 40 cents  while the Most Accurate Estimate is pegged at 51 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Incyte currently carries a Zacks Rank  3  which when combined with a positive ESP makes us confident of an earnings beat 
Note  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Factors Driving Growth
Incyte s lead drug  Jakafi  ruxolitinib   is a first in class JAK1 JAK2 inhibitor  approved for the treatment of patients with polycythemia vera   PV    and those with intermediate or high risk myelofibrosis   MF    including primary MF  post PV MF and post essential thrombocythemia MF  While the company markets the drug in the United States  it is marketed by Novartis   NYSE NVS   as Jakavi outside the country 
Incyte continues to gain traction from Jakafi s performance  The drug s revenues totaled  1 4 billion in 2018  up 22  from 2017  driven by strong patient demand 
We expect the trend to continue in the first quarter  The company expects Jakafi revenues of  1 580  1 650 million 
In order to expand patient population and increase commercial potential of the drug  the company is working toward expanding Jakafi s label  further  We expect investors to also focus on pipeline development  given the recent setbacks 
We remind investors that while Jakafi sales and royalties are key components of Incyte s revenue growth  Iclusig sales and Olumiant royalties are also contributing to the top line  Iclusig revenues are expected to be  90  100 million in 2019  This will also boost the company s performance in the to be reported quarter 
Key Anticipated Updates
Earlier in the year  Incyte and partner Eli Lilly and Company  NYSE LLY  announced that the two phase III studies  BREEZE AD1 and BREEZE AD2  evaluating the efficacy and safety of Olumiant monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis  AD  met the primary endpoint  The drug is already approved for the treatment of moderately to severely active rheumatoid arthritis   RA   in patients with inadequate response or intolerant to TNF inhibitor therapies 
Incyte suffered a setback when the FDA extended the review period of the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD   who have had an inadequate response to corticosteroids  However  the FDA extended the action date by three months to review additional data submitted by the company in response to the FDA s information requests 
The additional data have been determined by the FDA to constitute a major amendment to the sNDA  Hence  the new Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 
Share Price Performance
Incyte s stock has gained 16 8  in the year so far  outperforming the  s growth of 4 8  

 
Other Stocks to Consider
Here are two health care stocks worth considering with the right combination of elements to beat on earnings 
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  1 54  and a Zacks Rank  2  It is scheduled to release financial figures on May 2  You can see  
Aduro Biotech  Inc    NASDAQ ADRO   has an Earnings ESP of  82  and a Zacks Rank  2 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-incyte-incy-in-q1-earnings-200412635,200412635
171606,393122,LLY,Incyte  INCY  Q1 Earnings   Revenues Beat Estimates  Up Y Y ,opinion,"Incyte Corporation   NASDAQ INCY   reported strong results for the first quarter of 2019  wherein both earnings and sales beat expectations  Shares rose in pre market trading Incyte s stock has gained 21 9  in the past six months against the  s 3 6  decline The company reported earnings of 62 cents per share  which beat the Zacks Consensus Estimate of 40 cents  Incyte reported a loss of 7 cents in the year ago quarter Including milestones and contracts  revenues came in at  497 8 million  which increased 30  year over year and beat the Zacks Consensus Estimate of  475 6 million Quarter in DetailTotal product related revenues came in at  457 8 million  up 20  from the year ago quarter  Of these  Jakafi revenues came in at  375 6 million  up 20  from the year ago quarter  However  Jakafi revenues missed the Zacks Consensus Estimate of  379 million  Net product revenues of Iclusig amounted to  20 6 million  down from  20 8 million in the year ago quarter    Product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets grew 10  to  45 6 million  Olumiant s product royalty revenues came in at  16 million R D expenses were  243 million  down from  279 million in the year ago quarter  SG A expenses amounted to  124 million  up from  121 million in the prior year quarter 2019 Outlook Updated  The company expects Jakafi revenues of  1 580  1 650 million  same as before   Iclusig revenues are expected to be  90  100 million  R D expenses are expected to be  1 020  1 070 million compared with the earlier estimate of  1060  1 130 million  SG A expenses are anticipated to be  420  470 million Pipeline UpdatePipeline progress in the first quarter was impressive  The global phase III GRAVITAS 301 trial on itacitinib for the treatment of patients with steroid na ve acute GVHD has completed enrollment  Results from the study are expected later in the year Incyte expects to submit the NDA for pemigatinib as a second line treatment for patients with FGFR2 translocated cholangiocarcinoma in the second half of 2019  The company plans to initiate a phase III trial for the first line treatment of patients with cholangiocarcinoma in the coming months The primary endpoint was met in the phase II trial of ruxolitinib cream in patients with vitiligo Incyte has elected to no longer co fund the development of baricitiniband in order to reallocate the capital to develop its pipeline  However  Incyte will continue to receive royalties on global net sales of Olumiant  baricitinib   per the terms of its agreement with partner Eli Lilly   NYSE LLY   Our TakeIncyte s performance in the first quarter was impressive  Label expansion of Jakafi will further boost sales  The FDA is reviewing the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD   who have had an inadequate response to corticosteroids  The Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 The company s efforts to diversify its revenue base are encouraging  but pipeline setbacks are a concern Zacks Rank   Stock to ConsiderIncyte currently carries a Zacks Rank  3  Hold   
A better ranked stock in the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries a Zacks Rank  2  Buy   You can see  
Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-q1-earnings--revenues-beat-estimates-up-yy-200413228,200413228
171627,393143,LLY,Pfizer s Ibrance Gets FDA Approval For Breast Cancer In Men,opinion,"Pfizer  Inc  s   NYSE PFE   blockbuster medicine Ibrance gained FDA approval for the treatment of breast cancer in men  thereby expanding the drug s eligible patient population 
Ibrance  CDK 4 6 inhibitor  can now be prescribed in combination with an aromatase inhibitor or AstraZeneca s   NYSE AZN   Faslodex  fulvestrant  for the treatment of men with HR   HER2  metastatic breast cancer  The approval for the expanded indication is based predominately on real world data  a new approach to expanding the use of already approved innovative medicines 
Ibrance has been generating strong sales and is a key driver of the company s top line  The drug generated sales of  4 1 billion in 2018  With the expanded label  the drug should bring in more sales
Shares of Pfizer have declined 2  so far this year against the  s 4 4  increase 

 
Ibrance is a key drug in Pfizer s oncology portfolio  The company is exploring the possibility of expanding Ibrance into recurrent and subsequent early breast cancer as well as several non breast cancer indications like pancreatic and head and neck cancers 
However  competition in the breast cancer market has risen with launch of Eli Lilly s   NYSE LLY   Verzenio and Novartis    NYSE NVS   Kisqali in the past couple of years  Nonetheless  in key markets like the United States  Europe and Japan  Ibrance has maintained greater than 90  share of total CDK inhibitors class volume despite rising competition  
Pfizer currently carries a Zacks Rank  4  Sell  
You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-05,Zacks Investment Research,https://www.investing.com/analysis/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men-200404429,200404429
171628,393144,LLY,Selvita  Services And Oncology Businesses To Split,opinion,"Selvita s  WA SLVP  announcement of an intention to split into two separate companies was the hallmark event in the Q418 results presentation  By end of 2019  the drug discovery services and oncology R D will be split into separate listed entities  subject to financial authorities and shareholders  approvals  We believe both businesses have sufficient momentum to sustain such a split  The profitable Services segment again delivered substantial sales growth of 34  in 2018  The R D pipeline is progressing according to plan and two clinical trials with SEL24 and SEL120 could deliver data over 2019 2020  Our valuation is slightly higher than before at PLN1 34bn or PLN83 9 share 

A significant step in corporate history
With its Q418 results Selvita released a major announcement about its plans to split into two distinct companies  One company will provide drug discovery services while the other will focus on developing the innovative oncology compound portfolio  which roughly correspond to the current Services  including Ardigen  and Innovations business segments  Both companies will be listed on the Warsaw Stock Exchange  Selvita stated the rationale for the split is primarily related to the different risk and cash flow profiles of the businesses  Because both parts of the company are mature enough to continue as separate entities  Selvita believes the timing for the split is right 
Services segment backlog indicates good 2019
Selvita s reported total 2018 revenues of PLN110 1m  up 4  y o y  were largely in line with our expectations  Operating loss of PLN13 6m was slightly better than our expected PLN16 3m loss  as total operating expenses came in at PLN123 7m compared to our forecast PLN121 0m  As usual  Selvita released its first 2019 backlog with its Q418 results  The Services segment had already contracted revenues of PLN41 7m for 2019  up from PLN29 1m a year ago over the same period  which indicates another good year for this segment 
Valuation  Slightly up to PLN1 34bn or PLN83 9 share
Our valuation of Selvita is slightly higher at PLN1 34bn or PLN83 9 share versus PLN1 24bn or PLN77 6 share previously  Both the revision of the operating estimates and rolling the model forward had a small positive effect on the rNPV values of the R D projects and the DCF  Data readouts from ongoing clinical trials with SEL24 and SEL120 should be released over 2019 2020 

Business description
Selvita is an R D and drug discovery services company  It operates three business segments  Innovations Platform  internal R D pipeline   Research Services  medicinal chemistry biology  biochemistry  and Ardigen  a spin out bioinformatics company  52  owned   The lead asset is wholly owned SEL120  currently Phase I ready after the FDA approved an IND application in March 2019  Selvita is focusing on its other projects in a broad pipeline dedicated to oncology 
Details of transaction and the two new companies
According to the initial details released by Selvita  the innovative oncology company will control the current R D pipeline of small molecules and the platform technology  targeted therapeutics  cancer metabolism immunometabolism and immunooncology platforms   The Selvita branding will be retained by the services company  Around 170 employees will be part of the innovative oncology company and the remaining 325 will join the services company  The separation is expected to be complete by end of 2019  Subject to approval by shareholders and the supervisory board  current Selvita CEO Pawel Przewiezlikowski will be CEO of the oncology company and COO Boguslaw Sieczkowski will become CEO of the contract research company  both are co founders of Selvita   The current shareholding structure of Selvita should be maintained by both new companies  For each existing share in Selvita  the shareholders will receive one share in the innovative R D company and one share in the services company  All Ardigen  Bioinformatics spin off  shares owned by Selvita will be allocated to the services company and all NodThera s shares owned by Selvita will be allocated to the new R D company 
Between 2014 and 2018 Selvita s research Services grew by more than 30  per year to a total of PLN59m in 2018  The services company will seek to maximise its sales and profitability via organic growth and acquisition of complementary drugs discovery service providers  Of note is that the latter strategic option will become available as debt funding will be more accessible to the profitable services company 
We provided a detailed overview of Selvita s R D pipeline in our recent outlook report  including the two most advanced assets in clinical development  SEL24  a dual PIM FLT3 inhibitor  and wholly owned SEL120  a selective CDK8 inhibitor  SEL24 is out licensed to Menarini Group  and is now known as MEN1703   therefore we expect the new oncology company will focus on SEL120 and on advancing the broad preclinical pipeline  Selvita indicated that the existing pipeline of R D projects would allow it to progress one new drug candidate into the clinic every year 
Our take
We believe such a split will be beneficial for investors as it will offer investors an investment option to match their risk return profile  The Services segment is fast growing and profitable  As a standalone entity it will be able to diversify its capital structure  lower overall costs of capital and complement organic growth with acquisitions  The innovative R D company will likely resemble a classic drug developer  which tends to be a high risk but high reward type of business  In Selvita s case  the R D pipeline is broad and the company has the same business goals it described in its 2017 2021 development strategy  which are to 
sign a partnership contract for further development and commercialisation of SEL120 in Phase II on significantly better terms than for SEL24  and
independently develop and partner one R D project a year 
If these goals are met  the newsflow should be sufficient to support the share price  Therefore  both businesses appear to have enough momentum to continue as standalone entities  Data readouts could be released from both ongoing clinical trials with SEL24 and SEL120 this year  which are key catalysts for the share price as Selvita splits 
R D progress
According to the Q418 update  Selvita made progress across its R D pipeline and is on track with the plans announced in conjunction with the 2018 share issue 

Targeted therapeutics platform
The Phase I II trial with SEL24 MEN1703 in acute myeloid leukaemia  AML  patients is progressing according to plan and now is run solely by Menarini  which should provide trial updates at scientific and medical conferences in 2019  Selvita anticipates the first clinical data could be released in 2020 
The second lead drug candidate  SEL120  is now ready to enter the Phase I trial after the FDA approved an IND application in March 2019 in patients with AML or high risk myelodysplastic syndrome  The open label  dose escalation study is designed to evaluate safety  tolerability and recommended dose of SEL120  Selvita indicated that the activation of clinical centres in the US started in Q219 and administering SEL120 to the first patients could start in Q319 and  if all goes to plan  the data readout is planned for 2020  This focus on haematological malignancies is supported by the Leukemia and Lymphoma Society and Selvita has received US 1 1m in research funding in total since the collaboration was established in August 2017  However  the company believes the potential of SEL120 is much wider and could be used in various solid tumours  including in combinations with checkpoint inhibitors 
The targeted therapeutics platform also includes an ongoing project exploring the BRM SMARCA2 target in the so called synthetic lethality space and other projects with undisclosed epigenetic modulators  We reviewed all available preclinical data released by Selvita in our recent outlook report 
Immunooncology platform
The STING agonist project is at the most advanced discovery stage in this platform  One of the key potential competitive advantages of Selvita s compounds is that they are small molecules suitable for systemic administration  rather than several other technologies that are in a clinical stage and based on cyclic dinucleotides scaffolds that are mostly administered intratumorally  In 2018  Selvita continued optimising the compounds and aims to identify the drug candidate for late stage preclinical development by the end of 2019 
Another project in an earlier preclinical stage focuses on regulating the T cell dependent immune response  It involves the target HPK1  MAP4K1   which is one of the major proteins in the signalling cascade triggered by TCR activation  Inhibition of this kinase leads to prolonged activation of T cells and stimulates dendritic cells  antigen presentation  which eventually leads to improved mounting of the immune response directed against the cancerous cells 
Cancer metabolism and immunometabolism platform
In this platform Selvita has its own projects and a longstanding collaboration with Merck  compounds undisclosed   Of the internally run projects  the most advanced are focused on the adenosine pathway  more specifically on the modulation of the production of adenosine by tumour cells  CD39 CD73 enzymes  and its effects on immune cells  A2A B receptors  
Selvita is focusing on best in class dual A2A A2B receptor antagonists and expects to nominate the drug candidate for IND enabling studies in 2019  Compounds are differentiated versus competitors and showed excellent anti tumour efficacy in combination with immuno  and chemotherapies in preclinical studies  Entering the Phase I clinical trial is planned in 2020  Another project in this platform involves SHMT2 inhibitors in early discovery stages of preclinical development 
NodThera NLRP3 inflammasome technology
In June 2018 Selvita s spin out  NodThera  announced a  28m fundraise from a consortium of investors co led by Sofinnova Partners and 5AM Ventures  Selvita s last reported ownership of NodThera is 14  on a fully diluted basis  NodThera was created around Selvita s NLRP3 inflammasome inhibitor technology with first in class compounds  Inflammasomes have been identified as the molecular mechanism behind the activation cascade of interleukin  IL  1  IL 1 is a family of pro inflammatory cytokines that have been widely implicated in pain  inflammation and autoimmune conditions and more recently in cancer 
We note that inflammasome inhibitors continue to draw the pharma industry s attention  The most recent example is the deal announced on 1 April 2019 by Novartis and IFM Tre  Novartis paid  310m upfront and up to  1 265bn in potential milestones to acquire IFM Tre  Novartis gained access to a portfolio of two preclinical and one clinical NLPR3 antagonist for an array of chronic inflammatory disorders including atherosclerosis and non alcoholic steatohepatitis  IFM Tre was a spin out from IFM Therapeutics  which sold STING and NLRP3 assets targeting oncological indications to Bristol Myers Squibb  NYSE BMY  in August 2017 for  300m upfront and potential milestones of up to  1 01bn  IFM Therapeutics was seeded with just  2m in October 2015  so a combined upfront of  610m and potential milestones  2 28bn in less than five years represent a very attractive reward 
Financials
Selvita s reported total 2018 revenues of PLN110 1m  4  y o y  were largely in line with our expectations  The total top line y o y growth was achieved despite strong Q117  when a large income of PLN20 3m was recognised after the company out licensed SEL24 to Menarini Group  Selvita reports in three business segments  Services  Innovation  income from SEL24 was included in this segment  and Bioinformatics 
The Services segment generated sales of PLN59 1m  excluding subsidies  in 2018  an increase of 34  y o y  reflecting continuing solid organic growth  Subsidies in this segment were PLN3 2m  while operating profit was PLN8 8m versus PLN5 3m a year ago  improving the operating margin from 10 8  to 13 5  
Commercial revenues from the Innovations segment were PLN9 7m in 2018 vs PLN36 7m in 2017  with the out licensing of SEL24 to the Menarini Group in March 2017 the main reason behind the strong performance in 2017  In addition  Selvita stopped capitalising the R D costs in early 2018  Commercial revenues from this segment came from payments related to different partnerships  such as milestone payments from drug discovery collaborations  and therefore tend to be volatile from quarter to quarter but offer potentially higher margins  Subsidies in this segment were PLN26 2m  versus PLN15 9m a year ago   while the operating loss was PLN24 6m 
The Bioinformatics  Ardigen  segment recorded revenues of PLN8 6m versus PLN6 9m a year ago  This business was spun out from Selvita  which holds 52  of the shares  in October 2015 and in 2018 the sales grew by 24 3  to PLN8 6m  So while still a small operation for Selvita  the growth rate is very high  Revenues from subsidies in this segment were PLN2 6m and operating profit was PLN2 2m 
Selvita s 2018 net income was also affected by Selvita s spin out NodThera raising new funds from a consortium  Selvita changed the accounting of NodThera s shares from the equity method to fair value and booked PLN16 6m in profit 
We have made some revisions to our revenue estimates in each segment  Overall 2018 revenues slightly surpassed our expectations  As usual  Selvita released its first 2019 order backlog 
Services PLN41 7m  up from PLN29 1m over the same period a year ago 
Innovation PLN2 5m  down from PLN6 9m y o y 
Bioinformatics PLN6 7m  up from PLN4 7m y o y 
Subsidies PLN31 1m  up from PLN27 8m y o y 
The Services segment again appears to be poised for substantial growth in 2019  as does Bioinformatics  Subsidies should also increase as Selvita advances its R D pipeline  Contracted revenues for the Innovations segment could decrease this year  but as we describe above  the value in this segment is created via R D and actual revenues can fluctuate substantially  Operating loss of PLN13 6m was slightly better than our expected PLN16 3m  Total operating expenses were PLN123 7m compared to our expected PLN121 0m  Exhibit 2 summarises our estimate changes post Q418 results  Selvita reported cash of PLN125m at end Q418  PLN114m as of 22 March 2019  and PLN4 1m in debt 

Valuation
Our valuation of Selvita is slightly higher at PLN1 34bn or PLN83 9 share versus PLN1 24bn or PLN77 6 share previously  The revision of the operating estimates and rolling the model forward had a small positive effect on the rNPV values of the R D projects and the DCF  We maintain our valuation approach and assumptions discussed in detail in our last outlook report  We use risk adjusted NPV models with a discount rate of 12 5  for Selvita s R D projects at various stages  Separately  we use DCF based calculations with a discount rate of 10  to value the core drug discovery services business and research collaborations 
We have made one substantial update to our rNPV calculation by replacing the SHMT2 inhibitor project with STING  While both projects are active  we see the STING agonist making rapid progress towards clinical development  According to the latest update  Selvita aims to identify the drug candidate in this project for late stage preclinical development by the end of 2019  We use the following assumptions for this project 
Market potential  STING agonists have broad potential to be used in combinations with other chemotherapeutic agents and immunoncology drugs  such as checkpoint inhibitors  CPIs   The strong rationale for combinations with CPIs is based on the fact that they act late in the immunity cycle  which makes the tumour  visible  to T cells   while the STING pathway appears to prime cancer specific T cells  so both technologies are potentially synergistic  see the overview in our last outlook report   Because of the early stage of development and lack of clarity on specific indications  but to reflect the broad potential  we use  1bn as our peak sales assumption  in line with our other preclinical projects 
R D costs and timelines  We assume that a clinical candidate will be identified in 2019 and partnered in 2021  We assume the R D cost for Selvita to develop the asset to a partnership deal is  2 5m  Phase I will start in 2022  and the partner continues the development and launches in 2031 with peak sales reached in six years 
Licensing terms  We use the terms of the recent deal between Aduro and Eli Lilly  NYSE LLY  involving the preclinical stage STING asset  Lilly paid  12m upfront and  620m in milestone payments  We assume 7 10  royalty rates  An earlier deal between Aduro and Novartis was even more impressive  where Novartis paid  200m up front  invested  25m in Aduro  while up to  500m are due in milestones  We use the deal with Lilly to err on the conservative side and due to the fact that it is the most recent one  We assume market protection until late 2030 ",2019-04-08,Edison,https://www.investing.com/analysis/selvita-services-and-oncology-businesses-to-split-200404660,200404660
171629,393145,LLY,Why Eli Lilly  LLY  Is A Great Dividend Stock Right Now,opinion,"Whether it s through stocks  bonds  ETFs  or other types of securities  all investors love seeing their portfolios score big returns  But when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is that coveted distribution of a company s earnings paid out to shareholders  and investors often view it by its dividend yield  a metric that measures the dividend as a percent of the current stock price  Many academic studies show that dividends account for significant portions of long term returns  with dividend contributions exceeding one third of total returns in many cases 
Eli Lilly in Focus
Headquartered in Indianapolis  Eli Lilly  LLY  is a Medical stock that has seen a price change of 9 96  so far this year  The drugmaker is currently shelling out a dividend of  0 64 per share  with a dividend yield of 2 03   This compares to the Large Cap Pharmaceuticals industry s yield of 2 8  and the S P 500 s yield of 1 92  
Looking at dividend growth  the company s current annualized dividend of  2 58 is up 14 7  from last year  In the past five year period  Eli Lilly has increased its dividend 5 times on a year over year basis for an average annual increase of 4 06   Looking ahead  future dividend growth will be dependent on earnings growth and payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Lilly s current payout ratio is 40   meaning it paid out 40  of its trailing 12 month EPS as dividend 
LLY is expecting earnings to expand this fiscal year as well  The Zacks Consensus Estimate for 2019 is  5 65 per share  representing a year over year earnings growth rate of 1 80  
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  But  not every company offers a quarterly payout 
Big  established firms that have more secure profits are often seen as the best dividend options  but it s fairly uncommon to see high growth businesses or tech start ups offer their stockholders a dividend  During periods of rising interest rates  income investors must be mindful that high yielding stocks tend to struggle  That said  they can take comfort from the fact that LLY is not only an attractive dividend play  but also represents a compelling investment opportunity with a Zacks Rank of  2  Buy  ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/why-eli-lilly-lly-is-a-great-dividend-stock-right-now-200405500,200405500
171630,393146,LLY,Looking For A Growth Stock  3 Reasons Why Lilly  LLY  Is A Solid Choice,opinion,"Investors seek growth stocks to capitalize on above average growth in financials that help these securities grab the market s attention and produce exceptional returns  However  it isn t easy to find a great growth stock 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Eli Lilly  LLY  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drugmaker a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Lilly is 12 6   investors should actually focus on the projected growth  The company s EPS is expected to grow 1 8  this year  crushing the industry average  which calls for EPS growth of 1 5  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Lilly is 20 6   which is higher than many of its peers  In fact  the rate compares to the industry average of 10 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 4 3  over the past 3 5 years versus the industry average of 3 3  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Lilly  The Zacks Consensus Estimate for the current year has surged 0 6  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Lilly a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Lilly is a potential outperformer and a solid choice for growth investors ",2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice-200405524,200405524
171639,393155,LLY,Pharma Stock Roundup  AZN Inks Cancer Deal  ABBV  NVS   Others Get Drug Approvals,opinion,"This week s most eye catching news was AstraZeneca s   NYSE AZN   collaboration deal  potentially costing as much as  6 9 billion  with Japan s Daiichi Sankyo to jointly develop and commercialize a promising cancer treatment  In other news  AbbVie   NYSE ABBV   gained approval for risankizumab in Japan  which marked the first global approval for this key pipeline candidate  Novartis    NYSE NVS   multiple sclerosis candidate siponimod  which targets patients whose disease has progressed  gained FDA approval while AstraZeneca s type II medicine  Forxiga  gained approval in EU and Japan for type I diabetes Recap of the Week s Most Important HeadlinesAstraZeneca s  6 9B Collaboration Deal with Daiichi Sankyo  AstraZeneca announced a collaboration deal with Japan s Daiichi Sankyo to jointly develop and commercialize the latter s cancer candidate trastuzumab deruxtecan for an upfront payment of  1 35 billion as well as contingent payments of up to  5 55 billion   Daiichi  however  retained exclusive rights to the drug in Japan  The companies will equally share development and commercialization costs  AstraZeneca informed that it will fund the transaction partly through a share issue of up to  3 5 billion  AstraZeneca claims that trastuzumab deruxtecan  a proprietary antibody drug conjugate  ADC   has the potential to redefine the standard of care in cancer treatment  It is being developed in five pivotal late stage studies for HER2 expressing cancers  including breast and gastric cancer and in mid stage studies for HER2 expressing advanced colorectal cancer and metastatic non squamous HER2 overexpressing or HER2 mutated NSCLC  A first regulatory application is expected to be filed in the second half of 2019 for advanced or refractory breast cancer AstraZeneca s type II medicine  for a new indication   as an oral adjunct treatment to insulin in adults with type I diabetes  It is under review in the United States for the same indication with a decision expected in the second half of 2019  Farxiga Forxiga  a key driver of AstraZeneca s top line  recorded sales of almost  1 4 billionin 2018  representing growth of 30  Novartis Multiple Sclerosis Drug Gets FDA Approval  Novartis gained FDA approval for Mayzent  siponimod  to treat relapsing forms of multiple sclerosis including with active disease  relapsing remitting multiple sclerosis  RRMS  and clinically isolated syndrome  CIS   With the approval  Mayzent became the first oral medicine approved to treat active SPMS  The approval was based on data from the phase III EXPAND  which had shown that Mayzent significantly reduced the risk of disease progression  including impact on physical disability and cognitive decline  Mayzent is also under review in Europe AbbVie Gets First Regulatory Approval for Risankizumab  AbbVie announced the  for its key pipeline candidate  risankizumab  The Japanese regulatory authority granted approval to risankizumab  for plaque psoriasis  generalized pustular psoriasis  erythrodermic psoriasis and psoriatic arthritis  Risankizumab  which will be marketed by the trade name of Skyrizi  is under review in the United States and EU for plaque psoriasis  A decision in the United States is expected in the first half of the year  It is being studied in late stage studies for Crohn s disease Bayer J J Settle Xarelto Litigations  Bayer   OTC BAYRY   and partner J J   NYSE JNJ     including cases in federal and state courts  in connection with blood thinner Xarelto for  775 million  The more than 25 000 lawsuits were filed by patients who suffered a bleeding injury after taking Xarelto  The settlement resolves all pending claims related to Xarelto  thereby removing an overhang on the company and eliminating litigation expenses New Immunology Collaboration for Lilly  Eli Lilly   NYSE LLY   gained an exclusive  worldwide license to develop and commercialize  from private biotech  ImmuNext for an upfront payment of  40 million  The novel target can be developed into new medicines to treat autoimmune diseases  In addition to the upfront payment  Lilly will be entitled to pay up to approximately  565 million in development and commercialization milestone payments as well as future royalties on product sales to ImmuNext J J Files sBLA for Darzalex  J J filed a supplemental biologics license application  sBLA  seeking approval of its immunotherapy  Darzalex in combination with its proteasome inhibitor Velcade  bortezomib   thalidomide and dexamethasone  VTd   in newly diagnosed  population  The filing was based on data from a phase III CASSIOPEIA study J J also filed a supplemental new drug application  sNDA  to the FDA seeking approval to include data from the phase III CREDENCE study on the label of its type II diabetes medicine  Invokana  The study evaluated Invokana for slowing the progression of chronic kidney disease in patients with type II diabetes and chronic kidney disease who are at high risk of experiencing kidney failure Aldeyra Eye Drug Achieves Primary Endpoint in Phase III  Aldeyra Therapeutics  phase III  evaluating its experimental eye drop for allergic conjunctivitis  reproxalap  met the primary as well as the key secondary endpoints for both concentrations of this lead candidate  The company plans to meet with the FDA to discuss a drug application in the second half of the year  Reproxalap is also being studied in a late stage study for dry eye disease The NYSE ARCA Pharmaceutical Index declined 0 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions   It was a mixed performance in the last five trading sessions  While Glaxo recorded the highest gain of 1 6   Bristol Myers   NYSE BMY   declined the most  2 2   In the past six months  Lilly has been the biggest gainer  19 9   while Bristol Myers declined the most  22 9    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs--others-get-drug-approvals-200402330,200402330
171640,393156,LLY,3 Big Pharma Stocks To Add To Your Portfolio This April  ,opinion,"The Zacks  industry  comprising some of the biggest drugmakers in the world  has gained 4 9  in 2019 so far compared with the S P 500 s increase of 13 1   Large  Cap Pharma Versus S P 500 The S P 500 Index witnessed a bull run in the first quarter of 2019 despite pockets of volatility  Upbeat economic growth  improving business sentiment and a dovish Fed helped the S P 500 rally in the quarter  The large cap pharmaceutical industry has underperformed the S P 500 probably due to some pipeline related setbacks  Also  the fourth quarter results were mostly below expectations and the earnings and sales outlook for 2019 was rather soft Nonetheless  the sector is largely expected to pick up as the year progresses  
 The Large Cap Pharmaceuticals industry features among the top 34  of the 255 Zacks ranked industriesWe believe that new product sales ramp up as a result of rising demand driven by a growth in ageing population  successful innovation and product line extensions in important therapeutic areas  strong clinical study results  and frequent FDA approvals should help the big drug giants to do well this year despite broader macro issues or the industry s own challenges  Moreover  the industry is likely to perform well even if the global economy slows down this year  as is widely expected  This is because it is a defensive growth sector  which is almost insulated from broader macroeconomic factors Importantly  mergers and acquisition activity has risen this year relative from 2018  which positions the sector for growth  A key announcement this year was Bristol Myers    NYSE BMY   offer to buy Celgene   NASDAQ CELG   for  74 billion  the biggest merger in the industry  Other important acquisition announcements include Lilly s   NYSE LLY   purchase of small cancer biotech  Loxo Oncology and Merck s   NYSE MRK   pending acquisition of Immune Design  Meanwhile  Glaxo   NYSE GSK   closed its previously announced acquisition of small cancer biotech Tesaro in January Meanwhile  most big pharma companies are resorting to restructuring activities  which is increasing their financial capacity  The funds can be used to re stock pipelines with promising new drug candidates bought from smaller innovative drug biotech companies However  the sector faces its share of headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and major pipeline setbacks Nonetheless  we believe pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activity and appropriate utilization of cash should keep the sector afloat through the rest of this year In this scenario  investing in stocks with a large market cap is a prudent move given the fact that they control a large portion of an industry  Given this backdrop  it makes sense to invest in some of the bigshot drugmakers Here we have highlighted three stocks that may prove to be good buys  All these stocks carry a Zacks Rank  2  Buy  and have seen their share price and earnings estimates rise this year so far  You can see  A chart showing the share price movement of the three stocks this year so far is given below   Merck Shares of Merck have risen 8 8  this year so far  Merck s earnings estimates for 2019 have gone up 0 6  while that for 2020 has moved up by 0 4  in the past 30 days Merck s new products like Keytruda  Lynparza  and Bridion are contributing meaningfully to its top line  Sales of its blockbuster PD L1 inhibitor  Keytruda are gaining momentum with approval for additional indications  especially in first line lung cancer setting  We believe Keytruda has strong growth prospects based on increased utilization  recent approvals for new indications and potential additional approvals worldwide  Meanwhile  Merck s animal health and vaccine products are also performing strongly and remain core growth drivers Johnson   Johnson   NYSE JNJ  J J s shares have risen 8 3  this year so far  a decent recovery from the decline last year  Its earnings estimates for 2019 have gone up 0 1  in the past 30 days J J s sales growth accelerated in 2018 backed by above market sales growth in the Pharmaceutical segment and improving performance in Medical Devices unit  Though generic biosimilar headwinds in the Pharmaceutical segment will hurt J J s sales and profits in 2019  both are expected to accelerate in 2020 supported by drug launches  successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara  J J is also making rapid progress with its pipeline and line extensions  Meanwhile  share buybacks and restructuring initiatives should provide bottom line support Roche   OTC RHHBY  Roche s earnings estimates have increased 0 9  for 2019 over the past 30 days  The company s shares have increased 10 6  this year so far Roche s performance was impressive in 2018 as it combated biosimilar competition in Europe  Strong growth from Ocrevus  Perjeta  Tecentriq  Alecensa and Hemlibra has been more than offset by lower sales of MabThera Rituxan and Tarceva  In particular  multiple sclerosis drug Ocrevus witnessed strong growth  driven by increased demand  Meanwhile  the company continues to progress with its pipeline as it looks to restructure its portfolio beyond oncology into MS and hemophilia among others  The Ignyta acquisition of 2018 further strengthened Roche s cancer pipeline Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/3-big-pharma-stocks-to-add-to-your-portfolio-this-april-200402891,200402891
171645,393161,LLY,AVEO Reports Positive Results On Leukemia Drug  Shares Up,opinion,Shares of AVEO Oncology   NASDAQ AVEO   surged about 35  after the company along with partner Biodesix  Inc  announced positive results from phase Ib expansion cohort of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia  AML   However  shares of the company have slumped 57 5  in the past year compared with the  s decline of 5 8  Ficlatuzumab is a potent hepatocyte growth factor  HGF  inhibitory antibody product candidate  The phase Ib study was designed to assess the safety  tolerability and preliminary efficacy of ficlatuzumab combined with cytarabine in AML patients who are refractory to first line therapy  7 3  or have relapsed within one year of induction  a population known to have poor outcomes The maximally tolerated dose was 20 mg kg of ficlatuzumab on day 1  followed by 2 g m2 cytarabine daily on days 2 7  Of 12 patients who received ficlatuzumab and cytarabine at the maximally tolerated dose  one was non evaluable and 6 achieved a complete response  CR   Of 18 patients enrolled in the study  17 were evaluable and 9 achieved a CR  Elevated serum HGF level is an adverse prognostic factor  and these results showed that the anti HGF antibody ficlatuzumab combined with cytarabine holds potential to affect outcomes in patients with relapsed or refractory AML As a result  the company looks forward to considering additional studies with its partner Biodesix as a potential next step for the program  AVEO and Biodesix have a worldwide agreement to develop and commercialize ficlatuzumab  AVEO is also developing ficlatuzumab in combination with Lilly s   NYSE LLY   Erbitux in a phase II investigation for treating metastatic head and neck squamous cell carcinoma There are other companies too engaged in getting their candidates approved for the treatment of AML  Agios Pharmaceuticals  Inc    NASDAQ AGIO   is looking to get Tibsovo s label expanded to include the first line treatment of AML in patients with an isocitrate dehydrogenase 1  IDH1  mutation who are not eligible for standard therapy  Tibsovo is also being evaluated in combination with Celgene s   NASDAQ CELG   Vidaza for treating newly diagnosed AML patients who are ineligible for intensive chemotherapy  Agios plans to conclude enrollment in the study by 2020  AVEO Pharmaceuticals  Inc  Price    Zacks RankAVEO currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/aveo-reports-positive-results-on-leukemia-drug-shares-up-200403190,200403190
171658,393174,LLY,Eli Lilly  LLY  Flat As Market Gains  What You Should Know,opinion,"In the latest trading session  Eli Lilly  LLY  closed at  123 50  marking no change from the previous day  This change lagged the S P 500 s daily gain of 0 3   At the same time  the Dow lost 0 38   and the tech heavy Nasdaq gained 0 44  
Coming into today  shares of the drugmaker had gained 4 65  in the past month  In that same time  the Medical sector gained 2 07   while the S P 500 gained 2 91  
Investors will be hoping for strength from LLY as it approaches its next earnings release  On that day  LLY is projected to report earnings of  1 35 per share  which would represent year over year growth of 0 75  
LLY s full year Zacks Consensus Estimates are calling for earnings of  5 63 per share and revenue of  25 32 billion  These results would represent year over year changes of  1 44  and  3 1   respectively 
It is also important to note the recent changes to analyst estimates for LLY  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 21  higher within the past month  LLY is holding a Zacks Rank of  4  Sell  right now 
In terms of valuation  LLY is currently trading at a Forward P E ratio of 21 93  Its industry sports an average Forward P E of 15 09  so we one might conclude that LLY is trading at a premium comparatively 
It is also worth noting that LLY currently has a PEG ratio of 2 49  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 09 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 97  putting it in the top 39  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-03-12,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-flat-as-market-gains-what-you-should-know-200397072,200397072
171659,393175,LLY,Lilly s Cyramza Successful In Phase III First Line NSCLC Study,opinion,"Eli Lilly and Company   NYSE LLY   announced encouraging data from a phase III study   RELAY   evaluating cancer drug  CYRAMZA  in combination with Roche s   OTC RHHBY   Tarceva  erlotinib  in first line metastatic non small cell lung cancer   NSCLC   patients with EGFR mutations  Data from the study showed that the combination therapy met the primary endpoint of improving progression free survival   PFS    significantly delaying disease progression compared to placebo 
Cyramza is currently approved in combination with chemotherapy  docetaxel  for second line metastatic NSCLC  The drug is also approved for second line gastric and colorectal cancer  Lilly is also seeking approval of the drug for second line hepatocellular carcinoma or liver cancer 
The successful completion of the RELAY study may get approval for Cyramza s first indication in previously untreated patient population  The company plans to submit regulatory applications for the drug s label expansion in first line NSCLC in mid 2019  Please note that first line NSCLC has a significant market opportunity due to large number of patients  However  the segment is getting competitive with new approvals and several therapies under development 
In December 2018  the FDA approved a combination of Roche s Tecentriq in combination with Avastin and chemotherapy for first line metastatic non squamous NSCLC  Earlier in October  Merck s   NYSE MRK   Keytruda in combination with chemotherapy received approval for treating first line metastatic squamous NSCLC  Pfizer s   NYSE PFE   Vizimpro was approved in September for metastatic NSCLC with EGFR mutation  Several other therapies were approved for NSCLC related indications in 2018 
So far this year  Lilly s shares have gained 6 7  compared with the  s rise of 2 5  

 
Cyramza generated revenues of  821 4 million in 2018  recording a year over year increase of 8   Meanwhile  Cyramza is being evaluated in several studies as monotherapy or in combination with other therapies for additional indications 
Apart from Cyramza  Lilly is also developing a wide range of therapies for several indications  The company has launched 10 new drugs since 2014  which have shown strong sales growth  It expects to launch another new 10 drugs in the next five years  If the upcoming launches can replicate the impressive performance of the new marketed drugs  the company will be well poised for growth in the long term 
Lilly s marketed portfolio has diversified products including multiple oncology drugs as well as drugs for other non cancer diseases  The company s revenues are expected to be driven by strong demand for its new drugs including Trulicity  Jardiance  Taltz  Verzenio and Emgality  However  several legacy drugs are facing generic competition  Moreover  competition from other branded drugs as well as pricing pressure prevailing in the U S  markets will also unfavorably impact the company s top line in 2019 Eli Lilly and Company Price
 

   Zacks Rank
Lilly currently carries a Zacks Rank  4  Sell  
You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/lillys-cyramza-successful-in-phase-iii-firstline-nsclc-study-200397420,200397420
171660,393176,LLY,Why Is Incyte  INCY  Up 1 7  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Incyte  NASDAQ INCY   Shares have added about 1 7  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Incyte due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Incyte Q4 Earnings Miss Estimates  Revenues BeatIncyte reported mixed results for the fourth quarter of 2018  wherein earnings missed expectations while revenues beat the same  The company reported earnings of 40 cents per share  which missed the Zacks Consensus Estimate of 43 cents but was up from 2 cents reported in the year ago quarter Excluding milestone and contract  revenues came in at  528 4 million  Adjusting for the same  quarterly revenues were  468 4 million  up 25 2  year over year  Revenues beat the Zacks Consensus Estimate of  466 2 million Quarter in DetailTotal product related revenues came in at  468 3 million  up 25  from the year ago quarter  Of these  Jakafi revenues came in at  380 0 million  up 26  from the year ago quarter  driven by strong patient demand  Also  Jakafi revenues beat the Zacks Consensus Estimate of  378 million  Net product revenues of Iclusig amounted to  19 1 million  down from  19 5 million in the year ago quarter Product royalty revenues from Novartis for the commercialization of Jakafi in ex U S  markets grew 16  to  55 3 million  Olumiant s product royalty revenues came in at  13 8 million R D expenses were  274 million  flat with the year ago quarter  SG A expenses amounted to  97 million  up from  87 million in the prior year quarter  2018 ResultsRevenues came in at  1 8 billion  which increased from  1 4 billion in the year ago quarter and surpassed the Zacks Consensus Estimate of  1 70 billion  Earnings per share came in at  1 04 in 2018  missing the Zacks Consensus Estimate of  1 08 2019 OutlookThe company expects Jakafi revenues of  1 580  1 650 million  Iclusig revenues are expected to be  90  100 million R D expenses are expected to be  1030  1 100 million  SG A expenses are anticipated to be  420  470 million Pipeline UpdateIncyte recently suffered a setback when the FDA extended the review period of the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD  who have had an inadequate response to corticosteroids  The sNDA was submitted in August 2018  and the FDA granted it both Priority Review status and Breakthrough Therapy designation   However  the FDA extended the action date by three months to review additional data submitted by Incyte in response to the FDA s information requests  The additional data have been determined by the FDA to constitute a major amendment to the sNDA  Hence  the new Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 Nonetheless  Jakafi is also being evaluated in patients with acute and chronic steroid refractory GVHD who have an inadequate response to corticosteroids in the REACH2 and REACH3 clinical studies  respectively  Results are expected in the second half of 2019  Meanwhile  the global phase III GRAVITAS 301 trial on itacitinib as a treatment for patients with steroid na ve acute GVHD is ongoing  Results from the study are expected in 2019 The FDA has recently granted Breakthrough Therapy designation to pipeline candidate  pemigatinib  FGFR  for the treatment of previously treated  advanced metastatic or unresectable FGFR2 translocated cholangiocarcinoma  Incyte expects to submit an NDA for pemigatinib for the second line treatment of patients with FGFR2 translocated cholangiocarcinoma in the third quarter of 2019 A phase III trial on the cream formulation of Jakafi in patients with atopic dermatitis was initiated in December 2018  Data from the randomized phase II trial on Jakafi cream in patients with vitiligo are expected in 2019 Incyte and partner Eli Lilly  NYSE LLY  announced positive top line data from two late stage studies  evaluating their oral JAK inhibitor  Olumiant  baricitinib  as monotherapy for moderate to severe atopic dermatitis   AD    a type of eczema  Data from the phase III studies   BREEZE AD1 and BREEZE AD2   showed that the candidate met the primary endpoints of statistically significant improvements in patients compared to placebo  as measured by Investigator s Global Assessment for AD   IGA   score after treatment of 16 weeks  Full results are expected later in 2019  
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-incyte-incy-up-17-since-last-earnings-report-200398370,200398370
171662,393178,LLY,Eli Lilly  LLY  Stock Moves  0 01   What You Should Know,opinion,"In the latest trading session  Eli Lilly  LLY  closed at  128 30  marking a  0 01  move from the previous day  This change was narrower than the S P 500 s 1 9  loss on the day  Meanwhile  the Dow lost 1 77   and the Nasdaq  a tech heavy index  lost 2 5  
Prior to today s trading  shares of the drugmaker had gained 4 56  over the past month  This has outpaced the Medical sector s gain of 2 84  and the S P 500 s gain of 3 04  in that time 
LLY will be looking to display strength as it nears its next earnings release  The company is expected to report EPS of  1 35  up 0 75  from the prior year quarter 
LLY s full year Zacks Consensus Estimates are calling for earnings of  5 65 per share and revenue of  25 32 billion  These results would represent year over year changes of  1 8  and  3 1   respectively 
Investors should also note any recent changes to analyst estimates for LLY  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 57  higher  LLY is currently a Zacks Rank  3  Hold  
Digging into valuation  LLY currently has a Forward P E ratio of 22 72  This valuation marks a premium compared to its industry s average Forward P E of 15 45 
Also  we should mention that LLY has a PEG ratio of 2 58  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 14 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 96  putting it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-03-22,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-stock-moves-001-what-you-should-know-200400359,200400359
171665,393181,LLY,4 Trade Ideas For Eli Lilly,opinion,"Eli Lilly  NYSE LLY    LLY  moved out of a sideways consolidation and into a rising channel over the fall  It ran against rising trend resistance into 2019 before breaking that to the upside in February  A strong sell off to start March saw it continue lower to retest the break out level and hold  Now it is moving higher and closing in on the prior high 
The RSI is in the bullish zone with the MACD positive and looking to cross back up  Short interest is high at 10 1   There is no resistance over 130 75  Support lower comes at 126 60 and 123 then 119 and 117 50  The company is expected to report earnings next on April 30th  The stock pays a 2 01  dividend and it went ex dividend last on February 14th 
The April monthly options chain shows the large open interest at every  5  tick on the put side from 110 to 125 with some as well at 130  The 120 and 125 calls are biggest in that expiry  The May 3 expiry  which is the first to cover the earnings date  just opened so has little activity  The May monthly options show the 125 call strike the only one with big open interest 
Eli Lilly  Ticker   LLY

Trade Ideas
Buy the stock on a move over 130 75 with a stop at 127 50
Buy the stock on a move over 130 75 and add a May 3 Expiry 128 123 Put Spread   3 60  while selling the June 135 Calls   2 15  
Buy the April May 130 Call Calendar   1 30  and sell the April 124 Puts   1 00  
Buy the May 130 135 Call Spread   2 00  and sell the May 120 Puts   1 40  
Elsewhere look for Gold to resume its uptrend while Crude Oil continues higher  The US Dollar Index despite all the noise remains in a broad consolidation while US Treasuries are breaking higher  The Shanghai Composite continues in the uptrend while Emerging Markets fall back into consolidation 
Volatility looks to remain low but building putting some pressure on the equity index ETF s SPY  IWM and QQQ  Their charts are showing some divergence with the IWM pulling back in a short term trend reversal while the SPY holds and consolidates and the QQQ continues to higher highs  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-03-25,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-eli-lilly-bonus-idea-200400593,200400593
171667,393183,LLY,Lilly  LLY  Signs New Immunology Deal With Private Biotech,opinion,Eli Lilly   Company   NYSE LLY   announced an exclusive global licensing and research collaboration with small private biotech  ImmuNext  Inc  to advance the latter s preclinical novel target that has the potential to be developed into new medicines to treat autoimmune diseases  These medicines will work by regulating the metabolism of immune cells and is being considered a promising approach to treat autoimmune diseases ImmuNext will get an upfront payment of  40 million while being eligible to receive up to approximately  565 million in development and commercialization milestone payments as well as royalties on future product sales  ImmuNext has similar collaboration deals with other big pharma companies like Roche and Sanofi   NASDAQ SNY   Lilly s stock has risen 13 2  this year so far compared with 3 7  increase for the   Lilly has been quite active in terms of buyouts and collaboration deals in the past year  In February 2019  Lilly acquired small cancer biotech  Loxo Oncology  Inc   for  8 billion in cash  The deal will broaden Lilly s cancer portfolio into targeted medicines by adding Loxo s newly approved marketed drug Vitrakvi as well as three precision medicines to its pipeline for multiple tumor types  In addition  with the acquisition of California based immuno oncology biotech  ARMO Biosciences in June 2018  Lilly added pancreatic cancer candidate  pegilodecakin  to its pipeline Lilly also announced several business development transactions in 2018  including a licensing agreement which Chugai Pharmaceuticals for an oral GLP 1 agonist  a licensing and research collaboration with Dicerna Pharmaceuticals  utilizing its RNAi technology platform and a deal to acquire a promising pre clinical pain candidate from private biotech  Hydra Biosciences Its other important collaborations include one with NextCure Inc   to make novel immuno oncology cancer therapies  with Aduro Biotech  Inc    NASDAQ ADRO   to develop new immunotherapies for autoimmune and other inflammatory diseases  and with Swiss biotech AC Immune SA   NASDAQ ACIU   to jointly develop Morphomer tau aggregation inhibitors  which have the potential to treat Alzheimer s disease and other neurodegenerative diseases Lilly currently carries a Zacks Rank  3  Hold   You can see Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-signs-new-immunology-deal-with-private-biotech-200401559,200401559
171678,393194,LLY,Lilly To Bring Half Priced Version Of Popular Humalog Insulin,opinion,Eli Lilly   Company   NYSE LLY   announced that it will soon launch an authorized generic version of its popular insulin  Humalog in the United States at a lower list price  The list price of the authorized generic version  to be called Insulin Lispro and containing an identical molecule as Humalog  will be 50  lower than the current list price of Humalog  Insulin Lispro will be available in vial and pen  KwikPen  options  The vial is priced at  137 35 while KwikPens pack of five will cost  265 20  Lilly is working to make the insulin available as quickly as possible Humalog brought in sales of almost  3 billion in 2018  up 5  year over year  The branded drug will remain available for those wishing to access it through existing insurance plans Lilly s stock has risen 10 1  this year so far compared with a 3 9  increase for the    The move comes as the three largest insulin manufacturers  Lilly  Sanofi   NASDAQ SNY   and Novo Nordisk   NYSE NVO   face increasing scrutiny for steep prices of insulins   Prices have reportedly nearly doubled in the past five years  The insulin makers have defended the high list prices by saying that they have to pay significant rebates to pharmacy benefit managers to secure market share  However  uninsured patients suffer a lot due to the high list prices of insulins Last week  executives from several big pharma companies including Pfizer   NYSE PFE    Sanofi  J J  NYSE JNJ   AbbVie  NYSE ABBV  and others were grilled by senators regarding high drug prices  Senators emphasized that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations  They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection Lilly currently carries a Zacks Rank  3  Hold  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-03-04,Zacks Investment Research,https://www.investing.com/analysis/lilly-to-bring-halfpriced-version-of-popular-humalog-insulin-200394718,200394718
171680,393196,LLY,Lilly  LLY  Up 7 5  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Eli Lilly  LLY   Shares have added about 7 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Lilly due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Lilly Lags Q4 Earnings  Beats Sales  Lowers 2019 ViewLilly reported fourth quarter 2018 adjusted earnings per share of  1 33  which missed the Zacks Consensus Estimate of  1 36 and matched the lower end of the guided range of  1 33    1 38 per share Earnings rose 17  from the year ago quarter backed by robust growth in new product sales and higher operating income  A lower tax rate and reduction in shares outstanding from shares repurchase also led to higher earnings in the quarter However  as expected  earnings declined sequentially from third quarter levels due to U S  generic competition for Cialis and launch costs for Emgality Including acquired in process research and development  asset impairment  restructuring  and other special charges  fourth quarter earnings per share were  1 10 against a loss of  1 58 cents per share in the fourth quarter of 2017 Revenues in DetailQuarterly revenues of  6 44 billion beat the Zacks Consensus Estimate of  6 34 billion  Sales grew 5  year over year backed by strong demand for its new drugs led by Trulicity  Taltz  Jardiance and Basaglar  which made up for lower sales of established products like Cialis and Forteo Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 5  on sales Volumes rose 11  as increased demand for new products like Trulicity  Basaglar  Taltz  Jardiance and Verzenio offset lower volumes of some established products like Cialis due to loss of exclusivity  Volumes of Lilly s diabetes products rose 31  in the quarter New pharma products  products launched since 2014  drove 13 7  of volume growth and generated over  2 1 billion in revenues  representing nearly 38  total revenues  up from 31  in the previous quarter  The loss of exclusivity hurt volumes by 450 basis points driven almost entirely by Cialis U S  revenues grew 7  to  3 66 billion and ex U S  revenues rose 1  to  2 77 billion Despite the significant headwind from the loss of exclusivity of Cialis in the U S   Pharmaceutical revenues rose 5  in the quarter driven by volume growth  U S  Pharma revenues increased 6   while in Europe  pharma revenues rose 3   excluding currency impact  In Japan  pharma revenues rose 1   excluding currency impact  Pharma revenues in the rest of the world increased 10  Established products that recorded growth during the quarter included Strattera  up 9  to  107 2 million  and Alimta  up 6  to  556 9 million   Sales of all other established products declined in the quarter Forteo sales declined 15  to  437 1 million  Cymbalta sales declined 4  to  184 5 million  Humalog sales dropped 2  to  770 4 million  Zyprexa sales were down 27  to  110 8 million  Erbitux sales declined 5  to  159 8 million  Humulin sales declined 7  to  337 4 million Cialis sales declined 41  to  350 7 million as U S  sales were hurt by entry of generic competition  Outside U S  sales were hurt by loss of exclusivity in Europe Among the new products  Trulicity generated revenues  924 7 million  up 42  over year driven by higher demand in the United States and higher volumes and realized prices in ex U S  markets Cyramza revenues were  220 6 million  up 8  year over year driven by higher sales in both U S  and international markets Jardiance sales surged 35  to  193 2 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States which offset the negative impact of currency Basaglar recorded revenues of  232 2 million  up 51  year over year  In the United States  sales rose 59   benefiting from higher demand  which offset the impact of lower realized prices  due to increased volume in Medicare Part D  Taltz brought in sales of  307 0 million  up 78  year over year as U S  sales gained from higher demand and the impact of specialty pharmacy and wholesaler buying patterns  which made up for lower realized prices  Ex U S  sales were driven by increased volume from new launches  Taltz was launched for the second indication of psoriatic arthritis in late 2017 early 2018 in both the United States and Europe  which contributed to sales growth in the quarter Lartruvo generated revenues of  83 5 million in the quarter  higher than  76 9 million in the previous quarter  Though the failure of the ANNOUNCE confirmatory study on Lartruvo did not have any impact on fourth quarter results  Lilly is suspending promotion of Lartruvo and sales of the drug should decline sharply in 2019 Olumiant generated sales of  70 1 million in the quarter backed by launch uptake in new European markets  compared with  55 6 million in the previous quarter  In the United States  Olumiant recorded sales of  4 2 million  higher than  0 8 million in the previous quarter Verzenio  launched in the Unites States in late 2017  generated sales of  83 1 million in the quarter  which was less than  84 5 million in the previous quarter  This is because increased demand was more than offset by the negative impact of wholesaler buying patterns and lower realized prices in the United States  Meanwhile  the CDK4 6 inhibitors market is gradually slowing down  Verzenio was launched in several international markets in the fourth quarter of 2018 and generated ex U S  revenues of  6 6 million Emgality generated U S  revenues of  4 9 million in the fourth quarter Animal Health segment sales rose 3  to  816 5 million as higher prices and higher volume offset currency headwinds Gross Margin   Operating Income Adjusted gross margin of 76 6  in the quarter rose 50 basis points driven by manufacturing efficiencies  which offset the negative impact of lower prices  Excluding the effect of foreign exchange rates on international inventories sold  gross margin declined about 25 basis points Operating income increased 15  year over year to  1 62 billion on higher revenues and lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 190 basis points in the quarter to 51 1   This is because the company s cost saving efforts offset the impact of higher marketing costs to support Emgality s launch While marketing  selling and administrative expenses rose 3   R D expense declined 2  in the quarter Adjusted effective tax rate was 15 8   lower than 20 2  in the year ago quarter  driven primarily by the impact of U S  tax reform 2018 ResultsFull year 2018 sales rose 7  to  24 56 billion  marginally beating the Zacks Consensus Estimate of  24 46 billion  Revenues were slightly above the guided range of  24 3 billion to  24 5 billion Adjusted earnings for 2018 were  5 55 per share  missing the Zacks Consensus Estimate of  5 58 but up 30  year over year  Earnings came in at the lower end of the guided range of  5 55 to  5 60 per share 2019 Guidance LoweredLilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo and the study failure for Lartruvo The earnings forecast was reduced from a range of  5 90 to  6 00 to  5 55 to  5 65 per share  The earnings guidance continues to include a reduction of approximately 8 cents per share to reflect the non controlling interest portion of Elanco profits in 2019 Lilly now expects revenues to be between  25 1 billion and  25 6 billion in 2019  down from the prior expectations of  25 3 billion and  25 8 billion Gross margin is expected to be approximately 76 5   Adjusted tax rate is expected to be approximately 15  Marketing  selling and administrative expense are expected to be in a range of  6 4 billion to  6 7 billion  Research and development expense is expected to be in the range of  5 8 billion to  6 0 billion In 2019  revenue growth is expected to be driven by higher demand for its newer medicines including Trulicity  Jardiance  Taltz  Verzenio as well Emgality as some older drugs like Cialis lose patent exclusivity Lilly expects U S  regulatory action for nasal glucagon for hypoglycemia and lasmiditan for acute migraine in 2019 as well as line extension approvals for several medicines  which could drive revenue growth in 2019  Loxo s newly approved marketed drug Vitrakvi should also support the top line However  generic competition for several drugs including Cialis  rising pricing pressure in the United States and some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line 
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-up-75-since-last-earnings-report-can-it-continue-200395813,200395813
171683,393199,LLY,Celldex  CLDX  Q4 Loss Narrower Than Expected  Sales Beat,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   incurred adjusted loss of 95 cents per share in fourth quarter 2018  narrower than the Zacks Consensus Estimate of a loss of  1 20 and the year ago loss of  2 55  The loss has been adjusted for a gain of  1 65 million on fair value re measurement of contingent consideration  However  including the fair value re measurement item  the reported loss was 81 cents compared with a loss of 42 cents in the year ago quarter 
Total revenues in the quarter declined 49  year over year to  1 8 million  It also surpassed the Zacks Consensus Estimate of  1 million  The year over year decline was due to decrease in contract revenues from the International AIDS Vaccine Initiative and Frontier Biotechnologies 
However  the stock s performance has been disappointing in the past year  It has slumped 88 8  compared with the  s 18 9  decline 

 
Quarterly Details
Research and development expenses were down 109 4  year over year to  11 2 million during the quarter  mainly owing to lower personnel costs  and decline in clinical study and contract manufacturing related expenses  General and administrative expenses were  4 3 million  down 26 5  year over year  mainly attributable to lower personnel and commercial planningexpenses 
As of Dec 31  2018  Celldex had cash  cash equivalents and marketable securities of  94 million compared with  139 4 million as of Dec 31  2017  The biotech company s cash position was weakened by higher operating expenses  including costs related to discontinuation of glembatumumab vedotin development  partially offset by net proceeds from the sale of its common stock under a contract with Cantor 
Celldex believes that its cash position  as of December 2018 end  plus anticipated proceeds from the future sale of its common stock under the agreement with Cantor will be enough to meet working capital requirements and fund planned operations through 2020 
2018 Results
The company reported adjusted loss of  6 81 per share in 2018  wider than the Zacks Consensus Estimate of  5 85 and the year ago loss of  9 4 
Revenues were  9 5 million  down 25 2  year over year  However  the figure beat the Zacks Consensus Estimate of  9 2 million 
 Pipeline Focus
Following the discontinuation of the development of its earlier lead candidate glembatumumab vedotin in April 2018  Celldex is focused on the development of CDX 1140 and CDX 3379  Although the candidates are in early to mid stage studies  the company is progressing well with these 
In the earnings release  the company announced that currently enrollment is on track in a phase I study evaluating CDX 1140 in solid tumors  Interim data from CDX 1140 study  which showed desired safety profile  was presented in April 2019 
Moreover  in August  two separate cohorts were initiated in the study to evaluate CDX 1140 monotherapy with a dose of 0 36 mg kg  and a combination of CDX 1140 and CDX 301 
Enrollment is complete in the first stage of the phase II study  evaluating CDX 3379 in combination with Eli Lilly s   NYSE LLY   Erbitux for the treatment of advanced head and neck squamous cell cancer  Celldex plans to present updated data from the study in a future medical meeting in 2019 
Other pipeline candidates like varlilumab and CDX 301 are being evaluated externally through investigator sponsored studies and internally in combination studies  There are also several pre clinical candidates in the company s pipeline  including CDX 0159 
The company is evaluating varlilumab in a phase I II study in combination with Bristol Myers    NYSE BMY   Opdivo in five indications  namely colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma 
Celldex completed a one for fifteen reverse stock split  effective Feb 8  2019  On Feb 11  2019  Celldex common stock began trading on a split adjusted basis on the NASDAQ Capital Market Celldex Therapeutics  Inc  Price  Consensus and EPS Surprise

    
Zacks Rank and Stock to Consider
Celldex currently carries a Zacks Rank  3  Hold  
A better ranked stock is Celgene Corporation   NASDAQ CELG    carrying a Zacks Rank  1  Strong Buy   You can see  
Celgene s earnings per share estimates have increased from  9 29 to  10 01 for 2019 and from  11 58 to  12 12 for 2020 in the past 60 days 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q4-loss-narrower-than-expected-sales-beat-200395918,200395918
171685,393201,LLY,Pharma Stock Roundup  FDA OK s J J Antidepressant  CHMP Recommends Several Drugs,opinion,"This week  J J   NYSE JNJ   gained FDA approval for its antidepressant  Spravato  esketamine   It was the first approval for a depression drug in decades  Lilly   NYSE LLY   said that it will soon launch a cheaper version of its popular insulin  Humalog amid increasing pressure to lower drug costs  The Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency  EMA  meanwhile recommended marketing approval for several drugs 
Recap of the Week s Most Important Headlines
J J s Spravato Gets FDA Approval with a Boxed Warning  J J gets  esketamine  for treatment resistant depression  a difficult to treat mental disease  With the approval  Spravato  which works differently from all other currently available antidepressants  became the first new medicine in 30 years to treat depression 
While most antidepressants take a couple of weeks or months to show effects  Spravato works in hours  To avoid misuse and abuse of the drug  Spravato has been approved with a boxed warning on its label regarding a Risk Evaluation and Mitigation Strategy  REMS  and the risk of suicidal thoughts and behavior in pediatric patients and young adults 
CHMP Gives Positive Opinion to Several Drugs  Pfizer   NYSE PFE   gained positive CHMP opinion  which recommended conditional marketing approval of lorlatinib for ALK positive previously treated non small cell lung cancer   NSCLC   Lorlatinib will be marketed by the trade name of Lorviqua in the EU  In the United States  it gained FDA approval in the name of Lorbrena in November 2018 
The CHMP also gave a nod to AstraZeneca   NYSE AZN   and Merck s   NYSE MRK   application looking for approval of cancer drug Lynparza in a new patient population   germline BRCA mutated HER2 negative advanced breast cancer previously treated with chemotherapy  Lynparza is already approved in the United States for this indication  Merck also gained CHMP nod for a  across all current monotherapy indications 
AbbVie s   NYSE ABBV   filing looking for   its investigational interleukin 23  IL 23  inhibitor  for the treatment of moderate to severe plaque psoriasis  was also given a positive opinion by the CHMP  Risankizumab is also under review in the United States  where a decision from the FDA is expected in the first half of the year 
Glaxo received a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza  An inhaled version of zanamivir is marketed as Relenza by Glaxo while the intravenous version  if approved  will be called Dectova  The CHMP also recommended approval of Sanofi Regeneron s   asthma and Sanofi Lexicon s Zynquista  sotagliflozin  for type I diabetes 
The final decision by the European Union on these products is expected in the coming months 
Lilly to Launch Cheaper Insulin  Lilly announced plans to  of its popular insulin  Humalog  The list price of the authorized generic version  to be called Insulin Lispro and containing an identical molecule as Humalog  will be 50  lower than the current list price of Humalog  Insulin Lispro will be available in vial and pen  KwikPen  options  Lilly is working to make the insulin available as quickly as possible 
The FDA granted priority review to Lilly s filing looking for approval of label expansion of its CGRP antibody  Emgality  galcanezumab  for preventive treatment of episodic cluster headache  Lilly gained FDA approval for Emgality for the preventive treatment of migraine in adults in late September last year 
Roche s Tecentriq plus Avastin Combo Gets EU Nod in First Line Lung Cancer  Roche   OTC RHHBY   gained approval in the EU for Tecentriq in combination with Avastin and chemotherapy for the first line treatment of metastatic NSCLC based on results from the Phase III IMpower150 study  However  in EGFR mutant or ALK positive metastatic NSCLC patients  the combination is approved for use only after appropriate targeted therapy  In the U S  Tecentriq plus Avastin and chemotherapy was approved for the initial treatment of metastatic non squamous NSCLC with no EGFR or ALK genomic tumour aberrations in December last year 
The FDA accepted Roche s supplemental new drug application  sNDA  looking for approval of its antiviral medicine Xofluza in people at   The FDA s decision is expected on Nov 4  There are no approved therapies to treat the high risk influenza patient population  Xofluza was approved by the FDA in October 2018 for the treatment of acute  uncomplicated influenza in people 12 years of age or older  
Roche filed a sBLA looking for approval of a combination of Roche AbbVie s Venclexta plus Roche s Gazyva  obinutuzumab  as a first line therapy with a fixed duration of treatment in patients with chronic lymphocytic leukemia with co existing medical conditions  Moreover  the combination was granted a breakthrough therapy designation  BTD  by the FDA  the fifth one for Venclexta 
Allergan s Depression Candidate Fails  Allergan s three acute pivotal studies on depression candidate  rapastinel    The studies were evaluating rapastinel  its NMDA receptor modulator  as an adjunctive treatment of major depressive disorder  MDD  compared to placebo  both in combination with antidepressant therapy  ADT  
The FDA accepted Allergan s supplemental biologics license applications  sBLAs  looking to expand the label of the blockbuster product Botox for pediatric patients with upper and lower limb spasticity  While a decision on upper limb spasticity indication is expected in the second quarter of this year with the FDA granting priority review to the sBLA  the same for pediatric lower limb spasticity indication is expected in the fourth quarter  Botox is approved for both the indications in adults 
The NYSE ARCA Pharmaceutical Index declined 0 7  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 

 
Here is how the seven major stocks performed in the last five trading sessions 

 
It was a mixed performance in the last five trading sessions  While J J recorded the highest gain of 1 2   Pfizer declined the most  4 5   
In the past six months  Lilly remains the biggest gainer  18 7   while Bristol Myers declined the most  15 4   
 See the last pharma stock roundup here   
What s Next in the Pharma World 
Watch out for pipeline and regulatory updates next week 
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-08,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-oks-jj-antidepressant-chmp-recommends-several-drugs-200396000,200396000
171688,393204,LLY,The Zacks Analyst Blog Highlights  J J  Lilly  Pfizer  AstraZeneca And Merck s,opinion,"For Immediate Release
Chicago  IL   March 11  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  J J   NYSE JNJ    Lilly   NYSE LLY    Pfizer   NYSE PFE    AstraZeneca   NYSE AZN   and Merck s   NYSE MRK   
Here are highlights from Friday s Analyst Blog  
Pharma Stock Roundup  JNJ  LLY  PFE   More
This week  J J gained FDA approval for its antidepressant  Spravato  esketamine   It was the first approval for a depression drug in decades  Lilly said that it will soon launch a cheaper version of its popular insulin  Humalog amid increasing pressure to lower drug costs  The Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency  EMA  meanwhile recommended marketing approval for several drugs 
Recap of the Week s Most Important Headlines
J J s Spravato Gets FDA Approval with a Boxed Warning  J J gets  esketamine  for treatment resistant depression  a difficult to treat mental disease  With the approval  Spravato  which works differently from all other currently available antidepressants  became the first new medicine in 30 years to treat depression 
While most antidepressants take a couple of weeks or months to show effects  Spravato works in hours  To avoid misuse and abuse of the drug  Spravato has been approved with a boxed warning on its label regarding a Risk Evaluation and Mitigation Strategy  REMS  and the risk of suicidal thoughts and behavior in pediatric patients and young adults 
CHMP Gives Positive Opinion to Several Drugs  Pfizer gained positive CHMP opinion  which recommended conditional marketing approval of lorlatinib for ALK positive previously treated non small cell lung cancer   NSCLC   Lorlatinib will be marketed by the trade name of Lorviqua in the EU  In the United States  it gained FDA approval in the name of Lorbrena in November 2018 
The CHMP also gave a nod to AstraZeneca and Merck s application looking for approval of cancer drug Lynparza in a new patient population   germline BRCA mutated HER2 negative advanced breast cancer previously treated with chemotherapy  Lynparza is already approved in the United States for this indication  Merck also gained CHMP nod for a  across all current monotherapy indications 
Lilly to Launch Cheaper Insulin  Lilly announced plans to  of its popular insulin  Humalog  The list price of the authorized generic version  to be called Insulin Lispro and containing an identical molecule as Humalog  will be 50  lower than the current list price of Humalog  Insulin Lispro will be available in vial and pen  KwikPen  options  Lilly is working to make the insulin available as quickly as possible 
The FDA granted priority review to Lilly s filing looking for approval of label expansion of its CGRP antibody  Emgality  galcanezumab  for preventive treatment of episodic cluster headache  Lilly gained FDA approval for Emgality for the preventive treatment of migraine in adults in late September last year 
Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-03-10,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-jj-lilly-pfizer-astrazeneca-and-mercks-200396470,200396470
171705,393221,LLY,Aduro  ADRO  Q4 Earnings And Revenues Fall Shy Of Estimates,opinion,"Aduro BioTech  Inc    NASDAQ ADRO   incurred fourth quarter 2018 loss of 33 cents per share  wider than the Zacks Consensus Estimate of a loss of 23 cents but narrower than the year ago loss of 34 cents 
Revenues came in at  2 8 million  down 26 3  year over year due to changes in revenue recognition methodology  The top line also missed the Zacks Consensus Estimate of  5 9 million 
Shares of Aduro slipped 1 9  in after hours trading on Wednesday  In fact  the stock has plunged 30 5  in the past year 
Quarter in Detail
Research and development expenses declined 23 1  in the reported quarter to  17 6 million owing to lower expenses related to the company s antibody and live  attenuated  double deleted  LADD  programs 
General and administrative expenses were  9 million  up 2 3  year over year  primarily on higher stock based compensation expense and consulting costs 
Full Year Result
For 2018  Aduro generated revenues of  15 1 million  down 12 2  on a year over year basis  The company suffered net loss of  1 21 per share in 2018 
Pipeline Update
Aduro s three distinct technology platforms  designed to harness the body s natural immune system  are being utilized to develop treatments for several cancer indications and show potential for label expansion into auto immune and infectious diseases  The three well defined platforms are the LADD technology  STING pathway activator and the B select monoclonal antibody 
Aduro has a collaboration and license agreement with Novartis   NYSE NVS   for developing its lead STING Activator candidate  ADU S100 
Earlier this month  Aduro dosed the first patient in a phase I study  evaluating ADU S100 in combination with Bristol Myers    NYSE BMY   Yervoy  ipilimumab  for the treatment of relapsed refractory melanoma 
Earlier  ADU S100 was being evaluated as a single agent  However  the protocol was amended later to include the evaluation of ADU S100 in combination with Yervoy on a homogeneous patient population 
Last December  Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly   NYSE LLY   to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS STING inhibitor platform 
Also  in the same month  the company presented encouraging preclinical data on its first in class anti APRIL antibody  BION 1301  for the treatment of multiple myeloma at the 60th American Society of Hematology Annual Meeting  The findings showed that BION 1301 with a B cell maturation antigen  BCMA  targeted therapy  might have potential to augment anti myeloma activity  which supports the candidate s use as a first in class therapy for treating multiple myeloma 
Meanwhile  Aduro s LADD platform includes candidates  such as ADU 623  phase I   glioblastoma   ADU 741  phase I   metastatic castration resistant prostate cancer  and ADU 214  phase I   metastatic non small cell lung cancer   Aduro has a research and license deal with Janssen  a subsidiary of Johnson   Johnson  NYSE JNJ  for developing ADU 214 and ADU 741 
Zacks Rank
Aduro currently carries a Zacks Rank  2  Buy   You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates-200393702,200393702
171721,393237,LLY,Incyte  INCY  Q4 Earnings Miss Estimates  Revenues Beat,opinion,"Incyte Corporation   NASDAQ INCY   reported mixed results for the fourth quarter of 2018  wherein earnings missed expectations while revenues beat the same  The company reported earnings of 40 cents per share  which missed the Zacks Consensus Estimate of 43 cents but was up from 2 cents reported in the year ago quarter 
Excluding milestone and contract  revenues came in at  528 4 million  Adjusting for the same  quarterly revenues were  468 4 million  up 25 2  year over year  Revenues beat the Zacks Consensus Estimate of  466 2 million 
Quarter in Detail
Total product related revenues came in at  468 3 million  up 25  from the year ago quarter  Of these  Jakafi revenues came in at  380 0 million  up 26  from the year ago quarter  driven by strong patient demand  Also  Jakafi revenues beat the Zacks Consensus Estimate of  378 million  Net product revenues of Iclusig amounted to  19 1 million  down from  19 5 million in the year ago quarter 
Product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets grew 16  to  55 3 million  Olumiant s product royalty revenues came in at  13 8 million 
R D expenses were  274 million  flat with the year ago quarter  SG A expenses amounted to  97 million  up from  87 million in the prior year quarter 
2018 Results
Revenues came in at  1 8 billion  which increased from  1 4 billion in the year ago quarter and surpassed the Zacks Consensus Estimate of  1 70 billion  Earnings per share came in at  1 04 in 2018  missing the Zacks Consensus Estimate of  1 08 
2019 Outlook
The company expects Jakafi revenues of  1 580  1 650 million  Iclusig revenues are expected to be  90  100 million  R D expenses are expected to be  1030  1 100 million  SG A expenses are anticipated to be  420  470 million 
Pipeline Update
Incyte recently suffered a setback when the FDA extended the review period of the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD  who have had an inadequate response to corticosteroids  The sNDA was submitted in August 2018  and the FDA granted it both Priority Review status and Breakthrough Therapy designation  
However  the FDA extended the action date by three months to review additional data submitted by Incyte in response to the FDA s information requests  The additional data have been determined by the FDA to constitute a major amendment to the sNDA  Hence  the new Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 
Nonetheless  Jakafi is also being evaluated in patients with acute and chronic steroid refractory GVHD who have an inadequate response to corticosteroids in the REACH2 and REACH3 clinical studies  respectively  Results are expected in the second half of 2019  Meanwhile  the global phase III GRAVITAS 301 trial on itacitinib as a treatment for patients with steroid na ve acute GVHD is ongoing  Results from the study are expected in 2019 
The FDA has recently granted Breakthrough Therapy designation to pipeline candidate pemigatinib  FGFR  for the treatment of previously treated  advanced metastatic or unresectable FGFR2 translocated cholangiocarcinoma  Incyte expects to submit an NDA for pemigatinib for the second line treatment of patients with FGFR2 translocated cholangiocarcinoma in the third quarter of 2019 
A phase III trial on the cream formulation of Jakafi in patients with atopic dermatitis was initiated in December 2018  Data from the randomized phase II trial on Jakafi cream in patients with vitiligo are expected in 2019 
Incyte and partner Eli Lilly and Company   NYSE LLY   announced positive top line data from two late stage studies  evaluating their oral JAK inhibitor  Olumiant  baricitinib  as monotherapy for moderate to severe atopic dermatitis   AD    a type of eczema  Data from the phase III studies   BREEZE AD1 and BREEZE AD2   showed that the candidate met the primary endpoints of statistically significant improvements in patients compared to placebo  as measured by Investigator s Global Assessment for AD   IGA   score after treatment of 16 weeks  Full results are expected later in 2019 
Our Take
Incyte s performance in the fourth quarter was mixed  Nevertheless  Jakafi sales continue to be impressive 
However  Incyte s stock has lost 23 8  in the past six months compared with the  s 11 7  decline 

 
Pipeline setbacks continue to be a concern  The FDA s extension of the review period of the sNDA for the label expansion of Jakafi to treat acute GVHD was disappointing  Earlier  the company suffered a huge setback with the failure of the phase III study  ECHO 301  as it was one of the most promising candidates for Incyte  evaluating epacadostat in combination with Merck s   NYSE MRK   Keytruda 
Zacks Rank
Incyte currently carries a Zacks Rank  5  Strong Sell   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-q4-earnings-miss-estimates-revenues-beat-200388395,200388395
171722,393238,LLY,Are You Looking For A High Growth Dividend Stock  Eli Lilly  LLY  Could Be A Great Choice,opinion,"Getting big returns from financial portfolios  whether through stocks  bonds  ETFs  other securities  or a combination of all  is an investor s dream  But for income investors  generating consistent cash flow from each of your liquid investments is your primary focus 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is that coveted distribution of a company s earnings paid out to shareholders  and investors often view it by its dividend yield  a metric that measures the dividend as a percent of the current stock price  Many academic studies show that dividends make up large portions of long term returns  and in many cases  dividend contributions surpass one third of total returns 
Eli Lilly in Focus
Headquartered in Indianapolis  Eli Lilly  LLY  is a Medical stock that has seen a price change of 4 35  so far this year  The drugmaker is paying out a dividend of  0 56 per share at the moment  with a dividend yield of 2 14  compared to the Large Cap Pharmaceuticals industry s yield of 2 77  and the S P 500 s yield of 1 92  
Taking a look at the company s dividend growth  its current annualized dividend of  2 58 is up 14 7  from last year  In the past five year period  Eli Lilly has increased its dividend 4 times on a year over year basis for an average annual increase of 3 08   Any future dividend growth will depend on both earnings growth and the company s payout ratio  a payout ratio is the proportion of a firm s annual earnings per share that it pays out as a dividend  Lilly s current payout ratio is 40   This means it paid out 40  of its trailing 12 month EPS as dividend 
LLY is expecting earnings to expand this fiscal year as well  The Zacks Consensus Estimate for 2019 is  5 59 per share  which represents a year over year growth rate of 0 72  
Bottom Line
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages  investors like dividends for a variety of different reasons  However  not all companies offer a quarterly payout 
High growth firms or tech start ups  for example  rarely provide their shareholders a dividend  while larger  more established companies that have more secure profits are often seen as the best dividend options  Income investors have to be mindful of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  LLY is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/are-you-looking-for-a-highgrowth-dividend-stock-eli-lilly-lly-could-be-a-great-choice-200388823,200388823
171724,393240,LLY,Bayer Obtains Full Rights To Vitrakvi From Lilly s Loxo ,opinion,Bayer AG  DE BAYGN    OTC BAYRY   announced that it has exercised a right to gain exclusive licensing rights for the global development and commercialization of the TRK inhibitors   Vitrakvi  larotrectinib  and BAY 2731954  LOXO 195   Bayer has exercised this right under a change in control clause in the collaboration agreement with Loxo Oncology  Both Vitrakvi and BAY 2731954 are being developed globally for the treatment of adult and pediatric patients with advanced solid tumors harboring neurotrophic receptor tyrosine kinase  NTRK  gene fusions Shares of Bayer have declined 36  in the past year against the  s growth of 9 2  We remind investors that Bayer and Loxo Oncology entered into a global collaboration for the joint development and commercialization of larotrectinib and BAY 2731954  Following the change of control  Bayer will be solely responsible for the global development and commercialization of both larotrectinib and BAY 2731954  The sharing of U S  commercial costs and profits in equal parts will now be replaced by royalties to be paid by Bayer Larotrectinib was approved in November 2018 in the United States under the brand name Vitrakvi for the treatment of adult and pediatric patients with solid tumors with a NTRK gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity  and have no satisfactory alternative treatments or have progressed following treatment  BAY 2731954 is an oral candidate  which is in development for the treatment of patients with cancers that have acquired resistance to initial TRK therapy Bayer aims to strengthen its leadership in the field of cancer care  and has two very promising compounds in its precision oncology portfolio We further remind investors that Eli Lilly and Company   NYSE LLY   announced a definitive agreement to acquire Loxo Oncology for  8 billion and the deal closed on Feb 15 Bayer Aktiengesellschaft Price    Zacks Rank and Stocks to ConsiderBayer currently has a Zacks Rank  4  Sell  Some better ranked stocks are GlaxoSmithKline   NYSE GSK   and Bristol Myers Squibb   NYSE BMY    While GlaxoSmithKline sports a Zacks Rank  1  Strong Buy   Bristol Myers carries a Zacks Rank  2  Buy   You can see  GlaxoSmithKline s earnings per share estimates have increased from  2 86 to  2 95 for 2019 and from  2 93 to  3 05 for 2020 in the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  with average of 3 74  Bristol Myers  earnings per share estimates have increased from  4 07 to  4 16 for 2019 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 14 26  Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo-200389624,200389624
171725,393241,LLY,Pfizer   Lilly s Pain Candidate Succeeds In Back Pain Study,opinion,"Pfizer Inc    NYSE PFE   and Eli Lilly and Company   NYSE LLY   announced that a higher dose of their NGF inhibitor  tanezumab  met the primary endpoint in a phase III study  evaluating it in patients with chronic low back pain   CLBP   In the past six months  shares of Pfizer have risen 1  compared with the  s gain of 1 6  The phase III study evaluated two dosages   5 mg or 10 mg   of tanezumab  a non opioid candidate  subcutaneously administered every eight weeks for 56 weeks in patients with moderate to severe CLBP  followed by 24 week safety follow up period  The eligible patients experienced inadequate relief or are intolerant to analgesics and suffering from the disease for more than three consecutive months Top line data from the study showed that treatment with the 10 mg dose of tanezumab led to a statistically significant improvement in pain compared to placebo after 16 weeks of treatment  Although the lower dose of 5mg demonstrated numerical improvement in pain compared to placebo  it did not achieve statistical significance  Detailed results from the study will be submitted for future scientific publication and presentation The company estimates that there are 8 million patients with moderate to severe CLBP in the United States  which represents a significant opportunity for the candidate as currently available therapies do not have adequate patient response Apart from CLBP  tanezumab is also being developed for other pain indications  osteoarthritis and cancer pain  The companies have successfully completed two late stage studies evaluating tanezumab in patients with osteoarthritis pain Tanezumab works by inhibiting nerve growth factor  which suppresses pain signal in the body  Its approval will provide a safer pain medication for patients in the United States where opioid abuse is widespread and patients are largely underserved by the existing medications We remind investors that Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Teva Pharmaceutical Industries Limited   NYSE TEVA   are also developing a NGF antibody  fasinumab for treating osteoarthritis pain In a separate press release  Pfizer announced that the European Commission has granted approval to Zirabev  bevacizumab   its biosimilar version of Roche s cancer drug  Avastin  Zirabev is approved for the treatment of several cancer indications  for which the reference product is approved like colon cancer  metastatic breast cancer  unresectable advanced  metastatic or recurrent non small cell lung cancer   NSCLC    among others This is Pfizer s second oncology biosimilar to be approved in Europe  the first being Roche s another cancer drug  Herceptin  Meanwhile  Zirabev is also under review in the United States along with biosimilar versions of Rituxan and Herceptin with FDA decisions on all expected in 2019 Pfizer Inc  Price
    Zacks RankPfizer currently carries a Zacks Rank  4  Sell  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/pfizer--lillys-pain-candidate-succeeds-in-back-pain-study-200390032,200390032
171737,393253,LLY,Incyte Down As FDA Extends Review Period Of Jakafi For GVHD,opinion,"Shares of Incyte Corporation   NASDAQ INCY   declined 1 9  after the FDA extended the review period of the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD  who have had an inadequate response to corticosteroids 
The sNDA for the treatment of patients with acute GVHD was submitted in August 2018  and the FDA granted it both Priority Review and Breakthrough Therapy designation 
However  the FDA extended the action date by three months to review additional data submitted by Incyte in response to the FDA s information requests  The additional data has been determined by the FDA to constitute a major amendment to the sNDA 
Hence  the new Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 
The news comes as a disappointment for the company  as a label expansion of the drug would have boosted sales 
We remind investors that Jakafi  a first in class JAK1 JAK2 inhibitor  is already approved by the FDA for the treatment of people with polycythemiavera  PV  who have had an inadequate response to or are intolerant of hydroxyurea  Jakafi is also indicated for the treatment of people with intermediate or high risk myelofibrosis  MF   including primary MF  post polycythemiavera MF and post essential thrombocythemia MF 
The drug is marketed by Incyte in the United States and by Novartis   NYSE NVS   as Jakavi outside the United States 
Meanwhile  Jakafi is also being evaluated in patients with acute and chronic GVHD who have an inadequate response to corticosteroids in the REACH2 and REACH3 clinical studies  respectively  Both the studies are expected to be completed in 2019  and could support additional regulatory submissions in 2020 
Earlier in the week  Eli Lilly and Company   NYSE LLY   and Incyte Corporation announced positive top line data from two late stage studies  evaluating their oral JAK inhibitor  Olumiant  baricitinib  as monotherapy for moderate to severe atopic dermatitis   AD    a type of eczema  Data from the phase III studies   BREEZE AD1 and BREEZE AD2   showed that the candidate met the primary endpoints of statistically significant improvements in patients compared to placebo  as measured by Investigator s Global Assessment for AD   IGA   score after treatment of 16 weeks 
Incyte s stock has lost 5 5  in the past year compared with the  s 16 5  decline  We remind investors that the company suffered a huge setback with the failure of the phase III study  ECHO 301  as it was one of the most promising candidates for Incyte  evaluating epacadostat in combination with Merck s   NYSE MRK   Keytruda 

 
Additional pipeline setbacks will weigh on the company s shares 
Zacks Rank
Incyte currently carries a Zacks Rank  5  Strong Sell   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-02-08,Zacks Investment Research,https://www.investing.com/analysis/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd-200385953,200385953
171738,393254,LLY,Pharma Stock Roundup  Q4 Earnings At MRK  LLY  CHMP Nod For Several Drugs,opinion,"In a busy week for the pharma sector  drug giants Merck   NYSE MRK   and Eli Lilly   NYSE LLY   reported fourth quarter results along with Glaxo   NYSE GSK   and Sanofi   NASDAQ SNY    The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave positive recommendations  granting marketing approval to several drugs this week  Meanwhile  Sanofi gained FDA approval for Cablivi to treat a rare blood disorder while Glaxo signed a global immuno oncology collaboration with Germany s Merck KGaA Recap of the Week s Most Important HeadlinesInside Q4 Earnings  Merck s  as the company beat estimates for earnings as well as sales  Importantly  its PD 1 inhibitor  Keytruda continued its robust performance  recording sales of  2 15 billion in the quarter  up around 14  sequentially and 66  year over year  Its 2019 guidance was also in line with expectations Lilly s  as it beat estimates for sales but missed the same for earnings  However  Lilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology and the Lartruvo confirmatory study failure Glaxo   It expects earnings per share to decline 5 9  at constant exchange rates  CER  in 2019  which includes the impact of Advair generic launch and costs related to the acquisition of TESARO  It also assumes closure of the joint venture with Pfizer   NYSE PFE   for Consumer Healthcare business and divestment of certain nutrition brands like Horlicks in India and Bangladesh Sanofi s as it beat estimates for earnings and missed the same for sales  In 2018  Sanofi s business earnings grew 5   at the higher end of its guided range of 4  5   Sanofi expects business earnings to grow between 3  and 5  at CER in 2019 CHMP Gives Positive Opinion to Several Drugs  Pfizer gained positive CHMP opinion  which for its new lung cancer medicine  Vizimpro  dacomitinib  that was approved in the United States last September  The CHMP also gave nod to AstraZeneca s   NYSE AZN   application looking for approval of its type II diabetes medicine  Forxiga for a new indication   as an oral adjunct treatment to insulin in adults with type 1 diabetes  Sanofi also gained a positive CHMP opinion to include data from the phase III cardiovascular outcome study  ODYSSEY OUTCOMES  on the label of its anti PCSK9 therapy  Praluent Injection  A similar application is awaiting FDA s decision  which is expected in April Roche s   OTC RHHBY   filing for label expansion of Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A without factor VIII inhibitors was also given a positive opinion by the CHMP  Hemlibra is presently marketed for the treatment of haemophilia A patients with factor VIII prophylaxis  In the United States  a similar label expansion was approved in October last year The CHMP also gave nod to Merck s label expansion filing looking for approval of Keytruda  in combination with chemotherapy  as a first line treatment for   a difficult to treat lung cancer patient population   regardless of PD L1 expression  The filing was based on data from the phase III KEYNOTE 407 study  In the United States  a similar label expansion was approved in early October last year The final decision by the European Union on these products is expected in the coming months Glaxo s Immunotherapy Deal with Merck KGaA  Glaxo entered into a  to jointly develop and commercialize the latter s bifunctional fusion protein immunotherapy M7824  which has the potential to treat multiple difficult to treat cancers  Eight studies are ongoing or expected to be initiated this year on M7824 including studies in non small cell lung and biliary tract cancers  M7824 is designed to simultaneously target two immuno suppressive pathways in the body  TGF   and PD L1  which are commonly used by cancer cells to evade the immune system For the deal  Glaxo made an upfront payment of 300 million euros to Merck KGaA  which is also entitled to potential development commercial milestone payments  taking the potential deal value to up to 3 7 billion euros    4 2 billion   The partnership is another step in Glaxo s efforts to strengthen its oncology pipelineSanofi s Cablivi Gets FDA Approval  The FDA granted approval to Sanofi s Cablivi  caplacizumab  for the treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura  Cablivi was added to Sanofi s portfolio with the acquisition of Ablynx last year  In the EU  Cablivi was granted marketing authorization in September last year and was launched in the first market  Germany Sanofi also announced that a pivotal phase III study evaluating its pipeline candidate  isatuximab in combination with some standard of care medicines  of prolonging progression free survival in patients with relapsed refractory multiple myeloma  Sanofi plans to file regulatory applications for isatuximab later in 2019 Lilly s Olumiant Meets Endpoint in Eczema Study  Lilly and partner Incyte  NASDAQ INCY  announced that its  oral JAK inhibitor  Olumiant  baricitinib  met the primary endpoint in two    moderate to severe atopic dermatitis  AD   a type of eczema  Notably  the top line results showed that after 16 weeks of treatment  a statistically significant proportion of patients treated with baricitinib monotherapy achieved the primary endpoint compared to those treated with placebo  The primary endpoint was defined by the Investigator s Global Assessment for AD  IGA  score of clear or almost clear Roche Submits sBLA for Kadcyla  Roche submitted a supplemental biologics license application to the FDA looking for for adjuvant  after surgery  treatment of patients with HER2 positive early breast cancer who have residual disease after neoadjuvant  before surgery  treatment  Kadcyla  an antibody drug conjugate  is approved as monotherapy in second line setting for treating metastatic breast cancer in patients who have received treatment with Herceptin or and taxane since 2013  A potential approval will boost the prospects of the drug as it will expand the patient population FDA Accepts Merck s NDAs for Two Anti Bacterial Candidates  Merck announced that the FDA has accepted and granted priority review to its regulatory applications for two anti bacterial candidates  This includes a new drug application for MK 7655A  a fixed combination of relebactam with imipenem cilastatin and a supplemental NDA for label expansion of its antibacterial medicine  Zerbaxa  While Merck is looking to get MK 7655A approved for the treatment of complicated urinary tract infections  cUTI  and complicated intra abdominal infections  cIAI  caused by certain susceptible Gram negative bacteria  the Zerbaxa sNDA has been filed to get FDA nod for nosocomial pneumonia  While FDA action on MK 7655A is expected on Jul 16  that on Zerbaxa sNDA is expected on Jun 3 AstraZeneca s Medicines Get FDA s Priority Status  AstraZeneca s monoclonal antibody  MEDI8897 was granted  Breakthrough Therapy  and  Prime  designations in the United States and Europe  MEDI8897 is a next generation medicine being developed for the prevention of lower respiratory tract infection  LRTI  caused by respiratory syncytial virus  RSV  in infants  Meanwhile  AstraZeneca s new respiratory biologic Fasenra was granted Orphan Drug Designation  ODD  by the FDA for a new indication   hypereosinophilic syndrome  HES   Fasenra is presently marketed as an add on maintenance treatment for severe  eosinophilic asthmaThe NYSE ARCA Pharmaceutical Index declined 0 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions  In the last five trading sessions  while Glaxo recorded the highest gain of 3 5   Lilly declined the most  2   In the past six months  Merck has been the biggest gainer  16 4   while Bristol Myers declined the most  15 9    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-02-08,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs-200385685,200385685
171743,393259,LLY,Lilly To Begin Exchange Offer For Sale Of Balance Elanco Stake ,opinion,Eli Lilly   Company   NYSE LLY   announced that it will launch an exchange offer for shareholders in order to divest its remaining ownership interest in Elanco Animal Health Incorporated   NYSE ELAN   Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health   via an initial public offering  IPO  of a minority stake in 2018  Elanco Animal Health started trading on NYSE from Sep 20  2018  Lilly retained 80 2  stake in the Elanco Animal Health when it completed the IPO  which it wants to divest this year Under the exchange offer  Lilly shareholders can exchange all  some or none of their Lilly shares for shares of Elanco common stock owned by Lilly at 7  discount  Lilly expects the exchange offer to be tax free  except the cash received in lieu of fractional shares Lilly had long been exploring strategic alternatives for this business including a sale  merger or creation of a separate company through an IPO  Elanco raised over  4 billion through the IPO and debt offering  the vast majority of which was provided to Lilly as consideration for the businesses Lilly transferred to Elanco in connection with the IPO In 2013  Pfizer   NYSE PFE   had spun off its Animal Health business  which started trading on NYSE from Feb1  2013 under the name Zoetis  Inc    NYSE ZTS    However  Merck still owns the Animal Health segment  which accounts for almost 10  of its total revenues In the past year  Lilly s shares have risen 56 8  compared with the  s increase of 7    Last week  Lilly announced mixed fourth quarter results as it beat estimates for sales but missed the same for earnings  It lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology and the failure of Lartruvo study In 2019  Lilly s revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio as well as new migraine drug  Emgality as some older drugs like Cialis lose patent exclusivity  However  competitive pressure on Lilly s drugs is expected to rise in 2019  Generic competition for several drugs including Cialis  rising pricing pressure  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line Lilly currently carries a Zacks Rank  3  Hold  You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-10,Zacks Investment Research,https://www.investing.com/analysis/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake-200386320,200386320
171744,393260,LLY,Aduro Initiates Dosing In Phase I Melanoma Study On ADU S100,opinion,"Aduro BioTech  Inc    NASDAQ ADRO   announced that it has dosed the first patient in a phase I study  evaluating its lead STING Activator candidate  ADU S100  in combination with Bristol Myers    NYSE BMY   Yervoy  ipilimumab  for the treatment of relapsed refractory melanoma 
Earlier  ADU S100 was being evaluated as a single agent  However  the protocol was amended later to include the evaluation of ADU S100 in combination with Yervoy on a homogeneous patient population 
Shares of Aduro were up almost 5 4  following the news on Monday  However  the stock has plunged 42 9  in the past year  wider than the  decrease of 17 6  

 
This study is part of Aduro s ongoing research and development collaboration with Novartis   NYSE NVS   for ADU S100  The same will enroll patients afflicted with advanced melanoma  who have relapsed after or are refractory to other anti PD 1 antibodies  such as Bristol Myers  Opdivo  nivolumab  or Merck s   NYSE MRK   Keytruda  pembrolizumab  
ADU S100 is also being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas  Top line data from the same is expected soon 
Aduro is also conducting a phase Ib analysis to assess ADU S100 in combination with Novartis  PD 1 checkpoint inhibitor  PDR001  for treating solid tumors and lymphomas 
Notably  Aduro has been pursuing acquisitions and agreements to help sponsor its pipeline development 
We would like to remind investors that last December  Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly  NYSE LLY  to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS STING inhibitor platform 
Moreover  the company has granted Janssen Biotech  a subsidiary of Johnson   Johnson  NYSE JNJ   an exclusive  worldwide license to develop its cancer candidates  namely ADU 214 and ADU 741 
Zacks Rank
Aduro currently carries a Zacks Rank  2  Buy   You can see  
Zacks  Best Stock Picking Strategy
It s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/aduro-initiates-dosing-in-phase-i-melanoma-study-on-adus100-200387150,200387150
171758,393274,LLY,Merck s Keytruda Clinches CHMP Nod For Difficult Lung Cancer,opinion,Merck   Co   Inc    NYSE MRK   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  adopted a positive opinion  recommending an approval for the label expansion of its blockbuster PD 1 inhibitor  Keytruda  pembrolizumab   The company is seeking a nod for Keytruda in combination with chemotherapy or the first line treatment of adult patients with metastatic squamous non small cell lung cancer  NSCLC    a difficult to treat lung cancer population   regardless of PD L1 expression Following CHMP s favorable response  a decision in the EU is expected during the first quarter of 2019  On approval  this Keytruda combo will be the first anti PD 1 therapy to be approved in the EU for adult patients afflicted with metastatic squamous NSCLC The affirmative CHMP feedback was based on data from the phase III KEYNOTE 407 study  Outcomes from the same showed that the combination of Keytruda plus chemotherapy led to a significant improvement in both overall survival  OS  and progression free survival rates as compared to patients receiving only chemotherapy  Results presented from this study stole the limelight at the annual meeting of the American Society of Clinical Oncology last June In the United States  a similar label expansion was approved last October  This nod will help Merck gain access to a broader patient population and boost sales for its blockbuster drug Shares of Merck have surged 36 3  in the past year  outperforming the  increase of 7 2  Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer In a very short span of time  Keytruda has become the largest product in Merck s portfolio  The drug generated sales of  7 17 billion in 2018  reflecting a massive increase of 88  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are particularly gaining from a strong momentum in first line lung cancer indication as it is the only anti PD 1 medicine approved in first line setting Zacks Rank   Stocks to ConsiderMerck currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include H Lundbeck A S   OTC HLUYY    Novo Nordisk  CO NOVOb  A S   NYSE NVO   and Eli Lilly and Company   NYSE LLY    While H Lundbeck and Novo Nordisk sport a Zacks Rank  1  Strong Buy   Eli Lilly carries a Zacks Rank  2  Buy   You can see  H Lundbeck s earnings estimates have moved 5 2  north for 2019 over the past 60 days Novo Nordisk s earnings estimates have been revised 1 9  upward for 2019 over the past 60 days Eli Lilly s earnings estimates have been raised 1 4  for 2019 over the past 60 days  The stock has soared 55 1  in a year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer-200383673,200383673
171759,393275,LLY,Sanofi s Myeloma Candidate Meets Goal In Phase III Study,opinion,Sanofi  PA SASY    NASDAQ SNY   announced that a phase III study  evaluating its pipeline candidate   isatuximab   for the treatment of patients with relapsed refractory multiple myeloma  met the primary endpoint of prolonging progression free survival for the given patient population The study was examining isatuximab  an anti CD38 monoclonal antibody plus standard of care medicines  namely pomalidomide and lowdose dexamethasone compared with pomalidomide and low dose dexamethasone alone The open label phase III ICARIA MM program enrolled 307 patients suffering relapsed refractory multiple myeloma  who received two or more prior anti myeloma therapies  The safety profile of isatuximab was the study s secondary endpoint Data from this study will be submitted at an upcoming medical meeting and is expected to support the regulatory filling for the candidate  which is planned later this year Shares of Sanofi have increased 5 3  in the past year compared with the  rise of 6 9  Notably  Sanofi is focusing on its R D efforts for key technologies and diseases  which hold greater commercial potential  At the end of October 2018  Sanofi s pipeline included 40 pharmaceutical new molecular entities and vaccine candidates  which were in phase III analyses or under regulatory review Apart from isatuximab  Sanofi s portfolio has another promising candidate  which is cemiplimab  It is being evaluated for several cancer indications  In September 2018  Libtayo cemiplimab was approved in the United States for treating cutaneous squamous cell carcinoma while an approval in the EU is awaited by the first half of 2019  The drug is also being investigated for multiple other cancers including potentially pivotal trials in lung  cervical and skin cancers Sanofi has entered into a development and commercialization partnership agreement with Regeneron Pharmaceuticals   NASDAQ REGN   for Libtayo Zacks Rank   Stocks to ConsiderSanofi currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Novo Nordisk  CO NOVOb  A S   NYSE NVO   and Eli Lilly and Company   NYSE LLY    While Novo Nordisk sports a Zacks Rank  1  Strong Buy   Eli Lilly carries a Zacks Rank  2  Buy   You can see  Novo Nordisk s earnings estimates have been revised 1 9  upward for 2019 over the past 60 days Eli Lilly s earnings estimates have moved 1 4  north for 2019 over the past 60 days  The stock has soared 55 1  in a year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study-200383843,200383843
171760,393276,LLY,Eli Lilly  LLY  Lags Q4 Earnings  Tops Sales  Cuts 2019 View,opinion,"Indianapolis  IN based Eli Lilly and Company   NYSE LLY    boasts of a wide range of products that serve a vast number of therapeutic areas  The company focuses primarily on central nervous system disorders  metabolic diseases  autoimmune diseases  cardiovascular diseases and cancer  which are all high growth areas and represent significant commercial potential Lilly s earnings performance has been pretty impressive  Its earnings beat expectations in each of the last four quarters  with the average positive surprise being 10 03  Estimates have remained stable ahead of earnings releaseCurrently  Lilly has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Miss  Lilly missed fourth quarter earnings  The company reported EPS of  1 33 per share while our consensus called for EPS of  1 36 Revenues Beat  Revenues beat expectations  Lilly posted revenues of  6 44 billion  compared to our consensus estimate of  6 34 billion 2019 Outlook Lowered  Lilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology and the decision to cease promotion of new drug Lartruvo The earnings forecast was reduced from a range of  5 90 to  6 00 to  5 55 to  5 65 per share  Lilly now expects revenues to be between  25 1 billion and  25 6 billion down from the prior expectations of  25 3 billion and  25 8 billion in 2019 The Zacks Consensus Estimate for earnings and revenues is  5 87 per share and  25 38 billion  respectively Stock Price Impact  Shares were down around 2 5  in pre market trading Check back later for our full write up on this Lilly earnings report later  Eli Lilly and Company Price and Consensus
  
   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view-200384554,200384554
171763,393279,LLY,Sanofi  SNY  Q4 Earnings Top  Genzyme Unit Drives Sales Growth,opinion,"Sanofi  PA SASY    NASDAQ SNY   reported fourth quarter 2018 earnings of 63 cents per American depositary share  which beat the Zacks Consensus Estimate of 61 cents  Earnings increased 3 8  on a reported basis  At constant currency rates  CER   earnings grew 4 7   driven by strong top line growth and a reduced share count Fourth quarter net sales of the French pharma giant rose 3 5  on a reported basis to almost  10 26 billion   8 99 billion   Unfavorable exchange rate movements hampered sales by 0 4   At CER  sales increased 3 9  year over year  Sales missed the Zacks Consensus Estimate of  10 32 billion        In March 2018  Sanofi completed its acquisition of Bioverativ  and in September it closed the agreement to sell its European generics business  Zentiva  to Advent International  Adjusting for the Bioverativ acquisition and the Zentiva divestiture  sales rose 2 6  at constant structure  CS  and CER basis Improved Vaccine sales  double digit growth in Specialty Care unit and higher sales in Emerging Markets and the Consumer Healthcare segment offset persistent sluggishness in diabetes franchise and the loss of U S  exclusivity of Lantus and Renagel to drive top line growth Sales increased 8 7  at CER in the United States  At CER  sales rose 6  in the Emerging Markets and 6 7  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico   However  sales declined 4 8  in Europe at CER All growth rates mentioned below are on a year on year basis and at CER Segmental PerformancePharmaceuticals sales  including the emerging markets  rose 3  to  6 3 billion driven by growth in Rare Blood Disorder and Immunology franchises  partially offset by lower Diabetes and Established Rx products sales and the Zentiva divesture Sanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  Sanofi Genzyme Specialty Care GBU sales  including the emerging markets  surged 35 2  to  2 33 billion  led by Immunology and Rare Blood Disorder franchises  Sales rose 16 1  on a CS basis Sales of rare disease drugs increased 10 9  to  794 million driven by Gaucher  Pompe and Fabry therapies  Important drugs like Myozyme Lumizyme rose 10 7  to  226 million  Fabrazyme sales were  206 million  up 14 4   Cerezyme sales rose 9 3  to  190 million Oncology sales increased 8 1  to  387 million  Excluding Leukine  which was sold in January 2018  oncology sales grew 10 2   Key cancer drug Jevtana s sales were up 14 1  to  114 million In the oncology franchise  Sanofi and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN    gained FDA approval for Libtayo for metastatic cutaneous squamous cell carcinoma  CSCC   a type of skin cancer in September  Libtayo sales were  15 million in the United States and were consolidated by Regeneron In the immunology franchise  new atopic dermatitis drug Dupixent generated sales of  280 million in the quarter  up 24  on a sequential basis  Total prescriptions written for Dupixent in the United States grew 25  sequentially driven by a new marketing campaign and the recent U S  launch in asthma  In October  Dupixent was approved by the FDA as an add on maintenance treatment of moderate to severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid dependent asthma  Sales of the drug in the United States were  225 million while the same in Europe were  29 million New rheumatoid arthritis drug  Kevzara recorded sales of  31 million in the quarter compared with  22 million in the previous quarter  mirroring improved commercial coverage in the United States Sales of MS drugs rose 6 6  to  542 million  Aubagio sales increased 12 6  to  446 million while sales of Lemtrada fell 14 3  to  96 million Rare blood disorders franchise  added to Sanofi s portfolio with the acquisition of Bioverativ in March 2018  fetched sales of  294 million  up 5 7  on a pro forma basis  Along with the earnings release  Sanofi announced that the FDA has approved Cablivi  caplacizumab  for the treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura  Cablivi  approved by the European Commission in September  was launched in its first market  Germany in October  Sales of Cablivi in the fourth quarter were  3 million Diabetes and Cardiovascular GBU  including the emerging markets  declined 7 1  to  1 55 billion  The Diabetes franchise  including the emerging markets  declined 10 5  to  1 38 billion due to lower sales of key drugs   Lantus and Toujeo   in the United States Sales of diabetes drugs in the United States dropped 26 3  to  555 million due to pricing pressure and loss of Part D business  In Europe  it dipped 0 6   However  sales of diabetes drugs in the Emerging Markets were up 7 7  Lantus sales declined 19 7  to  866 million in the fourth quarter  Lantus sales plunged 37  in the United States due to lower average net price and change in coverage with respect to Sanofi s Part D business  In Europe  sales decreased 8 2  due to biosimilar competition and patient switching to Toujeo  In Emerging Markets  Lantus sales grew 7 7  Toujeo generated sales of  211 million in the reported quarter  down 2 3   Sales were down 29 1  in the United States while it rose in Europe and Emerging Markets Admelog  a rapid acting insulin  similar to Lilly s   NYSE LLY   Humalog  which was launched in the United Sales in April  achieved sales worth  57  which more than doubled from  26 million in the third quarter In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent  garnered worldwide sales of  82 million in the reported quarter  up 50 9   Sales of the other drug  Multaq  in this franchise were up 20 8  to  95 million General Medicines   Emerging Markets GBU sales came in at  3 05 billion  down 6 6   Sales of Established products were  2 13 billion  down 6 8  due to generic competition for Renvela Renagel in the United States and lower sales of Lovenox in Europe and Plavix in Japan Sales of Generics declined 33 8  to  278 million with sales declining sharply in Europe due to the Zentiva divestment while sales rose in United States and Emerging Markets Consumer Healthcare GBU sales were  1 19 billion  up 1 9  driven by higher sales in Emerging Markets and the United States  which offset lower sales in Europe Fourth quarter consolidated Sanofi Pasteur  Vaccines  sales were up 9 7  to  1 53 billion driven by successful influenza differentiation strategy and Menactra  The improvement seen in the third quarter continued into the fourth  improving from a weaker first half performance Costs RiseSelling  general and administrative expenses  SG A  inched up 1 1  at CER in the quarter  reflecting investments in product launches  R D expenses were up 13 5  at CER due to increased spending on late stage pipeline  Costs incurred for the consolidation of Bioverativ and Ablynx acquisitions also induced higher operating costs in the reported quarter 2019 OutlookSanofi expects business earnings to grow between 3  and 5  at CER in 2019  It anticipates a positive currency impact in the range of 1  2  on business earnings in 2019 Our TakeSanofi s fourth quarter 2018 results were mixed as it beat estimates for earnings and missed the same for sales  In 2018  Sanofi s business earnings grew 5   at the higher end of its guided range of 4  5   Growth was driven by contribution from the Bioverativ and Ablynx deals  higher vaccine sales and lower impact of patent expirations  The company s Specialty Care segment particularly is on a strong footing with the recent FDA approvals of new drugs Libtayo and Cablivi  and Dupixent for its second indication in asthma Sanofi s shares have slightly outperformed the in the past year  It has risen 9 9  in the said time frame compared with a 9 3  increase for the industry   Zacks Rank   Stock to ConsiderSanofi currently carries a Zacks Rank  3  Hold   You can  Sanofi Price  Consensus and EPS Surprise
     
A better ranked drug stock is Novo Nordisk  CO NOVOb  A S   NYSE NVO    which carries a Zacks Rank  2  Buy  Novo Nordisk s shares have risen 8 9  in the past three months  Its earnings estimates have risen 0 8  for 2019 and by 1 4  for 2020 over the past seven days Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth-200384930,200384930
171767,393283,LLY,A Look At Pharma ETFs Post Q4 Results,opinion,Total earnings of  of the total healthcare market capitalization that has reported so far are up 11 7  on revenue growth of 8 6   The growth rates seem impressive when compared with some of the other sectors  Earnings and revenue beat ratios of 71 8  and 79 5   respectively  also appear good Most of the industry bigwigs came up with solid results either beating earnings or revenue estimates or both but offered bleak outlook  Let s delve into some of them Earnings in FocusJohnson and JohnsonThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  1 97  a couple of cents ahead of the Zacks Consensus Estimate and 13 2  higher than the year ago quarter  Revenues inched up 1  year over year to  20 39 billion and edged past the Zacks Consensus Estimate of  20 1 billion  However  Johnson   Johnson  NYSE JNJ  offered a downbeat outlook for 2019  Revenues are expected in the range of  80 4  81 2 billion  flat to up 1   while earnings per share will likely range between  8 50 and  8 65  indicating growth of 5 7 7 6   read    Pfizer  NYSE PFE  Earnings per share of 64 cents came in a penny above the Zacks Consensus Estimate and revenues of  13 98 billion were ahead of the estimated  13 74 billion  On an annual basis  earnings per share and revenues rose 3  and 2   respectively  For 2019  the U S  drug giant guides revenues in the range of  52  54 billion and earnings per share in the range of  2 82  2 92 Merck Earnings per share came in at  1 04  surpassing the Zacks Consensus Estimate by a penny and improving 6  from the year ago quarter  Revenues grew 5  year over year to  11 billion  edging past the estimated  10 93 billion  Merck expects revenue in the range of  43 2  44 7 billion for this year and earnings per share of  4 57  4 72 Bristol Myers Bristol Myers reported earnings per share of 94 cents  9 cents above the Zacks Consensus Estimate and higher than the year ago earnings of 68 cents  Revenues grew 10  year over year to  5 97 billion but slightly fell short of the Zacks Consensus Estimate of  5 98 billion  The company reiterated its earnings per share guidance of  4 10  4 20 and revenue growth expectation in mid single digits  read    Eli Lilly  NYSE LLY  Eli Lilly missed earnings estimates but beat the same on revenues  Earnings of  1 33 per share were 3 cents lower than the Zacks Consensus Estimate but came in 17  higher than the year ago quarter  Revenues grew 5  to  6 44 billion and beat the estimated  6 34 billion  Eli Lilly reduced its 2019 revenue guidance to  25 1  25 6 billion from  25 3  25 8 billion and earnings guidance to  5 55  5 65 from  5 90  6 00 ETF AngleThe strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month  Below we have highlighted them in detail  These funds have a Zacks ETF Rank  2  Buy   suggesting a continuation of their outperformance  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 46 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top five holdings in the basket  accounting for a combined 45  of total assets  suggesting heavy concentration  The product has  393 5 million in AUM and charges 43 bps in fees and expense  Volume is light as it exchanges about 20 000 shares a day  The fund has gained 2  in a month SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  248 2 million  it trades in good volume of around 105 000 shares a day and charges 35 bps in fees a year  In total  the product holds 44 securities with the in focus five firms making up for at least 4  share each  The product is up 4 6  in the same period  read    VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus four firms account for more than 4  share each  The product has amassed  220 2 million in its asset base and trades in moderate volume of about 53 000 shares a day  Expense ratio comes in at 0 36   The fund has gained 4 2  in a month Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  471 1 million and sees lower volume of around 37 000 shares a day  The fund charges 57 bps in fees and expenses  Holding 30 stocks  the fund invests 2 8  in BMY and nearly 5  share each in the remaining four firms  The ETF has added 0 3  in a month First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 35  of assets  FTXH has a lower level of  4 1 million in AUM and 3 000 shares in average daily volume  It charges 60 bps in annual fees and is up 3 3  in the same time frame Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/a-look-at-pharma-etfs-post-q4-results-200385095,200385095
171787,393303,LLY,Lilly Pfizer s Osteoarthritis Pain Drug Succeeds In 2nd Study,opinion,"Eli Lilly and Company   NYSE LLY   and its partner Pfizer Inc    NYSE PFE   announced that their NGF inhibitor  tanezumab  met all co primary endpoints in a phase III study  evaluating it in patients with osteoarthritis   OA   pain Lilly s shares have rallied 17 1  in the past six months against the  s decrease of 2 5  The phase III study evaluated two dosages   2 5 mg or 5 mg   of tanezumab  subcutaneously administered every eight weeks for 24 weeks in patients with moderate to severe OA pain who have experienced inadequate relief or are intolerant to analgesics and suffering from the disease for more than six years  Top line data from the study evaluating the non opioid candidate showed that treatment with 5mg of tanezumab led to a statistically significant improvement in pain  physical function and the patients  overall assessment of their OA   the three primary endpoints   compared to placebo at 24 weeks The 2 5 mg dose achieved improvement of statistical significance compared to placebo in pain and physical function while a statistical difference was not observed for patients  overall assessment of their OA Data announced in July 2018 from the first phase III study in OA pain showed that tanezumab achieved improvement of statistical significance in similar endpoints at week 16   The positive results from the two studies highlight the potential of the candidate as a treatment option for a difficult to treat patient population  An estimated 11 million suffer from moderate to severe OA  which indicates significant prospects for the candidate We remind investors that Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Teva Pharmaceutical Industries Limited   NYSE TEVA   are also developing a NGF antibody  fasinumab for treating OA Tanezumab is also being evaluated for chronic low back pain and cancer pain  due to bone metastases   Notably  Lilly has been working on building its pipeline and finding novel treatment options for chronic pain In September 2018  Lilly launched Emgality  its CGRP antibody  from its pain portfolio for the preventive treatment of migraine in the United States during September  which could emerge as a significant contributor to long term growth  Another migraine candidate  lasmiditan  is under review  In December 2018  Lilly also entered into an agreement with Massachusetts based privately held Hydra Biosciences to add the latter s pre clinical pain candidate to its pain portfolio Eli Lilly and Company Price
    Zacks RankLilly currently carries a Zacks Rank  2  Buy   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/lillypfizers-osteoarthritis-pain-drug-succeeds-in-2nd-study-200381187,200381187
171788,393304,LLY,Eli Lilly  LLY  Q4 Earnings Coming Up  What s In The Cards ,opinion,"Eli Lilly and Company   NYSE LLY   will report fourth quarter and full year 2018 results on Feb 6  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 1 46  Lilly s shares have risen 43 6  in the past year against the  s decline of 21 9    Lilly s earnings performance has been pretty impressive  Its earnings beat expectations in each of the last four quarters  with the average positive surprise being 10 03   Eli Lilly and Company Price  Consensus and EPS Surprise
  
   Let s see how things are shaping up for this quarter Factors to ConsiderIn the fourth quarter  the company expects earnings in the range of  1 33    1 38 per share  This represents a sequential decline from third quarter levels due to U S  generic competition for key drug Cialis in September  higher R D costs in the fourth quarter  and launch costs for its newly launched CGRP antibody Emgality  Also  backing out the non controlling interest portion of Elanco profits is expected to have 2 to 3 cents negative impact on earnings in the fourth quarter  Lilly divested its Elanco animal health unit as an independent publicly traded company   Elanco Animal Health Incorporated   NYSE ELAN     via an initial public offering  IPO  of a minority stake in 2018 Like the previous couple of quarters  strong uptake trends of new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Verzenio are likely to make up for the decline in sales of established products like Strattera  Cialis  Effient and others due to loss of exclusivity The Zacks Consensus Estimate for Trulicity  Basalgar  Taltz  Jardiance and Cyramza s fourth quarter revenues is  928 million   208 million   300 million   191 million and  206 million  respectively Investors will be keen to know the sales numbers of new products like rheumatoid arthritis drug Olumiant  baricitinib  and advanced breast cancer treatment  Verzenio  Olumiant was launched in select European countries and in Japan in 2017 and in the United States  only for the lower dose  in June 2019  Verzenio was launched in the Unites States in the fourth quarter of 2017 Verzenio  so far  has generated impressive sales  In February  Verzenio gained FDA approval in the first line setting while the drug was approved in Europe and Japan in the third quarter  These line extensions could prove to be significant growth drivers for the drug in the fourth quarter  The Zacks Consensus Estimate for Verzenio fourth quarter sales is  110 million Olumiant is doing well in Europe backed by launch uptake in new markets  However  in United States  sales have been unimpressive  We expect the trend to continue in the fourth quarter Investor focus will also be on management s comments on the initial launch uptake of Emgality which gained FDA approval in September and could emerge as a significant contributor to long term growth However  the loss of exclusivity in some countries for Cialis  Effient  Strattera  Zyprexa  Cymbalta and Evista will hurt volumes  In September  Teva Pharmaceuticals  TEVA  announced the launch of a generic version of Cialis  which is expected to result in rapid erosion of sales of the branded drug in the fourth quarter  The Zacks Consensus Estimate for fourth quarter Cialis sales is  258 million Other older drugs like Forteo  Zyprexa and Erbitux might also record lower sales Earlier this month  Lilly announced that Lartruvo  which had won conditional approval two years back  failed to improve survival in patients with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE  Continued approval was contingent on verification of clinical benefit in a confirmatory study  With ANNOUNCE failing to confirm clinical benefit  Lilly said it will stop promoting Lartruvo while being in discussion with global regulators to determine the next steps for the drug  Though the negative update might not have any impact on fourth quarter results  sales of the drug should decline sharply in 2019 In early January  Lilly announced a definitive deal to acquire small cancer biotech  Loxo Oncology  Inc   for  8 billion in cash  In the quarter  Lilly also announced several collaboration deals including one with Aduro Biotech to develop cGAS STING Pathway Inhibitors  with Hydra Biosciences for a pre clinical pain candidate  Swiss biotech AC Immune to jointly develop Morphomer tau aggregation inhibitors and a cancer collaboration with small biotech  NextCure  Inc  Lilly management is expected to face numerous questions on its future plans for these acquisitions collaborations Earnings WhispersOur proven model does not conclusively show that Lilly will beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00  as both the Zacks Consensus Estimate as well as the Most Accurate Estimate is pegged at  1 36  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Lilly s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderLarge pharma stocks that have both a positive ESP and a favorable Zacks Rank include Merck   Co   Inc    NYSE MRK   has an Earnings ESP of  0 97  and a Zacks Rank of 3  The company is scheduled to report fourth quarter earnings on Feb 1  You can see  Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  0 89  and a Zacks Rank  3  The company is slated to release results on Feb 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-q4-earnings-coming-up-whats-in-the-cards-200382115,200382115
171789,393305,LLY,Lilly  LLY  Hits 52 Week High  Can The Run Continue ,opinion,"Have you been paying attention to shares of Eli Lilly and  LLY   Shares have been on the move with the stock up 7 7  over the past month  The stock hit a new 52 week high of  120 14 in the previous session  Eli Lilly and has gained 3 6  since the start of the year compared to the 5 6  move for the Zacks Medical sector and the  0 5  return for the Zacks Large Cap Pharmaceuticals industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on November 6  2018  Lilly reported EPS of  1 39 versus consensus estimate of  1 37 
For the current fiscal year  Lilly is expected to post earnings of  5 87 per share on  24 46 billion in revenues  Meanwhile  for the next fiscal year  the company is expected to earn  6 73 per share on  25 53 billion in revenues  This represents a year over year change of 5 17  and 4 38   respectively 
Valuation Metrics
Lilly may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as they provide investors with an additional way to sort through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Lilly has a Value Score of C  The stock s Growth and Momentum Scores are A and F  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 20 4X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 21 6X versus its peer group s average of 12 6X  Additionally  the stock has a PEG ratio of 1 83  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to look at the Zacks Rank for the stock  as this supersedes any trend on the style score front  Fortunately  Lilly currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Lilly fits the bill  Thus  it seems as though Lilly shares could still be poised for more gains ahead 
How Does Lilly Stack Up to the Competition 
Shares of Lilly have been rising  and the company still appears to be a decent choice  but what about the rest of the industry  Some of its industry peers are also looking good  including Bristol Myers Squibb  BMY   H Lundbeck A S  HLUYY   and Celgene  CELG   all of which currently have a Zacks Rank of at least  2 and a VGM Score of at least B  making them well rounded choices 
However  it is worth noting that the Zacks Industry Rank for this group is in the bottom half of the ranking  so it isn t all good news for Lilly  Still  the fundamentals for Lilly are promising  and it still has potential despite being at a 52 week high ",2019-01-31,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-hits-52week-high-can-the-run-continue-200382628,200382628
171790,393306,LLY,J J s Erleada Meets Both Primary Endpoints In Late Stage Study ,opinion,"Johnson   Johnson s   NYSE JNJ   subsidiary announced the unblinding of a  phase III study evaluating its newly launched prostate cancer drug  Erleada  apalutamide  plus androgen deprivation therapy  ADT  for the treatment of patients with metastatic castration sensitive prostate cancer  mCSPC   
Erleada is presently marketed in the United States for the treatment of men with non metastatic castration resistant prostate cancer  nmCRPC  who are at high risk of developing metastatic disease  It was approved in EU for the same indication in January 2019 
The phase III TITAN study was unblinded as it met both the primary endpoints  significantly improving radiographic progression free survival  rPFS  and overall survival  OS   The decision was based on the recommendation of Independent Data Monitoring Committee  which coincided with a pre planned analysis  Based on the positive data with Erleada  the committee recommended that patients on the placebo plus ADT arm be permitted to cross over to the apalutamide group 
Patients will continue to be followed for OS and long term safety as part of TITAN  Based on these data  the company plans to file regulatory applications to get approval for Erleada in this expanded patients population in 2019 
J J stock has declined 2 2  in the past year  against growth of 2 1  recorded by the  

 
Erleada was added to J J s portfolio through the August 2012 Aragon acquisition  Also  Erleada s approval has strengthened J J s prostate cancer franchise  especially as generic versions of J J s blockbuster prostate cancer drug  Zytiga have been launched by Apotex  Mylan   NASDAQ MYL   Teva   NYSE TEVA   and Patriot Pharmaceuticals  
Zacks Rank   Stock to Consider
J J currently carries a Zacks Rank  3  Hold  
Another stock worth considering is Eli Lilly and Company   NYSE LLY   carrying a Zacks Rank  2  Buy   You can see  
Lilly s earnings per share estimates have increased from  5 47 to  5 58 for 2018 and from  5 78 to  5 87 for 2019 in the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 10 03  
 Johnson   Johnson Price
 

    
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-02-01,Zacks Investment Research,https://www.investing.com/analysis/jjs-erleada-meets-both-primary-endpoints-in-latestage-study-200382342,200382342
171791,393307,LLY,Lilly Incyte s Olumiant Meets Endpoint In Eczema Studies,opinion,"Eli Lilly and Company   NYSE LLY   and Incyte Corporation   NASDAQ INCY   announced positive top line data from two late stage studies evaluating their oral JAK inhibitor  Olumiant  baricitinib   as monotherapy for moderate to severe atopic dermatitis   AD    a type of eczema  Data from the phase III studies   BREEZE AD1 and BREEZE AD2   showed that the candidate met the primary endpoints of statistically significant improvements in patients compared to placebo as measured by Investigator s Global Assessment for AD   IGA   score after treatment of 16 weeks Detailed data from these studies along with ongoing phase III studies on barcitinib will be presented and published at future scientific venues and in peer reviewed journals later in 2019 Olumiant was first approved in early 2017 for treating moderately to severely active rheumatoid arthritis   RA   in patients with inadequate response or intolerant to TNF inhibitor therapies in Europe  In June 2018  Olumiant received approval in the United States for similar indication  However  the FDA allowed only the lower dose of the drug In the past six months  Lilly s shares have outperformed the   The stock gained 17 8  while the industry rose 1 3  in the said time frame Olumiant is one of the drugs in Lilly s new pharmaceutical product portfolio  which is anticipated to be a key top line driver going ahead  The drug generated  132 5 million in the first nine months of 2018  Although sales in Europe were upbeat for the drug on the back of launch in new markets  U S  sales were weak in the third quarter  Olumiant s fourth quarter sales may provide an idea about the drug s demand in the country Lilly is also developing Olumiant as treatment for systemic lupus erythematosus and alopecia areata in mid to late stage studies Meanwhile  competition is on the rise in the JAK inhibitor segment as well as the eczema market with several approved as well as under development therapies from several companies  Regeneron Pharmaceuticals and Sanofi s Dupixent is approved for treating AD since 2017 while AbbVie   NYSE ABBV   and Pfizer   NYSE PFE   are developing their respective candidates for the indication in late stage studies  Eli Lilly and Company Price
    Zacks RankLilly currently carries a Zacks Rank  2  Buy   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/lillyincytes-olumiant-meets-endpoint-in-eczema-studies-200383617,200383617
171805,393321,LLY,The Zacks Analyst Blog Highlights  J J  Bristol Myers  Lilly  AbbVie And Merck,opinion,For Immediate ReleaseChicago  IL  January 28  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  J J   NYSE JNJ    Bristol Myers   NYSE BMY    Lilly   NYSE LLY   AbbVie   NYSE ABBV   and Merck   NYSE MRK   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  JNJ  BMY  LLY   MoreJ J and Bristol Myers set the earnings season in motion for the pharma space  Meanwhile  Lilly and AbbVie faced pipeline setbacks with failure of their late stage studies  Lilly s confirmatory study to convert soft tissue sarcoma drug Lartruvo s conditional approval to full approval and AbbVie s Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints Recap of the Week s Most Important HeadlinesInside J J   Bristol Myers  Q4 Earnings  J J beat estimates for both earnings and sales in the fourth quarter of 2018  Sales increased 1  from the year ago quarter to  20 4 billion while earnings per share rose 13 2  to  1 95 per share  Pharmaceutical segment sales rose 5 3  year over year  However  J J s  was below expectation Bristol Myers for earnings while missing the same for sales  Revenues were up 10  year over year to  6 billion while earnings rose 38  to  94 per share  However  the company announced the voluntary withdrawal of a label expansion application for Opdivo   low dose Yervoy combination in first line ling cancer  which pushed its share price down  Opdivo sales were up 33  in the fourth quarter  Bristol Myers confirmed its 2019 earnings guidance range of  4 10 to  4 20 Lilly s Confirmatory Study on Lartruvo Fails  Lilly s drug Lartruvo  which had won conditional approval two years back  with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE The ANNOUNCE study evaluated Lartruvo in combination with doxorubicin  a standard of care chemotherapy compared with doxorubicin alone  The study did not meet the primary endpoints of overall survival  OS  in the full study population or in the leiomyosarcoma  LMS  sub population  It was noticed that there was no difference in survival between the study arms for either population  The study thus did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as shown earlier in a phase II study  The clinical benefit achieved earlier had led to an accelerated approval of Lartruvo doxorubicin by the FDA and conditional marketing authorization by the European Medicines Agency in 2016 Continued approval was contingent on verification of clinical benefit in a confirmatory study  With ANNOUNCE failing to confirm clinical benefit  Lilly said it will stop promoting Lartruvo while remaining in discussion with global regulators to determine the next steps for the drug AbbVie s Imbruvica Fails in Pancreatic Cancer Study  AbbVie s late stage study evaluating its cancer drug  Imbruvica in combination with chemotherapy for metastatic pancreatic cancer  of statistically significant progression free or overall survival benefit The RESOLVE study evaluated Imbruvica plus chemotherapy agents nab paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents for the treatment of first line metastatic pancreatic cancer  one of the most aggressive and deadliest forms of cancer  Imbruvica  currently approved for nine cancer indications  has multi billion dollar potential and AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases FDA Accepts Merck s sNDAs for HIV Medicines  Merck s supplemental new drug applications  sNDAs  looking for label expansion of its two new HIV drugs   Pifeltro and Delstrigo   was accepted by the FDA  Pifeltro and Delstrigo were approved by the FDA in August for the treatment of adults with no prior antiretroviral treatment experience  The sNDAs are looking to get the HIV drugs approved for use in treatment experienced adults living with HIV 1 whose virus is suppressed to switch to Pifeltro  in combination with other antiretrovirals  or Delstrigo  The FDA is expected to give its decision on Sep 20  The sNDAs were based on data from the phase III DRIVE SHIFT study  Data from the study  presented in the past  has shown non inferior efficacy for those who switched to Delstrigo compared to those who continued on their baseline regimen Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-jj-bristolmyers-lilly-abbvie-and-merck-200380127,200380127
171812,393328,LLY,Ligand  LGND  Takes A Hit On Citron s Negative Research Report,opinion,"Shares of Ligand Pharmaceuticals   NASDAQ LGND   tumbled 16 5  after a short seller Citron Research issued a negative report on the stock Per Citron  Ligand s pipeline is  nothing but a pipe dream   The research report projects that the stock price has  80  downside from its current  trading levels  Ligand is currently trading at  110 4  while Citron has a  35 price target for Ligand Ligand s stock has plummeted 51 5  in the past six months compared with the  s decline of 15 3  The Citron report puts a big question on Ligand s claims of future revenues and recent acquisitions  Per the report  Ligand  which started off as a biopharmaceutical company  has failed to develop its own drugs  The company then changed its strategy and started acquiring candidate drugs technologies and forming partnerships with other pharma companies for the development of drugs  The company essentially provides development platforms enabling other drug companies to create drugs effectively  Ligand s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties The report says that Ligand has just four approved drugs  with one accounting for more than 75  of royalties and is set to lose patent exclusivity shortly  The report alleges Ligand s claims of pipeline future revenues coming from  The Big 6  as misleading   The big six companies include Sage Therapeutics  SAGE   Retrophin  Inc  Sermonix Pharmaceuticals  Bristol Myers Squibb  BMY   Eli Lilly  LLY  and Roivant Sciences However  per Citron  Ligand likes to name bigwigs like Bristol Myers and Lilly in its presentation of future revenues  while more than 60  of Ligand s  milestones  come from Viking Therapeutics  VKTX  and Vernalis Viking accounts for approximately 51  of Ligand s projected milestones  In October 2018  Ligand acquired Vernalis for  11 million and added two primary candidates   CPI 444 and RPL554   to its portfolio  However  RPL554 has failed in phase II studies  With one of the two drugs failing its trials and the acquisition price for the entire company being slightly more than a public shell  Citron has questioned Ligand s claims of potential milestones of  364 million Citron further cautions investors that if Ligand thought the Viking pipeline was promising  they would be buying Viking s stock and not their own  However  Ligand has been selling Viking stock since Sep 25  2018 While time will tell how the business for Ligand unfolds hereafter  Ligand s dependence on other companies for revenues as royalties is a concern Zacks RankLigand currently has a Zacks Rank  3  Hold  
You can see  Today s Stocks from Zackts  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/ligand-lgnd-takes-a-hit-on-citrons-negative-research-report-200376774,200376774
171813,393329,LLY,Here Is Why Growth Investors Should Buy Lilly  LLY  Now,opinion,"Investors seek growth stocks to capitalize on above average growth in financials that help these securities grab the market s attention and produce exceptional returns  However  it isn t easy to find a great growth stock 
By their very nature  these stocks carry above average risk and volatility  Moreover  if a company s growth story is over or nearing its end  betting on it could lead to significant loss 
However  the task of finding cutting edge growth stocks is made easy with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Our proprietary system currently recommends Eli Lilly  LLY  as one such stock  This company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
While there are numerous reasons why the stock of this drugmaker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Lilly is 9 1   investors should actually focus on the projected growth  The company s EPS is expected to grow 5 2  this year  crushing the industry average  which calls for EPS growth of 5 1  
Impressive Asset Utilization Ratio
Asset utilization ratio    also known as sales to total assets  S TA  ratio    is often overlooked by investors  but it is an important indicator in growth investing  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  Lilly has an S TA ratio of 0 55  which means that the company gets  0 55 in sales for each dollar in assets  Comparing this to the industry average of 0 49  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And Lilly is well positioned from a sales growth perspective too  The company s sales are expected to grow 4 4  this year versus the industry average of 3 2  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Lilly  The Zacks Consensus Estimate for the current year has surged 1 3  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Lilly a Zacks Rank  2 stock  it has earned itself a Growth Score of A based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions Lilly well for outperformance  so growth investors may want to bet on it ",2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/here-is-why-growth-investors-should-buy-lilly-lly-now-200377119,200377119
171817,393333,LLY,Pharma Stock Roundup  Regulatory Updates In Focus At PFE  BMY  RHHBY  SNY,opinion,"In a relatively quiet week with respect to news in the pharma sector  Pfizer s   NYSE PFE   regulatory application looking for the approval of rare disease pipeline candidate  tafamidis  was granted priority review by the FDA  While the FDA accepted Roche s   OTC RHHBY   label expansion application for approval of a Tecentriq based cancer combination for first line lung cancer  the European regulators approved Bristol Myers    NYSE BMY   Opdivo based cancer combination for a type of kidney cancer Recap of the Week s Most Important HeadlinesFDA Grants Priority Review to Pfizer s NDA for Tafamidis  The FDA granted  to Pfizer s new drug application  NDA  looking for approval of pipeline candidate tafamidis  which has been developed to treat transthyretin amyloid cardiomyopathy  ATTR CM   a rare and fatal illness associated with progressive heart failure Pfizer filed two NDAs for tafamidis  one for the meglumine form  20 mg capsule  and the other for a free acid form  61 mg capsule   The priority review designation is for the meglumine form with the FDA s decision on this NDA expected in July this year  The FDA decision for the NDA for the free acid form is expected in November with the filing getting a standard review period  The NDA filings are based on data from a phase III study  ATTR ACT EU Nod for Bristol Myers  Cancer Combo for Kidney Cancer  Bristol Myers announced that the  to its immuno oncology combination of Opdivo  3 mg kg  with Yervoy  1mg kg  as first line treatment option for patients with intermediate  and poor risk advanced renal cell carcinoma  the most common type of kidney cancer  The Opdivo   low dose Yervoy combination was approved to treat this indication in the United States in April  The approval is based on positive data phase III CheckMate 214 study  Please note that Opdivo   low dose Yervoy combination is also approved for patients with unresectable or metastatic melanoma in the United States FDA Accepts Roche s sBLA for Tecentriq in First Line NSCLC  The FDA has accepted Roche s supplemental biologics license application  sBLA  looking for approval of immunotherapy Tecentriq plus chemotherapy  Abraxane and carboplatin  for the first line treatment of metastatic non squamous non small cell lung cancer  The sBLA is based on data from the phase III IMpower130 study  The FDA s decision is expected on Sep 2  2019  The label expansion of the drug will boost sales  In December last year  Tecentriq was approved for use in combination with Avastin plus chemotherapy for first line metastatic non squamous NSCLC FDA Committee s Mixed Vote on Sanofi s Zynquista  An FDA advisory committee gave a mixed vote to Sanofi   NASDAQ SNY   and partner Lexicon Pharmaceuticals  diabetes candidate  Zynquista  sotagliflozin   which is under review in the United States for type I diabetes  The Endocrinologic and Metabolic Drugs Advisory Committee voted eight to eight on the question whether the benefits of the SGLT 1 and SGLT 2 inhibitor outweigh the risks to support an approval by the FDA  The FDA is expected to give its decision on Mar 22  2019  Zynquista is also under review in the EU Kitov s New Data Shows That NT219 has Anti Cancer Effect  Israel based small biotech Kitov Pharma Ltd   NASDAQ KTOV   announced new findings  which demonstrated its anti tumor resistance drug candidate  NT219 s unique mechanism of action  NT219 is a small molecule that presents a new concept in cancer therapy by targeting two pathways involved in cancer drug resistance  It is being developed to overcome cancer drug resistance and to boost the efficacy of numerous oncology drugs available now  It is being developed for use in combination with other cancer therapies  The data showed that even a short exposure of cancerous cells to NT219 was sufficient to trigger irreversible shutdown of cancer pathways  resulting in a long term anti cancer effect The NYSE ARCA Pharmaceutical Index rose 0 3  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions    It was a mixed performance in the last five trading sessions with Bristol Myers recording the maximum gain  3 9   and AstraZeneca   NYSE AZN   declining the most  7 1   in the same period In the past six months  Lilly   NYSE LLY   has been the biggest gainer  33 2   while Bristol Myers declined the most  12 3     See the last pharma stock roundup here  What s Next in the Pharma World Watch out for J J s fourth quarter and full year 2018 earnings results and pipeline and regulatory updates next week  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny-200377096,200377096
171818,393334,LLY,Pacira s Study On Exparel Label Expansion Meets Endpoints,opinion,"Shares of Pacira Pharmaceuticals  Inc    NASDAQ PCRX   went up 2 62  after the company announced that the phase IV study on its lead drug Exparel in patients undergoing Cesarean section  C section  achieved its primary endpoint  with a statistically significant reduction in total postsurgical opioid consumption through 72 hours  P 0 05  
Exparel also achieved statistical significance for reduction in pain intensity through 72 hours  Shares of the company have declined 4 9  in the past year compared with the  s decline of 19 8  

We remind investors that Exparel is a liposome injection of bupivacaine  which is indicated for single dose administration into the surgical site to produce postsurgical analgesia  In June 2018  the FDA also approved Exparel label to include administration via nerve block for prolonged regional analgesia  With this approval  Exparel is the first long acting  single dose nerve block available for patients undergoing upper extremity surgeries  such as total shoulder arthroplasty or rotator cuff repair 
The study also achieved statistical significance for relevant additional endpoints pre specified in the statistical analysis plan to better characterize the clinical benefit of the opioid reduction  includingtotal opioid consumption at one and two weeks  following C section and percentage of opioid spared patients  which was the composite endpoint In the study  patients undergoing elective C section and given spinal anesthesia were randomized to receive Exparel or the active comparator bupivacaine HCl  Patients in the Exparel arm were administered a transversus abdominis plane  TAP  field block with 10 mL Exparel admixed with 10 mL 0 25  bupivacaine HCl and 10 mL normal sterile saline injected bilaterally  Patients in the active comparator arm received a TAP field block with 10 mL 0 25  bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally 
The study showed that when added to the standard of care  an Exparel TAP block provided a superior long acting field block that not only adequately controlled patients  pain following C section  but also greatly reduced their need for opioids The company is also conducting a phase IV study of Exparel in spinal fusion surgery  The company is also launching a series of phase IV studies in soft tissue procedures  These studies will assess Exparel as part of its multimodal protocol for colon cancer and breast reconstruction surgery 
The company s efforts to expand Exparel s label to boost sales are encouraging 
Exparel sales were  82 2 million in the third quarter of 2018  rising 23  year over year Pacira Pharmaceuticals  Inc  Price

   Zacks Rank and Stocks to Consider
Pacira currently carries a Zacks Rank  3  Hold  
Some better ranked stocks worth considering are Merck   Co   Inc    NYSE MRK    AbbVie Inc    NYSE ABBV   and Eli Lilly and Co    NYSE LLY    While Merck sports a Zacks Rank  1  Strong Buy   AbbVie and Lilly carry a Zacks Rank  2  Buy   You can see  
Merck s earnings per share estimates have increased from  4 28 to  4 33 for 2018 and from  4 65 to  4 69 for 2019 over the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 3 96  
AbbVie s earnings per share estimates have increased from  7 86 to  7 93 for 2018 and over the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 3 54  
Lilly s earnings per share estimates have increased from  5 47 to  5 58 for 2018 and from  5 78 to  5 87 for 2019 over the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 10 03  
 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/paciras-study-on-exparel-label-expansion-meets-endpoints-200376879,200376879
171819,393335,LLY,Lilly Stops Lartruvo Promotion As Confirmatory Study Fails,opinion,"Eli Lilly and Company   NYSE LLY   announced that a phase III study  evaluating Lartruvo  olaratumab  in combination with doxorubicin for treating metastatic soft tissue sarcoma  STS   failed to meet the primary endpoint of overall survival  OS   The phase III ANNOUNCE study examining Lartruvo plus doxorubicin   standard of care chemotherapy   compared with doxorubicin alone  was unable to confirm the clinical benefit of OS within full study population as well as in leiomyosarcoma  LMS  sub population  In both study arms  there was no difference in survival rate for either population 
Shares of Lilly were down 2 16  following the news  However  the stock has surged 36 5  in the past year against the  decline of 0 7  

 
We would like to remind investors that in October 2016  the FDA granted an approval to Lartruvo combined with doxorubicin for treating adult patients with advanced STS  Back then  the Lartruvo combo showed an OS benefit  which led to accelerated approval in the United States and a conditional marketing authorization in the EU  which was contingent upon verification of clinical benefit in a confirmatory study 
However  data from this confirmatory ANNOUNCE analysis failed to validate clinical benefit  Consequently  Lilly decided to suspend the promotion of Lartruvo while in discussion with global regulators to determine the next steps for the drug 
The company plans to present data from this study at an upcoming medical conference and publish the results in a medical journal 
Following this unexpected development  Lilly has decided to book a pre tax charge in the  70 90 million range with regard to Lartruvo during first quarter 2019  This in turn  will leave an impact on Lilly s 2019 earnings per share  EPS  guidance by  0 17  EPS for 2019 is expected in the band of  5 52  5 62 on a reported basis and  5 90  6 on a non GAAP basis  Lilly is scheduled to announce fourth quarter and 2018 earnings on Feb 13  2019 
In the first nine months of 2018  Lartruvo generated sales of 221 2 million  soaring 53 6  year over year  Lartruvo is also being probed under phase II study in combination with gemcitabine and docetaxel for the treatment of advance STS 
Zacks Rank   Other Stocks to Consider
Lilly currently carries a Zacks Rank  2  Buy   Other top ranked stocks in large cap pharma include H Lundbeck A S   OTC HLUYY    Novo Nordisk  CO NOVOb  A S   NYSE NVO   and Novartis AG   NYSE NVS    While H Lundbeck sports a Zacks Rank  1  Strong Buy   Novo Nordisk and Novartis carry a Zacks Rank of 2  You can see  
H Lundbeck s earnings estimates have been raised 5 2  for 2019 over the past 60 days 
Novo Nordisk s earnings estimates have been revised 2 4  upward for 2019 over the past 60 days 
Novartis  earnings estimates have moved 0 4  north for 2019 over the past 60 days  The stock has inched up 2 3  in a year 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits
overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/lilly-stops-lartruvo-promotion-as-confirmatory-study-fails-200377734,200377734
171821,393337,LLY,J J s  JNJ  Q4 Earnings Beat  2019 Sales Forecast Soft,opinion,Johnson   Johnson s   NYSE JNJ   fourth quarter 2018 earnings came in at  1 97 per share  which beat the Zacks Consensus Estimate of  1 95 and increased 13 2  from the year ago period driven by higher revenues and better operating margins Adjusted earnings excluded after tax intangible amortization expense and some special items  Including these items  J J reported fourth quarter earnings of  1 12 per share against loss of  3 99 per share in the year ago quarter Sales came in at  20 39 billion  beating the Zacks Consensus Estimate of  20 1 billion  Sales increased 1  from the year ago quarter  reflecting an operational increase of 3 3  and an unfavorable currency impact of 2 3  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 3  on an operational basis  less than 6 1  increase seen in the previous quarter  Continued growth in the Pharmaceutical segment offset a softer performance in the Consumer and Medical Devices units Fourth quarter sales grew 1 5  in the domestic market to  10 63 billion and 0 4  in international markets to  9 77 billion  reflecting 5 1  operational growth and 4 7  negative currency impact Segment DetailsJ J s Pharma segment continued to perform well despite the impact of biosimilars on Remicade sales Pharmaceutical segment sales rose 5 3  year over year to  10 19 billion  reflecting 7 2  operational growth and 1 9  negative currency impact as sales rose in both domestic and international markets  Sales in the domestic market rose 2 8  to  5 94 billion  International sales grew 8 9  to  4 25 billion  operational increase of 13 7    Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 7 2   less than 8 2  in the previous quarter The strong performance was led by the company s oncology portfolio  Worldwide sales of J J s cancer drugs rose 22 1  in the quarter J J s cancer drugs like Imbruvica and Darzalex continued to perform well  Core products like Stelara and Invega Sustenna also contributed to growth  However  sales of some other key drugs like Simponi Simponi Aria and Xarelto declined in the quarter  Sales of Zytiga slowed down significantly from the previous quarter Imbruvica sales rose 34 7  to  703 million in the quarter  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV    Darzalex sales rose 57 4  to  584 million in the quarter  Stelara sales rose 33 6  to  1 44 billion in the quarter  Invega Sustenna sales rose 10 1  to  763 million in the quarter In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  667 million  up 9 3  year over year Simponi Simponi Aria sales declined 1 6  to  482 million in the quarter Zytiga sales rose 4 1  to  786 million in the quarter  Sales of Invokana Invokamet declined 14 6  to  228 million  Xarelto sales declined 14 4  in the quarter to  608 million Sales of Procrit Eprex declined 4 7  to  221 million in the quarter Sales of Remicade were down 15 6  in the quarter to  1 24 billion due to competition from biosimilars   While U S  sales declined 21 4   U S  exports went down 21 7   Remicade sales rose 9 7  in international markets  Please note that J Jmarkets Remicade in partnership with Merck   NYSE MRK   Newly launched Tremfya recorded sales of  175 million in the quarter compared with  171 million in the third quarter Medical Devices segment sales came in at  6 67 billion  down 4 4  from the year ago period  It included an operational decrease of 2 2  and negative currency movement of 2 2  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 3 3   better than 2 9  in the previous quarter Domestic market sales declined 3  year over year to  3 2 billion  International market sales decreased 5 6   operational decrease of 1 4   year over year to  3 45 billion The Consumer segment recorded revenues of  3 54 billion in the reported quarter  almost flat year over year  Moreover  on an operational basis  Consumer segment sales increased 3 3   which was offset by unfavorable foreign currency movement of 3 4  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 3 8  worldwide  a significant deceleration from 6 1  the previous quarter Sales in the domestic market rose 7 3  from the year ago period to  1 48 billion  Meanwhile  the international segment recorded a decline of 4 8  to  2 06 billion  The operational increase of 0 8  was offset by negative currency impact of 5 6  in the quarter 2018 ResultsFull year 2018 sales rose 6 7  to  81 58 billion  beating the Zacks Consensus Estimate of  81 36 billion and came ahead of the guided range of  81 to  81 4 billionAdjusted earnings for 2018 were  8 18 per share  exceeding the Zacks Consensus Estimate of  8 16 and up 12 1  year over year  Earnings were at the higher end of the guided range of  8 13    8 18 per share Forecast for 2019 J J issued earnings and sales guidance for 2019 J J expects 2019 adjusted earnings per share in the range of  8 50    8 65  The guidance range reflects an operational growth rate between 5 7  and 7 6   The Zacks Consensus Estimate for 2019 is  8 64 Revenues are expected in the range of  80 4 to  81 2 billion  which falls short of the Zacks Consensus Estimate for revenues of  82 61 billion The sales guidance reflects operational constant currency sales growth in the range of 0  to 1   Organically  excluding the impact of acquisitions and divestitures  sales growth is expected to be in the range of 2  to 3  on an operational basis Our TakeJ J beat estimates for both earnings and sales in the fourth quarter of 2018  pushing its shares up 1  in pre market trading  The sales guidance for 2019 was however below expectations J J s Pharma segment performed better than the market in 2018 despite the impact of biosimilars on Remicade sales  We believe that new products in all segments  successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from acquisitions will continue to drive the top line in 2019 The stock has depreciated 11 8  in the past year compared with a decrease of 0 8  recorded by the  A recent allegation by a Reuters article  which claimed that the company knew for decades that its baby powders contained asbestos  hasbeen an overhang on the stock s price lately  J J is fighting thousands of lawsuits alleging that its talc baby powders contain asbestos  which causes users to develop ovarian cancer  J J  in a statement  called the reports by Reuters  one sided  false  and inflammatory   J J said that independent tests by regulators  academic institutions and leading labs have proven that its talc based products never contained asbestos J J currently has a Zacks Rank  3  Hold   You can see   A better ranked large cap pharma stock is Eli Lilly   Company   NYSE LLY    holding a Zacks Rank  2  Buy  Lilly s earnings estimates have increased 1 4  for 2019 over the past 60 days  The company s shares have surged 36 5  in the past year Johnson   Johnson Price  Consensus and EPS Surprise   Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-q4-earnings-beat-2019-sales-forecast-soft-200377991,200377991
171847,393363,LLY,Eli Lilly  LLY  Dips More Than Broader Markets  What You Should Know,opinion,"Eli Lilly  NYSE LLY  closed at  114 68 in the latest trading session  marking a  1 29  move from the prior day  This move lagged the S P 500 s daily loss of 0 53   Meanwhile  the Dow lost 0 36   and the Nasdaq  a tech heavy index  lost 0 94  
Prior to today s trading  shares of the drugmaker had gained 1 15  over the past month  This has outpaced the Medical sector s loss of 3 96  and the S P 500 s loss of 1 47  in that time 
Investors will be hoping for strength from LLY as it approaches its next earnings release  which is expected to be January 30  2019  In that report  analysts expect LLY to post earnings of  1 37 per share  This would mark year over year growth of 20 18   Meanwhile  our latest consensus estimate is calling for revenue of  6 37 billion  up 3 34  from the prior year quarter 
Any recent changes to analyst estimates for LLY should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 2 24  higher  LLY is currently sporting a Zacks Rank of  2  Buy  
Valuation is also important  so investors should note that LLY has a Forward P E ratio of 19 62 right now  For comparison  its industry has an average Forward P E of 14 51  which means LLY is trading at a premium to the group 
We can also see that LLY currently has a PEG ratio of 1 67  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Large Cap Pharmaceuticals stocks are  on average  holding a PEG ratio of 1 92 based on yesterday s closing prices 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 49  which puts it in the top 20  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-dips-more-than-broader-markets-what-you-should-know-200375409,200375409
171848,393364,LLY,Bristol Myers  Drug Combination Gets EU Nod For Renal Cancer ,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the European Commission approved the immuno oncology combination of Opdivo and low dose Yervoy for the first line treatment of patients with intermediate  and poor risk advanced renal cell carcinoma  RCC   the most common type of kidney cancer  The approval was supported by results from the phase III CheckMate 214 study  which stopped following a planned interim analysis  The planned interim analysis showed that the combination of Opdivo  3 mg kg   plus low dose Yervoy  1 mg kg  demonstrated a significant increase in overall survival  OS   with 37  decreased risk of death in intermediate  and poor risk patients compared to a current standard of care  Pfizer s   NYSE PFE   Sutent  sunitinib     The combination of Opdivo plus Yervoy in first line RCC was approved in the United States in April last year  The combination is now approved for three types of tumors   renal  colorectal and melanoma  This should boost sales further  given the market potential Bristol Myers  shares have declined 13 7  in the past year  against the  s growth of 5 1   We note that Opdivo became the first PD 1 immune checkpoint inhibitor to gain regulatory approval in July 2014  It is currently approved in several countries  including the United States  the EU and Japan  for several cancer indications Meanwhile  the company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion of the drug into additional indications would give the product an access to a higher patient population and increase its commercial potential significantly We remind investors that Bristol Myers has offered  74 billion in cash and stock to acquire another cancer giant Celgene   NASDAQ CELG    The acquisition will enable Bristol Myers to diversify its portfolio  The combined company will have a dominant position in the oncology  immunology and inflammation spaces  In another big deal  Lilly   NYSE LLY   offered to take over Loxo Oncology for  8 billion to expand its oncology portfolio into precision medicines or targeted therapies Bristol Myers Squibb Company Price   Zacks RankBristol Myers currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-drug-combination-gets-eu-nod-for-renal-cancer-200375687,200375687
171862,393378,LLY,Nektar  ImaginAb Enter Into Immuno Oncology Collaboration,opinion,"Nektar Therapeutics   NASDAQ NKTR   has entered into a non exclusive license and clinical trial collaboration with privately held ImaginAb Inc  to support its immuno oncology pipeline  The deal will allow Nektar to use ImaginAb s CD8 ImmunoPET technology  which measures the density and distribution of tumor CD8  T cells in cancer patients ImaginAb s technology will allow Nektar to get a whole body view of immune system activity without using any invasive procedures on patients  This  in turn  will improve the company s understanding and help it rationally develop new immunotherapies The CD8 ImmunoPET technology can measure CD8  T cells in multiple tissues  including all target and non target tumor lesions  simultaneously  Notably  Nektar s immuno oncology pipeline consists of candidates that work by targeting CD8  T cells  For the immuno oncology therapies  this biomarker will potentially help expedite the development process However  Nektara and ImaginAb did not disclose the financial terms of the agreement In the past six months  shares of Nektar have lost 45 8  compared with the  s 20 6  decline Nektar is also developing several immuno oncology candidates  with NKTR 214 being a primary candidate among them Earlier  the company had entered into collaborations to develop NKTR 214 in combination with other therapies In November 2018  the company entered into clinical collaboration with Pfizer   NYSE PFE   to develop doublet or triplet combination therapies of NKTR 214 in several cancer indications  including metastatic castration resistant prostate cancer and squamous cell carcinoma of the head and neck Additionally  it has a collaboration with Bristol Myers   NYSE BMY   to evaluate NKTR 214 in combination with Bristol Myers  Opdivo alone or with Yervoy in more than 20 indications  In September 2018  Nektar and partner  Bristol Myers  initiated a phase III study to evaluate NKTR 214 plus Opdivo for treating previously untreated unresectable or metastatic melanoma Nektar s co development collaboration with Eli Lilly   NYSE LLY   to develop another immuno oncology candidate  NKTR 358  is also noteworthy Nektar Therapeutics Price
    Zacks RankNektar currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/nektar-imaginab-enter-into-immunooncology-collaboration-200372948,200372948
171863,393379,LLY,Pharma Stock Roundup  BMY To Buy CELG For  74B  MRK Gets Rights To NASH Candidate,opinion,"The pharma sector was relatively lying low this week with some news grabbing attention only towards the end  Top stories this week were Bristol Myers    NYSE BMY   offer to buy cancer giant Celgene Corporation   NASDAQ CELG   in a cash and stock deal worth  74 billion and Merck s   NYSE MRK   decision to exercise the option to in license a NASH candidate from partner NGM Biopharmaceuticals Recap of the Week s Most Important HeadlinesBristol Myers to Acquire Celgene for  74B  Bristol Myers began the year announcing one of the largest merger deals in the biotech pharma sector  The company is acquiring cancer drug specialist Celgene in a cash stock deal valued at  74 billion  Per the transaction  each Celgene shareholder will receive a consideration of  102 43  comprising one share of Bristol Myers  valued at  52 43 on Jan 2  2019  and  50 per share in cash  The deal makes strategic sense as the combination will create a premier innovative biopharma giant with leading franchises in oncology  immunology and inflammation and cardiovascular disease  The combined entity with have nine products generating more than  1 billion in sales and is expected to launch six products in the near term  Moreover  the consolidated company will have a deep and diverse early and late stage pipeline  Following the transaction  Bristol Myers is expected to realize cost synergies of approximately  2 5 billion by 2022  The company also separately issued adjusted earnings guidance for 2019 in the range of  4 10  4 20  While shares of Bristol Myers decline  that of Celgene were up on announcement of the news Meanwhile  Bristol Myers tyrosine kinase inhibitor   in combination with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia  Sprycel is also approved for Ph  chronic myeloid leukemia in chronic phase in pediatric patients Merck In Licenses NASH Candidate  Keytruda Gets 5 Approvals in Japan  Merck exercised its option to in license a NASH and type II diabetes candidate  NGM313  now renamed as MK 3655 from NGM Biopharmaceuticals  Inc  for  20 million  With this deal   to develop  manufacture and commercialize NGM313  a once monthly insulin sensitizer  Merck s one time option was triggered as NGM completed a phase Ib proof of concept study on the candidate  Data from the study presented last November showed that a single dose of the medicine led to a statistically significant reduction in liver fat content  LFC  and improvements in multiple metabolic parameters after five weeks of treatment  Merck plans to initiate a phase IIb study on the candidate while NGM Biopharmaceuticals retains the option to take a 50  cost and profit sharing partnership for NGM313 once the candidate enters late stage development Meanwhile  the company s PD 1 inhibitor Keytruda clinched five new label expansion approvals in Japan  These included three approvals as a first line treatment option for advanced non small cell lung cancer  NSCLC  and the other two as an adjuvant therapy for melanoma and in advanced microsatellite instability high  MSI H  tumors Pfizer Starts Pivotal Study on Alopecia Areata Candidate  Pfizer   NYSE PFE   initiated a  on its oral JAK3 inhibitor candidate  PF 06651600  for the treatment of moderate to severe alopecia areata   Alopecia areata is a chronic autoimmune skin disease causing hair loss   often patchy   on the scalp  face or body  Top line data from a phase IIa study on PF 06651600 was presented in September 2018  The study met the primary endpoint of improving hair re growth on the scalp as compared to baseline over 24 weeks  regimen AbbVie Inks New Immunotherapy Deal  AbbVie   NYSE ABBV   signed a strategic collaboration with private cancer biotech  Tizona Therapeutics  to develop and commercialize immunotherapies targeting the CD39 enzyme including pre clinical candidate TTX 030  AbbVie plans to begin clinical studies on TTX 030 in the first quarter of 2019  The company made an upfront payment of  105 million to Tizona for the license to its CD39 program while also buying an equity stake in the company The NYSE ARCA Pharmaceutical Index declined 1 4  in the last four trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  
 
Here is how the seven major stocks performed in the last four trading sessions 
 
 All the stocks except AstraZeneca   NYSE AZN   were in the red in the last four trading sessions with Bristol Myers declining the most  10 5    AstraZeneca rose 2 8  in the same period In the past six months  Lilly   NYSE LLY   has been the biggest gainer  28 5   while Bristol Myers declined the most  19 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early See Zacks  3 Best Stocks to Play This Trend   ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-bmy-to-buy-celg-for-74b-mrk-gets-rights-to-nash-candidate-200372973,200372973
171875,393391,LLY,Pfizer Xtandi Succeeds In Late Stage Prostate Cancer Study,opinion,"Pfizer Inc    NYSE PFE   and its Japanese partner Astellas Pharma announced that a phase III study   ARCHES   evaluating prostate cancer drug  Xtandi  enzalutamide   met its primary endpoint  The study was evaluating the drug in combination with androgen deprivation therapy   ADT   as a treatment for metastatic hormone sensitive prostate cancer  mHSPC  Data showed that the Xtandi combination therapy significantly improved radiographic progression free survival  rPFS   the primary endpoint  in the expanded patient population compared to ADT therapy alone  The safety profile of the drug was consistent with previously observed profiles in clinical studies evaluating it in castration resistant prostate cancer   CRPC    A detailed data will be presented at an upcoming medical congress Notably  Xtandi is already approved as a treatment for metastatic and non metastatic CRPC in the United States  A potential approval based on the above mentioned data in mHSPC patients will expand the patient population to include men with prostate cancer that has progressed outside the prostate gland but still responds to treatment to lower testosterone Pfizer s efforts to expand the label of the drug in new cancer patient population are commendable  Currently  the company is evaluating Xtandi in another late stage study   EMBARK   in hormone sensitive prostate cancer as well as mid stage studies for advanced breast cancer and hepatocellular carcinoma So far this year  shares of Pfizer have gained 15 8  compared with the  s 1 5  growth In a separate press release  the company announced that it is discontinuing the phase IIb STRIVE study evaluating its Staphylococcus aureus  S  aureus  multi antigen vaccine candidate  PF 06290510  The decision was based on recommendation from an independent Data Monitoring Committee  following a planned interim analysis Based on the data from STRIVE data  the committee concluded that there is a low statistical probability of successful completion of a phase III study on the candidate  At present  Pfizer is evaluating steps for potential future development of any S  aureus vaccine Pfizer Inc  Price
    Zacks Rank   Stocks to ConsiderPfizer has a Zacks Rank  3  Hold   You can see  Some other large cap pharma stocks worth considering are Eli Lilly and Company   NYSE LLY    Merck   Co   Inc    NYSE MRK   and Roche   OTC RHHBY    each carrying a Zacks Rank  2  Buy  Shares of Lilly have returned 29 4  this year so far  Estimates for 2018 and 2019 have increased 2  and 0 2   respectively  over the past 60 days Shares of Merck have surged 30 6  this year so far  Over the past 60 days  earnings estimates have risen 1 4  and 1 3   respectively  for 2018 and 2019 Over the past 60 days  Roche s earnings estimates have risen 0 8  and 2 6   respectively  for 2018 and 2019 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/pfizer-xtandi-succeeds-in-latestage-prostate-cancer-study-200370231,200370231
171877,393393,LLY,Bayer  BAYRY  Faces Generic Threat   Rising Competition ,opinion,We issued an updated report on Bayer  DE BAYGN  AG   OTC BAYRY   on Dec 24 Bayer AG is a life science company with core competencies in the areas of health care and agriculture Bayer is facing generic threats competition for many of its products  including the Yaz franchise  oral contraceptives   The genericization of key drugs would negatively impact revenues  We expect the declining Yaz sales trend to persist  Continued weak performance of key drugs could impact the company s top line and pull down the stock Bayer is expecting several pipeline and regulatory related news in the coming quarters  Any adverse pipeline related news has the potential to impact the stock adversely In August 2018  Bayer and partner Johnson and Johnson   NYSE JNJ   announced data from two late stage studies  wherein blood thinner drug  Xarelto failed to show statistical benefits  These studies were being evaluated to expand the drug s eligible patient population  Data from the two phase III studies   MARINER and COMMANDER HF   showed no significant difference between Xarelto and placebo for the primary efficacy endpoints  The MARINER and COMMANDER HF studies are part of Xarelto s large clinical development program EXPLORER  which evaluates the potential role of Xarelto in treating a wide range of critical medical needs Bayer s dependence on its pharmaceutical segment for growth is a concern  Bayer s stock has declined 44 8  year to date  against the  s growth of 1 8  Last month  the company announced a restructuring plan to streamline business and improve efficiency  The company plans to exit its Animal Health business  and management is currently assessing various options for this business  The decision to exit this business comes as part of the company s plan to focus on its core businesses of Pharmaceuticals  Consumer Health and Crop Science The company is making efforts to revive its Consumer Health division to target market growth in the coming years and improve profitability  The measures include a planned exit from product categories  which were not suiting the company s business model  In addition to the previously announced divestment of prescription dermatology products  Bayer will review its strategic options in the coming months  and most likely exit its sun care  Coppertone  and foot care  Dr  Scholl s  product lines  The company intends to focus on driving growth in its core Consumer Health categories Bayer is also planning to divest its 60  interest in German site services provider Currenta  as this business does not align with its existing model anymore  given the carve out of Covestro Bayer expects annual savings of  2 6 billion by 2022  as a result of its planned efficiency and structural measures  including the synergies expected from the acquisition of Monsanto  NYSE MON   We remind investors that in June 2018  Bayer acquired Monsanto for  63 million  The combined business is expected to boost Bayer s Crop Science segment Concurrently  the company plans to reduce its headcount by 12 000 118 200 by 2021  Majority of these job cuts will be in Germany However  the company has also received some new approvals  lately  The company also received new approvals for its candidates  In November  the company received approval by the FDA for Vitrakvi  larotrectinib   the first oral TRK inhibitor  It is approved for the treatment of adult and pediatric patients with solid tumors  with a neurotrophic receptor tyrosine kinase  NTRK  gene fusion without a known acquired resistance mutation  which are either metastatic or where surgical resection will likely result in severe morbidity  and have no satisfactory alternative treatments or have progressed following treatment In November 2018  it also received approval for Jivi  BAY94 9027  by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients aged 12 years or older with hemophilia A  Bayer Aktiengesellschaft Price    Zacks Rank   Stocks to ConsiderBayer currently carries a Zacks Rank  5  Strong Sell  Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY   and Eli Lilly and Company   NYSE LLY    Both the companies sport a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 84 to  3 87 for 2018 and  4 03 to  4 14 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 11 99  Lilly s earnings per share estimates have increased from  5 47 to  5 59 for 2018 and  5 78 to  5 90 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 10 03   Share price of the company has increased 28 6  year to date Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-25,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-faces-generic-threat--rising-competition-200371027,200371027
171878,393394,LLY,Forget J J  Buy These 3 Big Drug Stocks Instead In 2019,opinion,Johnson   Johnson s   NYSE JNJ   stock has declined more than 14  since Reuters reported that the pharma giant knew for decades that its baby powders contained asbestos J J faces thousands of lawsuits related to its baby powders in the United States  These allege that its talc based products  including its baby powders  contain asbestos  which causes its users to develop ovarian cancer The Reuters article informed that a scrutiny of J J s internal reports and other confidential documents showed that from 1971 to early 2000s  its raw talc and finished powders at times tested positive for trace amounts of asbestos In response  J J issued a statement wherein it called the reports by Reuters  one sided  false  and inflammatory   In an interview to CNBC  J J s chief executive officer  CEO   Alex Gorsky  said that the company  unequivocally  believes that its talc baby products do not contain asbestos  a fact demonstrated in thousands of tests and studies conducted over decades on nearly 100k patients  Meanwhile  J J also got ads published in leading newspapers  which stressed that the company has scientific evidence that its talc is safe It has been suggested that a link between talc and cancer may be due to the fact that talc and asbestos often occur together in deposits and get inadvertently mixed J J is in big trouble now after losing several billion in market capitalization since the article was published  Though the company might be able to put the issue behind it  as it has more than  30 billion of cash and baby products comprise only 2  of its sales  it will take some time for the stock to recover after the massive sell off In such a scenario  it is a good idea for near term investors to avoid this Zacks Rank  4  Sell  stock  Moreover  so far this year  the stock has declined 9 3   underperforming the industry s decline of 1 2   Its earnings estimates for 2019 have gone down by 0 2  over the past 60 days   You can see   Instead  investors can focus on three large drug stocks that may prove to be good buys  All these stocks carry a Zacks Rank  2  Buy  and have seen their share price and earnings estimates rise this year  Moreover  the industry features among the top 32  of the 257 Zacks ranked industriesA chart showing the share price movement of the three stocks this year so far is given below   Eli Lilly   Company   NYSE LLY  Lilly s earnings estimates have increased almost 3  for 2019 over the past 90 days  The company s shares have increased 31 5  this year so far Lilly s new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo and Verzenio are driving sales growth   The company is also on a strong footing in terms of its pipeline with several positive late stage data readouts this year along with various regulatory approvals  A key regulatory success for Lilly was the FDA approval of Emgality galcanezumab  a calcitonin gene related peptide  CGRP  antibody for migraine prevention  which could emerge as a significant contributor to long term growth Several key regulatory and pipeline events are expected in 2019  Any positive outcome will push up share price further This year  Lilly also added promising new assets through business development deals including pancreatic cancer candidate  pegilodecakin  which was added with the acquisition of ARMO Biosciences  Meanwhile  the separation of its animal health unit  Elanco  via an IPO  is a prudent decision in our viewas the unit was underperforming Merck   Co   Inc    NYSE MRK  Shares of Merck have also risen 31 5  this year so far  Merck s earnings estimates for 2019 have moved up 1 7  in the past 90 days Strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda aided the company  In a very short span of time Keytruda has become Merck s largest product  It is already approved for use in 12 indications across eight different tumor types in the United States  In fact  the Keytruda development program is also progressing rapidly  Several regulatory decisions for new indications in the United States as well as in Europe are due in 2019  which  if approved  can further boost sales Key recent drug approvals for Merck include Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection  Merck also gained several label expansion approvals for Keytruda and another cancer drug  Lynparza  which it markets in partnership with AstraZeneca   NYSE AZN   All these new drugs and line extension approvals can boost the company s pharmaceuticals sales in the future quarters Merck s animal health and vaccine products are also performing strongly and remain core growth drivers for Merck Merck also announced positive data from several late stage studies  mainly evaluating Keytruda for further line extensions  Merck also signed a co development deal with Japan s Eisai Co   Ltd for the latter s tyrosine kinase inhibitor  Lenvima  It also agreed to buy Viralytics Limited  an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers  which should strengthen its oncology portfolio Novartis AG   NYSE NVS   Shares of Novartis have risen 1  this year so far  Merck s earnings estimates for 2019 have gone up 0 5  in the past 60 days Novartis has a strong oncology portfolio  which continues to boost sales  The strong performance of Cosentyx and Entresto continues to boost performance  Novartis restructured its business and plans to focus on becoming a core drug focused company  powered by data and digital technologies  The company is looking to solidify its presence in the gene therapy space  It acquired small biotechs AveXis and Endocyte this year  which has strengthened its pipeline In addition to the stocks discussed above  would you like to know about our 10 top tickers to buy and hold for the entirety of 2019  These 10 are painstakingly handpicked from over 4 000 companies covered by the Zacks Rank  They are our primary picks poised to outperform in the year ahead ,2018-12-26,Zacks Investment Research,https://www.investing.com/analysis/forget-jj-buy-these-3-big-drug-stocks-instead-in-2019-200371249,200371249
171879,393395,LLY,Teva Stock Rises On Patent Settlement With Neos Therapeutics,opinion,"Shares of Teva Pharmaceutical Industries Ltd    NYSE TEVA   rose 8 4  on the news that it has entered into a confidential settlement and licensing agreement with Neos Therapeutics  Inc    NASDAQ NEOS   for resolving all ongoing patent litigations related to the launch of the generic version of the latter s Cotempla XR ODT  Teva had filed an abbreviated new drug application   ANDA   looking for approval of the generic version with the FDA last year The drug is an extended release  orally disintegrate tablet approved for the treatment of attention deficit hyperactivity disorder   ADHD   in pediatric patients The company s shares have decreased 16 6  so far this year compared with the  s decline of 28 6    Per the terms of the agreement  Neos Therapeutics has granted Teva rights to manufacture and commercialize a generic version of its ADHD drug beginning Jul 1  2026 or earlier under certain circumstances However  no further details are available  The agreement is due to be submitted to the Federal Trade Commission and the U S  Department of Justice Neos Therapeutics is a small drug company specializing in modified release drug delivery technology platforms  The company has three approved drugs  including Cotempla XR ODT  All of them are available for the treatment of ADHD Teva is facing significant challenges in the form of accelerated generic competition for its key multiple sclerosis injection  Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from generic launches and a massive debt load  These settlements provide a future roadmap for growth of the company s generics portfolio  Teva already has several generics in its ADHD portfolio including Lilly s   NYSE LLY   Strattera  Novartis    NYSE NVS   Focalin and Shire s Intuniv Teva Pharmaceutical Industries Ltd  Price
    Zacks RankTeva currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-26,Zacks Investment Research,https://www.investing.com/analysis/teva-stock-rises-on-patent-settlement-with-neos-therapeutics-200371328,200371328
171880,393396,LLY,4 Trade Ideas For Eli Lilly  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Eli Lilly  NYSE LLY    LLY  started higher in February and broke above resistance in July  That accelerated the move to consolidation in August  It has held over support since then  making higher highs along the way  Now it is moving higher up off of support and moving over the 20 day SMA 
The RSI is rising and over the mid line with the MACD about to cross up and near a move to positive  There is room to the top of the Bollinger Bands above  and resistance at 116 and 119  Support lower comes at 111 75 then 107 50 then 104 25  The stock pays a dividend and begins trading ex dividend February 14th  The company is expected to report next on February 13th 
The January options chain has biggest open interest at the 110 strike  The February chain shows the 120 call as the biggest open interest  In March the open interest is just starting to build 
Eli Lilly  Ticker   LLY

Trade Idea 1  Buy the stock on a move over 116 with a stop at 112 75 
Trade Idea 2  Buy the stock on a move over 116 and add a January 114 111   1 40  while selling the February 125 Calls  92 cents  to help fund it 
Trade Idea 3  Buy the January February 120 Call Calendar   1 60 
Trade Idea 4  Buy the February 105 120 bull Risk Reversal  84 cents 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which with one trading day left in the year sees equity markets putting in a strong case for a reversal this week  They are still a long way from confirming a bottom though and not just a bear flag build 
Elsewhere look for Gold to continue in its uptrend while Crude Oil may possibly pause in the downtrend  The US Dollar Index continues to consolidate sideways while US Treasuries pause in their uptrend  The Shanghai Composite and Emerging Markets continue to show an easier path to the downside 
Volatility looks to remain elevated keeping the bias lower for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts showed a strong bounce during the week but not enough to do anything to alter the current downtrends  Very short term uptrends are beginning  but it is too soon to declare a bottom  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-12-31,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-eli-lilly-bonus-idea-200371872,200371872
171906,393422,LLY,Incyte  INCY  Collaborates With Innovent For 3 Candidates,opinion,"Incyte   NASDAQ INCY   announced that it entered into a collaboration agreement with China based Innovent Biologics  Inc 
Both the companies have entered into the agreement through their respective subsidiaries  for the development of three clinical stage product candidates   pemigatinib  FGFR1 2 3 inhibitor   itacitinib  JAK1 inhibitor  and parsaclisib  PI3K  inhibitor   All the three candidates were discovered and developed by Incyte 
Financial Terms of the Agreement
Per the terms  Innovent will pay Incyte  40 million in cash  up front  In addition  Incyte is eligible to receive an additional  20 million in connection with the first investigational new drug  IND  application by Innovent in China  expected in 2019   In exchange  Innovent will receive the rights to develop and commercialize the three candidates in hematology and oncology in Mainland China  Hong Kong  Macau and Taiwan 
Moreover  Incyte will be eligible to receive up to  129 million in potential development and regulatory milestones  and up to  202 5 million in milestone achievements  Further  Incyte is eligible to receive tiered royalties from the high teens to the low twenties on future sales of products resulting from the collaboration  Meanwhile  Incyte retains an option to assist in the promotion of the three product candidates in China 
Strategic Value of the Transaction
Incyte expects Innovent s experienced leadership team and sizeable clinical network to expand the clinical program for itacitinib  pemigatinib and parsaclisib  A successful development of these candidates will strengthen Incyte s portfolio 
Our Take
The deal will provide Incyte with an influx of funds to further develop its pipeline  The company suffered a couple of pipeline setbacks  and hence is looking to strengthen the same 
The company suffered a huge setback with the failure of the phase III study  ECHO 301  as it was one of the most promising candidates for Incyte  evaluating epacadostat in combination with Merck s   NYSE MRK   Keytruda  Further  the approval of the 4mg dose of baricitinib  which the company is co developing with Eli Lilly   NYSE LLY    is also doubtful 
Incyte s stock has lost 30 4  in the year so far compared with the  s 20  decline 

 
Incyte s lead drug Jakafi continues to maintain momentum for the company as the underlying patient demand for the drug remains strong  Incyte s sNDA  seeking a label expansion of Jakafi for the treatment of steroid refractory acute graft versus host disease  GVHD   has been accepted for Priority Review by the FDA 
The agency has set a target action date of Feb 24  2019  An approval will further boost sales  Meanwhile  the REACH2 and REACH3 studies  evaluating steroid refractory acute and steroid refractory chronic GVHD  respectively  are ongoing in collaboration with Novartis   NYSE NVS    Incyte plans to enroll more than 300 patients in each of these studies  Data from these studies are expected in 2019 
However  Incyte s dependence on Jakafi is a concern 
Zacks Rank
Incyte currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-collaborates-with-innovent-for-3-candidates-200368849,200368849
171907,393423,LLY,Merck To Acquire Europe s Antelliq Group For  2 4 Billion,opinion,"Merck   Co   Inc    NYSE MRK   announced that it has reached a definitive agreement to acquire all the outstanding shares of French animal health company Antelliq Group for a reported 2 1 billion euros   2 38 billion  in cash  Merck will also bear Antelliq s debt of 1 15 billion euros   1 30 billion   which will be repaid upon closure of this transaction 
The takeover is expected to close in the second quarter of 2019  subject to customary closing conditions and the clearance by antitrust and competition law authorities 
Antelliq is a leading provider of digital animal identification  traceability and monitoring services to the animal health industry  The company generated sales of 360 million euros during the 12 month period ending September 30 
The acquisition is a good strategic fit for Merck as this will help it gain an access to a broader customer base and strengthen its Animal Health segment 
Shares of Merck have rallied 35 9  so far this year  outperforming the  increase of 5  

Over the years  Merck has seen consistent growth in its Animal Health segment and the buyout of Antelliq will complement the same to generate long term growth  Merck s Animal Health products have contributed almost 10  to its total revenues 
During the first nine months of 2018  Merck s Animal Health segment generated sales of  3 17 billion  reflecting an increase of 9 7  year over year  This upside was driven by high sales of Merck s companion animal products and livestock products  particularly ruminant and poultry products 
Merck is actively seeking acquisitions to build its long term portfolio  The company inked several licensing deals in the past few years and targets to snap up more such collaborations in the future  The June 2018 takeover of Australian company Viralytics Limited added Cavatak  the latter s experimental oncolytic immunotherapy  to Merck s cancer pipeline 
Meanwhile  in July 2017  Merck signed a profit sharing contract with AstraZeneca   NYSE AZN    which added two key assets  Lynparza selumetinib  to its oncology pipeline  Similarly  in March 2018  Merck struck a deal with Japan s Eisai to co develop and commercialize the latter s tyrosine kinase inhibitor  Lenvima  for several types of cancer 
Zacks Rank   Other Key Picks
Merck currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Co    NYSE BMY   and Eli Lilly and Co    NYSE LLY    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank of 2  You can see  
Bristol Myers  earnings estimates have been revised 6 3  upward for 2018 and 5 1  for 2019 over the past 60 days 
Lilly s earnings estimates have moved 2  north for 2018 and 0 2  for 2019 over the past 60 days  The stock has surged 32 6  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/merck-to-acquire-europes-antelliq-group-for-24-billion-200368860,200368860
171908,393424,LLY,Lilly s Taltz Outshines Humira In Psoriatic Arthritis Study,opinion,Eli Lilly   Company s   NYSE LLY   drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis  PsA  while also providing skin clearance in a head to head study comparing it with AbbVie  Inc  s   NYSE ABBV   blockbuster medicine Humira The primary endpoint of the phase IIb IV study   SPIRIT H2H   was the proportion of patients experiencing improved signs and symptoms of active PsA at week 24   This was measured by the proportion of patients simultaneously achieving at least 50  reduction in disease activity as defined by the American College of Rheumatology  ACR50  as well as the proportion of patients who achieve complete skin clearance   in other words  100  improvement from their baseline as measured by PASI 100 score The study met the primary and all major secondary endpoints  which were demonstrating non inferiority in ACR50 and superiority in PASI100 in Taltz compared with Humira  Detailed data from the study is expected to be presented at the upcoming scientific meetings Lilly s shares have rallied 28 3  this year so far compared with the  s increase of 5    Taltz was launched for the psoriatic arthritis indication in the United States last December and across some EU countries in 2018  It is also marketed for moderate to severe plaque psoriasis in adults  who are candidates for systemic therapy or phototherapy Taltz is an important revenue driver for Lilly  recording sales of  630 4 million in the first nine months of 2018  soaring 63  year over year  Data from the SPIRIT H2H study shows that doctors can comfortably prescribe Taltz as a first line biologic treatment for patients with active psoriatic arthritis  which may further increase demand for the drug Lilly is also conducting a head to head study to evaluate superiority of Taltz over J J s   NYSE JNJ   new drug  Tremfya  guselkumab   The study is likely to be completed by the end of next year Lilly currently carries a Zacks Rank  3  Hold   You can see  A better ranked large cap pharma stock is Merck   Co   Inc    NYSE MRK   with a Zacks Rank  2  Buy  Merck s earnings estimates have been revised 1 4  upward for 2018 and 1 3  for 2019 over the past 60 days  The stock has surged 33 7  this year so far 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/lillys-taltz-outshines-humira-in-psoriatic-arthritis-study-200369128,200369128
171939,393455,LLY,Bristol Myers To Study Opdivo In Combo With Vedanta s VE800,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that it has signed a collaboration deal with Massachusetts based  privately held Vedanta Biosciences  Inc  to evaluate its immuno oncology drug  Opdivo  in combination with Vedanta s lead microbiome based immuno oncology candidate  VE800 The collaboration study will evaluate Bristol Myers  PD 1 inhibitor  Opdivo  combined with VE800  a rationally defined human bacterial consortium for the treatment of patients with advanced or metastatic cancers The main idea of the study is to check whether the combination of Opdivo plus VE800 can improve outcomes for patients afflicted with advanced cancers As part of the transaction  Bristol Myers plans to make an equity investment in Vedanta Biosciences  The latter will control the VE800 program and retain the global research and development  R D  plus commercial rights of the same Shares of Bristol Myers have decreased 14 2  year to date against the  increase of 6 9   Notably  Bristol Myers has inked collaboration deals with several research institutes  small and large biotech and pharma companies including Johns Hopkins University  Johnson   Johnson   NYSE JNJ    AbbVie   NYSE ABBV    Lilly   NYSE LLY    Celgene  NASDAQ CELG   Nektar  Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments In November 2018  Bristol Myers signed a collaboration contract with Infinity Pharmaceuticals to evaluate the combination of Opdivo and the latter s investigational immunotherapy  IPI 549  for the treatment of advanced urothelial cancer  a type of bladder cancer  The main idea of the study is to check whether targeting the tumor microenvironment with IPI 549 will increase the activity of Opdivo for subjects suffering urothelial cancer We would like to remind investors that in July 2014  Opdivo became the first PD 1 immune checkpoint inhibitor to gain a regulatory approval  It is currently approved in several countries including the United States  the EU and Japan for several cancer indications Opdivo generated sales of  4 93 billion in the first nine months of 2018  reflecting a surge of 37  year over year  The drug continues to be a top revenue generator for the company Meanwhile  Bristol Myers is working on expanding the label of Opdivo further  Label expansion into additional indications would provide the product with access to a higher patient population and raise its commercial potential substantially Zacks RankBristol Myers currently carries a Zacks Rank  2  Buy   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-10,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-to-study-opdivo-in-combo-with-vedantas-ve800-200367018,200367018
171940,393456,LLY,Lilly Inks Deal With AC Immune For Potential Alzheimer s Drug,opinion,Eli Lilly   Company s   NYSE LLY   signed a collaboration agreement with Swiss biotech AC Immune SA   NASDAQ ACIU   to jointly develop tau aggregation inhibitors  which have the potential to treat Alzheimer s disease  AD  and other neurodegenerative diseases Per the deal  AC Immune will develop the tau aggregation inhibitors by leveraging its proprietary Morphomer platform  While AC Immune will conduct the phase I studies mainly on its lead molecule  ACI 3024  Lilly will fund and take care of further development and also get worldwide commercialization rights for the tau aggregation inhibitors in the area of AD Lilly will make an initial upfront payment of 80 Swiss francs to AC Immune and purchase  50 million note  convertible to equity position in AC Immune  In addition  AC Immune will be eligible to receive 60 million Swiss francs as potential near term development milestones  up to approximately 1 7 billion Swiss francs in other potential development  regulatory and commercial milestones and low double digit royalties Lilly has a decent pipeline for Alzheimer s disease and other neurological diseases  Its lead AD candidate is flortaucipir  which is in phase III development Alzheimer s  a fatal illness that causes progressive decline in memory  has always been a highly challenging area with not much progress being made in spite of significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease Lilly has had its share of failures in AD  In June this year  Lilly discontinued two late stage studies on its AD candidate lanabecestat on recommendation of the independent data monitoring committee  IDMC  In November 2016  Lilly s key candidate solanezumab failed to meet the primary endpoint in a late stage study that was conducted in patients with mild dementia due to AD  Lilly decided to drop the development of solanezumab  Lilly also suffered a major setback in August 2010 when it had to halt the development of another phase III Alzheimer s candidate  semagacestat Lilly s shares have risen 35 4  this year so far compared with the  s increase of 7 5    Among other companies  in May this year  J J   NYSE JNJ   halted development of atabecestat  its investigational BACE inhibitor  which was being developed for pre clinical stage Alzheimer s disease due to safety concerns In February this year  Merck   NYSE MRK   discontinued the second late stage study evaluating its BACE inhibitor verubecestat for the treatment of prodromal Alzheimer s disease as its success was unlikely Despite the setbacks  companies continue to invest heavily in developing Alzheimer s disease treatments  given the high commercial potential in this market  Success in this area means huge returns  This is because more than five million Americans are living with Alzheimer s disease with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Lilly currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/lilly-inks-deal-with-ac-immune-for-potential-alzheimers-drug-200367731,200367731
171941,393457,LLY,Is Eli Lilly And  LLY  Outperforming Other Medical Stocks This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Eli Lilly and  LLY  is a stock that can certainly grab the attention of many investors  but do its recent returns compare favorably to the sector as a whole  One simple way to answer this question is to take a look at the year to date performance of LLY and the rest of the Medical group s stocks 
Eli Lilly and is a member of our Medical group  which includes 841 different companies and currently sits at  2 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  LLY is currently sporting a Zacks Rank of  2  Buy  
Within the past quarter  the Zacks Consensus Estimate for LLY s full year earnings has moved 2 06  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that LLY has returned about 35 99  since the start of the calendar year  Meanwhile  the Medical sector has returned an average of 2 51  on a year to date basis  As we can see  Eli Lilly and is performing better than its sector in the calendar year 
To break things down more  LLY belongs to the Large Cap Pharmaceuticals industry  a group that includes 14 individual companies and currently sits at  66 in the Zacks Industry Rank  This group has gained an average of 12 06  so far this year  so LLY is performing better in this area 
Going forward  investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance ",2018-12-13,Zacks Investment Research,https://www.investing.com/analysis/is-eli-lilly-and-lly-outperforming-other-medical-stocks-this-year-200368207,200368207
171942,393458,LLY,J J Dips 10  As Reuters Says Company Knew Of Asbestos In Talc,opinion,Johnson   Johnson s   NYSE JNJ   stock was down more than 10  on Friday  after Reuters reported that the pharma giant knew for decades that its baby powders contained asbestos J J has more than 11 000 cases pending related to its baby powders containing talc in the United States  Most of these lawsuits allege that its talc based products  including its baby powders  contain asbestos  which causes its users to develop ovarian cancer So far this year  J J s stock has declined 4 8  against an increase of 5  recorded by the    Reuters  in its article  said that an examination of J J s internal reports and other confidential documents showed that from 1971 to early 2000s  its raw talc and finished powders sometimes tested positive for trace amounts of asbestos  The internal reports and other confidential documents were released as part of a lawsuit by plaintiffs J J issued a statement where it called the reports by Reuters  one sided  false  and inflammatory  Though J J has successfully defended a number of lawsuits related to its baby powders  there have been verdicts against the company  A major verdict was given in July per which J J was ordered by a jury in a St  Louis court to pay  4 69 billion in damages to 22 women who alleged that its baby powders contained asbestos  which caused them to develop ovarian cancer  The damages comprised  550 million in compensatory damages and  4 14 billion in punitive damages  In August  a judge at the Missouri trial court affirmed the jury s verdict  ordering J J to pay a hefty fine of  4 69 billion  J J vowed to appeal then J J has been consistently denying allegations  It has maintained in public statements that its talc products are completely safe and do not cause cancer  In its latest statement  J J said that independent tests by regulators  academic institutions and leading labs have proven that its talc based products have never contained asbestos The link between talc and cancer has been rumored for decades but remains scientifically unproven  Medical experts differ sharply on whether talc increases the risk of cancer in consumers who use it  The American Cancer Society notes that studies so far have produced mixed results  with some showing no link at all and some showing a slightly increased risk It has been suggested that a link between talc and cancer may be due to the fact that talc and asbestos often occur together in deposits and it gets inadvertently mixed The talc issue has been an overhang on J J s stock price for a while given the controversy surrounding this J J currently has a Zacks Rank  2  Buy   You can see   Other top ranked large cap pharma stocks are Merck   Co   Inc    NYSE MRK    Eli Lilly   Company   NYSE LLY   and Roche Holding  SIX ROG  AG   OTC RHHBY    all three carrying a Zacks Rank  2  Buy  Merck s earnings estimates have increased by 1 4  for 2018 and 1 3  for 2019 over the past 60 days  The company s shares have increased 35 9  this year so far Lilly s earnings estimates have increased 2  for 2018 and 0 2  for 2019 over the past 60 days  The company s shares have increased 32 5  this year so far Roche s earnings estimates for 2018 have gone up 0 9  while that for 2019 have moved up 2 6  in the past 60 days The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-12-16,Zacks Investment Research,https://www.investing.com/analysis/jj-dips-10-as-reuters-says-company-knew-of-asbestos-in-talc-200368749,200368749
171943,393459,LLY,Lilly  LLY  To Acquire Pain Candidate From Private Biotech,opinion,Eli Lilly and Company   NYSE LLY   announced that it has entered into an agreement with Massachusetts based privately held Hydra Biosciences  Inc  The move will add the latter s pre clinical pain candidate to the company s portfolio and also strengthen its pain pipeline portfolio Following this deal  Lilly is set to acquire Hydra s TRPA1 antagonist  which is being studied for the potential treatment of chronic pain syndromes Notably  Lilly has been working on building its pipeline and finding novel treatment options for chronic pain  With this transaction  Lilly is looking to add a promising pain candidate to its portfolio to have a better understanding of the Transient Receptor Potential  TRP  pathway in pain signaling  Financial terms of the deal have been kept under wraps Shares of Lilly have surged 32 6  so far this year  outperforming the  increase of 5  In its pain portfolio  Lilly launched Emgality  galcanezumab   its CGRP antibody  for the preventive treatment of migraine in the United States during September  which could emerge as a significant contributor to long term growth A new drug application  NDA  for another migraine candidate  lasmiditan  is also under review  The NDA seeks an approval of the oral 5 HT1F agonist for the treatment of acute migraine headaches  Lasmiditan was added to Lilly s portfolio with the 2015 acquisition of CoLucid Pharmaceuticals Meanwhile  Lilly along with Pfizer   NYSE PFE   is developing NGF inhibitor  tanezumab  subcutaneous   in late stage studies for osteoarthritis pain  chronic low back pain and cancer pain We remind investors that Pfizer and Lilly signed a contract for the joint development and commercialization of tanezumab across the world in 2013 Zacks Rank   Other Stocks to ConsiderLilly currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Merck   Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank of 2  You can see  Bristol Myers  earnings estimates have been revised 6 3  upward for 2018 and 5 1  for 2019 over the past 60 days Merck s earnings estimates have moved 1 4  north for 2018 and 1 3  for 2019 over the past 60 days  The stock has rallied 35 9  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-12-16,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-to-acquire-pain-candidate-from-private-biotech-200368720,200368720
171958,393474,LLY,4 Big Pharma Stocks To Add To Your Portfolio In December  ,opinion,"The performance of the drug biotech space has been mixed this year so far  The Zacks  industry  comprising some of the biggest drugmakers in the world  has gained 7 7  compared with the S P 500 s increase of 0 3  However  the riskier Zacks industry  which includes large as well as small biotech companies  has underperformed the S P 500  The biotech sector has declined 18 1  against the S P 500 s increase of 0 3   probably due to some pipeline setbacks faced by the industry  
Large  Cap Pharma and Biomed Genetics Versus S P 500  The Large Cap Pharmaceuticals industry features among the top 30  of the 255 Zacks ranked industries We believe that strong quarterly results  consistent increases in full year sales and earnings guidance  new product sales ramp up with rising demand  successful innovation and product line extensions  strong clinical study results  and frequent FDA approvals have helped these big drug giants to consistently do well this year despite broader macro issues as well as the industry s own challenges  Moreover  it is likely to perform well even if the global economy slows down next year  This is because it is a defensive growth sector  which is almost insulated from broader macroeconomic factors Importantly  mergers and acquisition activity is gaining momentum with the tax reform in place   Key acquisitions so far this year include Sanofi s   NYSE SNY   multi billion dollar buyouts of Ablynx and Bioverativ  Novartis    NYSE NVS   acquisition of AveXis and Roche s purchase of Foundation Medicine  Also  Glaxo s   NYSE GSK   buyout of Novartis  36 5  stake in their consumer health care joint venture was given a heads up by the investor community However  the sector faces its share of headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and major pipeline setbacks Drug pricing controversy was back in news this month after a Wall Street report stated that Pfizer   NYSE PFE   plans to increase the list prices of its 41 prescription drugs next year  The drug giant had put off such increases earlier this year as it faced criticism from President Donald Trump Nonetheless  we believe pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activity and appropriate utilization of cash should keep the sector afloat through the rest of this year and next In this scenario  investing in stocks with a large market cap is a prudent move given the fact that they control a large portion of an industry  Given this backdrop  it makes sense to invest in some of the bigshot drugmakers Here we have highlighted four stocks that may prove to be good buys  All these stocks carry a Zacks Rank  2  Buy  and have seen their share price and earnings estimates rise this year  You can see  A chart showing the share price movement of all the four stocks this year so far is given below   Eli Lilly   Company   NYSE LLY  Lilly s earnings estimates have increased 2  for 2018 and 1  for 2019 over the past 60 days  The company s shares have increased 36 8  this year so far Lilly s new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo and Verzenioare driving sales growth   The company is also on a strong footing in terms of its pipeline with several positive late stage data readouts this year along with various regulatory approvals  A key regulatory success for Lilly was the FDA approval of Emgality galcanezumab  a calcitonin gene related peptide  CGRP  antibody for migraine prevention  which could emerge as a significant contributor to long term growth Several key regulatory and pipeline events are expected in 2019  Any positive outcome will push up share price further This year  Lilly also added promising new assets through business development deals including pancreatic cancer candidate  pegilodecakin  which was added with the acquisition of ARMO Biosciences  Meanwhile  the separation of its animal health unit  Elanco  via an IPO  is a prudent decision in our viewas the unit was underperforming Merck   Co   Inc    NYSE MRK  Shares of Merck have risen 37 3  this year so far  Merck s earnings estimates for 2018 have gone up 1 6  while that for 2019 have moved up by 1 7  in the past 60 days Strong performance and positive regulatory updates related to its PD 1 inhibitor  Keytruda aided the company  In a very short span of time Keytruda has become Merck s largest product  It is already approved for use in 12 indications across eight different tumor types in the United States  In fact  the Keytruda development program is also progressing rapidly  Several regulatory decisions for new indications in the United States as well as in Europe are due in 2019  which  if approved  can further boost sales Key recent approvals for Merck include Steglatro and its fixed dose combinations for type II diabetes  two new HIV drugs   Pifeltro and Delstrigo   containing doravirine and Prevymis  letermovir  for cytomegalovirus  CVM  infection  Merck also gained several label expansion approvals for Keytruda and another cancer drug Lynparza  which it markets in partnership with AstraZeneca  AZN  All these new drugs and line extension approvals can boost the company s pharmaceuticals sales in the future quarters Merck s animal health and vaccine products are also performing strongly and remain core growth drivers for Merck Merck also announced positive data from several late stage studies  mainly evaluating Keytruda for further line extensions  Merck also signed a co development deal with Japan s Eisai Co   Ltd for the latter s tyrosine kinase inhibitor  Lenvima It also agreed to buy Viralytics Limited  an Australian pharmaceutical company that develops oncolytic immunotherapies for a range of cancers which should strengthen its oncology portfolio GlaxoSmithKline plcGlaxo s shares have risen 16 2  year to date  Glaxo s earnings estimates for 2018 have gone up 1 4  while that for 2019 have moved up by 1 3  in the past 60 days We think Glaxo possesses one of the stronger late stage pipelines in large cap pharma and the U K  based giant has made significant progress with its late stage pipeline this year  Data from several of the late state pipeline programs are expected in 2019  The performance of Glaxo s new products has been encouraging  The three newest products   Trelegy Ellipta  Shingrix and Juluca   are doing well  particularly Shingrix  These three products coupled with buyout of Novartis  stake in the Consumer Healthcare JV have strengthened Glaxo s competitive position Johnson   Johnson   NYSE JNJ  J J s shares have risen 4 9  this year  Its earnings estimates for 2018 have gone up 0 2  while that for 2019 have moved up by 0 6  in the past 60 days J J s Pharma segment is performing better than the market in 2018 despite the impact of biosimilars on sales of its blockbuster rheumatoid arthritis medicine  Remicade  Also  the Medical Devices and Consumer units are seeing improving organic growth trends J J has also raised its full year organic sales growth outlook thrice this year  Though quite a few key products in J J s portfolio like Remicade and Concerta are facing generic competition  we believe that new products in all segments  successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from recent acquisitions will continue to drive top line growth  J J enjoys a robust multi year pipeline of new drugs and line extensions  Share buybacks and restructuring initiatives should provide bottom line support The Hottest Tech Mega Trend of All             Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/4-big-pharma-stocks-to-add-to-your-portfolio-in-december-200363519,200363519
171959,393475,LLY,Why Is Incyte  INCY  Up 1 5  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Incyte  INCY   Shares have added about 1 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Incyte due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Incyte Misses on Q3 Earnings   RevenuesIncyte reported disappointing results for the third quarter of 2018  wherein both earnings and revenues missed expectations  The company reported a net income of 38 cents per share  which missed the Zacks Consensus Estimate of 40 cents but was up from 19 cents reported in the year ago quarter Quarterly revenues were  449 7 million  up 17 9  year over year  Excluding milestone payments  revenues came in at  429 7 million  which missed the Zacks Consensus Estimate of  443 0 million Quarter in DetailTotal product related revenues came in at  367 7 million  up 14 2  from the year ago quarter  Of these  Jakafi s revenues came in at  347 6 million  up 14  from the year ago quarter  driven by strong patient demand  Net product revenues of Iclusig amounted to  20 1 million  up from  18 1 million in the year ago quarter Product royalty revenues from Novartis AG for the commercialization of Jakafi in ex U S  markets grew 23  to  50 9 million  Olumiant s product royalty revenues came in at  11 million R D expenses were  251 million  up from  234 million in the year ago quarter  SG A expenses amounted to  85 million  up from  80 million in the prior year quarter 2018 Outlook UpdatedThe company expects Jakafi revenues of  1 370  1 400 million  previous guidance   1 350  1 400 million   Iclusig revenues are expected to be  80  85 million R D expenses are now expected to be  993  1 038 million  down from  1 008  1 103 million projected earlier  SG A expenses are expected to be  370  385 million compared with the previous guidance of  340  355 million Pipeline UpdateIncyte s supplemental New Drug Application  sNDA   seeking a label expansion of Jakafi for the treatment of steroid refractory acute GVHD  has been accepted for Priority Review by the FDA  The agency has set a target action date of Feb 24  2019  The application for approval was based on the successful REACH1 trial  additional results from which are expected later in the year Meanwhile  the global phase III GRAVITAS 301 trial of itacitinib as a treatment for patients with newly diagnosed acute GVHD is enrolling  Results from the study are expected in 2019  Assuming the trial is successful  Incyte expects to submit applications seeking marketing approval for itacitinib in major markets globally Data from the phase II trial on the cream formulation of Jakafi in adult patients with atopic dermatitis were encouraging  Hence  Incyte is planning to initiate a global  pivotal phase III trial for this indication  Data from the randomized phase II trial of Jakafi cream in patients with vitiligo are expected in 2019 The trial evaluating pemigatinib  formerly INCB54828  show promising efficacy in advanced cholangiocarcinoma patients with FGFR2 translocations  Incyte expects to submit an NDA for pemigatinib as a treatment for patients with advanced cholangiocarcinoma in 2019  The company expects to start a phase III trial for the first line treatment of patients with cholangiocarcinoma in the coming months  Enrollment in the continuous dosing cohort of the phase II trial of pemigatinib in patients with bladder cancer is now underway In June 2018  Incyte and partner Eli Lilly and Company  NYSE LLY  announced that the FDA has approved the 2 mg dose of Olumiant  baricitinib   a once daily oral medication for the treatment of adults with moderately to severely active rheumatoid arthritis  RA  who have had an inadequate response to one or more tumor necrosis factor  TNF  inhibitor therapies Consequently  Incyte obtained a  100 million milestone payment from Eli Lilly  However  the 4 mg dose of the drug was not approved  Lilly recently initiated a phase III trial of Olumiant in patients with systemic lupus erythematosus and a phase II III adaptive design trial of Olumiant in patients with severe alopecia areata  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Incyte has a strong Growth Score of A  a grade with the same score on the momentum front  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision looks promising  Notably  Incyte has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/why-is-incyte-incy-up-15-since-last-earnings-report-200363593,200363593
171960,393476,LLY,Merck  MRK  Receives Approval For 2 HIV Medicines In EU,opinion,"Merck   Co   Inc    NYSE MRK   announced that the European Commission has approved two new HIV drugs   Pifeltro and Delstrigo   containing  doravirine  a non nucleoside reverse transcriptase inhibitor  NNRTI   for the treatment of HIV 1 infection 
While Pifeltro is a once daily single tablet containing doravirine to be taken in combination with other antiretroviral agents  Delstrigo is a once daily fixed dose combination regimen containing doravirine  lamivudine and tenofovir disoproxil fumarate  In the EU  the drugs are indicated for the treatment of adults with HIV 1 infection without past or present evidence of resistance to the NNRTI class 
The approval was expected as in September  the Committee for Medicinal Products for Human Use of the European Medicines Agency had given a positive opinion recommending approval of the two medicines  Pifeltro and Delstrigo are expected to be launched in the EU in the first half of 2019 
So far this year  Merck s shares have outperformed the   Merck s shares have risen 37 2  in the period compared with 7 8  increase for the industry 

 
Pifeltro and Delstrigo were approved by the FDA in August  two months ahead of the action date in late October  In the United States  Pifeltro and Delstrigo are approved for use in adults with no prior antiretroviral treatment experience  Also  in the United States  Delstrigo was approved with boxed warning about post treatment acute exacerbation of hepatitis B infection 
The approval to the drugs was based on encouraging data from two pivotal studies   DRIVE AHEAD and DRIVE FORWARD   evaluating the safety and efficacy of Delstrigo and Pifeltro  respectively through 90 weeks 
Although there are several drugs approved to manage HIV virus infection  there is no cure available in the market  So far  Gilead Sciences   NASDAQ GILD   and GlaxoSmithKline   NYSE GSK   dominate the HIV drug segment with several drug regimens in their portfolio  The drugs from these companies generate billions of dollars in revenues every quarter 
Merck currently carries a Zacks Rank  2  Buy   You can  
Another top ranked large cap pharma stock is Eli Lilly   Company   NYSE LLY    carrying a Zacks Rank  2  Lilly s earnings estimates have increased 2  for 2018 and 1  for 2019 over the past 60 days  The company s shares have increased 36 8  this year so far 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-receives-approval-for-2-hiv-medicines-in-eu-200363729,200363729
171961,393477,LLY,Eli Lilly  LLY  Outpaces Stock Market Gains  What You Should Know,opinion,"Eli Lilly  LLY  closed the most recent trading day at  118 64  moving  1 4  from the previous trading session  This change outpaced the S P 500 s 0 82  gain on the day  Elsewhere  the Dow gained 0 79   while the tech heavy Nasdaq added 0 79  
Coming into today  shares of the drugmaker had gained 8 47  in the past month  In that same time  the Medical sector gained 5 35   while the S P 500 gained 3 94  
Wall Street will be looking for positivity from LLY as it approaches its next earnings report date  This is expected to be January 30  2019  The company is expected to report EPS of  1 36  up 19 3  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  6 37 billion  up 3 4  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  5 58 per share and revenue of  24 48 billion  These totals would mark changes of  30 37  and  7 02   respectively  from last year 
It is also important to note the recent changes to analyst estimates for LLY  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 1 96  higher  LLY currently has a Zacks Rank of  2  Buy  
Digging into valuation  LLY currently has a Forward P E ratio of 20 97  This represents a premium compared to its industry s average Forward P E of 14 88 
Meanwhile  LLY s PEG ratio is currently 1 82  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 04 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 96  putting it in the top 37  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow LLY in the coming trading sessions  be sure to utilize Zacks com ",2018-11-30,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-outpaces-stock-market-gains-what-you-should-know-200364114,200364114
171962,393478,LLY,Incyte  INCY  Announces Positive Data On Jakafi For GVHD,opinion,"Incyte Corporation   NASDAQ INCY   announced updated results from a pivotal phase II REACH1 study on lead drug Jakafi at the American Society of Hematology  ASH  Annual Meeting 2018 in San Diego  California 
The study evaluated Jakafi in combination with corticosteroids as a treatment for patients with acute graft versus host disease  GVHD  who have had an inadequate response to corticosteroids 
In the trial  68  of patients had Grade III or Grade IV disease at baseline  illustrative of an at risk patient population  The updated data show that responses were observed irrespective of grade or steroid refractory  SR  criteria  Responses to Jakafi were rapid and durable  The median time to response was seven days and the median duration of response  DOR  for patients who had a minimum of six months of follow up was 345 days 
The study had earlier met its primary endpoint  demonstrating an overall response rate  ORR  of 55   n 39 71  at Day 28 along with a best overall response rate  BORR    patients achieving a response at any time point during the study   of 73   n 52 71  
The updated results further reinforce the potential of Jakafi as a therapeutic option in GVHD and specifically reinforce the durability of responses seen in acute GVHD patients treated with Jakafi 
Incyte had already submitted a supplemental New Drug Application  sNDA  to the FDA on the basis of data from the REACH1 study  The FDA assigned priority review to the sNDA and set a target action date of Feb 24  2019 
Jakafi became the first FDA approved JAK inhibitor for any indication  It is also the first and the only product approved by the FDA for the treatment of rare blood cancers like myelofibrosis  November 2011  and polycythemia vera  December 2014  
Its label has been updated several times since approval  It was updated in June 2013 to include information on a new recommended dosing guidance for patients with low platelet count 
Incyte expects Jakafi revenues of  1 370  1 400 million in 2018  which is more than 20  growth in 2017 
The company is working to further expand Jakafi s label  Meanwhile  REACH2 and REACH3 studies  evaluating steroid refractory acute and steroid refractory chronic graft versus host disease  respectively  are ongoing in collaboration with Novartis   NYSE NVS    Incyte plans to enroll more than 300 patients in each of these studies  Data from these studies are expected in 2019 
Data from the phase II trial on the cream formulation of Jakafi in adult patients with atopic dermatitis were encouraging  Hence  Incyte is planning to initiate a global  pivotal phase III trial for this indication  Data from the randomized phase II trial on Jakafi cream in patients with vitiligo are expected in 2019 
Approval of new drugs and label expansion of existing drugs bode well for Incyte  In June 2018  Incyte and partner Eli Lilly and Company   NYSE LLY   announced that the FDA has approved the 2 mg dose of Olumiant  baricitinib   a once daily oral medication  for the treatment of adults with moderately to severely active rheumatoid arthritis  RA  who have had an inadequate response to one or more tumor necrosis factor  TNF  inhibitor therapies 
Incyte s stock has lost 29  in the year so far compared with the  s 13 8  decline 

 
The company suffered a huge setback with the failure of the phase III study  ECHO 301  as it was one of the most promising candidates for Incyte  evaluating epacadostat in combination with Merck s   NYSE MRK   Keytruda  Further  the approval of the 4mg dose of baricitinib is also doubtful 
Zacks Rank   Key Pick
Incyte carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-announces-positive-data-on-jakafi-for-gvhd-200365074,200365074
171963,393479,LLY,Eli Lilly  LLY  Is A Great Momentum Stock  Should You Buy ,opinion,"Momentum investing revolves around the idea of following a stock s recent trend in either direction  In the  long  context  investors will be essentially be  buying high  but hoping to sell even higher   With this methodology  taking advantage of trends in a stock s price is key  once a stock establishes a course  it is more than likely to continue moving that way  The goal is that once a stock heads down a fixed path  it will lead to timely and profitable trades 
While many investors like to look for momentum in stocks  this can be very tough to define  There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance  The Zacks Momentum Style Score  part of the Zacks Style Scores  helps address this issue for us 
Below  we take a look at Eli Lilly  LLY   which currently has a Momentum Style Score of B  We also discuss some of the main drivers of the Momentum Style Score  like price change and earnings estimate revisions 
It s also important to note that Style Scores work as a complement to the Zacks Rank  our stock rating system that has an impressive track record of outperformance  Eli Lilly currently has a Zacks Rank of  2  Buy   Our research shows that stocks rated Zacks Rank  1  Strong Buy  and  2  Buy  and Style Scores of A or B outperform the market over the following one month period 
You can see the current list of Zacks  1 Rank Stocks here    
Set to Beat the Market 
Let s discuss some of the components of the Momentum Style Score for LLY that show why this drugmaker shows promise as a solid momentum pick 
A good momentum benchmark for a stock is to look at its short term price activity  as this can reflect both current interest and if buyers or sellers currently have the upper hand  It s also helpful to compare a security to its industry  this can show investors the best companies in a particular area 
For LLY  shares are up 5 11  over the past week while the Zacks Large Cap Pharmaceuticals industry is up 3 85  over the same time period  Shares are looking quite well from a longer time frame too  as the monthly price change of 10 03  compares favorably with the industry s 3 59  performance as well 
Considering longer term price metrics  like performance over the last three months or year  can be advantageous as well  Shares of Eli Lilly have increased 10 3  over the past quarter  and have gained 35 39  in the last year  In comparison  the S P 500 has only moved  6 21  and 4 36   respectively 
Investors should also take note of LLY s average 20 day trading volume  Volume is a useful item in many ways  and the 20 day average establishes a good price to volume baseline  a rising stock with above average volume is generally a bullish sign  whereas a declining stock on above average volume is typically bearish  Right now  LLY is averaging 4 456 462 shares for the last 20 days 
Earnings Outlook
The Zacks Momentum Style Score encompasses many things  including estimate revisions and a stock s price movement  Investors should note that earnings estimates are also significant to the Zacks Rank  and a nice path here can be promising  We have recently been noticing this with LLY 
Over the past two months  7 earnings estimates moved higher compared to none lower for the full year  These revisions helped boost LLY s consensus estimate  increasing from  5 47 to  5 58 in the past 60 days  Looking at the next fiscal year  5 estimates have moved upwards while there have been 1 downward revision in the same time period 
Bottom Line
Given these factors  it shouldn t be surprising that LLY is a  2  Buy  stock and boasts a Momentum Score of B  If you re looking for a fresh pick that s set to soar in the near term  make sure to keep Eli Lilly on your short list ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-is-a-great-momentum-stock-should-you-buy-200365266,200365266
171965,393481,LLY,Why Is Lilly  LLY  Up 6 2  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Eli Lilly  LLY   Shares have added about 6 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Lilly due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Lilly Tops on Q3 Earnings  Misses Sales  Lifts 2018 OutlookLilly reported third quarter 2018 adjusted earnings per share of  1 39  which beat the Zacks Consensus Estimate of  1 37 per share  Earnings rose 32  from the year ago quarter backed by robust growth in new product sales and higher operating income  Meanwhile  lower tax rates and a reduction in shares outstanding from shares repurchase also led to higher earnings in the quarter Including acquisition related in process R D charges  asset impairment  restructuring and other special charges  third quarter earnings per share was  1 12 against a gain of 53 cents per share in the third quarter of 2017 Revenues in DetailQuarterly revenues of  6 06 billion missed the Zacks Consensus Estimate of  6 11 billion  Sales grew 7  year over year backed by strong demand for its new drugs  led by Trulicity  Taltz  and Verzenio  which made up for lower sales of established products like Strattera  Cialis and Forteo Foreign exchange hurt sales growth by 1  in the quarter  Also  lower realized prices had a negative impact of 4  on sales Volumes rose 12  as increased demand for new products like Trulicity  Basaglar  Taltz and Verzenio  offset lower volumes of some established products like Cialis  Strattera and Effient due to loss of exclusivity  Volumes of Lilly s diabetes products rose 30  in the quarter New pharma products  products launched since 2014  drove 14  of volume growth and generated over  1 9 billion in revenues  representing nearly 31  total revenues  up from 28  in the previous quarter  On the other hand  the loss of exclusivity for Strattera  Effient  Zyprexa  Axiron  Evista  and Cymbalta hurt volumes by 110 basis points  Lower demand for Cialis hurt volumes by 190 basis points While U S  revenues grew 11  to  3 45 billion  ex U S  revenues rose 2  to  2 62 billion Pharmaceutical revenues rose 8  in the quarter  U S  Pharma revenues increased 11   while in Europe  pharma revenues rose 1   excluding currency impact  In Japan  pharma revenues decreased 2   excluding currency impact  Pharma revenues in the rest of the world increased 15  Established products that recorded growth during the quarter included Humulin  up 7  to  322 1 million  and Alimta  up 1  to  520 5 million   Sales of all other established products declined in the quarter Forteo sales declined 12  to  390 8 million  Cymbalta sales declined 6  to  172 0 million  Humalog sales dropped 5  to  664 6 million  Zyprexa sales were down 22  to  109 9 million  Erbitux sales declined 2  to  159 5 million Cialis  erectile dysfunction  sales declined 17  to  467 1 million as U S  sales were hurt by lower demand due to the entry of generic sildenafil while outside U S  sales were hurt by loss of exclusivity in Europe  In September  Teva Pharmaceuticals announced the launch of a generic version of Cialis  which is expected to result in rapid erosion of sales in the future quarters Strattera sales declined 28  to  98 7 million due to loss of exclusivity Among the new products  Trulicity generated revenues of  816 2 million  up 55  year over year driven by higher demand in the United States and higher volumes in ex U S  markets Cyramza revenues were  198 4 million  up 1  year over year as higher international sales were offset by lower U S  sales  Cyramza s ex U S  revenues increased 4   as strong volumes were partially offset by lower realized prices  Cyramza U S  revenues decreased 4  driven by lower realized prices Jardiance sales surged 31  to  166 9 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States Basaglar recorded revenues of  201 2 million  up 38  year over year  In the United States  sales rose 37   benefiting from higher demand  which offset the impact of lower realized prices  due to increased volume in Medicare Part D and  and unfavorable changes to estimates for rebates and discounts Taltz brought in sales of  263 9 million compared with  220 1 million in the previous quarter as U S  sales gained from higher demand  which made up for lower realized prices while ex U S  sales were driven by increased volume from new launches  Taltz was launched for the second indication of psoriatic arthritis in late 2017 early 2018 in both the United States and Europe  which contributed to sales growth in the quarter Lartruvo  olaratumab  generated revenues of  76 9 million in the quarter  up 41  year over year driven by increased demand trends in the U S  market and increased volume from new launches in ex U S  markets  However  Lartruvo sales declined 3 8  sequentially in the quarter Olumiant generated sales of  55 6 million in the quarter backed by launch uptake in new European markets  compared with  44 7 million in the previous quarter  In the United States  Olumiant recorded sales of  0 8 million  which were less than  1 7 million in the previous quarter Verzenio  launched in the Unites States in late 2017  generated sales of  84 5 million in the quarter compared with  57 7 million in the previous quarter   In February  Verzenio gained FDA approval in the first line setting while the drug was approved in Europe and Japan in the third quarter  These line extensions could prove to be significant growth drivers for the drug  However  on the conference call  The company said it saw a slowdown in the growth of the CDK4 6 market though Verzenio gained market share in the quarter Animal Health segment sales rose 4  to  772 7 million as higher prices and higher volume offset currency headwinds Gross Margin   Operating Income Adjusted gross margin of 76 7  in the quarter rose 190 basis points driven by manufacturing efficiencies  favorable product mix and the positive effect of foreign exchange rates on international inventories sold  which offset the negative impact of lower prices Operating income increased 29  year over year to  1 69 billion due to higher revenues and lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 270 basis points in the quarter to 48 8  due to the company s cost saving efforts While marketing  selling and administrative expenses rose 2   R D expense was flat in the quarter Adjusted effective tax rate was 15 1   lower than 18 9  in the year ago quarter  driven primarily by the impact of U S  tax reform In the quarter  Lilly repurchased stock worth  1 billion 2018 Guidance UppedLilly raised its previously issued outlook for adjusted earnings while increasing the lower end of the total revenue guidance Adjusted earnings per share are now expected in the range of  5 55 to  5 60  higher than  5 40 to  5 50 expected previously  At the mid point of the range  the guidance represents an increase of 30  over 2017 versus 27  previously In the fourth quarter  the company expects earnings in the range of  1 33    1 38  This represents a sequential decline from third quarter levels due to U S  generic competition for Cialis in September  higher R D costs in the fourth quarter  and launch costs for Emgality  Also  backing out the non controlling interest portion of Elanco profits is expected to have a 2 to 3 cents negative impact on earnings in the fourth quarter The lower range of the revenue guidance for 2018 was slightly upped to  24 3 billion to  24 5 billion from  24 0 billion to  24 5 billion expected previously The sales guidance increase was due to strong performance of pharmaceuticals products  especially Lilly s diabetes drugs Gross margin is expected to be approximately 76   same as previous expectations Adjusted tax rate is expected to be approximately 16   previously 17   Marketing  selling and administrative expense guidance was raised from a range of  6 2  6 5 billion to  6 3  6 5 billion  Research and development expense guidance was kept intact in the range of  5 2  5 4 billion Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo  Verzenio and Olumiant are expected to continue to drive revenues  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 7 09  due to these changes 
VGM Scores
Currently  Lilly has a great Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Lilly has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-lilly-lly-up-62-since-last-earnings-report-200365685,200365685
171967,393483,LLY,Nektar  NKTR  Up 7 7  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Nektar Therapeutics  NKTR   Shares have added about 7 7  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Nektar due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Nektar Q3 Earnings and Revenues Beat EstimatesNektar Therapeutics incurred a loss of 56 cents per share for third quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 64 cents  The company had recorded a loss of 37 cents per share in the year ago period Quarterly revenues were  27 8 million compared with the year ago figure of  152 9 million  The significant decrease in revenues was attributable to  127 6 million in upfront fees received from Eli Lilly  NYSE LLY  in the third quarter of 2017 related to development and commercialization collaboration deal of NKTR 358  The top line beat the Zacks Consensus Estimate of  25 million Quarter in DetailThe top line comprised product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues In the third quarter  product sales declined 4 3  to  4 3 million from the year ago period   However  non cash royalty revenues increased 3 8  to  8 4 million The company reported royalty revenues of  10 3 million in the quarter  registering an improvement of 10 3  from  9 3 million a year ago License  collaboration and other revenues came in at  4 9 million compared with  131 1 million in the prior year  In the year ago period  the company recorded upfront fees from Eli Lilly related to a license agreement for NKTR 358 Research and development  R D  expenses escalated 56 6  to  102 9 million  primarily due to investments in pipeline  including key candidates NKTR 358  NKTR 214 and NKTR 262  It also included costs related to filing of a new drug application   NDA   for NKTR 181 General and administrative  G A  expenses were up 55 3  to  18 7 million in the reported quarter primarily owing to higher stock based compensation expenses 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  6 52  due to these changes 
VGM Scores
Currently  Nektar has a poor Growth Score of F  however its Momentum Score is doing a lot better with a C  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Nektar has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-12-06,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-up-77-since-last-earnings-report-can-it-continue-200366148,200366148
171968,393484,LLY,Mallinckrodt  MNK  To Separate Generics   Branded Businesses,opinion,"Mallinckrodt plc   NYSE MNK   announced that it intends to spin off its Specialty Generics Active Pharmaceutical Ingredients business and Amitiza into a new company 
The company expects to create two independent  appropriately capitalized  and publicly traded companies   one focused on innovative specialty pharmaceutical brands  and the other primarily on niche specialty generic products and API manufacturing  The spin off is expected to be completed by the second half of 2019 
Generic Business as New Company
The new generic business company is expected to be listed on the New York Stock Exchange  NYSE   and will assume the Mallinckrodt name and ticker symbol  while the independent Specialty Pharmaceutical Brands company will be renamed later 
The separation is planned to be executed through a pro rata distribution of common stock to the shareholders that is generally tax free for U S  federal income tax purposes 
Given the decline in sales  Mallinckrodt has been exploring a range of strategic alternatives for its Specialty Generics business from 2016  The company believes that operating independently will allow this new company to more rapidly capitalize on its growth opportunities  Sales from the new Specialty Generics company exceeded  850 million on a reported basis  inclusive of the Amitiza product since Feb 14  2018  
Headquartered in St  Louis  MO  the company will have roughly 1 600 employees  The portfolio includes a leading acetaminophen business  a portfolio of both API and generic finished dose forms of controlled substances and other drugs  a niche specialty generics development portfolio  and a strong U S  manufacturing footprint along with Amitiza  The company expects to launch as many as five new products in 2019 
Profile of The Specialty Pharmaceutical Brands Company
Following the spin off  ordinary shares of the renamed Specialty Pharmaceutical Brands company will continue to trade on the NYSE  The company will maintain its global headquarters in Staines upon Thames  United Kingdom  and its principal U S  office 
This company includes H P  Acthar Gel  Inomax  Ofirmev and the Therakos immunotherapy platform along with a robust pipeline 
Top line results from both the completed rheumatoid arthritis clinical trial and multiple sclerosis registry for H P  Acthar Gel are expected by the first half of 2019  The company expects to complete enrollment in phase IV trials for uveitis and lupus on the drug  and in the phase II trial on Acthar in amyotrophic lateral sclerosis in the second half of 2019  
Top line results from the company s development program for CPP 1X sulindac are anticipated in the first quarter of 2019  and trial results for both StrataGraft viable engineered skin tissue and terlipressin are expected to be available in the second half 2019 
Our Take
The spin off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business  which promises potential 
Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies  The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices 

 
Mallinckrodt s stock has lost 4 6  in the year so far  against the  s decline of 10 8   Shares were down 6 9  following the announcement 
Zacks Rank   Key Picks
Mallinckrodt carries a Zacks Rank  3  Hold  
Some better ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 63 to  3 87 for 2018 and from  3 92 to  4 08 for 2019 over the past 60 days 
Lilly s earnings per share estimates have increased from  5 47 to  5 58 for 2018 and from  5 77 to  5 79 for 2019 over the past 60 days 
Merck s earnings per share estimates have increased from  4 28 to  4 34 for 2018 and from  4 67 to  4 71 for 2019 over the past 60 days 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-07,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-to-separate-generics--branded-businesses-200366225,200366225
171984,393500,LLY,Pharma Stock Roundup  FDA Updates On MRK  AZN s Cancer Drugs  Bayer s Q3 Earnings,opinion,"This week FDA granted approval for a new indication of Merck s   NYSE MRK   cancer PD 1 inhibitor  Keytruda and gave priority review to label expansion applications filed by AstraZeneca   NYSE AZN   Merck and Roche   OTC RHHBY   for their cancer drugs  Bayer   OTC BAYRY   reported strong third quarter results Recap of the Week s Most Important StoriesMerck s Keytruda Gets FDA Nod for Liver Cancer  Merck s supplemental biologics license application  sBLA  looking to expand the label of Keytruda for previously treated patients with advanced hepatocellular carcinoma  HCC   the most common type of liver cancer  was   The sBLA filing was based on data from the phase II KEYNOTE 224 study Keytruda also in a phase III study  evaluating it for the second line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma  a difficult to treat cancer  Keytruda significantly improved overall survival  OS  compared to standard chemotherapy in the studyMerck also began a rolling submission of the biologics license application  BLA  for its investigational vaccine for Ebola Zaire disease  V920  The rolling submission is expected to be completed in 2019 AstraZeneca Merck s sNDA for Lynparza Gets FDA s Priority Review  AstraZeneca announced that the to a supplemental New Drug Application  sNDA  looking for label expansion of its advanced ovarian cancer drug  Lynparza in the first line setting  The sNDA filing was based on data from the phase III SOLO 1 study  which demonstrated that Lynparza led to a statistically significant and clinically meaningful improvement in progression free survival  PFS  compared to placebo in women with BRCA mutated  BRCAm  advanced ovarian cancer  The FDA s decision is expected in the first quarter of 2019  If approved for expanded use in the first line setting  sales of Lynparza can improve in the future quarters AstraZeneca announced an agreement with Swedish pharma company  Sobi  for an upfront consideration of  1 5 billion plus further contingent payments  About 130 AstraZeneca employees will also shift to Sobi as part of the transaction  In addition  the transaction gives rights to Sobi  officially  Swedish Orphan Biovitrum AB  to participate in the future U S  profits and losses of AstraZeneca s pipeline candidate  MEDI8897  which is also being developed for the same indication as Synagis  The Synagis sale is the latest of the several divestiture deals announced this year by AstraZeneca as it streamlines its portfolio AstraZeneca presented detailed data from a phase III cardiovascular outcomes study  DECLARE   TIMI 58  on type II diabetes drug Farxigaat the annual session of the American Heart Association In September  AstraZeneca had announced that Farxiga led to statistical significant reduction in hospitalization for heart failure  hHF  or CV death in the study  thereby meeting one of the two primary efficacy endpoints  Along with the latest release  AstraZeneca said that Farxiga significantly reduced the combined risk of hHF or CV death by 17  versus placebo  Meanwhile  for the other endpoint  though fewer major adverse cardiovascular events  MACE  were observed in the Farxiga arm  it did not reach statistical significance  8 8  for Farxiga vs  9 4  for placebo  Roche s Tecentriq sBLA Gets FDA s Priority Review  Roche s supplemental Biologics License Application  sBLA  looking for label expansion of its cancer drug  Tecentriq plus Abraxane  nab paclitaxel  for the first line treatment of people with PD L1 positive  metastatic triple negative breast cancer was accepted by the FDA  With the FDA granting priority review to the sBLA  a decision is expected by Mar 12  2019 Bayer Reports Strong Q3 Results  Bayer beat estimates for both earnings and sales in the third quarter  Sales rose more than 23 4   on a reported basis  in the quarter  While the company registered sales growth at Pharmaceuticals  sales declined at Consumer Health and Animal Health segments on a reported basis  The company reaffirmed its outlook for 2018 Lilly Updates on Migraine Candidates  Lilly   NYSE LLY     lasmiditan and Emgality  It filed a new drug application to the FDA for approval of lasmiditan for the acute treatment of migraine headaches  Lilly also plans to submit a supplemental biologics license application  sBLA  to the FDA for label expansion of its newly approved CGRP antibody  Emgality  galcanezumab  for another indication   preventive treatment of episodic cluster headache  a type of headache disorder  Emgality was approved by the FDA for the preventive treatment of migraine in adults in late September  The FDA also granted Breakthrough Therapy status to Emgality for the episodic cluster headache indication AbbVie Presents Mavyret Study Data  AbbVie s   NYSE ABBV   HCV medicine  Mavyret demonstrated high virologic cure rates in the   evaluating it for an expanded patient population  The study is evaluating Mavyret in treatment na ve HCV patients with compensated cirrhosis across all major genotypes  GT1 6   Mavyret is presently marketed in the United States for treatment na ve patients without cirrhosis  New data from cohort 1 of the study showed that on eight weeks of treatment with Mavyret  100  of genotype 1  2  4  5 and 6 treatment na ve HCV patients with compensated cirrhosis achieved SVR12 per protocol analysis  Mavyret recorded sales of  2 6 billion in the first nine months of 2018  commanding a global market share of 50  Bristol Myers Gets Positive CHMP Opinion for Cancer Combo   Bristol Myers   NYSE BMY   received a positive opinion of the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  The CHMP recommended approval of its immuno oncology combination of Opdivo  nivolumab  and low dose Yervoy  ipilimumab  as first line treatment option for patients with intermediate  and poor risk advanced renal cell carcinoma  The positive CHMP opinion was based on positive data phase III CheckMate  214 study Glaxo Gets EU Nod to Add IMPACT Data to Telegy Ellipta s Label  Glaxo s filing looking for was approved by the European Commission  With the approval  Telegy Ellipta  a single inhaler triple therapy  can be prescribed as a maintenance treatment to a broader COPD patient population   who are not adequately treated by a LABA LAMA combination in Europe  Until now Trelegy Ellipta was approved as a maintenance treatment to treat those COPD patients who are not adequately treated by an ICS LABA combination  A similar label update was approved by the FDA in April The NYSE ARCA Pharmaceutical Index declined 1 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions  Lilly recorded the highest gain  2   while Glaxo declined the most  2   in the last five trading sessions In the past six months  Lilly has been the biggest gainer  37 4   while Glaxo recorded the lowest gain  0 8    See the last pharma stock roundup here What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-15,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-updates-on-mrk-azns-cancer-drugs-bayers-q3-earnings-200359964,200359964
171989,393505,LLY,4 Trade Ideas For Eli Lilly  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Eli Lilly  NYSE LLY    LLY  rose up out of a long flat consolidation in July  It continued higher until the middle of August when it paused to digest the move  At the beginning of October it started higher again  finding resistance quickly and pulling back  This marked a channel that has held the stock price ever since  Friday it had moved up to resistance again and looked strong 
The RSI is moving into the bullish zone with the MACD rising and positive  There is resistance at 114 and 116 35  The Measured Move on a break higher is to 130  Support lower comes at 109 and 107 50 then 104 50  Short interest is low at 1 1  and the company is expected to report earnings next on February 13th  The stock just began trading ex dividend last week 
The December options chain shows biggest open interest at the 105 strike on the put side and 115 strike on the call side  In the January chain open interest is biggest at the 100 put and call  February chain  the first to cover the next earnings report  opens Monday  The April chain shows light open interest 
Eli Lilly  Ticker   LLY
Trade Idea 1  Buy the stock on a move over 114 with a stop at 109 
Trade Idea 2  Buy the stock on a move over 114 and add a December 110 105 Put Spread  90 cents  as protection  Sell the April 130 Call   1 15  to pay for the protection 
Trade Idea 3  Buy the April 115 December 120 Call Diagonal   5 35  
Trade Idea 4  Buy the April 105 120 bullish Risk Reversal   1 40  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which with November Options Expiration in the rear view mirror and traders looking forward to a short Thanksgiving week  sees equity markets hinting at reversing higher 
Elsewhere look for Gold to continue in its short term uptrend while Crude Oil pauses in its downtrend  The US Dollar Index is resuming its move higher while US Treasuries continue to consolidate in their downtrend  The Shanghai Composite is staging a possible reversal while Emerging Markets are trying to buck their downtrend 
Volatility looks to remain slightly elevated but drifting lower  easing the downward pressure on the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts show some signs of reversing in the short timeframe  while on the longer timeframe the consolidation is more obvious  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-11-19,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-eli-lilly-bonus-idea-200360463,200360463
171992,393508,LLY,Zafgen  ZFGN  Plunges As FDA Puts Hold On Diabetes Drug Trial,opinion,"Shares of clinical stage biopharmaceutical company Zafgen  Inc    NASDAQ ZFGN   slumped 40 5  after the company announced that the FDA has placed a clinical hold on the Investigational New Drug Application  IND  for its first U S  clinical trial of ZGN 1061 
ZGN 1061  the company s second generation  investigational MetAP2 inhibitor  is currently being evaluated for the treatment of type 2 diabetes 
The company received a letter from the FDA last week mentioning the clinical hold  citing the possibility of cardiovascular  CV  safety risk as seen in the company s prior compound 
The agency has outlined multiple potential paths for moving forward  including nonclinical or clinical options  to address these concerns in the ongoing development of the candidate 
As a result  Zafgen plans to assess these options and request a Type A meeting with the FDA to discuss further actions that can be taken regarding the program 
Meanwhile  Zafgen continues to advance its ongoing phase II trial of ZGN 1061 outside the United States  which includes a 1 8 mg dose cohort  Dosing in this trial was recently completed and no CV safety signals have been observed to date  Top line data from the trial are expected early 2019 
Previously  results from 12 weeks showed that ZGN 1061 met all primary endpoints  demonstrating proof of concept efficacy with robust A1C lowering effects  and a favorable safety and tolerability profile generally comparable to placebo 
Zafgen now expects the cash runway to extend through calendar year 2020  given the delay of additional clinical development for the candidate 
Zafgen s shares have gained 17 1  in the year so far  compared with the  decline of 7 7  

 
It has been a bumpy ride for the company of late  Earlier in 2016  the company terminated the development of its lead candidate  beloranib  which was in phase III development for the treatment of hyperphagia and obesity in patients with Prader Willi syndrome and phase II development for the treatment of obesity in patients with hypothalamic injury associated obesity 
We note that CV disease is the leading cause of death in patients with diabetes mellitus and quite a few of diabetes drugs are linked to adverse CV events  Hence  there has been a lot of emphasis on drugs with a better CV profile 
In 2017  the FDA expanded Novo Nordisk s   NYSE NVO   diabetes drug Victoza s label to reduce the risk of major adverse CV events  like heart attack  stroke and CV death  in adults with type 2 diabetes and established CV disease  Eli Lilly s   NYSE LLY   Jardiance is also indicated to reduce the risk of CV death in adults with type 2 diabetes 
Zacks Rank   Other Stock to Consider
Zafgen carries a Zacks Rank  2  Buy   Another top ranked stock from the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries a Zacks Rank  1  Strong Buy   You can see  
Gilead s earnings per share estimates increased from  6 60 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/zafgen-zfgn-plunges-as-fda-puts-hold-on-diabetes-drug-trial-200362866,200362866
172012,393528,LLY,Keryx s  KERX  Loss Narrower Than Expected In Q3  Sales Lag,opinion,"Keryx Biopharmaceuticals  Inc    NASDAQ KERX   incurred a loss of 12 cents per share  excluding  2 2 million in non cash interest expenses related to the amortization of a discount recognized in connection with the modification of the convertible senior notes  in the third quarter of 2018  narrower than Zacks Consensus Estimate of a loss of 13 cents  The loss was also narrower than the year ago loss of 20 cents 
Revenues came in at  28 million in the reported quarter  missing the Zacks Consensus Estimate of  30 million but up from the prior year quarter s  15 million 
Keryx s top line comprises revenues generated by its only marketed product Auryxia  ferric citrate   The drug is approved in the United States to control serum phosphorus levels in adults with chronic kidney disease  CKD  on dialysis  In September 2015  Keryx gained an EU approval for Fexeric  EU trade name for Auryxia  for the control of elevated serum phosphorus levels or hyperphosphatemia in adult patients with CKD including dialysis and non dialysis dependent CKD 
In November 2017  the FDA granted an approval for an additional indication of Auryxia to treat adults with iron deficiency anemia  IDA  as well as chronic kidney disease  not on dialysis  The approval is boosting the company s sales  given the IDA market s great potential 
The stock has lost 34 8  year to date  underperforming the  decline of 14 8  

 
Quarter in Detail
Auryxia s net product sales in the United States totaled  26 6 million  up 96  from  13 6 million in the prior year quarter 
Auryxia s prescription increased to 47 500 in the quarter  representing 9 4 million Auryxia tablets compared with about 25 200 prescriptions and 5 4 million Auryxia tablets in the third quarter of 2017 
During the quarter under consideration  more than 2000 additional physicians prescribed Auryxia compared with what was prescribed in the prior year quarter 
There was a shift in channel mix for Auryxia during the third quarter of 2018  with 61  of prescriptions coming through IMS reporting channels and 39  coming through specialty pharmacies  The shift in mix is due to the closing of Davita s specialty pharmacy business in September 2018 
Keryx recorded license revenues of  1 4 million during the third quarter  up 3 4  year over year 
Research and development expenses declined 14 9  to  7 8 million in the quarter 
Selling  general and administrative expenses were  26 5 million in the third quarter  up 16 3  from the year earlier period s figure of  22 7 million 
In June  Keryx signed a definitive merger agreement with Akebia Therapeutics  AKBA  to combine in an all stock consideration  The deal is expected to close by the end of 2018  subject to shareholder s approval and customary closing conditions  The merger is intended to create a fully integrated renal company with a complementary portfolio  comprising Keryx s Auryxia and Akebia s product candidate  Vadadustat Keryx Biopharmaceuticals  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
Keryx carries a Zacks Rank  3  Hold  
Some top ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 51 for 2018 and from  5 69 to  5 79 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 03   Shares of the company have increased 30 4  year to date 
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   Shares of the company have increased 34 1  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/keryxs-kerx-loss-narrower-than-expected-in-q3-sales-lag-200357767,200357767
172014,393530,LLY,Catalyst  CPRX  Reports Q3 Loss As Expected   Pipeline Update ,opinion,"Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   reported a loss of 8 cents per share in the third quarter of 2018  in line with the Zacks Consensus Estimate of a loss of 8 cents but wider than the year ago loss of 5 cents 
Being a development stage company  Catalyst does not have any approved product in its portfolio yet  Hence  the company did not generate any revenues in the quarter 
So far this year  Catalyst s shares have lost 21 2  compared with the  s 2 7  decline 

 
Quarter in Detail
Research and development  R D  expenses were  4 5 million  up 67 8  from the year ago quarter  Costs during the first nine months of 2018 increased due to rise in consulting expenses as Catalyst prepared to submit its new drug application  NDA  for Firdapse during the first quarter of 2018  milestone expenses in connection with the acceptance of Catalyst s NDA submission in May 2018  They also included expenses from Catalyst s medical affairs program  and compensation and related personnel costs  as Catalyst expands its headcount to support currently ongoing trials and programs  
General and administrative expenses totaled  3 6 million  up 127 5  from the year ago quarter  The increase in expenses is attributable to higher pre commercialization expenses  headcount costs and corporate expenses as Catalyst builds its infrastructure and commercial programs to prepare for a potential launch of Firdapse in 2019 
Pipeline Update
Currently  Catalyst has two candidates under development   Firdapse and CPP 115 
The FDA accepted the NDA for Firdapse  which the company had resubmitted for the treatment of Lambert Eaton myasthenic syndrome  LEMS   The FDA also granted a priority review status to the NDA and an action date of Nov 28  2018 is set for the same  The company expects to launch Firdapse in early 2019 assuming approval 
Catalyst expects top line results from Firdapse s phase III study for MuSK antibody positive myasthenia gravis in the second half of 2019 
The company also expects top line results from the phase III congenital myasthenic syndromes  CMS   CMS 001  study in the second  half of 2019 Catalyst Pharmaceuticals  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
 
Catalyst has a Zacks Rank  3  Hold  
Some top ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Eli Lilly and Company   NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 51 for 2018 and from  5 69 to  5 79 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 03   Shares of the company have increased 30 4  year to date 
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   Shares of the company have increased 34 1  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/catalyst-cprx-reports-q3-loss-as-expected--pipeline-update-200357782,200357782
172015,393531,LLY,Eli Lilly  LLY  Gains As Market Dips  What You Should Know,opinion,"Eli Lilly  LLY  closed the most recent trading day at  113 20  moving  0 88  from the previous trading session  This change outpaced the S P 500 s 1 97  loss on the day  At the same time  the Dow lost 2 32   and the tech heavy Nasdaq lost 2 78  
Prior to today s trading  shares of the drugmaker had gained 3 98  over the past month  This has outpaced the Medical sector s loss of 1 15  and the S P 500 s loss of 3 33  in that time 
Wall Street will be looking for positivity from LLY as it approaches its next earnings report date  This is expected to be January 30  2019  The company is expected to report EPS of  1 30  up 14 04  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  6 32 billion  up 2 63  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  5 51 per share and revenue of  24 45 billion  These totals would mark changes of  28 74  and  6 92   respectively  from last year 
Investors might also notice recent changes to analyst estimates for LLY  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 1 82  higher within the past month  LLY is currently sporting a Zacks Rank of  2  Buy  
Digging into valuation  LLY currently has a Forward P E ratio of 20 36  This valuation marks a premium compared to its industry s average Forward P E of 14 76 
Investors should also note that LLY has a PEG ratio of 1 81 right now  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Large Cap Pharmaceuticals stocks are  on average  holding a PEG ratio of 2 based on yesterday s closing prices 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 38  putting it in the top 15  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow LLY in the coming trading sessions  be sure to utilize Zacks com ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-gains-as-market-dips-what-you-should-know-200358425,200358425
172016,393532,LLY,Bayer  BAYRY  Beats On Q3 Earnings  Revenue Estimates,opinion,"Bayer AG  DE BAYGN  s   OTC BAYRY   third quarter 2018 earnings per share was 87 cents  per American Depositary Receipt   ADR    which beat the Zacks Consensus Estimate of 41 cents 
On Sep 20  2017  Bayer performed an ADR ratio change  With the new ratio  four Bayer ADRs correspond to one Bayer ordinary share  Third quarter 2018 core earnings per share incorporate the effect of ADR ratio change  Core earnings per share were down 12 5  year over year to 35 cents from 40 cents  per ADR 
Total sales in the quarter were approximately  11 79 billion  up 32 3  from 8 90 billion in the year ago quarter  Sales also beat the Zacks Consenus Estimate of  11 31 billion  While the company registered sales growth at Pharmaceuticals  business declined at Consumer Health and Animal Health  Sales at Crop Science increased compared with that in the year ago quarter 
Year to date  shares of the company have lost 37 9  compared with the  s growth of 8 0  

 
All growth rates mentioned below are on a year over year basis and after adjusting for currency and portfolio changes 
Quarter Highlights
The company completed the acquisition of Monsanto  NYSE MON  on Jun 7  2018  for  63 billion  including debt  With the acquisition  Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications  the best research and development platform and the leading digital farming business 
Bayer lost de facto control over the Covestro Group at the end of September 2017  As of Sep 30  2017  there are four reporting segments   Pharmaceuticals  Consumer Health  Crop Science and Animal Health  As such  total figures for the four Life Science segments will no longer be presented separately 
Revenues at the Pharmaceuticals segment increased 2 4  to  4 163 million in the third quarter  Growth was backed by consistent strong performance of key products like Xarelto  Eylea  Xofigo  Stivarga and Adempas  Strongest sales growth among the other top Pharmaceuticals products was recorded for the diabetes treatment Glucobay  driven by expanded volumes in China 
However  sales of Adalat  Bayer s product to treat hypertension and coronary heart disease  decreased 6 4  as expanded volumes in China were not sufficient to compensate for declines in Japan and Canada 
Consumer Health sales were down 1 7  year over year to  1 297 million in the third quarter  However  on a currency and portfolio adjusted basis  sales grew 3   All regions contributed to growth  but Asia Pacific delivered the strongest sales  with an increase of more than 9  
In the reported quarter  Crop Science sales were  3 733 million  up 83 8  from the year ago quarter  Sales included  2 2 billion from the acquisition of Monsanto and about  100 million from the businesses divested to BASF in August  Sales from the Animal Health segment came in at  304 million  down 15 3  from the year ago quarter 
The segment recorded growth in the Asia Pacific region on a currency  and portfolio adjusted basis  while business was down year over year in other regions  Bayer registered sales growth for the Seresto flea and tick collar  3   and the Baytril antibiotic  8 7    However  sales of the Advantage line of flea  tick and worm control products declined 34 7  on a currency  and portfolio adjusted basis  particularly in North America 
2018 Outlook
The company reaffirmed its outlook for 2018 to reflect the Monsanto acquisition 
Sales are expected to come in at more than  39 billion  corresponding to a mid single digit percentage increase on a currency  and portfolio adjusted basis 
Core earnings per share are expected to be between  5 70 and  5 90  On a currency adjusted basis  this corresponds to a high single digit percentage decline Bayer Aktiengesellschaft Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
Bayer is a Zacks Rank  4  Sell  stock 
Some top ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 51 for 2018 and from  5 69 to  5 80 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 03   Shares of the company have increased 34 1  year to date 
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   Shares of the company have increased 32 7  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-beats-on-q3-earnings-revenue-estimates-200358848,200358848
172017,393533,LLY,Shire s Filing Accepted By FDA For Gattex s Label Expansion,opinion,Shire plc   NASDAQ SHPG    the global leader in rare diseases  announced that the FDA has accepted for filing the company s supplemental new drug application  sNDA  to expand the label of Gattex  teduglutide  for injection to pediatric patients  aged 1 17 years old   with Short Bowel Syndrome  SBS  who are dependent on parenteral support Gattex is already indicated for the treatment of adult patients with SBS who are dependent on parenteral support  Shire submitted the sNDA to the FDA on Sep 11  2018  The FDA is expected to reach a decision in March 2019 The application was supported by data from two completed phase III studies as well as interim data from two ongoing extension studies  Both the phase III studies evaluated the efficacy  safety  and pharmacodynamics of Gattex in children with SBS who were stable on their required parenteral nutrition  PN  intravenous  IV  support that provided at least 30  of caloric and or fluid electrolyte needs for at least three months prior to screening Shares of the company have increased 16 6  year to date against the  s decline of 7 5    Shire s efforts to develop its Gastrointestinal  GI  franchise are encouraging  Gattex was added to the company s portfolio after it acquired NPS Pharma in February 2015  The acquisition also added Natpara Natpar  an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism  to Shire s portfolio  Natpar received conditional marketing authorization from European Commission  EC  in April 2017 as hormone therapy for the treatment of adult patients with chronic hypoparathyroidism  The NPS Pharma acquisition boosted Shire s revenues and also complements the company s GI portfolio In June 2016  Shire also licensed the global rights to all indications of Pfizer s   NYSE PFE   candidate  SHP647  formerly PF 00547659   SHP647  an investigational biologic  is being evaluated for the treatment of moderate to severe inflammatory bowel disease  Crohn s disease in phase I and phase II studies  The company is also expanding its immunology business  In September 2018  Shire acquired sanaplasma AG  a source plasma collection company headquartered in Switzerland  The acquisition of sanaplasma is expected to increase Shire s access to plasma in the longer term and add to its European plasma collection network  complementing existing core capabilities in plasma supply and manufacturing  This acquisition is expected to support growth of the Immunology business and help meet the needs of patients around the world Shire plc Price   Zacks Rank   Stocks to ConsiderShire is a Zacks Rank  3  Hold  stock Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY   and Eli Lilly and Company   NYSE LLY    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11 99  Lilly s earnings per share estimates have increased from  5 43 to  5 51 for 2018 and from  5 67 to  5 80 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 10 03   Shares of the company have increased 33 1  year to date 3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline  So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/shires-filing-accepted-by-fda-for-gattexs-label-expansion-200359120,200359120
172018,393534,LLY,Merck Starts Rolling BLA Submission For Ebola Vaccine V920,opinion,Merck   Co   Inc    NYSE MRK   announced that it has initiated the rolling submission of a biologics license application  BLA  to the FDA for its Ebola vaccine candidate V920  The investigational candidate is being developed for the treatment of the deadly Ebola Zaire disease The rolling submission comes in accordance with the FDA s Breakthrough Therapy Designation  which was granted to the candidate in July 2016  The designation from the regulatory body is intended to expedite the development and review of drugs with an early evidence of substantial potential clinical benefit to patients or benefit patients without current treatment options Merck expects to complete the rolling submission of the BLA in 2019 We would like to remind investors that another biotech company Inovio Pharmaceuticals   NASDAQ INO   is also currently evaluating its Ebola vaccine candidate   INO 4212   in a preclinical study  In October 2018  the company announced that INO 4212 provided 100  protection following a lethal dose of the Ebola virus in the study  The vaccine prompted long term immune responses in monkeys Shares of Merck have rallied 32 6  so far this year  outperforming the  increase of 8  Merck has several marketed vaccines in its portfolio like Gardasil Gardasil 9  ProQuad M M R II Varivax  RotaTeq  Pneumovax 23 and Zostavax In the last reported quarter  total vaccine sales were  2 2 billion  a 13  increase year over year  In vaccines  Gardasil Gardasil 9 sales soared 55  to  1 05 billion  gaining from easy year over year comparisons  the ongoing commercial launch in China and strong growth in Europe  In the United States too  demand trends remain strong  In the third quarter  Merck received an FDA approval for Gardasil 9 in an expanded patient population  women and men aged from 27 to 45   which can fetch in additional sales in the future quarters Proquad  M M R II and Varivax vaccines recorded combined sales of  525 million in the reported quarter Apart from the Ebola vaccine candidate  Merck is studying an investigational polyvalent conjugate vaccine  V114  The candidate is currently being evaluated in several phase III studies for the treatment of pneumococcal disease Merck   Co   Inc  Price and Consensus   Zacks Rank   Other Stocks to ConsiderMerck currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the pharma include Bristol Myers Squibb Company   NYSE BMY   and Eli Lilly and Company   NYSE LLY    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Eli Lilly carries a Zacks Rank of 2  You can  Bristol Myers  earnings estimates have been revised 6 1  upward for 2018 and 6 5  for 2019 over the past 60 days Eli Lilly s earnings estimates have moved 0 7  north for 2018 and 1 2  for 2019 over the past 60 days  The stock has surged 33 1  so far this year 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/merck-starts-rolling-bla-submission-for-ebola-vaccine-v920-200359197,200359197
172019,393535,LLY,AbbVie s HCV Drug Mavyret Succeeds In Label Expansion Study,opinion,"AbbVie  Inc    NYSE ABBV   announced that its successful hepatitis C virus  HCV  medicine  Mavyret demonstrated high virologic cure rates in a study evaluating the 8 week  pan genotypic  ribavirin free  once daily HCV treatment for an expanded patient population 
The phase IIIb EXPEDITION 8 study is evaluating Mavyret in treatment na ve HCV patients with compensated cirrhosis across all major genotypes  GT1 6   Mavyret is presently marketed in the United States for treatment na ve patients without cirrhosis  For patients with compensated cirrhosis  Mavyret is approved as a 12 week pan genotypic treatment option 
New data from cohort 1 of the study showed that on eight weeks of treatment with Mavyret  100  of genotype 1  2  4  5 and 6 treatment na ve HCV patients with compensated cirrhosis achieved SVR12 per protocol analysis  Cohort two of the study  evaluating treatment na ve genotype 3 patients without cirrhosis  is ongoing 
The data were presented at the Liver Meeting organized by the American Association for the Study of Liver Diseases  AASLD  in San Francisco  CA 
Mavyret has seen a highly successful launch because of the shorter duration treatment benefit it offers 
Mavyret  a combination of glecaprevir  a potent protease inhibitor and pibrentasvir  a NS5A inhibitor  gained approval in the United States  EU  Canada and Japan in 2017  Mavyret performed beyond expectations in the first year of launch  recording sales of almost  500 million in 2017  The drug recorded sales of  2 6 billion in the first nine months of 2018  commanding a global market share of 50  
Mavyret has the potential to rejuvenate growth in the HCV franchise  According to AbbVie  it may be used in up to 95  of HCV patients  depending on the stage of liver disease and prior treatment history 
So far this year  AbbVie s stock has declined 8 8  against the  s increase of 8  

 
AbbVie currently has a Zacks Rank  3  Hold   You can see  
Some better ranked pharma stocks include Johnson   Johnson   NYSE JNJ    Merck   NYSE MRK   and Eli Lilly   NYSE LLY    All are  2 Ranked  Buy  stocks 
J J s earnings estimates have risen 0 2  for 2018 and 0 5  for 2019 over the past 30 days  The stock has gained 3 6  this year so far 
Lilly s earnings estimates have risen 0 7  for 2018 and 0 2  for 2019 over the past 30 days  The stock has gained 33 1  this year so far 
Merck s earnings estimates have risen 1 4  for 2018 and 1 1  for 2019 over the past 30 days  The stock has gained 32 6  this year so far 
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/abbvies-hcv-drug-mavyret-succeeds-in-label-expansion-study-200359286,200359286
172039,393555,LLY,Eli Lilly Earnings Preview  New Drugs And New LOEs,opinion,"Judging by the stock s performance in 2018  investors seem to be happy with Eli Lilly  NYSE LLY  CEO David Ricks  progress on restructuring and delivering growth  Shares are up just over 26  year to date  beating the S P 500 s  SPX  1  increase and the S P Healthcare Select Sector s  IXV  6 7  climb 
The next update for investors and analysts is LLY s third quarter earnings  scheduled for before market open on Tuesday  Nov  6 
For Q3  LLY is expected to report adjusted EPS of  1 35 on revenue of  6 1 billion  according to third party consensus analyst estimates  In the same quarter last year  the company reported adjusted EPS of  1 05 on revenue of  5 66 billion  LLY has met or beat earnings estimates in the past six quarters  with the company beating by the widest margins in its two latest reports 
Analysts and investors are again likely to be looking for ongoing progress in CEO Ricks  progress on increasing manufacturing efficiencies and cutting costs  In Q2  operating expenses decreased 1  to  2 99 billion 
Within those costs  the company said it had cut marketing  selling and administrative expenses by 4   while research and development expenses were up 5   so management is clearly shifting focus to developing new drugs 
Pipeline and New Drugs
In Q2 2018  LLY s newer drugs Trulicity  Basaglar  Taltz and Verzenio were the main drivers of growth  As it takes time for newer drugs to ramp up  analysts and investors are likely to be looking to see how these drugs have continued to perform 
Just this morning  LLY announced that Trulicity  a type 2 diabetes treatment  demonstrated superiority in the reduction of cardiovascular events in its REWIND study  As many saw the results from this trial as a short term risk for the company  and a potential driver for Trulicity sales  management is likely to provide some more information about this study on tomorrow s call 
Trulicity has been the company s best selling drug lately and generated sales of  780 million in Q2 2018  up 62  year over year  Many of the LLY s other new drugs are designed to address different aspects of diabetes  Basaglar  a long acting insulin  had  201 8 million in sales  a 133  year over year increase  Jardiance s  another diabetes related drug  growth slowed down in the second quarter  up 43  year over year to  147 million 
Immunology has been another area of medicine LLY has said it s committed to  LLY s blockbuster drug within this category is Taltz  which treats plaque psoriasis and psoriatic arthritis  Sales of this drug increased 59  year over year in Q2 2018  to  220 million  Management said it plans to run head to head trials with competitor Johnson   Johnson s  JNJ  Tremfya to try to demonstrate superiority  If it succeeds  that would be one factor that would help sway doctors when writing prescriptions 
Loss of Exclusivity on Cialis
Loss of exclusivity  LOE  has always been a concern for drug makers and LLY has had a series of drugs that have lost protections in recent years  In Q2 2018  the LOE for Effient  Strattera  Cymbalta  Zyprexa  Evista and Axiron negatively impacted volume growth by 4 5   according to the company 
Cialis is one of the latest of LLY s blockbuster drugs that is currently looking at more competition  Management had attributed some loss of sales to Teva s  TEVA  generic sildenafil coming on the market in December 2017  That loss of sales is a trend the company expects to continue as generic tadalafil  the same compound as Cialis  was launched at the end of September by TEVA 
With very little time between TEVA s launch and the end of the quarter  analysts have indicated they aren t expecting a significant impact at this time  However  they might be looking for more information from management now that they ve seen a few weeks of sales 
In 2017  LLY reported that Cialis generated  2 32 billion in sales  roughly 10  of the company s revenue and its second highest selling drug at the time  In the first half of 2018  Cialis sales declined 11  year over year to  1 03 billion 
Elanco IPO
Tomorrow s report will be the first one since LLY spun off its animal health unit Elanco  ELAN   The IPO has been one factor for analysts  positivity towards LLY lately  ELAN was initially priced at  24 per share in its IPO and shares are now trading around  33  LLY sold 20  of its stake in ELAN in the offering  and management said it plans to divest the rest of it over time 
Originally  they had indicated they might look to divest the stake as early as 2019  so analysts are likely to be looking for more information about how LLY plans to go about exiting that business 

2018 Break Out  After trading sideways for several years  LLY has had a big breakout in 2018 and is up 26  year to date  The stock is sitting close to  104  a level of support the stock has been bouncing off of since the end of August 2018  LLY is compared to the S P Healthcare Select Sector Index  IXV  teal line  and the S P 500  SPX  purple line   Chart source  thinkorswim  by TD Ameritrade  Not a recommendation  For illustrative purposes only  Past performance does not guarantee future results 
Eli Lilly Options Trading Activity
LLY has had a big run in 2018  The stock went from a February low of  73 69 to hit a new all time high of  116 61 at the start of October  Shares were up  4 early on today after the company announced study results this morning  putting the stock about  6 away from its all time high 
Around tomorrow s earnings release  options traders have priced in a 3  stock move in either direction  according to the Market Maker Move indicator on the thinkorswim  platform  Implied volatility was at the 76th percentile as of this morning 
In short term trading at the Nov  9 weekly expiration  there hasn t been a whole lot of activity that stands out  At next week s Nov  16 monthly expiration  calls have been active at the 110 strike price  a level the stock has been trading around for much of October  Recent volumes have been heavier for puts and concentrated at the 105 strike 
Looking at the Dec  21 monthly expiration  both the 110 and 115 strike price on the call side have been more active  while the 105 strike has seen the heaviest trading on the put side 
Note  Call options represent the right  but not the obligation  to buy the underlying security at a predetermined price over a set period of time  Put options represent the right  but not the obligation to sell the underlying security at a predetermined price over a set period of time 
TD Ameritrade  commentary for educational purposes only  Member SIPC  Options involve risks and are not suitable for all investors  Please read Characteristics and Risks of Standardized Options ",2018-11-06,JJ Kinahan,https://www.investing.com/analysis/eli-lilly-earnings-preview-new-drugs-and-new-loes-200355206,200355206
172040,393556,LLY,Eli Lilly  LLY  Q3 Earnings Surpass Estimates,opinion,"Eli Lilly  LLY  came out with quarterly earnings of  1 39 per share  beating the Zacks Consensus Estimate of  1 37 per share  This compares to earnings of  1 05 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 46   A quarter ago  it was expected that this drugmaker would post earnings of  1 31 per share when it actually produced earnings of  1 50  delivering a surprise of 14 50  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Lilly  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  6 06 billion for the quarter ended September 2018  missing the Zacks Consensus Estimate by 0 70   This compares to year ago revenues of  5 66 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Lilly shares have added about 30 4  since the beginning of the year versus the S P 500 s gain of 2 4  
What s Next for Lilly 
While Lilly has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Lilly was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 27 on  6 34 billion in revenues for the coming quarter and  5 47 on  24 48 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 27  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-q3-earnings-surpass-estimates-200355291,200355291
172041,393557,LLY,Sanofi Eczema Drug Dupixent s SBLA Gets Priority Review,opinion,Sanofi  PA SASY    NYSE SNY   and partner Regeneron Pharmaceuticals   NASDAQ REGN   announced that the FDA has granted a priority review to its atopic dermatitis drug Dupixent s  dupilumab  supplemental Biologics License Application  sBLA   The sBLA is seeking label expansion of the drug to include adolescent patients who are 12 years to 17 years of age with moderate to severe atopic dermatitis  eczema  and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable  A decision from the FDA on approval of the sBLA is expected by Mar 11  2019 The sBLA was based on positive data from a phase III study  which evaluated Dupixent monotherapy  Data showed that signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients treated with the drug were significantly improved We remind investors that the drug is already approved in the United States and Europe for treating adult patients in similar indication Please note that the priority review designation from the FDA is generally granted to drugs with potential to provide significant improvements in the safety and effectiveness of the treatment plus prevention or diagnosis of a serious disease Dupixent has shown strong growth so far this year  An expanded patient population will certainly boost the prospects of the drug further  Moreover  the company and partner Regeneron are also working to expand Dupixent s label in other indications  In October  the FDA approved a label expansion of the drug as an add on maintenance treatment in adults and adolescents  12 years of age or older  with moderate to severe asthma However  we note that several other pharma companies are also developing their candidates drugs for the treatment of atopic dermatitis including Pfizer s   NYSE PFE   JAK1 inhibitor  PF 04965842   Lilly s   NYSE LLY   Olumiant and AbbVie s upadacitinib Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/sanofi-eczema-drug-dupixents-sbla-gets-priority-review-200356136,200356136
172042,393558,LLY,Mallinckrodt  MNK  Beats On Q3 Earnings Estimates  Ups View,opinion,"Mallinckrodt Public Limited Company   NYSE MNK   reported adjusted earnings of  2 10 per share in the third quarter of 2018  up from the year ago quarter s  1 82  The bottom line also beat the Zacks Consensus Estimate of  1 80 
Net sales in the quarter came in at  640 million  grew 6 5  year over year and surpassed the Zacks Consensus Estimate of  633 million 
Mallinckrodt s stock has gained 20 3  in the year so far  against the  s decline of 6 7  

Quarter in Detail
Acthar  Mallinckrodt s largest product  generated sales of  290 1 million  down 6  due to the residual impact of the previously reported patient withdrawal issues   
Inomax  its second largest product  generated sales of  133 2 million  up 6   driven by strong demand  Ofirmev sales increased 15 5  year over year to  87 1 million  owing to strong demand stemming from customers  focus on non opioid or multimodal pain management 
Sales of the Therakos immunology platform were  60 million  up 8 5   driven by increased demand in Europe 
Amitiza sales came in at  48 2 million  The drug was added to Mallinckrodt portfolio as a result of erstwhile Sucampo Pharmaceuticals  acquisition 
Adjusted selling  general and administrative expenses in the quarter decreased 1 4  to  175 8 million  Meanwhile  research and development expenses increased 67 4  to  78 5 million 
During the quarter  the company reduced total debt by  170 6 million  primarily comprising  150 million in repayments on its revolving credit facility and  15 million decrease in the receivable securitization  The company ended the quarter with net debt less than  6 billion 
2018 Guidance
Propelled by a strong performance in the third quarter of 2018  the company increased its annual guidance  Adjusted diluted earnings per share guidance for fiscal 2018 is expected to be  7 00  7 20  up from the previous guidance of  6 50  6 90 
The company did not provide any update on the revenue guidance  Its previous revenue guidance was 4 7  growth 
Our Take
The strong results in the third quarter bode well for Mallinckrodt  which has been in troubled waters for quite some time now  While Acthar sales continue to decline  the hospital portfolio looks solid 
This year is expected to be a transformative year for Mallinckrodt as the company strives hard to revive its product portfolio pipeline  The company also raised its annual earnings guidance  The Sucampo buyout will diversify the company s portfolio considering Amitiza s potential  Mallinckrodtis currently streamlining its business to focus better on its innovative medicines and therapies like terlipressin and StrataGraft  
Zacks Rank   Other Key Picks
Mallinckrodt carries a Zacks Rank  2  Buy  
Other top ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 81 for 2018 and from  3 83 to  4 03 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 47 for 2018 and from  5 69 to  5 78 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 15  
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-beats-on-q3-earnings-estimates-ups-view-200356417,200356417
172044,393560,LLY,AstraZeneca s  AZN  Q3 Earnings Beat  New Drugs Drive Sales,opinion,"AstraZeneca plc   NYSE AZN   beat the Zacks Consensus Estimate for both earnings and sales in the third quarter of 2018  With its product sales growing after a long time  Pascal Soriot  AstraZeneca s chief executive officer  said this marks  the start of a period of sustained growth  for several years  The Swiss pharma giant maintained its previously issued outlook for 2018  The stock rose slightly in pre market trading on November 8 This year so far  AstraZeneca s shares have risen 13  compared with the  s increase of 5    Third quarter 2018 core earnings of 36 cents per American Depositary Share   ADS   beat the Zacks Consensus Estimate of 33 cents  Core earnings per share of 71 cents declined 22  year over year at constant exchange rates   CER   hurt by lower revenues and operating profit Total revenues declined 13  at CER to  5 34 billion in the reported quarter  Revenues  however  beat the Zacks Consensus Estimate of  5 12 billion All growth rates mentioned below are on a year over year basis and at CER Product Sales RiseProduct sales rose 9  at CER in the quarter to  5 27 billion  Higher sales of newer medicines  particularly cancer drugs  and strong performance in emerging markets  mainly China  offset lower sales of many other legacy medicines to drive product sales growth  AstraZeneca s newer medicines sales rose 86  in the quarter as almost every new product it has launched in recent years has done well Externalization revenues were  74 million in the quarter  down 95  Externalization revenues are the revenues arising from AstraZeneca s externalization agreements Among AstraZeneca s various therapeutic areas  Oncology sales were up 57   New Cardiovascular  Renal and Metabolism  CVRM  was up 19   Respiratory sales rose 5  and other medicines were down 19  Newer ProductsAmong the newer medicines  Lynparza sales rose 12 7  sequentially to  169 million in the quarter  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   Tagrisso recorded sales of  506 million  up almost 20  year over year driven by increased testing rates and rapid uptake in the first line setting  Tagrisso was approved in first line setting for advanced lung cancer in the United States in April in EU in June and in Japan in August Imfinzi generated sales of  187 million in the quarter compared with  122 million in the second quarter  In February  Imfinzi was approved and immediately launched for the second indication in the United States   early stage lung cancer  NSCLC    which has driven sales higher in 2018 so far  The majority of sales in the third quarter were from the lung cancer indication  Imfinzi was approved in the EU for early stage lung cancer indication in September Calquence  which was launched in the United States in October last year  generated sales of  18 million in the third quarter compared with  12 million in the previous quarter Brilinta Brilique sales were  336 million in the reported quarter  up 20  year over year Farxiga recorded sales of  355 million in the quarter  up 27  as the medicine continued to lead the market in terms of volume New asthma medicine  Fasenra recorded sales of  86 million in the quarter  compared with  65 million in the previous quarter  AstraZeneca said Fasenra enjoys leadership position among novel biologic asthma medicines Bevespi  a LAMA LABA in a pressurized metered dose inhaler  recorded sales of  10 million in the quarter  higher than  8 million in the previous quarter amid slower than anticipated growth in LAMA LABA class Among other new medicines  Movantik Moventig recorded sales of  32 million in the quarter  up 7   while Iressa sales declined 4  to  131 million  Bydureon sales increased 19  to  152 million  Byetta sales were down 10  to  34 million and Onglyza sales rose 12  to  140 million Older ProductsCrestor sales declined 38  to  353 million  U S  and Europe sales were weak as multiple generic versions of the drug entered the market  Crestor sales rose 13  in Emerging Markets to  207 million due to higher demand in China  AstraZeneca is hopeful that the effects of the Crestor patent expiration in Europe and Japan will recede materially in 2019 Seroquel XR sales declined 35  to  40 million due to competition from generic launches Symbicort sales declined 7  in the quarter to  619 million due to pricing pressure in the United States and stiff competition in Europe  Pulmicort sales rose 10  to  264 million as higher sales in the emerging markets made up for a weaker performance in the United States and Europe Nexium recorded sales of  422 million  down 9  due to declining sales in the United States and Europe  In October  AstraZeneca announced its decision to divest prescription medicine rights to Nexium in Europe Meanwhile  sales of other legacy drugs including Faslodex  Zoladex  Arimdex  Casodex  Seloken and Synagis grew in the quarter while sales of others like Atacand and Daliresp Daxas declined Regional PerformanceIn the United States  product sales were up 25  to  1 74 billion as higher sales of newer products were partially offset by lower Symbicort sales  However  European markets witnessed a 5  decline in sales to  1 13 billion  Revenues from Emerging Markets were up 16  to  1 7 billion  primarily on the back of strong growth in China  up 32  to  954 million   In Established ROW market  comprising Japan  Canada and other markets   sales declined 11  to  697 million Profit DiscussionAstraZeneca s core gross margin declined one percentage points to 79 4   Core selling  general and administrative  SG A  expenses rose 7  to  2 26 billion due to investment in product launches line extensions In the quarter  core research and development  R D  expenses declined 6  to  1 24 billion  Operating margin declined 4 percentage points to 24 7  in the quarter due to lower revenues and higher SG A costs 2018 OutlookAstraZeneca maintained its previously issued earnings and sales outlook AstraZeneca expects core EPS for 2018 in the range of  1 65 to  1 75 per ADR  The company expects product sales to grow in low single digit percentage Management guided total externalization revenues and other income in 2018 to be less than 2017 Currency movements are expected to favorably impact product sales and core earnings per share by a low single digit percentage Adjusted R D costs are expected to decline in low single digit percentage versus prior expectation of being in line or decline in a low single digit percentage range from 2017 levels The company anticipates SG A costs to increase broadly in line with the rate seen year to date to support product launches like Fasenra and Imfinzi  Previously  the company expected this cost item to increase in low to mid single digit percentageAdjusted tax rate is expected to be in the range of 16  20  compared with 14  for 2017  AstraZeneca PLC Price  Consensus and EPS Surprise
    
Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Some better ranked pharma stocks include Johnson   Johnson   NYSE JNJ   and Eli Lilly   NYSE LLY    Both are  2 Ranked  Buy  stocks J J s earnings estimates have risen 0 2  for 2018 and 0 6  for 2019 over the past 30 days  The stock has gained 3 6  this year so far Lilly s earnings estimates have remained stable for 2018 and increased 0 2  for 2019 over the past 30 days  The stock has gained 29 9  this year so far Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-q3-earnings-beat-new-drugs-drive-sales-200356987,200356987
172045,393561,LLY,Nektar  NKTR  Q3 Earnings   Sales Beat Estimates  Shares Up,opinion,"Nektar Therapeutics   NASDAQ NKTR   reported a loss of 56 cents per share for the third quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 64 cents  The company had recorded a loss of 37 cents per share in the year ago period Nektar s stock was up 2 1  in pre market trading on Nov 8  Shares of Nektar have lost 36 5  so far this year compared with the  s decrease of 2 7  Quarterly revenues were  27 8 million compared with the year ago figure of  152 9 million  The significant decrease in revenues was attributable to  127 6 million in upfront fees received from Eli Lilly   NYSE LLY   in the third quarter of 2017 related to development and commercialization collaboration deal of NKTR 358  The top line beat the Zacks Consensus Estimate of  25 million Quarter in DetailThe top line comprises product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues In the third quarter  product sales declined 4 3  to  4 3 million from the year ago period   However  non cash royalty revenues increased 3 8  to  8 4 million The company reported royalty revenues of  10 3 million in the quarter  registering an improvement of 10 3  from  9 3 million a year ago License  collaboration and other revenues came in at  4 9 million compared with  131 1 million in the prior year  In the year ago period  the company recorded upfront fees from Eli Lilly related to a license agreement for NKTR 358 Research and development  R D  expenses escalated 56 6  to  102 9 million  primarily due to investments in pipeline  including key candidates NKTR 358  NKTR 214 and NKTR 262  It also included costs related to filing of a new drug application   NDA   for NKTR 181 Nektar is looking to get NKTR 181  an opioid analgesic  for the treatment of chronic low back pain  approved  A decision from the FDA is expected by May 29  2019 General and administrative  G A  expenses were up 55 3  to  18 7 million in the reported quarter primarily due to higher stock based compensation expenses Pipeline UpdateNektar is developing several candidates across important therapeutic areas including Onzeald in breast cancer and NKTR 181 in chronic pain  The company is also developing several immuno oncology candidates  with NKTR 214 being a primary candidate among them In November  the company entered into clinical collaboration with Pfizer   NYSE PFE   to develop doublet or triplet combination therapies of NKTR 214 in several cancer indications including metastatic castration resistant prostate cancer and squamous cell carcinoma of the head and neck  Per the terms of the agreement  Pfizer will initiate a phase Ib II study in 2019 to evaluate combination therapies of its cancer drugs candidates Bavencio  avelumab  and talazoparib or Xtandi  enzalutamide  with NKTR 214 In September  Nektar and partner  Bristol Myers   NYSE BMY    initiated a phase III study to evaluate NKTR 214 plus Opdivo  nivolumab  for treating previously untreated unresectable or metastatic melanoma Onzeald is currently being evaluated in a phase III  ATTAIN  study for the treatment of adults with advanced breast cancer  having brain metastases Nektar Therapeutics Price  Consensus and EPS Surprise
    Zacks RankNektar currently carries a Zacks Rank  4  Sell  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-q3-earnings--sales-beat-estimates-shares-up-200356980,200356980
172046,393562,LLY,Horizon Pharma  HZNP  Q3 Earnings   Sales Beat  Shares Rise,opinion,Horizon Pharma plc   NASDAQ HZNP   reported better than expected results for the third quarter of 2018   Following the news  the company s shares went up 16   Horizon Pharma s stock price has increased 53 7  year to date  against the  s decline of 14  The company reported third quarter adjusted earnings of 65 cents per share  which beat the Zacks Consensus Estimate of 50 cents and were higher than 26 cents reported in the year ago quarter The company reported record quarterly sales of  325 3 million  up 20  year over year  The top line also beat the Zacks Consensus Estimate of  315 million Quarter in DetailThe company realigned its structure to operate its strategic growth business   orphan and rheumatology   separately from its primary care business  Thus with effect from the second quarter of 2018  the company is reporting its financial results as two separate segments   the orphan and rheumatology segment  and the primary care segment  The company expects the new structure to help it better allocate resources in developing products for unmet treatment needs of patients with rare diseases Sales of the orphan and rheumatology segment were  219 9 million  up 25 3  from the prior year quarter  driven by continued strong growth of Krystexxa  Ravicti and Procysbi  Krystexxa sales increased 64  year over year to  70 2 million  The company is making significant investments in the commercial expansion of Krystexxa  which is expected to drive future net sales growth and margin expansion over time Third quarter 2018 net sales of the primary care segment were  105 4 million  up 10  year over year Adjusted research and development  R D  expenses were 5 9  of net sales  and adjusted SG A expenses were 39 3  of the same 2018 Guidance IncreasedHorizon Pharma expects sales to be  1 17  1 2 billion The company expects Krystexxa sales to increase more than 65  year over year in 2018 Other UpdatesThe company s pipeline candidate teprotumumab is being developed for the treatment of thyroid eye disease  TED   The phase III confirmatory study  OPTIC  evaluating teprotumumab for the treatment of moderate to severe active TED  completed enrollment on Sep 4  2018  and the top line results are expected in the second quarter of 2019 Horizon Pharma also presented a new phase II teprotumumab data that underscore the durable efficacy observed in thyroid eye disease The company is also working to maximize the role of Krystexxa to help more patients  including adapting its MIRROR immunomodulation study based on promising recent data to support potential for registration   The company expects to begin enrolling patients into the adapted protocol in the second quarter of 2019 The company is pursuing two development programs   HZN 003 and PASylated uricase technology   for next generation biologics for uncontrolled gout  to support and sustain the company s market leadership in uncontrolled gout   Horizon Pharma Public Limited Company Price  Consensus and EPS Surprise    Zacks Rank   Stocks to ConsiderHorizon Pharma has a Zacks Rank  3  Hold  Some top ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Eli Lilly and Company   NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  Lilly s earnings per share estimates have increased from  5 42 to  5 47 for 2018 and from  5 69 to  5 78 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 03   Shares of the company have increased 29 9  year to date Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   Shares of the company have increased 33 4  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-q3-earnings--sales-beat-shares-rise-200357061,200357061
172062,393578,LLY,Is Eli Lilly And  LLY  Stock Outpacing Its Medical Peers This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Has Eli Lilly and  LLY  been one of those stocks this year  A quick glance at the company s year to date performance in comparison to the rest of the Medical sector should help us answer this question 
Eli Lilly and is a member of our Medical group  which includes 845 different companies and currently sits at  5 in the Zacks Sector Rank  The Zacks Sector Rank considers 16 different groups  measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group 
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions  highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months  LLY is currently sporting a Zacks Rank of  2  Buy  
The Zacks Consensus Estimate for LLY s full year earnings has moved 0 03  higher within the past quarter  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Based on the most recent data  LLY has returned 26 39  so far this year  Meanwhile  stocks in the Medical group have gained about 1 84  on average  This shows that Eli Lilly and is outperforming its peers so far this year 
Breaking things down more  LLY is a member of the Large Cap Pharmaceuticals industry  which includes 14 individual companies and currently sits at  55 in the Zacks Industry Rank  This group has gained an average of 6 60  so far this year  so LLY is performing better in this area 
Investors in the Medical sector will want to keep a close eye on LLY as it attempts to continue its solid performance ",2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/is-eli-lilly-and-lly-stock-outpacing-its-medical-peers-this-year-200354829,200354829
172066,393582,LLY,Playing The Waiting Game  Plus MedTech  Pharma In Q3 Earnings,opinion,"Tuesday  November 6  2018Today has been a date long circled on many an investor s calendar  Results from today s tally will no doubt have a profound affect on the stock market  and perhaps even the way market participants view the overall U S  economy going forward  However  we won t get the final numbers until after today s opening bell  so until then we re just playing the waiting game That s right  I m talking about  the government jobs opening report  or JOLTS  for the month of September   What   Last month showed a record number of job openings for the last full month of summer  so in some ways we re looking in the rear view mirror  And a record number of job openings   7 1 million for August  pending a possible revision an hour or so from now   can be a double edged sword  on one hand  it speaks loudly to our historically robust labor market  on the other  it demonstrates employers are increasingly finding difficulty filling positions at particular earnings points with particular skill sets Of course  Election Day is today   the most anticipated Midterms in recent memory  Dozens of races both to fill congressional seats and state capitols are currently too close to call  and both Republican and Democratic parties have grown further apart since President Trump shocked the world with his upset win two years ago But following Midterm Elections  since World War 2  according to MarketWatch  the market has gone up every single time  Democrats have won majorities  Republicans have won them  but each time the market traded up as a result  So what does that tell you  The market hates uncertainty  once we find out who will be leading the government for the next two years  it will be easier to see where to invest one s money We re big on Pharma  MedTech and like minded stocks this morning as Q3 earnings season rages on  CVS Health Corp    NYSE CVS   topped expectations by 2 cents to  1 73 per share on revenues that marginally beat expectations to  47 27 billion in the quarter  Shares are up 2 5  following the report in today s pre market  This company also plans to purchase health insurer Aetna  NYSE AET   Zacks Rank  2  Buy  rated Eli Lilly   NYSE LLY   also surpassed expectations by 2 cents per share to  1 39  though quarterly sales missed the Zacks consensus by 0 7  to  6 06 billion  Following a strong  30  year to date for Lilly stock  shares are slightly down in today s pre market  Biotech major Regeneron   NASDAQ REGN   blew away estimates on the bottom line    5 87 per share versus  5 21 expected and  3 99 in the year ago quarter   while narrowly topping on sales to  1 66 billion  Share are up in today s pre market  albeit slightly  following a 5 6  upswing year to date  Perhaps strongest of all this morning came from Zacks Rank  2 rated Mallinckrodt   NYSE MNK    a player in the generics drug market  which posted  2 10 per share for a beat of 30 cents over the Zacks consensus  Sales of  640 million in the quarter beat slightly and was down year over year  However  this company which has traded up 20  from early January is up another 6 8  in today s pre market activity  Mark VickerySenior Editor
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/playing-the-waiting-game-plus-medtech-pharma-in-q3-earnings-200355536,200355536
172068,393584,LLY,September JOLTS Report In Spotlight,opinion,Today has been a date long circled on many an investor s calendar  Results from today s tally will no doubt have a profound affect on the stock market  and perhaps even the way market participants view the overall U S  economy going forward  However  we won t get the final numbers until after today s opening bell  so until then we re just playing the waiting game That s right  I m talking about  the government jobs opening report  or JOLTS  for the month of September   What   Last month showed a record number of job openings for the last full month of summer  so in some ways we re looking in the rear view mirror  And a record number of job openings   7 1 million for August  pending a possible revision an hour or so from now   can be a double edged sword  on one hand  it speaks loudly to our historically robust labor market  on the other  it demonstrates employers are increasingly finding difficulty filling positions at particular earnings points with particular skill sets Of course  Election Day is today   the most anticipated Midterms in recent memory  Dozens of races both to fill congressional seats and state capitols are currently too close to call  and both Republican and Democratic parties have grown further apart since President Trump shocked the world with his upset win two years ago But following Midterm Elections  since World War 2  according to MarketWatch  the market has gone up every single time  Democrats have won majorities  Republicans have won them  but each time the market traded up as a result  So what does that tell you  The market hates uncertainty  once we find out who will be leading the government for the next two years  it will be easier to see where to invest one s money We re big on Pharma  MedTech and like minded stocks this morning as Q3 earnings season rages on  CVS Health Corp    NYSE CVS   topped expectations by 2 cents to  1 73 per share on revenues that marginally beat expectations to  47 27 billion in the quarter  Shares are up 2 5  following the report in today s pre market  This company also plans to purchase health insurer Aetna  NYSE AET  Zacks Rank  2  Buy  rated Eli Lilly   NYSE LLY   also surpassed expectations by 2 cents per share to  1 39  though quarterly sales missed the Zacks consensus by 0 7  to  6 06 billion  Following a strong  30  year to date for Lilly stock  shares are slightly down in today s pre market Biotech major Regeneron   NASDAQ REGN   blew away estimates on the bottom line    5 87 per share versus  5 21 expected and  3 99 in the year ago quarter   while narrowly topping on sales to  1 66 billion  Share are up in today s pre market  albeit slightly  following a 5 6  upswing year to date Perhaps strongest of all this morning came from Zacks Rank  2 rated Mallinckrodt   NYSE MNK    a player in the generics drug market  which posted  2 10 per share for a beat of 30 cents over the Zacks consensus  Sales of  640 million in the quarter beat slightly and was down year over year  However  this company which has traded up 20  from early January is up another 6 8  in today s pre market activity ,2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/september-jolts-report-in-spotlight-200355477,200355477
172071,393587,LLY,Will Stocks Gain After The Elections    Earnings From CVS  LLY  HEAR ,opinion,"On today s episode of Free Lunch  Ryan McQueeney chats with Dave Bartosiak about the near term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report  The host also recaps earnings results from CVS  Eli Lilly  and Regeneron 
Want more video content from Zacks  Subscribe to  now 
Free Lunch is presented by Zacks Investment Research  It is streamed live  four times per week  and features breaking news and analysis from Zacks strategists  Free Lunch is available on YouTube  Facebook  NASDAQ FB  Live  Twitter  Ustream  and more 
U S  stocks moved modestly higher in morning trading Tuesday  the same day millions of citizens are heading to the polls to cast votes in the midterm elections 
Wall Street appears to be handicapping a Democratic shift in the House of Representatives  as most opinion polls are calling for the party to take control of the chamber  Those same polls are also predicting that the Republicans will retain their lead in the Senate  meaning we could soon have a split Congress 
Interestingly enough  stocks have historically performed better during periods of Congressional gridlock  and if anything  investors will be happy to move past the uncertainty of the elections themselves  Plus  many of the same fundamental tailwinds and headwinds affecting equity prices will remain  regardless of the federal government s s partisan makeup 
And as the votes roll in  so too are the Q3 earnings reports  This morning was a busy session for pre market reports in the broader medical space  with the likes of CVS   NYSE CVS    Eli Lilly   NYSE LLY    and Regeneron   NASDAQ REGN   filing before the bell 
Results from these companies were relatively positive  although mixed in some areas  CVS topped estimates on both lines and said its merger with Aetna  NYSE AET  would be complete by Thanksgiving  Eli Lilly surpassed EPS projections  and Regeneron crushed profit expectations but missed revenue estimates 
Ryan covers all of these reports and gives his perspective on how Wall Street is feeling about the midterms on today s show 
Later  he checks in with Dave Bartosiak to continue chatting about the near term outlook for stocks after the midterms  Dave starts by showing an interesting technical trend that has developed in the Nasdaq   where bulls and bears have battled to keep the stock above and below certain moving averages and indicators 
Dave also suggests that part of this battle has to do with the event risk of the midterms  so he explains how and why Wall Street prices in risk when facing these uncertainties 
Finally  Dave highlights Turtle Beach   NASDAQ HEAR    which is scheduled to announce its latest quarterly results after the bell  He touches on the sentiment surrounding the stock and recommends a specific options play for those who are optimistic about the gaming headset maker  Make sure to check out the show to hear more 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/will-stocks-gain-after-the-elections--earnings-from-cvs-lly-hear-200355631,200355631
172080,393596,LLY,Eli Lilly  LLY  Gains But Lags Market  What You Should Know,opinion,"Eli Lilly  LLY  closed the most recent trading day at  108 98  moving  0 59  from the previous trading session  This move lagged the S P 500 s daily gain of 1 09   Meanwhile  the Dow gained 0 97   and the Nasdaq  a tech heavy index  added 2 01  
Prior to today s trading  shares of the drugmaker had gained 0 35  over the past month  This has outpaced the Medical sector s loss of 10 02  and the S P 500 s loss of 7 81  in that time 
Investors will be hoping for strength from LLY as it approaches its next earnings release  which is expected to be November 6  2018  The company is expected to report EPS of  1 37  up 30 48  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  6 10 billion  up 7 9  from the year ago period 
LLY s full year Zacks Consensus Estimates are calling for earnings of  5 47 per share and revenue of  24 48 billion  These results would represent year over year changes of  27 8  and  7 05   respectively 
Investors might also notice recent changes to analyst estimates for LLY  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 08  higher  LLY currently has a Zacks Rank of  2  Buy  
In terms of valuation  LLY is currently trading at a Forward P E ratio of 19 8  For comparison  its industry has an average Forward P E of 14 15  which means LLY is trading at a premium to the group 
We can also see that LLY currently has a PEG ratio of 1 76  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 1 93 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 78  putting it in the top 31  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-gains-but-lags-market-what-you-should-know-200352720,200352720
172087,393603,LLY,AMAG Posts Wider Than Expected Q3 Loss  Beats On Revenues ,opinion,"AMAG Pharmaceuticals Inc    NASDAQ AMAG   reported adjusted loss from continuing operations of 84 cents per share in the third quarter of 2018  excluding a  35 9 million loss on extinguishment of debt   against earnings of  1 57 reported in the year ago quarter  The Zacks Consensus Estimate stood at a loss of 77 cents 
Quarterly revenues came in at  122 2 million  down approximately 1 7  from  124 3 million in the year ago quarter  The top line beat the Zacks Consensus Estimate of  118 million 
Shares of the company increased 41 6  year to date  against the  s decline of 16 2  

 
Quarter in Detail
The company completed the sale of Cord Blood Registry  CBR  in August 2018  Hence  CBR s results have been excluded from the financial results  The sale of CBR will allow the company to eliminate the senior notes from its capital structure and strengthen its balance sheet as it continues to generate adjusted earnings before interest  tax  depreciation and amortization  EBITDA   The company s long term strategy focuses on continuing to grow and further diversify its pharmaceutical portfolio  
Makena sales came in at  80 2 million  down 18  year over year due to supply disruptions of the Makena branded IM products along with generic competition entering the market in July of 2018 
Combined sales of Feraheme and MuGard amounted to  37 1 million  up 41  year over year 
Costs and expenses from continuing operations  including costs of product sales and services  were  141 6 million  down 62 6  from the year ago quarter 
Discontinued Operations
As a result of the sale of CBR for  530 million in cash  CBR has been classified as discontinued operations for accounting purposes  Net income from discontinued operations in the third quarter of 2018 was  95 5 million  of which  89 6 million was the gain on the sale of the business compared with  3 7 million of net income in the year ago period  The company paid off  475 million of high yield debt  eliminating nearly  40 million in annual cash interest expenses 
2018 Outlook
AMAG now expects revenues for 2018 to be  470  490 million  narrowed from its previous guidance of  450  490 million 
Others
During the quarter the company acquired AMAG 423  an orphan drug candidate for the treatment of severe preeclampsia  previously referred to as  Velo Option    reaffirming its focus on delivering innovative therapies that address unmet medical needs AMAG Pharmaceuticals  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
AMAG carries a Zacks Rank  3  Hold  
Some better ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 81 for 2018 and from  3 83 to  4 03 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 47 for 2018 and from  5 69 to  5 78 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 15   The stock has rallied 27 7  year to date 
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   The stock has rallied 29 9  year to date 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/amag-posts-widerthanexpected-q3-loss-beats-on-revenues-200354302,200354302
172090,393606,LLY,Shire s  SHPG  Earnings  Revenues Miss Estimates In Q3,opinion,"Shire plc   NASDAQ SHPG   reported third quarter 2018 earnings of  3 64  per American Depositary Share   ADS    which missed the Zacks Consensus Estimate of  3 65 by a penny and declined 4 5  from the year ago quarter s  3 81 
Revenues of  3 87 billion  up 5  year over year  missed the Zacks Consensus Estimate of  3 86 billion  The year over year increase was aided by growth in Immunology  recently launched products and international expansion 
Shire s shares have outperformed the  so far this year  rising 14 7  against the industry s 3 8  decline 

 
Quarter in Detail
Product sales increased 6  year over year to  3 75 billion  driven by Immunology  Genetic Diseases  Internal Medicine and Opthalmics  Royalties and other revenues were down 27  to  119 million 
The company introduced a new product franchise called Established Brands to capture revenues for its non promoted products that are facing or could face generic competition  such as Lialda and Pentasa 
The Immunology franchise  which includes sales of hereditary angioedema   HAE   drugs  registered sales of  1 19 billion  up 12  year over year  Genetic disease portfolio sales were up 6  to  381 million  driven by higher sales for Elaprase and Replagal  primarily in the international markets 
Sales of Hematology franchise was down 1  year over year to  905 million  As a result of the sale of Shire s Oncology franchise  completed on Aug 31  2018  Oncology product sales decreased to  51 million from  69 million in the year ago quarter 
Sales at Opthalmics franchise rallied 21  to  93 million due to strong Xiidra demand growth 
Sales from Internal Medicine franchise grew 10  to  177 million 
Neuroscience franchise sales came in at  732 million  up 6  year over year  Vyvanse sales increased 11   owing to U S  price increase and continued growth in the international markets  
Sales of Established Products increased 14  to  217 million due to impact from generic competition  offset by favorable sales deductions and some stocking for Lialda in the third quarter compared to the year ago quarter 
Research and development  R D  costs were up 0 3  to  393 million  while selling  general   administrative  SG A  expenses decreased 4 9  to  779 5 million 
2018 Outlook 
The company updated its 2018 guidance to adjust for the sale of its Oncology franchise  The company now expects earnings per ADS guidance of 14 77  15 37 per share  updated from the previous range of  14 90  15 50  Total revenues are expected to be  15 3  15 8 billion  updated from the previous guidance of  15 4  15 9 billion
Other Activities
On Aug 31  2018  Shire completed the sale of its Oncology franchise to Servier S A S   Servier  for  2 4 billion  The franchise included the global rights to Oncaspar  and ex U S  and ex Taiwan rights to Onivyde along with Oncology pipeline assets  A combination of proceeds from the sale of Shire s Oncology franchise  non GAAP free cash flow and existing cash balances were utilized to repay debt during the year 
On Sep 6  2018  Shire announced the acquisition of sanaplasma AG  a source plasma collection company headquartered in Switzerland  Sanaplasma AG adds 14 new centers in the Czech Republic and Hungary to Shire s Europe based plasma collection network 
The acquisition of Shire by Takeda is expected to close in the first half of 2019  which is subject to receipt of additional regulatory clearances and approval by the shareholders of both companies  Takeda has already received clearances from regulatory agencies in the United States  Japan  China and other countries  and is in discussions with the European Commission as part of its phase 1 review of the proposed acquisition 
Shire launched Takhzyro  the first monoclonal antibody to prevent hereditary angioedema  HAE  attacks  in the United States  It also received approval for this treatment in Canada and a positive opinion from the Committee for Medicinal Products for Human Use  CHMP   recommending marketing authorization in Europe 
On Oct 18  2018  Shire announced that the FDA Gastrointestinal Drugs Advisory Committee voted unanimously that the risk benefit profile of prucalopride supports the approval of this NDA  which has an action date of Dec 21  2018 Shire plc Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
Shire carries a Zacks Rank  4  Sell  
Some better ranked stock worth considering are Bristol Myers Squibb Co    NYSE BMY    Eli Lilly and Co    NYSE LLY   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Lilly and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 81 for 2018 and from  3 83 to  4 03 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average beat of 11 99  
Lilly s earnings per share estimates have increased from  5 42 to  5 47 for 2018 and from  5 69 to  5 78 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10 15   The stock has rallied 27 7  year to date 
Merck s earnings per share estimates have increased from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3 96   The stock has rallied 29 9  year to date 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/shires-shpg-earnings-revenues-miss-estimates-in-q3-200354293,200354293
172121,393637,LLY,Pfizer  Can Pfizer Grow To Targets With LOE Headwinds Ahead ,opinion,"Can Pfizer  NYSE PFE  Grow with Several Upcoming Revenue Headwinds 
The key topic for Pfizer is whether the company will be able to grow revenue in the mid single digits going into the early 2020s  The company faces between  7 billion to  9 billion in loss of exclusivity  LOE  revenue headwinds from now until 2025  Notable headwinds include LOEs from Enbrel and Lyrica  and recent supply issues in its sterile injectables 
Management believes they can achieve mid single digit revenue growth  or more  starting in 2020  when the LOE headwinds begin to subside  Given Pfizer s broad portfolio  the company will need a number of existing drugs to outperform  and help from the pipeline  Several key drugs should generate higher than average company growth  but will likely need some of its label expansion efforts to work out to provide more upside  Consensus estimates suggests analysts do not expect the company to hit mid single digit growth rates currently 

Headwinds include Lyrica  Enbrel  and Sterile Injectables
Analysts are skeptical given the sizable headwinds ahead for the company  The company will face LOEs in Lyrica and Enbrel  and is still resolving sterile injectable manufacturing issues 
Lyrica  Lyrica is used to treat several indications  including epilepsy  neuropathic pain  and generalized anxiety disorder  The drug made up roughly 10  of total sales in 2017 despite having lost product exclusivity in European markets in 2014  The company will lose US patent protection at the end of 2018  and management expects a generic to come to market by mid 2019  As a result  analysts model a significant sales erosion in 2019  Lyrica is expected to represent a significant portion of the total LOE headwind  although management is hopeful that they will be able to return to growth once they annualize the Lyrica generic launch in 2020 
Enbrel  Enbrel is a blockbuster drug that treats a number of indications for arthritis and psoriasis  Drug sales have seen double digit declines outside of the US as biosimilar generics in Europe have grown over time  Analysts expect Enbrel to continue to decline  putting pressure on the Inflammation and Immunology segment  I I  for several years  Xeljanz  another drug in the I I segment  detailed later in this article   could potentially offset declines here and turn the segment positive if the drug is able to achieve management s expectations 

Sterile Injectables  Pfizer s sterile injectables have been another source of revenue headwind for the company  Hospira faced manufacturing issues and lost roughly  500 million in sales in 2017  In 2018  these issues have persisted  and the segment declined a further 11  in 1Q18  Management has a remediation plan in place to upgrade its facilities and to bring on additional supply in 2019  They expect further declines in 2Q18 before turning to growth in the second half of the year  bringing the full year to flattish growth  If management is able to completely resolve these issues  the sterile injectables business could turn to growth beyond 2018 

Ibrance  Xtandi  Xeljanz  and Biosimilars Could Drive Upside to Estimates
Given the revenue headwinds  Pfizer will likely need to execute on a number of label expansions for key drugs to hit targets  Biosimilar success and the pipeline also represent areas of upside 
Ibrance  Ibrance is a oral combination treatment for women with a specific kind of metastatic breast cancer  There are about 150 000 women in the US with metastatic breast cancer  Within that group  about 60  have the subtype that Ibrance works with  HR   HER2    Ibrance is used in combination with hormone therapy to treat metastatic breast cancer 
Ibrance should continue to see strong growth in the coming years  with analysts expecting growth of up to  7 billion in sales by 2022  from 2017 sales of  3 billion  

One of the primary drivers of growth  and potential sources of upside  is the expansion of the market for CDK4 6 inhibitor treatment on metastatic breast cancer  The CDK4 6 inhibitor market is roughly  10 billion in size  and is expected to grow significantly  Ibrance was the first CDK4 6 inhibitor with its approval in 2015  There are two other CDK4 6 inhibitors on the market   Eli Lilly s  NYSE LLY  Verzenio and Novartis   NYSE NVS  Kisqali  both approved in 2017  CDK4 6 inhibitor treatment is still in its early to mid stages of adoption  Currently  only about 60  of newly diagnosed HR   HER2  patients will receive a CDK inhibitor agent for first line usage  Given the strength of data  oncologists believe penetration will continue to grow as physicians become more aware of the drugs 
International expansion should also drive near term growth  Ibrance sales in the US has tapered over the last several quarters  and management believes that new launches in the EU and Japan should fuel growth moving forward 

A significant longer term driver  and potential source of upside  is the potential expansion into earlier stage breast cancer  The company currently has several trials  PALLAS and PENELOPE B  that are expected to produce readouts some time in 2020  The patient population size here is significantly larger than in late stage breast cancer and therefore could meaningfully expand Ibrance sales  Furthermore  the company has several other trials looking into other areas of expansion  including neoadjuvant breast cancer  readout expected in the fall of 2018  and HER2   Note that Pfizer recently announced that Ibrance  narrowly  missed its secondary overall survival  OS  endpoint in its PALOMA 3 trial  However  investors do not view this as a significant setback 
Xtandi  Xtandi is used to treat advanced prostrate cancer  While the drug has done well for Pfizer  there are some concerns around upcoming sales for several reasons  First  Xtandi sales recently missed consensus estimates in the last quarter  Second  investors now see increased competition on the horizon with a potential Zytiga generic launch in 4Q18 and Johnson and Johnson s Erleada launch  as the drug was approved earlier this year  
However  management expects the drug to continue to grow in the face of these headwinds  Management cites Xtandi s competitive advantage over the competition   its ability to be dosed without steroids 
Additionally  the company is pursuing a number of line extensions  In February  Pfizer released PROSPER trial results for non metastatic castration resistant prostate cancer  nmCRPC  in February that showed strong results   Pfizer noted that the median metastasis free survival was 36 6 months compared to 14 7 months for ADT alone  The company has a PDUFA date coming up in July  and investors now widely expect Xtandi to receive approval for nmCRPC and launch in 2H18 
Longer term  Pfizer is also pursuing the hormone sensitive prostrate cancer indications  Pfizer expects metastatic hormone sensitive results in early 2020 and non metastatic hormone sensitive results in early 2021  Receiving approval for these adjacent indications will be key to driving upside to Xtandi consensus estimates  and investors will therefore be on the lookout for positive progress 
Xeljanz  Xeljanz is used for the treatment of rheumatoid arthritis and psoriatic arthritis  Xeljanz sales has ramped at a slower than expected rate  but has eventually grown to a sizable  1 3 billion in 2017  Like Xtandi and Ibrance  sales were recently slowed in 1Q18 due to supply issues 
Looking ahead  management believes the company is still on track to hit its full year targets  The drug recently won approval for ulcerative colitis  a chronic inflammatory bowel disease  and management believes this can add an additional  1 billion in sales  Investors will be watching for signs of outperformance within this indication 

Biosimilars  While biosimilars represent a smaller portion of Pfizer sales  the area represents a potential longer term growth opportunity for the company  Key biosimilars include Inflectra  Nivestim  and Retacrit  Inflectra in particular has been slow to gain share from Johnson   Johnson s  NYSE JNJ  Remicade since its launch  as share still sits in the single digits  However  the estimated price discount is now much higher since launch  and analysts believe share gains could accelerate 
Beyond Inflectra  management plans to launch an additional five biosimilars within the next two years  Of note  Pfizer received a CRL on Herceptin in April due to technical issues  and believes the issues can be resolved in time to meet its original launch expectations 
Pipeline  While this article focused primarily on existing drugs  the pipeline represents an obvious additional area of potential upside  In May  the company noted that they had 96 projects in the pipeline  with 28 in phase 3 and 12 in registration  Of the 96 projects  management believes that potentially 25 30 of these could receive approvals through 2022  with up to 15 having blockbuster potential  One key drug to watch is Tafamidis  which management highlighted as the most risky asset  The company will need to execute on this front in order to increase the odds that sales grow in the mid single digits after 2020 

A Quick Note on Pricing
Trump recently threatened to stop pharmaceutical companies from pursuing price increases  and has even singled out Pfizer for its recent pricing actions  While his call out received media attention and a Pfizer response to not raise pricing  investors were already discounting the back and forth as an optical PR move  The weighted average pricing net of rebates  because rebates also grow each year  grew by 3  last year and was flat in 1Q18  according to Pfizer  Pfizer stock is largely flattish since Trump s tweet on July 9th ",2018-07-11,The Non-Consensus,https://www.investing.com/analysis/pfizer-can-pfizer-grow-to-targets-with-loe-headwinds-ahead-200330236,200330236
172122,393638,LLY,Why Pfizer s Q2 Earnings Results Might Be Weaker Than You d Like,opinion,"Don t get your hopes up for a blowout second quarter from the big pharma company 
When Pfizer  NYSE PFE  reported its first quarter results in May  there were things to like    but things to dislike  too  The big pharma company s earnings soared and topped Wall Street expectations  Revenue  however  came in lower than the consensus analysts  estimate 
What should investors expect when Pfizer announces its second quarter earnings results on July 31  I suspect the drugmaker s numbers might be weaker than you d like them to be  Here are three reasons why 
1  Same old headwinds will still be blowing
Pfizer s biggest challenges in the first quarter came from declining sales of products that have lost exclusivity and continued product shortages with its sterile injectables business  Don t count on improvement on either of these fronts 
It wouldn t surprise me if these headwinds hurt Pfizer even more in Q2 than they did in Q1 because of Viagra  Last year  the erectile dysfunction drug made more revenue in the second quarter than it did in the first quarter  Pfizer reported a 45  year over year decline in sales in its last quarter following Viagra s loss of exclusivity at the end of 2017  I think the year over year drop could look even worse when the company announces its Q2 results 
Those sterile injectables product shortages probably won t get any better  either  In Pfizer s Q1 conference call  COO Albert Bourla said that the company expected sales to fall again in the second quarter 
2  Question marks for key blockbusters
The top three growth engines for Pfizer right now are Ibrance  Eliquis  and Xeljanz  However  in the first quarter  sales growth for both Ibrance and Xeljanz was slower than analysts projected  The big question for Pfizer in Q2 is whether these blockbuster drugs will deliver growth at expected levels 
When asked about the relative underperformance in Q1 for Ibrance  Pfizer CEO Ian Read replied that the company thought that it was due to  inventory movements   In his introductory comments during the Q1 conference call  Read said that revenue for both Ibrance and Xeljanz were negatively impacted by  customer buying patterns   I believe these explanations are correct and could be lesser issues in the second quarter 
At the same time  though  I wouldn t discount the possibility that Pfizer s growth could be affected by competition from newer products on the market  Eli Lilly and Company  NYSE LLY   for example  recently reported Q2 sales of nearly  58 million for breast cancer drug Verzenio  Novartis  NYSE NVS  announced that its breast cancer drug Kisquali generated sales of  59 million in the second quarter  Both Verzenio and Kisquali compete directly against Ibrance 
3  Fewer one time boosts than in Q1
There s one area where Pfizer is almost guaranteed to see a worse performance in the second quarter than it did in Q1  The company s other income in the first quarter was around  320 million  but Pfizer projects total other income in 2018 of  400 million  It s a mathematical certainty that Q2 other income will be lower if Pfizer s full year estimate is accurate 
This large amount of other income in the first quarter stemmed primarily from one time milestone payments of around  115 million and  110 million in unrealized gains on equity securities  In the second quarter of 2017  Pfizer had  66 million in other income  Unless the company records nearly all of the remaining other income it expects for the rest of 2018 in Q2  both year over year and quarter over quarter comparisons will be negative 
This isn t a huge deal  However  a few million here and a few million there can add up  With continued challenges from sinking sales for drugs that have lost exclusivity and sterile injectables product shortages  along with uncertainties for Ibrance and Xeljanz  fewer one time boosts could make a difference in whether Pfizer meets or misses Q2 estimates 
But better days lie ahead
It might sound like I m down on Pfizer  but I m not  I think the company could announce disappointing second quarter results    although there s at least an outside chance of a pleasant upside surprise  However  whatever Pfizer reports in Q2 probably won t matter much in the big scheme of things 
What really matters for Pfizer is its long term prospects  I d argue that the big pharma company looks pretty good on that score  The negative issues that Pfizer faces right now should become less of a drag over the next few years  The company s pipeline is probably more promising than it s ever been  In the meantime  Pfizer continues to generate strong cash flow and keeps on paying a dividend that should bring smiles to investors  faces 
Sure  there are things to dislike about Pfizer  Some of those things will likely be quite evident when the company provides its second quarter update  But I think there s a lot more to like about this stock over the long run than there is to dislike ",2018-07-30,Keith Speights,https://www.investing.com/analysis/why-pfizers-q2-earnings-results-might-be-weaker-than-youd-like-200334461,200334461
172123,393639,LLY,Eli Lilly Rises After Trial Results  as Market Cycles Point to Buying Opportunity,opinion,"Eli Lilly and Company  NYSE LLY  traded 5  higher on Thursday morning  after reporting positive results from recent trials for a new diabetes treatment 
The global pharmaceutical company announced the results of trials for its  glucose dependent insulinotropic polypeptide  and  GLP 1 receptor agonist  treatments  Specifically  they produced a 2 4  reduction in blood glucose and an average of 11 kilograms in weight reductions in people with type 2 diabetes 
 These clinical trial results are unprecedented  and the impressive blood glucose and weight reductions seen may lead to a new treatment option for people with diabetes   explained Juan Frias of the National Research Institute 
Looking at the LLY chart below  with regard to its market cycles  we see the stock as beginning the rising phase of its current  minor  cycle  It is still early in the cycle and so we see a bit more potential upside 
However  this stock has been a runaway train  and so we believe a pullback is likely  Given its positive momentum  a drop to near  106 would likely be a buying opportunity  
For more from Slim  or to learn about cycle analysis  check out the askSlim Market Week show every Friday on our YouTube channel ",2018-10-04,Steve Miller,https://www.investing.com/analysis/eli-lilly-rises-after-trial-results-as-market-cycles-point-to-buying-opportunity-200346988,200346988
172124,393640,LLY,Sanofi s  SNY  Q3 Earnings And Sales Surpass Estimates,opinion,"Sanofi  PA SASY    NYSE SNY   reported third quarter 2018 earnings of  1 07 per American depositary share  which beat the Zacks Consensus Estimate of 98 cents  Earnings increased 8 2  on a reported basis  At constant currency rates   CER    earnings grew 11 2  Third quarter net sales rose 3 7  on a reported basis to almost  10 91 billion   9 39 billion   Sales also beat the Zacks Consensus Estimate of  10 88 billion  Unfavorable exchange rate movements hurt sales by 2 6   At CER  sales increased 6 3  year over year          Sales increased 5 5  at CER in the United States  At CER  sales rose 10 4  in Emerging Markets  1 9  in Europe and 9 4  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico  Shares were up 3 9  in pre market trading  following strong earnings and sales growth  In the past six months  Sanofi s shares have risen 10 5  compared with 7 1  increase for the   All growth rates mentioned below are on a year on year basis and at CER Segmental PerformancePharmaceuticals sales  including emerging markets  rose 3 2  to  6 2 billion on a reported basis  However  at CER  Pharmaceuticals sales rose 6 1  driven by growth in Rare Blood Disorder and Immunology franchises  partially offset by lower Diabetes and Established Rx products sales Sanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  Sanofi Genzyme Specialty Care GBU sales  including emerging markets  increased 34 6  to  2 2 billion  driven by contribution from new immunology drugs   Dupixent and Kevzara   and higher sales of rare disease drugs Sales of MS drug  Aubagio rose 12 6  to  426 million while sales of Lemtrada fell 10 6  to  99 million Sales of rare disease drugs like Myozyme Lumizyme improved 13 7  to  209 million  Fabrazyme sales were  191 million  up 12   Cerdelga sales came in at  41 million  up 32 3   Aldurazyme sales were up 8  to  49 million and Cerezyme sales rose 3 9  to  165 million Oncology sales increased 4 7  to  380 million  Excluding Leukine  which was sold in January  oncology sales grew 6 7   Jevtana sales were up 17 8  to  106 million  Thymoglobulin recorded sales of  75 million  up 7   Taxotere sales were up 2 3  to  44 million  Zaltrap and Eloxatin sales were up 15 8  and 8 9  to  22 million and  49 million  respectively  Mozobil sales remained flat at  42 million Dupixent dupilumab for treating atopic dermatitis was launched in the United States and the EU in 2017  Dupixent generated sales of  225 million in the third quarter compared with  176 million in the second quarter of 2018  Total prescriptions written for Dupixent in the United States grew 16  sequentially  Sales of the drug in Europe were  20 million Sanofi and Regeneron s   NASDAQ REGN   rheumatoid arthritis drug  Kevzara  sarilumab  was launched in the United States  United Kingdom  the Netherlands and Germany in 2017   The drug was launched in Italy  France  Switzerland and Spain in the third quarter  Kevzara recorded sales of  22 million in the quarter compared with  20 million in the previous quarter Rare blood franchise  which was added with the acquisition of Bioverativ in March 2018  brought in sales of  282 million Diabetes and Cardiovascular GBU  including emerging markets  declined 6 3  to  1 54 billion  The Diabetes franchise  including emerging markets  declined 9 2  to  1 38 billion due to lower sales of key drugs   Lantus and Toujeo   in the United States Sales of diabetes drugs in the United States declined 24 3  to  571 million due to pricing pressure and loss of Part D business In Europe  it fell 2 2   However  sales of diabetes drugs in Emerging Markets were up 13 4  Lantus sales declined 18 2  to  897 million in the quarter  Lantus sales declined 31 7  in the United States due to lower average net price and change in coverage in Sanofi s Part D business  In Europe  sales declined 12  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  215 million in the reported quarter  up 10 7   However  sales were down 15 7  in the United States Soliqua Suliqua generated sales of  20 million in the quarter compared with  17 million in the previous quarter In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent garnered worldwide sales of  68 million in the reported quarter  up 64 3   Sales of the other drug in this franchise  Multaq  were up 13 6  to  93 million General Medicines   Emerging Markets GBU sales came in at  3 2 billion  up a mere 0 6   Sales of Established products were  2 13 billion  down 3 2  due to generic competition for Renvela Renagel in the United States and rising competition for Synvisc Sales of Generics fell 5 6  to  383 million with lower sales in Europe while sales were flat in Emerging markets  In September  Sanofi closed the agreement to sell its European generics business  Zentiva  to Advent International Consumer Healthcare GBU sales were  1 11 billion  up 4 1   driven by growth in Emerging markets  Sales in Europe were up 3 4  due to higher sales of drugs of Allergy Cough   Cold and Digestive categories  Allergy Cough   Cold and Pain categories drove sales up 2 9  in the United StatesThird quarter consolidated Sanofi Pasteur  Vaccines  sales were up 8 2  to  2 1 billion  Vaccines sales were boosted by recovery in supply of polio vaccine  Pentaxim  in China and growth in sales of Menactra and Flublok Costs RiseSelling general and administrative expenses  SG A  increased 1 6  at CER in the quarter  reflecting investments in immunology and consolidation of Albynx and Bioverativ s operating expenses  partially offset by lower expense for the diabetes program  R D expenses were up 9 5  at CER  reflecting increased spending on immuno oncology and diabetes programs and acquisition cost related to Bioverativ and Ablynx 2018 Expectations RaisedSanofi increased the lower end of its earnings growth expectation for 2018 and expects business earnings to grow between 4  and 5  at CER  previously 3 5    The company expects currency movement to have unfavorable impact of 6  on earnings Our TakeSanofi s third quarter 2018 earnings and sales beat estimates  Sanofi looks well poised to return to growth in the second half of the year with a strong third quarter performance Its 2018 guidance looks upbeat  Growth is being driven by contribution from the Bioverativ and Ablynx deals  improving vaccine sales and decreasing impact of patent expirations  The company Specialty Care segment particularly is on a strong footing with the recent FDA approvals of new drugs Libtayo  cutaneous squamous cell carcinoma   Cablivi  acquired thrombotic thrombocytopenic purpura  and Dupixent for its second indication in asthma Sanofi Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderSanofi currently carries a Zacks Rank  4  Sell  You can see  A couple of better ranked drug biotech stocks include Eli Lilly   Company   NYSE LLY   and Merck   Co   Inc    NYSE MRK    Both the stocks carry a Zacks Rank  2  Buy  Lilly s earnings estimates for 2018 and 2019 have risen from  5 42 to  5 47 and from  5 69 to  5 78  respectively  over the past 60 days  The stock has gained 29 1  this year so far Merck s shares have risen 30 2  this year so far  Its earnings estimates have risen from  4 26 to  4 34 for 2018 and from  4 58 to  4 71 for 2019 over the past 60 days 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/sanofis-sny-q3-earnings-and-sales-surpass-estimates-200352496,200352496
172125,393641,LLY,The Pharmaceuticals Industry Stock Outlook  A Steady Path Ahead,opinion,The Zacks industry comprises some of the largest global companies that develop multi million dollar drugs for a broad range of therapeutic areas such as neuroscience  cardiovascular and metabolism  rare diseases immunology and oncology  Some of these companies also make vaccines  animal health  medical devices and consumer related healthcare products  All these companies invest millions of dollars in their product pipelines as well as line extensions of their already marketed drugs  Here are the three major themes in the industry Demand driven growth in sales of new products  successful innovation and product line expansion  strong clinical study results  frequent FDA approvals  continued strong performance of key products  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending are some of the factors driving this industry s growth  A faster drug approval process and the proposed removal of outdated regulations  which are escalating costs and slowing down innovation  are the other positives  Mergers and acquisitions  M A  activity is on the rise following the tax reform  Big players are on the lookout for companies with innovative pipelines technology  Meanwhile  in licensing deals continue to be popular with several big companies collaborating with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both the larger companies and the smaller ones  While the large companies are able to boost their pipelines with promising candidates  the smaller ones gain access to a non dilutive source of funds that allows them to continue investing in their pipelines  Headwinds for the industry include government scrutiny of high drug prices  pricing pressure  increasing competition  rising competition related to biosimilar and generic  a slowdown in growth of legacy products and major pipeline setbacks Overall  we believe that pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activities should keep the sector afloat  going forward Zacks Industry Rank Indicates Bright ProspectsThe group s  is basically the average of the Zacks Rank of all the member stocks The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank  76  which places it at the top 30  of more than 250 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  Looking at the aggregate earnings estimate revisions  it appears that analysts are gaining confidence in this group s earnings growth potential  In the past year  the industry s earnings estimate for the current year has increased by 5 5  while it is up 3 1  for 2019 Before we present a few large drug stocks that are well positioned to outperform the market based on a strong earnings outlook  let s take a look at the industry s stock market performance and current valuation Industry Outperforms Sector   S P 500The Zacks Large Cap Pharmaceuticals Industry is a 14 stock group within the broader  sector  The industry has outperformed the S P 500 as well as the Zacks Medical Sector on a year to date basis While the stocks in this industry have collectively risen 2 3  year to date  the Zacks S P 500 composite and the Zacks Medical Sector have declined 0 4  and 3 2   respectively  Year to Date Price Performance  Industry s Current ValuationOn the basis of forward 12 month price to earnings  P E  ratio  which is a commonly used multiple for valuing large pharma companies  the industry is currently trading at 14 62X compared to the S P 500 s 15 78X and the Zacks Medical sector s 18 62X Over the last five years  the industry has traded as high as 18 10X  as low as 13 94X  and at a median of 15 85X  as the chart below shows  Forward 12 Month Price to Earnings  P E  Ratio   Bottom LineIn order to succeed in a changing global market and evolv ing healthcare landscape  pharma ceutical companies need to adopt innovative business models  invest in new technologies  increase investments in personalized medicines and seek external partners and collabora tors for complementary strengths The sector may face some volatility due to the drug pricing issue  pricing re imbursement pressure  increasing competition  slowdown in legacy product sales  loss of patent exclusivity of some key drugs and pipeline related setbacks However  pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  product launches  increased M A activity and appropriate utilization of cash should keep the sector on a strong footing In the Large Cap Pharmaceuticals universe  one stock currently sports a Zacks Rank  1  Strong Buy   while four companies have a Zacks Rank  2  Buy   Most of these companies have witnessed positive earnings estimate revisions in the past 60 days You can see  Bristol Myers Squibb Company  NYSE BMY   BMY   The Zacks Consensus Estimate for this New York based drugmaker s current year EPS has been revised 6 1  upward over the past 60 days  Bristol Myers has a Zacks Rank  1  However  the stock has declined 18 4  so far this year Price and Consensus  BMY Merck   Co   Inc   MRK   This Kenilworth  NJ based drug giant has seen 29 5  rise in its share price this year so far   The Zacks Consensus Estimate for this  2 Ranked stock s current year EPS has risen 1 1  over the past 60 days Price and Consensus  MRK Eli Lilly   Company  LLY   The stock of this Indianapolis  IN based drugmaker has risen 28 3  year to date  The current fiscal Zacks Consensus Estimate EPS estimate for this Zacks Rank  2 company has risen 0 9  over the past 60 days Price and Consensus  LLY Johnson   Johnson  NYSE JNJ   JNJ   The stock of this New Brunswick  NJ maker of drugs medical  and consumer products has risen 0 8  so far this year  The consensus estimate for the current year EPS has been revised 0 2  upward over the past 60 days  J J has a Zacks Rank  2 Price and Consensus  JNJ Roche Holding  SIX ROG  AG  RHHBY   Shares of this Swiss drugmaker have declined 5 3  this year so far  The Zacks Consensus Estimate for current year EPS has been revised 4 1  upward over the past 60 days  Roche has a Zacks Rank  2 Price and Consensus  RHHBY 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/the-pharmaceuticals-industry-stock-outlook-a-steady-path-ahead-200352652,200352652
172141,393657,LLY,Has Eli Lilly And  LLY  Outpaced Other Medical Stocks This Year ,opinion,"The Medical group has plenty of great stocks  but investors should always be looking for companies that are outperforming their peers  Eli Lilly and  LLY  is a stock that can certainly grab the attention of many investors  but do its recent returns compare favorably to the sector as a whole  One simple way to answer this question is to take a look at the year to date performance of LLY and the rest of the Medical group s stocks 
Eli Lilly and is one of 763 individual stocks in the Medical sector  Collectively  these companies sit at  12 in the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  LLY is currently sporting a Zacks Rank of  2  Buy  
The Zacks Consensus Estimate for LLY s full year earnings has moved 5 63  higher within the past quarter  This shows that analyst sentiment has improved and the company s earnings outlook is stronger 
According to our latest data  LLY has moved about 1 95  on a year to date basis  In comparison  Medical companies have returned an average of 1 61   As we can see  Eli Lilly and is performing better than its sector in the calendar year 
Looking more specifically  LLY belongs to the Large Cap Pharmaceuticals industry  a group that includes 14 individual stocks and currently sits at  205 in the Zacks Industry Rank  On average  stocks in this group have lost 2 80  this year  meaning that LLY is performing better in terms of year to date returns 
Investors in the Medical sector will want to keep a close eye on LLY as it attempts to continue its solid performance ",2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year-200326067,200326067
172142,393658,LLY,LLY Vs  NVO  Which Stock Should Value Investors Buy Now ,opinion,"Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Eli Lilly  LLY  and Novo Nordisk  CO NOVOb   NVO   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Eli Lilly has a Zacks Rank of  2  Buy   while Novo Nordisk has a Zacks Rank of  5  Strong Sell  right now  This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that LLY is likely seeing its earnings outlook improve to a greater extent  However  value investors will care about much more than just this 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
LLY currently has a forward P E ratio of 16 87  while NVO has a forward P E of 17 83  We also note that LLY has a PEG ratio of 1 47  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  NVO currently has a PEG ratio of 2 40 
Another notable valuation metric for LLY is its P B ratio of 6 46  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  NVO has a P B of 14 94 
These metrics  and several others  help LLY earn a Value grade of B  while NVO has been given a Value grade of C 
LLY has seen stronger estimate revision activity and sports more attractive valuation metrics than NVO  so it seems like value investors will conclude that LLY is the superior option right now ",2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/lly-vs-nvo-which-stock-should-value-investors-buy-now-200326411,200326411
172143,393659,LLY,Novo Nordisk s  NVO  Oral Ozempic Positive In Diabetes Study,opinion,"Novo Nordisk   NYSE NVO   announced positive headline results of two phase III studies PIONEER 4 comparing 14 mg oral formulation of Ozempic  semaglutide  as a treatment for adults with type II diabetes to Victoza1 8 mg and placebo and PIONEER 7 comparing oral formulation of Ozempicas a treatment for adults with type II diabetes to sitagliptin 100 mg  
We remind investors that in December 2017  the FDA approved Ozempic once daily pre filled pen to improve glycaemic control in type II diabetes patients  It is also approved in Europe  Japan and Canda for the same indication 
The 52 week PIONEER 4 study achieved its primary objective according to the primary statistical approach by demonstrating a non inferior reduction in blood glucose levels  HbA1c  and statistically significant and superior weight loss at 26 weeks with oral Ozempic compared to Victoza  
Ozempic also provided statistically significant and superior reductions in HbA1c and weight compared to placebo  For week 26 and week 52  respectively  people treated with Ozempic experienced a reduction in HbA1cof 1 3  and 1 2  compared to 1 1  and 0 9  with Victoza whereas placebo declined 0 1  and increased 0 2  
Ozempic also demonstrated weight loss of 4 7 kg at 26 weeks and 5 kg at 52 weeks versus 3 2 kg and 3 1 kg with Victoza  and 0 7 kg and 1 2 kg with placebo at 26 and 52 weeks respectively The increased weight loss with oral Ozempic was also significant compared to Victoza and placebo 
The 52 week PIONEER 7 study also achieved its primary objective accordingto the primary statistical principle by demonstrating that people treated with oral semaglutide experienced a statistically significant reduction in HbA1cof 1 4  compared to 0 7  with sitagliptin at week 52  The reduction in body weight of 2 9 kg with oral semaglutide was statistically significantly greater at week 52 compared to 0 8 kg with sitagliptin  
Novo Nordisk plans to report the PIONEER 3 study comparing 3  7 and 14 mg oral semaglutide with 100 mg sitagliptin before the end of second quarter of 2018  
Shares of the company have moved down 16 6  year to date compared with the  s decline of 4 4  

 
We remind investors that in May 2018  Novo Nordisk announced headline results from PIONEER 2  the second phase IIIa study with oral formulation of Ozempic for treatment of adults with type II diabetes  The study evaluated the efficacy and safety of 14 mg oral Ozempic compared with 25 mg Eli Lilly   NYSE LLY   and Boehringer Ingelheim s Jardiance  empagliflozin  with type II diabetes inadequately controlled on metformin 
The 52 week study achieved its primary objective and demonstrated a statistically significant and superior improvement in HbA1c with oral Ozempic compared to Jardiance at 26 weeks  
By mid 2018  the company plans to initiate a cardiovascular outcomes study called SOUL for Ozempic  Also the company plans to initiate a phase IIIa program called STEP in 2018 to explore the potential of once weekly Ozempic as a treatment for people with obesity 
This will also include the cardiovascular outcomes trial  SELECT  which will investigate the impact of Ozempic on the incidence of major adverse cardiovascular events compared to placebo in patients with established cardiovascular disease and either overweight or obesity 
In GLP 1 market  Lilly s Trulicity and AstraZeneca s   NYSE AZN   once weekly Bydureon are competitors to Novo Nordisk s Ozempic Novo Nordisk A S Price

    
Zacks Rank   Stocks to Consider
Novo Nordisk has a Zacks Rank  5  Strong Sell  
A better ranked stock from the same space is Aeglea BioTherapeutics  Inc    NASDAQ AGLE   carrying a Zacks Rank  2  Buy   You can see  
Aeglea s loss per share estimates have narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   The stock has rallied 101 3  so far this year 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers 
Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-nvo-oral-ozempic-positive-in-diabetes-study-200326913,200326913
172144,393660,LLY,Incyte  INCY  Announces Positive Results On Jakafi For GVHD,opinion,Incyte Corporation   NASDAQ INCY   announced that the phase II trial  REACH1  evaluating lead drug Jakafi in combination with corticosteroids for the treatment of patients with steroid refractory acute graft versus host disease  GVHD   met its primary endpoint The data from the study showed that Jakafi demonstrated an overall response rate  ORR  of 55  at day 28 Moreover  the number of patients achieving a response at any point of time  during the study  was 73  Propelled by positive data from the REACH 1 study  Incyte now plans to file a Supplemental New Drug Application  sNDA  with the FDA for the label expansion of Jakafi  for the treatment of steroid refractory acute GVHD  during the third quarter of 2018 Incyte also plans to present full details from the study  at an upcoming scientific meeting We note that Jakafi  a first in class JAK1 JAK2 inhibitor  is already approved by the FDA for the treatment of people with polycythemia vera  PV   who have had an inadequate response to or are intolerant of hydroxyurea The drug is also indicated for the treatment of people with intermediate or high risk myelofibrosis  MF   including primary MF  post polycythemia vera MF and post essential thrombocythemia MF  Incyte has a collaboration agreement with Novartis   NYSE NVS   for Jakafi  While Jakafi is marketed by Incyte in the United States  it is marketed by Novartis outside the country Jakafi s performance has been impressive so far  In order to expand the patient population and increase the commercial potential of the drug  the company is working on expanding the drug s label  further  In October 2017  the FDA approved a label update of the drug to include the addition of new patient reported outcome  PRO  data from the COMFORT I study as well as updating the warning related to progressive multifocal leukoencephalopathy A potential label expansion for GVHD shall further boost sales Incyte s stock has lost 23 5  in the year so far compared with the  s 5 2  decline  Meanwhile  apart from the steroid refractory acute GVHD study  the REACH trial program also includes the ongoing phase III studies in steroid refractory acute GVHD  REACH2  and steroid refractory chronic GVHD  REACH3   both in collaboration with Novartis  Data from the studies are expected in 2019 Incyte is also making efforts to develop other candidates and reduce its dependence on Jakafi The FDA has recently approved the 2 mg dose of Olumiant  baricitinib   a once daily oral medication for the treatment of adults with moderately to severely active rheumatoid arthritis  RA   who have had an inadequate response to one or more tumor necrosis factor  TNF  inhibitor therapies  Incyte and Eli Lilly   NYSE LLY   have a partnership for Olumiant However  Incyte suffered a setback with epacadostat  The external Data Monitoring Committee  eDMC  review of the pivotal phase III study  ECHO 301  evaluating epacadostat in combination with Merck s   NYSE MRK   Keytruda in patients with unresectable or metastatic melanoma  determined that the study did not meet the primary endpoint of improving progression free survival in the overall population compared to pembrolizumab monotherapy   Zacks RankIncyte currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-announces-positive-results-on-jakafi-for-gvhd-200327119,200327119
172145,393661,LLY,Merck  MRK  Presents New Data From Januvia Diabetes Studies,opinion,Merck   Co   Inc   NYSE MRK   presented new data from two studies  evaluating its type II diabetes drug Januvia  sitagliptin  as a treatment option on type II diabetes patients  who initiate insulin therapy and those with a mild renal impairment The CompoSIT I study showed higher reduction of blood glucose level in patients  who initiated insulin dosage while continuing treatment with Januvia compared with those who discontinued Januvia  The CompoSIT R trial evaluated subjects with mild renal impairment  who were not adequately controlled by metformin  Data from this study showed that treatment with Januvia resulted in non inferiority and superiority in reducing blood glucose levels  A1C  as compared to patients  treated with AstraZeneca s   NYSE AZN   Farxiga  dapagliflozin  These data were presented at the American Diabetes Association meeting in Orlando  FL Shares of Merck have gained 8 4  year to date versus the  decline of 4 4  Combined sales of Januvia and Janumet declined 3  in 2017 due to ongoing pricing pressure  Merck s Januvia franchise is facing pricing pressure due to higher discounts and rebates to maintain good managed care coverage  In the first quarter of 2018  sales of Januvia Janumet rose 7  to  1 4 billion Last April  the FDA denied an approval to include cardiovascular outcomes on the labels of Januvia and Janumet  With death toll from cardiovascular disease being significantly higher among adults suffering diabetes in comparison to those without it  the addition of positive cardiovascular findings would have helped drive sales of these drugs  Moreover  with Eli Lilly   NYSE LLY   and Boehringer Ingelheim including the cardiovascular indication on the label of their SGLT 2 inhibitor  Jardiance  DPP IV inhibitors like Januvia could see patients switching to SGLT 2 inhibitors The latest addition to Merck s diabetes franchise is Steglatro ertugliflozin  approved as a monotherapy as well as two fixed dose combinations with metformin and with Januvia in the United States last December and in the EU  this March  It is important to note that Merck markets Steglatro in a partnership with Pfizer  Inc   NYSE PFE  Merck currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is H Lundbeck A S   OTC HLUYY    sporting a Zacks Rank  1  Strong Buy   You can see H Lundbeck s earnings estimates have been revised 11 6  upward for 2018 and 4 3  for 2019 in the past 60 days  The stock has soared 44  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-24,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-presents-new-data-from-januvia-diabetes-studies-200327590,200327590
172173,393689,LLY,Abbvie Roche s Leukemia Drugs Combination Gets FDA Approval,opinion,AbbVie  Inc    NYSE ABBV   announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche s   OTC RHHBY   Rituxan for the treatment of patients with relapsed refractory chronic lymphocytic leukemia   CLL   or small lymphocytic lymphoma  SLL   with or without 17p deletion  who have received at least one prior therapy Venclexta is jointly marketed by AbbVie and Roche s Pharma arm  Genentech in the United States and by AbbVie outside the United States The FDA approval for combination use was based on positive data from the phase III MURANO study of Venclexta plus Rituxan in relapse refractory CLLData from the study  presented in September last year  showed that the combination led to a profound improvement in progression free survival compared to Teva Pharmaceutical s   NYSE TEVA   Treanda plus Rituxan BR   Results from the study showed that a fixed duration of treatment with Venclexta plus Rituxan significantly reduced the risk of disease progression or death by 81  compared with BR  Overall response rate  ORR  was 92  in the Venclexta Rituxan arm compared to 72  for BR Concurrently  the FDA also approved Venclexta as a monotherapy for CLL or SLL patients  with or without 17p deletion  Until now  as a monotherapy  Venclexta was approved to treat patients with CLL with 17p deletion  as detected by an FDA approved test The FDA approval for label expansion of Venclexta for this indication should expand the patient population for Venclexta significantly and boost its commercial potential  With the latest approval  Venclexta Rituxan becomes the first oral  chemotherapy free  fixed duration treatment option for CLL patients  Also  this summer  AbbVie will file a regulatory application in the United States for Venclexta in acute myeloid leukemia  AML  while a phase III program in multiple myeloma is also progressing well AbbVie s shares have gained 3 8  this year so far against the  s decline of 3 7  AbbVie currently carries a Zacks Rank  3  Hold   A better ranked large cap pharma stock is Eli Lilly   Company   NYSE LLY    with a Zacks Rank  2  Buy   You can see Lilly s earnings estimates increased 5 8  for 2018 and 3 2  for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 8 20   Shares of Lilly have gained 2  this year so far The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-10,Zacks Investment Research,https://www.investing.com/analysis/abbvieroches-leukemia-drugs-combination-gets-fda-approval-200323983,200323983
172174,393690,LLY,AstraZeneca s Tagrisso Wins EU Nod For First Line Lung Cancer,opinion,AstraZeneca PLC   NYSE AZN   announced that the European Commission has approved the label expansion of its lung cancer drug  Tagrisso  osimertinib   With this latest development  Tagrisso can be used for first line treatment of adult patients with locally advanced or metastatic non small cell lung cancer  NSCLC   whose tumors have EGFR mutations Tagrisso was hitherto approved in the United States  European Union  Japan and China as a second line treatment option for patients with EGFR mutation positive NSCLC Earlier in April 2018  the FDA gave a nod to Tagrisso  osimertinib  in the first line setting The EU approval was expected as in April  the Committee for Medicinal Products for Human Use lent a positive opinion recommending approval of Tagrisso in the first line setting The approval was based on encouraging data from the phase III FLAURA study  which compared Tagrisso with the standard of care EGFR tyrosine kinase inhibitor therapy in the first line lung cancer setting Data from the study showed that the chance of progression or death risk was reduced by more than half in the Tagrisso arm compared with the commonly used EGFR inhibitors  The median progression free survival was 18 9 months for patients on Tagrisso compared with 10 2 months in the comparator arm  Tagrisso was well received in the trial with a safety profile  consistent with the previous studies In the first quarter of 2018  Tagrisso recorded sales of  338 million  up 89  year over year  driven by increased testing rates in the United States and Japan  This approval in the first line setting is likely to boost sales of Tagrisso in the coming quarters Apart from Tagrisso  AstraZeneca markets several cancer drugs like Imfinzi  Lynparza among others  The company markets Lynparza in partnership with Merck   Co   Inc    NYSE MRK    Oncology sales now comprise almost 25  of AstraZeneca s total product sales and the metric also rose 19  in 2017 Shares of AstraZeneca have gained 4 9  year to date versus the  decline of 3 7   AstraZeneca currently carries a Zacks Rank  3  Hold   You can see   Better ranked stocks in the same sector include H Lundbeck A S   OTC HLUYY   and Eli Lilly and Company   NYSE LLY    While H Lundbeck sports a Zacks Rank  1  Eli Lilly carries a Zacks Rank  2  Buy  H Lundbeck s earnings per share estimates have been revised 11 6  upward for 2018 and 4 3  for 2019 in the last 60 days  The stock has substantially soared 40 8  year to date Eli Lilly and Company s earnings per share estimates have risen 5 8  for 2018 and 3 2  for 2019 in the last 60 days  The stock has increased 2  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-10,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-tagrisso-wins-eu-nod-for-firstline-lung-cancer-200323964,200323964
172175,393691,LLY,J J  JNJ  Accepts Platinum Equity s Offer For LifeScan Unit,opinion,"Johnson   Johnson   NYSE JNJ   has accepted a  2 1 billion offer from a private equity firm  Platinum Equity  for the sale of its LifeScan diabetes device unit  The company had announced the receipt of a binding offer from Platinum Equity in March The LifeScan unit makes blood glucose monitoring products and generated revenues of  1 5 billion last year J J stock has declined 12 3  this year so far  which compares unfavorably with a decrease of 4  recorded by the  The move was in line with J J s strategic plans for its diabetes business  The company has been planning to streamline its non core assets since last year  As part of the streamlining efforts  J J had announced the closing of operations at its Animas Corporation diabetes care unit in October last year  The company has arranged a deal with medical device maker  Medtronic  Inc    NYSE MDT   for the transition of patients on Animas insulin pump to Medtronic pump  Meanwhile  J J also received an offer of  2 8 billion from Fortive Corporation   NYSE FTV   earlier this month for its Advanced Sterilization Products business Moreover  sales in J J s Diabetes Care franchise declined 9 7  in 2017 to  1 6 billion due to price decline and competitive pressure  Thus  streamlining these assets is likely to boost margins as well cash position of the company Johnson   Johnson Price
    Zacks RankJ J currently carries a Zacks Rank  3  Hold   Eli Lilly and Company   NYSE LLY   is a better ranked large cap pharma stock  which carries a Zacks Rank  2  Buy   You can see  Lilly s earnings per share estimates moved up from  4 87 to  5 15 for 2018 and from  5 29 to  5 46 for 2019 in the last 60 days  Shares of the company are up 1 3  this year so far The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-12,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-accepts-platinum-equitys-offer-for-lifescan-unit-200324607,200324607
172195,393711,LLY,J J Receives Buyout Offer For Sterilization Products Unit,opinion,"Johnson   Johnson   NYSE JNJ   announced that Fortive Corporation   NYSE FTV   has offered to acquire its Advanced Sterilization Products   ASP   business  a unit of its surgical systems and instruments subsidiary Ethicon  Fortive has proposed a binding offer with an aggregate value of  2 8 billion for the unit  The offer comprises  2 7 billion in cash and  100 million in retained net receivables J J has 120 days to accept the offer during which it plans to consult with various work councils  If the offer is accepted  the transaction is expected to close in early 2019 ASP is a global leader in providing offerings including capital  consumables and software for use in innovative sterilization and disinfection solutions to protect patients against hospital acquired infections  The business unit generated sales of  775 million in fiscal 2017 J J is in the process of streamlining its business as part of its strategic roadmap for better resource utilization and driving shareholders  return  Earlier in March  the company received a binding offer from a private equity firm  Platinum Equity  for its LifeScan diabetes device unit  The firm has offered approximately  2 1 billion for the unit  It has already announced the closing of Animas Corporation in October 2017 Shares of J J have lost 12 1  so far this year compared with the  s 3 9  decrease Fortive expects to create a global market leader with the potential acquisition of ASP which has large installed base and very strong brands  This will also help the company to expand its reach in the attractive medical sterilization and disinfection market with strong growth potential Fortive stated that this acquisition is in line with its long term strategy and expects the deal to be accretive to earnings in its first full year of operation Johnson   Johnson Price
    Zacks Rank   Stocks to ConsiderJ J currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector include H Lundbeck A S   OTC HLUYY   and Eli Lilly and Company   NYSE LLY   While H Lundbeck sports a Zacks Rank  1  Strong Buy   Lilly carries a Zacks Rank  2  Buy   You can see  H  Lundbeck s earnings estimates increased from  3 20 to  3 57 for 2018 and from  3 24 to  3 38 for 2019 over the last 30 days  The company came up with an average four quarter positive surprise of 9 8   The company s stock has gained 32 4  so far this year Lilly s earnings estimates increased from  4 88 to  5 12 for 2018 and from  5 29 to  5 46 for 2019 over the last 60 days  The company came up with a positive earnings surprise in all the four trailing quarters with an average beat of 8 2  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/jj-receives-buyout-offer-for-sterilization-products-unit-200323075,200323075
172196,393712,LLY,The Zacks Analyst Blog Highlights  Bristol Myers  Merck  Roche  Lilly And AbbVie,opinion,For Immediate ReleaseChicago  IL   June 11  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Bristol Myers   NYSE BMY    Merck   NYSE MRK    Roche   OTC RHHBY    Lilly   NYSE LLY   and AbbVie   NYSE ABBV   Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Friday s Analyst Blog Pharma Stock Roundup  Merck  Lilly   MoreThis week was ruled by cancer data presentations at the annual meeting of the American Society of Clinical Oncology   ASCO   in Chicago by pharma bigwigs like Bristol Myers  Merck and Roche  among others  JAK inhibitors were in the news this week with Lilly finally gaining FDA approval for its rheumatoid arthritis   RA   candidate Olumiant  baricitinib  in the United States while AbbVie presented positive top line data from its fifth late stage study on upadacitinib in RA Recap of the Week s Most Important StoriesUpdate from ASCO  Merck stole the show at ASCO after presenting data from several cancer studies of its PD L1 inhibitor  Keytruda  Key presentations were from two pivotal lung cancer trials  KEYNOTE 042 study evaluated Keytruda monotherapy in newly diagnosed lung cancer patients while  evaluated Keytruda in combination with chemotherapy in difficult to treat squamous non small cell lung cancer  NSCLC   Both the studies showed that treatment with Keytruda led to improved survival  Particularly  data from the KEYNOTE  407 study  which evaluated Keytruda in combination with chemotherapy for the first line treatment of metastatic squamous NSCLC was considered  practice changing  by investors Four and five years follow up data presented from two  showed that treatment with Keytruda led to long term survival benefit  Interim data from a cohort of a phase II study  KEYNOTE 158  evaluating Keytruda as a monotherapy in patients with previously treated advanced small cell lung cancer  SCLC  demonstrated encouraging response rates in the overall population of SCLC patients as well as in patients whose tumors express PD L1  Keytruda also demonstrated encouraging ORR in studies evaluating the Lenvima Keytruda combination in four different tumor types and Keytruda monotherapy for the first line treatment of advanced clear cell RCC Bristol Myers and Nektar Therapeutics  NKTR  presented preliminary data from a mid stage study evaluating NKTR 214 in combination with Bristol Myers PD L1 inhibitor  Opdivo in several tumor types  The response rates in melanoma and kidney cancer patients did not impress investors  resulting in a 42  drop in Nektar s stock on Monday    Read more   Bristol Myers also presented data on Opdivo at ASCO  In a late stage study evaluating Opdivo versus Yervoy in a broad range of patients with resected stage III or IV melanoma  Opdivo demonstrated sustained  superior recurrence free survival versus Yervoy  In another study  Opdivo plus chemotherapy showed improved PFS versus chemotherapy in first line lung cancer patients with PD L1 expression  1  Novartis  NVS  announced positive data from a combination study on breast cancer drug Kisqali and from two long term leukemia studies on Tasigna   Read more    Roche presented data from a late stage study  which showed that Tecentriq  atezolizumab  plus chemotherapy reduced the risk of disease worsening or death  PFS  by 29  in advanced squamous NSCLC patients versus chemotherapy alone AbbVie presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta  venetoclax  for the first line treatment of patients with chronic lymphocytic leukemia  CLL   The data demonstrated high rates of responses in such patients  Also  interim data from a late stage study evaluating Imbruvica plus Roche s Rituxan in Waldenstr m s macroglobulinemia  a rare form of Non Hodgkin s lymphoma  showed that the combination significantly reduced the risk of disease progression or death by 80  compared to placebo plus Rituxan Lilly Gets FDA Nod for Lower Dose of Olumiant  Eli Lilly and partner Incyte gained FDA approval for the lower dose of  2 mg  of the companies  JAK inhibitor  Olumiant  The FDA did not approve the higher dose  4 mg  and the drug s label was approved with a boxed warning stating risk of serious infections  malignancies and thrombosis  Olumiant is already marketed in Europe and Japan and generated sales of  32 2 million in the first quarter of 2018  In the United States  Lilly faced significant trouble in getting FDA nod for Olumiant  In April last year  the FDA had issued a complete response letter for the new drug application seeking approval of Olumiant  requesting additional information to determine the most appropriate doses  This year in April  an FDA advisory committee had recommended approval of the lower dose of the drug while not recommending the higher dose of 4 mg on inadequate safety profile to support an approval relative to its benefits   Read more    AbbVie s 5th Late Stage Upadacitinib Study Succeeds AbbVie s oral JAK 1 selective inhibitor  upadacitinib  met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program  Top line data from the study showed thata significantly higher proportion of patients treated with upadacitinib in both 15 and 30 mg doses achieved superior responses compared to chemotherapy agent methotrexate  AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year    Read more   Glaxo Completes Buyout of Novartis  Stake in Consumer Healthcare JV  Glaxo announced that it has completed its previously announced deal to buy out Novartis  36 5  stake in the Consumer HealthCare joint venture for  13 billion   9 2 billion  With the acquisition of Novartis  stake  Glaxo now has 100  ownership of its Consumer Healthcare unit  which includes products such as Sensodyne and Flonase  Glaxo and Novartis created the JV in 2015 as part of a three part transaction between the two companies by combining their consumer divisions Roche s Haemophilia A Candidate Gets Priority Review  Roche s sBLA looking for label expansion of its drug  Hemlibra for people with haemophilia A without factor VIII inhibitors was granted priority review by the FDA  Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors  With the FDA granting priority review  a decision is expected on Oct 14Separately  Roche s cancer drug Rituxan gained FDA approval for a new indication  moderate to severe pemphigus vulgaris  PV   a potentially life threatening diseaseThe NYSE ARCA Pharmaceutical Index rose 1 7  in the last five trading sessions Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-06-10,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-bristol-myers-merck-roche-lilly-and-abbvie-200323885,200323885
172221,393737,LLY,Celldex  CLDX  Q1 Loss Wider Than Expected  Shares Down,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   incurred first quarter 2018 loss  excluding goodwill impairment charges  of 19 cents per share  wider than the Zacks Consensus Estimate of a loss of 17 cents but narrower than the year ago loss of 28 cents  Lower costs and higher revenues led to the year over year improvement Total revenues in the quarter soared 165  year over year to  4 1 million  beating the Zacks Consensus Estimate of  2 03 million  The manufacturing service agreement with the International AIDS Vaccine Initiative and Frontier Biotechnologies drove the top line Shares of the company fell 6 5  on May 10 on the wider than expected loss and discontinuation of development of three candidates including earlier announced glembatumumab vedotin However  the stock has not done too well so far this year  It has declined 74 6  compared with the  s 11 3  decrease  Quarterly DetailsResearch and development expenses were down 15 1  year over year to  21 9 million during the quarter  General and administrative expenses were  5 6 million  down 22 2  year over year As of Mar 31  2017  Celldex had cash  cash equivalents and marketable securities of  123 2 million compared with  139 4 million as of Mar 31  2018  The biotech company s weakened cash position was due to higher operating expense  partially offset by net proceeds raised from sales of its common stock this month under a contract with Cantor 2018 OutlookCelldex expects that its cash position as of the end of December plus  6 1 million in net proceeds generated from the sale of its common stock in the last two months and the anticipated proceeds from any future sales of common stock under the agreement with Cantor will be adequate to fund the working capital requirements as well as planned operations through 2020 Discontinued Clinical StudiesIn April 2018  the company announced the failure of its antibody drug conjugate   ADC   candidate  glembatumumab vedotin in phase IIb METRIC study  evaluating it in breast cancer  Following the failure  the company has decided to discontinue the development of the candidate across all indications  including metastatic melanoma Apart from glembatumumab vedotin  Celldex announced in its earnings release the discontinuation of development of early phase ADC candidate  CDX 014 and antibody fusion protein candidate  CDX 1401  The company has taken this decision for better allocation of its resources Pipeline FocusCelldex is now focusing on development of CDX 1140 and CDX 3379  Varlilumab and CDX 301 will be evaluated externally through investigator sponsored studies  However  the company will evaluate varlilumab and CDX 301 internally in combination studies  There are several preclinical candidates in its pipeline  including CDX 0159 In January 2018  the company closed enrollment for phase II trial  evaluating varlilumab with Bristol Myers    NYSE BMY   Opdivo including cohorts in five indications namely colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma A phase II study is currently evaluating CDX 3379  a human monoclonal antibody  in combination with Eli Lilly s   NYSE LLY   Erbitux for the treatment of advanced head and neck squamous cell cancer A phase I study is evaluating CDX 1140 in several solid tumors and Celldex is planning to add cohorts to evaluate CDX 1140 in combination with CDX 301 or varlilumab  An investigator initiated study is evaluating CDX 301 in advanced non small cell lung cancer Celldex Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderCelldex currently carries a Zacks Rank  3  Hold   Enanta Pharmaceuticals  Inc    NASDAQ ENTA   is a better ranked stock in the drugs sector  carrying a Zacks Rank of  2  Buy   You can see  Enanta s earnings per share estimates significantly increased from 86 cents to  2 48 for 2018 over the last 30 days  The company came up with an average beat of 372   The stock has surged 68 9  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q1-loss-wider-than-expected-shares-down-200315453,200315453
172222,393738,LLY,Nektar  NKTR  Q1 Loss Wider Than Expected  Sales Soar Y Y,opinion,"Nektar Therapeutics   NASDAQ NKTR   reported a loss of 60 cents per share for the first quarter of 2018  which was wider than the Zacks Consensus Estimate of a loss of 52 cents and the year ago figure of 42 cents due to higher R D costs Nektar s stock was up 2 8  on May 11 following the earnings release  Shares of Nektar have outperformed the  so far this year  The stock has risen 33  while the industry is up 0 6  Quarterly revenues soared 53 8  from the year ago period to  38 million  This upside can mainly be attributed to a  10 million milestone payment under the collaboration agreement with Shire plc   NASDAQ SHPG   related to the approval of hemophilia drug  Adynovi  in Europe  The top line came in line with the Zacks Consensus Estimate Quarter in DetailThe top line comprised product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues In the first quarter  product sales rose 32 4  to  6 3 million from  4 8 million a year ago   Moreover  non cash royalty revenues increased 3 9  to  6 9 million The company reported royalty revenues of  11 1 million in the quarter under review  registering an improvement of 53 5  from  7 2 million a year ago License  collaboration and other revenues came in at  13 7 million compared with  6 1 million in the prior year  an upside of 125 3  Research and development  R D  expenses escalated 62 8  to  99 4 million  primarily due to investments in pipeline including key candidates NKTR 358  NKTR 214 and NKTR 181 General and administrative  G A  expenses were up 56  to  18 7 million in the reported quarter primarily due to higher stock based compensation Pipeline UpdateThe company received a major boost in February when it announced a global strategic collaboration agreement with Bristol Myers Squibb   NYSE BMY    Per the agreement  the companies will jointly develop and commercialize Nektar s lead immuno oncology candidate  NKTR 214  in combination with Bristol Myers  Opdivo  nivolumab  and Opdivo plus Yervoy  ipilimumab  Moreover  pursuant to the contract  the company received  1 0 billion in upfront payment and proceeds of  850 million from share purchase in April In the same month  Nektar began dosing in a phase I II study   REVEAL   to evaluate a combination of its two candidates NKTR 262  a toll like receptor agonist  and NKTR 214  an immuno stimulatory CD122 biased agonist  in advanced or metastatic solid tumor cancers Moreover  the company has also collaborated with Takeda to develop NKTR 214 in combination with the latter s TAK 659  a dual SYK and FLT 3 inhibitor  in liquid and solid tumors  First study under this collaboration is expected to start in the second half of 2018  which will evaluate the combination in non Hodgkin lymphoma In May  Nektar initiated a dose ranging phase Ib study to evaluate NKTR 358  a regulatory T cell stimulator  in patients with systemic lupus erythematosus  an autoimmune disease  The company has a worldwide license agreement with Eli Lilly   NYSE LLY   related to the development of NKTR 358 Apart from these  the company s pipeline includes two late stage candidates  Onzeald and NKTR 181 Onzeald is currently under evaluation in a phase III  ATTAIN  study for the treatment of adults with advanced breast cancer  having brain metastases  The company is developing NKTR 181 for the treatment of chronic pain  A new drug application is expected to be filed with the FDA this month Nektar Therapeutics Price and EPS Surprise
    Zacks RankNektar carries a Zacks Rank  4  Sell  You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-13,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-q1-loss-wider-than-expected-sales-soar-yy-200315999,200315999
172223,393739,LLY,Eli Lilly Gets FDA Approval For Taltz In Genital Psoriasis ,opinion,Eli Lilly   Company   NYSE LLY   announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection  Taltz  With the latest approval  Taltz label will now include data for psoriasis involving the genital area  which impacts roughly 63  of psoriasis patients over the course of their disease Taltz is already marketed for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy as well as for active psoriatic arthritis  Taltz works by specifically targeting IL 17A  a protein that plays a role in driving underlying inflammation in psoriasis The drug recorded sales of  146 5 million in the first quarter of 2018  The label expansion will expand the eligible patient population of the drug  which should drive sales going forward The approval for genital psoriasis was based on data from a study evaluating patients with moderate to severe psoriasis involving the genital area  In the study  Taltz demonstrated a significant improvement compared to placebo at 12 weeks in the severity of psoriasis affecting the genital area  overall psoriasis  genital itch and the impact of genital psoriasis on sexual activity in such patients Though many other drugs like Novartis    NYSE NVS   Cosentyx  J J s   NYSE JNJ   Tremfya and AbbVie s   NYSE ABBV   Humira are approved to treat plaque psoriasis  Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasisTaltz is also being studied in a late stage study for axial spondyloarthritis Year to date  Lilly s shares have declined 2 6  compared with the  s decline of 3 8   Lilly currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-05-22,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-gets-fda-approval-for-taltz-in-genital-psoriasis-200318729,200318729
172253,393769,LLY,Lilly  LLY  Tops On Q1 Earnings  Raises  18 View  Stock Up ,opinion,"Eli Lilly   Company   NYSE LLY   reported first quarter 2018 adjusted earnings per share of  1 34  which beat the Zacks Consensus Estimate of  1 13 per share by 18 6   Earnings rose 37  from the year ago quarter backed by robust volume driven growth in new product sales and lower operating costs and tax rates Including asset impairment  restructuring  and other special charges  first quarter earnings per share were  1 16 against a loss of 10 cents in the first quarter of 2017 Revenues in DetailQuarterly revenues of  5 70 billion also beat the Zacks Consensus Estimate of  5 53 billion  Sales grew 9  year over year backed by strong performance of new drugs and favorable currency movement  which made up for lower sales of established products like Strattera  Cialis and Forteo Volumes rose 2  as increased demand for new products like Trulicity  Cyramza  Taltz  Basaglar  Jardiance and Lartruvo offset decline in sales of some established products  However  volume growth was softer than 4  in the previous quarter Higher realized prices for several drugs contributed 3  to sales growth in the quarter  Foreign exchange rate also had a favorable impact of 4  While U S  revenues grew 8  to  3 16 billion  ex U S  revenues rose 11  to  2 55 billion Pharmaceutical revenues rose 11  in the quarter  However  decreased demand for food animal products continued to hurt sales in Lilly s Animal Health segment Established products that recorded growth during the quarter include Humalog  up 12  year over year to  791 7 million   Humulin  up 4  to  325 9 million  and Trajenta  up 25  to  141 1 million   Sales of all other established products declined in the quarter Forteo sales declined 10  to  313 2 million due to decreased volume from unfavorable wholesale and retail buying patterns in the United States Cymbalta sales declined 3  to  169 6 million while Erbitux sales declined 3  to  149 6 million Alimta sales rose 2  to  499 6 million as higher sales in United States offset sales decline in international markets  In ex U S  markets  sales declined 3  to  254 3 million due to competitive pressure and loss of exclusivity in certain countries  However  sales of Alimta increased 8  to  245 3 million in the United States due to increased volume and higher realized prices Zyprexa sales declined 17  to  122 6 million due to loss of exclusivity in Japan Cialis sales declined 7  to  495 4 million hurt by lower demand in United States and loss of exclusivity in Europe Strattera sales declined 33  to  130 7 million due to loss of exclusivity Among the new products  Trulicity generated revenues of  678 3 million  up 82  year over year  with U S  revenues benefiting from growth in the GLP 1 market and market share gains Cyramza revenues were  183 6 million  up 7  year over year  backed by strong demand  Cyramza s ex U S  revenues increased 10   benefiting from strong volumes and currency benefit  partially offset by lower realized prices  U S  revenues increased 3  driven by increased volume and higher realized prices Jardiance sales surged 104  to  151 million  driven by increased market share within the growing SGLT2 class in the United States and increased volume outside the United States Basaglar recorded revenues of  166 0 million compared with  153 8 million in the previous quarter  It generated revenues of  126 7 million in the United States  which improved sequentially driven by increased demand as the drug gained Medicare Part D formulary access Taltz brought in sales of  146 5 million compared with  172 5 million in the previous quarter as higher ex U S  revenues were offset by lower U S  sales  which were hurt by unfavorable specialty pharmacy buying patterns Lartruvo  olaratumab  generated revenues of  64 4 million in the quarter compared with  59 0 million in the previous quarter Olumiant  baricitinib  has been launched in select European countries and in Japan for moderate to severe rheumatoid arthritis  The drug generated sales of  32 2 million in the quarter backed by strong launch uptake in Germany  compared with  23 0 million in the previous quarter The drug is under review in the United States  Lilly and partner Incyte Corporation   NASDAQ INCY   re submitted the NDA for baricitinib in January  In a setback to the company  on Monday  Lilly informed that the FDA Advisory Committee has recommended approval of the 2 mg dose of the JAK inhibitor while not recommending the higher dose of 4 mg on the ground that its safety profile is not adequate to support an approval relative to its benefits  The final decision from the FDA is expected in June this year  Please note that in April last year  the FDA had issued a complete response letter  CRL  for the new drug application  NDA  for baricitinib on safety concerns Verzenio  which was launched in the Unites States in the fourth quarter of 2017  generated sales of  29 7 million in the quarter compared with  21 million in the previous quarter Elanco Animal Health segment sales declined 1  to  761 3 million due to decreased demand for food animal products Lilly is exploring strategic alternatives for this business including a sale  merger or creating a separate company through an initial public offer  A decision regarding the same is expected to be announced in July  Lilly might ultimately opt to retain the business Gross Margin   Operating Income Adjusted gross margin of 75 1  in the quarter decreased 270 basis points as manufacturing efficiencies and higher realized prices were offset by negative product mix and the effect of foreign exchange rates on international inventories sold Operating income increased 29  year over year to  1 60 billion due to lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 710 basis points in the quarter to 46 9  due to the company s cost saving efforts 2018 EPS Guidance UppedLilly raised its previously issued outlook for adjusted earnings as well as sales Adjusted earnings per share are now expected in the range of  5 10 to  5 20  higher than  4 81 to  4 91 expected previously  to reflect the expected benefit from higher operating profits and lower tax rates The revenue range was also slightly upped to  23 7 billion to  24 2 billion from  23 0 billion to  23 5 billion expected previously Gross margin is expected to be approximately 75   same as previously expected  Adjusted tax rate is expected to be approximately 17   previously approximately 18   Marketing  selling and administrative expense guidance was tightened to a range of  6 2  6 3 billion compared with  6 1  6 4 billion previously  Research and development expense guidance was slightly increased to a range of  5 2  5 4 billion compared with  5 0  5 2 billion previously due to increased funding requirement for pipeline development Our TakeLilly s first quarter results were impressive as it beat estimates for both earnings and sales and also raised its 2018 guidance for both metrics  Shares of the drug giant rose more than 2  in pre market trading However  year to date  Lilly s shares have declined 5  compared with the  s decline of 4 7  Going forward  Lilly s new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo  Verzenio and Olumiant are expected to continue to drive revenues However  competitive pressure on Lilly s drugs is expected to rise this year  Challenges remain for the company in the form of loss of patent exclusivity for products like Cialis this year and the impact of generic competition for Strattera  Effient and Axiron  The latest baricitinib setback was a disappointment Lilly carries a Zacks Rank  2  Buy   You can see  Eli Lilly and Company Price  Consensus and EPS Surprise
    Stocks to ConsiderOther top ranked large cap pharma stocks include Merck   NYSE MRK   and Pfizer   NYSE PFE    Both carry a Zacks Rank  2 While Merck s shares have risen 7 1  this year so far  its earnings estimates for 2018 and 2019 increased 1 7  and 0 7   respectively over the past 90 days Pfizer s earnings estimates for 2018 and 2019 rose 6 9  and 5 5   respectively over the past 90 days  The stock has gone up by 1 6  this year so far Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-24,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-tops-on-q1-earnings-raises-18-view-stock-up-200308291,200308291
172254,393770,LLY,Q1 Earnings Drag Pharma ETFs Down,opinion,Total earnings for  of the total healthcare market capitalization are up 14 7  on revenue growth of 8 1   The growth rates seem unimpressive when compared with some of the other sectors  Earnings and revenue beat ratios of 88 9  and 75   respectively  are also not great either Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on Apr 17  followed by Eli Lilly and Company   NYSE LLY   and Bristol Myers Squibb Company   NYSE BMY   on Apr 24 and Apr 26  respectively  Other major U S  drug companies   Merck   NYSE MRK   and Pfizer   NYSE PFE     reported on May 1  These industry bigwigs came up with earnings or revenue beat or both Earnings in FocusJohnson and JohnsonThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  2 06  5 cents ahead of the Zacks Consensus Estimate and 12 6  higher than the year ago quarter  Revenues grew 12 9  year over year to  20 01 billion and edged past the estimated  19 4 billion  Johnson   Johnson raised its revenue guidance from  80 60  81 40 billion to  81 0  81 8 billion but maintained its earnings per share outlook of  8 00  8 20  which reflects growth of 6 8  9 6   read    PfizerThe U S  drug giant surpassed earnings estimates but lagged on revenues  Earnings per share of 77 cents came in 3 cents above the Zacks Consensus Estimate while revenues of  12 9 billion fell shy of the estimated  13 1 billion  On an annual basis  earnings per share and revenues rose 12  and 1   respectively  For 2018  Pfizer expects revenues in the range of  53 5  55 5 billion and earnings per share of  2 90  3 00 MerckMerck also beat earnings estimates but missed on revenues  Earnings per share came in at  1 05  surpassing the Zacks Consensus Estimate of 99 cents and improving 19 3  from the year ago quarter  Revenues inched up 6  year over year to  10 04 billion and were below the estimated  10 12 billion  Merck increased its 2018 revenue guidance to  41 8  43 0 billion from  41 2  42 7 billion and earnings per share guidance to  4 16  4 28 from  4 08  4 23 Bristol MyersBristol Myers topped estimates on both fronts  It reported earnings per share of 94 cents  9 cents above the Zacks Consensus Estimate and ahead of the year ago earnings of 84 cents  Revenues grew 5  to  5 19 billion and edged past the Zacks Consensus Estimate of  5 18 billion  The company raised 2018 earnings per share guidance to  3 35  3 45 from  3 15  3 30  see    Eli LillyEli Lilly also surpassed earnings and revenue estimates  Earnings of  1 34 outpaced the Zacks Consensus Estimate by 21 cents and came in 37  higher than the year ago quarter  Revenues grew 9  to  5 7 billion and beat the estimated  5 53 billion  Like the other drug makers  Eli Lilly also raised its 2018 revenue guidance to  23 7  24 2 billion from  23  23 5 billion and earnings guidance to  5 10  5 20 from  4 81  4 91 ETF AnglePharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space  pushing many funds to 52 week lows  Below  we have highlighted them in detail  These funds have a Zacks ETF Rank  3  Hold  iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top five holdings in the basket  accounting for a combined 39 6  of total assets  suggesting heavy concentration  The product has  365 3 million in AUM and charges 44 bps in fees and expense  Volume is light as it exchanges about 21 000 shares a day  The fund has shed 4 5  in a month SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  326 1 million  it trades in good volume of around 95 000 shares a day and charges 35 bps in fees a year  In total  the product holds 43 securities with the in focus five firms taking over 4  share each  The product was down 6  in the same period  read    VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  The in focus five firms account for more than 4  share each  The product has amassed  237 4 million in its asset base and trades in a moderate volume of about 102 000 shares a day  Expense ratio comes in at 0 35   The fund has lost 2  in a month PowerShares Dynamic Pharmaceuticals Fund   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  511 6 million and sees lower volume of around 52 000 shares a day  The fund charges 56 bps in fees and expenses  Holding 30 stocks  the fund invests at least 4  share each in BMY  PFE and LLY  The ETF has lost 3 1  in a month First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  Of these  Pfizer and Johnson   Johnson account for more than 8  share each while Merck  Bristol Myers and Eli Lilly make up for more than 4  each  FTXH has a lower level of  3 million in AUM and 2 000 shares in average daily volume  It charges 60 bps in annual fees and has shed 4 1  in the same time frame Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/q1-earnings-drag-pharma-etfs-down-200313261,200313261
172256,393772,LLY,AVEO Pharmaceuticals  AVEO  Q1 Loss Wider Than Expected,opinion,"AVEO Pharmaceuticals  Inc    NASDAQ AVEO   reported first quarter 2018 loss of 8 cents per share  wider than the Zacks Consensus Estimate of a loss of 7 cents but narrower than the year ago loss of 12 cents  However  excluding gains related to a change in fair value of warrant liability  the company reported a loss of 6 cents per share AVEO s first drug  Fotivda  tivozanib  received EU approval in August 2017 for the first line treatment of advanced renal cell carcinoma   RCC    The company is focused on launching the drugs in the European countries  Currently  the drug is available in Germany  Austria and the United Kingdom  The company is entitled to receive double digit royalty payments from EUSA Pharma on net sales of the drug in Europe  However  Fotivda is not yet approved in the United States for RCC The company did not record any Fotivda sales during the quarter  AVEO s top line comprises collaboration and licensing revenues and partnership royalties  Total revenues in the first quarter were approximately  1 million  down 59 5  from the year ago figure  Revenues were almost in line with the Zacks Consensus Estimate of  0 98 million Shares of the company crashed 10  on May 8  presumably as the company said it is postponing the data readout from key phase III TIVO 3 study  AVEO s share price movement shows that the stock has underperformed the  so far this year  Specifically  the company s shares have lost 20 3  compared with the industry s decrease of 11 9  Operating ExpensesResearch   development expenses were down 32 1  to about  5 4 million  However  general and administrative expenses increased 12  year over year to  2 6 million Cash GuidanceAVEO expects that its present cash resources of  27 million will allow the company to fund its planned operations through the first quarter of 2019 Pipeline UpdatesConcurrent with the earnings release  the company announced that it is deferring the anticipated topline data readout from TIVO 3 study evaluating Fotivda in first line RCC in the third quarter of 2018  It was previously expected in the second quarter  AVEO is conducting the study to address the overall survival concerns from the TIVO 1 study identified by the FDA  Data from TIVO 3 study along with TIVO 1 study will be included in the regulatory application for approval of Fotivda in the United States In April  AVEO announced the launch of Fotivda by its partner EUSA Pharma in Austria  In February  the drug was launched in the United Kingdom which triggered a milestone payment of  2 million from EUSA Pharma In February 2018  AVEO announced data from the phase II portion of TiNivo study evaluating tivozanib in combination with Bristol Myers    NYSE BMY   PD1 inhibitor  Opdivo  in metastatic RCC  Data from the study showed that 64  patients achieved ORR  The disease control rate achieved by the combination therapy was 100   In January  data presented from a phase I II study evaluating Fotivda in advanced hepatocellular carcinoma showed that Fotivda achieved a median PFS of 5 5 months at week 24  The median OS achieved was 7 5 months Apart from Fotivda  AVEO is also developing ficlatuzumab in combination with Lilly s   NYSE LLY   Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma  Another phase Ib study is evaluating ficlatuzumab in combination with Nab paclitaxel and gemcitabine in treatment naive pancreatic cancer  These studies were initiated in December last year Other UpdatesIn February  the company appointed industry veteran  John H  Johnson  with over 30 years of experience to its board of directors In January  AVEO announced that it has refinanced its existing debt facility of  20 million with Hercules Capital  The company said that the terms of the new facility will help it to have an additional  12 1 million in cash flow over 2018 and 2019 compared to the prior loan AVEO Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderAVEO currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates moved up from  4 40 to  4 43 and remained stable at  5 32 for 2018 and 2019  respectively  in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 24 88   The company s stock is up 14 9  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-05-08,Zacks Investment Research,https://www.investing.com/analysis/aveo-pharmaceuticals-aveo-q1-loss-wider-than-expected-200314811,200314811
172257,393773,LLY,Pharma Stock Roundup  LLY To Buy Cancer Biotech  J J  AZN  Roche Announce Updates,opinion,"This week Eli Lilly   NYSE LLY   announced an all cash deal tobuy immuno oncology biotech  ARMO Biosciences  Inc    NASDAQ ARMO    J J s   NYSE JNJ   multiple myeloma drug Darzalex gained FDA approval for combination use in first line setting while Roche   OTC RHHBY   announced a couple of regulatory pipeline updates on its PD L1 inhibitor  Tecentriq  AstraZeneca   NYSE AZN   sold rights to a schizophrenia product and its PARP inhibitor  Lynparza gained marketing approval in the EU Recap of the Week s Most Important StoriesLilly to Expand Immunotherapy Pipeline with ARMO  Eli Lilly announced a definitive agreement to buy California based immuno oncology biotech ARMO BioSciences for  50 per share or approximately  1 6 billion in an all cash deal  The acquisition will add ARMO s lead product candidate  pegilodecakin to Lilly s cancer pipeline  Pegilodecakin  a PEGylated IL 10  is being studied in a late stage study in pancreatic cancer as well as early stage studies in lung and renal cell cancer  melanoma and other solid tumor types  ARMO BioSciences went public in January this year Lilly has a well laid out oncology strategy  which involves building on key cancer treatments like Cyramza  Lartruvo and Verzenio as foundational agents while focusing on developing new standard of care changing therapies and combination regimens  including immuno therapies  The ARMO BioSciences acquisition  which adds a promising next generation immunotherapy pipeline asset to Lilly s portfolio  is in line with this strategy  The transaction is expected to close by the end of the second quarter of 2018J J Darzalex Gets FDA Nod in First Line Setting  J J s multiple myeloma drug  Darzalexgained FDA approval in first line setting  With the latest approval  Darzalex can now be prescribed in combination with bortezomib  melphalan and prednisone  VMP  for the treatment ofpatients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation  With theapproval in first line setting expected this year  it is expected that Darzalex saleswill improve further going forward J J also announced data from two phase III studies evaluating its investigational compound esketamine nasal spray in combination with newly initiated oral antidepressant   NIOD   in patients with treatment resistant depression compared to placebo nasal spray and the NIOD  The combination demonstrated a statistically significant  clinically meaningful rapid reduction of depressive symptoms on treatment with flexibly dosed esketamine nasal spray plus NIOD compared to placebo plus NIOD in the study in adults  However  in the study conducted on elderly patients aged 65 and older  though the esketamine arm witnessed clinically meaningful effects compared to the placebo arm  the study narrowly missed statistical significance for its primary efficacy endpoint  The results were presented at the annual meeting of the American Psychiatric Association AstraZeneca Sells Seroquel Rights to Luye Pharma  AstraZeneca announced an agreement to sell Seroquel and Seroquel XR  a treatment for schizophrenia and bipolar disease  rights in the UK  China and other international markets to Luye Pharma Group  The total consideration is  538 million  which includes upfront payment of  260 million as well as certain future payments to AstraZeneca  The transaction  expected to close in the second quarter  is part of the company s efforts to focus on its three main therapy areas of Oncology  Cardiovascular  Renal   Metabolism and Respiratory Sales of Seroquel Seroquel XR have been declining as the drug is facing generic competition since November 2016  In 2017  Seroquel XR recorded sales of  332 million  representing a year over year decline of 55  AstraZeneca  Merck s PARP inhibitor  Lynparza tablets  gained EUapproval for use as a maintenance therapy in platinum sensitive relapsed ovarian cancer  regardless of patients  BRCA mutation status  The approval thus expands the eligible patient population for Lynparza  Approval for the same indication in the United States was received in August last year Roche s Tecentriq in Focus  Roche s supplemental Biologics License Application  sBLA  for label expansion of its PD L1 inhibitor Tecentriq was granted priority review by the FDA  With the latest application  Roche is looking to get Tecentriq approved in combination with Avastin  bevacizumab  plus carboplatin and paclitaxel for first line treatment of advanced non squamous non small cell lung cancer  NSCLC   The FDA s decision is expected on Sep 5  2018 Tecentriq is presently marketed for the treatment of second line metastatic NSCLC  Label expansion in first line setting should boost the drug s sales further  Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  mUC  who are not eligible for cisplatin chemotherapy  The drug recorded sales of CHF457 million in 2017 In another news on Tecentriq  Roche announced that a late stage study evaluating the drug in combination with Cotellic in heavily pre treated patients with advanced or metastatic colorectal cancer  CRC  did not meet its primary endpoint of overall survival  OS  compared to regorafenib The NYSE ARCA Pharmaceutical Index rose 1 6  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
 
 Here is how the seven major stocks performed in the last five trading sessions All stocks were in the green last week except Bristol Myers   NYSE BMY    which declined 0 6   Lilly rose the most  3 6   In the past six months  Glaxo   NYSE GSK   has been the biggest gainer  13 7    while Bristol Myers declined the most  16 2    See the last pharma stock roundup here  Pharma Stock Roundup What s Next in the Pharma World Watch out for FDA decisions on many pipeline drugs and line extensions of marketed products this month 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lly-to-buy-cancer-biotech-jj-azn-roche-announce-updates-200315466,200315466
172272,393788,LLY,FDA Nods For Bristol Myers  Colorectal Cancer Combo Therapy,opinion,Bristol Myers Squibb Company   NYSE BMY   has announced that its supplemental Biologics License Application  sBLA  for its PD 1 immune checkpoint inhibitor  Opdivo  nivolumab   in combination with Yervoy  ipilimumab  has been accepted by the FDA under priority review The company seeks an approval for label expansion of the combination therapy for addressing patients  previously treated with microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  metastatic colorectal cancer  mCRC   A response from the regulatory body is awaited on Jul 10  2018 The Opdivo Yervoy combo regimen has also been granted a Breakthrough Therapy Designation by the FDA for the aforementioned indication Notably  Opdivo acquires a nod in several countries including the United States  the EU and Japan for several cancer indications Shares of the company have rallied 11 7  in the past year  outperforming the  s gain of 3 4   The acceptance of the application was based on positive data from Phase II CheckMate 142 study  announced in January 2018  evaluating the combination therapy for the given indication Results from the study showed that the primary endpoint of objective response rate per investigator assessment was 55  with a median follow up of 13 4 months  The overall survival rate at one year was 85  and the median OS was not yet reached  The outcomes showed that Opdivo plus Yervoy provide a durable clinical relief in patients with dMMR or MSI H metastatic colorectal cancer The data demonstrated statistically significant and clinically meaningful improvements in key patient reports including symptoms  functioning and quality of life Significantly  this combination procedure is also under assessment in a phase III  Checkmate 227 trial as a first line treatment for non small cell lung cancer  NSCLC   Last month  Bristol Myers announced positive data from the program  reflecting superior progression free survival in first line NSCLC patients compared with chemotherapy  This is the first study to examine combination regimes of two immune oncology drugs in first line NSCLC patients with high tumor mutation burden Per the company s press release  colorectal is one of the most common cancer types and the third leading cause for terminal disease related deaths in the United States  Approximately  140 000 new cases of CRC are expected to be diagnosed annually in the country  Moreover  patients with MSI H or dMMR metastatic CRC have mild possibility to benefit from conventional chemotherapy treatment  Hence  approval of this combo treatment will provide the company with access to a huge patient population base  in need of an alternative treatment option to apprehend the disease However  Bristol Myers faces a fierce competitive pressure in the immuno oncology space  In fact  Opdivo battles against stiff rivalry from Merck s   NYSE MRK   anti PD 1 immunotherapy Keytruda and Roche s Tecentriq  Merck s Keytruda is also being analyzed in a phase III study for CRC  Hence  label expansion of Opdivo Yervoy combination will lend the company a wider population base of patients for Opdivo A few approved drugs to treat patients with CRC are Lilly s   NYSE LLY   Cyramza  Roche s   OTC RHHBY   Avastin and Amgen s Vectibix Bristol Myers Squibb Company Price    Zacks RankBristol Myers carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-03-27,Zacks Investment Research,https://www.investing.com/analysis/fda-nods-for-bristolmyers-colorectal-cancer-combo-therapy-200301541,200301541
172273,393789,LLY,VTv Therapeutics Crashes On Alzheimer s Drug Study Failure ,opinion,"Shares of vTv Therapeutics  Inc    NASDAQ VTVT   plummeted significantly after the company announced dismal results from the part A of the phase III trial  STEADFAST  on pipeline candidate  azeliragon vTv Therapeutics  stock has plunged 50 6  in the last six months as against the  decline of 18 9    The candidate was being evaluated in patients suffering from Alzheimer s disease  The results showed that the candidate did not meet co primary efficacy endpoint as patients taking azeliragon versus placebo did not improve in cognitive or functional outcomes as measured by theAlzheimer s Disease Assessment Scale cognitive subscale  ADAS cog  and the Clinical Dementia Rating Scale Sum of Boxes  CDR sb  The study comprised two independent and identical randomized  double blind  placebo controlled phase III trials  part A and part B   The azeliragon treated group in part A showed a 4 4 point decline from baseline in ADAS Cog and a 1 6 point dip from baseline in CDR sb compared to a placebo fall of 3 3 and 1 6  respectively  However  these differences were not statistically significant  azeliragon was generally well tolerated with a 25  withdrawal rate over 18 months that was similar in both the placebo and treatment arms Consequently  vTv Therapeutics discontinued ongoing studies involving azeliragon  including the open label extension study and part B of the STEADFAST study Nevertheless  a substantial portion of patients in part B of STEADFAST will have completed 12 months of treatment under the study protocol The failure of the late stage study is disappointing for investors as the successful development and subsequent commercialization of the candidate would have significantly boosted growth prospects given the complexity of the drugs Of late  there has been many failures of drugs being developed for Alzheimer s  In February 2018  Merck   NYSE MRK   announced that it will stop the phase III study  APECS  which was evaluating verubecestat  MK 8931   an investigational small molecule inhibitor of the beta site amyloid precursor protein cleaving enzyme 1  BACE1   in patients with prodromal Alzheimer s disease  The decision was taken after an external Data Monitoring Committee  which assessed overall benefit risk during a recent interim safety analysis  concluded that it was unlikely that positive benefit risk was possible   In January 2018  Pfizer   NYSE PFE   announced plans to end its research efforts to discover new drugs for Alzheimer s and Parkinson s diseases  Eli Lilly   NYSE LLY   is another major company which has suffered many failures in its attempt to develop drugs for Alzheimer s Zacks RankvTv Therapeutics currently carries a Zacks Rank  4  Sell  You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/vtv-therapeutics-crashes-on-alzheimers-drug-study-failure-200304425,200304425
172275,393791,LLY,Celldex s Phase II Breast Cancer Study Fails  Shares Plunge,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   announced the failure of its lead pipeline candidate  glembatumumab vedotin  in a phase IIb breast cancer study   METRIC  The candidate failed to meet the primary endpoint of progression free survival   PFS   benefit over Roche s   OTC RHHBY   chemotherapy  Xeloda  in the treatment of metastatic triple negative breast cancers that overexpress gpNMB An assessment of the data from the mid stage study showed that glembatumumab vedotin achieved a PFS of 2 9 months versus 2 8 months for Xeloda  The candidate was also not able to demonstrate significant advantage in key secondary endpoints  including overall response rate  duration of response and overall survival Following the failure  Celldex has decided to discontinue studies evaluating glembatumumab vedotin across all indications  The company is currently restructuring its pipeline to focus on five candidates in ongoing clinical studies  which includes varlilumab  It may also reduce its workforce With no approved products in Celldex s portfolio  the discontinuation of clinical studies following the failure of its lead candidate came as a major setback  pulling the stock down by more than 60  on Apr 16  The stock has declined 73 2  so far this year  compared with the  s decline of 8 2  Celldex is evaluating varlilumab  a CD27 agonist  in combination with Bristol Myers    NYSE BMY   Opdivo in a mid stage study in several indications  Another phase II study is currently enrolling patients to evaluate CDX 3379 in combination with Eli Lilly s   NYSE LLY   Erbitux for the treatment of head and neck cancer The company will provide revised estimates in its first quarter earnings release to include the impact of its restructuring initiatives Celldex Therapeutics  Inc  Price
    Celldex carries a Zacks Rank  3  Hold   You can see  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/celldexs-phase-ii-breast-cancer-study-fails-shares-plunge-200306296,200306296
172276,393792,LLY,Merck s Keytruda Betters Survival In Lung Cancer Combo Study,opinion,Merck s   NYSE MRK   shares increased 2 59  on Apr 16 after it presented full data from the pivotal phase III KEYNOTE 189 study  Data from the same showed that Keytruda combined with Eli Lilly s   NYSE LLY   Alimta  pemetrexed  and platinum chemotherapy  cisplatin or carboplatin  significantly improved overall survival  thereby reducing the death risk by half  51   compared with chemotherapy alone The study evaluated the combination therapy for first line treatment of patients with metastatic non squamous non small cell lung cancer  NSCLC  regardless of PD L1 expression  The combo treatment showed progress in overall survival irrespective of PD L1 expression including patients with tumors testing negative for PD L1 Meanwhile  a significant improvement in progression free survival  PFS  was observed with decrease in death risk by 48  in the Keytruda combination arm compared with the chemotherapy arm  The median PFS was 8 8 months in the Keytruda arm compared with 4 9 months in the chemotherapy one  A PFS improvement was also observed in patients  whose tumors tested negative for PD L1 The results were presented at the annual meeting of the American Association for Cancer Research Notably in January this year  Merck had announced that the study met both its primary endpoints  PFS and OS as well Importantly  Keytruda is the first PD1 inhibitor in combination to show OS in patients with NSCLC Last May  this combination therapy was granted an accelerated approval by the FDA for the aforementioned indication  The nod was based on tumor response rate and PFS data from the KEYNOTE 021 trial  Hence  the positive readouts from the KEYNOTE 189 confirmatory study will help the company gain a continued approval for the combo therapy  which should in turn support uptake and sales We remind investors that in the third quarter of 2017  Merck had mentioned that it is including the overall survival  OS  as a co primary endpoint in the KEYNOTE 189 program  which could defer the readout from the study to 2019  It was then estimated that the evaluation would be completed by February 2019  However  the company released data from KEYNOTE 189 study a year earlier than expected in January 2018 Merck s shares have gained 6 2  so far this year versus the 2 7  decline of its   Concurrently  Bristol Myers   NYSE BMY   also reported data from a phase III study on its blockbuster drug Opdivo for NSCLC  However  Merck s Keytruda combination demonstrated better overall survival compared with Opdivo Zacks Rank   Key PickMerck carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 78 to  4 40 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 60 7  over a year Breaking News  Cryptocurrencies Now Bigger Than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-betters-survival-in-lung-cancer-combo-study-200306262,200306262
172277,393793,LLY,5 Drug Stocks Poised To Surpass On Earnings This Quarter,opinion,"The first quarter earnings season has just kicked off  Per the latest   the bottom line of S P 500 companies is expected to increase at a highly impressive rate of 16 6  on a year over year basis  This prospective upside marks the maximum quarterly earnings growth pace in seven years  The report further predicts that 11 of the 16 Zacks sectors are projected to exhibit double digit earnings growth in the to be reported quarter  Total revenues for the same set of companies are projected to grow 7 5  However  focusing our attention on the  and  sector  we note that both these sectors have decreased 6 2  and 4 2   respectively  since February this year due to broader market pressure  Further  the S P 500 index has registered a decline of 6 2  since the second month of 2018 We remind investors that the U S  stock market is facing a severe volatility since the last couple of months despite a strong start this year  This downside can mainly be attributable to a potentially damaging trade war between the world s two largest economies  United States and China  since this February After President Donald Trump announced plans to impose tariffs on up to  60 billion of annual Chinese imports  China retaliated by notifying its intention to levy tariffs on 128 U S  products  Such aggressive exchange has triggered tensions of a possible trade dispute between the two countries  Moreover  sluggish large cap tech stocks are cited as another reason for this plummet in the market Despite the recent market unrest  an optimistic sentiment revolves around the remaining year  Notably  the biotech sector is likely to improve as the year advances  We expect new product sales to thrive in tandem with rising demand  This apart  a successful innovation and a host of product launches  strong clinical study outcomes  more frequent FDA nods  solid performance of key products  growing demand for drugs  especially to deal with rare to treat diseases  an ageing population and an escalated healthcare expenditure are some of the factors to keep the sector stable  You can see  
It is important to note that the outlook for the upcoming first quarter results looks bright  Per the Earnings Preview  the broader Medical sector  inclusive of drug  biotech as well as Medical Device companies  is expected to record 6 3  year over year growth in revenues and a 7 8  rise in earnings How to Pick Potential Q1 WinnersGiven the enormity of the healthcare space  the task of selecting stocks with possibilities to beat estimates could appear quite daunting  But the Zacks proprietary methodology makes this job fairly simple  One way to carve out the top choices this reporting cycle is by looking at the stocks with the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive   It is observed that a positive earnings surprise delivered by a company mostly leads to its stock price appreciation Per the well researched quantitative model  an Earnings ESP is used for identifying stocks with higher or 70  chances of pulling off a positive surprise in the impending earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  
Per our proven methodology  we culled three stocks from large cap pharma and two from the medical drug sector  poised to surpass estimates in the to be reported quarter The three large cap stocks are as follows Our first pick is AbbVie Inc  NYSE ABBV       This North Chicago  IL based company has an Earnings ESP of  0 24  and a Zacks Rank  3  The stock has seen the Zacks Consensus Estimate for first quarter 2018 earnings being pegged at  1 78 per share  Besides this  the company boasts an encouraging earnings track record  exceeding expectations in all the last four quarters with an average beat of 1 81   AbbVie is scheduled to report earnings numbers on Apr 26 Our next choice is Eli Lilly   Company     The stock has an Earnings ESP of  0 73  and a Zacks Rank  2  The consensus mark for first quarter earnings stands at  1 13 per share  Headquartered in Indianapolis  IN  Lilly has an excellent positive earnings surprise history  The company s average beat over the trailing four quarters is 4 08   Lilly is slated to announce results on Apr 24 Pfizer Inc     too has a pleasing earnings profile with the company having consistently outpaced expectations in all the last four quarters with an average beat of 4 97   It looks perfectly poised to repeat this winning streak this time around as well  This New York based player is Zacks  2 Ranked and has an Earnings ESP of  2 62   The consensus mark for first quarter bottom line is pegged at 73 cents per share  Pfizer is scheduled to release financial figures on May 1 Given below are the two medical drug stocks Our first pick from the medical drug sector is Catalent  Inc      This New Jersey based company has an Earnings ESP of  1 70  and a Zacks Rank of 3  The Zacks Consensus Estimate for first quarter earnings is pegged at 39 cents per share  The company flaunts a positive earnings surprise record  outshining expectations in all the last four quarters with an average beat of 16 44   Catalent is expected to report earnings on May 3 Our next choice is Aratana Therapeutics  Inc      The stock has an Earnings ESP of  37 14  and is a  3 Ranked player  The consensus mark for first quarter loss stands at 18 cents per share  Based in Kansas  Aratana has an outstanding earnings history with consecutive estimate beats in the trailing four quarters  the average being 11 74   The company is slated to announce results on May 4 Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/5-drug-stocks-poised-to-surpass-on-earnings-this-quarter-200306227,200306227
172302,393818,LLY,AVEO Pharmaceuticals  AVEO  Q4 Loss Widens  Shares Down,opinion,"AVEO Pharmaceuticals  Inc    NASDAQ AVEO   reported fourth quarter 2017 adjusted loss of 8 cents per share  excluding gains due to a change in fair value of warrant liability   wider than the Zacks Consensus Estimate of a loss of 2 cents as well as the year ago loss of 13 cents  However  including gains related to a change in fair value of warrant liability  the company reported earnings of 3 cents 
AVEO s first drug  Fotivda  tivozanib  received EU approval in August 2017 for the first line treatment of advanced renal cell carcinoma  RCC   Subsequently  in November 2017  AVEO along with its partner EUSA Pharma  launched the drug in Europe  starting with Germany  The company is entitled to receive double digit royalty payments from EUSA Pharma on net sales of the drug in Europe  However  Fotivda is not yet approved in the United States for RCC 
AVEO s top line mainly comprises collaboration revenues  milestone and other payments  Total collaboration revenues in the fourth quarter were approximately  0 08 million  down 20  compared with the year ago figure  Revenues missed the Zacks Consensus Estimate of  1 million 
Shares of the company have declined more than 4  on Mar 13  following the earnings release  due to wider loss and lower sales  However  on a year to date basis  AVEO s share price movement shows that the stock has outperformed the   Specifically  the company s shares have gained 3 9  compared with the industry s increase of 3  

Quarterly Highlights
Research   development expenses were down 26  to about  5 7 million  However  general and administrative expenses increased 26 3  year over year to  2 4 million 
Pipeline Updates
In October 2017  AVEO announced results of a pre planned futility analysis of phase III TIVO 3 study  comparing Fotivda to Bayer s   OTC BAYRY   Nexavar  as treatment for patients with refractory advanced RCC  Based on the results  the company will continue the study unmodified  The data from this study along with the previously completed TIVO 1 study will support the regulatory application for approval in the United States 
In December 2017  the company announced the completion of enrollment in phase II portion of phase Ib II TiNivo study  evaluating Fotivda in combination with Bristol Myers    NYSE BMY   Opdivo in RCC  The company expects to provide updates from the study in the second half of 2018 
Apart from Fotivda  AVEO is also developing ficlatuzumab in combination with Lilly s   NYSE LLY   Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma  Another phase Ib study is evaluating ficlatuzumab in combination with Nab paclitaxel and Gemcitabine in treatment naive pancreatic cancer  These studies were initiated in December last year 
2017 Results
Full year sales stood at  7 6 million  missing the Zacks Consensus Estimate of  11 3 million  However  the top line drastically increased 204  compared with the year ago figure of  2 5 million 
The full year earnings of 61 cents per share were narrower than the Zacks Consensus Estimate of 64 cents  However  the bottom line is wider than the year ago loss of 39 cents 
Cash Guidance
AVEO expects that its present cash resources of  33 5 million will allow the company to fund its planned operations through the first quarter of 2019 AVEO Pharmaceuticals  Inc  Price  Consensus and EPS Surprise

   Zacks Rank
AVEO carries a Zacks Rank  3  Hold   You can see  
Breaking News  Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved 
Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-03-14,Zacks Investment Research,https://www.investing.com/analysis/aveo-pharmaceuticals-aveo-q4-loss-widens-shares-down-200298175,200298175
172303,393819,LLY,Is Eli Lilly And Company  LLY  Stock A Good Value Pick Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Eli Lilly and Company   NYSE LLY   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Lilly has a trailing twelve months PE ratio of 18 4  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 21 3  If we focus on the long term PE trend  Lilly s current PE level puts it below its midpoint over the past five years  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the sector s trailing twelve months PE ratio  which stands at 20 2  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Lilly has a forward PE ratio  price relative to this year s earnings  of just 16 2  so it is fair to say that a slightly more value oriented path may be ahead for Lilly stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Lilly has a P S ratio of about 3 6  This is marginally higher than the S P 500 average  which comes in at 3 4 right now  Nonetheless  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years Also  LLY is toward the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Lilly currently has a Zacks Value Style Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Lilly a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Lilly is just 1 5  a level that is lower than the industry average of 2 1  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate What About the Stock Overall Though Lilly might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of A and a Momentum score of B  This gives LLY a Zacks VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mostly trending higher  The current quarter has seen no estimates go higher in the past sixty days compared to one lower  while the full year estimate has seen nine upward and one downward revisions in the same time period As a result  the current quarter consensus estimate has risen by 5 6  in the past two months  while the full year estimate has increased 3 6   You can see the consensus estimate trend and recent price action for the stock in the chart below Eli Lilly and Company Price and Consensus    Even though Lilly has a better estimates trend  the stock has just a Zacks Rank  3  Hold   That is why we are looking for in line performance from the company in the near term Bottom LineLilly is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a robust industry rank  among the Top 18   should boost investor confidence However over the past two years  the industry has underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this the positive estimate revisions and robust value metrics  and we believe that we have a strong value contender in Lilly The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/is-eli-lilly-and-company-lly-stock-a-good-value-pick-now-200298737,200298737
172304,393820,LLY,Roche Tecentriq Phase III Combo Study Meets Primary Endpoint ,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   subsidiary Genentech announced that a phase III study  evaluating a combination of its PD L1 inhibitor Tecentriqplus chemotherapy  carboplatin and Abraxane  for first line treatment of advanced lung cancer met its co primary endpoint of progression free survival   PFS    The IMpower131 study showed that the combination reduced the risk of disease worsening or death  PFS  compared with chemotherapy alone in the initial treatment of patients with advanced squamous non small cell lung cancer   NSCLC   
However  the above results did not show a statistically significant overall survival   OS   benefit  Hence the study will be continued  and the interim data will be presented at an upcoming oncology congress 
Over a year  shares of Roche have declined 8 2  against the  s growth of 8 1  

 
Tecentriq is marketed for the treatment of second line metastatic NSCLC  Label expansion in the first line setting should boost the drug s sales further  Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  mUC  who are not eligible for cisplatin chemotherapy  The drug recored sales of CHF457 million in 2017 
In February 2018  Roche announced positive results from the phase III IMmotion151 study on Tecentriq in combination with oncology drug Avastin  bevacizumab  as a first line treatment for advanced or metastatic renal cell carcinoma  The study met its co primary endpoint of investigator assessed PFS in patients whose disease expressed the PD L1 protein  Results showed that patients who received Tecentriq plus Avastin had a 26  reduced risk of disease worsening or death  PFS  compared to people treated with Sutent 
We remind investors that Merck s    NYSE MRK   PD L1 inhibitor Keytruda is approved by the FDA  both as monotherapy and in combination with Lilly s    NYSE LLY   Alimta and carboplatin for the first line treatment of patients with metastatic nonsquamous NSCLC Roche Holding AG Price

    
Zacks Rank   Another Stock to Consider
Roche carries a Zacks Rank  2  Buy  
Another top ranked stock from the same space is Regeneron Pharmaceuticals   NASDAQ REGN   sporting a Zacks Rank  1  Strong Buy   You can see  
Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2   respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-03-20,Zacks Investment Research,https://www.investing.com/analysis/roche-tecentriq-phase-iii-combo-study-meets-primary-endpoint-200299507,200299507
172305,393821,LLY,Pfizer s Chantix Fails In Phase IV Study In Young Smokers,opinion,"Pfizer Inc    NYSE PFE   announced that its smoking cessation drug  Chantix  varenicline  failed in a phase IV study  evaluating it in adolescent smokers  The study was being conducted as a regulatory post marketing commitment in smokers aged 12 to 16 years in the United States and 12 to 17 years in Europe The complete study results are expected to be presented at an upcoming scientific congress and will be published later in a peer reviewed medical journal Chantix is already on the market as a prescription drug for helping adults aged 18 and over  along with counseling  to stop smoking Shares of the company were down 3 1  on Mar 23  Meanwhile  Pfizer s shares have declined 4 8  so far this year  compared with the  s decline of 5 8  in that period The dose ranging multi centre phase IV study evaluated Chantix for smoking cessation in nicotine dependent adolescents in combination with age appropriate counselling  The study evaluated two dosages of the drug   0 5 mg once and twice daily Chantix failed to meet the primary endpoint of the four week continuous abstinence rate compared to placebo at weeks 9 through 12 The adverse events observed in the study were similar to those seen in an earlier study conducted in adult smokers Pfizer is planning to submit data from this study to the FDA for pediatric exclusivity determination  Pediatric exclusivity is granted for six months in return for conducting studies in pediatric patients  With the failure of the study on young smokers  it is unlikely to receive the exclusivity In another setback for Pfizer  GlaxoSmithKline   NYSE GSK   terminated talks to buy the former s consumer healthcare business  Last week  England based Reckitt Benckiser also announced to drop its buyout plans for the segment Pfizer Inc  Price
    Zacks Rank   Other Key PicksPfizer currently carries a Zacks Rank  2  Buy  Some other top ranked stocks in the health care sector include Horizon Pharma Public Limited Company   NASDAQ HZNP   and Eli Lilly and Company   NYSE LLY    Both the stocks carry a Zacks Rank  2  You can see  Horizon Pharma s earnings estimates increased from  1 30 to  1 43 for 2018 and from  1 54 to  1 77 for 2019 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68 92  Lilly s earnings per share estimates increased  4 84 to  4 85 for 2018 and from  5 26 to  5 29 for 2019 over the last 30 days  The company delivered a positive earnings surprise in all the four trailing quarters with an average beat of 4 08   The company s shares have increased 23  so far this year 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/pfizers-chantix-fails-in-phase-iv-study-in-young-smokers-200300849,200300849
172308,393824,LLY,Roche s Tecentriq Combo Study Meets Co Primary Endpoint,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   subsidiary Genentech announced that a phase III study  evaluating a combination of its PD L1 inhibitor Tecentriq  atezolizumab  and Avastin  bevacizumab  plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co primary endpoint of overall survival  OS  
The IMpower150 study showed that the patients with advanced non squamous non small cell lung cancer  NSCLC  who were treated with the combination treatment lived longer compared with Avastin plus carboplatin and paclitaxel 
The company plans to submit these additional data to global health authorities as well as to the FDA and the European Medicines Agency  EMA  soon 
Over a year  shares of Roche have declined 12 3  against the  s growth of 2 8  

In December 2017  the company had announced interim results from the IMpower 150 study  The IMpower150 study showed that Tecentriq and Avastin plus chemotherapy reduced the risk of disease worsening or death by 38  compared with those who were treated with Avastin plus chemotherapy  In November 2017  Roche mentioned that the III IMpower150 study met its co primary endpoint of progression free survival 
Tecentriq is approved for the treatment of second line metastatic NSCLC  Label expansion in the first line setting should boost the drug s sales further  Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  mUC  who are not eligible for cisplatin chemotherapy  The drug recorded sales of CHF457 million in 2017 
We remind investors that Merck s   NYSE MRK   PD L1 inhibitor Keytruda is approved by the FDA  both as monotherapy and in combination with Lilly s    NYSE LLY   Alimta and carboplatin for the first line treatment of patients with metastatic nonsquamous NSCLC Roche Holding AG Price

    
Zacks Rank   Other Stock to Consider
Roche carries a Zacks Rank  2  Buy  
Another top ranked stock from the same space is Regeneron Pharmaceuticals   NASDAQ REGN    sporting a Zacks Rank  1  Strong Buy   You can see  
Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions  New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-combo-study-meets-coprimary-endpoint-200300880,200300880
172326,393842,LLY,Why Is Eli Lilly  LLY  Down 7 2  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Eli Lilly and Company   NYSE LLY    Shares have lost about 7 2  in the past month  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is LLY due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Lilly Tops Q4 Earnings and Sales  Ups 2018 Earnings OutlookLilly reported fourth quarter 2017 adjusted earnings per share of  1 14  which beat the Zacks Consensus Estimate of  1 08 per share by 5 6   Earnings rose 20  from the year ago quarter backed by robust volume driven growth in new product sales  lower SG A costs and a higher other income Including a  1 9 billion charge related to U S  tax reform and restructuring  amortization and other charges  fourth quarter 2017 loss per share was  1 58 per share  against earnings of 73 cents in the fourth quarter of 2016 Revenues in DetailQuarterly revenues of  6 16 billion also beat the Zacks Consensus Estimate of  5 96 billion by 3 3   Sales grew 7  year over year backed by strong performance of new drugs and favorable currency movement  which made up for lower sales of established products like Strattera  Humalog  Cialis and Effient Volumes rose 4  as strong performance of new products like Trulicity  Taltz  Basaglar  Jardiance and Lartruvo offset decline in sales of established products  Higher realized prices for several drugs also contributed 2  to sales growth in the quarter  Foreign exchange rate also had a favorable impact of 1  New products drove 12  of volume growth and generated over  1 4 billion in revenues  representing nearly 23  total revenues  up from 22  in the previous quarter  On the other hand  the loss of exclusivity for Cymbalta  Strattera  Effient  Axiron  Zyprexa and Evista hurt volumes by 540 basis points While U S  revenues grew 6  to  3 42 billion  ex U S  revenues rose 8  to  2 74 billion Pharmaceutical revenues rose 9  in the quarter  However  worldwide competitive pressure hurt sales in Lilly s Animal Health segment Established products that recorded growth during the quarter include Forteo  up 21  to  513 2 million   Humulin  up 2  to  362 6 million   Cymbalta  up 6  to  192 8 million  and Erbitux  up 10  to  168 9 million   Sales of all other established products declined in the quarter Humalog sales declined 5  to  782 2 million due to lower realized prices in the United States Alimta sales declined 3  to  525 2 million  reflecting lower demand in ex U S  markets due to competitive pressure and loss of exclusivity in certain countries  However  sales of Alimta increased 1  in the United States due to increased volume  partially offset by lower realized prices Zyprexa sales declined 1  to  152 2 million due to loss of exclusivity in Japan Cialis sales declined 12  to  597 4 million hurt by worldwide lower demand Strattera sales declined 60  to  98 3 million  Effient sales declined 56  to  62 3 million in the quarter  Both the drugs saw lower demand due to loss of exclusivity Among the new products  Trulicity generated revenues of  649 million  up 93  year over year  with U S  revenues benefiting from growth in the GLP 1 market and market share gains Cyramza revenues were  204 8 million  up 16  year over year  backed by strong demand  Cyramza s ex U S  revenues increased 15   benefiting from strong volumes in Japan  partially offset by lower realized prices  U S  revenues increased 17  driven by increased volume Jardiance sales rose 88  to  143 2 million  driven by increased market share within the growing SGLT2 class in the United States and increased volume outside the United States Basaglar recorded revenues of  153 8 million compared with  145 7 million in the previous quarter  It generated revenues of  114 4 million in the United States  almost flat sequentially  as changes in estimates for rebates and discounts  which increased revenues in the third quarter  were missing in the fourth Taltz brought in sales of  172 5 million compared with  151 3 million in the previous quarter Lartruvo  olaratumab  generated revenues of  59 million in the fourth quarter compared with  54 5 million in the previous quarter Olumiant  baricitinib  has been launched in select European countries and in Japan  The drug generated sales of  23 0 million in the fourth quarter compared with  16 4 million in the previous quarter backed by strong launch uptake in Germany Verzenio  which was launched in the Unites States in the fourth quarter of 2017  generated sales of  21 million Elanco Animal Health segment sales declined 6  to  790 9 million as worldwide competitive pressure continued to hurt sales in the segment Food animal products revenues declined 8  hurt by market access pressure and competitive pressure in cattle Companion animal revenues rose 1  due to inclusion of  36 5 million of revenues from the acquisition of Boehringer Ingelheim Vetmedica s U S  feline  canine and rabies  acquired in January 2017   Excluding Boehringer Ingelheim  companion animal revenues declined due to competitive pressure and lower U S  distributor inventory levels Lilly is exploring strategic alternatives for this business including a sale  merger or creating a separate company through an initial public offer  A decision regarding the same is expected to be announced in July and Lilly may ultimately opt to retain the business Gross Margin   Operating IncomeAdjusted gross margin of 76 5  in the quarter decreased 90 basis points as manufacturing efficiencies and higher realized prices were offset by negative product mix and the effect of foreign exchange rates on international inventories sold  Excluding the effects of foreign exchange on international inventory sold  gross margins increased over 130 bps Operating income increased 20  year over year to  1 46 billion due to lower operating costs  Total operating expenses  including research and development and marketing  selling and administrative expenses   as a percent of revenues  declined 340 basis points in the quarter to 52 8  While marketing  selling and administrative expenses declined 1   R D expenses rose 2  in the quarter 2017 ResultsFull year 2017 sales of  22 87 billion topped the Zacks Consensus Estimate of  22 65 billion  Revenues were within the guided range of  22 4 billion and  22 7 billion  Sales rose 8  year over year Adjusted earnings for 2017 were  4 28 per share  topping the Zacks Consensus Estimate of  4 22 per share as well as the guided range of  4 15 to  4 25  Earnings rose 22  year over year 2018 EPS Guidance UppedLilly raised its previously issued 2018 adjusted earnings outlook to reflect the expected benefit from the new tax laws  Adjusted earnings per share are now expected in the range of  4 81 to  4 91 compared with  4 60 to  4 70 expected previously  However  revenues are still expected in the range of  23 0 billion and  23 5 billion Gross margin is expected to be approximately 75   same as previously expected  Adjusted tax rate is expected to be approximately 18   previously approximately 21 5   Marketing  selling and administrative expenses are still expected in the range of  6 1  6 4 billion  while research and development expenses are projected to be  5 0  5 2 billion Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Lartruvo  Verzenio and Olumiant are expected to drive revenues  In 2018  Animal Health revenues are expected to be flat to slightly up versus 2017  After being slightly negative in the first half  Animal Health revenues are expected to improve in the second half supported by new product launches Expected Impact of U S  Tax ReformAs a result of the new tax laws  Lilly anticipates paying taxes on overseas cash and earnings of approximately  3 6 billion  With increased access to foreign cash following the U S  tax reforms  Lilly believes now it will have more than  9 billion of extra funds across its global operations  which it does not intend to hold for a long time  Over 2018 and 2019  Lilly plans to use this cash first to support its products pipeline  then for business development via in licensing or acquisition and finally to return to shareholders via dividend and share buybacks  It also plans to use roughly  2 billion of repatriated cash to reduce its gross debt level 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision lower for the current quarter Eli Lilly and Company Price and Consensus
    VGM Scores
At this time  LLY has a great Growth Score of A  though it is lagging a lot on the momentum front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is primarily suitable for growth investors while also being suitable for those looking for value and to a lesser degree momentum 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of this revision looks promising  Interestingly  LLY has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/why-is-eli-lilly-lly-down-72-since-its-last-earnings-report-200295546,200295546
172327,393843,LLY,Celldex  CLDX  Q4 Loss Narrows  Revenues Beat  Shares Up,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   has incurred fourth quarter 2017 loss  excluding income tax benefit of  19 1 million  of 17 cents per share  narrower than both the Zacks Consensus Estimate of a loss of 23 cents as well as the year ago loss of 30 cents  Lower costs and higher revenues led to this upside Total revenues in the quarter soared 84 4  year over year to  3 5 million  beating the Zacks Consensus Estimate of  1 91 million  The manufacturing service agreement with the International AIDS Vaccine Initiative drove the top line Shares of the company rose 2  in after hours trading on Mar 7 However  the stock has not done too well in the past year  Shares of the company have underperformed its industry  having declined 28 4  compared with the  s 3 9  decrease  Quarterly DetailsResearch and development expenses declined 4 5  from the year ago period to  23 5 million  General and administrative spend improved 50 6  to  5 9 million As of Dec 31  2017  Celldex had cash  cash equivalents and marketable securities of  139 4 million compared with  140 5 million as of Sep 30  2017  The biotech company s weakened cash position was due to higher operating expense  partially offset by net proceeds raised from sales of its common stock this month under the contract with Cantor 2017 ResultsTotal revenues for the year surged 87 8  to  12 7 million  higher than the Zacks Consensus Estimate of  10 57 million Net loss for 2017  excluding income tax benefit of  24 3 million  came in at 91 cents per share  slightly wider than the Zacks Consensus Estimate of 90 cents  However  the company had reported  1 27 of loss a year ago 2018 OutlookCelldex expects that its cash position as of December 2017 end plus  6 1 million in net proceeds generated from the sale of its common stock in the last two months and the anticipated proceeds from any future sales of common stock under the agreement with Cantor will be adequate to fund the working capital requirements as well as the planned operations through 2018 Pipeline UpdateCelldex s most advanced pipeline candidate is antibody drug conjugate  glembatumumab vedotin  currently under evaluation for the treatment of triple negative breast cancer  phase IIb METRIC study  and metastatic melanoma  phase II   Enrolment in the key METRIC study was completed in August 2017 with top line data expected in the second quarter of 2018  The company also plans to file a biologics license application in the second half of 2019 In the melanoma study  Celldex added a fourth cohort  a glembatumumab plus CDX 301 arm  The combination will be studied on patients with failed prior checkpoint therapy Apart from glembatumumab vedotin  promising candidates in the company s pipeline include varlilumab  CDX 3379 and CDX 014 In January 2018  the company closed enrollment for phase II trial  evaluating varlilumab with Bristol Myers    NYSE BMY   Opdivo including cohorts in five indications namely colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma Celldex expanded its phase I study in January  assessing CDX 014 in advanced renal cell carcinoma to include patients with ovarian clear cell carcinoma In November 2017  the company initiated a phase II program on CDX 3379 in combination with Eli Lilly s   NYSE LLY   Erbitux in patients with head and neck squamous cell carcinoma  having developed resistance to Erbitux The company also commenced a phase I study in the same month to evaluate CDX 014 for treating locally advanced or metastatic solid tumorsCelldex Therapeutics  Inc  Price  Consensus and EPS Surprise
     Zacks Rank   Stock to ConsiderCelldex carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 78 to  4 15 for 2018 over the last 30 days  The company pulled off positive surprises in three of the trailing four quarters with an average beat of 24 88   Share price of the company has climbed 53 4  over a year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q4-loss-narrows-revenues-beat-shares-up-200296735,200296735
172328,393844,LLY,Pharma Stock Roundup  MRK Signs New Cancer Deal  DERM s Acne Candidate Fails ,opinion,"Last week  U S  Senator Tina Smith expressed concerns that big pharma companies plan to use their large corporate tax savings to reward shareholders instead of bringing down costs of expensive drugs and benefiting consumers  The Senator questioned through letters to CEOs of five big pharma companies   Pfizer   NYSE PFE    Merck   NYSE MRK    Johnson   Johnson   NYSE JNJ    AbbVie   NYSE ABBV   and Abbott Labs   NYSE ABT     how they plan to use their extra cash Please note that on their Q4 conference calls held earlier this year  most big pharma companies discussed what they plan to do with the extra cash they save from the new tax bill  These companies plan to invest the extra cash in capital expenditures  products pipeline  in licensing or acquisition deals or rewarding shareholders through higher dividends and share buybacks  Not many talked about taking any steps to lower prescription drug costs This apart  key announcements this week included the failure of Dermira  Inc  s   NASDAQ DERM   acne candidate in two pivotal late stage studies  Merck s oncology collaboration with Japan s Eisai  expansion of Jardiance clinical studies by Eli Lilly   NYSE LLY   and FDA committee backing for Pfizer s Xeljanz for the third indication Recap of the Week s Most Important StoriesDermira Shares Sink as Acne Candidate Fails  Shares of Dermira plunged after it announced that its acne candidate  olumacostat glasaretil  surprisingly failed to meet the primary endpoint in either of the two pivotal phase III studies    CLAREOS 1 and CLAREOS 2  The company said that it will likely stop olumacostat glasaretil s development following this failure   Read More   Merck to Jointly Develop Eisai s Cancer Drug Lenvima  Similar to last year s profit sharing deal with AstraZeneca   NYSE AZN    Merck announced an oncology collaboration with Japan s Eisai Co   Ltd  Per this deal  the companies will jointly develop and commercialize Eisai s tyrosine kinase inhibitor  Lenvima  both as a monotherapy and in combination with Merck s anti PD 1 therapy  Keytruda for several types of cancer  For the deal  Merck will give Eisai an upfront payment of  300 million  The companies will share global development and marketing costs as well as gross profits from Lenvima equally   Read More  Pfizer s Xeljanz sNDA Gets FDA Committee Backing  Pfizer s supplemental new drug application to include the ulcerative colitis  UC  indication in its label received a backing from an FDA advisory committee  The FDA s Gastrointestinal Drugs Advisory Committee  GIDAC  voted unanimously in favor of the JAK inhibitor  The FDA s decision is expected in June  Xeljanz  which is already approved to treat rheumatoid arthritis and active psoriatic arthritis  recorded sales of  1 35 billion in 2017  representing growth of 45  year over year AstraZeneca Looks for Forxiga EU Approval in Type I Diabetes  AstraZeneca s application looking to get its SGLT 2 inhibitor  Forxiga  approved for a new indication    an oral adjunct treatment to insulin in type 1 diabetes  T1D  patients    was accepted by the European Medicines Agency  Forxiga is presently approved as a monotherapy as well as a combination therapy to treat type 2 diabetes  If approved  Forxiga will become the first SGLT 2 inhibitor approved in Europe for the treatment of T1D as an oral treatment adjunct to insulin   Read More   Glaxo Presents Asthma HIV Data  Glaxo   NYSE GSK   presented data from OSMO study on a new respiratory medicine  Nucala  at American Academy of Allergy  Asthma   Immunology  AAAAI  and World Allergy Organization  WAO  Joint Congress in Orlando  Data from the study showed that patients whose asthma was uncontrolled with Xolair witnessed improved asthma control on switching to Glaxo s new respiratory medicine  Nucala Glaxo also presented interim data from a phase IIIb study  INSPIRING  on investigational HIV candidate dolutegravir at a medical conference in Boston   Read More   Meanwhile  Glaxo gained approval to expand the European label of its once daily LABA ICS combination treatment  Relvar Ellipta  Now  Relvar Ellipta can be used in the EU in patients whose asthma is already adequately controlled by an ICS LABA  With the label update  doctors can prescribe asthma patients to switch to once daily Relvar Ellipta from their current twice daily ICS LABA  while experiencing comparable benefit in lung function and safety profile Lilly  Boehringer to Expand Jardiance Clinical Studies  Lilly and partner Boehringer Ingelheim announced plans to initiate two phase III EMPERIAL studies  which will evaluate the effect of Lilly s SGLT2 inhibitor Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure irrespective of whether they have type II diabetes  Though the presently ongoing phase III EMPEROR outcomes studies are evaluating the effect of Jardiance on long term morbidity and mortality outcomes in people with heart failure  the EMPERIAL studies will investigate if treatment with Jardiance can help improve the everyday lives of people living with chronic heart failure   Read More    The NYSE ARCA Pharmaceutical Index was up 2 6  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
 Here is how the seven major stocks performed In the last five trading sessions  all the seven major stocks rose  The largest gainers were Glaxo  4 3    J J  3 8   and Lilly  3 2   In the last six months  while Bristol Myers   NYSE BMY   gained 6 5   Merck declined 15 9    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regulatory and pipeline news from pharma stocks Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-09,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-signs-new-cancer-deal-derms-acne-candidate-fails-200296923,200296923
172348,393864,LLY,Solid Q4 Earnings Drive Pharma ETF Outlook,opinion,Total earnings for  of the total healthcare market capitalization are up 8 2  on revenue growth of 6 5   Not only are the growth rates impressive  the earnings and revenues beat ratios of 83 8  and 86 5   respectively  are great too  The robust numbers have pushed healthcare stocks higher by an average 1 2  against the 0 2  gain for the S P 500 in response to earnings announcements Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on Jan 23  followed by Pfizer   NYSE PFE   and Eli Lilly and Company   NYSE LLY   on Jan 30 and Jan 31  respectively  Other major U S  drug companies   Merck   NYSE MRK   and Bristol Myers Squibb Company   NYSE BMY     reported on Feb 2 and Feb 5  respectively  These industry primes posted solid results with either earnings or revenue beats or both Johnson and Johnson Earnings in FocusThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  1 74  a couple of cents ahead of the Zacks Consensus Estimate and 10 1  higher than the year ago quarter  Revenues grew 11 5  year over year to  20 2 billion but fell shy of the Zacks Consensus Estimate of  20 22 billion  Johnson   Johnson issued its 2018 outlook with earnings per share of  8 00  8 20 and revenues of  80 60  81 40 billion  read    Pfizer Earnings in FocusThe U S  drug giant came up with both earnings and revenue beat  Earnings per share of 62 cents came in six cents above the Zacks Consensus Estimate and revenues of  13 7 billion were also ahead of the estimated  13 6 billion  On an annual basis  earnings per share and revenues rose 32  and 1   respectively  For 2018  Pfizer guided revenues in the range of  53 5  55 5 billion and earnings per share of  2 90  3 00 Merck Earnings in FocusMerck beat the earnings estimate while missed on revenues  Earnings per share came in at 98 cents  surpassing the Zacks Consensus Estimate of 94 cents and improving 10  from the year ago quarter  Revenues inched up 3  year over year to  10 43 billion and were below the Zacks Consensus Estimate of  10 45 billion  Merck issued the 2018 revenue guidance of  41 2  42 7 billion and earnings per share guidance of  4 08  4 23 Bristol Myers Earnings in FocusBristol Myers topped the estimates on both fronts  It reported earnings per share of 68 cents  a penny above the Zacks Consensus Estimate and above the year ago earnings of 63 cents  Revenues grew 4  to  5 45 billion and edged past the Zacks Consensus Estimate of  5 31 billion  The company provided 2018 earnings per share guidance of  3 15  3 30  see    Eli Lilly Earnings in FocusEli Lilly also surpassed the earnings and revenue estimates  Earnings of  1 14 outpaced the Zacks Consensus Estimate by seven cents and came in 20  higher than the year ago quarter  Revenues grew 7  to  6 16 billion and beat the estimated  5 96 billion  Unlike the other drug makers  Eli Lilly raised its 2018 earnings guidance to  4 81  4 91 from  4 60  4 70 while maintained its revenue outlook in the range of  23  23 5 billion ETF AngleAlthough pharma ETFs saw terrible trading over the past one month in the latest global market rout  the string of earnings beat bolstered confidence in the space  compelling investors to cash in on the beaten down prices  Below  we have highlighted them in detail  These funds have a Zacks ETF Rank  3  Hold   suggesting room for upside in the days ahead  read    PowerShares Dynamic Pharmaceuticals Fund   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  620 3 million and sees lower volume of around 54 000 shares a day  The fund charges 56 bps in fees and expenses  Holding 30 stocks  the fund invests more than 4  share each in BMY  PFE  JNJ and LLY  The ETF has lost 8 6  in a month iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top five holdings in the basket  accounting for a combined 37 9  of total assets  suggesting heavy concentration  The product has  420 3 million in AUM and charges 44 bps in fees and expense  Volume is light as it exchanges about 26 000 shares a day  The fund has shed 8 2  in a month SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to the pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  378 6 million  it trades in good volume of around 110 000 shares a day and charges 35 bps in fees a year  In total  the product holds 41 securities with the in focus five firms taking over 4  share each  The product was down 9 1  in the same period VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  The in focus five firms account for at least 4  share each  The product has amassed  249 2 million in its asset base and trades in a moderate volume of about 76 000 shares a day  Expense ratio comes in at 0 35   The fund has lost 7 5  in a month  read    First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 29 securities in its basket  Of these  Pfizer and Johnson   Johnson account for more than 7  share each while Merck  Bristol Myers and Eli Lilly makeup for more than 3  each  FTXH has a lower level of  2 2 million in AUM and 1 000 shares in averaged daily volume  It charges 60 bps in annual fees and has shed 8 5  in the same time frame Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/solid-q4-earnings-drive-pharma-etf-outlook-200289111,200289111
172349,393865,LLY,Pfizer Announces FDA Acceptance Of NDA For NSCLC Candidate,opinion,"A new drug application   NDA   for Pfizer s   NYSE PFE   anaplastic lymphoma kinase   ALK   tyrosine kinase inhibitor   TKI   candidate  lorlatinib has been accepted by the FDA  The NDA sought approval of lorlatinib for the treatment of patients ALK positive metastatic non small cell lung cancer   NSCLC   who have received prior treatment with one or more ALK TKIs  The NDA has also been granted priority review  A decision is expected in August 2018 Similar applications seeking marketing authorization in Europe and Japan have also been accepted by the regulatory agencies of the respective countries Shares of Pfizer were up almost 1 5  following the news  The stock has returned 6 3  in the past year  underperforming the  s gain of 11  in that period Pfizer submitted the regulatory applications based on positive data from phase II portion of a phase I II study  evaluating lorlatinib in several cohorts based on prior therapies Non small cell lung cancer occurs in 85  of the patients who have lung cancer  the leading cause of cancer death worldwide Lung cancer is an attractive avenue for pharmaceutical companies due to the widespread occurrence of the disease  However  it is also one of the most competitive spaces due to the presence of a large number of players  Several large and small companies are either developing or have approved therapies for the treatment of various forms of lung cancer We remind investors that last month Merck   NYSE MRK   announced encouraging results from a phase III study evaluating its anti PD 1 therapy  Keytruda  in combination with Eli Lilly s   NYSE LLY   Alimta and carboplatin in NSCLC  We also note that Roche   OTC RHHBY   recently presented data on Tecentriq in novel combinations across a broad range of tumors including lung cancer Blockbuster drugs like Bristol Myers  Opdivo is approved for treating NSCLC  among others Pfizer  Inc  Price
    Zacks RankPfizer carries a Zacks Rank  2  Buy   You can  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/pfizer-announces-fda-acceptance-of-nda-for-nsclc-candidate-200290074,200290074
172350,393866,LLY,Lilly s Taltz Positive In Phase III Label Expansion Study,opinion,"Eli Lilly and Company   NYSE LLY   announced positive top line data from a phase III label expansion study evaluating its psoriasis drug  Taltz  ixekizumab   in patients with ankylosing spondylitis   AS    The drug met the primary endpoint of improvement in the signs and symptoms of AS and all secondary endpoints as well Taltz  an IL 17A antagonist  is currently approved for the treatment of adults with moderate to severe plaque psoriasis or active psoriatic arthritis  PsA  Shares of the company are down 3 3  in the past year  underperforming the  s gain of 11 2  in that period   The phase III study   COAST V   evaluated the drug in AS patients who have not received any prior treatment with a biologic disease modifying anti rheumatic drug  The study consisted of a placebo arm and an active control arm with AbbVie s   NYSE ABBV   arthritis drug  Humira  Data from the study showed that treatment with Taltz led to statistically significant improvement as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40 at 16 weeks Additional data from the study is expected to be presented later this year Ankylosing spondylitis is a type of spondyloarthritis affecting pelvic joints and spine  It is characterized by chronic inflammatory back pain  stiffness and impaired function and mobility Taltz sales increased 14  quarter over quarter in the last quarter of 2017  on the back of strong uptake  In January 2018  the drug received approval in Europe for PsA  which is expected to boost sales of the drug in the first quarter of 2018 However  several drugs are approved for the treatment of AS including Humira and Novartis    NYSE NVS   Cosentyx  Other companies are developing their therapies for treating AS  which includes Galapagos    NASDAQ GLPG   filgotinib  Eli Lilly and Company Price
     Zacks RankLilly carries a Zacks Rank  3  Hold  You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/lillys-taltz-positive-in-phase-iii-label-expansion-study-200290318,200290318
172370,393886,LLY,Lilly s Elanco Aratana s Veterinary Medicine Gets EU Nod,opinion,Eli Lilly and Company s   NYSE LLY   animal health subsidiary  Elanco  and partner Aratana Therapeutics  Inc    NASDAQ PETX   have together announced that their veterinary medicine  Galliprant  grapiprant tablets   has been granted a marketing authorization in the EU for the treatment of pain associated with mild to moderate osteoarthritis  OA  in dogs Notably  OA is incurable and is one of the most common causes of chronic pain in dogs  However  if diagnosed early  the pain and inflammation can be controlled  enabling the arthritic dogs to lead an improved quality of life The drug was approved in the United States in March 2016 for the aforementioned indication and subsequently  launched last January  This is the first piprant approved for use in the United States for once daily use in dogs with OA  Also  it can be administered to patients as young as nine months Shares of Lilly have underperformed the in a year  The stock has rallied 12   comparing unfavorably with the industry s increase of 18 5  in the period   We remind investors that the approval in the EU was made on the positive opinion granted by the European Medicine Agency s Committee for Medicinal Products for Veterinary Use  recommending the approval in November 2017 While Lilly s Elanco has exclusive marketing rights to Galliprant globally  it co promotes the product with Aratana in the United States Elanco makes parasiticides  pain and dermatology medicines for food as well as companion animals  Last January  the division acquired German drugmaker Boehringer Ingelheim s Vetmedica U S  pet vaccines unit along with a fully integrated manufacturing and R D  research and development  site for  885 million Notably  Lilly bought the animal health division of Novartis   NYSE NVS   in early 2015  strengthening the Elanco division of the company  The Elanco segment recorded sales of  740 6 million in third quarter 2017  up 5  year over year Eli Lilly and Company Price     Zacks Rank   Key PicksLilly carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Exelixis  Inc    NASDAQ EXEL    sporting a Zacks Rank  1  Strong Buy   You can see  Exelixis  earnings per share estimates have been revised upward from 72 cents to 73 cents for 2018 over the last 60 days  The company pulled off a positive earnings surprise in each of the trailing four quarters with an average beat of 572 92   Share price of the company has soared 59 8  in a year s time Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-11,Zacks Investment Research,https://www.investing.com/analysis/lillys-elancoaratanas-veterinary-medicine-gets-eu-nod-200279886,200279886
172371,393887,LLY,Lilly  LLY  Beats On Q4 Earnings  Raises 2018 EPS Guidance,opinion,"Eli Lilly and Company   NYSE LLY   reported fourth quarter 2017 adjusted earnings per share of  1 14  which beat the Zacks Consensus Estimate of  1 08 per share by 5 6   Earnings rose 20  from the year ago quarter backed by higher operating profits Revenues BeatQuarterly revenues of  6 16 billion also beat the Zacks Consensus Estimate of  5 96 billion by 3 4   Sales grew 7  year over year backed by strong performance of new drugs and favorable currency movement to a lesser extent  partially offset by lower sales of established products like Strattera  Humalog  Cialis and Effient  Lilly s established products portfolio recorded a decline of 6 3  in worldwide revenues Volumes rose 4  as strong performance of new products like Trulicity  Taltz  Basaglar  Jardiance and Lartruvo offset decline in sales of established products  Higher realized prices for several drugs also contributed 2  to sales growth in the quarter  Foreign exchange rate also hada favorable impact of 1  Segment RevenuesPharmaceutical revenues rose 9  in the quarter backed by 12  volume growth of the new products While U S  revenues grew 6  to  3 42 billion  ex U S  revenues rose 8  to  2 74 billion Established products that recorded growth during the quarter include Forteo  up 21  to  513 2 million   Humulin  up 2  to  362 6 million   Cymbalta  up 6  to  192 8 million  and Erbitux  up 10  to  168 9 million   Sales of all other established products declined in the quarter Humalog sales declined 5  to  782 2 million due to lower realized prices in the United States  Moreover in December 2017  the FDA approved Sanofi s   NYSE SNY   Admelog  a biosimilar version of Humalog  This approval will certainly increase competition  Alimta sales declined 3  to  525 2 million  reflecting lower demand in ex U S  markets due to competitive pressure and loss of exclusivity in certain countries  However  sales of Alimta increased 1  in the United States due to increased volume  partially offset by lower realized prices Zyprexa sales declined 1  to  152 2 million due to loss of exclusivity in Japan Cialis sales declined 12  to  597 4 million hurt by worldwide lower demand Strattera sales declined 60  to  98 3 million  Effient sales declined 56  to  62 3 million in the quarter  Both the drugs saw lower demand due to loss of exclusivity Among the new products  Trulicity generated revenues of  649 million  up 93  year over year  with U S  revenues benefiting from growth in the GLP 1 market and market share gains Cyramza revenues were  204 8 million  up 16  year over year  backed by strong demand  Cyramza s ex U S  revenues increased 15   benefiting from strong volumes in Japan  partially offset by lower realized prices  U S  revenues increased 17  driven by increased volume Jardiance sales  up 88  to  143 2 million  were driven by increased market share within the growing SGLT2 class in the United States and increased volume outside the United States Basaglar recorded revenues of  153 8 million compared with  145 7 million in the previous quarter  Basaglar   Lilly and partner Boehringer Ingelheim s follow on insulin to Sanofi s blockbuster drug  Lantus   was launched in the United States in mid December 2016 Taltz brought in sales of  172 5 million compared with  151 3 million in the previous quarter  reflecting strong uptake  In December 2017  the drug was approved for psoriatic arthritis and launched in the United States  The European Commission also approved the drug last week Lartruvo  olaratumab  generated revenues of  59 million in the fourth quarter of 2017 compared with  54 5 million in the previous quarter  Lartruvo was launched in the United States and the EU for soft tissue sarcoma in the fourth quarter of 2016 Lilly and partner Incyte Corporation s   NASDAQ INCY   rheumatoid arthritis drug  Olumiant  baricitinib  has been launched in select European countries and in Japan  The drug generated sales of  23 million in the fourth quarter of 2017 compared with  16 2 million in the previous quarter backed by strong launch uptake in Germany However  in the United States  Lilly received a complete response letter from the FDA for baricitinib in April for want of additional data  The company has re submitted the application in late 2017 Verzenio  which was launched in the Unites States in the fourth quarter of 2017  Generated a sales of  21 million Lilly s Elanco Animal Health segment sales declined 6  to  790 9 million due to decrease in food animal revenues  down 8  to  547 4 million   However  companion animal revenues increased 1   including revenues from the acquisition of Boehringer Ingelheim Vetmedica s U S  feline  canine and rabies vaccine portfolio  acquired in January 2017  which was offset by competitive pressure and lower demand in the United States Gross Margin Down but Operating Income RisesAdjusted gross margin of 76 5  in the quarter decreased 90 basis points as manufacturing efficiencies were offset by negative product mix and the effect of foreign exchange rates on international inventories sold Operating income increased 20  year over year to  1 46 billion  Total operating expenses  as a percent of revenues  declined 340 basis points in the quarter to 52 8  2018 EPS Guidance UppedLilly raised its previously issued 2018 adjusted earnings outlook  Adjusted earnings per share are now expected in the range of  4 81 to  4 91 compared with  4 60 to  4 70 expected previously  reflecting positive impact of the U S  tax reform  However  revenues are still expected in the range of  23 0 billion and  23 5 billion Gross margin is expected to be approximately 75   same as previously expected  Adjusted tax rate is expected to be approximately 18   previously approximately 21 5   Marketing  selling and administrative expenses are still expected in the range of  6 1  6 4 billion  while research and development expenses are projected to be  5 0  5 2 billion Our TakeLilly s fourth quarter 2017 results were strong with the company beating estimates on both counts  Meanwhile expectations for a lower tax rate due to new tax laws propelled the company to raise its 2018 earnings outlook Shares were up 1 1  in pre market trading  Lilly s share price has risen 11 7  in the past year compared with an increase of 24 2  for the   Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo are expected to see higher revenues  Lilly is also progressing well with its pipeline  The FDA approval for Taltz s line extension will also boost Lilly s product revenues  In October 2017  Lilly has announced that it is looking to sell or spin off its Elanco Animal Health business  Potential sale of its underperforming Animal Health segment may help improve margins However  Alimta will continue to be impacted by competition  Other headwinds include competition from immuno oncology agents as well as loss of exclusivity for many drugs in emerging markets Eli Lilly and Company Price  Consensus and EPS Surprise
     Zacks Rank   Stock to ConsiderLilly carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is AbbVie Inc    NYSE ABBV    carrying a Zacks Rank  2  Buy   You can see  AbbVie s earnings estimates increased from  6 56 to  7 30 for 2018 over the last 30 days  The company came up with a positive surprise in all the trailing four quarters with an average beat of 1 81   The stock is up 89 7  in the past year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-beats-on-q4-earnings-raises-2018-eps-guidance-200285583,200285583
172380,393896,LLY,AbbVie s RA Candidate Meets Endpoints In 3rd Phase III Study,opinion,AbbVie Inc    NYSE ABBV   announced that its investigational oral JAK 1 selective inhibitor  upadacitinib  met the primary endpoints in a phase III study from its SELECT program  which evaluated the candidate for the treatment of patients with rheumatoid arthritis   RA   AbbVie s shares have outperformed the  so far this year  The stock has surged 55 5  compared with the industry s 16 1  rally The phase III study   SELECT MONOTHERAPY   evaluated upadacitinib monotherapy in moderate to severe RA patients who were not responsive to methotrexate for a period of 14 weeks  Both the once daily doses  15 mg and 30 mg  evaluated in the study demonstrated superiority in ACR20 response and low disease activity  LDA  compared to methotrexate The ACR20 response was achieved in 68  of the patients receiving 15 mg dose while the response rate was 71  for the 30 mg dose versus 41  for methotrexate  The LDA was achieved in 41   28  and 8  of patients receiving 30 mg  15 mg or methotrexate  respectively Upadacitinib is being evaluated in a large program  which includes six studies on RA patients  AbbVie is also developing the candidate in psoriatic arthritis  Crohn s disease  ulcerative colitis  ankylosing spondylitis and atopic dermatitis The candidate has also met endpoints in two phase III studies from the SELECT program  The SELECT MONOTHERAPY study supported the potential of the candidate in treating RA patients without a background methotrexate therapy Successful development of upadacitinib will boost AbbVie s RA portfolio  which already includes the blockbuster drug  Humira  Sales of Humira   13 5 billion  accounted for 66  of net revenues in the first nine months of 2017 The approval of Incyte Corporation   NASDAQ INCY     Eli Lilly and Company s   NYSE LLY   Olumiant in Europe in February 2017 has not had any significant impact on Humira s sales  as it is approved in patients who are unresponsive to TNF inhibitors like Humira  Moreover  Olumiant s new drug application received a complete response letter from the FDA in April this year  Meanwhile  upadacitinib may be in direct line of competition with Olumiant as both are JAK inhibitors AbbVie Inc  Price   Zacks Rank   Stock to ConsiderAbbVie carries a Zacks Rank  3  Hold  Celldex Therapeutics  Inc    NASDAQ CLDX   is a better ranked stock in the pharma sector  carrying a Zacks Rank  2  Buy   You can see  Celldex s loss estimates narrowed from 93 cents to 90 cents for 2017 and from 90 cents to 89 cents over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 36  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/abbvies-ra-candidate-meets-endpoints-in-3rd-phase-iii-study-200275094,200275094
172381,393897,LLY,Merck s Keytruda Gets Approved For Bladder Cancer In Japan,opinion,"Merck   Co   Inc    NYSE MRK   announced that its anti PD 1 therapy  Keytruda  pembrolizumab   has been approved in Japan for previously treated patients with urothelial carcinoma  a type of bladder cancer  This approval makes Keytruda eligible to be indicated for four types of cancer in Japan 
Notably  Keytruda has already been approved in the United States and the EU for the first and second line treatments in patients with the aforementioned indication  Apart from bladder cancer  Keytruda is approved for many malignant disease types and treatment settings including lung cancer  melanoma  head and neck cancer and classical hodgkin lymphoma  It is also approved as a combination therapy with Eli Lilly s   NYSE LLY   lung cancer drugs  Alimta  pemetrexed  and carboplatin  pem carbo  
Merck s shares have lost 6 6  in the last year  comparing unfavorably with the 16  increase of its  

 
The approval was based on positive data from phase III KEYNOTE 045 study  The trial outcomes showed a clinically meaningful and improved overall survival  OS  benefit of Keytruda compared with chemotherapy in patients with the given indication  In the program  Keytruda demonstrated a 27  reduction in death risk as compared to chemotherapy  Moreover  the median OS was 10 3 months in the Keytruda arm in comparison to 7 3 with chemotherapy 
Significantly  Merck commercializes Keytruda in Japan in collaboration with Taiho Pharmaceutical company 
Per the company s press release  the incidence of bladder cancer in Japan is anticipated to increase over time  Approximately  66 000 patients are detected with bladder cancer in the country with 21 000 new cases diagnosed in 2015  Hence  the market opportunity for Keytruda is fairly wide in the country 
Keytruda fetched in global sales of  2 5 billion in the first nine months of 2017  up 173  year over year  Sales continue to be driven by the launch of new indications globally  Keytruda sales in the United States gained particularly from a strong momentum in the new indication of the first line therapy of lung cancer  Outside the United States  Keytruda sales were primarily driven by the melanoma indication 
We remind investors that Keytruda is the first anti PD 1 therapy to gain an FDA approval and is being studied for more than 30 types of cancer in above 650 studies including 400 plus combination trials Merck   Company  Inc  Price

    
Zacks Rank   Key Picks
Merck carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   and AcelRx Pharmaceuticals  Inc    NASDAQ ACRX    both carrying a Zacks Rank  2  Buy   You can see  
Sucampo s earnings per share estimates have moved north from  1 15 to  1 19 for the current year in the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 63   Share price of the company has surged 28 6  year to date 
AcelRx stock has seen the Zacks Consensus Estimate for current year loss per share being narrowed from  1 03 to 99 cents over the last 30 days 
Investor Alert  Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-approved-for-bladder-cancer-in-japan-200277367,200277367
172399,393915,LLY,Intersect ENT  XENT  SINUVA Implant Receives FDA Approval,opinion,"Intersect ENT  Inc    NASDAQ XENT   received approval from the FDA for SINUVA Sinus Implant  The company has been focused on developing innovative therapies for chronic sinusitis patients SINUVA is an exclusive approach to treat recurrent nasal polyp disease in patients who have undergone ethmoid sinus surgery  Per management  approximately 635 000 Americans have gone through these surgeries and are looking for treatments to cure side effects Intersect ENT expects SINUVA to be costlier than other products in the portfolio  However  higher price will not dent the company s gross margins in the upcoming fourth quarter  It has a long term expected earnings growth rate of 25  Notably  nasal polyps are inflammations along the lining of nasal passage or sinus resulting in congestion  infections and low sense of smell  SINUVA is Intersect ENT s fourth commercial product  which is likely to be introduced to physicians across the country in the following months Shares Shine Bright
Year to date  Intersect ENT has had a solid run on the bourses  trading above the market at large   The company returned 163 2  comparing favorably with the  s rally of only 23 2   Also  the current return is higher than the S P 500 index s increase of 21 7  over the same time frame  The stock has a Zacks Rank  3  Hold   You can see 
 Market Trends Buoy OptimismIntroduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market  Per a report by Persistence Market Research  the Center of Disease Control and Prevention  CDC  has revealed that 11 7 million people in the United States get diagnosed with chronic sinusitis on a regular basis Considering the solid prospects of the market  we believe that Intersect ENT will gain strong market traction in the upcoming days  A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi   NYSE SNY    Abbott Laboratories   NYSE ABT   and Eli Lilly And Company   NYSE LLY   Our TakeIntersect ENT s fourth quarter operating expenses are likely to rise  thanks to the one time expenses related to the SINUVA launch  production of demo units and costs related to market access infrastructure Among latest developments  PROPEL Contour is expected to be an important driver for Intersect ENT  Products like PROPEL and PROPEL mini are drug eluting implants for patients suffering from chronic sinusitis  It offers products and therapies for ear  nose and throat surgeons to improve treatment of patients with chronic diseases Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-12-12,Zacks Investment Research,https://www.investing.com/analysis/intersect-ent-xent-sinuva-implant-receives-fda-approval-200272886,200272886
172400,393916,LLY,Lilly Issues Guidance For 2018  New Drugs To Drive Top Line,opinion,Eli Lilly and Company   NYSE LLY   issued financial guidance for 2018  which was in line with market expectations  The company also re affirmed the previously issued 2017 projection as well as its long term expectations Shares were up more than 1  in Wednesday  So far this year  Lilly s share price has risen 19 5  compared with an increase of 17 7  for the  2018 ForecastIn 2018  adjusted earnings per share are expected to be between  4 60 and  4 70  representing growth in the range of low double digit  Revenues are expected to be between  23 0 billion and  23 5 billion  representing growth of about 3  at the mid point of 2017 and 2018 ranges  Foreign exchange impact is expected to benefit revenues by about 90 basis points  The Zacks Consensus Estimate for sales and earnings is pegged at  23 07 billion and  4 66 per share  respectively Lilly s new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance  Verzenio and Lartruvo have been driving revenues and the trend is expected to continue in 2018  Strong uptake trends of Lilly s new drugs have been instrumental in leading the company to increase its 2017 sales outlook twice this year   However  competitive pressure on Lilly s drugs is expected to rise next year  Novo Nordisk s   NYSE NVO   Ozempic semaglutide  which received FDA approval this month  can pose strong competition to Lilly s key new growth driver  Trulicity on launch  Meanwhile  Sanofi s   NYSE SNY   Admelog  the biosimilar version of Lilly s blockbuster rapid acting insulin Humalog  which also received FDA approval this month  can hurt sales of Lilly s branded drug on launch  As it is  the company is facing loss of exclusivity on a number of its products in various markets while pricing headwinds are hurting sales of its older diabetes products As far as its pipeline is concerned  in 2018  the company expects regulatory action on its rheumatoid arthritiscandidate  Olumiant baricitiniband migraine preventioncandidate galcanezumab  While a new drug application  NDA  for galcanezumab already under review in the United States  a NDA for Olumiant is expected to be re submitted in January  We remind investors that in April this year  Lilly received a complete response letter  CRL  from the FDA for Olumiant  The FDA required additional clinical data  which will delay the approval of the drug  Olumiant was approved in the EU in February  The company also expects label expansions for its newly launched breast cancer drug  Verzenio Marketing  selling and administrative expenses are expected in the range of  6 1  6 4 billion  while research and development expenses are projected to be  5 0  5 2 billion  Adjusted gross margin is expected to be approximately 75   Adjusted tax rate is expected to be approximately 21 5  Importantly  the company mentioned that the guidance assumes no major healthcare reform in the United States and continuation of current US corporate tax system 2017 Guidance ReaffirmedLilly maintained its previously issued 2017 adjusted earnings and sales outlook for 2017  Adjusted earnings per share are expected in the range of  4 15 to  4 25  Revenues are expected in the range of  22 4 billion and  22 7 billion  Gross margin is expected to be approximately 76   Adjusted tax rate is expected to be approximately 21  Marketing  selling and administrative expenses are still expected in the range of  6 4  6 6 billion  while research and development expenses are projected to be  5 1  5 2 billion Long Term Targets in PlaceLilly further reiterated its annual revenue growth target of at least 5  through 2020 on a constant currency basis backed by robust volumes  Additionally  the company expects operating margin  excluding currency impact on international inventories sold  to be at least 30   as a percentage of revenues  in 2020 Lilly carries a Zacks Rank  3  Hold   You can see    A better ranked stock in the biotech genetics sector is Emergent BioSolutions Inc    NYSE EBS   with a Zacks Rank  1  Strong Buy  Emergent BioSolutions  earnings estimates have moved up by 11 5  for 2018 over the last 7 days  Share price of the company has risen 40 3  year to date Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/lilly-issues-guidance-for-2018-new-drugs-to-drive-top-line-200273382,200273382
172401,393917,LLY,Pharma Stock Roundup  Teva Announces Major Job Cuts  Lilly Provides 2018 Outlook ,opinion,"Key announcements this week were Teva Pharmaceutical Industries Ltd  s   NYSE TEVA   restructuring plan and Eli Lilly and Company s   NYSE LLY   2018 outlook  Focus also remained on data presentation at the annual conference of the American Society of Hematology   ASH   where companies like J J  Roche   OTC RHHBY    Bristol Myers Squibb   NYSE BMY   and Merck   NYSE MRK   were present Recap of the Week s Most Important StoriesASH Highlights  Several companies were at ASH with data on approved and pipeline drugs  Roche presented phase II data showing that polatuzumab vedotin plus bendamustine and MabThera Rituxan   BR   increased complete response rates compared to BR alone in previously treated aggressive lymphoma  Complete response rates increased from 15  to 40  on the addition of polatuzumab vedotin to BR and patients treated with this combination lived longer compared to patients on BR alone  11 8 months versus 4 7 months   Roche also presented data on a Tecentriq Avastin combination in certain people with advanced kidney cancer  Read more    and a Venclexta Venclyxto   MabThera Rituxan combination in previously treated chronic lymphocytic leukemia  Read more    Bristol Myers was also present at ASH with data on Sprycel  dasatinib   which when added to standard chemotherapy showed a three year survival benefit in pediatric patients with newly diagnosed Ph  acute lymphoblastic leukemia  Read more    The company and partner Seattle Genetics also presented interim results from a phase I II study on a combination of Adcetris and Opdivo in relapsed or refractory Hodgkin lymphoma  Combination data showed an objective response rate of 83  and a complete response rate of 62  Lilly Provides 2018 Outlook  Lilly provided its outlook for 2018 saying that it expects recently launched products like Trulicity  Taltz  Basaglar  Jardiance  Verzenio  Cyramza  Olumiant and Lartruvo to drive low single digit revenue growth  The company expects 2018 earnings per share of  4 60    4 70 on revenues of  23    23 5 billion  However  challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera  Effient and Axiron  U S  pricing access pressure will also remain a headwind in 2018 Meanwhile  the company continues to expect 2017 earnings of  4 15 to  4 25 per share on revenues of  22 4    22 7 billion  Lilly raised its quarterly dividend by 8  as well  The company also reaffirmed its guidance of average annual revenue growth of at least 5  from 2015 to 2020 and said that it expects operating margin of at least 30  in 2020 On the pipeline front  Lilly expects regulatory action in the United States for baricitinib  treatment of rheumatoid arthritis   galcanezumab  migraine treatment  and a new indication for Verzenio  breast cancer   and the launch of a new indication for Taltz in psoriatic arthritis in 2018  Read more     The stock has gained 17 6  year to date  compared to the 17 7  rally of the  it belongs to Teva Shares Up on Restructuring Plan  After weeks of speculation that Teva will be cutting down its workforce  the company announced a restructuring plan that will see about 14 000 job cuts  more than 25  of the company s global workforce  over the next two years with the majority expected in 2018 The new CEO s goal is to reduce the cost base  simplify the organization and improve business performance  profitability  cash flow generation and productivity  The company expects to cut  3 billion from its  16 1 billion cost base  estimated for 2017  by the end of 2019  The plan also calls for the optimization of the global generics portfolio  especially in the United States  through price adjustments and or product discontinuation Several manufacturing plants in the United States  Europe  Israel and Growth Markets as well as R D facilities  headquarters and other office locations across all geographies will be shut down or divested  As far as the pipeline is concerned  all R D programs will be reviewed so that core projects can be identified while other projects are terminated immediately The company also suspended dividend payments and annual bonus and said it will continue to look for opportunities to divest non core assets These steps come at a time when Teva is facing several challenges   the company has significant financial obligations in the coming four years while the environment remains challenging in the company s largest generic market  the United States   Teva also expects fewer generic product launches in the United States Teva s shares were up 10 2  on the restructuring announcement as investors cheered the steps taken by the company though execution remains key   Priority Review for Bristol Myers s Opdivo Yervoy Combination  The FDA has granted priority review to Bristol Myers s supplemental Biologics License Application  sBLA  for the label expansion of Opdivo for use in combination with Yervoy for the treatment of intermediate  and poor risk patients with advanced renal cell carcinoma   RCC    With the regulatory agency granting priority review  a response should be out on Apr 16  2018 R D Updates from Sanofi  PA SASY   Sanofi   NYSE SNY   provided an update on its pipeline  71 R D projects including 37 new molecular entities and novel vaccines  at an analyst meeting this week  The company said that it expects to start at least 10 late stage studies in 2018  At least 10 pivotal phase III studies are expected to start over the next 12 months  During this period  Sanofi expects to file for regulatory approval of two investigational cancer drugs  cemiplimab and isatuximab   a type I diabetes treatment  sotagliflozin  and a potential treatment for uncontrolled  persistent asthma  dupilumab  In fact  Sanofi and partner Regeneron announced positive topline results from a pivotal mid stage study on cemiplimab in 82 patients with advanced cutaneous squamous cell carcinoma   CSCC    the second deadliest skin cancer after melanoma  Overall response rate   ORR   of 46 3  was observed in the study  The companies have started submitting a rolling Biologics License Application   BLA   for the PD 1 antibody with the submission expected to complete in the first quarter of 2018  Read more    Meanwhile  Sanofi gained FDA approval for Admelog  insulin lispro injection   a rapid acting insulin similar to Lilly s Humalog  for the management of blood sugar levels at mealtime  Admelog was approved in the EU earlier this year in July  Read more    Updates on Merck s Keytruda  Merck provided a couple of updates related to its anti PD 1 therapy  Keytruda  this week  The company said that an sBLA seeking label expansion for the use of Keytruda for the treatment of relapsed or refractory primary mediastinal large B cell lymphoma   PMBCL   has been granted priority review by the FDA  The company also presented data at ASH which showed that the use of Keytruda resulted in an overall response rate of 41  in this difficult to treat patient population  With the FDA granting priority review  a response from the agency should be out by Apr 3  2018  Approval would make this the second blood cancer indication for Keytruda with the earlier indication being for use in certain patients with classical Hodgkin lymphoma  Read more    However  Keytruda failed to meet the primary endpoint of overall survival in a pivotal study for the second line treatment of patients with advanced gastric or gastroesophageal junction   GEJ   adenocarcinoma  Progression free survival in the PD L1 positive population also failed to show statistical significance Merck is a Zacks Rank  3  Hold  stock   you can see  Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index declined 1 8  over the last five trading sessions  Among major stocks  AstraZeneca was up 3 3  while Merck gained 3 1   Over the last six months  Bristol Myers was up 15 4  while GlaxoSmithKline   NYSE GSK   declined 17 1   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for regulatory and pipeline news from pharma stocks Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-teva-announces-major-job-cuts-lilly-provides-2018-outlook-200273605,200273605
172414,393930,LLY,United Therapeutics PAH Drug s Exclusivity Period Extended,opinion,United Therapeutics Corporation   NASDAQ UTHR   reported that the FDA has granted six months pediatric exclusivity to its pulmonary arterial hypertension  PAH  drug  Adcirca  tadalafil   This will delay generic competition for the drug for an additional six months The pediatric exclusivity has pushed back patent expiry of the oral PDE 5 inhibitor to May 2018  The patent was otherwise set to expire this month  This means a generic version of the drug cannot be approved until then Shares of United Therapeutics were up 2 6  on Monday  in response to the positive development  However  a look at United Therapeutics  share price movement shows that the stock has underperformed the this year so far  United Therapeutics stock has declined 12  during this period  while the industry rose 2  We remind investors that United Therapeutics bought exclusive rights to commercialize Adcirca for the treatment of PAH in the United States from Eli Lilly   NYSE LLY   in November 2008  Tadalafil is also sold by Lilly as Cialis for erectile dysfunction The additional exclusivity for Adcirca was based on some study data submitted by Lilly to the FDA Separately  United Therapeutics will be required to pay higher royalties on sales of Adcirca  effective from next month  per a previously announced amendment to the licensing agreement  The royalty rate on Adcirca sales is up from 5  to 10   United Therapeutics also has to make milestone payments of  325 000 for each  1 000 000 in net product sales Adcirca generated sales of  300 4 million in the nine months of 2017  up 15 8  year over year Meanwhile  the company has three more PAH products in its portfolio   Remodulin  Tyvaso and Orenitram  With these products  United Therapeutics has a varied range of therapies targeting the PAH market Lately  growth of Orenitram  Tyvaso and Remodulin has slowed down due to competition  mainly from Actelion s new drug  Uptravi  selexipag   Actelion is now part of Johnson   Jonson   NYSE JNJ    Also some patients are staying longer on front line oral AMBITION combination therapy  Adcirca   Gilead s   NASDAQ GILD   Letairis  and delaying the transition to inhaled injectable therapies like Tyvaso Remodulin  thereby hurting their demand Meanwhile  Remodulin  which accounts for more than 35  of United Therapeutics  total sales  could start facing generic competition after June 2018 United Therapeutics carries a Zacks Rank  3  Hold   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them  Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-11-20,Zacks Investment Research,https://www.investing.com/analysis/united-therapeutics-pah-drugs-exclusivity-period-extended-200267244,200267244
172415,393931,LLY,Lilly s  LLY  Taltz Gets Approval For Label Expansion In US,opinion,"Eli Lilly and Company   NYSE LLY   announced that the FDA has approved the label expansion of its psoriasis drug  Taltz  to include the treatment of active psoriatic arthritis  PsA  in adults We note that Taltz is presently approved for treating moderate to severe plaque psoriasis in adults who can have systemic therapy or phototherapy The drug has grown more than 50  in the first nine months of 2017 and contributed significantly to revenues and volumes  This approval for an expanded label in the United States is expected to further boost its growth Lilly s stock price has increased 26 9  in the past one year  outperforming the  s gain of 20  Coming back to the news  the FDA s approval for Taltz  label expansion was based on data from two phase III studies   SPIRIT P1 and SPIRIT P2   evaluating the drug in active PsA patients  who have not received any  antirheumatic drug therapy or who have failed one or two  tumor necrosis factor   TNF   inhibitors  respectively The drug achieved a reduction of 20  or more in a composite measure of disease activity  ACR20  in more than half of the patient population in both the studies at 24 weeks The drug  80 mg mL  can be injected as single agent or in combination with any disease modifying antirheumatic drug like methotrexate However  Taltz will face competition from several drugs  especially Novartis    NYSE NVS   Cosentyx  as both the drug works by targeting IL 17A  Cosentyx is also approved for PsA and plaque psoriasis PsA is a chronic form of inflammatory arthritis  which is painful and progressive as well  Per the press release  approximately 1 6 million people in the United States are affected by the disease  Apart from Cosentyx  Johnson   Johnson s   NYSE JNJ   Stelara and AbbVie Inc  s   NYSE ABBV   Humira among others are fighting for market share Eli Lilly and Company Price
    Lilly carries a Zacks Rank  3  Hold   You can see  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-12-03,Zacks Investment Research,https://www.investing.com/analysis/lillys-lly-taltz-gets-approval-for-label-expansion-in-us-200270216,200270216
172416,393932,LLY,Pfizer Reports Updated Data From Phase III Study On Ibrance,opinion,"Pfizer Inc    NYSE PFE   announced encouraging new data of a post hoc analysis from a phase III study  evaluating the combination of its breast cancer drug  Ibrance  palbociclib   with Novartis    NYSE NVS   Femara  letrozole  for the first line treatment of ER   HER2  metastatic breast cancer 
Notably  data from the study will be presented at the San Antonio Breast Cancer Symposium  SABCS  on Dec 8 
Ibrance is approved in the United States for treating HR  HER2  advanced or metastatic breast cancer in combination with an aromatase inhibitor as an initial endocrine based therapy in postmenopausal women  It is also approved to be used with AstraZeneca s   NYSE AZN   Faslodex in women with disease progression following the endocrine therapy  Presently  Ibrance is approved in more than 75 countries 
Pfizer s shares are up 9 9  so far this year  comparing unfavorably with the  s return of 16 5  

 
In the PALOMA 2 study  it was seen that a combination of Ibrance and Femara led to an improvement in progression free survival  PFS  or the time before recurrence of tumor growth by more than a year compared with Femara plus placebo  In other words  the study showed that the median PFS for women treated with Ibrance plus Femara was 27 6 months compared with 14 5 months for the Femara placebo combination arm  thereby indicating a 44  reduction in the risk of disease progression 
PALOMA 2 had enrolled 666 women in all from 186 global sites across 17 countries  The updated results and the safety profile from the post hoc analysis are consistent with the primary data from the PALOMA 2 study  reported last November 
We remind investors that Ibrance in combination with Femara was cleared in the United States under an accelerated approval in February 2015 for treatment of HR  HER2  advanced or metastatic breast cancer  In April  Pfizer received a regular approval for the drug based on data from the PALOMA 2 trial  Also  around the same time  Ibrance s label was expanded covering a few more indications to be used in combination with any aromatase inhibitor and not just Femara 
Pfizer is exploring the possibility of expanding Ibrance into recurrent and subsequent early breast cancer as well as several non breast cancer indications like pancreatic and head and neck cancers 
Ibrance has been generating strong sales as a key driver of the company s top line  The drug logged sales of  2 41 billion in the first nine months of 2017  up 61  year over year  On successful label expansion  the drug should reap in more revenues 
However  in the breast cancer market  competition for Ibrance has increased with recent launches for Eli Lilly s   NYSE LLY   Verzenio and Novartis  Kisqali Pfizer  Inc  Price

   Zacks Rank
Pfizer carries a Zacks Rank  3  Hold   You can see  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-12-07,Zacks Investment Research,https://www.investing.com/analysis/pfizer-reports-updated-data-from-phase-iii-study-on-ibrance-200271486,200271486
172431,393947,LLY,Merck  MRK  Q3 Earnings Top  Sales Lag  Keytruda Stays Strong,opinion,"Merck   Co   Inc    NYSE MRK   reported third quarter 2017 adjusted earnings of  1 11 per share  which beat the Zacks Consensus Estimate of  1 03 by 7 8   Earnings rose 3 7  year over year 
Among other items  adjusted earnings exclude a charge related to its new oncology collaboration with Britain s AstraZeneca   NYSE AZN   
Revenues for the quarter declined 2  year over year to  10 33 billion  Sales also missed the Zacks Consensus Estimate of  10 51 billion  Currency movement positively impacted revenues by 1   Excluding currency impact  sales declined 3  year over year 
Lost sales in some markets due to a network cyber attack in June hurt the top line in the quarter  Meanwhile  unfavorable comparisons with the third quarter of last year hurt sales 
Quarter in Detail
The Pharmaceutical segment generated revenues of  9 2 billion  down 3   down 4  excluding Fx impact  year over year as continued strong sales of PD 1 inhibitor  Keytruda were offset by lower sales of key products like diabetes drug Januvia and HPV vaccine Gardasil Gardasil 9  As in the previous quarters  loss of market exclusivity for several drugs also hurt the top line 
Keytruda brought in sales of  1 05 billion in third quarter 2017  up 21  sequentially and 194  year over year  Sales continued to be driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in the indication of first line lung cancer 
Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer 
Meanwhile  the Keytruda development program significantly advanced in the first half with regulatory approvals for four new indications in the United States and an additional indication in Europe  Key recent approvals include that for advanced bladder cancer  advanced microsatellite instability high cancers and first approval as a combination therapy with Eli Lilly s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo  in lung cancer 
The new approvals have expanded the patient population  which we believe drove sales in the third quarter 
Zepatier brought in sales of  468 million  down from  517 million in the previous quarter 
Bridion  sugammadex  Injection generated sales of  185 million in the quarter  up 33  year over year  driven by the strong uptake following its launch in the United States 
Meanwhile  combined sales of Remicade  lost exclusivity in Europe and facing stiff biosimilar competition in the region   Cubicin  lost patent protection in the United States in June 2016   Zetia  lost market exclusivity in the United States in December 2016  and Vytorin  lost U S  exclusivity in April 2017  declined  800 million in the quarter 
Remicade sales declined 31  to  214 million in the quarter  Merck markets the branded version of Remicade outside the United States while Johnson   Johnson   NYSE JNJ   markets the rheumatoid arthritis drug within the country 
Cubicin sales plunged 71  to  91 million in the quarter  The Zetia Vytorin franchise recorded sales of  462 million  down 51  due to loss of exclusivity for both Zetia and Vytorin 
Sales of Isentress and the Januvia Janumet  diabetes  franchise also declined in the quarter  The Januvia Janumet franchise recorded sales of  1 53 billion in the quarter  down 2  from the year ago quarter due to continued pricing pressure 
Isentress sales declined 17  in the quarter to 310 million  Lower volumes demand due to competitive pressure hurt sales of Isentress 
Gardasil Gardasil 9 sales declined 22  to  675 million  The production shutdown following the cyber attack resulted in supply constraints  which adversely impacted sales in the United States  However sales rose in Europe  boosted by the addition of sales from the terminated vaccine joint venture with Sanofi   NYSE SNY   and in Asia Pacific backed by strong demand 
Merck s Animal Health segment generated revenues of  1 billion  up 16   up 14  excluding Fx impact  from the year ago quarter  primarily driven by higher sales of companion animal products  primarily Bravecto  companion animal vaccines and contribution from the Vall e acquisition 
Gross Margins   Costs Rise                                                   
Adjusted gross margin came in at 76   up 70 basis points  bps  from the year ago quarter   attributable to favorable effects of product mix  which offset the costs related to the cyber attack 
Marketing and administrative  M A  expenses increased 1  to  2 4 billion in the reported quarter  Research and development  R D  spend increased 8  to  1 8 billion in the quarter 
2017 Guidance
Merck raised its previously issued adjusted earnings guidance while raising its sales guidance marginally   for the second time this year  The company expects adjusted earnings in the range of  3 91  3 97 compared with  3 76  3 88 expected earlier  The adjusted earnings guidance includes less than 1  negative impact from currency fluctuation  comparing favorably with approximately 1  previously 
Revenues are expected in the range of  40 0 billion    40 5 billion compared with the earlier forecast of  39 4 billion    40 4 billion  including negative currency impact of less than 1    versus approximately 1  previously  
Operating expenses are still expected to increase year over year at a mid single digit rate  The increased costs are attributable to increased investments behind the ongoing launches  remediation expenses related to the cyber attack  as well as additional R D costs associated with the new oncology collaboration with AstraZeneca 
Our Take
Merck s third quarter results were mixed as the company beat estimates for earnings but missed the same for sales  Despite a relatively weaker sales performance  Merck raised its previously issued adjusted earnings guidance for 2017 and also upped its sales guidance marginally 
Shares were down 2  in pre market trading in response to lower sales of Merck s multiple medicines  This year so far  Merck s shares have underperformed the   Merck s shares have risen 5 3  this year comparing unfavorably with a 16 1  increase for the industry 

All eyes were on the performance of Keytruda  which is being touted as a key long term growth driver for Merck  The drug continued its strong performance with sales crossing the  1 billion mark this quarter 
However  the company has suffered some notable pipeline setbacks this year  Earlier this month  Merck decided not to seek approval for its CETP inhibitor anacetrapib for cholesterol management as its clinical profile was not strong enough to support regulatory filings  Last month  Merck discontinued development of two of its HCV programs saying that the HCV market is becoming extremely crowded  Also  three combination studies of Keytruda for multiple myeloma were placed on clinical hold following reports of death in the Keytruda groups in July
Merck carries a Zacks Rank  3  Hold   You can see  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-q3-earnings-top-sales-lag-keytruda-stays-strong-200221556,200221556
172436,393952,LLY,Pharma ETFs Down Post Q3 Earnings,opinion,Total earnings for  of the total healthcare market capitalization are up 7 6  on revenue growth of 4 6   Though earnings growth appears solid compared with many other sectors  earnings and revenue beat ratios of 72 5  and 58 8   respectively  look disappointing Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on Oct 17  followed by Eli Lilly and Company   NYSE LLY   and Bristol Myers Squibb Company   NYSE BMY   on Oct 24 and Oct 26  respectively  Two other major U S  drug companies  Merck   NYSE MRK   and Pfizer   NYSE PFE    reported on Oct 27 and Oct 31  respectively  These industry primes posted solid results with either earnings or revenue beats or both Johnson and Johnson Earnings in FocusThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  1 90  10 cents ahead of the Zacks Consensus Estimate and 13 1  higher than the year ago quarter  Revenues grew 10 3  year over year to  19 65 billion and edged past the Zacks Consensus Estimate of  19 28 billion  Johnson   Johnson raised its full year earnings per share guidance to  7 25  7 30 from  7 12  7 22 and revenue guidance to  76 1  76 5 billion from  75 8  76 1 billion  read    Pfizer Earnings in FocusThe U S  drug giant came up with an earnings beat and in line revenues  Earnings per share of 67 cents came in a couple of cents above the Zacks Consensus Estimate while revenues of  13 7 billion were in line with the estimate of  13 17 billion  On a year over year basis  earnings per share and revenues rose 10  and 1   respectively  For 2017  Pfizer narrowed the revenue guidance range to  52 4  53 1 billion from  52  54 billion while raised the earnings per share guidance range to  2 58  2 62 from  2 54  2 60 Merck Earnings in FocusMerck beat the earnings estimate while missed on revenues  Earnings per share came in at  1 11  surpassing the Zacks Consensus Estimate of  1 03 and improving 3 7  from the year ago quarter  Revenues declined 2  year over year to  10 33 billion and were below the Zacks Consensus Estimate of  10 51 billion  Merck raised its revenue guidance to  40  40 5 billion from  39 4  40 4 billion and earnings per share guidance to  3 91  3 97 from  3 76  3 88 for this year Bristol Myers Earnings in FocusBristol Myers missed on earnings while beats on revenues  It reported earnings per share of 75 cents  a couple of cents below the estimate  Revenues grew 7 1  to  5 25 billion and edged past the Zacks Consensus Estimate of  5 19 billion  The company raised its earnings per share guidance to  2 95  3 05 from  2 90  3 00  see    Eli Lilly Earnings in FocusEli Lilly topped the Zacks Consensus Estimate on both fronts  Earnings of  1 05 outpaced the Zacks Consensus Estimate by couple of cents and came in 19  higher than the year ago quarter  Revenues grew 9  to  5 66 billion and beat the  5 52 billion estimate  Like other drug makers  Eli Lilly also raised its 2017 revenue and earnings guidance  It now expects revenues in the range of  22 4  22 7 billion compared with the previous expectation of  22 0  22 5 billion and earnings per share in the range of  4 15  4 25 versus  4 10  4 20 expected previously ETF AngleThe string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month  Below  we have highlighted these in detail  These funds have a Zacks ETF Rank  3  Hold  with a High risk outlook PowerShares Dynamic Pharmaceuticals Fund   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  663 7 million and sees a lower volume of around 52 000 shares a day  The fund charges 56 bps in fees and expenses  Holding 30 stocks  the fund invests around 22 8  share in the in focus five firms  The ETF has lost 6  in a month iShares U S  Pharmaceuticals ETF This ETF provides exposure to 42 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top five holdings in the basket accounting for a combined 40 3  of total assets  suggesting heavy concentration  The product has  594 5 million in AUM and charges 44 bps in fees and expense  Volume is light as it exchanges about 19 000 shares a day  The fund has shed 6  in a month  read    SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to the pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  396 6 million  it trades in a good volume of around 90 000 shares a day and charges 35 bps in fees a year  In total  the product holds 39 securities with the in focus five firms taking nearly 5  share each  The product was down 7  in the same period VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  Johnson   Johnson  Pfizer  Bristol Myers  and Eli Lilly accounts for at least 5  share each while Merck makes up for 4 4  of assets  The product has amassed  262 4 million in its asset base and trades in a moderate volume of about 67 000 shares a day  Expense ratio comes in at 0 35   The fund has lost 5 9  in a month  Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-down-post-q3-earnings-200263769,200263769
172437,393953,LLY,Novo Nordisk   4 Other Pharma Stocks In Focus On World Diabetes Day,opinion,"World Diabetes Day is celebrated every year on November 14  The theme this year is  Women and diabetes   our right to a healthy future   The focus is on emphasizing the importance of providing women  diabetics as well as those at risk of being diagnosed with diabetes  with affordable and equitable access to essential diabetes drugs and technologies  self management education and information needed to achieve optimal diabetes outcomes and strengthen their capacity to prevent type II diabetes  The ninth leading cause of death in women across the world  diabetes accounts for 2 1 million deaths every year According to information provided by the International Diabetes Foundation   IDF    more than 199 million women have diabetes with this figure expected to rise to 313 million by 2040  Among these  more than 60 million women are of reproductive age with one in seven births being affected by gestational diabetes  Gestational diabetes is associated with a higher risk of type II diabetes in the mother as well as the child Moreover  many people with type II diabetes remain unaware of their condition for a long period of time and this may lead to diabetes related complications by the time the disease is diagnosed  Women with type II diabetes are considered to be 10 times more likely to suffer from heart disease compared to women without the condition Other diabetes related complications include blindness  lower limb amputation and kidney failure Given these statistics and complications  it is not surprising that several healthcare companies devote a significant amount of R D dollars on developing treatments and devices for diabetes and diabetes management  The diabetes market is highly crowded with companies coming out with innovative treatments promising higher efficacy with lower side effects  Currently available diabetes drugs include different classes of treatments like DPP 4 inhibitors  Januvia  Onglyza  Trajenta   GLP 1 receptor agonists  Victoza  and SGLT 2  Invokana  Farxiga  apart from metformin and insulin In addition to drugs  the diabetes care market includes glucose monitoring systems  insulin delivery systems as well as insulin pumps Stocks to Watch on World Diabetes DayThis World Diabetes Day  here is a look at some of the key pharma companies in the diabetes market Denmark based Novo Nordisk  CO NOVOb  A S   NYSE NVO   is among the key players in the global diabetes market  The company s diabetes portfolio comprises products like Tresiba  a once daily new generation insulin   Xultophy  a once daily single injection combination of Tresiba and Victoza   Ryzodeg  a soluble formulation of Tresiba and NovoLog   Fiasp  fast acting mealtime insulin   a new formulation of NovoLog  and Victoza  GLP 1  Recent developments include Victoza and Tresiba s label updates  Victoza s U S  label now reflects prevention of cardiovascular events while Tresiba s EU label reflects significant reduction in the risk of severe hypoglycemia  as well as a positive FDA advisory panel vote for semaglutide  Approval could come later this quarter However  pricing pressure in the United States remains a major challenge for the diabetes care market while intense competition across the globe also remains a headwind Shares of Novo Nordisk have gained 38 8  year to date  significantly outperforming the  14 5  rally  Novo Nordisk is a Zacks Rank  3  Hold  stock   you can see  
French drugmaker Sanofi   NYSE SNY   is another key player in the diabetes market  However  the company s Diabetes franchise is under pressure with key product  Lantus  facing increasing competitive pressure at the payor level and biosimilar competition in several European markets  Toujeo  Apidra  Amaryl  Lyxumia and Soliqua are some of the other diabetes products in the company s portfolio  Sanofi expects its global Diabetes sales to decline 6 8  annually  at constant exchange rates  over the 2015 2018 timeframe  Pricing pressure  increasing competition and formulary exclusions will continue impacting the segment Despite the challenges in the diabetes market  Sanofi continues to work on expanding and strengthening its diabetes portfolio and currently has five diabetes candidates in its pipeline including SAR438335  GLP 1R GIPR dual agonist  phase I for type II diabetes   SAR425899  GLP 1R GCGR dual agonist  phase II for type II diabetes   sotagliflozin  oral SGLT 1 2 inhibitor  phase III for type I and type II diabetes   SAR341402  rapid acting insulin  phase III for type I and II diabetes  and efpeglenatide  long acting GLP 1 receptor agonist  phase III for type II diabetes scheduled to commence this quarter   Late stage combination studies for sotagliflozin in type II diabetes are scheduled to commence this quarter Shares of Sanofi are up 10 4  year to date  compared to the  14 5  rally 
Diabetes  New Cardiovascular   Metabolic Diseases  is one of the growth platforms at AstraZeneca plc   NYSE AZN    Key products in AstraZeneca s diabetes portfolio include Farxiga  Onglyza  and Bydureon among others  Recent approvals include an improved device for Bydureon  Bydureon BCise  and a combination of Farxiga and Bydureon for type II diabetes AstraZeneca s Diabetes franchise sales in the United States are also feeling the impact of intense pricing pressure and competition Shares of AstraZeneca  a Zacks Rank  3 stock  are up 20 5  year to date  compared to the  14 5  rally 
Eli Lilly and Company   NYSE LLY   is another well known player in the diabetes market  Lilly has a strong portfolio of diabetes treatments including Trulicity  GLP 1   Jardiance  SGLT 2   Trajenta  Humulin  Basaglar  Humalog  and Glyxambi  The company has a diabetes alliance with Boehringer Ingelheim for several of these products  Lilly also has a strong diabetes pipeline  While the company expects pricing pressure to continue in the diabetes market in 2018  the exclusion of Jardiance from the CVS health formulary could also impact the company s diabetes franchise sales Shares of Lilly are up 12 7  year to date  compared to the  14 5  rally  Lilly is also a Zacks Rank  3 stock 
Merck   Co   Inc  s   NYSE MRK   diabetes franchise  which accounted for 16 7  of third quarter 2017 pharma segment sales  consists of products like Januvia and Janumet  However  like its peers  Merck s diabetes segment sales continue to be affected by pricing pressure Merck  along with partner Pfizer   NYSE PFE    is currently seeking FDA approval for ertugliflozin and two fixed dose combination products  ertugliflozin and Januvia  ertugliflozin and metformin  with a response from the FDA expected in December 2017 
Merck is also a Zacks Rank  3 stock  The company s shares have declined 6 4  year to date  compared to the  14 5  rally 
Although the diabetes market is currently facing intense pricing pressure and competition  the market remains lucrative considering the growing prevalence of the disease and the demand for new and better treatments Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk--4-other-pharma-stocks-in-focus-on-world-diabetes-day-200264916,200264916
172439,393955,LLY,J J Presents Positive New Data For Diabetes Drug Invokana,opinion,"Johnson   Johnson   NYSE JNJ   presented new data from a large CANVAS outcomes program on its type II diabetes drug  Invokana  SGLT2 inhibitor   demonstrating an improved renal outcome  The data was presented at the annual meeting of the American Heart Association Scientific Sessions in California and published in the Circulation 
So far this year  Johnson   Johnson s share price has increased 21 1   comparing favorably with the 14 4  rally of the  it belongs to 

This new analysis of CANVAS showed a reduction in the risk of the composite renal endpoint in both patient groups   with a history of CV disease  secondary prevention  and those with only risk factors for CV disease  primary prevention   Also  Invokana demonstrated reduction in the risk of hospitalization due to heart failure  HHF  in both patient groups  No new adverse events were reported during this additional analysis 
We remind investors that in June  the company reported data from the CANVAS program  which demonstrated that Invokana was successful in reducing the risks of cardiovascular  CV  outcomes in type II diabetes patients  who have established cardiovascular  CV  disease or are at a risk for CV disease  Invokana reduced major adverse CV events or MACE by 14  compared with placebo  MACE is a composite endpoint of CV death  non fatal myocardial infarction or non fatal stroke  However  the study also showed that the drug increased the risk of amputations 
Last month  J J submitted a supplemental new drug application  sNDA  to the FDA for the label expansion of Invokana to include the cardiovascular indication based on the data from the CANVAS program 
Many pharma companies are working hard to get the labels of their diabetes medicines updated to include the cardiovascular benefits  With death from cardiovascular diseases being significantly higher in adults with diabetes compared with those without it  the addition of positive CV outcomes on labels of diabetes drugs can give sales a shot in the arm 
Eli Lilly   Company   NYSE LLY   received both FDA and EU approvals last year to include the CV risk reduction data from the EMPA REG OUTCOME study on the label of Jardiance  Additionally  in August  Novo Nordisk s   NYSE NVO   Victoza  liraglutide  was approved by the FDA for a new indication to reduce the risk of major adverse cardiovascular  CV  events in adults with type II diabetes and established CV disease 
However  in May  Merck   Co   Inc    NYSE MRK   was denied an approval by the FDA to include cardiovascular outcomes data from the TECOS trial on the labels of its DPP IV inhibitor  Januvia  sitagliptin  and other medicines containing Januvia 
AstraZeneca s Bydureon also failed to reduce the cardiovascular risk in a phase IIIb IV cardiovascular outcomes study  EXSCEL Johnson   Johnson Price

   Zacks Rank
Johnson   Johnson carries a Zacks Rank  2  Buy   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/jj-presents-positive-new-data-for-diabetes-drug-invokana-200265536,200265536
172442,393958,LLY,AstraZeneca s Faslodex Gets FDA Nod For Use With Verzenio,opinion,AstraZeneca  plc   NYSE AZN   announced that the FDA has granted approval to a new indication for its breast cancer drug  Faslodex The label of Faslodex will now be expanded to include combination use with Eli Lilly s   NYSE LLY   new CDK4 6 inhibitor Verzenio abemaciclib to treat women with HR   HER2  advanced or metastatic breast cancer whose disease has progressed after endocrine therapy The FDA approval was based on the MONARCH 2 study data  which showed that Faslodex Verzeniosignificantly improved progression free survival  16 4 months  compared to Faslodex  placebo Shares of this London  United Kingdom based pharma giant have gained 22 2  so far this year  comparing favorably with the  s growth of 14  In August  Faslodex had received FDA approval for a label extension in the first line monotherapy setting for the treatment of postmenopausal women with HR  advanced breast cancer  Until this approval  Faslodex was only approved for advanced breast cancer in later lines of treatment We believe that the FDA approval for two new indications for Faslodex in three months can improve sales of the drug in the future quarters  The drug has generated sales of  703 million in 2017 so far  up 16  year over year Also  please note that this is the second time that Faslodex has been approved for use in combination with a CDK4 6 inhibitor  It is already marketed in combination with Pfizer s   NYSE PFE   Ibrance AstraZeneca carries a Zacks Rank  3  Hold   A better ranked stock in the large cap pharma sector is Johnson   Johnson   NYSE JNJ   with a Zacks Rank  2  Buy   You can see  Shares of J J are up 20 7  so far this year while earnings estimates for 2018 have gone up by 1 2  over the past 30 days Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-faslodex-gets-fda-nod-for-use-with-verzenio-200265755,200265755
172468,393984,LLY,What To Expect From Big Pharmas After J J s Solid Q3 Results ,opinion,"Johnson   Johnson   NYSE JNJ   was the first large cap pharma stock to report its earnings results for this season on Oct 17  J J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook  Shares of J J were up more than 3  on Tuesday 
J J s sales growth accelerated in the third quarter leading the company to post its first positive sales surprise after almost a year  Higher sales in the pharmaceutical segment as well as positive contribution from the Actelion deal pulled up the top line in the quarter  J J acquired Swiss biotech Actelion in June this year for  30 billion 
Overall  the pharma sector has witnessed a great turnaround this year after the drug pricing issue crippled its performance last year 
After declining 5 2  last year  the industry has risen 18 2  this year so far  outpacing 14 2  gain for the S P 500 in the same time frame 
New product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals  11 new drugs approved in Q3 alone  and continued strong performance of legacy products have played a pivotal role in bringing the sector on track this year 
These factors are likely to drive the sector through the rest of this year and probably the next despite challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and generic competition for certain key drugs 
J J s better than expected results  especially the strong performance of its Pharmaceuticals segment  have raised optimism for another strong quarterly performance by the pharma sector  mainly the large cap companies 
Let s have a closer look at what to expect from six big pharma stocks when they report this month early next month  Five out of the six companies are expected to deliver earnings beat this quarter 
Pfizer  Inc    NYSE PFE  
Pfizer is scheduled to announce third quarter results on Oct 31 before the market opens  With a Zacks Rank  3  Hold  and of  1 04   the chances of the stock beating the Zacks Consensus Estimate in the third quarter is high  You can uncover the best stocks to buy or sell before they re reported with our  
New products like Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain  and Eliquis  blood thinner  are expected to contribute to Pfizer s top line meaningfully  However  the loss of exclusivity and associated generic competition for products like Pristiq Vfend  Zyvox and Celebrex and the expiration of a few co promotion agreements will continue to hamper top line growth  Blockbuster drug Enbrel sales will continue to be soft in the quarter due to biosimilar competition 
Pfizer surpassed the Zacks Consensus Estimate in two of the trailing four quarters  as shown in the chart below Pfizer  Inc  Price and EPS Surprise

   Bristol Myers Squibb Company   NYSE BMY  
Bristol Myers is scheduled to release results on Oct 26 before the market opens  Similar to Pfizer  our quantitative model indicates an earnings beat for Bristol Myers  This Zacks Rank  3 stock has an Earnings ESP of  1 05  
You can see  
Bristol Myers  high profile immuno oncology drug  Opdivo  is likely to drive the company s top line in the to be reported quarter  Opdivo s U S  sales are driven by the melanoma  second line non small cell lung cancer and renal cell carcinoma indications 
Recent label expansions into the classical Hodgkin lymphoma and head and neck cancer indications will also boost the drug s sales 
Bristol Myers outpaced the Zacks Consensus Estimate in three of the trailing four quarters  as reflected in the chart below Bristol Myers Squibb Company Price and EPS Surprise

   Merck   Company  Inc    NYSE MRK  
Merck is scheduled to release results on Oct 27 before the market opens  With a Zacks Rank  3 and Earnings ESP of  0 61   the chances of the stock beating the Zacks Consensus Estimate in the third quarter is high 
Merck s new products like Keytruda  cancer   Zepatier  HCV  and Bridion  sugammadex  Injection will likely drive revenues this quarter as well  Keytruda sales in the United States are gaining  particularly from strong momentum in the new indication of first line lung cancer  The Keytruda development program significantly advanced in the first half with regulatory approvals for four new indications in the United States and an additional indication in Europe  The new approvals expand the patient population and are expected to drive sales further 
However  genericization and increasing competition will likely remain overhangs 
Merck outpaced the Zacks Consensus Estimate in each of the trailing four quarters  as reflected in the chart below Merck   Company  Inc  Price and EPS Surprise

   GlaxoSmithKline plc   NYSE GSK  
Brentford  UK based GlaxoSmithKline is expected to report results on Oct 25  GlaxoSmithKline is also expected to outperform in the third quarter due to its Zacks Rank  2  Buy  and Earnings ESP of  1 80  
Glaxo s Pharmaceuticals and Vaccines business segments are expected to perform well  Glaxo s Pharmaceuticals segment is expected to continue being driven by strong sales of new HIV products  Tivicay and Triumeq 
However  many of Glaxo s key drugs like Lovaza and Avodart are facing declining sales due to generic competition  Moreover  sluggish sales growth in the Consumer Healthcare segment due to a slowdown in market conditions and the impact of divestures may negatively impact the top line in the third quarter 
Notably  the company surpassed the Zacks Consensus Estimate in three of the trailing four quarters  as shown in the chart below GlaxoSmithKline PLC Price and EPS Surprise

   Eli Lilly and Company   NYSE LLY  
Eli Lillyis slated to announce third quarter results on Oct 24 before the market opens  With a Zacks Rank  3 and Earnings ESP of  0 07   the chances of an earnings beat in the to be reported quarter is high 
Continuing the trend of the past few quarters  new products like Trulicity  Cyramza  Taltz and Jardiance are likely to support the top line in the reported quarter 
However  sluggish performance of Alimta  Cymbalta and Zyprexa are expected to continue in the third quarter due to the loss of exclusivity 
Notably  Eli Lilly surpassed the Zacks Consensus Estimate in two of the trailing four quarters  as shown in the chart below Eli Lilly and Company Price and EPS Surprise

   Novartis AG   NYSE NVS  
Swiss company   is scheduled to report its results on Oct 24  before market opens  Novartis is not expected to beat estimates in the third quarter due its Zacks Rank  3 and an Earnings ESP of  0 40  
The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis  given the potential in the CAR T therapy space  Moreover  new products like Cosentyx and Entresto are expected to boost the top line  Cosentyx has been strong and the company has grabbed market share from rivals like AbbVie s Humira and Amgen s Enbrel  Cosentyx achieved blockbuster status in 2016 
However  a weak Alcon business and generic competition for several of its key drugs is expected to hurt revenues in this quarter 
Notably  Novartis outpaced the Zacks Consensus Estimate in each of the trailing four quarters  as reflected in the chart below Novartis AG Price and EPS Surprise

   The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-big-pharmas-after-jjs-solid-q3-results-200219638,200219638
172469,393985,LLY,Novartis Reports Positive Results On Thrombocytopenia Drug ,opinion,"Novartis AG   NYSE NVS   announced encouraging results on Revolade from the EXTEND study The open label extension study from four trials  TRA100773A  TRA100773B  TRA102537 RAISE and TRA108057 REPEAT  showed long term disease control in chronic persistent immune thrombocytopenia  ITP  patients  The research evaluated patients for up to 8 years of continuous treatment  The study found that majority of patients maintained a substantial clinical response and might not need concomitant ITP medications any further Patients suffering from ITP have a low number of platelets which in turn does not let the blood to clot resulting in bruising and bleeding   The study results showed that nearly 70  of patients maintain platelet counts without rescue therapy for prolonged periods  reducing the overall risk of bleeding   In addition  more than one third of patients permanently stopped one or more concomitant ITP medications  including corticosteroids  danazol  azathioprine   The results establish long term safety profile and demonstrates treatment benefit with Revolade We note that the drug is approved in the United States and Europe for the treatment of thrombocytopenia in pediatric patients 1 year or older with chronic ITP who have had an insufficient response to corticosteroids and immunoglobulins  It is marketed as Promacta in the United States We remind investors that the drug was acquired from GlaxoSmithKline plc    NYSE GSK    Novartis has a collaboration agreement with Ligand Pharmaceuticals  Inc     NASDAQ LGND   for the marketing of the drug Novartis is currently going through a transitional stage  In March 2015  Novartis acquired certain oncology products and pipeline compounds from Glaxo  In exchange  it sold its non influenza Vaccines business to Glaxo  In January 2015  Novartis divested its Animal Health Division to Eli Lilly and Company   NYSE LLY    The company s blockbuster drug  Diovan  is facing stiff generic competition in the United States  EU and Japan  Gleevec lost exclusivity in the United States in February 2016  The company also lost patent protection for the drug in EU in December 2016 leading to generic competition  The loss of patent protection for these top selling drugs continue to hurt sales Nevertheless  Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu  and Kisqali  The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space  Growth drivers like Cosentyx and Entresto  more than offset the impact of generic erosion  mainly due to Glivec Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-positive-results-on-thrombocytopenia-drug-200219849,200219849
172470,393986,LLY,Eli Lilly  LLY  Tops Q3 Earnings   Sales  Ups 2017 View,opinion,"Indianapolis  IN based Eli Lilly and Company   NYSE LLY    is a global healthcare company with core products in a number of primary care pharmaceutical markets  Lilly generates revenues from its pharmaceutical product and animal health segments The company s portfolio includes Zyprexa  schizophrenia and bipolar disorder   Gemzar  pancreatic cancer   Evista  osteoporosis   Cymbalta  depression   Cialis  erectile dysfunction   Strattera  attention deficit hyperactivity disorder   ADHD   Erbitux  cancer  and Alimta  chemotherapy   Lilly also has a strong presence in the diabetes market  However  many of its key products like Cymbalta and Alimta are facing generic competition  The company also has some new products like Trulicity  Cyramza  Jardiance  and Taltz in its portfolio which are driving revenues Lilly s earnings performance has been mixed with earnings missing expectations in two of the last four quarters while beating the same in the other two  bringing the average negative surprise to 0 89  Currently  Lilly has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Lilly beat on third quarter earnings  The company reported EPS of  1 05 per share while our consensus called for EPS of  1 03 Revenues Beat  Revenues also beat expectations  Lilly posted revenues of  5 66 billion  compared to our consensus estimate of  5 52 billion 2017 Outlook Upped  Lilly raised its previously issued 2017 adjusted earnings and sales outlook   for the second time this year  Adjusted earnings per share are now expected in the range of  4 15 to  4 25 compared with  4 10 to  4 20 expected previously  Revenues are expected in the range of  22 4 billion and  22 7 billion  up from  22 0  22 5 billion expected previously  The Zacks Consensus Estimate for earnings and revenues is  4 15 per share and  22 43 billion  respectively Strategic Initiatives  Concurrent with the earnings release  Lilly said it is exploring strategic alternatives for the Elanco Animal Health business including a spin off  sale  merger or creating a separate company through an initial public offer  A decision regarding the same is expected to be made by middle of next year and Lilly may ultimately opt to retain the business Stock Price Impact  Shares were up 1 5  in pre market trading Check back later for our full write up on this Lilly earnings report later Eli Lilly and Company Price and Consensus
    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-lly-tops-q3-earnings--sales-ups-2017-view-200220678,200220678
172489,394005,LLY,Lilly Wins Favorable Ruling From U S  PTO In Alimta Dispute,opinion,Eli Lilly   Company   NYSE LLY   announced that it has received a favorable ruling from the U S  Patent and Trademark Office  PTO  in a dispute related to the vitamin regimen patent on its key cancer drug  Alimta  pemetrexed disodium  In an inter partes review  IPR  ruling  the U S  PTO validated the Alimta vitamin regimen patent  thereby removing a major overhang for Lilly  Markedly  the IPR was initiated by Neptune Generics and Sandoz  the generic arm of Novartis AG   NYSE NVS   We remind investors that in January this year  the U S  Court of Appeals ruled in favor of Lilly in a lawsuit against generic drugmaker Teva Pharmaceuticals   NYSE TEVA   regarding the validity and infringement of the same patent  confirming the earlier decisions by a district court  The U S  PTO s IPR ruling is consistent with these previous Alimta decisions So far this year  Lilly s share price has risen 19 1  comparing favorably with  s growth of 17 9    Although the compound patent covering Alimta in the United States expired in January this year  the vitamin regimen patent will remain valid till June 2021  plus pediatric exclusivity expiring in 2022   if Alimta s patent is ultimately upheld through all the remaining challenges   The compound patent has already expired in major European countries and Japan in Dec 2015 More than ten generic manufacturers including Teva and Sandoz are seeking approvals in the United States to market generic forms of Alimta prior to the expiration of its vitamin regimen patents Notably  Alimta is one of the top revenue grossers at Lilly and a longer commercial life for Alimta would provide top line support as several products in Lilly s portfolio are already facing patent expiration The entry of generic competition for Alimta following the loss of effective patent protection will cause a rapid decline in revenues for the product In the first half of 2017  Alimta sales declined 13  year over year to  1 02 billion  Outside the United States  the sales of this cancer drug are being hurt due to loss of exclusivity in several countries  However  its U S  sales are being affected by increased competition owing to the entry of immuno oncology agents in the market  The favourable IPR narrows down the chances of generic competition to Alimta  which could have hurt sales more Lilly carries a Zacks Rank  3  Hold   You can see  A better ranked large cap drug company from the same space is Pfizer  Inc   NYSE PFE  holding a Zacks Rank  2  Buy   In 2017  shares of the company have rallied 10 8  5 Trades Could Profit   Big League   from Trump Policies                                                                                                            If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-10-06,Zacks Investment Research,https://www.investing.com/analysis/lilly-wins-favorable-ruling-from-us-pto-in-alimta-dispute-200217478,200217478
172490,394006,LLY,Lilly s  LLY  Verzenio Fails In Phase III Lung Cancer Study,opinion,"The series of setbacks continues for Eli Lilly and Company   NYSE LLY   as the company announced that its phase III JUNIPER study failed to meet the primary endpoint  The study was evaluating Verzenio in advanced non small lung cancer   NSCLC   with KRAS mutation  Shares fell 1  on Tuesday after the announcement Verzenio received approval for treating metastatic breast cancer last month in patients where the disease progressed after platinum based chemotherapy Lilly s shares are up 17 1  so far this year  slightly underperforming the  s gain of 18 3  in the period The JUNIPER study compared Verzenio with Roche Astella Pharma s Tarceva in stage IV lung cancer patients who have progressed after platinum based chemotherapy and may have received an additional systemic therapy  The study did not meet its primary endpoint of overall survival  However  it showed some improvement in secondary endpoints of progression free survival in patients and overall response rate A successful completion of the study would have given Verzenio an edge over Pfizer Inc s   NYSE PFE   Ibrance and Novartis AG s   NYSE NVS   Kisqali  which are only approved for breast cancer Lilly is currently evaluating Verzenio in multiple studies in NSCLC  including a combination therapy with Merck s   NYSE MRK   Keytruda  an anti PD 1 therapy We remind investors that Lilly faced two major setbacks in the past one year  These included a complete response letter from the FDA for its rheumatoid arthritis candidate  baricitinib  in April 2017 and a failed study on Alzheimer s candidate solanezumab in November last year Meanwhile  Lilly is also facing generic competition due to loss of exclusivity for several key drugs including Zyprexa and Cymbalta  Moreover  Alimta is facing competition from immuno oncology agents in the United States Given the recent setbacks  generic competition and absence of drugs nearing approval  Lilly may struggle to maintain the growth pace that it has shown so far this year Eli Lilly and Company Price and Consensus
    Lilly carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-10,Zacks Investment Research,https://www.investing.com/analysis/lillys-lly-verzenio-fails-in-phase-iii-lung-cancer-study-200218232,200218232
172491,394007,LLY,Merck Will Not Seek Approval For CETP Inhibitor Anacetrapib,opinion,"Merck   Co   Inc    NYSE MRK   announced that it is not going ahead with filing the regulatory applications seeking approval for anacetrapib  a cholesteryl ester transfer protein  CETP  inhibitor that it had developed for cholesterol management 
The stock was down more than 1  on Wednesday  Merck s shares have risen 8 3  this year so far compared with an 18 3  increase for the  

 
Detailed data from a large phase III cardiovascular outcomes study  REVEAL  announced in August showed that anacetrapib and a statin reduced the risk of major coronary events  composite of coronary death  myocardial infarction and coronary revascularization  by 9  relative to placebo in patients with atherosclerotic vascular disease who are already receiving an effective cholesterol treatment 
While anacetrapib reduced the risk to 10 8   the same was 11 8  for patients on a placebo and a statin  However  no significant benefit was observed in reducing the risk of ischemic stroke 
Top line data from the study was announced in June 2017 wherein the company said that the study had met the primary endpoint  It was also said that anacetrapib s safety profile was in line with that observed in previous studies with the most significant side effect being the accumulation of anacetrapib in adipose or fat tissue for years after taking the drug 
Merck had clearly said then that it was not sure whether the data was strong enough to seek approval  Merck said it will consider whether to file regulatory applications with the FDA and other agencies after reviewing the results with external experts  It was apprehended by investors that the accumulation of anacetrapib in fat tissues could get in the way of regulatory approval 
Following a thorough evaluation of data and discussions with external experts  Merck decided not to seek approval for anacetrapib as its clinical profile did not support regulatory filings 
We remind investors that three previous experimental CETP inhibitors had failed in their respective studies  CETP inhibitors are designed to raise HDL cholesterol levels or what is known as  good  cholesterol 
In 2015  Eli Lilly   NYSE LLY    terminated the development of its late stage CETP inhibitor  evacetrapib based on the recommendation of an independent data monitoring committee  which suggested that chances of meeting the primary endpoint were low  Back in 2006  Pfizer   NYSE PFE   suspended the late stage development of its CETP inhibitor  torceptrapib  due to safety issues  In 2012  Roche   OTC RHHBY   discontinued the development of its CETP inhibitor  dalcetrapib  due to lack of efficacy 
Merck carries a Zacks Rank  4  Sell  
You can see  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/merck-will-not-seek-approval-for-cetp-inhibitor-anacetrapib-200218466,200218466
172511,394027,LLY,Johnson   Johnson Files SNDA For Label Expansion Of Invokana ,opinion,Johnson   Johnson s   NYSE JNJ   announced that it has submitted a supplemental new drug application  sNDA  to the FDA for the label expansion of its diabetes drug Invokana  to include the cardiovascular indication based on data from a large CANVAS outcomes program The application  to include the indication of risk reduction of cardiovascular events in type II diabetes patients  also applies to Invokana s fixed dose combinations  Invokamet and Invokamet XR The filing was based on data from the CANVAS Program which evaluated Invokana  a SGLT2 inhibitor compared with placebo on CV events in type II diabetes patients who have established cardiovascular  CV  disease or are at risk for CV disease  The primary endpoint of the study was defined as major adverse cardiovascular events  MACE   which included CV death  nonfatal myocardial infarction and nonfatal stroke  The study showed that Invokana was successful in reducing the risks of heart attacks and strokes  The CANVAS program comprised two  nearly identical large outcomes studies called CANVAS and CANVAS R  However  the study also showed that the drug increased the risk of amputations So far this year  Johnson   Johnson s share price has increased 14 7  comparing unfavorably with a gain of 17 6  recorded by the  it belongs to Many pharma companies are working hard to get the labels of their diabetes medicines updated to include their cardiovascular benefits  With death from cardiovascular diseases being significantly higher in adults with diabetes compared to those without diabetes  the addition of positive CV outcomes on labels of diabetes drugs can give sales a shot in the arm Eli Lilly   Company   NYSE LLY   received FDA approval last year to include CV risk reduction data from the EMPA REG OUTCOME study on the label of Jardiance  The updated label including the cardiovascular indication was launched in Jan 2017 while the American Diabetes Association  ADA  has also updated its diabetes treatment guidelines  The European Commission also approved the Jardiance label update for the cardiovascular indication in 2016 In August 2017  Novo Nordisk s   NYSE NVO   Victoza  liraglutide   was approved by the FDA for  a new indication to reduce the risk of major adverse cardiovascular  CV  events in adults with type II diabetes and established CV disease  The FDA s decision was based on the results from the landmark LEADER trial  which demonstrated that Victoza statistically significantly reduced the risk of cardiovascular death  non fatal heart attack or non fatal stroke by 13  versus  placebo  when added to standard of care  with an absolute risk reduction of 1 9  However  in May  Merck   Co   Inc    NYSE MRK   was denied approval by the FDA to include cardiovascular outcomes data from the TECOS study on the labels of its DPP IV inhibitor Januvia  sitagliptin  and other medicines containing Januvia AstraZeneca s Bydureon also failed to reduce cardiovascular risk in a phase IIIb IV cardiovascular outcomes study  EXSCEL Johnson   Johnson Price   Johnson   Johnson carries a Zacks Rank  4  Sell   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-files-snda-for-label-expansion-of-invokana-200216791,200216791
172529,394045,LLY,Narasimhan To Replace Jimenez As Novartis  NVS  CEO In 2018,opinion,"Novartis AG   NYSE NVS   announced that its Chief Executive Officer  CEO   Joseph Jimenez will step down from his position in 2018  Vasant Narasimhan  M D   Global Head of Drug Development and Chief Medical Officer  will replace him effective Feb 1  2018  Narasimhan is a member of the Executive Committee and joined Novartis in 2005 
Narasimhan led the Consumer Health Division and was the Division Head of Novartis Pharmaceuticals 
Novartis is currently going through a transitional stage  In March 2015  Novartis acquired certain oncology products and pipeline compounds from GlaxoSmithKline plc   NYSE GSK   for  16 billion  In exchange  it sold its non influenza Vaccines business to Glaxo for  7 1 billion 
In January 2015  Novartis divested its Animal Health Division to Eli Lilly   NYSE LLY   for approximately  5 4 billion 
The company s blockbuster drug  Diovan  is facing stiff generic competition in the United States  EU and Japan  Gleevec lost exclusivity in the United States in February 2016  The company also lost patent protection for the drug in EU in December 2016 leading to generic competition  The loss of patent protection for these top selling drugs continue to hurt sales 
Of late  the performance of the Alcon business has been quite disappointing due to lower surgical equipments sales as a result of competition faced by intraocular lens and a slowdown in demand for equipment purchases  Despite the restructuring initiatives of the company  the segment s performance remains dismal  In particular  the surgical business is taking longer to turnaround 
Hence  Novartis is mulling strategic options for Alcon which includes retaining the business to separation via capital transactions such as a spin off or an initial public offering  The company will throw light on its plans for Alcon later in 2017 
Last week  the company got a boost when the FDA has approved its breakthrough gene transfer treatment  Kymriah  tisagenlecleucel  suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL   The approval opens up new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r r B cell ALL which comprises approximately 25  of cancer diagnoses among children under 15 years and is the most common cause of childhood cancer in the United States 

Novartis stock has rallied 14 8  in the year so far compared with the  s 12 3  gain 
Zacks Rank   Key Pick
Novartis currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Aduro Biotech  Inc    NASDAQ ADRO   which carries a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates narrowed from  1 44 to  1 32 for 2017 and from  1 33 to  1 24 for 2018 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-09-05,Zacks Investment Research,https://www.investing.com/analysis/narasimhan-to-replace-jimenez-as-novartis-nvs-ceo-in-2018-200211622,200211622
172530,394046,LLY,Choosing Wisely  Aytu BioScience  AYTUD  Stock vs  Lipocine  Inc   LPCN ,opinion,"Both Aytu BioScience and Lipocine  Inc  are advancing novel testosterone replacement therapies  but when placed side by side  which stock may make investors pumped for joy 
As of today  the testosterone replacement therapy market is a hot sector  with companies focused on grabbing as much of the estimated  2 billion market as they can 
Two emerging companies  in particular  are focused on delivering shareholders both near and long term value propositions by advancing their unique TRT products  one of which has recently hit the market  And  while several large pharmaceuticals are well entrenched in the TRT market already  their products  like AndroGel  AbbVie Inc  NYSE ABBV    Axiron  Eli Lilly and Company  NYSE LLY    and Fortesta  Endo International PLC  NASDAQ ENDP    are plagued with the most severe of FDA warnings  the dreaded  
Thus  with the market opportunity open to treatments that may provide a better solution without the known risks of currently marketed TRT products  let s place two peer competitors side by side to determine the chances of either of the two taking a bite out of the current market potential 
Is Aytu BioScience The  Wise Choice  
Although Aytu  OTC AYTUD  has experienced a tough month in August  likely attributable to the recent capital raise  the company has never been stronger from a clinical and marketing perspective  Now  that the split is old news and with shares trading above  3 70 per share  the distractions of the past month may soon get replaced with investor optimism about the company s lead TRT product  Natesto 
Natesto has the potential to become a game changer in the TRT market  Although AYTU is marketing with a much smaller budget than those with already approved therapies on the market  at some point investors believe that wisdom will soon replace big pharma muscle  making Natesto the TRT of choice for prescribing physicians 
And  when looking at published clinical data  the case for a market leading Natesto should not be cast off as pure fodder  In fact  when comparing Natesto to Lipocine s pipeline TRT  Tlando  as well as to a host of other big name drugs  Natesto has demonstrated statistically better efficacy and appears to be a safer and more effective treatment than most all TRT products currently on the market 
Keeping the focus only on both company s TRT products  other promising AYTU pipeline products won t get considered  However  investors should not discount the value inherent to the AYTU pipeline consisting of a male infertility product MiOXSYS and a female sexual wellness product Fiera  and like Natesto may offer significant and compelling market advantages  Okay  so what about Natesto s bid to be best in class 
First off  Natesto is the only nasally administered TRT on the market  And  while some investors may not understand the significance of that issue  users of the product will  Being nasally administered helps to alleviate inadvertent transfer of testosterone  provides consistent and efficient dosing  and offers significant convenience over topically applied products 
Because of these advantages  Natesto is the only currently marketed FDA approved topical TRT product not labeled with the severe FDA required Black Box warning  However  those safety and convenience issues are just the tip of the iceberg in the advantages column  there is more to Natesto to justify its place in the  2 billion TRT market 
It s no accident that Natesto has been called the potential best in class therapy on the market  Coming off of its recent spike of over 300  in new prescription volume  Natesto is grabbing the attention of physicians due to the proven effectiveness of the product  which also leaves behind the severe side effects for patients 
The differentiating factors are apparent  Natesto reduces or eliminates the potential for accidental transfer and does not require a man taking the product to quarantine himself from a female or child to quarantine while the product is applied  Additionally  being a hand s free application  Natesto offers consistent dosing in a measured treatment  and that s an important issue since excessive intake of testosterone is not necessarily a good thing for patients 
Of perhaps higher importance  though  is that Natesto does not significantly reduce levels of LH and FSH hormones in the body  which has caused side effects in patients  including reducing sperm count and decreasing testicle size  that use products like AndroGel  Axiron  Fortesta  and injectable products  Not only does Natesto maintain proper hormone levels in patients  but Natesto also eliminates the potential for users getting hooked on testosterone treatments to maintain healthy testosterone levels 
Natesto excels in other areas of concern as well  demonstrating a better safety profile over long acting gels and injections that have been shown to increase hematocrit concentrations in the patient  That is  the treatments make the patient s blood thicker  which may lead to stroke and cardiac related complications in patients  From a safety perspective  Natesto is best in class  but what about the efficacy 
The safety profile is significant  but it s how Natesto performs that is the real story  Marketed as  testosterone in seconds   Natesto is now the first and only FDA approved intranasal TRT on the market  In a clinical trial  the majority of patients achieved statistically significant improvement in each of the five domains of erectile function  In most cases  the effect on normalizing erectile function occurred within the first thirty days of treatment 
In addition to the benefits mentioned  70  of men in the Natesto pivotal trial said they would switch from their current TRT to treatment with Natesto  Thus  no surprise that Natesto has seen a sharp trend higher in new prescription rates  with new authorizations for the product doubling since May of 2017  Also  90  of men taking Natesto get their testosterone levels back to  normal   which is higher than other TRTs 
Most men taking Natesto see their moods improve as soon as thirty days from starting treatment  The market is estimated to stand at approximately  2 billion currently  and if AYTU maintains the current trend  even a 10  market penetration can return over  200 million in new revenues 
Now that AYTU has roughly only four million shares outstanding  a revenue spike of that magnitude would most likely cause a disproportionate rise higher in company market cap  which currently reflects anemic value considering this potentially game changing product  Adding in the potential of Aytu s other marketed products  the company may be a very wise choice for investors seeking long term value and probability for share price appreciation 
Is Lipocine  Inc  The  Wise Choice  
Lipocine Inc   NASDAQ LPCN  is developing a testosterone product called Tlando  Although the product is not yet on the market  LPCN is the closest peer to Aytu from a market perspective 
LPCN is taking a different approach for Tlando  testing an orally administered dose of testosterone  which the company plans to submit to the FDA for approval in the coming months  Importantly  investors need to know that the FDA has already denied the application for Tlando once  but LPCN is preparing to try for approval once again  relying on similar data from the original rejected application 
A potential drawback for the oral administration of Tlando  is that patients will be required to keep a consistent diet  maintaining certain fat content and calorie intake  And  this is the case for each dosing  If patients fail to adhere to specific dietary requirements  patients are unlikely to see a meaningful rise in testosterone levels  which would be a huge problem and a potential marketing nightmare for the product 
A significantly more adverse scenario is that during the company s FDA studies  a handful of men reached testosterone levels of over 2500 ng dl  which is both extremely high and dangerous 
In addition to potential FDA problems looming for Tlando  the company itself said in a press release that LPCN 1021  Tlando  only  generally met  the pre specified per dose secondary endpoints for twice daily oral administration  In layman s terms  the product either meets the endpoint  or it doesn t  and when the company itself publishes mixed messages  investors should pay close attention 
Also important to note is that the FDA will be highly unappeased if men being treated by Tlando exceed the 2500 ng dl level  making the chances for approval unlikely  And to add insult to potential misery  as far as the FDA is concerned  when endpoints are  generally met   product support is unlikely  Their word s  not mine 
The biggest issue for Tlando compared to Natesto  though  is that when placed side by side  Tlando does not get as many men to normal testosterone levels  Company sponsored studies demonstrate a significant edge in benefit from Natesto  with 90  of males reaching normal testosterone levels  compared to just 70  of patients reaching normal testosterone levels when using Tlando 
The FDA has made it known that at least 75  of men taking the testosterone product must reach normal T levels  so it is difficult to understand how the FDA would even approve Tlando  Additionally  with Tlando known to produce dangerously high testosterone concentrations in some men  the road to approval may be far tougher than even the most optimistic investor may be willing to admit 
The  Wisest Choice  
Comparing the two  AYTU emerges as a clear  wise choice  for investors wanting exposure to the multi billion dollar TRT market  Interestingly  LPCN has a current market cap of roughly  75 million compared to Aytu s approximately  15 million market cap  From both a product and valuation standpoint  the opportunity for growth is substantial in the Aytu BioScience camp  particularly when you consider that there is no regulatory risk for Ayu  The product is already on the market and growing rapidly  Although a slim chance exists for approval for Tlando  the product would most likely get met with considerable marketing difficulties  Conversely  with Aytu s Natesto already approved and marketed  the promise again lay squarely in the Aytu potential 
Now that the TRT comparisons are noted  it s fair to factor in both AYTU s and LPCN s additional pipeline opportunities  While a slight opportunity may have existed for LPCN to present itself in a better light  the company is yet to produce an impressive clinical statistic  Thus  the clear advantages still weigh heavily in Aytu s favor  solidifying their position as the better of the two  With a pipeline focused on making use of a combined market opportunity of more than  11 million dollars in the bank following their recent capital raise  in this case  Aytu BioScience is the superior choice for investors looking to  choose wisely ",2017-09-06,Modest Money,https://www.investing.com/analysis/choosing-wisely-aytu-bioscience-aytud-stock-vs-lipocine-inc-lpcn-200211654,200211654
172531,394047,LLY,Lilly Incyte s Baricitinib Meets Endpoint In Eczema Study,opinion,Eli Lilly and Company   NYSE LLY   and partner Incyte Corporation   NASDAQ INCY   announced that its pipeline candidate  baricitinib  met the primary endpoint in a phase II study in patients with moderate to severe atopic dermatitis  AD   a type of eczema So far this year  Lilly s shares have underperformed the industry  While  the stock has been up 12 9   the  gained 17  Notably  the results showed that after 16 weeks of treatment  61  of patients treated with baricitinib  4 mg  in plus topical corticosteroid  TCS  achieved a 50  or greater improvement in the signs and symptoms of AD versus 37  in patients treated with TCS alone  Thereby  suggesting that baricitinib may have the potential to become an oral treatment option for patients suffering from atopic dermatitis who are unable to achieve adequate control with topical steroids   However  in patients treated with the 2 mg dose group of baricitinib in combination with TCS  the primary endpoint was not statistically different compared to treatment with TCS alone  At four weeks of treatment  68  of patients treated with baricitinib  4 mg  plus TCS combination and 62  of patients treated with baricitinib  2 mg  plus TCS combination witnessed an improvement in the signs and symptoms of AD compared to 16  of patients in TCS alone Therefore  based on the phase II results  Lilly and Incyte plan to initiate a phase III study for atopic dermatitis later this year Baricitinib  a once daily oral medication  is already marketed in the EU by the trade name of Olumiant for the treatment of rheumatoid arthritis  RA  We remind the investors that in the United States the FDA had issued a complete response letter  CRL  for baricitinib s new drug application  NDA  for rheumatoid arthritis in April  In fact  the FDA had asked for additional clinical data to determine the most appropriate doses as well as to further characterize safety concerns across treatment arms In July  Lilly had declared that the NDA resubmission for baricitinib will not occur in 2017 and will be delayed by a minimum of 18 months But  in August  Lilly and Incyte announced that they will re submit the NDA for baricitinib much faster than previously expected  To this end  the NDA is expected to be re submitted in January  2018 Consequently  the company expects the revised submission  which will include new safety and efficacy data  to be classified by the FDA as a Class II resubmission  A decision from the FDA is therefore expected in six months  Importantly  a new clinical study will not be required Markedly  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi s    NYSE SNY   Dupixent Injection was recently launched in the United States for the treatment of adults with moderate to severe AD in March  2017    Currently  the drug is under review in the EU for the same indication Eli Lilly and Company Price    Zacks RankLilly carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/lillyincytes-baricitinib-meets-endpoint-in-eczema-study-200213559,200213559
172546,394062,LLY,Nektar s  NKTR  Shares Fall Post Wider Q2 Loss  Revenues Lag ,opinion,"Nektar Therapeutics    NASDAQ NKTR   shares have declined almost 9  since Aug 8 after the company reported second quarter results  The biotech reported a wider than expected loss while sales missed estimates 
Nektar s second quarter 2017 loss of 39 cents per share was wider than the Zacks Consensus Estimate of a loss of 35 cents  This reported loss was also wider than the year ago loss of 36 cents per share 
Nektar s shares have significantly outperformed the so far this year  The company s shares have surged 46 3  while the industry has registered a decrease of 4 1  

Quarterly revenues rose 5 5  to  34 6 million from the year ago quarter  This increase in revenues can mainly be attributed to the rise in product sales and royalty revenues  However  the top line missed the Zacks Consensus Estimate of  36 million 
Quarter in Detail
The top line comprised product sales  royalty revenues  non cash royalty revenues  license  collaboration and other revenues 
In the second quarter  product sales increased 21 7  to  15 7 million from  12 9 million a year ago  However  non cash royalty revenues decreased 18 5  to  6 6 million 
The company reported royalty revenues of  7 4 million  registering a huge improvement of 111 4  in the second quarter compared with  3 5 million in the year ago quarter  This was mainly thanks to royalty revenues from Movantik sales 
License  collaboration and other revenues came in at  4 8 million  down 42 2  compared with  8 3 million a year ago  This fall in revenues can mainly be attributed to the recognition of  3 2 million  received from Daiichi Sankyo for the sublicense of Onzeald  formerly known as NKTR 102  in Europe in second quarter 2016 
Research and development  R D  expenses climbed 15 1  to  60 3 million  primarily due to investments in pipeline  including key candidates  NKTR 358 and NKTR 181 
General and administrative  G A  expenses were up 45 5  to  16 million  This massive jump can mainly be attributed to a payment of  7 million for settlement of a litigation regarding a cross license agreement with Enzon  Inc   a Florida based pharma company 
Pipeline Update
The most advanced candidate in the company s portfolio is Onzeald  currently under accelerated assessment in the EU for treatment of adults with advanced breast cancer  having brain metastases  However  the company was informed last month by the Committee for Medicinal Products for Human Use  CHMP  that it had adopted a negative opinion for the conditional marketing application for the candidate in the EU  Subsequently  in the same month  the company filed a request for examining the opinion adopted by the CHMP 
Apart from Onzeald  another candidate in the company s immuno oncology portfolio is NKTR 214  A phase I II study evaluating NKTR 214 as a potential combination treatment regimen with Bristol Myers Squibb s   NYSE BMY   Opdivo is underway  During the second quarter  Nektar announced that it has started dosing patients in the trial and plans to enroll up to 260 patients in eight target cancer indications  The company expects to report initial data from the dose escalation part of the study soon 
Notably  in May  Nektar announced a research collaboration agreement with Japanese pharma company  Takeda Pharmaceuticals  to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio 
Last month  Nektar announced that it has entered into a strategic collaboration contract with Eli Lilly and Company   NYSE LLY   to co develop NKTR 358  phase I study ongoing  for treatment of a number of autoimmune and other chronic inflammatory conditions 
2017 Outlook Updated
Nektar raised its revenue outlook for 2017 to account for a  150 million upfront payment it expects to receive from Lilly  The company now estimates revenue in the range of  215  225 million compared with  145  155 million  projected previously 
Driven by the same reason  Nektar also raised its expected cash position for the year ending 2017 with approximately  350 million compared with  225 million  estimated previously Nektar Therapeutics Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
Nektar currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Enzo Biochem  Inc    NYSE ENZ    carrying a Zacks Rank  2  Buy   You can see  
Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 60 days  The company came up with a positive earnings surprise in all the trailing four quarters with an average beat of 55 83   The stock surged 58 3  so far this year 
Will You Make a Fortune on the Shift to Electric Cars   
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-08-11,Zacks Investment Research,https://www.investing.com/analysis/nektars-nktr-shares-fall-post-wider-q2-loss-revenues-lag-200206829,200206829
172547,394063,LLY,Merck s CETP Inhibitor Reduces Cardiovascular Risk By 9 ,opinion,Merck   Co   Inc    NYSE MRK   announced detailed data from a large phase III cardiovascular outcomes study  REVEAL  evaluating anacetrapib  a cholesteryl ester transfer protein  CETP  inhibitor in patients with cardiovascular disease Data from the phase III study showed that anacetrapib and a statin reduced the risk of major coronary events  composite of coronary death  myocardial infarction  and coronary revascularization  by 9  relative to placebo in patients with atherosclerotic vascular disease who are already receiving an effective cholesterol treatment  While anacetrapib reduced the risk to 10 8   the same was 11 8  for patients on a placebo and a statin  However  no significant benefit was observed in reducing the risk of ischemic stroke The detailed data were published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress Merck s shares have risen 7 2  this year so far  comparing unfavorably with an 11 2  increase for the  Top line data from the study was announced in June 2017 wherein the company said that the study had met the primary endpoint  It also said that the CETP inhibitorled to significant reduction in major coronary eventsversus placebo in patients at high risk of cardiovascular events who are already receiving an effective cholesterol treatment  However  the details have only been mentioned now The company funded REVEAL study was conducted in more than 30 000 patients who were taking atorvastatin   a common medicine for lowering  bad  cholesterol or LDL   for a median duration of at least four years It was also said that anacetrapib s safety profile was in line with that observed in previous studies with the most significant side effect being the accumulation of anacetrapib in adipose or fat tissue for years after taking the drug As announced in June  Merck is not sure whether the data are strong enough to seek approval and plans to review the results with external experts  The company will then consider whether to file regulatory applications with the FDA and other agencies We remind investors that three previous experimental CETP inhibitors had failed in their respective studies  CETP inhibitors are designed to raise HDL cholesterol levels or what is known as  good  cholesterol In 2015  Eli Lilly and Company   NYSE LLY   terminated the development of its late stage CETP inhibitor  evacetrapib based on the recommendation of an independent data monitoring committee  which suggested that chances of meeting the primary endpoint were low  Back in 2006  Pfizer  Inc    NYSE PFE   had suspended the late stage development of its CETP inhibitor  torceptrapib  due to safety issues  In 2012  Roche   OTC RHHBY   discontinued the development of its CETP inhibitor  dalcetrapib  due to lack of efficacy However  uncertainty regarding whether or not the company will actually file the data with regulators remains  It is apprehended that the accumulation of anacetrapib in fat tissues could get in the way of regulatory approval Merck carries a Zacks Rank  3  Hold   You can see  4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/mercks-cetp-inhibitor-reduces-cardiovascular-risk-by-9-200210415,200210415
172548,394064,LLY,Lilly Incyte To Re File Baricitinib NDA Faster Than Expected,opinion,Eli Lilly   Company   NYSE LLY   and partner Incyte Corporation   NASDAQ INCY   announced that they will re submit the new drug application  NDA  for its rheumatoid arthritis  RA  drug  baricitinib much faster than previously expected  The NDA is expected to be re submitted in January next year In July  Lilly had said that the NDA resubmission for baricitinib will not occur this year and will be delayed by a minimum of 18 months  At that time  Lilly had said that it will evaluate options for resubmission  including further discussions with the FDA or conducting an additional clinical study In the latest press release  Lilly Incyte said that the matter was discussed with the FDA this month  Lilly expects the revised submission  which will include new safety and efficacy data  to be classified by the FDA as a Class II resubmission  A decision from the FDA is therefore expected in six months  Importantly  a new clinical study will not be required Shares of Incyte were up more than 10  on Wednesday while that of Lilly were up around 2 5   So far this year  Lilly s share price has risen 6 8  compared with an increase of 11 3  for the  The FDA had issued a complete response letter  CRL  for baricitinib earlier this year in April  At that time  the agency had told the companies that it is unable to approve baricitinib NDA in its current form  The FDA had asked for additional clinical data to determine the most appropriate doses as well as to further characterize safety concerns across treatment arms Baricitinib  a once daily oral medication  is already marketed in the EU by the trade name of Olumiant  The drug generated sales of  4 8 million in the second quarter of 2017 and  1 9 million in the first quarter Baricitinib is also being studied in phase II studies for the treatment of atopic dermatitis and systemic lupus erythematosus while the phase III program for psoriatic arthritis is expected to begin next year The RA market is highly crowded given the presence of treatments like Humira and Xeljanz among others  The latest entrant in this crowded market is Sanofi  PA SASY   Inc    NYSE SNY   and Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN    Kevzara  which was launched in the U S  in JuneLilly carries a Zacks Rank  3  Hold   You can see    One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/lillyincyte-to-refile-baricitinib-nda-faster-than-expected-200210806,200210806
172562,394078,LLY,Merck  MRK  Beats On Q2 Earnings And Sales  Keeps 2017 View,opinion,"Merck   Co   Inc    NYSE MRK   reported second quarter 2017 earnings of  1 01 per share  which easily beat the Zacks Consensus Estimate of 87 cents by 16 1   Earnings also rose 8 6  from the year ago period Revenues for the quarter increased 1  year over year to  9 93 billion  beating the Zacks Consensus Estimate of  9 79 billion  Currency movement negatively impacted revenues by 1   Excluding currency impact  sales rose 2  year over year Quarter in DetailThe Pharmaceutical segment posted revenues of  8 76 billion  up 1   up 2  excluding Fx impact  year over year mainly backed by strong sales of PD 1 inhibitor  Keytruda Keytruda brought in sales of  881 million in second quarter 2017  up 51  sequentially and 180  year over year  Sales continued to be driven by launch of new indications globally Keytruda sales in the U S  gained particularly from strong momentum in the new indication of first line lung cancer  approved in Oct 2016  In the last 2 3 months  there were a series of regulatory approvals for the label expansion of Keytruda that should drive sales going forward  Important approvals include that for advanced bladder cancer  advanced microsatellite instability high cancers and first approval as a combination therapy with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   in lung cancer However  earlier this month  a pivotal phase III study of Keytruda in head and neck squamous cell carcinoma failed to meet the primary endpoint of overall survival  Also  three combination studies of Keytruda for multiple myeloma were placed on clinical hold  this month  following reports of death in the Keytruda groups Meanwhile  competition in the immuno oncology market is rising following recent FDA approval of Pfizer  Inc  s   NYSE PFE   Bavencio  avelumab  in Merkel cell carcinoma  MCC  and bladder cancer and AstraZeneca plc s   NYSE AZN   Imfinzi  durvalumab  in bladder cancer Zepatier brought in sales of  517 million  up from  378 million in the previous quarter  attributable to ongoing launches globally Bridion  sugammadex  Injection generated sales of  163 million in the quarter  up 44  year over year  driven by the strong uptake from launch in the U S Meanwhile  combined sales of Remicade  lost exclusivity in Europe and facing stiff biosimilar competition in the region   Cubicin  lost patent protection in the U S  in Jun 2016   Zetia  lost market exclusivity in the U S  in Dec 2016  and Vytorin  lost U S  exclusivity in Apr 2017  declined  830 million in the quarter  Sales of Isentress and the Januvia Janumet  diabetes  franchise also declined in the quarter Remicade sales declined 39  to  208 million in the quarter  Merck markets the branded version of Remicade outside the U S  while Johnson   Johnson  NYSE JNJ  markets the rheumatoid arthritis drug in the U S  This week  Merck launched Renflexis  a biosimilar version of Remicade  in the U S Cubicin sales plunged 71  to  103 million in the quarter  The Zetia Vytorin franchise recorded sales of  549 million  down 45  due to loss of exclusivity for both Zetia and Vytorin The Januvia Janumet franchise recorded sales of  1 51 billion in the quarter  down 8  from the year ago quarter due to lower sales in the U S  due to pricing pressure and lower customer inventory levels Isentress sales declined 17  in the quarter to  282 million  Lower volumes demand due to competitive pressure is hurting sales of Isentress Vaccine sales were primarily driven by increases in Gardasil and Pneumovax vaccines  Vaccine sales were also boosted by the addition of approximately  70 million   40 million from Gardasil  of sales from the terminated vaccine joint venture with Sanofi  PA SASY   Gardasil Gardasil 9 sales climbed 19  to  469 million driven by strong demand in Asia Pacific and the favorable timing of sales in Brazil Merck s Animal Health segment posted revenues of  955 million  up 6   up 7  excluding Fx impact  from the year ago quarter  primarily driven by higher sales of companion animal products Margin DiscussionAdjusted gross margin came in at 77 6   up 190 basis points  bps  quarter attributable to favorable effects of product mix and lower inventory write offsMarketing and administrative  M A  expenses increased 3  to  2 4 billion in the reported quarter  Research and development  R D  spend increased 8  to  1 7 billion in the quarter 2017 GuidanceDespite lowering its expectations for negative impact of currency exchange rates  the company maintained its previously adjusted earnings guidance while raising its sales guidance marginally  The company expects adjusted earnings in the range of  3 76  3 88 including approximately 1 0  negative foreign exchange impact  versus 1 5  previously  Revenues are expected in the range of  39 4 billion    40 4 billion compared with the earlier forecast of  39 1  40 3 billion  including negative currency impact of approximately 1   versus 1 5  previously  Operating expenses are expected to increase year over year at a mid single digit rate compared with a low single digit rate expected previously Our TakeMerck s second quarter earnings were encouraging as the company beat both on sales and earnings  Strong performance of new products like Keytruda  Bridion and Zepatier and higher sales of vaccines and animal health franchises offset lower sales of diabetes franchise and loss of market exclusivity for many drugs Merck s shares have risen 8 2  this year so far  comparing unfavorably with 9 9  increase for the  Merck also announced a cancer collaboration with AstraZeneca to jointly commercialize and develop the latter s PARP Inhibitor  Lynparza  both as monotherapy and in combination studies  for multiple cancer types  Lynparzais presently marketed for advanced ovarian cancer  Meanwhile  Merck will independently develop combination medicines with Lynpraza and Keytruda  For the deal  Merck will pay up to  8 5 billion in total consideration  including  1 6 billion in upfront payments 
Merck also said that a network cyber attack in June disrupted its global operations which could result in a temporary delay in fulfilling orders of some products Merck   Company  Inc  Price  Consensus and EPS Surprise
    Merck carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-27,Zacks Investment Research,"https://www.investing.com/analysis/merck-(mrk)-beats-on-q2-earnings-and-sales,-keeps-2017-view-200204340",200204340
172566,394082,LLY,AbbVie  ABBV  Tops Q2 Earnings   Revenues  Outlook Intact,opinion,"AbbVie Inc    NYSE ABBV   reported better than expected results in the second quarter of 2017  The company surpassed both earnings and sales expectations 
In the year so far  AbbVie s shares have rallied 11 8   thus favorably comparing with the  s increase of 9 9  

The biopharmaceutical company reported second quarter 2017 earnings of  1 42 per share that marginally beat the Zacks Consensus Estimate of  1 40 per share by 1 4   Earnings grew 12 7  year over year 
The company posted revenues of  6 94 billion in the reported quarter  which again narrowly surpassed the Zacks Consensus Estimate of  6 93 billion  Revenues also increased 8  year over year  On operational basis  revenue increased 8 9  
Quarter in Detail
Key drug Humira recorded sales growth of 14 9   on an operational basis  with revenues coming in at  4 72 billion  Sales in the U S  increased 18  to  3 2 billion  Humira sales in the ex U S  market were up 9 1  on operational basis and 5 5  on reported basis to  1 52 billion  Growth across all three major market categories drove the upside despite increasing competition from new classes of drugs as well as indirect biosimilar competition in international markets 
Second quarter net revenue from Imbruvica stood at  626 million  up 42 6  year over year   U S  sales of Imbruvica were  528 million  up 37 6  compared to the year ago figure  AbbVie recorded  98 million of international profit sharing with Johnson   Johnson   NYSE JNJ   
Other products that delivered an impressive performance include Duodopa  showing revenues of  81 million  up 16  on operational and 12 7  on reported basis  Another product called Creon reported revenues of  196 million  up 9 5  on both operational and reported basis 
HCV product Viekira recorded sales of  225 million  down 14 4  sequentially  Sales were also down on operational and reported basis by 45 9  and 46 4   respectively  due to intense pricing and competitive pressure in the HCV market 
Adjusted SG A expenses dipped 2 2  to  1 41 billion while R D expenses escalated 21 6  to  1 21 billion in the quarter  Adjusted operating margin was 44 6  of sales in the reported quarter 
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017  The company maintains its adjusted EPS in the range of  5 44  5 54  thus reflecting year over year growth of 13 9  at the mid point AbbVie Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
AbbVie currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Eli Lilly and Company   NYSE LLY   and Sanofi   NYSE SNY    both carrying a Zacks Rank  2  Buy   You can see  
Eli Lilly s earnings per share estimates inched up from  4 11 to  4 14 for 2017 and from  4 35 to  4 49 for 2018  over the last 30 days  The company s shares have shot up 12 9  so far this year 
Sanofi s earnings per share estimates increased from  3 18 to  3 24 for 2017 and from  3 30 to  3 38 for 2018  over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 5 10   Shares of the company have risen 18 9  so far this year 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-28,Zacks Investment Research,"https://www.investing.com/analysis/abbvie-(abbv)-tops-q2-earnings---revenues,-outlook-intact-200204376",200204376
172567,394083,LLY,Q2 Earnings Fail To Impress Pharma ETF,opinion,"Total earnings for  of the total healthcare market capitalization are up 6  on revenue growth of 4 1   Though earnings growth is weak compared with many other sectors  earnings and revenue beat ratios of 85  and 70   respectively  are particularly encouraging  In fact  healthcare is the fourth sector that surprised investors the most on earnings  trailing aerospace  technology and materials Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on July 18  followed by Eli Lilly and Company   NYSE LLY   and Bristol Myers Squibb Company   NYSE BMY   on July 25 and July 27  respectively  Two other major U S  drug companies   Merck   NYSE MRK   and Pfizer   NYSE PFE     reported on July 28 and August 1  respectively  These industry primes posted solid results with earnings beat while a few lagged on the revenue front Johnson and Johnson Earnings in FocusThe world s biggest maker of healthcare products continued its long streak of earnings beat but narrowly missed the top line estimate  Earnings per share came in at  1 83  4 cents ahead of the Zacks Consensus Estimate and 5 2  higher than the year ago quarter  Revenues grew 1 9  year over year to  18 84 billion but fell shy of the Zacks Consensus Estimate of  18 89 billion Johnson   Johnson raised its full year earnings per share guidance to  7 12  7 22 from  7 00  7 15 and revenue guidance to  75 8  76 1 billion from  75 4  76 1 billion  The Zacks Consensus Estimate was pegged at  7 10 for earnings per share and  75 71 billion for revenues at time of earnings release  JNJ has gained 0 9  to date since its earnings announcement  read    Pfizer Earnings in FocusThe U S  drug giant beat on earnings but missed on revenues  Earnings per share of 67 cents came in couple of cents above the Zacks Consensus Estimate while revenues of  12 9 billion fell shy of our estimate of  13 billion  On an annual basis  earnings per share rose 5  and revenues declined 2  For 2017  Pfizer expects revenues in the range of  52  54 billion and raised the lower end of the earnings per share guidance to  2 54  2 60 from  2 50  2 60  The Zacks Consensus Estimate is correctly pegged at  52 79 billion for revenues and  2 56 for earnings per share  Shares of PFE are up 1 8  since the earnings announcement Merck Earnings in FocusEarnings per share came in at  1 01  surpassing the Zacks Consensus Estimate of 87 cents and improving 8 6  from the year ago quarter  Revenues inched up 1  year over year to  9 93 billion and were above the Zacks Consensus Estimate of  9 79 billion Merck raised its revenue guidance from  39 1  40 3 billion to  39 4  40 4 billion while reiterated earnings per share projection at  3 76  3 88 for this year  The Zacks Consensus Estimate is currently pegged at  40 32 billion for revenues and  3 86 for earnings per share  The stock has lost 0 3  following its earnings announcement Bristol Myers Earnings in FocusBristol Myers reported earnings per share of 74 cents  a penny ahead of our estimate and increased 7  from the year ago quarter  Revenues grew 6  to  5 14 billion and edged past the Zacks Consensus Estimate of  5 07 billion The company raised its low end of earnings per share guidance to  2 90  3 00 from  2 85  3 00 for this year  The Zacks Consensus Estimate at the time of the earnings announcement was pegged at  2 94  Shares of BMY are down 0 9  to date since the earnings announcement  see    Eli Lilly Earnings in FocusEarnings of  1 11 at Eli Lilly outpaced the Zacks Consensus Estimate by seven cents and came in 29  higher than the year ago quarter  Revenues grew 8  to  5 82 billion and beat our estimate of  5 59 billion Like other drug makers  Eli Lilly also raised its 2017 revenue and earnings guidance  It now expects revenues in the range of  22 0  22 5 billion compared with the previous expectation of  21 8  22 3 billion and earnings per share in the range of  4 10  4 20 versus  4 05  4 15 expected previously  The Zacks Consensus Estimate at the time of the earnings release was pegged at  22 18 billion for revenues and  4 12 for earnings per share  Shares of LLY have lost 3 3  since the earnings release ETF AngleThe string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past 10 days  Below  we have highlighted them in detail PowerShares Dynamic Pharmaceuticals Fund   WA PJP  
This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  722 9 million and sees moderate volume of around 70 000 shares a day  The fund charges 57 bps in fees and expenses  Holding 30 stocks  the fund invests around 5  share each in the in focus five firms  The ETF has lost 4 3  over the past 10 days and has a Zacks ETF Rank of 3 or  Hold  rating with a High risk outlook  read    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 41 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are among the top six holding in the basket accounting for a combined 38 2  of total assets  suggesting heavy concentration  The product has  691 9 million in AUM and charges 44 bps in fees and expense  Volume is light as it exchanges about 18 000 shares a day  The fund has shed 4  over the past 10 days and has a Zacks ETF Rank of 2 or  Buy  rating with a High risk outlook SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to the pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  448 7 million  it trades in good volume of around 116 000 shares a day and charges 35 bps in fees a year  In total  the product holds 40 securities with the in focus five firms taking over 4  share each  The product was down 6 6  in the same period and has a Zacks ETF Rank of 2 with a High risk outlook VanEck Vectors Pharmaceutical ETF   V PP  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  Johnson   Johnson takes the top spot in the basket with 9  of assets while Pfizer  Bristol Myers  Merck and Eli Lilly collectively accounts for 20  of assets  The product has amassed  279 3 million in its asset base and trades in a moderate volume of about 119 000 shares a day  Expense ratio comes in at 0 35   The fund has lost 6 3  over the past 10 days  It has a Zacks ETF Rank of 3 with a Medium risk outlook  read     Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-08-06,Zacks Investment Research,https://www.investing.com/analysis/q2-earnings-fail-to-impress-pharma-etf-200205676,200205676
172568,394084,LLY,Celldex  CLDX  Q2 Loss Narrows  Revenues Beat  Shares Up,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   incurred second quarter 2017 loss of 23 cents per share  which was narrower than the Zacks Consensus Estimate of a loss of 25 cents as well as the year ago loss of 32 cents per share  Lower costs and higher revenues led to the narrower loss in the quarter Total revenue in the quarter rose 171 4  year over year to  3 8 million  beating the Zacks Consensus Estimate of  0 82 million  The manufacturing service agreement with the International AIDS Vaccine Initiative led to higher revenues in the quarter Shares of the biotech company rose 4 3  in after hours trading on Tuesday However  the stock has not done too well this year so far  It has declined 27 7  year to date against the 9 7  increase registered by the  Research and development expenses declined 2 7  from the year ago period to  25 0 million  General and administrative spend declined 16 7  to  6 5 million As of Jun 30  2017  Celldex had cash  cash equivalents and marketable securities of  154 0 million compared with  167 0 million as of Mar 31  2017  Celldex expects that this cash plus anticipated proceeds from the future sales of its common stock under the agreement with Cantor will be enough to fund working capital requirements and planned operations through 2018  However  the guidance assumes that Celldex will pay future Kolltan contingent milestones  if any  in stock and not in cash Pipeline UpdateCelldex s most advanced pipeline candidate is glembatumumab vedotin  currently being evaluated for the treatment of triple negative breast cancer  phase IIb   METRIC study  and metastatic melanoma  phase II   Enrolment in the METRIC study is expected to be completed in September this year  with top line data expected in the second quarter of 2018 Data from the phase II metastatic melanoma study of glemba  as a single agent  was presented in June at the annual meeting of the American Society of Clinical Oncology  ASCO   Glemba performed well in the single agent setting with 11  response rate  a 52  disease control rate and a median duration of response of six months in patients who have failed three or four prior lines of therapy  The study also includes two new cohorts  a glembatumumab plus varlilumab arm   data expected by year end   and a glembatumumab plus checkpoint inhibitor arm  including either Bristol Myers Squibb Company s   NYSE BMY   Opdivo or Merck   Co  Inc  s   NYSE MRK   Keytruda Apart from glembatumumab vedotin  Celldex has several promising candidates in its pipeline  including varlilumab and CDX 014  phase I advanced renal cell carcinoma  among others Varlilumab is being evaluated in combination with Bristol Myers Opdivo in a phase II study that includes cohorts in five indications   colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma  Celldex plans to complete enrolment across all cohorts in the phase II portion of the study in the first quarter of 2018  Meanwhile  the company presented data from the phase 1 potion of varlilumab Opdivo combination study at ASCO in June  The data showed that the combination was well tolerated at all tested dose levels without any increased autoimmunity or inappropriate immune activation With the Kolltan acquisition in Nov 2016  Celldex gained rights to two of Kolltan s cancer pipeline candidates  CDX 0158 and CDX 3379  While CDX 0158 is being evaluated in a phase I study for refractory gastrointestinal stromal tumors GIST and other KIT positive tumors  data expected by year end   a phase II study on CDX 3379 in patients with recurrent metastatic head and neck squamous cell cancer who are refractory to Eli Lilly   Company   NYSE LLY   Bristol Myers  Erbitux is expected to be initiated in the fourth quarterCelldex Therapeutics  Inc  Price  Consensus and EPS Surprise
    Celldex carries a Zacks Rank  4  Sell  You can see  More Stock News  Tech Opportunity Worth  386 Billion in 2017          From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future                                                                                                                                                                                                                                                                                                                                                          Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/celldex-cldx-q2-loss-narrows-revenues-beat-shares-up-200206348,200206348
172579,394095,LLY,Is A Beat In The Cards For Eli Lilly  LLY  In Q2 Earnings ,opinion,"We expect Eli Lilly and Company   NYSE LLY   to beat expectations when it reports second quarter 2017 results on Jul 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 2 08  So far this year  Lilly s share price has risen 13 8  compared with an increase of 11 9  for the Zacks classified  industry Lilly s earnings performance has been mixed with earnings missing expectations in two of the last four quarters  while beating in the other two  bringing the average negative surprise to 2 28  Let s see how things are shaping up for this quarter Factors at PlayContinuing the trend of the past few quarters  new products like Trulicity  Cyramza  Taltz and Jardiance are likely to support the top line in the second quarter  While Trulicity sales are being driven by growth in the GLP 1 market and market share gains  Jardiance sales should continue to be driven by increased market share within the growing SGLT2 class In Dec 2016  the FDA approved Jardiance for the CV indication  launched in Jan 2017  while the American Diabetes Association  ADA  updated its diabetes treatment guidelines  At the first quarter call  management had said that since the launch of the CV indication and ADA s addition of Jardiance to its treatment guidelines  Jardiance new to therapy volume has increased by 75   This is expected to translate into higher sales However  sales of Alimta  Cymbalta and Zyprexa are expected to continue to decline due to the loss of exclusivity  Cymbalta has lost exclusivity in Europe and Canada  Zyprexa in Japan and Alimta in several countries outside U S  Also  lower demand in the U S  due to competitive pressure mainly from immuno oncology agents is hurting Alimta s U S  sales Nevertheless  older products like Humalog  Trajenta and Forteo should continue to do well Newly launched drugs like Basaglar and Lartruvo should add to the top line  Basaglar   Lilly and partner Boehringer Ingelheim s follow on insulin to Sanofi s   NYSE SNY   blockbuster drug  Lantus   was launched in the U S  in mid Dec 2016  Lartruvo  olaratumab  was launched in the U S  and the EU for soft tissue sarcoma in the fourth quarter of 2016  Both the new drugs are expected to generate decent revenues in the to be reported quarter Another new drug  Olumiant has been launched in select European countries and should add to the top line in the second quarter  The drug is under review in the U S   In Apr 2017  Lilly received a complete response letter  CRL  from the FDA for baricitinib  The FDA requires additional clinical data  which will delay the approval of the drug  An update on the same is expected on the conference call Animal Health segment sales suffered last quarter due to global competitive pressure  It remains to be seen if trends improve this quarter What Our Model IndicatesOur proven model shows that Lilly is likely to beat on earnings because it has the right combination of the two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  The   which represents the difference between the Most Accurate estimate   1 04 per share  and the Zacks Consensus Estimate   1 03 per share   is  0 97   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Lilly has a Zacks Rank  2  The combination of Lilly s favorable Zacks Rank  2 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Eli Lilly and Company Price and EPS Surprise
    Other Stocks to ConsiderA couple of stocks in the large cap pharmaceuticals sector that also have a positive Earnings ESP and a favorable Zacks Rank are Novo Nordisk  CO NOVOb  A S   NYSE NVO    scheduled to release results on Aug 9  has an Earnings ESP of  7 14  and a Zacks Rank  3  You can see  Pfizer  Inc    NYSE PFE   has an Earnings ESP of  1 54  and a Zacks Rank  3  The company is scheduled to release results on Aug 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-eli-lilly-(lly)-in-q2-earnings-200202052,200202052
172580,394096,LLY,Merck s Biosimilar Insulin Gets Tentative FDA Approval ,opinion,"Merck   NYSE MRK   announced that the FDA has granted a tentative approval to Lusduna Nexvue  the company s biosimilar version of Sanofi s   NYSE SNY   Lantus  insulin glargine  for treatment of people with type I and type II diabetes  Lusduna Nexvue delivers insulin in a pre filled dosing device 
Note that the candidate was formerly known as MK 1293  The FDA has granted a provisional approval to its trade name Lusduna Nexvue  to be used once the product is made available in the U S 
Merck s shares have underperformed the  so far this year  The stock has gained 6 9  compared with the broader industry s increase of 13 2  

Though Lusduna met all the regulatory safety and efficacy standards  the approval is tentative due to an ongoing litigation with Sanofi  PA SASY   The final approval of Lusduna is subject to a resolution of the Sanofi litigation 
In September last year  Sanofi sued Merck for patent infringement on Lantus  The litigation automatically invoked a stay on the final FDA approval of Lusduna for up to 30 months  or in the event  a court rules in favor of Merck  whichever is sooner  Notably  Lantus has been a major contributor to the Sanofi s top line having accounted for 14 1  of the total sales in 2016 
However  the company considers the conditional approval as a significant milestone as it is advancing the candidate another step closer to the market 
We remind investors that Merck is developing Lusduna in collaboration with Samsung  KS 005930  Bioepis  Under the agreement terms  Merck is responsible for clinical development  manufacturing and commercialization  while Bioepis is partially funding the development 
Currently  an application for regulatory approval of Lusduna for treatment of patients with type I and type II diabetes is under review in the EU 
We remind investors that Eli Lilly and Company   NYSE LLY   is already marketing a  follow on  insulin glargine product  Basalgar  since Dec 2016 
In a separate press release  Merck announced a collaboration with Pfizer   NYSE PFE   modernization of pharmaceutical packaging with the introduction of corning valor glass that enhances the storage and delivery of drug formulations Merck   Company  Inc  Price

   Zacks Rank
Merck currently carries a Zacks Rank  2  Buy   You can see  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-07-21,Zacks Investment Research,https://www.investing.com/analysis/merck's-biosimilar-insulin-gets-tentative-fda-approval-200202746,200202746
172586,394102,LLY,Key Takeaways From Lilly s  LLY  Q2 Call  Baricitinib  Cancer Pipeline,opinion,"Yesterday  big pharma player  Eli Lilly and Company   NYSE LLY   reported better than expected second quarter results and raised its outlook for the year  However  shares were down 3  with investors focusing on the company s update regarding its investigational rheumatoid arthritis  RA  treatment  baricitinib Here is a look at a few key takeaways from Lilly s conference call How Did Key Drugs Perform Lilly s second quarter 2017 revenues increased 8  from the year ago quarter to  5 8 billion  topping the Zacks Consensus Estimate of  5 6 billion  New products like Trulicity  Taltz  Basaglar  Jardiance  Lartruvo and Cyramza performed well and drove volume growth  Late life cycle products like Cialis and Forteo drove price growth Alimta continued to face significant competitive headwinds while Zyprexa  Cymbalta  Evista  Strattera and Axiron were impacted by loss of exclusivity  Cialis was also affected by lower volume in the U S  reflecting a decline in the overall erectile disorder  ED  market as well as the presence of generics Animal health revenue declined during the quarter reflecting market access pressure and competitive pressure in cattle and swine  Read more    Baricitinib Facing Significant DelayLilly announced that there will be a delay of at least 18 months in the resubmission of the regulatory application for baricitinib  which is being developed in collaboration with Incyte   NASDAQ INCY    This means the resubmission will not take place this year The FDA had issued a complete response letter  CRL  for baricitinib earlier this year in April  At that time  the agency had told the companies that it is unable to approve baricitinib  a once daily oral medication for the treatment of moderate to severe RA  in its current form  The FDA had asked for additional clinical data to determine the most appropriate doses as well as to further characterize safety concerns across treatment arms Although Lilly disagrees with the FDA s conclusions and believes the comprehensive clinical data supports a positive benefit risk profile  the company will enter into discussions with the FDA to determine the kind of study needed to better define the benefit risk profile of baricitinib Meanwhile  Lilly and Incyte have plans to explore baricitinib for other indications with a late stage study in psoriatic arthritis slated to commence next year while studies in atopic dermatitis and lupus continue  Phase II atopic dermatitis data will be presented at a scientific forum by year end We note that baricitinib was approved in the EU under the trade name Olumiant in Feb 2017  The European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  recently agreed that the label should be updated to include a precaution for patients who have risk factors for deep venous thrombosis  DVT  and pulmonary embolism  PE   Oncology R D StrategyLilly provided an in depth look at its oncology R D strategy  The company s strategy involves building on key treatments like Cyramza  Lartruvo and abemaciclib as foundational agents while it will focus on developing new standard of care changing therapies that clear a very high bar and will span a variety of mechanisms including immune oncology  For now  Lilly will focus on seven candidates for priority internal development and three additional candidates  Ang2 MAb  CSF1R MAb and merestinib  with study data pending  The rest of the molecules in the pipeline will be partnered The seven molecules that have made it to Lilly s priority development list include abemaciclib which is already under FDA review  TIM 3 MAb  PD L1 MAb  Erk 1 2 inhibitor  TGFb RI KI  PI3 mTOR inhibitor and prexasertib  About 10 molecules are earmarked for external or partnered development    while three of these assets are owned by third parties  Lilly is looking for partners for the remaining seven    a FGFR 3 ADC  ralimetinib  a FGFR inhibitor  a notch inhibitor  galunisertib  a CXCR4 peptide antagonist and emibetuzumab Bottom LineAlthough Lilly delivered a  beat and raise  quarter  the company s results got overshadowed by the baricitinib update  Investors were disappointed by the delay in the resubmission of the baricitinib regulatory filing in the U S  with the company saying that there could be a minimum delay of 18 months  With several products facing generic competition and competitive pressure increasing  Lilly needs to focus on bringing new products to market  The company s decision to prioritize its oncology pipeline makes sense  Lilly is a Zacks Rank  2  Buy  stock    you can see   Year to date  Lilly s shares have gained 11 8   just about topping the  11 2  rally 
Watch out for earnings reports from other large cap pharma companies like Merck   Co   Inc    NYSE MRK   and Pfizer Inc    NYSE PFE    Merck  a Zacks Rank  2 stock has a pretty good earnings track record having surpassed expectations in each of the last four quarters with an average surprise of 4 36   Merck will be reporting Q2 results on Jul 28 Pfizer s track record is mixed with the company topping expectations in two of the last four quarters  Pfizer  which will be reporting on Aug 1  has a positive  of 1 54  for the second quarter The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/key-takeaways-from-lilly's-(lly)-q2-call:-baricitinib,-cancer-pipeline-200203573",200203573
172598,394114,LLY,Incyte   Lilly s Olumiant Gets Marketing Approval In Japan ,opinion,"Incyte Corporation   NASDAQ INCY   and partner Eli Lilly and Company   NYSE LLY   announced that Japan s Ministry of Health  Labor and Welfare  MHLW  granted marketing approval for Olumiant  baricitinib  2 mg and 4 mg tablets  The drug will be used for treating rheumatoid arthritis  RA   including the prevention of structural injury of joints  in patients with inadequate response to standard of care therapies Olumiant demonstrated significant improvement in the signs and symptoms of RA compared to standard of care therapies The approval triggers a  15 million milestone payment from Eli Lilly to Incyte  which the latter expects to recognize in the third quarter of 2017 The move is likely to boost sales of Olumiant  Approximately 700 000 800 000 people suffer from RA and women are three times more likely to be affected than men Thus  there is substantial demand for such drugs The approval provides Incyte with a valuable source of revenues  given the potential for milestones and royalties under the company s license agreement with Eli Lilly  Olumiant is being studied for additional indications as well   atopic dermatitis  phase IIa  and systemic lupus erythematosus  phase II   We remind investors that both Lilly and Incyte announced an exclusive worldwide license and collaboration agreement in Dec 2009 for the development and commercialization of Olumiant and certain follow on compounds for patients with inflammatory and autoimmune diseases  The drug was approved in the EU in Feb 2017 However  in Apr 2017  Incyte received a Complete Response Letter  CRL  from the FDA for Olumiant  The FDA requires additional clinical data  which will delay the approval of the drug  The FDA had earlier extended the review period as well  The company suffered a major setback due to the delay Incyte s shares have rallied 25 5  year to date  while the Zacks classified  industry gained 6 4  Incyte s growth driver Jakafi continues to drive growth  The increase in Jakafi sales is driven by patient demand and is expected to boost revenues  While most of the demand is due to a larger established patient base in myelofibrosis  polycythemia vera is also expected to be a major long term driver of Jakafi growth  While Incyte markets the drug in the U S   it is marketed by Novartis   NYSE NVS   as Jakavi outside the U S  An approval of Olumiant in other countries will boost Incyte s top line We note that Incyte has collaborated with Merck   NYSE MRK   among others for another candidate in its pipeline  epacadostat 
Zacks Rank
Incyte currently carries a Zacks Rank  3  Hold   You can see  
5 Trades Could Profit  Big League  from Trump Policies 
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-04,Zacks Investment Research,https://www.investing.com/analysis/incyte---lilly's-olumiant-gets-marketing-approval-in-japan-200199037,200199037
172599,394115,LLY,Sanofi Versus AstraZeneca  Large Cap Pharma Stock Faceoff,opinion,After being battered by the drug pricing controversy in 2016  the pharma biotech sector has turned around this year  The first half has been pretty strong for companies in this space The sector does have its share of challenges in the form of rising competition  high profile pipeline setbacks  slowdown in growth of mature products and loss of exclusivity for certain key drugs  The drug pricing issue remains a headline risk this year too Nonetheless  strong performance of newer drugs  evolving pipelines  impressive clinical trial results  new drug approvals  continued strong performance of legacy products and rising demand are some of the factors that promise a sustained recovery in the sector Within this broad sector  one of the better performing industries is  Large Cap Pharmaceuticals  which includes some of the world s largest and most recognizable drug making companies In this sector  Sanofi   NYSE SNY     headquartered in Paris  France   and AstraZeneca plc   NYSE AZN     based in Cambridge  the United Kingdom   have been attracting attention this year Both stocks carry a Zacks Rank  2  Buy   You can see  Meanwhile  the Large Cap Pharmaceutical Industry is currently ranked 53rd out of 265 industries by Zacks  placing it in the top 20  of all industries  While they share the same Zacks Rank and operate in the same strong industry  the stocks differ from each other in what they offer to investors  These stocks also look well placed to enjoy a good run going forward New Drugs Contributing WellAstraZeneca boasts a strong product portfolio and is one of the key players in the global cardiovascular market  Though its key products like Crestor and Nexium have been facing declining sales due to generic competition  newer drugs like antiplatelet treatment Brilinta  Lynparza  ovarian cancer   Farxiga Forxiga  type II diabetes  Movantik Moventig  opioid induced constipation  and Tagrisso  lung cancer  are off to an encouraging start  AstraZeneca is looking for further label expansions for these drugs Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including cardiovascular diseases  diabetes  oncology  and CNS disorders  among others  Sanofi also possesses one of the world s leading vaccine operations Sanofi has also been progressing with new product launches  Among the recently approved drugs  Lemtrada and Aubagio  Sanofi s oral treatment for relapsing forms of multiple sclerosis  MS   are generating strong sales  We believe that both Lemtrada and Aubagio possess significant commercial potential Key Drug Approvals this YearImportant drugs of Sanofi and AstraZeneca were approved launched this year  Sanofi s Rheumatoid arthritis  RA  drug Kevzara was approved in the U S   Canada and the EU this year  Meanwhile  Dupixent dupilumab was approved by the FDA for treating atopic dermatitis in Mar 2017 and is now available to adult patients in the U S  The drug is under review in the EU for the same indication  Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  was launched in the U S  in Jan 2017 and is expected to be launched in Europe later this year These new drugs have the potential to boost Sanofi s sales in the next few years  Particularly  weare optimistic on sales prospects of Dupixent  which could prove to be an important growth driver for the company  Dupixent is being evaluated for several other indications like asthma and nasal polyposis For AstraZeneca  key pipeline candidate  Imfinzi  durvalumab  was approved in the U S  for treatment experienced urothelial carcinoma  UC  in May 2017  Meanwhile  Imfinzi  durvalumab  is being evaluated for multiple cancers  either alone or in combination with other regimens   including phase III trials in first line urothelial cancer  NSCLC  small cell lung cancer and head and neck squamous cell carcinoma  HNSCC  among others  Imfinzi is expected to be a key top line growth driver for AstraZeneca in the long term Pipeline MattersFor any pharma or biotech company  the pipeline is of utmost importance and plays an important role in investment decisions  So  it always makes sense to take a look at a company s pipeline Sanofi is focusing its R D efforts on key technologies and diseases  which hold greater commercial potential  At the end of Apr 2017  Sanofi s pipeline comprised 46 pharmaceutical new molecular entities and vaccine candidates in development  of which 13 were in phase III studies or under regulatory review  Promising candidates include sotagliflozin  SGLT 1 and SGLT 2 inhibitor for diabetes  and isatuximab  multiple myeloma and acute lymphoblastic leukemia  Promising candidates in AstraZeneca s pipeline or under regulatory review include benralizumab  asthma and chronic obstructive pulmonary disease  COPD   ZS 9  hyperkalemia  tralokinumab  asthma   anifrolumab  systemic lupus erythematosus and lupus nephritis   roxadustat  anemia in patients with chronic kidney disease  and AZD3293  Alzheimer s disease   AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline  The company s target is to launch at least six new oncology medicines between 2014 and 2020  Immuno oncology  a therapeutic area  is presently attracting a lot of interest and represents huge commercial potential Meanwhile both the companies have been streamlining their business by pursuing regular accretive business development deals  Sanofi has collaboration agreements with companies like Regeneron Pharmaceuticals  Inc    NASDAQ REGN   while AstraZeneca is pursuing co development deals with companies like Nektar  Eli Lilly   Company   NYSE LLY   and others to boost its pipeline  The companies have also made strategic acquisitions  both big and small  from time to time Meanwhile  both the companies are working on reducing the impact of genericization on key products by trimming their cost structure to drive operational efficiency Share Price  Estimate Revisions and ValuationIn terms of share price  both stocks have moved more or less in tandem and therefore it is difficult to single out a winner  As discussed  both stocks have risen so far this year  This comes after share price declines witnessed in 2016 Shares of AstraZeneca have risen 25  so far this year  outperforming a gain of 12 1  for the Zacks classified  industry Sanofi has risen 18 2  this year  also outperforming the Large Cap Pharma sector Sanofi s earnings estimates for 2017 have gone up 3 3  while that for 2018 have moved up 1 2  in the past 60 days  Sanofi s earnings performance has also been pretty impressive  with steady positive surprises  The average earnings beat for the last four quarters is 5 10  AstraZeneca s earnings estimates for 2017 went up 0 5  while that for 2018 moved up 3 3  in the past 60 days  Its earnings performance has also been pretty impressive  with consistent positive surprises  The average earnings beat for the last four quarters is 142 6  However  when we compare the stocks  valuation on a P E basis  Sanofi holds an edge A study of AstraZeneca s forward P E  F12M basis  multiple reflects that the stock is quite overvalued  The multiple currently stands at 18 23  stretched when compared to its own range  median of 18 20   Comparison with the Zacks categorized Large Cap Pharma industry is unfavorable as the current P E  F12M basis  for the industry is 15 96 for the last three months Sanofi  on the other hand  is trading at a discount using the same forward P E  F12M basis  multiples  The multiple currently stands at 14 76 for Sanofi  representing a discount to that of the Large Cap Pharma industry  The stock is also attractively valued when compared to its own range  median of 15 10  AstraZeneca is also overvalued when compared with the S P 500 P E  F12M basis  multiple of 17 88 while Sanofi is undervalued compared to the same A Neck and Neck Contest Without doubt  both Sanofi and AstraZeneca have delivered the goods this year and choosing between the two is a tall order  Both have their share of strengths and weaknesses  Both Sanofi and AstraZeneca are facing generic competition and pricing pressure for some products  The diabetes businesses of both the companies are having a tough time due to competitive pressure  They have also bitter experiences in the form of pipeline and regulatory setbacks  So we can say that the two companies stand on an equal footing to take on the second half Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-07-05,Zacks Investment Research,https://www.investing.com/analysis/sanofi-versus-astrazeneca:-large-cap-pharma-stock-faceoff-200199532,200199532
172607,394123,LLY,Novo Nordisk s Victoza Gets FDA Panel Nod For Label Expansion,opinion,Novo Nordisk  CO NOVOb  A S   NYSE NVO   announced that the Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  of the FDA voted 17 2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes  The positive panel recommendation bring Novo Nordisk a step closer to get the cardiovascular indication included on the label of its key top line driver Victoza Victoza is a once daily human glucagon like peptide 1  GLP 1  analogue approved for adult type II diabetes  The drug is one of the main revenue contributors for the company Novo Nordisk s share price shows that the company has outperformed the Zacks classified  industry year to date  The stock rallied 20 4  compared with the industry s gain of 12 4  We note that the Advisory Committee s favorable vote was based on data from the LEADER cardiovascular outcomes trial  which involved more than 9 300 people with type II diabetes at high risk of major cardiovascular events  The study evaluated the cardiovascular benefit of Victoza over a period of up to 5 years in  The study compared the addition of either Victoza or placebo to the standard of care  with the Victoza arm meeting the primary endpoint of non inferiority  Results also demonstrated superiority of Victoza in a statistically significant reduction of cardiovascular risk As instances of death due to cardiovascular diseases are significantly higher in adults with diabetes compared with those without diabetes  the addition of positive cardiovascular outcomes on the label of the diabetes drug can give sales a boost The supplemental new drug application for Victoza to include the cardiovascular indication was submitted to the FDA in October 2016 and regulatory feedback in the US is expected in the third quarter of 2017 We remind investors that Eli Lilly and Company   NYSE LLY   received FDA approval last year to include cardiovascular risk reduction data from the EMPA REG OUTCOME study on the label of Jardiance  The updated label including the cardiovascular indication was launched in Jan 2017 while the American Diabetes Association  ADA  has also updated its diabetes treatment guidelines  The European Commission also okayed the Jardiance label update for the cardiovascular indication in 2016 However  in Apr 2017  Merck   Co   Inc    NYSE MRK   was denied approval by the FDA to include cardiovascular outcomes data from the TECOS study on the labels of its DPP IV inhibitor Januvia  sitagliptin  and other medicines containing Januvia AstraZeneca s   NYSE AZN   Bydureon also failed to reduce cardiovascular risk in a phase IIIb IV cardiovascular outcomes study EXSCEL  Novo Nordisk A S Price and Consensus    Zacks RankNovo Nordisk currently carries a Zacks Rank  2  Buy   You can see Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-06-20,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk's-victoza-gets-fda-panel-nod-for-label-expansion-200196658,200196658
172611,394127,LLY,Why You Should Add Novo Nordisk Stock To Your Portfolio,opinion,Headquartered in Bagsvaerd  Denmark  Novo Nordisk  CO NOVOb    NYSE NVO   is healthcare company and a with leadership in the global diabetes market  It looks like a great stock to buy now  Here are some reasons for the same Favorable Rank and Solid VGM Score  Novo Nordisk holds a Zacks Rank  2  Buy  and a favorable  of  A   Back tested results show that only stocks with a VGM Style Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  offer the best upside potential  You can see  Rising Estimates and Share Price Movement  Earnings estimates for Novo Nordisk moved up 0 9  and 0 8  for 2017 and 2018  respectively  over the past 30 days  Also  the company s earnings performance has been pretty impressive  as it has delivered positive surprises in three of the trailing four quarters  In fact  the average earnings beat over the last four quarters is 3 15  Although the company s share price declined last year  the same rose so far this year  Shares of Novo Nordisk have rallied 21 9  this year so far while the Zacks classified  industry gained 13 2  Strong Foothold in the Diabetes Market  Novo Nordisk has a strong presence in the Diabetes care market with a global value market share of 27   Top line is being consistently driven by strong sales within diabetes and obesity care with the main growth coming from Victoza  Tresiba  NovoRapid and Saxenda Victoza  a once daily human GLP 1 analogue is expected to continue to be a significant contributor to the company s top line  Earlier this week  the company announced that the Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  of the FDA voted 17 2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes  The positive panel recommendation brings Novo Nordisk a step closer to get the cardiovascular indication included on the label of Victoza  Though the FDA is not bound by the Advisory Committee s decision   it usually does follow it  The addition of positive cardiovascular outcomes data on the label of the diabetes drug can give sales a boost New Products and Others Nearing Approval  The company has recently received approvals for many new drugs The company s once daily single injection combination of Tresiba and Victoza   IdegLira which is already marketed in Europe has received FDA approval and will be launched in the U S  soon Rebinyn  Coagulation Factor IX  Recombinant   GlycoPEGylated  for the treatment of adults and children with hemophilia B was approved in the U S  and granted marketing authorization in Europe this year These drugs should contribute to the company s revenues going ahead Also included are Fiasp  fast acting insulin aspart  which is already marketed in the EU and a regulatory filing has been made in the U S  Regulatory applications have been filed in the U S   EU and Japan for another candidate semaglutide  diabetes  Novo Nordisk also has a strong pipeline  primarily focusing on therapeutic proteins within insulin  GLP 1  blood clotting factors and human growth hormone  We are encouraged by the company s efforts to develop new treatments for diabetes  which is its core area of expertise ConclusionNovo Nordisk faces its share of challenges such as generic competition for some key drugsThe diabetes market is highly crowded given the presence of companies like Eli Lilly and Company   NYSE LLY   which has a strong portfolio of diabetes treatments including Trulicity  GLP 1   Jardiance   Some other companies include Merck   Co   Inc    NYSE MRK   consisting of products like Januvia and Janumet and Sanofi s   NYSE SNY   Lantus However  Novo Nordisk s top line should be driven by its diabetes drugs  Victoza and Tresiba   Further   the addition of positive cardiovascular outcomes data on the label of the Victoza can give sales a boost Novo Nordisk A S Price and Consensus    Looking for Ideas with Even Greater Upside  Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-add-novo-nordisk-stock-to-your-portfolio-200197009,200197009
172612,394128,LLY,Novartis Cardiovascular Drug Positive  NSCLC Drug Approved,opinion,"Shares of Novartis AG   NYSE NVS   were up after the company announced positive top line results from the global phase III study  CANTOS  The study evaluated the efficacy  safety and tolerability of ACZ885  canakinumab  in combination with standard of care in patients with a prior heart attack and inflammatory atherosclerosis In fact  shares touched a fresh 52 week high of  86 90 on the results  The study met the primary endpoint  The candidate demonstrated canakinumab when used in combination with standard of care reduced the risk of major adverse cardiovascular events  MACE   Novartis will present the full data later in 2017 The positive results provided a boost to shareholders sentiments as its other cardiovascular candidate RLX030  serelaxin  did not meet its primary endpoints Novartis also announced that the FDA has approved Tafinlar  dabrafenib  in combination with Mekinist  trametinib  for the treatment of patients suffering from metastatic non small cell lung cancer  NSCLC  whose tumors express the BRAF V600E mutation The combination was granted Breakthrough Therapy designation in Jul 2015 for the treatment of advanced or metastatic BRAF V600E mutation positive NSCLC patients who have received chemotherapy previously 60  of treatment na ve and previously treated patients with BRAF V600E mutant metastatic NSCLC responded to Tafinlar   Mekinist in a pivotal study We note that the Tafinlar   Mekinist combination was approved by the European Commission  EC  in Mar 2017 for the treatment of patients with BRAF V600 advanced mutation positive NSCLC We remind investors that the combination of Tafinlar and Mekinist is already approved in the U S  and EU for the treatment of patients with unresectable or MM who have a BRAF V600 mutation  Both Tafinlar and Mekinist are also approved individually as single agents for the treatment of patients with unresectable or metastatic melanoma Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Co    NYSE LLY    Both Tafinlar and Mekinist were acquired from Glaxo Novartis also reported that ophthalmology candidate RTH258  brolucizumab  6 mg met the primary and key secondary endpoints in two phase III studies  HAWK and HARRIER  The studies enrolled more than 1 800 patients with neovascular age related macular degeneration  nAMD  in the trials  The primary and key secondary efficacy endpoints were non inferiority of RTH258 to Regeneron Pharmaceuticals s   NASDAQ REGN   Eylea in mean change in best corrected visual acuity  BCVA  from baseline to week 48  and average mean change over the period of week 36 48  respectively Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
The Best   Worst of Zacks
Today you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-06-25,Zacks Investment Research,"https://www.investing.com/analysis/novartis-cardiovascular-drug-positive,-nsclc-drug-approved-200197520",200197520
172617,394133,LLY,Merck s CETP Inhibitor Reduces CV Risk In Phase III Study,opinion,"Merck   Co   Inc    NYSE MRK   announced that a large late stage cardiovascular outcomes study  REVEAL  evaluating anacetrapib  a cholesterol lowering medicine  met the primary endpoint by reducing cardiovascular  CV  risk 
Top line data from the phase III study showed that anacetrapib  a cholesteryl ester transfer protein  CETP  inhibitor  led to significant reduction in major coronary events  composite of coronary death  myocardial infarction  and coronary revascularization  versus placebo in patients at high risk of cardiovascular events who are already receiving an effective cholesterol treatment  Anacetrapib s safety profile was in line with that observed in previous studies with the most significant side effect being the accumulation of anacetrapib in adipose or fat tissue for years after taking the drug 
Merck s shares are up 11 3  year to date  comparing unfavorably with an increase of 14 9  witnessed by the Zacks classified  industry 

The company funded REVEAL study was conducted in approximately 30 000 patients who were taking atorvastatin   a common medicine for lowering  bad  cholesterol  or LDL   for a median duration of at least four years 
Detailed results from the study are expected to be presented at a medical conference in Europe in August  Merck is not sure whether the data are strong enough to seek approval and plans to review the results with external experts  The company will then consider whether to file regulatory applications with the FDA and other agencies 
The positive results from the REVEAL study were a surprise because three previous experimental CETP inhibitors had failed  CETP inhibitors are designed to raise HDL cholesterol levels or what is known as  good  cholesterol 
 In 2015  Eli Lilly and Company   NYSE LLY   terminated the development of its late stage CETP inhibitor  evacetrapib based on the recommendation of an independent data monitoring committee  which suggested that chances of meeting the primary endpoint were low  Back in 2006  Pfizer  Inc    NYSE PFE   had suspended the late stage development of its CETP inhibitor  torceptrapib  due to safety issues  Then in 2012  Roche   OTC RHHBY   discontinued the development of its CETP inhibitor  dalcetrapib  due to lack of efficacy 
However  uncertainty regarding whether or not the company will actually file the data with regulators has raised investor concern  It is apprehended that the accumulation of anacetrapib in fat tissues could get in the way of regulatory approval 
Merck carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/merck's-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study-200198018,200198018
172622,394138,LLY,Novartis Gets EC Nod For Lung Cancer Drug s Label Expansion ,opinion,"Novartis AG   NYSE NVS   announced that the European Commission has approved a label expansion of oncology drug Zykadia The drug is now approved for the first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors are anaplastic lymphoma kinase  ALK  positive An approval was on the cards as the Committee for Medicinal Products for Human Use  CHMP  had rendered a positive opinion on the same The first line approval of Zykadia is based on positive results from an open label  randomized multicenter global phase III trial ASCEND 4  The results showed that the study met its primary endpoint and demonstrated a 45  reduction in the risk of disease progression in the Zykadia arm  compared with the chemotherapy arm  Patients treated with first line Zykadia had a median progression free survival  PFS  of 16 6 months compared with 8 1 months for patients treated with standard first line pemetrexed platinum chemotherapy with pemetrexed maintenance We note that Zykadia is already approved for the treatment of adult patients with ALK  advanced NSCLC previously treated with crizotinib  The FDA  also approved the expanded use of the drug for the same in May 2017 As per estimates  lung cancer causes more deaths than colon  breast and prostate cancer combined  Approximately 1 8 million new cases of lung cancer are diagnosed every year Last week  the FDA approved Tafinlar  dabrafenib  in combination with Mekinist  trametinib  for the treatment of patients suffering from metastatic NSCLC whose tumors express the BRAF V600E mutation  We note that the Tafinlar   Mekinist combination was approved by the European Commission in Mar 2017 for the treatment of patients with BRAF V600 advanced mutation positive NSCLC We remind investors that the combination of Tafinlar and Mekinist is already approved in the U S  and EU for the treatment of patients with unresectable or MM who have a BRAF V600 mutation  Both Tafinlar and Mekinist are also approved individually as single agents for the treatment of patients with unresectable or metastatic melanoma Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Co    NYSE LLY    Both Tafinlar and Mekinist were acquired from Glaxo Merck s   NYSE MRK   Keytruda is also approved for the first line treatment of patients with metastatic NSCLC whose tumors have high PD L1 expression as determined by an FDA approved test  with no EGFR or ALK genomic tumor aberrations Novartis has outperformed the Zacks classified industry in the last six months  The stock has rallied 17 0  compared with the  industry s gain of 13 8  Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold  
You can see  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-ec-nod-for-lung-cancer-drug's-label-expansion-200198331,200198331
172651,394167,LLY,J J s Invokana Lowers Heart Issues  Raises Amputation Risk,opinion,Johnson   Johnson   NYSE JNJ   announced data from a large CANVAS outcomes program  which demonstrated that its type II diabetes drug Invokana  canagliflozin  was successful in reducing the risks of heart attacks and strokes  However  the study also showed that the drug increased the risk of amputations The data were presented at the annual meeting of the American Diabetes Association and published by the New England Journal of Medicine The CANVAS program comprised two  nearly identical large outcomes studies called CANVAS and CANVAS R Data from the CANVAS CV outcomes study showed that its SGLT2 inhibitor  Invokana reduced major adverse CV events or MACE by 14  versus placebo in diabetes patients at risk for or with a history of CV disease  MACE is a composite endpoint of CV death  non fatal myocardial infarction or non fatal stroke While the risk of CV death was reduced by 13  that of nonfatal MI and nonfatal stroke  was reduced by 15  and 10   respectively  The data also showed that Invokana reduced risk for hospitalization for heart failure  HHF   Meanwhile  the study also demonstrated the CV safety of Invokana and superiority compared to placeboOn the other hand  CANVAS R study showed that Invokana was beneficial in delaying progression of albuminuria and reducing the risk of renal death and renal replacement therapy However  an increased risk of amputations was identified in both the studies  which was almost double that of placebo  The observation was consistent with the black boxed warning on Invokana s label on the increased amputation risk associated with the use of the drug J J s shares have outperformed the Zacks classified industry so far this year  The company s shares have gained 14 4  compared with the industry s gain of 10 8  Many pharma companies are working hard to get the labels of their diabetes medicines updated to include their cardiovascular benefits With death from cardiovascular diseases being significantly higher in adults with diabetes compared to those without diabetes  the addition of positive CV outcomes on labels of diabetes drugs can give sales a shot in the arm  Almost all these companies are conducting CV outcomes studies to evaluate the cardiovascular benefits of their diabetes drugs  While some diabetes drugs have been successful in lowering CV risk in high risk diabetic patients in outcomes studies  some have not Eli Lilly   Company   NYSE LLY   received FDA approval last year to include CV risk reduction data from the EMPA REG OUTCOME study on the label of Jardiance  The updated label including the cardiovascular indication was launched in Jan 2017 while the American Diabetes Association  ADA  has also updated its diabetes treatment guidelines  The European Commission also approved the Jardiance label update for the cardiovascular indication in 2016  The company expects the inclusion of this data to improve sales of Jardiance  On the first quarter conference call  Lilly said that since the launch of the CV indication and ADA s addition of Jardiance to its treatment guidelines  its new to therapy volume has increased 75  However  last month  Merck   Co   Inc    NYSE MRK   was denied approval by the FDA to include cardiovascular outcomes data from the TECOS study on the labels of its DPP IV inhibitor Januvia  sitagliptin  and other medicines containing Januvia AstraZeneca plc s   NYSE AZN   Bydureon also failed to reduce cardiovascular risk in a phase IIIb IV cardiovascular outcomes study  EXSCEL J J carries a Zacks Rank  3  Hold   You can see  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-12,Zacks Investment Research,"https://www.investing.com/analysis/j-j's-invokana-lowers-heart-issues,-raises-amputation-risk-200194936",200194936
172652,394168,LLY,Lilly Plans New Outcomes Study To Expand Jardiance Label ,opinion,Eli Lilly and Company   NYSE LLY   along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance  empagliflozin  for treatment of patients with chronic kidney disease Last year  Lilly received an FDA approval to include cardiovascular risk reduction data from EMPA REG OUTCOME study on the label of Jardiance  The updated label carrying cardiovascular indication was launched in Jan 2017 while the American Diabetes Association  ADA  has also restructured its diabetes treatment guidelines The European Commission had okayed the Jardiance label update for cardiovascular indication in 2016  Notably  Jardiance is the first and only medicine approved to reduce the risk of cardiovascular death in patients with type II diabetes Shares of Lilly have underperformed the Zacks classified  industry so far this year  The stock has gained 10  compared with the broader industry s growth of 10 7  Plans for new outcomes study is supported by cardiovascular and renal insights from the EMPA REG OUTCOME research  Although the trial was not primarily designed to assess the effect of Jardiance on kidney outcomes  kidney assessment was part of a pre specified exploratory analysis plan of additional endpoints  The latest chronic kidney outcomes study would enroll chronic kidney disease patients both with and without type II diabetes  Significantly  Lilly and Boehringer entered into a partnership agreement in 2011 to jointly develop and commercialize a portfolio of diabetes compounds Per the company s press release  approximately two out of three chronic kidney diseases occur as a result of cardiovascular complications  Besides  around 15  of adults in the U S  are affected by kidney diseases  Hence  there is immense market potential to address the hugely unmet needs of patients affected by chronic kidney diseases in the U S Eli Lilly and Company Price   Zacks Rank   Key PicksLilly currently carries a Zacks Rank  3  Hold   Better ranked stocks in healthcare sector include VIVUS  Inc    NASDAQ VVUS    Bayer  DE BAYGN  AG   OTC BAYRY   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While VIVUS and Bayer sports a Zacks Rank  1  Strong Buy   Regeneron carries a Zacks Rank  2  Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in last 60 days  The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 233 69  Bayer s earnings per share estimates increased from  8 75 to  8 89 for 2017 and from  9 41 to  9 57 for 2018 in the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 10 25  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10 in the last 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 0 45  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-13,Zacks Investment Research,https://www.investing.com/analysis/lilly-plans-new-outcomes-study-to-expand-jardiance-label-200194857,200194857
172653,394169,LLY,Pfizer   Lilly Get Fast Track Designation For Pain Candidate,opinion,Pfizer Inc    NYSE PFE   and Eli Lilly and Company   NYSE LLY   announced that the FDA has granted fast track designation to their pipeline candidate  tanezumab for the treatment of chronic pain in patients with osteoarthritis  OA  and chronic low back pain  CLBP  We note that the FDA s fast track process facilitates development and expedites the review of drugs to treat serious conditions and fill an unmet medical need  The candidate is the first nerve growth factor  NGF  inhibitor to receive this designation So far this year  shares of Lilly and Pfizer have risen 10 5  and 0 3   respectively  underperforming the Zacks classified  industry  which has increased 10 7  in that period An ongoing phase III program comprising six studies is evaluating the subcutaneous administration of tanezumab for treating OA  CLBP or cancer pain in patients who were treated with approved therapies but did not experience adequate pain relief  The results from the studies are expected in 2018 In Oct 2013  the two companies signed an agreement for the joint development and commercialization of tanezumab across the world According to the company s press release  chronic pain is a significant health problem in the U S  with more than 27 million Americans currently suffering from osteoarthritis and 23 million living with chronic low back pain  However  the majority of them experience inadequate pain relief after treatment with currently available pain medications We are encouraged by the FDA s decision to grant fast track designation to tanezumab  especially considering its potential patient population We remind investors that Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Teva Pharmaceutical Industries Limited   NYSE TEVA   are also developing a NGF antibody  fasinumab for treating OA and CLBP  However  in Oct 2016  the phase IIb study evaluating fasinumab in CLBP was placed under clinical hold by the FDA while another phase III study is ongoing for the treatment of OA Zacks RankPfizer and Lilly carry a Zacks Rank  3  Hold   You can see  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-06-13,Zacks Investment Research,https://www.investing.com/analysis/pfizer---lilly-get-fast-track-designation-for-pain-candidate-200195186,200195186
172681,394197,LLY,Novartis Reports Positive Data On Breast Cancer Drug Kisqali,opinion,"Novartis AG   NYSE NVS   announced positive data from the phase III study  MONALEESA 2 on breast cancer drug Kisqali The study reinforced the efficacy and safety of Kisqali plus letrozole in postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer A median progression free survival  PFS  of 25 3 months for Kisqali plus letrozole and 16 0 months for letrozole were observed after an additional 11 months of follow up  Moreover  after two years of treatment  the progression free survival rate was 54 7  in the Kisqali plus letrozole arm compared with 35 9  in patients treated with letrozole alone The data also showed that the safety profile of Kisqali plus letrozole remained consistent and the incidence of laboratory and electrocardiogram irregularities is similar to that observed at the first interim analysis Meanwhile  Novartis continues to evaluate Kisqali in multiple trials  in combination with different hormonal therapies  across a broad range of patients Earlier in 2017  the FDA approved Kisqali in combination with an aromatase inhibitor as initial endocrine based therapy for treatment of postmenopausal women with HR  HER2  advanced or metastatic breast cancer However  stiff competition in the breast cancer markert is a deterrent  Roche   OTC RHHBY   with drugs like Herception  Perjeta and Kadcyla continues to pose challenge Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and an improved formulation of Exjade Earlier in the month  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  recommended the approval of a label expansion of Zykadia  ceritinib  to include the first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors are anaplastic lymphoma kinase  ALK  positive Novartis  has outperformed the Zacks classified industry year to date  The stock has rose 12 6  compared with the  industry s gain of 10 6  We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Company   NYSE LLY   
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-positive-data-on-breast-cancer-drug-kisqali-200192939,200192939
172682,394198,LLY,Pfizer Provides Final Update On Phase II Talazoparib Study,opinion,Pfizer Inc    NYSE PFE   announced data from its phase II study  ABRAZO  which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive  gBRCA   mutations  showing anti tumor activity  The results were presented at the Annual Meeting of the American Society of Clinical Oncology  ASCO  in Chicago Talazoparib is a poly ADP ribose polymerase  PARP  inhibitor  which is being investigated for cancer types with deficiencies in DNA damage repair  DDR  Shares of Pfizer have underperformed the Zacks classified  industry so far this year  The stock has gained 0 2  during the period  while the broader industry witnessed an increase of 11 4  The phase II study evaluated safety and efficacy of talazoparib in patients with heavily pretreated gBRCA  advanced breast cancer in two cohorts One cohort investigated talazoparib in patients who developed disease progression after responding to prior platinum based chemotherapy  achieving a 21  objective response rate  ORR   Another cohort treated patients with at least three lines of non platinum based therapy and subsequently developed disease progression  This cohort achieved a 37  ORR The candidate is also being evaluated in an open label  randomized phase III study  EMBRACA to compare the safety and efficacy of talazoparib versus protocol specific physician s choice of chemotherapy in patients who have locally advanced and or metastatic breast cancer with gBRCA  mutations Talazoparib was added to Pfizer s pipeline with the acquisition of cancer focused biopharma company Medivation  Inc The breast cancer market provides immense commercial potential  We note that Novartis AG s   NYSE NVS   Kisqali has been recently approved while the FDA s Oncologic Drugs Advisory Committee voted in favor of approval of Puma Biotechnology  Inc  s   NASDAQ PBYI   neratinib in May 2017  Moreover  Eli Lilly and Company s   NYSE LLY   abemaciclib is in late stages of development  The oncology market is attracting a lot of attention with several companies inking deals and working on bringing their candidates to this high revenue potential market Pfizer  Inc  Price   Zacks Rank Pfizer currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-04,Zacks Investment Research,https://www.investing.com/analysis/pfizer-provides-final-update-on-phase-ii-talazoparib-study-200193283,200193283
172683,394199,LLY,Novartis Presents Data On Tafinlar Mekinist Combination ,opinion,"Novartis AG   NYSE NVS   announced results from a phase II study  BRF113220  on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology  ASCO  
The results from the study showed a durable survival benefit for some patients with BRAF V600 mutation positive metastatic melanoma  MM  when treated with the combination of Tafinlar   Mekinist  The study enrolled 162 patients who received either Tafinlar monotherapy  150 mg BID   n   54  or the Tafinlar   Mekinist combination  150 mg BID 2 mg QD   n   54   20 patients  37   were evaluated in the study after five years 
Among these  seven  13   remained in the Tafinlar monotherapy arm and 13  24   in the combination therapy arm  demonstrating that overall survival  OS  with combination therapy is superior to monotherapy 
The company plans to evaluate additional phase III long term survival data 
In addition  Novartis presented results from a phase II study  COMBI MB  which showed a positive  statistically significant intracranial response for patients with BRAF V600 mutation positive MM when treated with the combination of Tafinlar   Mekinist 
We remind investors that the combination of Tafinlar and Mekinist is already approved in the U S  and EU for the treatment of patients with unresectable or MM who have a BRAF V600 mutation  Both Tafinlar and Mekinist are also approved individually as single agents for the treatment of patients with unresectable or metastatic melanoma 
Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Co    NYSE LLY    Both Tafinlar and Mekinist were acquired from Glaxo 

Novartis  has outperformed the Zacks classified industry year to date  The stock has rallied 18 5  compared with the  industry s gain of 14 3  
Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold  
A better ranked stock in healthcare sector include VIVUS  Inc    NASDAQ VVUS   which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates lessened from 50 cents to 39 cents for 2017 in the last 30 days  The company posted positive earnings surprises in all four trailing quarters with average beat of 233 69  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/novartis-presents-data-on-tafinlar-mekinist-combination-200193328,200193328
172684,394200,LLY,Novartis  Bristol Myers Collaborate For Opdivo Combination,opinion,"Novartis AG   NYSE NVS   announced that it has entered into clinical research collaboration with Bristol Myers Squibb Company   NYSE BMY   Per the terms of the agreement  Bristol Myers will investigate the safety  tolerability  and efficacy of Novartis s Mekinist in combination with its own Opdivo and Opdivo   Yervoy regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair  MSS mCRC pMMR  The study will be conducted by Bristol Myers Squibb  The study is expected to establish recommended dose regimens and the preliminary anti tumor activity of the combination therapies Both the companies will determine the data from the study to determine optimal approaches and potential clinical development of these combinations We note that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Co    NYSE LLY   Mekinist was acquired from Glaxo We note that Opdivo became the first PD 1 inhibitor to be approved for a hematological malignancy   classic Hodgkin lymphoma in both the U S   May 2016  and the EU  Nov 2016   In Nov 2016  Opdivo gained the FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy  The FDA approved Opdivo for the treatment of patients with previously treated locally advanced or mUC in Feb 2017 In Oct 2015  Bristol Myers Squibb s Opdivo and Yervoy combination regimen became the first immuno oncology combination to receive regulatory approval for the treatment of metastatic melanoma Bristol Myers continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly Approval of new drugs and label expansion of existing ones are likely to bode well for Novartis which is facing generic competition for key drugs 
Novartis has outperformed the Zacks classified industry year to date  The stock has rallied 12 3  compared with the  industry s gain of 10 8   On the other hand  Bristol Myers  share price decreased 110 2  in the last 12 months 

Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-06,Zacks Investment Research,"https://www.investing.com/analysis/novartis,-bristol-myers-collaborate-for-opdivo-combination-200193589",200193589
172685,394201,LLY,Novartis   NVS  Tasigna Receives Label Update Nod In EU,opinion,"Novartis AG   NYSE NVS   announced that the European Commission  EC  has approved the inclusion of Treatment free Remission  TFR  data in the oncology drug Tasigna s Summary of Product Characteristics  SmPC  We note that Tasigna is approved for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia  Ph  CML  in adult patients resistant or intolerant to at least one prior therapy  including Gleevec  Also  it is approved for the treatment of adult patients with newly diagnosed Ph  CML in chronic phase TFR helps in maintaining molecular response  MR  after stopping tyrosine kinase inhibitor  TKI  therapy in Ph CMIL patients in chronic phase  The approval was based on efficacy and safety findings from the 48 week analyses of two open label trials  ENESTfreedom and ENESTop by the European Commission Novartis is evaluating more than 1 000 patients as part of the Tasigna TFR studies  which include ENESTfreedom and ENESTop along with two other ongoing company sponsored TFR studies and multiple investigator initiated studies Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and an improved formulation of Exjade  Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Co    NYSE LLY   Novartis  has outperformed the Zacks classified industry year to date  The stock has rallied 12 3  compared with the  industry s gain of 10 4  Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  The recent FDA approval of Kisqali  for use in combination with an aromatase inhibitor for the first line treatment of postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer will further boost the oncology portfolio  Meanwhile  the FDA approved a label expansion of Zykadia to include the first line treatment of patients with metastatic non small cell lung cancer  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
Zacks Rank   Key Pick
Novartis currently carries a Zacks Rank  3  Hold  
A top ranked stock in healthcare sector include VIVUS  Inc    NASDAQ VVUS   which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates lessened from 50 cents to 39 cents for 2017 in the last 60 days  The company posted positive earnings surprises in all four trailing quarters with average beat of 233 69  
3 Stocks to Ride a 588  Revenue Explosion 
At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold  By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-06,Zacks Investment Research,https://www.investing.com/analysis/novartis'-(nvs)-tasigna-receives-label-update-nod-in-eu-200193816,200193816
172703,394219,LLY,Novartis   NVS  Lung Cancer Drug Gets Positive CHMP Opinion ,opinion,"Novartis   NYSE NVS   recently announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has recommended the approval of a label expansion of Zykadia  ceritinib  to include the first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors are anaplastic lymphoma kinase  ALK  positive 
Upon approval  Zykadia will provide a new treatment option for previously untreated and newly diagnosed patients with ALK positive advanced NSCLC 

Novartis  has outperformed the Zacks classified industry year to date  The stock has rose 11 5  compared with the  industry s gain of 8 6  
We note that Zykadia is currently approved in the European Union  EU  for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib 
The European Commission will take the CHMP recommendation while reviewing the application but is not bound by it  A decision from the EC is expected within two months 
Earlier in the year  the FDA granted Zykadia Breakthrough Therapy designation for first line treatment of patients with ALK positive NSCLC with metastases to the brain  The application is under priority review in the U S 
In Oct 2016  the FDA approved Merck   Co   Inc  s   NYSE MRK   Keytruda for the treatment of patients with metastatic NSCLC whose tumors express PD L1 as determined by an FDA approved test  The approval was the first FDA approval of a checkpoint inhibitor for first line treatment of lung cancer 
We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Company   NYSE LLY   
Going forward  we expect approval of new drugs and label expansion of existing ones to bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/novartis'-(nvs)-lung-cancer-drug-gets-positive-chmp-opinion-200190686,200190686
172704,394220,LLY,AstraZeneca s Bydureon Fails To Reduce Cardiovascular Risk,opinion,AstraZeneca plc   NYSE AZN   announced top line results from the EXSCEL study evaluating the cardiovascular  CV  safety profile of its type II diabetes drug Bydureon  Though the study met the primary safety objective in the study  Bydureon  a human glucagon like peptide 1  GLP 1  analogue  failed to reduce the risk of major adverse cardiovascular events The Phase IIIb IV cardiovascular outcomes study was carried out in more than 1400 patients from 35 countries with type II diabetes with or without additional cardiovascular  CV  risk factors or prior CV events  The study compared the effect of once weekly Bydureon  exenatide extended release  versus placebo on reducing the risk of MACE in such patients MACE is a composite endpoint of CV death  non fatal myocardial infarction or non fatal stroke  Data from the study showed that Bydureon did not increase the risk of MACE and showed a consistent safety profile  Meanwhile  fewer CV events were observed in the Bydureon arm  However  the efficacy objective of a superior reduction in CV risk did not reach statistical significance AstraZeneca s shares are up 29 3  year to date  comparing favorably with an increase of 13 5  witnessed by the Zacks classified  industry Coming back to the latest news  EXSCEL was jointly run by two academic research organizations  Full data from the study will be presented at the annual meeting of European Association for the Study of Diabetes  EASD  to be held in September With death from cardiovascular disease being significantly higher in adults with diabetes compared to those without diabetes  the addition of positive cardiovascular outcomes data on labels of diabetes drugs can help drive sales  While some diabetes drugs have demonstrated cardiovascular benefit in studies  some others have not Novo Nordisk  CO NOVOb  AS    NYSE NVO   key diabetes drug Victoza  also a GLP 1 analogue  has in the past  shown a statistically significant reduction of cardiovascular risk in the LEADER cardiovascular outcomes study in type II diabetes patients  The application to include the LEADER data on Victoza s label is under review in the U S  and EU Eli Lilly   Company   NYSE LLY   and Boehringer Ingelheim received FDA approval last year to include CV risk reduction data from the EMPA REG OUTCOME study on the label of their SGLT 2 inhibitor  Jardiance  The updated label including the cardiovascular indication was launched in Jan 2017  The European Commission also approved the Jardiance label update for the cardiovascular indication in 2016 However  last month  Merck   Co   Inc    NYSE MRK   was denied approval by the FDA to include cardiovascular outcomes data from the TECOS study on the labels of its DPP IV inhibitor Januvia  sitagliptin  and other medicines containing Januvia Zacks Rank   Stocks to ConsiderAstraZeneca currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana   Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca's-bydureon-fails-to-reduce-cardiovascular-risk-200191140,200191140
172705,394221,LLY,Pharma Stock Roundup  Label Expansion For Merck Drug  Aerie Up On Eye Data,opinion,"This week  there were quite a few regulatory updates with Merck   NYSE MRK   getting FDA approval for yet another indication for Keytruda while Bristol Myers   NYSE BMY   got priority review for a regulatory application for Opdivo Recap of the Week s Most Important StoriesAerie Soars on Positive Eye Data  Aerie s   NASDAQ AERI   shares shot up almost 34  to a new 52 week high on positive late stage data on its fixed dose combination candidate  Roclatan  Aerie intends to file for FDA approval in the first half of 2018 if 12 month safety results  due in the third quarter of 2017  are positive  Meanwhile  the company expects to submit for European approval in the second half of 2019 with a late stage study scheduled to commence in mid 2017  Read more     Aerie is a Zacks Rank  2  Buy  stock    you can see  Aerie is up 42 4  year to date  YTD   outperforming the Zacks categorized  industry which is up 7 3  so far in 2017 Another Approval for Merck s Keytruda  Merck s anti PD 1 therapy Keytruda is on a roll with the drug now gaining FDA approval for use in adult and pediatric patients with unresectable or metastatic  microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or colorectal cancer that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan  This makes Keytruda the first cancer therapy approved for use based on a biomarker regardless of tumor type  This approval comes shortly after the company got approval for the first  as well as second line treatment of certain patients with locally advanced or metastatic urothelial carcinoma  a type of bladder cancer Moreover  Keytruda got priority review in the U S  for the treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma in patients who have already received two or more lines of chemotherapy  A response from the FDA should be out by Sep 22  2017  Read more    Merck also announced an exclusive worldwide license agreement with Teijin Pharma for an experimental Alzheimer s disease candidate  an anti tau antibody in preclinical stage  Merck has been working on developing treatments for Alzheimer s though the company suffered a setback earlier this year when verubecestat was halted in a phase II III study Pfizer Biosimilar Gets Advisory Panel Support  Pfizer s   NYSE PFE   biosimilar version of Epogen and Procrit  epoetin alfa  was recommended for approval by the FDA s Oncologic Drugs Advisory Committee  ODAC  across all indications  This is the first time a biosimilar erythropoiesis stimulating agent  ESA  has been recommended for approval by an FDA advisory panel  While the FDA is not required to do so  it usually follows the recommendation of its advisory panels GW Pharma Epilepsy Data Published  GW Pharma   NASDAQ GWPH   announced the publication of phase III data on Epidiolex  cannabidiol  for children with Dravet syndrome in The New England Journal of Medicine  Epidiolex  a liquid formulation of purified  plant derived cannabidiol  CBD   is being evaluated for the treatment of several rare and severe pediatric onset epilepsy disorders  Results from the Dravet syndrome study showed that Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment resistant children when added to existing treatment  GW Pharma remains on track to file for FDA approval in mid 2017 Bristol Myers Drug Gets Priority Review  Bristol Myers got priority review status for its regulatory application for the label expansion of Opdivo for use in hepatocellular carcinoma  HCC  patients who have been on Nexavar  sorafenib   With the FDA granting priority review  a response should be out by Sep 24  2017  Read more    Sanofi  PA SASY   Regeneron RA Drug Gets FDA Nod on Second Attempt  It proved to be second time lucky for Sanofi   NYSE SNY   and partner Regeneron with the companies gaining FDA approval for their rheumatoid arthritis  RA  treatment  Kevzara  The companies had got a complete response letter  CRL  for the IL 6R antibody in Oct 2016 due to manufacturing issues  While Kevzara has blockbuster potential  the RA market is highly crowded given the presence of treatments like Humira and Xeljanz among others  Sanofi and Regeneron have priced Kevzara at  39 000 year  a discount of about 30  to the U S  wholesale acquisition cost for the two most widely used TNF alpha inhibitors  Moreover  the patient population is huge with many patients spending years on different treatments without achieving their treatment goals  With RA affecting about 1 3 million Americans  Kevzara represents a new treatment option for patients  Read more    Sanofi has outperformed the Zacks categorized  industry YTD with shares gaining 21 2  while the industry is up 10 6  Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index was up slightly  0 7   over the last five trading sessions  Merck was up 1 8  while Glaxo slipped 1 6   Over the last six months  AstraZeneca was up 26 7  while Bristol Myers was down 4 6   See the last pharma stock roundup here    
What s Next in the Pharma World Companies like Pfizer  Lilly   NYSE LLY    AstraZeneca  Bristol Myers  Merck KGaA and Merck will all be at the annual meeting of the American Society of Clinical Oncology  ASCO  showcasing data on approved and pipeline candidates targeting cancer Meanwhile  a response from the FDA regarding a once daily formulation of Isentress  for use in combination with other antiretroviral therapies for the treatment of HIV 1 in treatment na ve patients or patients whose virus remains suppressed after treatment with an initial regimen of 400 mg of Isentress twice daily   is expected by May 27  2017 
Looking for Ideas with Even Greater Upside Most of Zacks  investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-26,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-label-expansion-for-merck-drug,-aerie-up-on-eye-data-200191681",200191681
172706,394222,LLY,Eli Lilly s  LLY  Cancer Drug Cyramza Positive In Phase III ,opinion,"Eli Lilly and Company   NYSE LLY   announced positive results from a phase III RANGE study evaluating its oncology drug  Cyramza  ramucirumab   for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma Note that Cyramza is already approved in the U S  both as a single agent and when combined with another in the form of a second line treatment for advanced or metastatic gastric cancer  In the case of metastatic NSCLC and metastaftic colorectal cancer  the drug is approved in combination with another agent  as a second line treatment Shares of Lilly have underperformed the Zacks classified  industry so far this year  The stock has gained 8 2  compared to the broader industry s 10 2  The RANGE study is designed to evaluate safety and efficacy of Cyramza in combination with docetaxel Vs placebo and docetaxel in patients with urothelial cancer  The study met its primary end points and demonstrated an improved progression free survival  PFS  in patients with the given indication  The study was globally conducted in 531 patients The secondary endpoints of the study include overall survival  objective response and disease control rates and duration of response  The company believes that results related to overall survival  OS  are likely to be required for global regulatory submissions  Lilly expects OS data by mid 2018 We remind investors that Cyramza recorded sales of  171 2 million in the first quarter of 2017  Another drug  Alimta  is also a key product in the company s oncology portfolio  After Alimta  Cyramza accounts for highest share in the company s revenue from the oncology division  Cyramza s contribution to revenues is crucial  considering the company s top line is under pressure due to genericization of drugs like Alimta and Erbitux among others Per the company s press release  bladder cancer accounts for majority of all urothelial carcinoma  Approximately 430 000 people worldwide are annually affected by bladder cancer  causing over 165 000 deaths In fact  in the U S   bladder cancer is the sixth most common type of cancer  In 2017  around 79 000 new cases and nearly 17 000 deaths are estimated from bladder cancer  Hence approval of the drug for this indication will provide the company with access to a huge population base of patients affected by the disease The label expansion of Cyramza looks encouraging enough  Several studies on Cyramza are underway  evaluating it as a single agent and in combination with other anti cancer therapies for treatment of multiple tumor types  It is being assessed under broad global development program that has enrolled over 10 000 patients across more than 70 trials worldwide  Label expansion of Cyramza should boost sales over the long term Eli Lilly and Company Price

   Zacks Rank   Key Picks
Lilly currently carries a Zacks Rank  3  Hold   Better ranked stocks in healthcare sector include VIVUS  Inc    NASDAQ VVUS    Bayer  DE BAYGN  AG   OTC BAYRY   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While VIVUS sports a Zacks Rank  1  Strong Buy   Bayer and Regeneron carry a Zacks Rank  2  Buy   You can see  
VIVUS s loss per share estimates tapered from 50 cents to 39 cents for 2017 in the last 30 days  The company posted positive earnings surprises in all four trailing quarters with an average beat of 233 69  
Regeneron s earnings per share estimates increased from  10 17 to  10 52 for 2017 and from  10 90 to  12 10  over last 30 days  The company posted positive earnings surprises in two of the four trailing quarters with average beat of 0 45  
Bayer s earnings per share estimates increased from  8 36 to  8 85 for 2017 and from  8 88 to  9 53 for 2018  over last 30 days  The company posted positive earnings surprises in three of four trailing quarters with average beat of 10 25  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly's-(lly)-cancer-drug-cyramza-positive-in-phase-iii-200192731,200192731
172730,394246,LLY,5 Reasons Why Merck  MRK  Is A Good Stock To Buy Now ,opinion,Kenilworth  NJ based Merck   Co   Inc    NYSE MRK   is a research driven pharmaceutical company  which is a global leader in the discovery and development of vaccines and pharmaceutical drugs  The company currently makes noteworthy treatments or vaccines for HPV  type 2 diabetes  cancer  and HIV  among others  It looks like a great stock to buy now  Here are some reasons for the same Favorable Rank  Rising Estimates   Share Price  Merck carries a Zacks Rank  2  Buy   You can see  Merck s earnings estimates for 2017 as well as 2018 went up by 0 3  in the past 7 days following its strong earnings and raised outlook  In fact  Merck s earnings performance has been pretty impressive  with the company exceeding earnings expectations consistently  The average positive earnings surprise over the last four quarters is 4 36  Share price of the company has risen 16 6  in the past one year while the Zacks classified  industry registered an increase of 4 5  Strong Q1 Results  Merck beat estimates for both earnings and sales in the first quarter of 2017 and also raised its 2017 guidance Merck s Pharmaceutical segment revenues rose 1  year over year as strong performance of new products like Keytruda  Bridion and Zepatier and higher sales of vaccines and animal health franchises offset lower sales of the Januvia Janumet franchise and loss of market exclusivity for many drugs Successful New Products  Merck s new products like Keytruda and Zepatier should continue to contribute meaningfully to the top line   In the first quarter of 2017  Keytruda sales rose 20 9  sequentially and 134 5  year over year while Zepatier sales rose 65  sequentially Keytruda is the first anti PD 1 therapy to gain FDA approval  Keytruda sales received a boost with the approval in the first line lung cancer setting  In fact  Keytruda is continuously growing and expanding into new indications and markets globally  In Mar Apr 2017  Keytruda received FDA and EU approval for refractory classical Hodgkin lymphoma  cHL    the first Keytruda approval for hematologic malignancy indication  In May  Merck got a boost with the FDA granting accelerated approval to Keytruda for use in combination with Eli Lilly   Company s   NYSE LLY   cancer drug Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen  for the first line treatment of metastatic non squamous non small cell lung cancer  NSCLC   irrespective of PD L1 expression  Note that this is the first FDA approval for Keytruda as combination therapy Keytruda uptake in first line lung cancer indication and potential label expansion   with FDA action pending on multiple regulatory applications   are catalysts for the stock in 2017 Deep Pipeline  Merck has also made significant progress with its pipeline and is working on bringing new products to the market Merck has more than 10 candidates in phase III development  The company has prioritized its pipeline so that the candidates with the highest potential get the required support  Some of the important pipeline candidates include MK 0859  anacetrapib   cholesterol management   verubecestat  prodromal Alzheimer s disease   MK 8228 letermovir  cytomegalovirus  CVM  infections  and MK 8835 ertugliflozin  type II diabetes   in partnership with Pfizer  Inc    NYSE PFE    Meanwhile  Keytruda is being studied for more than 30 types of cancer Merck  in order to build its long term portfolio  is tapping external sources as well  The company entered into several licensing deals in the last couple of years with expectation of more such deals in the future Aggressive Cost Cutting Initiatives  Merck will continue to focus on cost cutting initiatives to drive the bottom line  Merck has a global restructuring program in progress  which is aimed at reducing the cost structure and increasing efficiency  It intends to reduce the number of manufacturing sites  including animal health sites  and consolidate other facilities  The company expects annual savings of about  4 0  4 6 billion once the restructuring program is completed Merck also divested segments like the Consumer Care business to Germany s Bayer  DE BAYGN  AG   OTC BAYRY   in 2014 so that it can focus on its core areas of expertise  The company is also returning value to shareholders in the form of share buybacks and dividends ConclusionMerck has its share of headwinds  Like many of its peers  Merck is facing headwinds in the form of generic competition for several key products  Pricing pressure and rising competition in the immuno oncology market is also a significant concernHowever  we believe the new drug approvals  a solid pipeline and aggressive savings will pave the way for growth this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-merck-(mrk)-is-a-good-stock-to-buy-now-200189685,200189685
172731,394247,LLY,Endocyte  ECYT  Focused On Two Lead Pipeline Candidates,opinion,"We issued an updated report on Endocyte  Inc    NASDAQ ECYT   on May 17 
Endocyte s share price has increased 10 2  year to date  while the Zacks classified  industry gained 4 9  

Currently  the company is focused on the development of two candidates  EC1456 and EC1169  both of which are in phase I 
Endocyte is focusing on the development of its second generation folate targeted agent  EC1456  as second line treatment for non small cell lung cancer  NSCLC   identified by the companion imaging agent etarfolatide  It has already initiated the expansion phase of the study on EC1456 in select folate receptor positive NSCLC cancer patients  A dose of 6 0 mg m2 has been established as the maximum twice a week dose and is being used in the expansion phase of the study 
Patients included in this expansion phase of the trial are expected to receive first line chemotherapy and may also be treated with anti PD 1 therapy  Initially  anti tumor response of the single agent will be evaluated  Notably  positive results would lead to its evaluation as combination therapies in indications such as triple negative breast cancer  ovarian cancer and endometrial cancer 
Although several companies are aggressively working on bringing new cancer treatments to market  demand for improved and targeted therapies makes this a space with high commercial potential  In fact  Endocyte uses its proprietary technology platform to develop various new small molecule drug conjugates  SMDCs  for a range of diseases  Each SMDC consists of three modules  a targeting ligand  a linker and a drug payload 
Also  the company is working on generating a pipeline of SMDC candidates though this modular approach  including EC1456 and EC1169  advanced metastatic castration resistant prostate cancer mCRPC   phase I ongoing   among others  Moving ahead  successful development of targeted SMDCs that are able to penetrate deep into dense solid tumors and have a shorter half life might help Endocyte gain an edge over existing therapies 
Apart from these candidates  Endocyte is working on the development of companion imaging agents  These agents utilize the same modular structure as the SMDCs to replace the drug payload with an imaging agent 
The companion imaging agents facilitate the identification of patients who are most likely to benefit from Endocyte s SMDC treatment  This should help in expanding the market for SMDCs  thereby boosting growth at the company  Currently  the company is evaluating EC1169 in a phase I study for metastatic castration resistant prostate cancer  mCRPC  
Patients are being scanned with its companion imaging agent  EC0652 to identify the presence of prostate specific membrane antigen  The first part of the phase I study has been completed  and the company has started the second part  confirming 6 5 mg m2 once a week as the maximum clinical dose  In this expansion phase of the study  two cohorts of mCRPC patients  be evaluated 
The company is also nearing completion of preclinical work required to file an Investigational New Drug  IND  application for EC2629  which is its first candidate to target disease cells and simultaneously impact the tumor micro environment by shutting down tumors associated with macrophages  Moving ahead  Endocyte expects to file an IND for EC2629 by mid 2017 
However  the company has very few candidates in its pipeline with all of them in the early or mid stages of development  Unfavorable results from any of these studies may lead to their postponement or discontinuation  thereby impacting shares adversely 
Endocyte s products are expected to face intense competition in the market from both large pharma companies and small and mid sized companies  Several companies are either pursuing the development of or marketing drugs that target NSCLC  prostate cancer  ovarian cancer and endometrial cancer  or other oncology pathways on which Endocyte focuses 
Furthermore  the market for lung cancer therapies is already crowded with treatments like Pfizer Inc  s   NYSE PFE   Xalkori and Eli Lilly and Company s   NYSE LLY   Alimta and Cyramza  and AstraZeneca Plc s   NYSE AZN   Tagrisso among others Endocyte  Inc  Price and Consensus
    Zacks Rank
Endocyte currently carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/endocyte-(ecyt)-focused-on-two-lead-pipeline-candidates-200190101,200190101
172732,394248,LLY,Sanofi Wins Favorable CHMP Opinion For Biosimilar Humalog,opinion,"Sanofi  PA SASY    NYSE SNY   recently announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has given a positive opinion  recommending marketing approval to a biosimilar version of Eli Lilly   Company s   NYSE LLY   Humalog  insulin lispro   The biosimilar candidate was submitted for approval in EU in Sep 2016 Please note that a final decision from EU on the marketing authorization for Insulin Lispro Sanofi is expected in the coming months Shares of Sanofi have outperformed the Zacks classified  industry so far this year  The stock has gained 21 9  during the period  while the broader industry witnessed an increase of 8 6  Coming back to the latest news  the positive opinion was supported by data from a pharmacokinetic phase I study and two multi center phase IIIa studies  SORELLA 12 and SORELLA 2   While the phase I study evaluated the product s similarity in exposure and activity compared to Humalog  the phase III studies were designed to evaluate the safety and efficacy compared to Humalogd  The studies were conducted in more than 1 000 adults with type I or type II diabetes We remind the investors that Sanofi s Diabetes franchise is under pressure with key product  Lantus  facing increasing competition at the payor level  The drug is also exposed to biosimilar competition in several European markets  Moreover  Lilly s Basaglar  a follow on insulin glargine product of Lantus entered the U S  market in Dec 2016  Sanofi expects its global Diabetes sales to decline 4 8  annually  at constant exchange rates  over 2015 2018 During the first quarter 2017 conference call  management warned that the U S  diabetes franchise sales will decline faster through the rest of the year  The Diabetes franchise  including emerging markets  declined 6  to  1 66 billion in the first quarter of 2017  The decrease is anticipated due to exclusion from the UnitedHealth Group Inc    NYSE UNH   formulary plans  which started on Apr 1  2017 as well incremental effect from the CVS Health Corp    NYSE CVS   formulary exclusion Sanofi Price

   Zacks Rank
Sanofi currently carries a Zacks Rank  2  Buy   You can see  
Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time 
One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/sanofi-wins-favorable-chmp-opinion-for-biosimilar-humalog-200190677,200190677
172749,394265,LLY,Eli Lilly  LLY  Up 8 1  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Eli Lilly and Company   NYSE LLY    Shares have added about 8 1  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Lilly Misses on Fourth Quarter Earnings  Beats on RevenuesLilly s fourth quarter results were mixed with the company beating on revenues but missing earnings expectations Lilly s fourth quarter 2016 adjusted earnings per share of  0 95 missed the Zacks Consensus Estimate of  0 99 by 4   Earnings  however  rose 22  from the year ago quarter backed by higher volume driven sales growth  Including special items  earnings were up 62  to  0 73 per share in the quarter Revenue in DetailQuarterly revenues grew 7  to  5 76 billion  Sales beat the Zacks Consensus Estimate of  5 55 billion by 3 8   Excluding the impact of foreign exchange  worldwide revenues grew 6   The top line was primarily driven by strong performance in the key diabetes franchise  Lilly s new products contributed more than 700 million to sales this quarter with Trulicity and Cyramza doing well  At the conference call  Lilly said it expects to launch three new products by the end of 2018 Higher volumes and a slightly favorable impact of foreign currency  1   were partially offset by lower realized prices Volumes rose 8  as higher volumes of new products like Trulicity  Cyramza  Taltz and Jardiance and older products like Humalog Humulin as well as the Animal Health division was offset by lower volumes of established products like Zyprexa  Alimta and Cymbalta U S  revenues grew 14  to  3 22 billion  reflecting higher volume of products like Trulicity  Humalog  Taltz and Jardiance as well as companion animal products  Higher realized prices also propelled U S  sales Ex U S  revenues declined 1  to  2 54 billion mainly due to lower volumes and realized prices  Higher volumes of newer products like Cyramza  Jardiance and Trulicity were partially offset by lower volumes of Zyprexa  Cymbalta and Alimta due to the loss of exclusivity  Cymbalta has lost exclusivity in Europe and Canada  Zyprexa in Japan and Alimta in several countries Products that recorded growth during the quarter include Forteo  up 12  to  422 5 million   Humalog  up 3  to  819 8 million   Strattera  up 10  to  243 2 million  and Cialis  up 6  to  676 3 million  Alimta sales  however  declined 14  to  541 6 million  reflecting lower demand in the U S  due to competitive pressure mainly from immuno oncology agents  Outside the U S   sales of Alimta were hurt by loss of exclusivity in several countries Zyprexa sales declined 33  to  153 million due to loss of exclusivity Humulin sales decreased 1  in the quarter as higher sales in the U S  were offset by lower volumes in outside U S  markets Erbitux sales declined 13  to  153 7 million in the quarter Lilly s Animal Health segment sales increased 3  to  837 6 million  Favorable wholesaler buying patterns for companion animal products in the U S   and higher food animal products  sales in ex U S  markets drove segment sales Among new products  Trulicity generated revenues of  337 million  almost double from last year s fourth quarter  with U S  revenues benefiting from growth in the GLP 1 market and market share gains  Cyramza revenues were  177 1 million  up 51  year over year backed mainly by higher outside U S  revenues  Cyramza s ex U S  revenues benefited from strong uptake in the gastric cancer indication in Japan  However  U S  revenues declined  being hurt by competition in the non small cell lung cancer indication Jardiance sales   76 1 million  were driven by increased market share within the growing SGLT2 class  In Dec 2016  the FDA approved Jardiance for the CV indication while the American Diabetes Association updated its diabetes treatment guidelines  Management believes that both these factors will drive growth of Jardiance and the SGLT 2 class Basaglar recorded revenues of  39 5 million  Basaglar was launched in the U S  in mid Dec 2016 where it generated revenues of  15 8 million largely due to initial stocking Portrazza brought in sales of  3 8 million while Taltz brought in sales of  61 3 million Lartruvo generated revenues of  11 9 million in the quarter  Lartruvo was launched in the U S  in late Oct 2016 where it generated revenues of  11 0 million  In Europe  it was launched in mid November with the company booking initial sales in Germany and Austria in December Gross Margins   Operating Income RiseAdjusted gross margin of 77 4  in the quarter increased 10 basis points primarily driven by increased volume in the U S  and manufacturing efficiencies Operating income increased 33  to  1 22 billion due to higher revenues  Total operating expenses  R D  marketing  selling and administrative expenses  were flat in the quarter  Marketing  selling and administrative expenses were flat in the quarter as lower costs related to established products were offset by higher spending on new products  R D was also flat in the quarter Lilly bought back shares worth  300 million during the quarter and has  2 35 billion left in its  5 billion share buyback program 2016 ResultsFull year sales rose 6  to  21 22 billion  barely beating the Zacks Consensus Estimate of  21 03 billion  Revenues were in line with the guidance range of  20 8 billion to  21 2 billion Adjusted earnings for 2016 were  3 52 per share  up 3  year over year but falling short of the Zacks Consensus Estimate of  3 56  Earnings were in line with the guidance range of  3 50 to  3 60 2017 ForecastAdjusted earnings per share are expected in the range of  4 05 to  4 15  representing a growth rate of 15  to 18    Revenues are expected in the range of  21 8  22 3 billion  While new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo are expected to see higher revenues in 2017  Lilly expects some established products like Trajenta  Forteo and Humalog to continue doing well  The Animal Health division is also expected to see revenue growth Gross margin is expected to be approximately 77   Adjusted tax rate is expected to be approximately 22  Marketing  selling and administrative expenses are expected in the range of  6 4  6 6 billion  while research and development expenses are projected to be  4 9  5 1 billion 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimate flatlined during the past month  There has been one upward revision for the current quarter compared to one downward Eli Lilly and Company Price and Consensus
    VGM Scores
At this time  Eli Lilly s stock has a nice Growth Score of  B   however its Momentum is doing a bit better with an  A   Charting a somewhat similar path  the stock was allocated a grade of  B  on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  A   If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is suitable for value  growth and momentum investors 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-04-24,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-(lly)-up-8.1-since-earnings-report:-can-it-continue-200184636,200184636
172750,394266,LLY,Merck  MRK  Beats On Q1 Earnings   Sales  Ups Annual View,opinion,"Merck   Co   Inc    NYSE MRK   reported first quarter 2017 earnings of 88 cents per share  which beat the Zacks Consensus Estimate of 83 cents  However  earnings declined 1 1  from the year ago period 

Merck s shares rallied 6 1  so far this year  while the Zacks classified  industry gained 6 6  
Revenues for the quarter increased 1  year over year to  9 4 billion  beating the Zacks Consensus Estimate of  9 3 billion  The increase in revenues was driven by the continued momentum of Keytruda in oncology as well as the strength of the vaccine and other franchises and animal health 
Currency movement negatively impacted revenues by 2  
Quarter in Detail
Merck s Pharmaceutical segment posted revenues of  8 2 billion  up 1  year over year driven by oncology  hepatitis C and vaccines  largely offset by the loss of market exclusivity for several products  as well as lower sales in the diabetes franchise 
Keytruda recorded sales of  584 million in the reported quarter  up from  249 million in the year ago quarter  Sales continued to be driven by label expansion of the drug   During the quarter  the FDA approved the drug for the treatment of patients with refractory classical Hodgkin lymphoma  cHL  or for patients with cHL who have relapsed after three or more prior lines of therapy 
In addition  the European Commission also approved Keytruda for the first line treatment of non small cell lung cancer  NSCLC  in adults whose tumors have high PD L1 expression  tumor proportion score of 50  or more  with no EGFR or ALK positive tumor mutations  Keytruda sales gained from launches in new indications like first line lung cancer  approved in Oct 2016   and recurrent or metastatic head and neck cancer  approved in Aug 2016  in the U S   and second line NSCLC across the world 
Januvia Janumet franchise recorded sales of  1 3 billion in the quarter  down 5  from the year ago due to the timing of customer purchases in the U S 
Gardasil Gardasil 9 sales climbed 41  to  532 million 
Zepatier brought in sales of  378 million  up from  229 million in the fourth quarter of 2016  due to ongoing launches 
Meanwhile  combined sales of Remicade  lost exclusivity in Europe and facing stiff biosimilar competition in the region   Nasonex  generic version launched in the U S  in Mar 2016   Cubicin  lost patent protection in the U S  in Jun 2016  and Zetia  lost market exclusivity in the U S  in Dec 2016  declined by  686 million in the quarter 
Sales of Remicade  marketed in partnership with Johnson   Johnson   NYSE JNJ    continue to be dampened by biosimilar competition with biosimilars benefiting from increased new patient starts as well as patient switching  In this regard  note that Pfizer Inc    NYSE PFE   launched its Inflectra injection  a biosimilar version of Remicade  in the U S  in late Nov 2016 
Merck s Animal Health segment posted revenues of  939 million  up 13  from the year ago quarter  primarily driven by higher sales of companion animal products 
Adjusted gross margins came in at 77 8  compared to 77  in the year ago quarter  Marketing and administrative  M A  expenses increased 3  to  2 4 billion in the reported quarter  Research and development  R D  spend increased 14  to  1 8 billion in the quarter  due to the timing of customer purchases in the United States 
2017 Guidance
Merck updated its 2017 earnings and revenues guidance  The company now expects adjusted earnings in the range of  3 76  3 88  an increase from the earlier figure of  3 72  3 87 per share  including approximately 1 5  negative foreign exchange impact  The Zacks Consensus Estimate was  3 83 per share 
Merck now expects revenues in the range of  39 1  40 3 billion  compared to the earlier forecast of  38 6 billion  40 1 billion  including negative currency impact of approximately 1 5   The Zacks Consensus Estimate of  39 7 billion was well within the updated guidance 

Merck   Company  Inc  Price and EPS Surprise

   Our TakeMerck s first quarter earnings were encouraging as the company beat both on sales and earnings driven by Keytruda sales along with upside from vaccines and animal health franchises  The growth in Keytruda more than offset the decline in sales from Zetia  Januvia  and Remicade among others  We expect investors to focus on the upcoming PDUFA dates for Keytruda for the treatment of patients with metastatic or advanced NSCLC regardless of PD L1 expression  May 10  and for the treatment of patients with locally advanced or metastatic urothelial cancer  Jun 14  Another pharma giant Eli Lilly and Company   NYSE LLY   is also facing loss of exclusivity for many of its key drugs in the emerging markets Merck currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/merck-(mrk)-beats-on-q1-earnings---sales,-ups-annual-view-200186546",200186546
172775,394291,LLY,Eli Lilly s Rheumatoid Arthritis Drug Gets CRL In The U S ,opinion,Eli Lilly and Company   NYSE LLY   and its partner Incyte Corporation   NASDAQ INCY   recently announced that they have received a Complete Response Letter  CRL  from the FDA regarding the new drug application  NDA  for baricitinib  Lilly was seeking approval of baricitinib for the treatment of moderate to severe rheumatoid arthritis  RA  in the U S We remind investors that baricitinib was approved in EU in Feb 2017 for the given indication  The drug is to be marketed by the trade name of Olumiant in EU  It was the first JAK inhibitor to receive approval to treat RA in the EU Lilly s shares declined more than 4  and Incyte s shares lost more than 13  in pre market trading on Monday  in response to this news  However  Lilly s shares have outperformed the Zacks classified  industry so far this year  Shares of the company gained 16 7  while the industry registered an increase of 5 4  Coming back to the latest news  the letter states that the FDA is unable to approve the application in its present form  The agency has asked for additional information to determine the most appropriate doses of baricitinib  Moreover  additional data is required to further characterize safety concerns across treatment arms We remind investors that Lilly had submitted a regulatory application for baricitinib in the U S   last January  Subsequently  this January  Lilly and its partner Incyte announced that the FDA has extended the time to review the NDA for baricitinib  Previously  the FDA was expected to give a decision early this year  However  Lilly submitted additional information on the regulatory agency s behest  which the latter deemed a Major Amendment to the NDA  In order to review the additional data  the FDA extended the Prescription Drug User Fee Act  PDUFA  date by three months We note that the NDA of baricitinib was supported by four pivotal phase III clinical trials in patients with moderate to severe active RA  An additional phase III study was initiated to support clinical development in China Baricitinib is being co developed by Lilly and Incyte under an exclusive global license and collaboration agreement inked in Dec 2009 Meanwhile  baricitinib is being evaluated in phase II studies for the treatment of atopic dermatitis and systemic lupus erythematosus  A phase III study evaluating the candidate for the treatment of psoriatic arthritis is expected to be initiated this year According to the company  more than 23 million individuals in the world suffer from RA  The disease affects about three times more women than men  Hence  the potential market opportunity for the drug is huge across the globe Eli Lilly and Company Price    Zacks Rank   Key PicksLilly currently carries a Zacks Rank  2  Buy   Some better ranked stocks in the health care sector are Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 30 days  The company posted a positive surprise in three of the four trailing quarters with an average beat of 291 54  Galena s loss per share estimates narrowed from  1 12 to 58 cents for 2017 and over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 53 83  Sell These Stocks  Now Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500   ,2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly's-rheumatoid-arthritis-drug-gets-crl-in-the-u.s.-200183123,200183123
172776,394292,LLY,Stocks Shrug Geopolitics  Domestic Data,opinion,"U S  equities finished higher on the day  apparently dismissing political uncertainty of late  as well as lackluster domestic economic data  Manufacturing and housing data came in below expectations  which followed softer than anticipated consumer inflation and retail sales reports while the markets were closed on Good Friday  Elsewhere  Treasuries were mixed  while gold  the U S  dollar and crude oil prices fell 
The Dow Jones Industrial Average  DJIA  rose 184 points  0 9   to 20 637  the S P 500 Index gained 20 points  0 9   to 2 349  and the NASDAQ Composite increased 52 points  0 9   to 5 857  In moderate volume  704 million shares were traded on the NYSE and 1 4 billion shares changed hands on the NASDAQ  WTI crude oil lost  0 53 to  52 65 per barrel and wholesale gasoline was  0 01 lower at  1 72 per gallon  Elsewhere  the Bloomberg gold spot price declined  2 91 to  1 282 78 per ounce  and the dollar index  a comparison of the U S  dollar to six major world currencies  was down 0 3  at 100 31 
Shares of Eli Lilly and Co   NYSE LLY  83  and Incyte Corp   NASDAQ INCY  125  fell after their treatment for rheumatoid arthritis was rejected by the U S  Food and Drug Administration  FDA   The FDA said in a letter that it is unable to approve the application in its current form and indicated clinical data are needed to determine the most appropriate doses  Both companies said they disagree with the FDA s conclusions and the timing of a resubmission will be based on further discussions with the agency  LLY reaffirmed its 2017 financial guidance and INCY said it is evaluating the impact on its previously issued R D expenses guidance for 2017 
Arconic Inc  NYSE ARNC  27  announced that Chairman and Chief Executive Officer  CEO  Klaus Kleinfeld has stepped down  and David Hess will serve as Interim CEO  while Patricia Russo was appointed to serve as Interim Chair  The company said Kleinfeld stepped down by mutual agreement after the Board learned that amid a proxy fight  without consultation with or authorization by the Board  he had sent a letter directly to a senior officer of Elliot Management that the Board determined showed poor judgement  The company added that the decision was not made in response to the proxy fight or Elliot Management s criticisms of its strategy  leadership or performance and is not in any way related to the financials or records of the company  Shares were modestly higher 
Homebuilder sentiment and regional manufacturing slip more than expected 
The National Association of Home Builders  NAHB  Housing Market Index showed homebuilder sentiment this month declined to 68 from 71 in March  which was the highest level since June 2005  and compared to the Bloomberg expectation of a dip to 70  A 50 mark separates good and poor conditions  The NAHB said even with this month s modest drop  builder confidence is on very firm ground  and builders are reporting strong interest among potential home buyers  However  builders are facing several challenges  such as hefty regulatory costs and ongoing increases in building material prices 
Along with  ramping up  tomorrow s  will bring a look at housing construction activity in the form of housing starts and building permits  Starts are projected to decline 3 0  month over month to an annualized rate of 1 250 000 units  while permits are forecasted to rise 2 8  to an annual rate of 1 250 000 units 
The Empire Manufacturing Index showed output from the New York region fell more than expected but remained in expansion territory  a reading above zero  for April  The index dropped to 5 2 from March s unrevised 16 4 level  with the Bloomberg forecast calling for a 15 0 reading 
Treasuries finished mixed  as the yield on the2 Year note declined 2 basis points  bps  to 1 19   while the yields on the 10 Year note and the 30 Year bond rose 2 bps to 2 25  and 2 91   respectively 
Bond yields and the U S  dollar have come under pressure recently amid flared up geopolitical concerns  President Donald Trump s comments that he thought the greenback was getting  too strong   and some cooler than expected inflation data 
Investors appear to be shying away from risk  resulting in a pullback in stocks  We view this as temporary  although patience will be required and sharper downturns could occur within the ongoing bull market   Hard  economic data hasn t accelerated to the same degree as  soft  data  confidence survey based   and some convergence is expected  Political and geopolitical uncertainty abounds  while the Fed has begun to address the slow draining of its balance sheet  Global earnings have aided stock market gains  but the expectations bar is getting higher to hurdle  The next several weeks should show whether gains will persist or if expectations may have gone too far 
In addition to tomorrow s housing data  the Federal Reserve s industrial production and capacity utilization report is slated for release  with production expected to show a 0 4  m m increase during March  while utilization is forecasted to have moved higher to 76 2  
Asia mixed as many international markets remained closed
Stocks in Asia finished mixed amid heightened geopolitical concerns after another missile test by North Korea  while European markets remained closed for the Easter holiday  along with those in Hong Kong and Australia  The yen continued to gain ground amid the elevated uneasiness  likely limiting gains in Japan as stocks ticked only slightly higher 
Chinese economic data is in focus as the nation reported that its 1Q GDP grew at a 6 9  year over year  y y  pace  from the 6 8  expansion posted in 4Q  where it was expected to remain  Also  China s retail sales  industrial production and fixed asset investment all topped expectations  but mainland Chinese shares declined  China s markets were hampered by the heightened North Korean tensions and exacerbated concerns about further regulatory crackdowns on the markets  Stocks in South Korea rose modestly  while those traded in India fell ",2017-04-19,Marvin Clark,"https://www.investing.com/analysis/stocks-shrug-geopolitics,-domestic-data-200183537",200183537
172786,394302,LLY,Novartis  NVS  In Licenses Ophthalmic Drug From Lubris LLC,opinion,"Novartis AG   NYSE NVS   recently announced that it has exercised an option to in license ECF843 for ophthalmic indications worldwide  outside Europe  from Lubris LLC 

A look at Novartis  share price movement over the past one year shows that the stock has underperformed the Zacks classified  industry  Novartis  stock decreased 1 9  during this period  while the industry gained 1 9  
The company did not provide any financial details  The closing of the deal is subject to customary closing conditions that includes regulatory approvals 
We note that ECF843 is a recombinant human lubricin  rh Lubricin  protein  developed by Lubris  ECF843 demonstrated the potential to provide immediate improvement of symptoms by increasing lubrication across various eye and tear surfaces as well as an improvement in signs of dry eye within 28 days without reporting treatment related adverse events 
We note that Novartis has a diverse portfolio in ophthalmology and dry eye treatments with a global portfolio of artificial tear products that includes Systane  Tears Naturale and Genteal 
In Dec 2016  the company entered into a definitive agreement to acquire Encore Vision  Inc   a privately held company focused on the development of a novel treatment for presbyopia to strengthen its ophthalmology portfolio  The transaction will add Encore Vision s lead candidate  EV06  a first in class disease modifying topical treatment for presbyopia to the company s ophthalmology pipeline  Financial details of the transaction were  however  not disclosed 
We note that Novartis combined its retina medicines business with the Alcon pharmaceuticals business in 2016 which is now operating as one ophthalmology franchise under Novartis Pharmaceuticals 
The performance of the Alcon business has been disappointing due to lower surgical equipments sales owing to competition faced by intraocular lens and a slowdown in demand for equipment purchases  Novartis is mulling strategic options for Alcon which includes retaining the business to separation via a capital markets transaction such as a spin off or an initial public offering 
We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc s   NYSE GSK   certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Company   NYSE LLY    In Oct 2015  it acquired a portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and added bispecific antibodies through a collaboration with Xencor  Inc    NASDAQ XNCR   in Jun 2016 
Going forward  we expect approval of new drugs and label expansion of existing ones to bode well for Novartis  Also  strong performance of growth products should be able to offset the impact of generic competition for Gleevec 
Novartis currently carries a Zacks Rank  4  Sell   You can see  
Zacks  Best Private Investment Ideas                 
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-07,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-in-licenses-ophthalmic-drug-from-lubris-llc-200181719,200181719
172790,394306,LLY,Infinity Pharmaceuticals Focuses On Lead Candidate IPI 549,opinion,"We issued an updated report on Infinity Pharmaceuticals  Inc    NASDAQ INFI   on Apr 7 
Infinity s share price shows that the company has outperformed the Zacks classified  industry year to date  The stock rose 79 3  compared with the industry s gain of 0 2  

The company is currently focused on the development of its lead immuno oncology candidate  IPI 549  In Nov 2016  it had entered into a clinical trial collaboration with Bristol Myers Squibb Company   NYSE BMY   to evaluate IPI 549 in combination with the latter s checkpoint inhibitor Opdivo in patients with advanced solid tumors  Once the dose escalation phase on the combination is complete  an expansion phase will evaluate the combination in patients with selected solid tumors  including non small cell lung cancer  NSCLC   melanoma and squamous cell carcinoma of the head and neck  SCCHN  in the second half of 2017  In 2017  Infinity plans to report phase I data from the monotherapy dose escalation phase and the IPI 549 plus Opdivo dose escalation phase 
In fact  Infinity s progress with IPI 549 has been impressive  Moreover  clinical trial collaboration with Bristol Myers has provided the company with a strong partner with expertise in the field of immuno oncology  In addition  it is likely to allow Infinity to expedite the development of IPI 549 
In Oct 2016  the company entered into a license agreement with Verastem under which it granted exclusive worldwide rights to develop and commercialize its oncology candidate duvelisib to the latter  The agreement will see Infinity receiving up to  28 million across two milestone payments    6 million upon positive data  currently anticipated in the first half of 2017  from the randomized monotherapy phase III DUO study in patients with relapsed refractory CLL and  22 million upon the first regulatory approval of duvelisib inside or outside of the U S  In addition  Infinity is eligible to receive tiered mid to high single digit royalties on net sales of duvelisib  subject to approval  It will also be responsible for the royalties on net sales of duvelisib owed by the company to Mundipharma International Corporation and Purdue Pharmaceutical  Overall  we are optimistic about the deal as it is expected to provide Infinity with much needed funds 
In fact  Infinity has undergone a total of four restructuring drives since Jun 2016  This  in turn  has led to reduction of its employee headcount by an aggregate of 174 positions  representing approximately 79  from the Dec 31  2015  The company also announced that it will grant the rights to develop and commercialize duvelisib to Verastem  The company is also evaluating its current facility leases 
But besides IPI 549  Infinity has no approved product in its portfolio at the moment  This has led the company to totally depend on this particular candidate for growth  Consequently  too much focus on the successful development and approval of only one candidate might result in regulatory setbacks related to IPI 549 
Currently  Infinity faces stiff competition in the fields of immuno oncology from companies like Bristol Myers  AstraZeneca Plc   NYSE AZN    Celgene  NASDAQ CELG   Merck  NYSE MRK   Novartis  Pfizer  NYSE PFE   Roche and Eli Lilly and Company   NYSE LLY   among others 
Infinity Pharmaceuticals  Inc  Price    Zacks Rank
Infinity currently sports a Zacks Rank  1  Strong Buy   You can see  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-09,Zacks Investment Research,https://www.investing.com/analysis/infinity-pharmaceuticals-focuses-on-lead-candidate-ipi-549-200182033,200182033
172791,394307,LLY,Merck s Bid To Add Cardiovascular Data On Januvia Label Fails,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug  Januvia  sitagliptin  and other medicines containing Januvia The FDA issued a complete response letter to Merck s supplemental new drug applications  sNDA  seeking approval to include data from the TECOS  Trial Evaluating Cardiovascular Outcomes with Sitagliptin  trial on labels of Januvia  Janumet  Januvia  metformin HCl  and Janumet XR  an extended release formulation of Janumet  Merck is reviewing the letter and will discuss further steps with the FDA Merck s shares are up 7 2  so far this year  comparing favorably with an increase of 5 7  witnessed by the Zacks classified  industry As it is  the Januvia franchise  Januvia Janumet  is facing pricing pressure due to higher discounts and rebates to maintain good managed care coverage  The franchise recorded sales of  1 51 billion in the fourth quarter of 2016  up 4  from the year ago quarter as higher sales in the U S  offset lower sales in Japan  In 2016  the franchise s sales were  6 1 billion  up 2  year over year Note that the diabetes space is highly crowded with drugs like Eli Lilly   Company s   NYSE LLY   Tradjenta and Jardiance  Novo Nordisk  CO NOVOb  A S s   NYSE NVO   Victoza and Tresiba and Johnson   Johnson s   NYSE JNJ   Invokana  among others Importantly  with Lilly and Boehringer Ingelheim receiving FDA approval last year to include the cardiovascular  CV  indication on the label of their SGLT 2 inhibitor  Jardiance  DPP IV inhibitors like Januvia could see patients switching to SGLT 2 inhibitors  Cardiovascular disease is very common in adults with type II diabetes  With about 50  of deaths in type II diabetics resulting from CV disease  the addition of this data to Jardiance s label can lead to a major surge in the sales of the drug  The latest setback adds to Merck s woes for the diabetes franchise Merck currently carries a Zacks Rank  3  Hold   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them  Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-09,Zacks Investment Research,https://www.investing.com/analysis/merck's-bid-to-add-cardiovascular-data-on-januvia-label-fails-200181990,200181990
172793,394309,LLY,J J  JNJ  To Kick Off Pharma Q1 Earnings  Will It Beat ,opinion,We expect Johnson   Johnson   NYSE JNJ    a healthcare bellwether  to beat expectations when it reports first quarter 2017 results on Apr 18  before the opening bell  Last quarter  the company reported a positive earnings surprise of 1 28  J J s share price is up 8 8  so far this year  significantly ahead of the 5 5  increase witnessed by the Zacks classified industry J J has consistently surpassed earnings expectations  The company s earnings beat expectations in each of the last four quarters  with an average positive surprise of 2 43  Let s see how things are shaping up for this announcement Will its Pharma Segment Continue to Drive Results In the Pharmaceutical segment  new products like Imbruvica  Xarelto and Darzalex are performing impressively  Robust patient uptake in new indications  product approvals and demonstrated efficacy are propelling sales of Imbruvica  While Xarelto continues to gain market share and broader reimbursement  Darzalex is gaining acceptance as a treatment for multiple myeloma  Other drugs like Stelara  Invega Sustenna  and Simponi should also contribute meaningfully to the top line However  at the fourth quarter conference call  J J said that Pharma segment is expected to see sluggish growth in 2017 compared with 2016 as quite a few products in its portfolio like Remicade and Concerta have slowed down and are facing competition  While biosimilar competition hurt key arthritis drug Remicade sales outside the U S  in the fourth quarter  management said that Pfizer  Inc  s   NYSE PFE   at risk biosimilar launch of Inflectra did not have any significant impact until the results were announced  Management is expected to comment on the impact of Pfizer s Remicade biosimilar on first quarter sales J J continues to expect no biosimilar competition for Procrit in the U S  or generic competition for Zytiga  Risperdal Consta  or Invega Sustenna in 2017 Meanwhile  hepatitis C virus  HCV  treatment Olysio s sales will keep declining due to increased competition  while Invega continues to face a sales decline due to generic competition However  J J expects growth to accelerate in both the Medical Devices and Consumer segments in 2017 The Consumer segment sales improved sequentially in the fourth quarter on the back of global Beauty and OTC products  It remains to be seen if the positive trend continues in the soon to be reported quarter What Our Model IndicatesOur proven model shows that J J is likely to beat on earnings because it has the right combination of the two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  The   which represents the difference between the Most Accurate estimate   1 78 per share  and the Zacks Consensus Estimate   1 77 per share   is  0 57   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  J J has a Zacks Rank  3  The combination of J J s favorable Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderA couple of stocks in the large cap pharmaceuticals sector that also have a positive Earnings ESP and a favorable Zacks Rank are Bristol Myers Squibb Company   NYSE BMY   is expected to release results on Apr 27  The company has an Earnings ESP of  4 05  and a Zacks Rank  3  You can see  Eli Lilly and Company   NYSE LLY   has an Earnings ESP of  1 04  and a Zacks Rank  2  The company is scheduled to release results on Apr 25 The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-04-12,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-to-kick-off-pharma-q1-earnings:-will-it-beat-200182756,200182756
172797,394313,LLY,Zoetis  ZTS  Inks Agreement To Acquire Nexvet Biopharma,opinion,Zoetis Inc    NYSE ZTS   announced an agreement to buy Nexvet Biopharma plc   NASDAQ NVET   for an aggregate equity valuation of approximately  85 million  Nexvet is a biologic therapeutics company developing monoclonal antibody  mAb  therapies for companion animals Per the agreement  Zoetis will pay  6 72 for each share of Nexvet  a premium of 66  to the latter s closing price as of Apr 12  Zoetis expects the acquisition to strengthen its pipeline for chronic pain management in dogs and cats Nexvet s pipeline candidates include ranevetmab and frunevetmab for the treatment of chronic pain associated with osteoarthritis in dogs and cats  respectively Zoetis shares gained 9 4  in the past one year  outperforming the Zacks classified  industry  which remained flat in the same period The acquisition has already received unanimous approval from Nexvet s board of directors and awaits approval of its shareholders and the Irish high court  The deal is expected to be completed in the second half of 2017 Treatment of chronic pain in companion animals is estimated to be a  400 million industry  Zoetis already serves the industry through its drug  Rimadyl for the treatment of osteoarthritis pain and inflammation in dogs  Another of its non steroidal anti inflammatory drug  Trocoxil is approved in EU for the same indication as Rimadyl  Zoetis is a pioneer in antibody therapy solutions  The company also has presence in vaccines  parasiticides  medicated feed additives and other pharmaceuticals Zoetis has been working on strengthening its product portfolio through acquisitions and deals  It acquired a veterinary diagnostic focused company  Scandinavian Micro Biodevices  for  80 million in Aug 2016  The acquisition added a suite of specialty test instruments and cartridges to its diagnostics portfolio and pipeline in the fast growing segment of animal health The acquisition of Nexvet may help the company to protect its leading position in osteoarthritis pain in animals in the face of stiff competition from bigger companies like Merck   Co   Inc  s   NYSE MRK   Merck Animal Health  Eli Lilly and Company s   NYSE LLY   Elanco  Bayer  DE BAYGN  Animal Health  the animal health division of Bayer  and Boehringer Ingelheim Animal Health  the animal health division of Boehringer Ingelheim  Zoetis currently carries a Zacks Rank  3  Hold   You can see  Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/zoetis-(zts)-inks-agreement-to-acquire-nexvet-biopharma-200183127,200183127
172810,394326,LLY,Lilly  Jardiance Label To Add Cardiovascular Indication,opinion,"Eli Lilly   Company   NYSE LLY   recently announced that the FDA  has approved the inclusion of cardiovascular  CV  risk reduction data from the EMPA REG OUTCOME study on its type II diabetes drug Jardiance s  SGLT 2 inhibitor  label Jardiance was approved in 2014 for lowering blood sugar in adults with type II diabetes  Now  the FDA has approved a new indication for the drug to reduce the risk of cardiovascular death in adults with type II diabetes  We remind investors that Lilly and its partner  Boehringer Ingelheim  received a positive FDA panel recommendation in June for the inclusion of this data It remains to be seen if the company s stock reverses the decline following the negative solanezumab news announced last month  On Nov 23  Lilly announced that its high profile investigational Alzheimer s disease drug  solanezumab  failed to meet the primary endpoint in a late stage study  With the failure  Lilly decided to drop the development of solanezumab  The stock declined sharply on the news and hit a 52 week low on the same day Lilly s share price has declined 9  in the past one month  The decline in share price compares unfavorably with a decrease of 1 3  witnessed by the Zacks classified Large Cap Pharma industry Coming back to the latest news  cardiovascular disease is very common in adults with type II diabetes  With about 50  of the deaths in type II diabetics globally resulting from the CV disease  the addition of this data to Jardiance s label is expected to improve sales of the drug  Jardiance recorded sales of  47 5 million in the last reported third quarter of 2016 The landmark EMPA REG OUTCOME trial showed that irrespective of the type of cardiovascular disease at baseline  Jardiance tablets reduced the risk of cardiovascular death in adults with type II diabetes and established cardiovascular disease compared to placebo when added to standard of care The EMPA REG OUTCOME trial was carried out on more than 7 000 patients  from 42 countries  with type II diabetes and cardiovascular disease  It is regarded as the first long term trial of a diabetes medication to show a reduction in cardiovascular death in adults with type II diabetes and established cardiovascular disease Other diabetes drugs in Lilly s portfolio like Glyxambi and Synjardy could also benefit as both belong to the Jardiance family The new indication is expected to give Lilly a competitive advantage over the other oral type II diabetes medicines  The diabetes market is pretty crowded given the presence of companies like Novo Nordisk  CO NOVOb  A S   NYSE NVO    Johnson   Johnson   NYSE JNJ   and Merck   Co  Inc    NYSE MRK   Lilly carries a Zacks Rank  4  Sell  LILLY ELI   CO Price and Consensus
    You can see  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-12-05,Zacks Investment Research,https://www.investing.com/analysis/lilly:-jardiance-label-to-add-cardiovascular-indication-200168386,200168386
172811,394327,LLY,Economic Calendar And Watch List 12 15 2016,opinion,"Morning Notes
US Futures are relatively flat this morning while European markets trade higher by roughly  1  as markets digest the news of a 25 bp rate hike by the FOMC yesterday afternoon  Asian stocks closed predominantly lower 
Technicals

The SPY  NYSE SPY  pulled off record highs throughout yesterday s session and closed just off the intraday lows  Support will lie at the low of yesterday s range at  225 37  followed by  224 26 and  221 38  Resistance will lie at the high of yesterday s range at  228 23  followed closely by record highs at  228 34 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open 
  Others On Watch  
Eli Lilly and Company  NYSE LLY 
athenahealth Inc  NASDAQ ATHN 
Economic Calendar
8 30 Weekly initial unemployment claims expected  3 000 to 255K
8 30 November CPI expected  0 2 
8 30 December Empire manufacturing survey business conditions expected  2 5
8 30 December Philadelphia Fed business outlook survey expected  1 5
8 30 Q3 current account balance expected   111 6B
8 30 USDA weekly Export Sales
9 45 December Markit manufacturing PMI expected  0 4
10 00 December NAHB housing market index expected unchanged
Notable Earnings Before Open
NONE
Notable Earnings After Close
NONE",2016-12-16,Warrior Trading,https://www.investing.com/analysis/economic-calendar-and-watch-list-12-15-2016-200169904,200169904
172831,394347,LLY,Incyte  Eli Lilly Offer Positive Phase III Data On Baricitinib,opinion,"Incyte Corporation   NASDAQ INCY   and Eli Lilly and Company   NYSE LLY   provided updates from two phase III studies  RA BEAM and RA BUILD  on baricitinib for the treatment of rheumatoid arthritis  RA  RA BEAM evaluated baricitinib  in comparison to AbbVie Inc  s   NYSE ABBV   Humira  in patients who had active moderate to severe RA  despite ongoing treatment with methotrexate  RA BUILD  on the other hand  evaluated the candidate  in comparison to placebo  in patients with moderate to severe RA who previously had an inadequate response to  or were intolerant of  at least one conventional synthetic disease modifying antirheumatic drug  csDMARD  and had not received a biologic DMARD Findings from both the studies demonstrated that patients on the baricitinib  4 mg  arm experienced significant improvements in joint pain  severity of morning joint stiffness and tiredness  compared to both placebo and Humira Results were presented at an annual meeting of the American College of Rheumatology  ACR  Association of Rheumatology Health Professionals  ARHP  INCYTE CORP Price
 

   In a separate press release  Incyte and Eli Lilly announced new data analyses from the same studies  Data from three post hoc analyses on baricitinib showed improvements in RA symptoms in patients irrespective of age  body mass index  BMI  and previous treatments with csDMARDs We note that in Jan 2016  Eli Lilly submitted a regulatory application for baricitinib in both the U S  and the EU for the treatment of patients with mild to moderate severe RA  As per a WHO Global Burden of Disease Report  over 23 million people suffer from RA across the world Meanwhile  baricitinib is being evaluated in phase IIa study for the treatment of atopic dermatitis and in a phase II study for the treatment of systemic lupus erythematosus LILLY ELI   CO Price
 

   Zacks Rank   Key PicksIncyte is a Zacks Rank  2  Buy  stock  while Eli Lilly carries a Zacks Rank  3  Hold   Cambrex Corp    NYSE CBM   is a top ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Cambrex s earnings estimates have increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19 78  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-11-15,Zacks Investment Research,"https://www.investing.com/analysis/incyte,-eli-lilly-offer-positive-phase-iii-data-on-baricitinib-200164830",200164830
172832,394348,LLY,Eli Lilly Hits 52 Week Low On Poor Data On Alzheimer s Drug,opinion,"Indianapolis  IN based Eli Lilly and Company s   NYSE LLY   shares tumbled to a new 52 week low of  64 18 on Nov 23 after the company announced disappointing data from a late stage study on its Alzheimer s disease candidate  solanezumab  The company s shares closed a little higher at  68 00  reflecting a decline of almost 11  from the close of the last trading session What Led to the Decline Eli Lilly announced that solanezumab failed to meet the primary endpoint in a phase III study  EXPEDITION3  in patients with mild Alzheimer s dementia The study revealed that patients treated with solanezumab failed to demonstrate a statistically significant slowdown in cognitive deterioration compared to placebo Consequently  the company has decided not to submit the regulatory submissions for the candidate  These unfavorable findings will result in a fourth quarter 2016 charge of approximately  150 million  pre tax   or approximately 9 cents per share  after tax   Eli Lilly will issue an updated guidance for 2016 and reveal its expectations for 2017 next month We remind investors that this is not the first time that solanezumab has failed to meet the primary endpoint in late stage studies  In Aug 2012  the company announced that solanezumab failed to meet the primary endpoint in two phase III EXPEDITION studies   EXPEDITION1 and EXPEDITION2   in patients with mild to moderate Alzheimer s disease Earlier this year  the company s shares took a hit when it changed the primary endpoint for the EXPEDITION3 study  While the original study design included co primary endpoints of cognition and function  the company decided to proceed with a single primary endpoint of cognition Dementia due to Alzheimer s disease accounts for 60 80  of all dementia cases  As many as 47 million people are estimated to be living with dementia across the world  Moreover  people affected by the disease are expected to increase to nearly 75 million in 2030 and 131 million in 2050 The market thus represents huge commercial potential and a successfully developed product could generate billions of dollars of sales once launched  However  successful development of therapies for the treatment of Alzheimer s disease is very challenging  with a number of companies already having failed to do so Meanwhile  Eli Lilly  in collaboration with AstraZeneca plc   NYSE AZN    is currently evaluating another Alzheimer s disease  candidate  AZD3293  in a phase III study  AZD3293 enjoys fast track status in the U S LILLY ELI   CO Price
 

   Eli Lilly carries a Zacks Rank  3  Hold  Stock to ConsiderInvestors looking for a couple of favorably placed stock in the health care sector may consider Vanda Pharmaceuticals  Inc    NASDAQ VNDA   and Cambrex Corp    NYSE CBM    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days  while its earnings estimates increased from 16 cents to 17 cents for 2017  The company posted a positive earnings surprise in three of the last four quarters  with an average beat of 56 65   Its share price has surged 86  year to date Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-25,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-hits-52-week-low-on-poor-data-on-alzheimer's-drug-200166671,200166671
172833,394349,LLY,Health Care  Are Investors Fleeing Defensive Sectors ,opinion,"The Health Care sector rally that started with President elect Trump s victory on November 8th  and the defeat of Proposition 61 in California  has fizzled out ahead of the Financial and  return to global growth  rally within other sectors like Basic Materials  etc 
Given the surprise announcement around Eli Lilly  NYSE LLY  and their Alzheimer s drug on Wednesday  sending the stock down  10  I thought readers would want to be updated on Health Care sector earnings for Q4  16 and 2017 
Q4  16 expected Health Care sector earnings growth
11 25 16    5 7 
11 23 16   5 9 
11 18 16   5 9 
11 11 16   5 9 
11 4 16   6 4 
10 28 16   8 1 
10 21 16   8 1 
10 14 16   8 3 
10 7 16   8 4 
9 30 16   8 3 
This is a pretty normal downward revision pattern for a coming quarter for Health Care 
2017 expected Health Care sector earnings growth  
11 25 16   8 6 
10 1 16   10 1 
Analysis   conclusion  The health care sector has been written about previously  here and   Our positions haven t changed with a sector underweight  and the largest single position being Pfizer  NYSE PFE   which looks due for a bounce  Biotech is technically in good shape  but stopped rallying a few days after the election 
Health Care could become a victim of the  relative value  or  relative earnings growth  syndome  as one sector that has been a leader in the weaker  low return markets of the last few years  it could be that investors are rotating out of Health Care into sectors like Financials and Basic Materials  as these sectors will benefit directly from specific growth initiatives of the new President and Administration 
The fact is Health Care has more defensive characteristics  and with a full on economic growth agenda being planned  that consistent  stable earnings growth may not be as valued as it was in a no growth environment 
The iShares Nasdaq Biotechnology ETF  NASDAQ IBB  remains technically intact while the iShares US Pharmaceuticals Fund  NYSE IHE  looks to be in better shape than the VanEck Vectors Pharmaceutical Fund  NASDAQ PPH   although the PPH ETF will be given more time  A heavy volume trade through and close below  50  and the PPH would likely be sold 
Readers will be updated again near year end 2016 ",2016-11-26,Brian Gilmartin,https://www.investing.com/analysis/whats-up-with-the-health-care-sector--investors-fleeing-defensive-200166685,200166685
172834,394350,LLY,J J  JNJ  Stands Tall In 2016  Reasons For Outperformance,opinion,Johnson   Johnson   NYSE JNJ    the bellwether among healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Concerta In a year which saw the pharma sector struggling with media and political focus on high prices of drugs  J J s share price is up 9 5  in the year to date period  This compares favorably with the 8 0  fall for the Zacks classified Large Cap Pharma industry JOHNSON   JOHNS Price   Let us analyse the reasons for the same Consistently Strong Results  Regular Guidance Increases  J J has consistently delivered strong earnings results  It also came up with positive sales and earnings surprises in all the three quarters of 2016  Moreover  the company raised its full year earnings expectations in these three quarters Pharma Division Well Poised  Johnson   Johnson has one of the most diverse revenue streams in the industry in the pharmaceutical division  The segment accounts for around 47  of its total revenues  The company boasts several multi million dollar drugs covering a broad range of areas such as neuroscience  cardiovascular and metabolism  immunology  oncology and infectious diseases vaccines  The segment continues to perform well despite challenges like generic competition for a few products  potential biosimilar competition and lower revenues from the hepatitis C virus  HCV franchise  However  Pfizer Inc s   NYSE PFE   upcoming launch of biosimilar Remicade   Inflectra   creates some uncertainty regarding the segment s sales prospects in 2017  In fact  this explains why J J s shares have declined 3 9  since elections compared to a 1  decline for the Large Cap Pharma industry which gained significantly post elections  The company suffered the decline despite strong third quarter results announced on Oct 18  wherein it beat on all fronts and raised the lower end of its earnings outlook for the year However  we believe that the U S  Remicade biosimilar impact may be manageable  J J should be able to retain share as the 15  discount offered by Pfizer may not really end up in huge patient switches especially with the products not being interchangeable New Products Driving Sales  New products like Imbruvica  Xarelto and Darzalex have been well received by the market  Zytiga and Imbruvica are notable among the company s successful launches in the oncology portfolio  While strong patient uptake with new indications  approvals and demonstrated efficacy are driving sales of Imbruvica  Xarelto continues to gain market share and broader reimbursement  Darzalex is gradually gaining strong acceptance as a treatment for multiple myeloma The company is also working toward expanding the label of currently marketed products like Simponi  Stelara  Zytiga and Imbruvica which should further aid its top line Pipeline Matters  Johnson   Johnson  which has launched 12 new products since 2011  intends to seek approval for more than 10 new products between 2015 and 2019  The company said that each of these products have blockbuster potential  The company is targeting more than 40 line extensions of existing and new drugs as well  This should help it to lessen the impact of the genericization of key products in the pharma portfolio Key candidates in the company s pipeline include esketamine  treatment resistant depression   apalutamide  pre metastatic prostate cancer   imetelstat  myelofibrosis and myelodysplastic syndrome   sirukumab  rheumatoid arthritis and major depressive disorder   guselkumab  psoriasis  and niraparib  prostate cancer  among others ConclusionLike many of its peers like Eli Lilly and Company   NYSE LLY   and Merck   Co   Inc    NYSE MRK    J J is facing generic competition and pricing pressure for some products in its pharmaceutical segment  J J also had issues with its consumer segment manufacturing facilities Yet  we believe J J s diversified business model  deep pipeline  lack of cyclicality and strong financial position will continue to help the company navigate tough times  Meanwhile  J J s evolving product mix should drive growth in the face of biosimilar competition and market dynamics J J carries a Zacks Rank  3  Hold   You can see  Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ,2016-11-29,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-stands-tall-in-2016:-reasons-for-outperformance-200167395,200167395
172857,394373,LLY,Incyte  INCY  Stock Up As Q3 Earnings   Revenues Rise Y Y,opinion,Incyte Corporation   NASDAQ INCY   reported third quarter earnings of 11 cents  including the impact of a change in fair value of acquisition related contingent consideration and unrealized gain on long term investment   The Zacks Consensus Estimate was of breakeven results  Incyte had reported a loss of 5 cents per share in the year ago quarter Incyte s shares were up 3 5  on the news Quarterly revenues came in at  269 5 million  up 44  year over year  and beat the Zacks Consensus Estimate of  262 6 million  The strong top line growth was driven by higher sales of Jakafi in the U S  and Iclusig in Europe as well as royalties from ex U S  sales of Jakavi  We note that while Incyte markets the drug in the U S   it is marketed by Novartis AG   NYSE NVS   as Jakavi outside the U S Quarter in DetailJakafi sales surged 39   year over year to  223 9 million  Net product revenues of Iclusig amounted to  12 7 million  Product royalty revenues from Novartis for the commercialization of Jakafi in ex U S  markets surged 63  to  29 6 million However  contract revenues plunged approximately 60 9  to  3 2 million Research and development  R D  expenses were up 8 4  to  143 2 million  Selling  general and administration  SG A  expenses amounted to  75 8 million  up 59 2  year over year 2016 Outlook UpdatedIncyte has revised its outlook for 2016  Based on its third quarter performance of Jakafi in the reported quarter  the company now expects Jakafi revenues in the range of  850  855 million  previous expectation   825  835 million  Iclusig revenues are  however  still expected in the range of  25  30 million  We note that Incyte gained rights to develop and commercialize Iclusig in the EU and 22 other countries  including Switzerland  Norway  Turkey  Israel and Russia from ARIAD Pharmaceuticals  Inc    NASDAQ ARIA   in Jun 2016 R D expenses are now expected in the range of  570  580 million  compared to the earlier guidance of  620  630 million  The reduction mainly reflects slower than anticipated growth in the headcount  and phasing certain expenses from the company s programs and pipeline development into the next year  SG A expenses are still expected in the range of  285  310 million Pipeline UpdateIncyte continues to progress with its pipeline  Epacadostat is currently being evaluated in a phase III study  ECHO 301  in combination with Keytruda for the first line treatment of patients with advanced or metastatic melanoma  Epacadostat is also being evaluated in several phase I II combination studies across multiple tumor types Baricitinib  a JAK1 JAK2 inhibitor is under regulatory review globally for the treatment of patients with rheumatoid arthritis  If approved  anticipated in early 2017   Incyte will become eligible to earn regulatory and commercial milestones as well as royalties on its global net sales We note that Incyte is co developing baricitinib with Eli Lilly and Company   NYSE LLY   INCYTE CORP Price  Consensus and EPS Surprise    Zacks RankIncyte currently has Zacks Rank  2  Buy   Another equally ranked stock in the healthcare sector is ARIAD Pharmaceuticals  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-01,Zacks Investment Research,https://www.investing.com/analysis/incyte-(incy)-stock-up-as-q3-earnings---revenues-rise-y-y-200162288,200162288
172858,394374,LLY,How Tweets from Bernie Sanders Lowered Eli Lilly Stock Prices,opinion,"On his Twitter feed  Senator Bernie Sanders has highlighted a variety of news topics ranging from Native Americans to the Dakota Access Pipeline and the AT T Inc  NYSE T  Time Warner Inc  NYSE TWX  merger  However  his comments on pharmaceutical prices in general and the cost of insulin in particular have drawn the biggest reaction  On October 30 and 31  2016  he blasted Mylan  NASDAQ MYL   the makers of EpiPen  and stated that  the entire pharmaceutical industry is out of control   Sanders then posted several infographics showing disparities between the prices of popular pharmaceuticals  such as Crestor  Abilify and Celebrex  in the United States and Canada 
On November 1  Sanders singled out Eli Lilly  NYSE LLY   Novo Nordisk  CO NOVOb  and other companies that manufacture insulin  Health care analysts have reported that the prices of some insulin products have increased by 700 percent since 1997  A vial of Lilly s Humalog that used to cost less than  20 now costs nearly  140  He also criticized Sanofi  PA SASY  s insulin product Lantus Solostar  which costs  70 in France and  450 in America 
Following the controversial tweets  Eli Lilly stock prices slumped by as much as 2 7 percent falling to  71 per share  Just a few weeks earlier  the company s stock topped  83  a price that was close to its 2016 high in January  The October rise was due to an announcement that Lilly s subsidiary would acquire Boehringer Ingelheim s rabies vaccine portfolio  However  year to date figures show that Eli Lilly stock prices are down by more than 13 percent 
For years  Humalog has been a top seller in the fast acting insulin category  Although the list price has increased  some sources say that the net selling price has fallen by 24 percent  Sales of Humalog missed expectations by  100 million in the last quarter  Eli Lilly has failed to meet analyst expectations in three of the past four quarters 
Novo Nordisk stock has also fallen since late October  Revenue from its insulin product Victoza was up 10 percent  However  its stock prices plummeted from  40 per share to  35 when officials lowered the company s growth estimates 
Bernie Sanders s tweets also forced prices of ARIAD Pharmaceuticals Inc  NASDAQ ARIA  down by 15 percent back in mid October  He highlighted the industry s greed and mentioned that the cost of Ariad s leukemia medication costs more than  16 000 for a month s supply after two price hikes in one year 
Some experts say that the pharmaceutical giants are bracing for pricing oversight during Hillary Clinton s impending presidency  Others believe that the pharmaceutical industry is affected by the perennial pre election stock slump ",2016-11-02,Jesse Boskoff,https://www.investing.com/analysis/how-tweets-from-bernie-sanders-lowered-eli-lilly-stock-prices-200162389,200162389
172859,394375,LLY,Merrimack  MACK   What Awaits The Stock In Q3 Earnings ,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   is scheduled to report third quarter 2016 results on Nov 9  Last quarter  Merrimack delivered a negative earnings surprise of 17 65   Let s see how things are shaping up for the company this quarter Factors Influencing the QuarterApart from license and collaboration fees  Merrimack s top line comprises revenues generated by its only marketed product  Onivyde  The drug is approved in the U S   in Oct 2015   in combination with fluorouracil  5 FU  and leucovorin  for the treatment of metastatic adenocarcinoma of the pancreas in patients who were previously treated with Eli Lilly and Company s   NYSE LLY   Gemzar based therapy Onivyde s initial uptake has been encouraging  We expect the drug to contribute significantly to third quarter revenues Merrimack s efforts on commercializing Onivyde and driving awareness about the drug bode well  The company has also been engaged in visiting key institutions  educating physicians  and providing active patient and oncology practice support services Inclusion of the drug in the National Comprehensive Cancer Network  NCCN  clinical practice guidelines in Oncology for pancreatic adenocarcinoma should accelerate patient access  Moreover  its sales to major clinical institutions are expected to increase  going ahead In Jul 2016  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  rendered a positive opinion on the approval of Onivyde  We expect the company to offer further details on the regulatory front during its third quarter earnings call Meanwhile  Merrimack is working on expanding Onivyde s label into other indications such as front line pancreatic cancer  pediatric solid tumors and glioma  Investors are expected to remain focused on pipeline updates by the company Surprise HistoryMerrimack s track record has been decent so far with a four quarter average positive earnings surprise of 1 26   The company has beaten estimates twice in the last four trailing quarters  met the same once and missed them in the remaining one quarter MERRIMACK PHAR Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that Merrimack is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat expectations  But that is not the case here as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  23 33   This is because the Most Accurate Estimate stands at a loss of 37 cents and the Zacks Consensus Estimate is pegged at a loss of 30 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Although the company s Zacks Rank  2 enhances the predictive power of the ESP  its negative ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks that Warrant a LookHere are a couple of health care stocks that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Tokai Pharmaceuticals  Inc    NASDAQ TKAI   is expected to release third quarter results on Nov 8  The company has an Earnings ESP of is  18 42  and it carries a Zacks Rank  2  You can see  Synergy Pharmaceuticals  Inc    NASDAQ SGYP   is expected to report third quarter results on Nov 14  It has an Earnings ESP of  18 18  and a Zacks Rank  2 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/merrimack-(mack):-what-awaits-the-stock-in-q3-earnings-200163449,200163449
172860,394376,LLY,Merrimack  MACK  Q3 Loss Lower Than Expected  Stock Up,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   reported a loss of 23 cents per share in the third quarter of 2016  narrower than the Zacks Consensus Estimate of 30 cents Quarterly revenues came in at  28 1 million  down 16 7  sequentially  Revenues were  however  above the Zacks Consensus Estimate of  27 4 million Merrimack s shares gained 9  following the release of its third quarter results Quarter in DetailMerrimack s top line comprises revenues generated by its only marketed product  Onivyde  and license and collaboration fees Onivyde sales in the reported quarter amounted to  14 5 million  up 12 4  sequentially  primarily driven by an increase in the number of new patients on therapy  as well as longer treatment duration  Shipment of the drug from specialty distributors to individual accounts and facilities grew 18  sequentially Note that in Oct 2015  Onivyde was approved in the U S   in combination with fluorouracil  5 FU  and leucovorin  for the treatment of patients suffering from metastatic adenocarcinoma of the pancreas  who were previously treated with Eli Lilly and Company s   NYSE LLY   Gemzar based therapy  This October  Onivyde gained approval in the EU for the same indication License and collaboration revenues came in at  12 4 million  down 35 8  sequentially Research and development expenses were  32 1 million  down 21 8   Likewise  general and administrative expenses were also declined 12 6  to  18 1 million OutlookMerrimack has lowered its expense guidance for 2016  The company now expects research and development and selling  general and administrative expenses in the range of  235 5  245 5 million in 2016  compared with its earlier projection of  243 5  263 5 million Meanwhile  adjusted research and development and selling  general and administrative expenses  excluding anticipated milestone obligations to PharmaEngine of  35 5 million  are expected in the range of  200  210 million Merrimack has also revised its guidance for milestone achievements related to Onivyde  The company anticipates milestone payment of  4 5 million in 2016  compared to  46 5 million projected earlier  The remaining net milestones of  42 million  are expected in the first half of 2017 Pipeline UpdateIn Oct 2016  an abbreviated New Drug Application  ANDA  for a generic version of Doxil  doxorubicin HCl liposome injection  was accepted for review by the FDA  Merrimack has an agreement with Teva Pharmaceutical Industries Limited   NYSE TEVA    under which Merrimack is responsible for the development and commercial supply of the bulk form of Doxil Meanwhile  Merrimack is working on expanding Onivyde s label into other indications such as front line pancreatic cancer  pediatric solid tumors and glioma Our TakeMerrimack s third quarter results were encouraging with the company reporting a narrower than expected loss and revenues surpassing expectations  Initial uptake of Onivyde has been encouraging and should boost the top line  going forward  We are also positive on the company s efforts to develop its pipeline candidates MERRIMACK PHAR Price  Consensus and EPS Surprise
    Zacks Rank   Key PicksMerrimack Pharma carries a Zacks Rank  3  Hold   Cambrex Corporation   NYSE CBM   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Cambrex s earnings estimates have increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19 78  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-10,Zacks Investment Research,"https://www.investing.com/analysis/merrimack-(mack)-q3-loss-lower-than-expected,-stock-up-200164144",200164144
172861,394377,LLY,5 Pharma Stocks In Focus On World Diabetes Day,opinion,"Every year  World Diabetes Day is celebrated on Nov 14  This year  the theme is  eyes on diabetes  with a focus on promoting the importance of screening to ensure early diagnosis of type II diabetes and reduce the risk of serious complications According to information provided by the International Diabetes Foundation  IDF   about 415 million adults were living with diabetes in 2015 with the number expected to increase to around 642 million or one in ten adults by 2040  Moreover  many people with type II diabetes remain unaware of their condition for a long period of time and this may lead to diabetes related complications by the time the disease is diagnosed Diabetes can often be the cause of other complications like blindness  cardiovascular disease  lower limb amputation and kidney failure  It is estimated that about one third of the 415 million adults living with diabetes will develop some form of diabetic retinopathy while more than 93 million adults currently living with diabetes already have diabetic retinopathy Meanwhile  as per IDF  global health spending to treat diabetes and manage complications was estimated to be about  673 billion in 2015 Given these statistics  it is not surprising that several healthcare companies devote a significant amount of R D dollars on developing treatments and devices for diabetes and diabetes management  The diabetes market is highly crowded with companies coming out with innovative treatments promising higher efficacy with lower side effects  Currently available diabetes drugs include different classes of treatments like DPP 4 inhibitors  Januvia  Onglyza  Tradjenta   GLP 1 receptor agonists  Byetta  Victoza  and SGLT 2  Invokana  Farxiga  apart from metformin and insulin therapy Stocks to Watch on World Diabetes DayToday on World Diabetes Day  here is a look at some of the key pharma companies in the diabetes market Denmark based Novo Nordisk  CO NOVOb  A S   NYSE NVO   is one of the key players in the global diabetes market  The company s diabetes portfolio comprises products like Tresiba  a once daily new generation insulin   Xultophy  a once daily single injection combination of Tresiba and Victoza   Ryzodeg  a soluble formulation of Tresiba and NovoLog   NovoLog  insulin aspart  and Victoza  GLP 1   However  the franchise is under pressure reflecting increased competition in the basal insulin segment  a continued decline in the premix segment  and the increasingly tough pricing environment in the U S  within diabetes care  Formulary changes giving preference to follow on biologics will also weigh on performance As far as its pipeline is concerned  Novo Nordisk announced on its third quarter call that it will not continue current development projects within oral insulin and combinations involving oral insulin  Meanwhile  the company is currently seeking FDA approval for IDegLira  a fixed ratio combination of Tresiba and Victoza  though the FDA action date was pushed back by 3 months with a decision now expected in December  GLP 1 med semaglutide remains a key pipeline candidate with regulatory filings expected by year end  Novo Nordisk also intends to focus on disease areas adjacent to diabetes including end organs like the liver  kidneys and the cardiovascular system 
NOVO NORDISK AS Price  Consensus and EPS Surprise   French drugmaker Sanofi  PA SASY    NYSE SNY   also holds a key position in the diabetes market  However  Sanofi s Diabetes franchise is under pressure with key product  Lantus  facing increasing competitive pressure at the payor level and biosimilar competition in several European markets  Moreover  Basaglar  a follow on insulin glargine product is expected to enter the U S  market in mid December  Sanofi expects its global Diabetes sales to decline 4 8  annually  at constant exchange rates  over the 2015 2018 timeframe 
Despite the challenges in the diabetes market  Sanofi continues to work on expanding and strengthening its diabetes portfolio and currently has quite a few diabetes programs in its pipeline including LixiLan  fixed ratio Lantus  Adlyxin  FDA response expected in November   SAR342434  insulin lispro  under EU review   sotagliflozin  oral SGLT 1 2 inhibitor  phase III for type I diabetes and phase III ready for type II diabetes  and efpeglenatiden  long acting GLP 1 receptor agonist  phase II  
SANOFI AVENTIS Price  Consensus and EPS Surprise   Another well positioned company in the diabetes market is Eli Lilly and Company   NYSE LLY    Lilly has a strong portfolio of diabetes treatments including Trulicity  GLP 1   Jardiance  SGLT 2   Trajenta  Humulin  Humalog  and Glyxambi  Lilly has a diabetes alliance with Boehringer Ingelheim for several of these products  Lilly could well see a surge in sales of Jardiance provided the FDA gives its nod for the addition of EMPA REG OUTCOME study data  which showed cardiovascular  CV  risk reduction  to Jardiance s label   a decision from the FDA is expected on Dec 4  2016  Lilly also has a strong diabetes pipeline 
LILLY ELI   CO Price  Consensus and EPS Surprise   Kenilworth  NJ based Merck   Co   Inc  s   NYSE MRK   diabetes franchise  which accounted for about 16 5  of third quarter 2016 pharma segment sales  consists of products like Januvia and Janumet  On its third quarter call  Merck said that Januvia continues to be the leading DPP 4 treatment of choice in the market  The company expects Januvia s 2017 formulary access to remain similar to that seen in 2016 though pricing pressure in the U S  is expected to continue   Merck s NDA for MK 1293  a follow on insulin glargine  Lantus  candidate is currently under FDA review while the company and its partner Pfizer Inc    NYSE PFE   expect to file for approval of ertugliflozin as monotherapy and as a fixed dose combination with metformin or Januvia by year end 
MERCK   CO INC Price  Consensus and EPS Surprise   Diabetes is one of the six growth platforms for AstraZeneca plc   NYSE AZN    Key products in AstraZeneca s diabetes portfolio include Farxiga  Onglyza  Bydureon and Byetta  The company is also evaluating a combination of Farxiga and Bydureon for type II diabetes 
ASTRAZENECA PLC Price  Consensus and EPS Surprise   Despite pricing pressure and growing competition  diabetes remains a lucrative market given the growing prevalence of the disease and the demand for new treatments  Apart from Novo Nordisk and Merck  all the above mentioned companies are Zacks Rank  3  Hold  stocks  While Novo Nordisk is a Zacks Rank  4  Sell  stock  Merck carries a Zacks Rank  2  Buy   You can see  
Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-11-13,Zacks Investment Research,https://www.investing.com/analysis/5-pharma-stocks-in-focus-on-world-diabetes-day-200164468,200164468
172877,394393,LLY,J J s Psoriasis Drug Shows Superior Efficacy Over Humira,opinion,"Johnson   Johnson   NYSE JNJ   subsidiary  Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab  over AbbVie Inc  s   NYSE ABBV   drug Humira in the treatment of moderate to severe plaque psoriasis 
Data from the VOYAGE 1 trial  n 837  showed that significantly higher proportions of patients with moderate to severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo  73  of the patients receiving guselkumab achieved near complete skin clearance versus 2 9  on placebo 
The active comparator arm of the VOYAGE trial evaluated guselkumab versus top selling medicine Humira  The study demonstrated the statistically significant efficacy of guselkumab compared to Humira after week 16 which was maintained through 48 weeks of treatment  Almost 50  of patients treated with Humira achieved near complete skin clearance versus 73  for guselkumab JOHNSON   JOHNS Price
 

   Humira is also approved for the treatment of rheumatoid arthritis and other autoimmune conditions 
The data was presented at the European Academy of Dermatology and Venereology  EADV  Congress in Austria 
Guselkumab  an anti IL 23 human monoclonal antibody  is being evaluated in three pivotal phase III studies   VOYAGE 1  VOYAGE 2 and NAVIGATE   for moderate to severe plaque psoriasis  A phase II trial evaluating guselkumab in moderate to severely active psoriatic arthritis is also ongoing 
J J carries a Zacks Rank  3  Hold   Stocks worth considering in the large cap healthcare sector are Eli Lilly and Co    NYSE LLY   and Abbott Laboratories   NYSE ABT   
Eli Lilly has a Zacks Rank  2  Buy   You can see the  
Eli Lilly has delivered an average four quarter positive earnings surprise of 4 31   Its earnings estimate for 2016 has risen by 0 3  while that for 2017 has risen more than 2  over the last 90 days 
Abbott  also enjoying a Zacks Rank  2  has delivered positive earnings surprises for the past four straight quarters  with an average surprise of 3 11  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-03,Zacks Investment Research,https://www.investing.com/analysis/j-j's-psoriasis-drug-shows-superior-efficacy-over-humira-200156844,200156844
172879,394395,LLY,Merrimack s Onivyde Positive In Pancreatic Cancer Study,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   announced encouraging final data from a phase III study  NAPOLI 1  on Onivyde  in combination with fluorouracil  5 FU  and leucovorin  in the treatment of patients with metastatic pancreatic ductal adenocarcinoma  mPDAC   following treatment with Eli Lilly and Company s   NYSE LLY   Gemzar  gemcitabine  based therapy Data from the study demonstrated a high level of clinical evidence  thereby validating the use of Onivyde as a meaningful treatment option for metastatic pancreatic cancer Results confirmed overall survival and progression free survival benefit of the Onivyde regimen  The disease control rate was found to be almost double in patients treated with Onivyde  in combination with 5 FU and leucovorin  compared to 5 FU and leucovorin alone  Results were presented at the congress of the European Society for Medical Oncology MERRIMACK PHAR Price
    We note that in Oct 2015  Onivyde was approved in the U S  for use in combination with fluorouracil  5 FU  and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following Gemzar based therapy  However  Onivyde s label contains a black box warning regarding severe neutropenia and diarrhea Onivyde is currently under review in the EU  In Jul 2016  Merrimack received a positive opinion from the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  In the U S   the combination was added to the National Comprehensive Cancer Network  NCCN  2016 clinical practice guidelines in oncology as a category I treatment option for patients with pancreatic adenocarcinoma  Meanwhile  it was given a category 2B status in the European Society for Medical Oncology  ESMO  2015 clinical practice guidelines We remind investors that Merrimack has an exclusive licensing agreement with Shire plc   NASDAQ SHPG   for the development and commercialization of Onivyde outside the U S  and Taiwan According to the American Cancer Society  approximately 50 000 patients are diagnosed with pancreatic cancer each year in the U S  Moreover  the World Health Organization estimates that approximately 338 000 new cases of pancreatic cancer occur each year in the world Currently  Merrimack is working on expanding Onivyde s label to include metastatic colorectal cancer  pediatric solid tumors and glioma  among others The company currently carries a Zacks Rank  3  Hold  A Stock to ConsiderGeron Corporation   NASDAQ GERN   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   The company has delivered a positive earnings surprise in each of four trailing quarters  bringing the average beat to 20 78   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-11,Zacks Investment Research,https://www.investing.com/analysis/merrimack's-onivyde-positive-in-pancreatic-cancer-study-200158378,200158378
172895,394411,LLY,Merck  MRK  Updates Outlook Following Q2 Earnings Beat ,opinion,"Merck   Co   reported second quarter 2016 earnings of 93 cents per share  surpassing the Zacks Consensus Estimate by a penny and increasing 8 1  from the year ago period 



	Revenues for the quarter grew 1  to  9 8 billion  in line with the Zacks Consensus Estimate  Currency movement negatively impacted revenues by 2  The Quarter in Detail
	Merck s Pharmaceutical segment posted revenues of  8 7 billion  up 2   Products like Keytruda  Cubicin and ProQuad performed well  New product  Keytruda  brought in sales of  314 million in the second quarter of 2016  up from  249 million in the first quarter of 2016  Sales continue to be driven by new indications and geographical expansion  Zetia Vytorin sales grew 4  to  994 million reflecting the impact of price increases for Zetia in the U S 
	Recently launched HCV product Zepatier brought in sales of  112 million  up from  50 million in the first quarter  Januvia Janumet sales grew 2  to  1 6 billion 
	Cubicin sales came in at  357 million  Cubicin lost patent protection in Jun 2016 and sales are expected to fall significantly 
	Meanwhile  Remicade  loss of exclusivity in Europe and increasing biosimilar competition in this region   Nasonex  generic version launched in the U S  in Mar 2016   Gardasil Gardasil 9  reflecting the timing of public sector purchases  and Isentress all recorded a decline in sales 
	Merck s animal health segment posted revenues of  898 million  up 7  from the year ago quarter 
	Marketing and administrative expenses declined 5  to  2 4 billion in the second quarter of 2016  R D spend grew 17 7  to  1 9 billion in the second quarter of 2016 reflecting higher licensing costs and increased clinical development spending Updates Guidance
	Merck raised the bottom end of its 2016 earnings guidance to  3 67    3 77 per share  including an approximately 1  negative impact from foreign exchange 
	Revenue guidance was narrowed to  39 1    40 1 billion  including an approximately 2  negative impact from foreign exchange  The Zacks Consensus Estimate for earnings and revenues is currently  3 72 per share and  39 6 billion  respectively 
	Meanwhile  Merck continues to expect marketing and administrative spend to decline from 2015 levels and R D spend to be slightly above 2015 levels  The company spent  6 6 billion and  9 8 billion on R D and marketing and administrative matters  respectively  in 2015 Our Take
	Merck s second quarter earnings were better than expected  while revenues were in line  The top line will remain under pressure mainly due to increased competition as well as generic competition  Merck will continue to look toward cost cutting initiatives to drive the bottom line 

	We are encouraged by the company s efforts to expand its pipeline and focus on core areas of expertise  The company has made significant progress with its pipeline and is working on bringing new products to market  New products like Keytruda should contribute meaningfully to the top line 
	Merck is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company  NYSE BMY    Johnson   Johnson  NYSE JNJ   and Eli Lilly and Company  NYSE LLY    All three are Zacks Rank  2  Buy  stocks 


		MERCK   CO INC Price


  ",2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-updates-outlook-following-q2-earnings-beat-200144971,200144971
172896,394412,LLY,AbbVie  ABBV  Beats On 2Q Earnings  Revenues  Ups View,opinion,AbbVie Inc    NYSE ABBV   reported second quarter 2016 earnings of  1 26 per share  up 16 7  from the year ago quarter and surpassing the Zacks Consensus Estimate of  1 20 per shareRevenues increased 17 5  to  6 43 billion in the second quarter of 2016  beating the Zacks Consensus Estimate of  6 24 billion The Quarter in DetailsKey drug Humira recorded growth of 17 4  with revenues coming in at  4 1 billion  U S  sales increased 26 7    2 7 billion  driven by growth across all three major market categories  rheumatology  dermatology and gastroenterology  Ex U S  sales grew 3  to  1 4 billion  Growing awareness  favorable clinical data  additional indications and expansion into new markets should help the product to continue contributing significantly to the top line Other products that performed well include Duodopa  up 31 2  to  73 million  and Creon  up 12 9  to  180 million   Meanwhile  products like Synagis and Kaletra  HIV  recorded a decline in revenues HCV product Viekira recorded sales of  419 million  slightly above  414 million in the first quarter of 2016  Competition in the HCV market has intensified  AbbVie recorded Imbruvica U S  sales of  384 million and  55 million of international profit sharing Raises 2016 OutlookAbbVie raised its 2016 EPS outlook to  4 73    4 83 per share from the previous range of  4 62    4 82 per share  The Zacks Consensus Estimate is currently  4 76 per share Our TakeAbbVie s second quarter results were good with the company surpassing expectations on all fronts  Humira and Imbruvica continued to perform well while Viekira continues to feel the impact of additional competition and the label update With several companies working on bringing Humira biosimilars to market  AbbVie has been focusing on diversifying its revenue base and lowering its dependence on the product  AbbVie is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Bristol Myers Squibb Company   NYSE BMY    Johnson   Johnson   NYSE JNJ   and Eli Lilly and Company   NYSE LLY    All three are Zacks Rank  2  Buy  stocks ABBVIE INC Price  ,2016-07-28,Zacks Investment Research,"https://www.investing.com/analysis/abbvie-(abbv)-beats-on-2q-earnings,-revenues,-ups-view-200145089",200145089
172897,394413,LLY,Merrimack  MACK   Can The Stock Surprise In Q2 Earnings ,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   is scheduled to report second quarter 2016 results on Aug 4  Last quarter  Merrimack delivered an earnings surprise of  15 38   Let s see how things are shaping up for the company this quarter Factors Influencing This QuarterMerrimack s only marketed product  Onivyde  gained approval in the U S  in Oct 2015  in combination with fluorouracil  5 FU  and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas in patients who were previously treated with Eli Lilly and Company s   NYSE LLY   Gemzar based therapy The company s efforts on commercializing Onivyde and driving awareness about the drug bode well  Merrimack has also been engaged in visiting key institutions  educating physicians  and providing active patient and oncology practice support services Sales of the drug are expected to increase in major academic centers  Inclusion of the drug in the National Comprehensive Cancer Network  NCCN  clinical practice guidelines in Oncology for pancreatic adenocarcinoma was a major boost to the company 
The guidelines recognized the product as category 1 second line therapy for metastatic adenocarcinoma of the pancreas in patients who were previously treated with Gemzar based therapy  This further validated the importance of the drug for patients suffering from metastatic pancreatic cancer  Consequently  the number of sites to have Onyvide on formulary had almost doubled last quarter and should continue to do so in the to be reported quarter as well Last month  the company received a positive opinion from the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  on Onyvide for its use in combination with fluorouracil  5 FU  and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed after Gemzar based therapy  We expect the company to offer further details on the regulatory front during its second quarter earnings call Meanwhile  a number of studies for a potential label expansion of Onivyde to include other indications such as front line pancreatic cancer  pediatric solid tumors and glioma are ongoing  The company is also progressing on with its two other late stage candidates   MM 302 and MM121 seribantumab  Investors are expected to remain focused on pipeline updates by the company License and collaboration revenues are expected to drive substantial top line growth at the company in the to be reported quarter Surprise HistoryMerrimack s track record has been impressive so far  The company has beaten estimates in three of the last four trailing quarters and reported in line with estimates in one  The average positive earnings surprise is  11 93  MERRIMACK PHAR Price and EPS Surprise
   What Our Model IndicatesOur proven model does not conclusively show that Merrimack is likely to beat earnings this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat expectations  But that is not the case here as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is 0 00  Zacks Rank  Although the company s Zacks Rank  3 enhances the predictive power of the ESP  its 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Ironwood Pharmaceuticals   NASDAQ IRWD   has an Earnings ESP of  13 33  and a Zacks Rank  2  The company is expected to report earnings on Aug 4 Exelixis  Inc    NASDAQ EXEL   has an Earnings ESP of  3 70  and a Zacks Rank  3  The company is scheduled to report results on Aug 3 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-01,Zacks Investment Research,https://www.investing.com/analysis/merrimack-(mack):-can-the-stock-surprise-in-q2-earnings-200145523,200145523
172898,394414,LLY,Bristol Myers Tanks  Buy These Two Large Cap Pharma Stocks Instead,opinion,"Several large cap pharmaceutical stocks are making waves on Friday as shares of Bristol Myers Squibb   NYSE BMY   tanked more than 17  following the news that its cancer drug failed to meet targets in a late stage study 
Bristol Myers was testing a drug called Opdivo  which has already been approved to treat some forms of cancer  to see if it would be successful in fighting advanced non small cell lung cancer  Unfortunately  Opdivo failed to meet its primary endpoint of improvement in progression free survival 
On the other hand  shares of Bristol Myers rival Merck   NYSE MRK   are surging more than 10  because its drug Keytruda  which competes with Opdivo  was more successful in a similar trial recently  Bristol Myers did open its study to a wider patient population  exposing itself to more risk  but it looks like investors are willing to call this a win for Merck right now 
 Also Read   
With Bristol Myers being such a massive entity in the pharmaceutical industry  today s news is incredibly important for the market  The stock is now down about 8  on the year  and it makes sense that investors may be looking a different direction 
Luckily  the Zacks Rank indicates that a couple of other stocks in the large cap pharmaceutical industry might be better options right now  The first one we ll look at is Johnson   Johnson   NYSE JNJ    which is currently a Zacks Rank  2  Buy  
In comparison to an industry that has remained relatively flat in 2016  shares of Johnson   Johnson have gained a little over 20  year to date  The company has a ridiculous track record of beating earnings expectations  consistently outperforming the Zacks Consensus Estimate for nearly a decade  Johnson   Johnson has also seen ten positive estimate revisions for its full year earnings within the past 30 days 
Another stock to note right now is Eli Lilly and Company   NYSE LLY    another Zacks Rank  2  Buy   While Eli Lily and Co  has struggled throughout the year  shares have bounced back  gaining nearly 8 5  over the last 12 weeks  In its most recent earnings report  the company outperformed the Zacks Consensus Estimate by a penny  and analysts have been busy revising estimates for the remainder of the year 
In the past 30 days  we ve seen three positive estimate revisions for the company s current quarter earnings versus just one negative revision  In that same timeframe  we ve seen four positive revisions for Eli Lilly and Co  s full year earnings  In just the past week  the Zacks Consensus Estimate for the company s earnings has gone up by a penny 
Despite the negative news from Bristol Myers today  pharma investors can see that estimate revision activity points to other stocks right now ",2016-08-05,Zacks Investment Research,"https://www.investing.com/analysis/bristol-myers-tanks,-buy-these-two-large-cap-pharma-stocks-instead-200146452",200146452
172900,394416,LLY,Epizyme Doses First Patient In Phase II Mesothelioma Study,opinion,Epizyme  Inc    NASDAQ EPZM   announced that it has dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma  characterized by BAP1 loss of function The study will first evaluate the safety and pharmacokinetic profile of the candidate in patients  n 12  with relapsed or refractory mesothelioma  regardless of BAP1 status  This will be followed by a two stage study in patients  n 55  with relapsed or refractory mesothelioma characterized by BAP1 loss of function As per the company s press release  about 12 000 individuals are affected by mesothelioma each year in the major markets  Out of this  40 60  of individuals have tumors characterized by BAP1 loss of function  Median overall survival for patients with mesothelioma ranges from 8 to 14 months from the time of diagnosis We note that the most commonly used first line treatment for mesothelioma is Eli Lilly and Company s   NYSE LLY   Alimta  approved in 2004 for mesothelioma1   used in combination with cisplatin or carboplatin EPIZYME INC Price   We remind investors that Epizyme is currently evaluating tazemetostat in a phase II study in adults with relapsed or refractory non Hodgkin lymphoma  in a phase II study in adults and in a phase I study in children with certain genetically defined solid tumors  including INI1 negative or SMARCA4 negative rhabdoid tumors  renal medullary carcinoma  epithelioid sarcoma  other INI1 negative tumors and synovial sarcoma Moreover  a couple of combination studies on tazemetostat are expected to begin in 2016  Under a collaboration agreement with Roche Holding  SIX ROG  AG s   OTC RHHBY   Genentech  Epizyme will evaluate tazemetostat  in combination with Tecentriq  atezolizumab   for the treatment of patients with diffuse large B cell lymphoma  The company will also evaluate the candidate in combination with R CHOP for the same indication  in collaboration with the Lymphoma Study Association Meanwhile  Aduro BioTech  Inc    NASDAQ ADRO   is currently evaluating its immunotherapy candidate  CRS 207  in combination with Alimta and cisplatin  as the front line treatment for patients with unresectable malignant pleural mesothelioma Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-14,Zacks Investment Research,https://www.investing.com/analysis/epizyme-doses-first-patient-in-phase-ii-mesothelioma-study-200147993,200147993
172904,394420,LLY,Eli Lilly s Future Is Changing,opinion,"Eli Lilly and Company  NYSE LLY  is a blue chip stock that has paid a consistent dividend since the early 1970s 
The company s total dividends paid have increased from 4 55 cents per share in 1972 to a projected  2 04 per share in fiscal year 2016 
However  the company s dividend growth rate has materially slowed  and the dividend payout ratio is now over 80  
Should investors be concerned that Eli Lilly could be poised for years of flat dividends or possibly even a cut to the dividend 
Let s take a look at the business Business AnalysisEli Lilly is a global pharmaceutical company with an operating history that dates back to the late 1800s  In 2015  they generated sales of nearly  20 billion  which is down from the recent peak of  24 3 billion in 2011 
In general  the pharmaceutical industry can be a pretty good space to invest in for dividend investors seeking a stable dividend income over time 
Dividend investors do not have to worry about economic cycles or cyclical end markets leading to an unanticipated dividend cut when investing in this recession resistant industry 
Besides analyzing all the usual important financial ratios  dividend investors instead need to pay attention to the quality of the product portfolio and pipeline of new products along with any significant legal issues the company could have outstanding 
Eli Lilly operates the business through two business segments   human pharmaceutical products  84  of sales  and animal health products  16   
The Human Pharmaceutical Products business produces therapeutics targeting areas including endocrine  neuroscience  oncology  and cardiovascular  Their key drugs targeting these markets are Humalog  diabetes   Alimta  cancer   Forteo  osteoporosis   Cialis  cardiovascular   and Cymbalta  depression   They have 6 different billion dollar revenue drugs  and their top ten drugs add up to nearly 70  of sales 
The Animal Health Products business produces drugs for companion animals as well as farm animals  In January 2015  they completed the acquisition of Novartis Animal Health for  5 3 billion dollars to improve their competitive position within the market  particularly within companion animal and swine markets 
Like many other large pharmaceutical companies  Eli Lilly recently transitioned through a difficult time with a patent expiration in many key drugs  They lost patent protection on Zyprexa  2010 revenue of  5 billion   Cymbalta  2012 revenue of  5 billion   and Humalog  2012 revenue  2 4 billion  Source  Simply Safe Dividends
However  they are not completely out of the woods yet  Over the next few years they face patent expiration in key markets for large products including Alimta  13  of sales   Cialis  11    Forteo  7    Cymbalta  4    Zyprexa  4    Strattera  3    and Effient  2   
Thankfully  Eli Lilly invests around 20  of sales in research and development  above peers who average in the mid teens 
These investments have resulted in a rather robust pipeline of new products in their late stage pipeline and even a few recent introductions to the market 
The major therapeutics investors need to keep an eye on are Jardiance  Type 2 diabetes   Baricitinib  Rheumatoid arthritis   Taltz  Psoriasis   and Solanezumab  Alzheimer s  
The revenue potential from these products is expected to be quite significant  Jardiance has already been launched and is expected to be a multibillion dollar product  While Baricitinib and Taltz aren t expected to have the same sales potential as Jardiance  they are both expected to be billion dollar plus selling drugs 
The real question mark in Eli Lilly s late stage pipeline is Solanezumab  which is used to treat Alzheimer s 
The benefits to patients and sales potential from this therapeutic could be substantial  but to date no pharmaceutical company has been approved for a treatment that has proven to slow Alzheimer s effects  In other words  Solanezumab remains a long shot 
When the entire pipeline and recent launches are considered  Eli Lilly is positioned to have the potential to launch 20 new products in 10 years  2014 through 2023   This gives the management team confidence in their projections for at least 5  annual revenue growth through the rest of the decade despite key drugs coming off patent protection 
Furthermore  shareholders should benefit from improved margins at the company  The management team has committed to an OPEX to revenue ratio of 50  or less in 2018  This would represent an improvement from a GAAP OPEX to revenue ratio of nearly 58  in 2015 
Clearly if management is able to execute on this margin improvement from increased efficiency in R D and marketing  selling  and administrative costs  it would be a great achievement and would allow for significant dividend increases Dividend Safety Analysis  Eli LillyWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend  Eli Lilly s dividend and fundamental data charts can all be seen by  
Our Dividend Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more  A score of 50 is average  75 or higher is considered excellent  and 25 or lower is considered weak 
Investors can learn more about our Dividend Safety Scores and view their track record  
Eli Lilly s Dividend Safety Score is 59  which indicates that the dividend is somewhat safer than the average stock in the market and unlikely to be cut 
If Eli Lilly is able to execute on their strategy and the recent drug launches meet expectations  the company s dividend safety will continue to rise 
The company expects 2016 non GAAP EPS of  3 50  3 60 with the major difference between GAAP and non GAAP being amortization of intangible assets from recent acquisitions  As dividend investors  we feel comfortable with this adjustment as this is a non cash charge 
If the company maintains the  0 51 per share quarterly dividend for the fourth quarter of 2016 like we expect  then the company s payout ratio would be around 57  for 2016 
This is much healthier than the 88  payout ratio the company reported in 2014 and 2015 and puts the company closer to its historical payout ratio in the 45 65  range over the past decade Source  Simply Safe Dividends
Let s take a closer look at some of the other important drivers of the Dividend Safety Score 
As of the end of the second quarter 2016  Eli Lilly had  9 3 billion dollars of debt of which  646 million is due within a year  This debt is offset by cash of  3 2 billion dollars  making total net debt  6 1 billion 
This is a very comfortable amount of debt for the company as illustrated by a net debt to EBIT ratio of just 1 6x 
Furthermore  the company s EBIT Interest expense ratio is very healthy at over 20x  Dividend investors can feel comfortable that the company isn t over leveraged  Eli Lilly also maintains healthy investment grade credit ratings with the major agencies Source  Simply Safe Dividends
The company has also been a consistent free cash flow generator over time  which is what we would expect from this recession proof business Source  Simply Safe Dividends
The main reason for the decrease in free cash flow in 2015 was due to non core business reasons  change in deferred income taxes and payments for interest rate swaps  rather than a deterioration in the business 
Thus  dividend investors should not worry about the greater than 100  free cash flow payout ratio in 2015 Source  Simply Safe Dividends Dividend Growth AnalysisOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Eli Lilly s Divided Growth Score is only 29  which indicates that the company s dividend growth potential is below average 
However  Eli Lilly s management has announced that they plan to return to annual dividend increases for shareholders after keeping the dividend relatively constant since 2009 at  1 96 per share 
The company did a slight dividend increase in 2015 and is on track to do the same in 2016  but these were not major payout raises  roughly 2    As seen below  dividend growth has steadily decelerated over the last 20 years Source  Simply Safe Dividends
Management s confidence for publicly committing to annual dividend increases comes from their conviction in the pipeline and recently launched products 
Chairman  President   CEO John Lechleiter said it best himself of the  
 Finally with the strength of our current business and pipeline  we plan to return to annual dividend increases to our shareholders beginning in December of this year  and to return excess cash via share repurchases  
In terms of the magnitude of the expected dividend increases  the company is in the same boat as investors   they really aren t sure  Here is John Lechleiter with some more commentary from the second quarter 2016 call 
  So with those caveats  I think that we feel very comfortable providing that as a framework for investors thinking about Lilly in the next five years with all these potential scenarios  a number of which could provide upside above this number and then coupled with the guidance we ve given about not only our operating  or OpEx to sales  but this morning reaffirming our belief that we could also improve our gross margin as a percentage of sales over this period as well  
While we don t expect Eli Lilly to increase their yearly dividend payments in the double digits  we feel comfortable forecasting low  to mid single digit dividend increases as long as the new product launches are successful and the pipeline meets exceptions ValuationEli Lilly currently trades at nearly 22x 2016 earnings estimates and offers a dividend yield of 2 6  
Assuming that management can execute on their strategy  sales should grow in the mid single digits with additional growth in free cash flow coming from margin expansion  This should lead to earnings growth in the high single to low double digits over the next five years 
While this certainly appears bullish for the stock  investors are paying a premium for those future earnings today 
Thus  we would expect the P E multiple to come down overtime so expected annual returns from investing in Eli Lilly are probably closer to 7  than to the higher expected earnings growth rate ConclusionEli Lilly is emerging from a very difficult time period due to large patent expirations over the last five years 
Furthermore  the company is not completely out of the woods yet due to some major drugs losing patent exclusivity over the next two years  It is a testament to the business model and management team that the company didn t have to cut their dividend during this difficult stretch 
Conversely  if new therapeutic introductions meet expectations  the promising pipeline proves itself out  and management executes on margin expansion plans  then investors look poised to reapyears of predictable dividend increases 
At a current valuation of nearly 22x this year s expected earnings  investors seem to be giving the company credit for their pipeline and new product introductions 
While we are not opposed to investing in pharmaceutical companies  we would prefer to invest in a company that has its expected growth coming from products that are more proven 
This is especially the case when we are paying a valuation premium and only generating a 2 6  dividend yield  which isn t really enough dividend income for retirement living 
Thus  for now we are keeping our capital invested in the current companies in our  instead ",2016-08-29,Brian Bollinger,https://www.investing.com/analysis/eli-lilly's-future-is-changing-200150653,200150653
172906,394422,LLY,Express Scripts  New Program To Lower Diabetes Care Costs,opinion,"Pharmacy benefit manager Express Scripts Holding Company   NASDAQ ESRX   has launched the Diabetes Care Value Program As part of the Express Scripts SafeGuardRx suite of pharmacy solutions  this program aims to improve pharmacy care while controlling plan costs for patients suffering from diabetes The program will be implemented in Mar 2017 and it comprises a network of preferred pharmacies With strong criticism being voiced against high prices of specialty drugs  the focus is on better management of healthcare costs as consumers are becoming increasingly proactive about healthcare decisions  Through the program  Express Scripts guarantees per patient spending caps  which will lead to participating plans experiencing an average increase in diabetes drug spend in 2017 Express Scripts will assume the financial risk for drug spending in excess of the caps in order to protect its clients from higher costs and budget uncertainty  Members of participating plans will receive 90 day supplies of their diabetes maintenance medications from more than 10 000 pharmacies across the U S EXPRESS SCRIPTS Price
    Launch of the new program will broaden Express Scripts s range of services  We remind investors that the company s SafeGuardRx suite of pharmacy solutions was designed to better manage specialty spending  thereby establishing a higher standard for patient outcome  The portfolio also includes the Hepatitis Cure Value Program  the Cholesterol Care Value Program  the Oncology Care Value Program and the Express Scripts Inflation Protection Program Concurrently  Express Scripts announced that its 2017 National Preferred Formulary will include multiple preferred basal insulins  The company plans to enlist Eli Lilly and Company s   NYSE LLY   follow on insulin Basaglar  assuming market entry later this year  as a preferred product for the National Preferred Formulary  alongside the originator product  Lantus Express Scripts currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Actelion Ltd    OTC ALIOF    Both the stocks sport a Zacks Rank  1  Strong Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-08-30,Zacks Investment Research,https://www.investing.com/analysis/express-scripts'-new-program-to-lower-diabetes-care-costs-200151071,200151071
172917,394433,LLY,Eli Lilly  Boehringer Collaborate For Metastatic Breast Cancer,opinion,"Eli Lilly and Company   NYSE LLY   announced a clinical trial collaboration with Boehringer Ingelheim under which the safety and tolerability of Eli Lilly s abemaciclib will be evaluated in combination with Boehringer s BI 836845 in a phase Ib study for the treatment of patients with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR   HER2   metastatic breast cancer  mBC  
The deal assumes that these two agents  in combination  could offer a more complete pathway interference and could potentially prolong cell cycle arrest  For HR   HER2  mBC patients  this could mean a reversal of resistance to hormone therapy 
We note that abemaciclib is a CDK 4 and CDK 6 inhibitor while BI 836845 is an IGF 1 IGF 2 ligand neutralizing antibody LILLY ELI   CO Price   The study  which will be sponsored by Boehringer  is expected to begin enrollment in late 2016  On the basis of phase Ib study results  the collaboration could well expand to include phase II studies in patients with HR   HER2  mBC and other solid tumors 
We note that abemaciclib enjoys Breakthrough Therapy status in the U S  for the treatment of advanced or metastatic breast cancer  Per the companies  press release  breast cancer is the most common cancer in women across the world and about 246 600 women are expected to be diagnosed with invasive breast cancer resulting in approximately 40 450 deaths in the U S  this year  Of all early stage breast cancer cases diagnosed in the U S   approximately 30  are expected to become metastatic 
In addition to ongoing studies  MONARCH  currently evaluating abemaciclib for breast cancer  a phase III study on abemaciclib for the treatment of lung cancer is in progress 
This is not the first time that these two companies have come together  We remind investors that Eli Lilly and Boehringer have a global agreement for the development and commercialization of a portfolio of diabetes compounds 
Eli Lilly is currently a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Innoviva  Inc    NASDAQ INVA    Abbott Laboratories   NYSE ABT   and Johnson   Johnson   NYSE JNJ    While Innoviva sports a Zacks Rank  1  Strong Buy   Abbott and Johnson   Johnson carry a Zacks Rank  2  Buy  ",2016-07-13,Zacks Investment Research,"https://www.investing.com/analysis/eli-lilly,-boehringer-collaborate-for-metastatic-breast-cancer-200141844",200141844
172919,394435,LLY,J J  JNJ  May Beat Q2 Earnings  Will The Stock Gain ,opinion,"Johnson   Johnson   NYSE JNJ    a bellwether in the health care sector  will be reporting second quarter results on Jul 19  before the opening bell The company s track record is pretty good with J J beating earnings estimates in the last four quarters with an average earnings surprise of 2 13  Let s take a look at how things are shaping up for the second quarter of the year Will the Pharma Segment Drive Results Again J J s pharma segment  which performed well in the first quarter  should continue performing well on the back of products like Stelara  Imbruvica  Xarelto  Simponi and Invega Sustenna Imbruvica s label was expanded in early March for the first line treatment of patients suffering from chronic lymphocytic leukemia  This has expanded the patient population significantly Meanwhile  robust market growth and increased penetration with the psoriatic arthritis indication should boost Stelara sales  Investors will also be focused on the performance of the company s new cancer treatment  Darzalex  which is already off to a good start However  Olysio sales will keep declining due to additional competition while Invega will be impacted by generic competition  Moreover  sales of the company s SGLT2 inhibitor  Invokana Invokamet  could be affected by the addition of warnings regarding the increased risk of bone fractures  competition and formulary status  Zytiga is also facing increased competition J J continues to assume no biosimilar competition for Procrit or Remicade in the U S  even though the FDA recently approved a Remicade biosimilar  Inflectra   J J also does not expect generic competition this year for Zytiga  Risperdal Consta  and Invega Sustenna The Medical Device business has also been under pressure with several markets in this segment facing challenges in the form of austerity measures  pricing pressure and a slowdown in elective surgeries  which have all contributed to more tempered growth rates  Soft global market conditions and pricing challenges will continue impacting the performance of this business 
Meanwhile  the consumer business is slowly recovering from the impact of the manufacturing issues that had affected this segment The company s M A strategy will be a key focus area on the second quarter call  J J s share buyback program  worth up to  10 billion  should also boost the bottom line Currency and devaluation in Venezuela will remain headwinds  There will also be some working down of inventory in China where the slowdown in the economy had led to high distributor inventory levels What Our Model IndicatesOur proven model shows that J J is likely to beat estimates this quarter because it has the right combination of two key ingredients Positive Zacks ESP  Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 80   This is very meaningful and a leading indicator of a likely positive earnings surprise for shares Zacks Rank  2  Buy   Note that stocks with Zacks Ranks of  1   2 and  3 have a significantly higher chance of beating earnings  The sell rated stocks   4 and  5  should never be considered going into an earnings announcement The combination of J J s Zacks Rank  2 and  1 80  ESP makes us very confident in looking for a positive earnings beat on Jul 19 JOHNSON   JOHNS Price and EPS Surprise   Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  6 91  and carries a Zacks Rank  2  It will be reporting results on Jul 25 The Earnings ESP for Novartis AG   NYSE NVS   is  0 85  and it carries a Zacks Rank  3  The company is scheduled to release results on Jul 19 Eli Lilly and Company   NYSE LLY   has an Earnings ESP of  2 35  and a a Zacks Rank  3  The company is scheduled to release results on Jul 26 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-15,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-may-beat-q2-earnings:-will-the-stock-gain-200142133,200142133
172943,394459,LLY,Lilly s  LLY  R D Update  Targets 20 New Launches By 2023,opinion,Eli Lilly and Company   NYSE LLY   provided an update on its pipeline and research and development  R D  efforts and said that it has the potential to launch 20 new products in a 10 year time frame starting 2014 and extending through 2023  The company is also looking to launch an average of two new indications or line extensions for approved products every year during this time period Lilly s key areas of focus are diabetes  oncology  immunology  neurodegeneration and pain Within the immunology segment  Lilly launched Taltz  psoriasis  in the U S  recently and is currently seeking approval for baricitinib  rheumatoid arthritis   Taltz is being evaluated for additional indications like psoriatic arthritis and axial spondyloarthritis while baricitinib is in phase II studies for atopic dermatitis and systemic lupus erythematosus Lilly has strong expertise in the field of oncology and is focused on three key areas of disease modification  tumor cell signaling  tumor microenvironment and immuno oncology  Key approved products include Cyramza and Portrazza while important pipeline candidates include olaratumab  under regulatory review for advanced soft tissue sarcoma with FDA response expected in the fourth quarter  and abemaciclib  breast cancer as well as other types of cancer   Lilly expects its immuno oncology portfolio to have five differentiated molecules in clinical testing by year end  and as many as 11 by the end of 2018 Lilly has a strong position in the diabetes market as well with key products including Humalog  Humulin and Tradjenta  Other products in the diabetes portfolio include Trulicity  Basaglar  Jardiance  Synjardy and Glyxambi  Lilly and partner Boehringer Ingelheim are currently seeking FDA approval for the addition of cardiovascular  CV  risk reduction data from the EMPA REG OUTCOME study on Jardiance The companies also intend to conduct two outcome studies investigating Jardiance for the treatment of people with chronic heart failure Lilly s pain pipeline  which is an emerging research area for the company  currently has two late stage candidates    galcanezumab  cluster headache and migraine  launch expected in 2018   and tanezumab  osteoarthritis pain  chronic lower back pain and cancer pain   Tanezumab is being developed in partnership with Pfizer  Inc    NYSE PFE   Finally  the most interesting candidate in Lilly s neurodegeneration portfolio is solanezumab which is being evaluated for Alzheimer s disease  With data readout from a phase III study expected in late 2016  investor focus will remain on this candidate  Lilly has another Alzheimer s disease candidate in its pipeline  AZD3293  which is being developed in collaboration with AstraZeneca plc   NYSE AZN      Lilly is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the large cap pharma sector are Pfizer and Sanofi   NYSE SNY    While Pfizer is a Zacks Rank  1  Strong Buy  stock  Sanofi is a Zacks Rank  2  Buy  stock ,2016-05-24,Zacks Investment Research,"https://www.investing.com/analysis/lilly's-(lly)-r-d-update,-targets-20-new-launches-by-2023-200132153",200132153
172946,394462,LLY,Incyte Reports Five Year Data From Phase III Study On Jakafi,opinion,Incyte Corporation   NASDAQ INCY   announced five year data from a phase III study  COMFORT I  on Jakafi for the treatment of patients with intermediate 2 or high risk myelofibrosis  MF  The randomized  double blind  placebo controlled study evaluated the long term safety and efficacy of Jakafi  compared to placebo  in patients  n 309  with intermediate 2 or high risk primary MF  post polycythemia vera MF or post essential thrombocythemia MF Data from the study demonstrated a 31  reduction in the risk of death in patients treated with Jakafi compared to the placebo arm  Results also revealed that 59  of the patients who continued on treatment with Jakafi achieved at least a 35  reduction in spleen volume at any given time We note that Jakafi is currently approved in the U S  for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea  Jakafi is also approved for the treatment of patients with intermediate or high risk MF  including primary MF  post polycythemia vera MF  and post essential thrombocythemia MF  The company has a collaboration agreement with Novartis AG   NYSE NVS   for the commercialization of Jakavi in ex U S  markets In the first quarter of 2016  Jakafi recorded sales of  183 3 million  up 58 9  year over year  The company has raised its guidance for net product sales from Jakafi in 2016 to the range of  815 million to  830 million  old guidance   800  815 million  Meanwhile  Incyte is working on expanding Jakafi s label  In Apr 2016  the company acquired the rights to develop and commercialize Jakafi from Eli Lilly and Company   NYSE LLY   for the treatment of graft versus host disease  GVHD   A phase III study on Jakafi for GVHD is expected to begin in the second half of the year However  the company discontinued the evaluation of Jakafi in two phase III studies   JANUS 1 for the second line treatment of advanced or metastatic pancreatic cancer and JANUS 2 study for the treatment of pancreatic cancer  The decision was made after a planned interim analysis of the JANUS 1 study demonstrated that Jakafi  in combination with Xeloda  capecitabine   failed to show a sufficient level of efficacy to warrant continuation Currently  Incyte carries a Zacks Rank  3  Hold   Bristol Myers Squibb Company   NYSE BMY   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/incyte-reports-five-year-data-from-phase-iii-study-on-jakafi-200134491,200134491
172948,394464,LLY,Incyte s Jakafi Positive In Phase III For Polycythemia Study,opinion,Incyte Corporation   NASDAQ INCY   announced new 28 week data from a phase III study  RESPONSE 2  on Jakafi for the treatment polycythemia vera  PV  The multi center  open label  randomized study evaluated the safety and efficacy of Jakafi  in comparison to the best available therapy  in patients with PV who are resistant to or intolerant of hydroxyurea  dependent on phlebotomy for hematocrit control and do not have an enlarged spleen Data from the study demonstrated that 62  of patients treated with Jakafi achieved hematocrit control without phlebotomy  compared to the 18  of patients treated with the best available therapy  Results were presented at the Congress of the European Hematology Association Jakafi was generally well tolerated  Results from the RESPONSE 2 study were consistent with data from the RESPONSE study  which evaluated patients suffering from inadequately controlled PV with an enlarged spleen We note that Jakafi is currently approved in the U S  for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea  Jakafi is also approved for the treatment of patients with intermediate or high risk myelofibrosis  MF   including primary MF  post PV MF  and post essential thrombocythemia MF  The company recorded Jakafi sales of  183 3 million in the first quarter of 2016  up 58 9  year over year Meanwhile  Incyte  along with Eli Lilly and Company   NYSE LLY    announced results from a pivotal long term extension study  RA BEYOND  on its rheumatoid arthritis  RA  candidate  baricitinib  which were presented at the Annual European Congress of Rheumatology The RA BEYOND study evaluated patients who had completed the pivotal 24 week RA BUILD study  Patients dosed with baricitinib in the RA BUILD study continued to receive baricitinib at the dose of either 2 mg or 4 mg  while patients receiving placebo were switched to baricitinib 4 mg in the RA BEYOND study Results from the study demonstrated superiority of baricitinib over placebo in preventing progressive radiographic structural joint damage in patients with RA at 24 weeks  These treatment benefits were maintained through 48 weeks Apart from RA BEYOND  the company presented data from two other phase III studies   RA BEGIN and RA BEAM   on baricitinib  Data from the studies revealed that baricitinib resulted in significant improvements in pain  fatigue and the ability to perform daily activities compared to methotrexate and AbbVie Inc  s   NYSE ABBV   Humira We remind investors that Eli Lilly submitted a regulatory application for the approval of oral once daily baricitinib for the treatment of moderately to severely active RA in both the U S  and the EU in the first quarter of the year According to the WHO Global Burden of Disease Report  more than 23 million people in the world suffer from RA  It has also been estimated that approximately three times as many women as men are affected by RA Incyte currently carries a Zacks Rank  3  Hold   Bristol Myers Squibb Company   NYSE BMY   is a better ranked stock in the health care sector with a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/incyte's-jakafi-positive-in-phase-iii-for-polycythemia-study-200135286,200135286
172949,394465,LLY,Merck s Biosimilar Version Of Lantus Tops Phase III Studies,opinion,Merck   Co  Inc    NYSE MRK   announced encouraging data from two phase III studies on its insulin glargine candidate  MK 1293  for the treatment of type I and type II diabetes The two randomized  active controlled  open label studies evaluated the safety and efficacy of MK 1293  in comparison to Sanofi s   NYSE SNY   Lantus  insulin glargine  Data from the studies revealed that MK 1293 demonstrated non inferiority in change from baseline A1C  average blood glucose  and had a similar safety profile as Lantus after 24 weeks in patients with type I and type II diabetes  thereby achieving the primary endpoint  In addition  the studies met the pre specified secondary efficacy endpoints of statistical A1C equivalence to Lantus  thereby establishing that the investigational treatment was similar  within a certain range  to the current therapy Results were presented at the Scientific Sessions of the American Diabetes Association Merck is developing MK 1293 in collaboration with Samsung  KS 005930  Bioepis  Under the agreement terms  Merck is responsible for clinical development  manufacturing and commercialization while Bioepis is partially funding development Currently  an application for regulatory approval of MK 1293 for the treatment of patients with type I and type II diabetes is under review in the EU  The company expects to submit a regulatory filing for the candidate in the U S  this year We note that the diabetes market is heavily crowded and several companies are working on bringing new and improved treatments to market We remind investors that Eli Lilly and Company   NYSE LLY   is already marketing a biosimilar version of Lantus in the EU  which is expected to hit U S  markets after Dec 15  2016 Merck currently carries a Zacks Rank  3  Hold   Bristol Myers Squibb Co    NYSE BMY    with a Zacks Rank  1  Strong Buy   is a better ranked stocks in the health care sector Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-14,Zacks Investment Research,https://www.investing.com/analysis/merck's-biosimilar-version-of-lantus-tops-phase-iii-studies-200135952,200135952
172954,394470,LLY,Incyte Gains On Jakafi s Breakthrough Status For Acute GVHD,opinion,"Incyte Corporation   NASDAQ INCY   announced that the FDA has granted Breakthrough Therapy status to Jakafi  outside the U S   Jakavi  for the treatment of patients suffering from acute graft versus host disease  GVHD   Incyte s shares gained 4  on the news 
We note that the FDA usually grants Breakthrough Therapy status to expedite the development and review of drugs for the treatment of serious or life threatening conditions  and to help ensure that people have access to them through FDA approval as soon as possible  In order to obtain this status  preliminary clinical evidence is required demonstrating that the drug may have clinically significant improvement over available therapy 
We are encouraged by the FDA granting Breakthrough Therapy status to Jakafi for acute GVHD  Currently  there are no approved treatments for patients with acute GVHD 
Incyte expects to initiate a pivotal development program on Jakafi for GVHD in the second half of 2016 
We remind investors that Incyte and Eli Lilly and Co    NYSE LLY   agreed to amend their license  development and commercialization agreement in Mar 2016 to enable the former to independently develop and commercialize Jakafi for GVHD 
Subsequently in Apr 2016  Incyte and Novartis AG   NYSE NVS   also agreed to amend their collaboration and license agreement granting the latter the rights to research  develop and commercialize Jakafi for GVHD outside the U S 
We note that Jakafi is approved in the U S  for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea  It is also approved for the treatment of patients with intermediate or high risk myelofibrosis  MF   including primary MF  post polycythemia vera MF  and post essential thrombocythemia MF  While Incyte markets the drug in the U S   it is marketed by Novartis outside the country 
Incyte is a Zacks Rank  3  Hold  stock  Bristol Myers Squibb Company   NYSE BMY   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  ",2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/incyte-gains-on-jakafi's-breakthrough-status-for-acute-gvhd-200138158,200138158
172955,394471,LLY,Eli Lilly Stock Up On FDA Advisory Panel Vote For Jardiance,opinion,Eli Lilly and Company s   NYSE LLY   shares are up almost 4  following a positive FDA panel recommendation for its type II diabetes drug  Jardiance  SGLT 2 inhibitor   Lilly and its partner  Boehringer Ingelheim  are seeking FDA approval for the inclusion of data from the EMPA REG OUTCOME study  which showed cardiovascular  CV  risk reduction The FDA s Endocrinologic and Metabolic Drugs Advisory Committee met to review the data and voted 12 11 that enough evidence exists to establish that Jardiance reduces CV death in adults with type 2 diabetes and established CV disease While the FDA usually follows the advice of its advisory panel  it is not required to do so  Considering the vote in favor of label expansion was so close  concerns remain that the FDA might ask for another study However  inclusion of this data in the label would be a huge boost for Lilly  With about 50  of deaths in type II diabetics resulting from CV disease  the addition of this data to Jardiance s label would lead to a major surge in sales Meanwhile  earlier this year  Lilly and Boehringer had announced plans to conduct two outcome studies investigating Jardiance for the treatment of people with chronic heart failure  The studies are scheduled to begin by next April and will be conducted in patients with chronic heart failure both with and without type II diabetes While the diabetes market holds immense commercial potential  it is pretty crowded given the presence of companies like Novo Nordisk  CO NOVOb  A S   NYSE NVO    Johnson   Johnson   NYSE JNJ   and Merck   Co  Inc    NYSE MRK   among others Lilly is a Zacks Rank  3  Hold  stock  Johnson   Johnson is a better ranked stock in the large cap pharma sector with a Zacks Rank  2  Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-29,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly-stock-up-on-fda-advisory-panel-vote-for-jardiance-200139272,200139272
172971,394487,LLY,Crude Oil Continues To Descend While Dollar Jumps,opinion,"After yesterday s sharp nosedive on global growth concerns and a flare up in the Middle East  investors today were treated to a tumultuous session  as the clear uncertainty supplied the markets sizable swings back and forth across the flatline  only to finish mixed and nearly where they began  Treasuries were far less volatile  but finishing mixed amid the insecurity  while crude oil prices continued to descend  gold was modestly higher and the U S  dollar jumped  News on the equity front was headlined by lackluster December sales figures from the automakers 
The Dow Jones Industrial Average  DJIA  rose 10 points  0 1   to 17 159  the S P 500 Index gained 4 points  0 2   to 2 017  but the Nasdaq Composite fell 12 points  0 2   to 4 891  In moderate volume  864 million shares were traded on the NYSE and 1 9 billion shares changed hands on the Nasdaq  WTI crude oil fell  0 79 to  35 97 per barrel  but wholesale gasoline lost  0 03 to  1 29 per gallon  while the Bloomberg gold spot price increased  4 00 to  1 078 61 per ounce  Elsewhere  the dollar index a comparison of the U S  dollar to six major world currencies was 0 5  higher at 99 37 
The major automakers reported U S  December sales today  with Fiat Chrysler Automobiles NV s  N FCAU  9  Chrysler brand posting adjusted sales growth of 4 5  year over year  y y   compared to the 11 3  gain estimated by FactSet  The figures are being adjusted to account for two more selling days this year compared to the same period a year ago  Ford Motor Co   N F  14  posted an adjusted 0 7  y y rise in sales  below the forecasted 4 9  gain  while General Motors Co s  N GM  32  sales declined 1 8   compared to the projected 3 8  growth  FCAU was slightly higher  while F and GM were both lower 
Eli Lilly and Co   N LLY  84  traded higher after the company reaffirmed its full year 2015 guidance  but it issued a full year 2016 outlook that missed expectations 
Smith   Wesson Holding Corp   O SWHC  26  rallied after the firearm manufacturer raised its 3Q and full year guidance  due to a stronger than expected sell through rate of its products and data for the month of December indicating  strong growth  versus the same period a year ago 
Treasuries mixed in midst of uneasy global markets 
Treasuries finished higher  while the U S  economic calendar was void of any major releases today  Bond yields declined yesterday courtesy of the global equity market selloff centered on Chinese growth concerns following another dose of disappointing manufacturing data  as well as elevated tensions in the Middle East that flared up over the weekend  The yield on the 2 year note declined 2 basis points  bps  to 1 02   the yield on the 10 year note was flat at 2 25   while the 30 year bond rate gained 2 bps to 3 01  
Tomorrow s domestic economic calendar will be robust  with ADP s private sector payroll report expected to show 198 000 jobs were gained in December  the trade balance forecasted to show the deficit widened slightly to  44 0 billion in November  and factory orders projected to show a 0 2  month over month dip  However  the headlining releases will likely be the ISM and Markit s services sector reads  expected to show expansion for the sector accelerated slightly in December  while the day will culminate with the Federal Reserve s December meeting minutes  after which the Central Bank hiked rates for the first time since before the financial crisis 
In contrast to a weakening manufacturing sector  the services side of the economy  representing 88  of U S  activity  remained healthy throughout 2015 and looks to continue that performance entering 2016  Also  the Fed has bent over backwards to soothe concerns by noting its desire to move gradually  allowing for the economy and markets to adjust  Slow rate hiking cycles have typically been positive for stocks  A key determinant of the pace at which the Fed continues to raise rates is likely to center around the U S  dollar  with continued strength likely slowing the pace  while any sustained countertrend moves in the dollar  commodity prices or inflation could trigger a faster pace  We believe this will remain a focus by investors in 2016  and is likely to contribute to some of the volatility we believe will persist across the equity and fixed income markets 
Europe recovers somewhat from yesterday s drop  Asia mostly lower in volatile action  European equities finished higher  recovering some of yesterday s selloff that was the worst start to a year ever for the Stoxx Europe 600 Index  per Bloomberg  as data caused a flare up in Chinese economic growth concerns and tensions in the Middle East escalated  Stocks in the region may have found some support from a drop in the euro versus the U S  dollar  as well as reports of a plethora of measures from Chinese authorities to try to stabilize the markets  Bond yields in the region traded lower  while economic reports showed German unemployment fell more than expected in December  and the eurozone consumer price inflation estimate rose by a smaller amount than anticipated for last month 
Stocks in Asia finished mostly to the downside in volatile action in the wake of yesterday s global selloff that came amid economic growth concerns following disappointing Chinese data and escalated tensions in the Middle East  Mainland Chinese and stocks in Hong Kong declined modestly  as the markets recovered somewhat on signs that Chinese authorities stepped in to try to stabilize the markets  China s central bank conducted the biggest liquidity injection into the markets since September  after it intervened to support the yuan  which has fallen sharply as of late to exacerbate sentiment 
Also  Chinese state controlled funds were said to have bought equities and the country s securities regulator signaled that a selling ban on major investors will remain beyond this week s expiration date  per Bloomberg  which cited people familiar with the matter 
Japanese securities declined as well  extending yesterday s drop which was the worst start to a year since 2008  per Bloomberg  with the yen remaining near a two month high following yesterday s rally on the uneasy global sentiment  Meanwhile  Australian equities fell markedly amid broad based weakness  led by oil and gas issues as oil prices continued to slide despite the heightened geopolitical concerns  Rounding out the day  markets in India declined  while South Korean listings bucked the trend  finishing higher with the won showing some weakness 
Tomorrow s international economic calendar will be dominated by the Services and Composite PMIs from Markit across Europe  while investors will also get employment figures from Italy  PPI data from the eurozone and housing prices from the U K 
Schwab Center for Financial Research   SCFR   is a division of Charles Schwab  N SCHW    Co   Inc  The information contained herein is obtained from third party sources and believed to be reliable  but its accuracy or completeness is not guaranteed  This report is for informational purposes only and is not a solicitation  or a recommendation that any particular investor should purchase or sell any particular security  The investment information mentioned here may not be suitable for everyone  Each investor needs to review an investment strategy for his or her own particular situation before making any investment decision  All expressions of opinions are subject to change without notice in reaction to shifting market conditions ",2016-01-06,Marvin Clark,https://www.investing.com/analysis/on-the-market-378900,378900
172972,394488,LLY,Solid Q1 Earnings Fail To Boost Pharma ETFs,opinion,"Like the past several quarters  the healthcare sector has impressed with strong Q1 earnings  This is especially true as total earnings for  are up 8 8  on revenue growth of 11 2   with earnings and revenue beat ratios of 80  and 70   respectively  In fact  healthcare is the fourth best performing sector in terms of earnings growth trailing autos  construction  and consumer discretionary 

Among the most notable players  Johnson   Johnson    NYSE JNJ   was the first major drug company to report earnings on April 19  followed by Eli Lilly and Company    NYSE LLY    and Bristol Myers Squibb Company    NYSE BMY    on April 26 and April 28  respectively  Two other major U S  drug companies   Pfizer    NYSE PFE    and Merck    NYSE MRK      reported on May 3 and May 5  respectively  These industry primes posted solid results raising their full year outlook that boosted investors  confidence in the space  Notably  Eli Lilly missed our earnings estimates while Merck lagged on the revenue front Johnson and Johnson Earnings in Focus
The world s biggest maker of healthcare products continued its long streak of earnings beat and beat our estimate on the top line buoyed by strong prescription drug revenues and a weakening dollar  Earnings per share came in at  1 68  four cents ahead of the Zacks Consensus Estimate and 7 7  higher than the year ago earnings  Revenues inched up 0 6  year over year to  17 5 billion and edged past the Zacks Consensus Estimate of  17 42 billion  read    
Johnson   Johnson raised its guidance for fiscal 2016  The company now expects revenues in the range of  71 2  71 9 billion compared with the previous forecast of  70 8  71 5 billion  Additionally  the earnings per share guidance has been raised from  6 43  6 58 to  6 53  6 68  The Zacks Consensus Estimate at the time of the earnings release was pegged at  71 5 billion for revenues and  6 52 for earnings per share  These were higher than the mid point of the company s projection  JNJ has gained 0 2  to date since its earnings announcement Pfizer Earnings in Focus
The U S  drug giant also topped the Zacks Consensus Estimate for both the top and the bottom lines  and raised the guidance for fiscal 2016  Earnings per share of 67 cents and revenues of  13 0 billion were ahead of our estimates by 12 cents and  1 0 billion  respectively  Notably  earnings per share grew 32  while revenues jumped 20  year over year 
For fiscal 2016  Pfizer upped its revenue guidance to  51 53 billion from  49  51 billion and earnings per share guidance to  2 38  2 48 from  2 20  2 30  The mid points were much higher than the Zacks Consensus Estimate of  51 3 billion for revenues and  2 29 for earnings per share at the time of the earnings release  Shares of PFE are down 0 4  since the earnings announcement Merck Earnings in Focus
Earnings per share came in at 89 cents  four cents ahead of the Zacks Consensus Estimate and 4 7  higher than the year ago earnings  Revenues slipped 1 2  year over year to  9 3 billion  and were slightly below the Zacks Consensus Estimate of  9 5 billion 
Merck now expects earnings per share in the range of  3 65  3 77 and revenues in the band of  39 0  40 2 billion for 2016  This is in contrast with the previous guidance of  3 60  3 75 and  38 7  40 2 billion  respectively  The Zacks Consensus Estimate at the time of the release was pegged at  3 71 for earnings per share and  40 1 billion for revenues  The stock has lost about 1 3  following its earnings announcement  see    Bristol Myers Earnings in Focus
Bristol Myers reported earnings per share of 74 cents  outpacing our estimate by 8 cents and increasing 4  from the year ago quarter  Also  revenues rose 9  to  4 39 billion and edged past the Zacks Consensus Estimate of  4 24 billion 
Like the other drug makers  the company also revised its earnings per share outlook upward to  2 50  2 60 from  2 30  2 40 for fiscal 2016  The low end was much higher than our estimate of  2 42 at the time of the earnings announcement  Revenues are expected to grow in the low double digit range  Shares of BMY are down 1 5  to date since the earnings announcement Eli Lilly Earnings in Focus
Earnings of 83 cents at Eli Lilly missed the Zacks Consensus Estimate by a couple of cents and came in 5  lower than the year ago earnings  Revenues grew 5  to  4 86 billion but fell short of our estimate of  4 87 billion 
However  Eli Lilly raised its 2016 earnings per share guidance to  3 50  3 60 from  3 45  3 55 and revenue guidance to  20 6  21 1 billion from  20 2  20 7 billion  The Zacks Consensus Estimate at the time of the earnings release was pegged at  3 55 for earnings and  20 7 billion for revenues  Shares of LLY have tumbled 3 41  since the earnings release ETF Angle
The string of earnings beat and upbeat outlook failed to boost pharma stocks and ETFs as the industry is grappling with drug pricing issues  read    
Below  we have highlighted the ETFs in detail PowerShares Dynamic Pharmaceuticals Fund   
This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  1 1 billion and sees good volume of around 192 000 shares a day  The fund charges 56 bps in fees and expenses from investors  Holding 23 stocks  the fund invests over 5  share each in the in focus five firms  The ETF shed about 7 4  over the past 10 days and has a Zacks ETF Rank of 3 or  Hold  rating with a High risk outlook  read    
iShares U S  Pharmaceuticals ETF   

This ETF provides exposure to 42 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms occupy the top five holdings in the basket accounting for combined 40 6  of total assets  suggesting heavy concentration  The product has  607 8 million in AUM and charges 45 bps in fees and expense  Volume is moderate as it exchanges about 52 000 shares a day  The fund has lost 7 9  over the past 10 days and has a Zacks ETF Rank of 3 with a Medium risk outlook 
SPDR S P Pharmaceuticals ETF   

This fund provides exposure to the pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of over  465 9 million  it trades in moderate volume of around 190 000 shares a day and charges 35 bps in fees a year  In total  the product holds 40 securities with the in focus five firms taking nearly 5  share each  The product was down 9 73  in the same period and has a Zacks ETF Rank of 3 with a Medium risk outlook 
Market Vectors Pharmaceutical ETF   

This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  Pfizer  Bristol Myers  Johnson   Johnson and Merck make up for over 5  share each while Eli Lilly accounts for 4 7  of assets  The product has amassed  261 3 million in its asset base and trades in a moderate volume of about 105 000 shares a day  Expense ratio came in at 0 36   The fund has lost 5 3  over the past 10 days  It has a Zacks ETF Rank of 2 or  Buy  rating with a Medium risk outlook  read    ",2016-05-05,Zacks Investment Research,https://www.investing.com/analysis/solid-q1-earnings-fail-to-boost-pharma-etfs-200128545,200128545
172991,394507,LLY,4 Stocks To Watch  CLDX  LLY  RDUS  TGTX ,opinion,"The stock market closed really well on Tuesday  With that kind of spike  there was off the lows and the thrust  I always look for important lows  I think at least the short term bottoms have been put in  But there will have to be a follow through  Let s take a look at some new stocks  some old stocks  and a few stocks that are intriguing to me  and see how they are doing 
Celldex Therapeutics  Inc   NASDAQ CLDX  is coming along nicely  On Tuesday  it was up 25 cents to 25 73  or 1   on 1 2 million shares  When the base was forming in early 2014  a swing was put on it  it broke out in early 2015  and worked its way up very nicely in a 5 wave advance  Since then it s had many 5 wave declines  or consolidations  that have lasted for the last three and a half months  So  it looks like this stock is getting ready for something  It s been moving up  the volume has increased a little  and it s right underneath resistance at the 50 day moving average at 25 87  and closed about 14 cents underneath that  If it gets a punch through here  and takes out the recent highs around 26 84  look for it to head up towards the short term target at 30  then 32 1 2  and then 36 
Eli Lilly and Company  NYSE LLY  has been doing great  During the last year and a half  it has gone from the 47 range all the way up to Tuesday s high at 88 78  After the big run up in June  it spiked on heavy volume  formed a nice  bullish falling wedge  popped  broke out  but there was no follow through  It then had another 3 day pullback on low volume  and was followed by the last four up days in a row  On Tuesday  it broke out  and popped out of the wedge  up 2 38 to 88 73  or 2 76   on 6 9 million shares  It appears this stock wants to go to the low to mid 90 s  Look for 95 6 as its target 
Radius Health  Inc   NASDAQ RDUS  swing trade is acting great as well  It had a breakout mid June  a swing was put on it  it popped  pulled back  and is now in a rising wedge  which is sometimes very bullish in an uptrend  If it maintains volume and breaks out above the 17 1 2 range in the next couple days  it could run to 80  and then near 100 
TG Therapeutics  Inc   NASDAQ TGTX  is a swing trade that appears to be setting up nicely  It formed a little head and shoulders  popped through the neckline  then pulled back from resistance  and formed a nice little flag  On Tuesday  it broke out  up only 35 cents to 17 47  or 2   but volume is pushing up to nearly a million shares  If it can get through this zone  which it looks like it s going to do  look for it to move up towards 20  and beyond 20 to the mid 20 s 
Other stocks on Harry s Charts of the Day included Cynosure  Inc   NASDAQ CYNO   Himax Technologies  Inc   NASDAQ HIMX   MOBILEYE N V   NYSE MBLY   Novavax  Inc   NASDAQ NVAX   Ophthotech Corporation  NASDAQ OPHT   Synergy Pharmaceuticals  Inc   NASDAQ SGYP   SunEdison  Inc   NYSE SUNE   TerraForm Power  Inc   NASDAQ TERP   and TeleCommunication Systems Inc   NASDAQ TSYS  ",2015-07-08,Harry Boxer,"https://www.investing.com/analysis/cldx,-lly,-rdus,-tgtx-257582",257582
172992,394508,LLY,Probiodrug On Track For PQ912 Data Mid 2016  ,opinion,Probiodrug AG  AMS PDB  continues to expect data from the Phase IIa study of lead product candidate PQ912 around mid 2016  In the meantime  Eli Lilly  NYSE LLY  is expected to announce initial data from the Phase I trial of its antibody targeting pGlu Abeta in Q415  This will have read across to PBD C06  Probiodrug s preclinical pGlu Abeta antibody  Current cash should provide sufficient funding until the PQ912 data readout  when Probiodrug may seek to partner PQ912  We value Probiodrug at  217 5m or  32 1 share ,2015-09-24,Edison,https://www.investing.com/analysis/probiodrug:-on-track-for-pq912-data-mid-2016-266033,266033
172993,394509,LLY,Sell This Pharma Stock Before It Goes Limp  LLY,opinion,"Would you take a drug that caused side effects such as headaches  muscle pain  dizziness  vomiting  uncontrollable flatulence  intestinal bleeding  blindness  or gynecomastia  man boobs  
I bet you re shouting   No  
But if the benefits of the drug far outweighed the risks   and the risks themselves weren t inherently great   you might change your mind 
Similarly  when deciding whether to make an investment  we need to assess the risks and potential reward 
Of course  this isn t a perfect analogy  Unlike the probability of adverse effects from drugs  investment risks tend to vary significantly over time  In particular  many healthcare stocks have dramatically different risk profiles than they did in the past 
Yet  few investors have seemed to notice 
That s partly because the  does have a lot to offer  Conservative investors have been drawn to the defensive qualities of the drug and medical device producers  while more aggressive traders and investors have gravitated towards high growth biotechnology stocks 
Accordingly  the healthcare sector has been a stellar performer over the past five years  The Health Care Select Sector SPDR  N XLV  has produced a total return of 142 3  compared with a 90 3  return for the SPDR S P 500  N SPY  
But that sort of outperformance has significantly altered the risk return prospects for many healthcare stocks 
Eli Lilly and Company  N LLY   a major pharmaceutical company  is perhaps the best example  Not many people found Eli Lilly attractive in late 2010 because its stock wasn t going up  Ironically  the stock has been on a tear ever since  gaining 159  on a total return basis  Plain and simple  LLY is in a sector that caught fire  and it became a momentum stock 
As a result  Eli Lilly s valuation is now sky high  The following chart shows Eli Lilly s enterprise value to EBITDA multiple and price to sales ratio over the past 10 years 

Here  the effects of the healthcare biotech boom are clearly evident as the company s valuation has reached a stratospheric level in 2015 
However  we can t lose sight of the underlying fundamentals of the company when risk appetites in the market are so high  The following table compares various metrics for Eli Lilly to their levels at the end of 2010 

Eli Lilly s revenue has actually declined over the past five years  in large part due to expiring patents  Operating profit has shrunk from  6 5 billion all the way down to  2 3 billion 
Meanwhile  Eli Lilly s profit margin has been cut nearly in half  It ll be very challenging to return margins to their prior levels for a variety of reasons  For example  the patent on Cialis  a high margin erectile dysfunction drug  expires in 2017  Also  there s been increased scrutiny on drug pricing in the media and on the Presidential campaign trail 
It seems as though Eli Lilly will need a few drugs from its internal development pipeline to become blockbusters just to prevent revenues and margins from deteriorating even further 
On top of all that  the company s net debt  debt minus cash  has soared 
Because of these negative trends and slow growth prospects  Eli Lilly s ridiculous valuation isn t warranted  LLY isn t a growth stock  but it is trading at growth stock multiples 
Unsurprisingly  most large caps with such high valuations   even those with higher growth   perform poorly  So  even if your heart is healthy enough for stock market activity  it s best to stay away 
To drive this point home  I ran a backtest  Let s just say someone went off their anti psychotic medication and decided they were only going to own ultra expensive  large cap dividend payers 
The following chart shows the performance of dividend paying stocks  ex financials  with market caps greater than  10 billion and EV EBITDA multiples greater than 20 times 

Over the past 10 years  you would have actually lost money if you followed a strategy of buying these richly valued stocks and equally weighting them in a portfolio every quarter  The S P 500 had far better results 
Thus  if you hold LLY   or any overvalued dividend payer   for more than four hours  please seek medical attention immediately ",2015-10-21,Alan Gula,https://www.investing.com/analysis/sell-this-pharma-stock-before-it-goes-limp-268806,268806
172994,394510,LLY,Retailers Gearing Up For Big Holiday Season ,opinion,"Eli Lilly and Company  N LLY  accepts them as truth despite a horrible track record of  predication   If retailers are gearing up for big holiday shopping season  so should I 
The message of the market  however  debunks the expectation of big holiday shopping season  Significant underperformance of the retail stocks against the broader market since 2013  a declining retail stock to S P 500 ratio similar to the 2005 to 2007 deterioration  red boxes   suggests that retailers should be gearing down  not up  for what will likely be a disappointing holiday shopping season  chart  

Headline  Retailers gear up for big holiday shopping season
Over half of U S  retailers plan to hire seasonal workers during the holiday season  up from only 43  last year  Overall  the full time hiring in the fourth quarter could be the strongest since 2006  according to a survey by CareerBuilder com",2015-11-10,Eric De Groot,https://www.investing.com/analysis/retailers-always-gearing-up-for-big-holiday-season-270879,270879
173011,394527,LLY,Calithera Biosiences IPO  Outlook Neutral,opinion,"Based in South San Francisco Calithera Biosciences  CALA  scheduled an  84 million IPO on the NASDAQ with a market capitalization of  223 million at a price range midpoint of  14 for Thursday  Oct  2  2014 
Summary
CALA is a clinical stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer  CALA s focus in on solid tumors  leukemias  lymphomas and multiple myeloma
The full IPO calendar is available at 
Management

Manager  Leerink Partners  Joint managers  Wells Fargo Securities  JMP Securities
End of lockup  180 days   Tuesday  March 31  2015  End of 25 day quiet period  Monday  Oct  27  2014
Valuation 

Conclusion
Neutral  Price to book of 1 9  In three Phase 1 clinical trials  Shareholders may buy  15mm
CALA is currently conducting three Phase 1 clinical trials of CB 839 in the United States in patients with solid tumors  leukemias  lymphomas and multiple myeloma  To put the conclusions and observations in context  the following is reorganized  edited and summarized from the full S 1 referenced above 
Business  CALA is a clinical stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer 
Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery  and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients 
CALA s lead product candidate  CB 839  is an internally discovered  first in class inhibitor of glutaminase  a critical enzyme in tumor metabolism 
CALA is currently evaluating CB 839 in three Phase 1 clinical trials in solid and hematological tumors  CALA s lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a first in class therapeutic agent for this novel target 
CALA s ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets 
The field of tumor metabolism seeks to exploit the unique ways in which cancer cells take up and utilize nutrients in order to grow and survive  It is now recognized that cancer cells rely on certain metabolic processes  or pathways  to a much greater extent than normal cells 
The enhanced use of these pathways by cancer cells often results in a dependence on  or  addiction  to  these pathways that is not observed in normal cells  This creates an opportunity to selectively suppress the growth of cancer cells with therapeutic agents that specifically target these metabolic pathways 
CALA s lead product candidate in tumor metabolism  CB 839  takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival  CB 839 inhibits glutaminase  an enzyme required by cancer cells to utilize glutamine effectively  In preclinical studies  CB 839 demonstrated broad antitumor activity in tumor cell lines  inhibited the growth of human tumors in animal models and was well tolerated in toxicity studies 
CB 839 was also synergistic with several approved cancer therapeutics that are part of the current standard of care 
CALA is currently conducting three Phase 1 clinical trials of CB 839 in the United States in patients with solid tumors  leukemias  lymphomas and multiple myeloma 
The purpose of these trials is to evaluate the safety of CB 839 both as a single agent and in combination with approved therapies and to seek preliminary evidence of efficacy 
CALA anticipates completing the ongoing single agent dose escalation stage of these trials by the end of 2014 
CALA then plans to enroll patient cohorts in select tumor types predicted to be sensitive to CB 839 based on results from its preclinical studies 
CB 839 will be tested in these tumor types either as a single agent or in combination with approved therapies 
CALA expects data to be available from its single agent trials in mid 2015 and from its combination trials in late 2015 
Pending input from the U S  Food and Drug Administration  or the FDA  on the results of CALA s Phase 1 trials and its Phase 2 trial protocols  CALA plans to initiate in late 2015 or early 2016 one or more Phase 2 clinical trials to study CB 839 as a single agent or in combination with approved therapies 
CALA believes CB 839 has the potential to be an important new therapeutic agent with a novel mechanism of action for the treatment of a broad range of cancers and is the only selective glutaminase inhibitor currently in clinical trials 
CALA s clinical program seeks to identify cancers that will be most sensitive to CB 839 to allow the greatest benefit for patients and to pursue the most efficient path to regulatory approval 
CALA currently retains all commercial rights to CB 839 and have been granted a U S  patent which includes composition of matter coverage for CB 839 through 2032 
Intellectual property As of June 30  2014  the intellectual property portfolio for CALA s tumor metabolism program  which includes CB 839  consists of one issued U S  patent directed to composition of matter for CB 839  which expires in 2032 
CALA also has six pending U S  patent applications and 17 corresponding pending PCT and foreign patent applications directed to compositions of matter for CB 839 and related chemical compounds  as well as methods of using these compounds 
These pending patent applications also include one pending U S  patent application relating to methods for measuring various biomarkers in cancer patients to identify patients suitable for treatment with glutaminase inhibitors 
With respect to CALA s tumor immunology program  which includes the preclinical development of its arginase inhibitor  CALA considers trade secrets and know how to be CALA primary intellectual property 
Trade secrets and know how can be difficult to protect  Despite CALA s efforts to protect its trade secrets  its competitors may discover its trade secrets  either through breach of its confidentiality agreements  independent development  or publication of information including its trade secrets 
Competition CALA s principal competitors in the field of tumor metabolism include Advanced Cancer Therapeutics  LLC  Agios Pharmaceuticals Inc    NASDAQ AGIO   Astrazeneca Plc  NYSE AZN   Cornerstone Pharmaceuticals  Inc   Eli Lilly and Company  NYSE LLY   Forma Therapeutics Holdings  LLC  Glaxosmithkline plc  NYSE GSK   Novartis International AG  OTC NVSEF   Pfizer Inc  NYSE PFE     3 V Biosciences  Inc   and Roche Holding Ltd  OTC RHHBY   and its subsidiary Genentech Inc 
CALA s principal competitors in the field of tumor immunology include AstraZeneca plc  Ono Pharmaceuticals  Co   Ltd   NewLink Genetics Corporation  Incyte Corporation  Merck   Co   Bristol Myers Squibb Company  CureTech Ltd  and EMD Serono  Inc 
5  shareholders pre IPO
Entities affiliated with Delphi Ventures VIII  L P  19 5 
Morgenthaler Venture Partners IX  L P  18 3 
Advanced Technology Ventures VIII  L P  18 3 
Adage Capital Management  LP 18 1 
Entities affiliated with T  Rowe Price Associates  Inc  7 2 
Entities affiliated with Wellington Management Company  LLP 6 0  
Longwood Fund II LP 5 8 
Dividend Policy No dividends are planned 
Use of proceeds CALA intends to use the  75 million in proceeds from its IPO as follows 
 25 0 to  35 0 million to further the clinical development of CB 839 through completion of Phase 2 clinical trials 
 10 to  15 million to further the development of its arginase inhibitor program through a Phase 1 clinical trial 
 5 to  10 million to fund its research and drug discovery activities related to additional product candidates  including the advancement of a third program to submission of an Investigational New Drug application  and
the remaining proceeds for working capital and general corporate purposes 
Disclaimer  This CALA IPO report is based on a reading and analysis of CALA s S 1 filing  which can be found  and a separate  independent analysis by   There are no unattributed direct quotes in this article ",2014-10-02,Francis Gaskins,https://www.investing.com/analysis/calithera-biosiences-ipo:-outlook-neutral-227712,227712
173012,394528,LLY,Thursday s Swing Trading List  AGN  COH  EXC  FB  LLY,opinion,"Here s Today s Swing Trading watch list 
Long Allergan  Allergan Inc  NYSE AGN  


Long Coach  Coach Inc  NYSE COH 

Long Exelon  NYSE EXC 

Long Facebook  NASDAQ FB 

Short Eli Lilly   Co   NYSE LLY ",2015-01-08,Ryan Mallory,"https://www.investing.com/analysis/thursday's-swing-trading-list:-agn,-coh,-exc,-fb,-lly-237755",237755
173034,394550,LLY,Moyes  Noise And Signals From The Capital Markets,opinion,The dismissal of Manchester United s manager David Moyes is getting more attention today than the global capital markets where trillions of dollars are exchanging hands every day  It is a testimony to the sociological representation in the capital markets  as well as to the absence of fresh incentives  In some ways  it is the perfect transition from the holiday mode that began for some last Thursday to what is likely to be a more eventful next few days  The week s events still lie ahead  These include the euro area flash PMI and the HSBC flash manufacturing PMI for China  Australia s Q1 CPI  the Reserve Bank of New Zealand s policy meeting  Canada s retail sales and US durable goods orders  Today s news stream is light  China formally confirmed the 2  required reserve reduction for some rural banks  This has been largely signaled last week  The USD CNY has been gently trending higher  most recently since April 10 and today it rose to its best level in 14 months  The spot yuan rate was 1 2  below the fixing  as the PBOC allows part of the new 2  band to be explored  The flash PMI will be reported tomorrow  The Shanghai Composite rose today  0 3    the first advance in four sessions  led by financials and telecoms  Technology was weighed down by concerns that the rash of new public offerings approved last week  46 companies  included many in this space  The Australian government was somewhat critical of the neutral stance of the central bank given the appreciation of the AUD  The market shrugged off the comments  The Australian dollar is the strongest major currency today  gaining 0 3  against the dollar  Australia s Q1 CPI will be reported tomorrow  and it is expected to rise above 3  on the headline rates and 2 9  on the trimmed and weighted mean basis from 2 7  and 2 6  respectively  Such an increase may bolster speculation of an RBA rate hike before the end of the year  This is turn could see the Australian dollar try again to establish a foothold above  0 9400  European shares have continued their advance that began prior to the holiday  Led by pharmaceuticals  European shares are up for a third consecutive session  The Dow Jones STOXX 600 is up almost 1  through the European morning  There has been a flurry of activity  as Novartis  NYSE NVS  reportedly will sell its vaccine division to Glaxosmithkline  NYSE GSK      7 1 bln   and its animal health unit to Eli Lilly   NYSE LLY      5 4 bln  and buy Glaxo s cancer drugs   16 bln   There is also speculation that Pfizer  NYSE PFE  may purchase AstraZeneca  AZN   The Canadian dollar is the only major currency that has slipped against the dollar so far today  There is some concern that the delay in the Keystone pipeline has dampened sentiment  The USD CAD had slipped to about CAD1 0860 on April 9 and has now closed the North American session above CAD1 10 for four sessions coming into today  Our bias remains on the upside though initial resistance is pegged in the CAD1 1070 area  The wholesale trade report is unlikely to elicit much of a market reaction  Tomorrow s retail sales report is more important  Canadian officials are hoping for a transition from household consumption toward exports and investment  After a 1 3  rise in January retail sales  a 0 5  gain is expected in February s report  The dollar has finished the North American session higher against the yen for seven consecutive sessions coming into today  The USD JPY made a marginal new high  but seems stuck at the 50  retracement level of the drop since April 4th s push above JPY104  Its advancing streak will be challenged today  Initial support is seen near JPY102 20  Today s US data includes the Richmond Fed survey  April  and existing home sales  March   Neither are market movers  Bernanke speaks before the Economic Club of Canada near midday  ET  and his topic  Eight Years of Crisis Management at the Federal Reserve and the Way Forward  may draw interest  even if not fresh trading incentives ,2014-04-22,Marc Chandler,"https://www.investing.com/analysis/moyes,-noise-and-signals-from-the-capital-markets-210290",210290
173035,394551,LLY,Eli Lilly s Cyramza Misses Primary Goal In Liver Cancer Study,opinion,"Eli Lilly s  NYSE LLY  oncology treatment  Cyramza  failed to meet the primary endpoint in a global  randomized  double blind study  REACH  conducted in hepatocellular  liver  cancer patients 
Cyramza plus best supportive care was compared to placebo plus best supportive care for the second line treatment of patients who have been treated with Nexavar  sorafenib  in the first line setting  Although overall survival favored the Cyramza arm  results were not statistically significant 
Meanwhile  meaningful improvements in key secondary endpoints like progression free survival  overall response rate and time to progression were observed with single agent Cyramza  Safety data was in line with that seen in previous studies conducted with single agent Cyramza 
Eli Lilly intends to meet with regulatory authorities to discuss the overall efficacy especially that seen in specific subpopulations 
The results are disappointing as Cyramza s label expansion would increase the commercial potential of the treatment significantly  Eli Lilly has faced a setback with Cyramza earlier too when it failed to achieve the primary endpoint in a phase III breast cancer study 
Eli Lilly has orphan drug status for Cyramza for liver cancer in the U S  as well as the EU  Liver cancer  once it advances  is very difficult to treat   surgery is no longer an option and with no approved treatments in the second line setting  patients depend on supportive care 
Cyramza is currently approved as a single agent for the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma in patients whose disease has progressed after treatment with fluoropyrimidine  or platinum containing chemotherapy  Eli Lilly is evaluating Cyramza for second line non small cell lung cancer  regulatory filing scheduled this year  as well as colorectal cancer  phase III data due later this year  
Eli Lilly  which is facing generic competition for drugs like the Zyprexa  Cymbalta and Evista  needs to bring new products to market to help make up for the loss of revenues to genericization 
Eli Lilly is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Allergan  NYSE AGN   Gilead Sciences  Inc   NASDAQ GILD  and Regeneron Pharmaceuticals  NASDAQ REGN   All three are Zacks Rank  1  Strong Buy  stocks ",2014-06-13,Zacks Investment Research,https://www.investing.com/analysis/eli-lilly's-cyramza-misses-primary-goal-in-liver-cancer-study-215906,215906
173036,394552,LLY, How Are 19th Century Companies Doing Today ,opinion,"Trading stocks sometimes feels like a very modern phenomenon  so it s easy to forget that some of the companies we re investing in go back a century or more  While 21st century tech startups dominate the headlines  old established companies can often be high quality investments  Eli Lilly and Company  NYSE LLY   which was founded in 1876  is up 76  since I recommended it in 2011 
Figure 1 shows 10 other companies that have been around since the 19th century and compares them based on return on invested capital  ROIC  and revenue growth in the past year 
Figure 1  19th Century Companies Today

The second oldest company on the list  Colgate Palmolive Company  NYSE CL   is also the top value creator for investors  Its 22 9  ROIC is more than double any other company on the list and puts it in the top quintile of all the companies we cover  CL is also the only stock in Figure 1 to earn our Attractive rating 
Not all the companies here have adapted to the modern world as well as CL  The bottom five companies on the list have ROICs in the bottom 40  of all companies we cover and earn our Dangerous or worse rating 
Disclosure  David Trainer and Sam McBride receive no compensation to write about any specific stock  sector  or theme ",2014-07-08,David Trainer,https://www.investing.com/analysis/how-are-19th-century-companies-doing-today-218660,218660
173055,394571,LLY,U S  Stocks Finish Higher Following Retail Sales Data,opinion,U S  equities were solidly higher at the closing bell  with financial and health care stocks leading the way  Stocks advanced after the Commerce Department reported U S  retail sales rose a seasonally adjusted 1 1  in September  with spending increasing across every segment except department stores The retail sales measurement topped expectations  economists surveyed by MarketWatch expected retail sales to rise by 0 9   In addition  the Commerce Department revised sales figures for August and July  Retail sales climbed 1 2  in August   the fastest rate in almost two years   instead of 0 9  as previously reported  The increase in July sales was revised up to 0 7  from 0 6  Health care stocks led gains on the S P 500  with Eli Lily Co   LLY  the top gainer after the drug maker released positive results from its late stage study of gastric cancer drug ramucirumab  Financial Stocks were the second best performing sector  boosted by Citigroup s  C  report that in Q3  it earned  1 06 per share on revenue of  19 4 bln  vs  the analyst consensus of  0 99 per share on revenue of  18 79 bln  according to Capital IQ In other developments  the New York Federal Reserve Bank reported that the Empire State manufacturing index rose to negative 6 2 in October from negative 10 4 in September  Economists polled by MarketWatch expected the index to improve to negative 4 0 Commodity prices were mostly lower today due to a climbing greenback  Oil futures were lower during the majority of the session  but ended up closing nearly even at  91 85  Gold for December delivery fell  22 10  or 1 3   to  1 737 60 an ounce on the Comex division of the New York Mercantile Exchange  its lowest settlement price since mid September Here s where the market stand at end of day Dow Jones Industrial Average up 95 38   0 72   to 13 424 23S P 500 up 11 54   0 81   to 1 440 13Nasdaq Composite Index up 20 07   0 66   to 3 064 18GLOBAL SENTIMENT Nikkei 225 Index up 0 51 Hang Seng Index up 0 05 Shanghai China Composite Index down 0 28 FTSE 100 Index up 0 32 DAX up 0 38 CAC 40 up 1 03 UPSIDE MOVERS     TISA  Company announces broad based reseller deal with Jack Henry  JKHY      BCOM  Class action suit withdrawal leads to surge in share price     PRXI  Reports Q2 2012 revenue of  13 4 million compared to  8 2 million in Q2 of the previous year DOWNSIDE MOVERS     DCTH  Shares slide after grants NDA to company  but doesn t assign it priority review status     ALU  More layoffs at company send shares to under  1     HRS  Lazard Capital downgrades shares to Sell ,2012-10-16,Midnight Trader,https://www.investing.com/analysis/u.s.-stocks-finish-higher-following-retail-sales-data-139898,139898
